0001739104-20-000005.txt : 20200228 0001739104-20-000005.hdr.sgml : 20200228 20200228104620 ACCESSION NUMBER: 0001739104-20-000005 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 137 CONFORMED PERIOD OF REPORT: 20191231 FILED AS OF DATE: 20200228 DATE AS OF CHANGE: 20200228 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elanco Animal Health Inc CENTRAL INDEX KEY: 0001739104 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 825497352 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38661 FILM NUMBER: 20666526 BUSINESS ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 BUSINESS PHONE: 877-352-6261 MAIL ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 10-K 1 elan-20191231.htm 10-K elan-20191231
10-KfalseDecember 31, 20192019FYElanco Animal Health Inc.0001739104YesNoYesLarge Accelerated Filerfalsefalsefalse12.4398,532,256--12-31P5YP3YP5YP1Y01P1Y00017391042019-01-012019-12-31iso4217:USD00017391042019-06-30xbrli:shares00017391042020-02-2500017391042018-01-012018-12-3100017391042017-01-012017-12-31iso4217:USDxbrli:shares00017391042019-12-3100017391042018-12-310001739104us-gaap:CommonStockMember2016-12-310001739104us-gaap:AdditionalPaidInCapitalMember2016-12-310001739104elan:NetParentCompanyInvestmentMember2016-12-310001739104us-gaap:RetainedEarningsMember2016-12-310001739104us-gaap:AccumulatedTranslationAdjustmentMember2016-12-310001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2016-12-310001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2016-12-3100017391042016-12-310001739104elan:NetParentCompanyInvestmentMember2017-01-012017-12-310001739104us-gaap:AccumulatedTranslationAdjustmentMember2017-01-012017-12-310001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2017-01-012017-12-310001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2017-01-012017-12-310001739104us-gaap:CommonStockMember2017-12-310001739104us-gaap:AdditionalPaidInCapitalMember2017-12-310001739104elan:NetParentCompanyInvestmentMember2017-12-310001739104us-gaap:RetainedEarningsMember2017-12-310001739104us-gaap:AccumulatedTranslationAdjustmentMember2017-12-310001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2017-12-310001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2017-12-3100017391042017-12-310001739104elan:NetParentCompanyInvestmentMember2018-01-012018-12-310001739104us-gaap:RetainedEarningsMember2018-01-012018-12-310001739104elan:NetParentCompanyInvestmentMember2018-01-0100017391042018-01-010001739104us-gaap:AccumulatedTranslationAdjustmentMember2018-01-012018-12-310001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2018-01-012018-12-310001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-01-012018-12-310001739104us-gaap:CommonStockMember2018-01-012018-12-310001739104us-gaap:AdditionalPaidInCapitalMember2018-01-012018-12-310001739104us-gaap:CommonStockMember2018-12-310001739104us-gaap:AdditionalPaidInCapitalMember2018-12-310001739104elan:NetParentCompanyInvestmentMember2018-12-310001739104us-gaap:RetainedEarningsMember2018-12-310001739104us-gaap:AccumulatedTranslationAdjustmentMember2018-12-310001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2018-12-310001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310001739104us-gaap:RetainedEarningsMember2019-01-012019-12-310001739104us-gaap:AccumulatedTranslationAdjustmentMember2019-01-012019-12-310001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-01-012019-12-310001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310001739104us-gaap:AdditionalPaidInCapitalMember2019-01-012019-12-310001739104us-gaap:CommonStockMember2019-01-012019-12-310001739104elan:AratanaTherapeuticsInc.Memberus-gaap:CommonStockMember2019-01-012019-12-310001739104elan:AratanaTherapeuticsInc.Memberus-gaap:AdditionalPaidInCapitalMember2019-01-012019-12-310001739104elan:AratanaTherapeuticsInc.Member2019-01-012019-12-310001739104us-gaap:CommonStockMember2019-12-310001739104us-gaap:AdditionalPaidInCapitalMember2019-12-310001739104elan:NetParentCompanyInvestmentMember2019-12-310001739104us-gaap:RetainedEarningsMember2019-12-310001739104us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-12-310001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001739104elan:AratanaTherapeuticsInc.Member2019-12-31elan:brandelan:country0001739104us-gaap:IPOMember2018-09-242018-09-24xbrli:pure0001739104us-gaap:IPOMember2018-09-240001739104us-gaap:IPOMember2019-12-310001739104us-gaap:SeniorNotesMember2018-08-280001739104us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2018-09-240001739104us-gaap:LineOfCreditMemberelan:TermCreditFacilityMember2018-09-2400017391042018-09-242018-09-240001739104us-gaap:AccountingStandardsUpdate201602Member2019-01-010001739104elan:ContractWithCustomerLiabilityMemberus-gaap:GeographicConcentrationRiskMembercountry:US2019-01-012019-12-310001739104elan:ContractWithCustomerLiabilityMemberus-gaap:GeographicConcentrationRiskMembercountry:US2018-01-012018-12-310001739104elan:ContractWithCustomerLiabilityMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:NonUsMember2018-01-012018-12-310001739104elan:ContractWithCustomerLiabilityMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:NonUsMember2019-01-012019-12-310001739104us-gaap:RevenueFromContractWithCustomerMemberelan:ProductReturnConcentrationRiskMember2019-01-012019-12-310001739104us-gaap:RevenueFromContractWithCustomerMemberelan:ProductReturnConcentrationRiskMember2018-01-012018-12-310001739104elan:CompanionAnimalDiseasePreventionMember2019-01-012019-12-310001739104elan:CompanionAnimalDiseasePreventionMember2018-01-012018-12-310001739104elan:CompanionAnimalDiseasePreventionMember2017-01-012017-12-310001739104elan:CompanionAnimalTherapeuticsMember2019-01-012019-12-310001739104elan:CompanionAnimalTherapeuticsMember2018-01-012018-12-310001739104elan:CompanionAnimalTherapeuticsMember2017-01-012017-12-310001739104elan:FoodAnimalFutureProteinAndHealthMember2019-01-012019-12-310001739104elan:FoodAnimalFutureProteinAndHealthMember2018-01-012018-12-310001739104elan:FoodAnimalFutureProteinAndHealthMember2017-01-012017-12-310001739104elan:FoodAnimalRuminantsAndSwineMember2019-01-012019-12-310001739104elan:FoodAnimalRuminantsAndSwineMember2018-01-012018-12-310001739104elan:FoodAnimalRuminantsAndSwineMember2017-01-012017-12-310001739104elan:ProductCategoryStrategicExitsMember2019-01-012019-12-310001739104elan:ProductCategoryStrategicExitsMember2018-01-012018-12-310001739104elan:ProductCategoryStrategicExitsMember2017-01-012017-12-310001739104elan:AratanaTherapeuticsInc.Member2019-07-182019-07-180001739104elan:AratanaTherapeuticsInc.Member2019-07-180001739104elan:GalliprantMember2019-07-180001739104elan:GalliprantMember2019-01-012019-12-310001739104elan:AratanaTherapeuticsInc.Memberus-gaap:InProcessResearchAndDevelopmentMember2019-07-180001739104elan:AratanaTherapeuticsInc.Memberus-gaap:MarketingRelatedIntangibleAssetsMember2019-07-180001739104elan:AratanaTherapeuticsInc.Memberus-gaap:OtherIntangibleAssetsMember2019-07-180001739104elan:AratanaTherapeuticsInc.Member2018-01-012018-12-310001739104elan:PrevtecMicrobiaInc.Member2019-07-312019-07-310001739104elan:PrevtecMicrobiaInc.Member2019-07-310001739104elan:PrevtecMicrobiaInc.Memberus-gaap:InProcessResearchAndDevelopmentMember2019-07-310001739104elan:PrevtecMicrobiaInc.Memberus-gaap:MarketingRelatedIntangibleAssetsMember2019-07-310001739104elan:PrevtecMicrobiaInc.Memberus-gaap:OtherIntangibleAssetsMember2019-07-310001739104elan:BoehringerIngelheimVetmedicaInc.Member2017-01-032017-01-030001739104elan:BoehringerIngelheimVetmedicaInc.Member2017-01-030001739104elan:BoehringerIngelheimVetmedicaInc.Memberus-gaap:MarketingRelatedIntangibleAssetsMember2017-01-012017-12-310001739104elan:BoehringerIngelheimVetmedicaInc.Member2017-01-012017-12-310001739104elan:BayerAnimalBusinessMember2019-08-192019-08-190001739104us-gaap:FacilityClosingMember2017-12-310001739104us-gaap:EmployeeSeveranceMember2017-12-310001739104us-gaap:FacilityClosingMember2018-01-012018-12-310001739104us-gaap:EmployeeSeveranceMember2018-01-012018-12-310001739104us-gaap:FacilityClosingMember2018-12-310001739104us-gaap:EmployeeSeveranceMember2018-12-310001739104us-gaap:FacilityClosingMember2019-01-012019-12-310001739104us-gaap:EmployeeSeveranceMember2019-01-012019-12-310001739104us-gaap:FacilityClosingMember2019-12-310001739104us-gaap:EmployeeSeveranceMember2019-12-310001739104us-gaap:LineOfCreditMemberelan:TermCreditFacilityMember2019-12-310001739104us-gaap:LineOfCreditMemberelan:TermCreditFacilityMember2018-12-310001739104elan:A3.912SeniorNotesDue2021Memberus-gaap:SeniorNotesMember2018-08-280001739104elan:A3.912SeniorNotesDue2021Memberus-gaap:SeniorNotesMember2019-12-310001739104elan:A3.912SeniorNotesDue2021Memberus-gaap:SeniorNotesMember2018-12-310001739104elan:A4.272SeniorNotesDue2023Memberus-gaap:SeniorNotesMember2018-08-280001739104elan:A4.272SeniorNotesDue2023Memberus-gaap:SeniorNotesMember2019-12-310001739104elan:A4.272SeniorNotesDue2023Memberus-gaap:SeniorNotesMember2018-12-310001739104elan:A4.9SeniorNotesDue2028Memberus-gaap:SeniorNotesMember2018-08-280001739104elan:A4.9SeniorNotesDue2028Memberus-gaap:SeniorNotesMember2019-12-310001739104elan:A4.9SeniorNotesDue2028Memberus-gaap:SeniorNotesMember2018-12-310001739104us-gaap:NotesPayableOtherPayablesMember2019-12-310001739104us-gaap:NotesPayableOtherPayablesMember2018-12-310001739104us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2018-09-052018-09-050001739104us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2018-09-050001739104us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2019-12-310001739104us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2018-12-310001739104us-gaap:LineOfCreditMemberelan:TermCreditFacilityMember2018-09-050001739104us-gaap:LineOfCreditMemberelan:TermCreditFacilityMember2018-09-052018-09-050001739104us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001739104us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2019-12-310001739104us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310001739104us-gaap:FairValueInputsLevel3Memberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001739104us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2019-12-310001739104us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2019-12-310001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310001739104us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2019-12-310001739104us-gaap:OtherCurrentLiabilitiesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2018-12-310001739104us-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2018-12-310001739104us-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2018-12-310001739104us-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2018-12-310001739104us-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2018-12-310001739104us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2018-12-310001739104us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2018-12-310001739104us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2018-12-310001739104us-gaap:FairValueInputsLevel3Memberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2018-12-310001739104us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2018-12-310001739104us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2018-12-310001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2018-12-310001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2018-12-310001739104us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2018-12-310001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2018-12-310001739104us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2018-10-012018-10-31iso4217:CHF0001739104us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2018-10-310001739104us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMemberus-gaap:ForeignExchangeContractMember2019-01-012019-12-310001739104us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMemberus-gaap:ForeignExchangeContractMember2018-01-012018-12-310001739104us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2019-01-012019-12-310001739104us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2018-01-012018-12-310001739104us-gaap:MarketingRelatedIntangibleAssetsMember2019-12-310001739104us-gaap:MarketingRelatedIntangibleAssetsMember2018-12-310001739104us-gaap:ComputerSoftwareIntangibleAssetMember2019-12-310001739104us-gaap:ComputerSoftwareIntangibleAssetMember2018-12-310001739104us-gaap:OtherIntangibleAssetsMember2019-12-310001739104us-gaap:OtherIntangibleAssetsMember2018-12-310001739104us-gaap:InProcessResearchAndDevelopmentMember2019-12-310001739104us-gaap:InProcessResearchAndDevelopmentMember2018-12-310001739104us-gaap:ComputerSoftwareIntangibleAssetMember2019-01-012019-12-310001739104us-gaap:ComputerSoftwareIntangibleAssetMember2018-01-012018-12-310001739104us-gaap:ComputerSoftwareIntangibleAssetMember2017-01-012017-12-310001739104srt:MinimumMember2019-01-012019-12-310001739104srt:MaximumMember2019-01-012019-12-310001739104us-gaap:MarketingRelatedIntangibleAssetsMember2019-01-012019-12-310001739104us-gaap:OtherIntangibleAssetsMember2019-01-012019-12-310001739104srt:MinimumMemberus-gaap:BuildingMember2019-01-012019-12-310001739104srt:MaximumMemberus-gaap:BuildingMember2019-01-012019-12-310001739104srt:MinimumMemberus-gaap:EquipmentMember2019-01-012019-12-310001739104srt:MaximumMemberus-gaap:EquipmentMember2019-01-012019-12-310001739104us-gaap:LandMember2019-12-310001739104us-gaap:LandMember2018-12-310001739104us-gaap:BuildingMember2019-12-310001739104us-gaap:BuildingMember2018-12-310001739104us-gaap:EquipmentMember2019-12-310001739104us-gaap:EquipmentMember2018-12-310001739104us-gaap:ConstructionInProgressMember2019-12-310001739104us-gaap:ConstructionInProgressMember2018-12-310001739104elan:ElancoStockCompensationPlansMember2018-12-310001739104elan:ElancoStockCompensationPlansMember2019-02-280001739104elan:ElancoStockCompensationPlansMember2019-12-310001739104elan:ElancoStockCompensationPlansMember2019-01-012019-12-310001739104elan:ElancoStockCompensationPlansMember2018-01-012018-12-310001739104us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-12-310001739104us-gaap:RestrictedStockUnitsRSUMember2018-01-012018-12-310001739104us-gaap:RestrictedStockUnitsRSUMember2018-12-310001739104us-gaap:RestrictedStockUnitsRSUMember2019-12-310001739104us-gaap:PerformanceSharesMember2018-12-310001739104us-gaap:PerformanceSharesMember2019-01-012019-12-310001739104us-gaap:PerformanceSharesMember2019-12-310001739104us-gaap:EmployeeStockOptionMember2019-01-012019-12-310001739104us-gaap:EmployeeStockOptionMember2019-12-310001739104elan:LillysStockBasedCompensationProgramMember2019-01-012019-12-310001739104elan:LillysStockBasedCompensationProgramMember2018-01-012018-12-310001739104elan:LillysStockBasedCompensationProgramMember2017-01-012017-12-310001739104us-gaap:ForeignCountryMember2019-12-310001739104us-gaap:DomesticCountryMember2019-12-310001739104us-gaap:StateAndLocalJurisdictionMember2019-12-310001739104elan:DomesticForeignAndStateTaxAuthoritiesMember2019-12-310001739104elan:DomesticForeignAndStateTaxAuthoritiesMemberelan:TaxYear2020To2039Member2019-12-310001739104srt:ScenarioPreviouslyReportedMemberus-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2018-12-310001739104srt:ScenarioPreviouslyReportedMemberus-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2017-12-310001739104us-gaap:ValuationAllowanceOfDeferredTaxAssetsMembersrt:RestatementAdjustmentMember2018-12-310001739104us-gaap:ValuationAllowanceOfDeferredTaxAssetsMembersrt:RestatementAdjustmentMember2017-12-310001739104us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2018-12-310001739104us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2017-12-310001739104us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2019-01-012019-12-310001739104us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2018-01-012018-12-310001739104us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2019-12-310001739104srt:ScenarioPreviouslyReportedMember2018-12-310001739104srt:ScenarioPreviouslyReportedMember2017-12-310001739104srt:ScenarioPreviouslyReportedMember2016-12-310001739104srt:RestatementAdjustmentMember2018-12-310001739104srt:RestatementAdjustmentMember2017-12-310001739104srt:RestatementAdjustmentMember2016-12-310001739104us-gaap:RevolvingCreditFacilityMemberelan:BayerAnimalBusinessMember2019-08-190001739104elan:TermLoanMemberelan:BayerAnimalBusinessMember2019-08-190001739104elan:BridgeFacilityMemberelan:BayerAnimalBusinessMember2019-08-190001739104us-gaap:CustomerConcentrationRiskMemberelan:CustomerAMemberus-gaap:SalesRevenueNetMember2019-01-012019-12-310001739104us-gaap:CustomerConcentrationRiskMemberelan:CustomerAMemberus-gaap:SalesRevenueNetMember2018-01-012018-12-310001739104us-gaap:CustomerConcentrationRiskMemberelan:CustomerAMemberus-gaap:SalesRevenueNetMember2017-01-012017-12-310001739104us-gaap:ProductMember2019-12-310001739104us-gaap:ProductMember2018-12-310001739104country:US2019-01-012019-12-310001739104country:US2018-01-012018-12-310001739104country:US2017-01-012017-12-310001739104us-gaap:NonUsMember2019-01-012019-12-310001739104us-gaap:NonUsMember2018-01-012018-12-310001739104us-gaap:NonUsMember2017-01-012017-12-310001739104country:US2019-12-310001739104country:US2018-12-310001739104country:US2017-12-310001739104country:GB2019-12-310001739104country:GB2018-12-310001739104country:GB2017-12-310001739104elan:OtherForeignCountriesNotSeparatelyDisclosedMember2019-12-310001739104elan:OtherForeignCountriesNotSeparatelyDisclosedMember2018-12-310001739104elan:OtherForeignCountriesNotSeparatelyDisclosedMember2017-12-31elan:segment0001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2019-12-310001739104us-gaap:PensionPlansDefinedBenefitMember2018-12-310001739104us-gaap:PensionPlansDefinedBenefitMember2017-12-310001739104us-gaap:PensionPlansDefinedBenefitMember2019-01-012019-12-310001739104us-gaap:PensionPlansDefinedBenefitMember2018-01-012018-12-310001739104us-gaap:PensionPlansDefinedBenefitMember2019-12-3100017391042019-09-012019-09-300001739104us-gaap:PensionPlansDefinedBenefitMember2017-01-012017-12-310001739104us-gaap:DefinedBenefitPlanCashMemberus-gaap:PensionPlansDefinedBenefitMember2019-12-310001739104us-gaap:FixedIncomeSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMember2019-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2019-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2019-12-310001739104elan:OtherAlternativeInvestmentsMemberus-gaap:PensionPlansDefinedBenefitMember2019-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2019-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2019-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2019-12-310001739104us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2019-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2019-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMemberus-gaap:FairValueInputsLevel1Member2019-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2019-12-310001739104us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2019-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2019-12-310001739104elan:FixedIncomeSecuritiesDevelopedMarketsMemberus-gaap:PensionPlansDefinedBenefitMember2019-12-310001739104elan:FixedIncomeSecuritiesDevelopedMarketsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Member2019-12-310001739104elan:FixedIncomeSecuritiesDevelopedMarketsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2019-12-310001739104us-gaap:FairValueInputsLevel3Memberelan:FixedIncomeSecuritiesDevelopedMarketsMemberus-gaap:PensionPlansDefinedBenefitMember2019-12-310001739104elan:FixedIncomeSecuritiesDevelopedMarketsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2019-12-310001739104elan:FixedIncomeSecuritiesEmergingMarketsMemberus-gaap:PensionPlansDefinedBenefitMember2019-12-310001739104elan:FixedIncomeSecuritiesEmergingMarketsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Member2019-12-310001739104elan:FixedIncomeSecuritiesEmergingMarketsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2019-12-310001739104us-gaap:FairValueInputsLevel3Memberelan:FixedIncomeSecuritiesEmergingMarketsMemberus-gaap:PensionPlansDefinedBenefitMember2019-12-310001739104elan:FixedIncomeSecuritiesEmergingMarketsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2019-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2019-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel1Member2019-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel2Member2019-12-310001739104us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2019-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2019-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Member2019-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2019-12-310001739104us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMember2019-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2019-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2018-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMemberus-gaap:FairValueInputsLevel1Member2018-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2018-12-310001739104us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2018-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2018-12-310001739104elan:FixedIncomeSecuritiesDevelopedMarketsMemberus-gaap:PensionPlansDefinedBenefitMember2018-12-310001739104elan:FixedIncomeSecuritiesDevelopedMarketsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Member2018-12-310001739104elan:FixedIncomeSecuritiesDevelopedMarketsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2018-12-310001739104us-gaap:FairValueInputsLevel3Memberelan:FixedIncomeSecuritiesDevelopedMarketsMemberus-gaap:PensionPlansDefinedBenefitMember2018-12-310001739104elan:FixedIncomeSecuritiesDevelopedMarketsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2018-12-310001739104elan:FixedIncomeSecuritiesEmergingMarketsMemberus-gaap:PensionPlansDefinedBenefitMember2018-12-310001739104elan:FixedIncomeSecuritiesEmergingMarketsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Member2018-12-310001739104elan:FixedIncomeSecuritiesEmergingMarketsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2018-12-310001739104us-gaap:FairValueInputsLevel3Memberelan:FixedIncomeSecuritiesEmergingMarketsMemberus-gaap:PensionPlansDefinedBenefitMember2018-12-310001739104elan:FixedIncomeSecuritiesEmergingMarketsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2018-12-310001739104us-gaap:HedgeFundsMemberus-gaap:PensionPlansDefinedBenefitMember2018-12-310001739104us-gaap:HedgeFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Member2018-12-310001739104us-gaap:HedgeFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2018-12-310001739104us-gaap:FairValueInputsLevel3Memberus-gaap:HedgeFundsMemberus-gaap:PensionPlansDefinedBenefitMember2018-12-310001739104us-gaap:HedgeFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2018-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberelan:DefinedBenefitPlanEquityLikeFundsMember2018-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberelan:DefinedBenefitPlanEquityLikeFundsMemberus-gaap:FairValueInputsLevel1Member2018-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberelan:DefinedBenefitPlanEquityLikeFundsMember2018-12-310001739104us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberelan:DefinedBenefitPlanEquityLikeFundsMember2018-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberelan:DefinedBenefitPlanEquityLikeFundsMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2018-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2018-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMemberus-gaap:FairValueInputsLevel1Member2018-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanRealEstateMember2018-12-310001739104us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2018-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2018-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2018-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel1Member2018-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel2Member2018-12-310001739104us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2018-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2018-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Member2018-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2018-12-310001739104us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMember2018-12-310001739104us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2018-12-31elan:plan0001739104us-gaap:DefinedBenefitPostretirementHealthCoverageMember2019-12-310001739104us-gaap:DefinedBenefitPostretirementHealthCoverageMember2018-12-310001739104elan:EliLillyandCompanyMemberelan:ElancoAnimalHealthIncorporatedAndSubsidiariesMember2018-12-310001739104elan:EliLillyandCompanyMemberelan:ElancoAnimalHealthIncorporatedAndSubsidiariesMember2018-09-1800017391042018-09-192018-09-190001739104us-gaap:MajorityShareholderMemberelan:TransitionalServicesAgreementMember2019-12-310001739104us-gaap:MajorityShareholderMemberelan:TransitionalServicesAgreementMember2018-12-310001739104us-gaap:MajorityShareholderMemberelan:OtherRelatedPartyActivitiesMember2019-12-310001739104us-gaap:MajorityShareholderMemberelan:OtherRelatedPartyActivitiesMember2018-12-310001739104us-gaap:MajorityShareholderMemberelan:LocalCountryAssetPurchasesMember2019-12-310001739104us-gaap:MajorityShareholderMemberelan:LocalCountryAssetPurchasesMember2018-12-310001739104us-gaap:MajorityShareholderMember2019-12-310001739104us-gaap:MajorityShareholderMember2018-12-310001739104elan:IntellectualPropertyAndTechnologyLicenseAgreementMemberus-gaap:MajorityShareholderMember2019-01-012019-12-31elan:renewal_term0001739104elan:IntellectualPropertyAndTechnologyLicenseAgreementMemberus-gaap:MajorityShareholderMember2019-12-310001739104us-gaap:MajorityShareholderMemberelan:TollManufacturingArrangementMember2019-01-012019-12-310001739104us-gaap:MajorityShareholderMemberelan:TollManufacturingArrangementMember2018-01-012018-12-310001739104us-gaap:MajorityShareholderMemberelan:TransitionalServicesAgreementMember2019-01-012019-12-310001739104us-gaap:MajorityShareholderMemberelan:TransitionalServicesAgreementMember2018-01-012018-12-310001739104us-gaap:MajorityShareholderMemberus-gaap:CostOfSalesMemberelan:TransitionalServicesAgreementMember2018-01-012018-12-310001739104us-gaap:MajorityShareholderMemberus-gaap:CostOfSalesMemberelan:TransitionalServicesAgreementMember2017-01-012017-12-310001739104us-gaap:MajorityShareholderMemberelan:TransitionalServicesAgreementMemberus-gaap:ResearchAndDevelopmentExpenseMember2018-01-012018-12-310001739104us-gaap:MajorityShareholderMemberelan:TransitionalServicesAgreementMemberus-gaap:ResearchAndDevelopmentExpenseMember2017-01-012017-12-310001739104us-gaap:MajorityShareholderMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberelan:TransitionalServicesAgreementMember2018-01-012018-12-310001739104us-gaap:MajorityShareholderMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberelan:TransitionalServicesAgreementMember2017-01-012017-12-310001739104us-gaap:MajorityShareholderMemberelan:TransitionalServicesAgreementMember2017-01-012017-12-310001739104us-gaap:MajorityShareholderMemberelan:ManufacturingSupportMember2018-01-012018-12-310001739104us-gaap:MajorityShareholderMemberelan:ManufacturingSupportMember2017-01-012017-12-310001739104us-gaap:MajorityShareholderMember2019-01-012019-12-310001739104us-gaap:MajorityShareholderMember2018-01-012018-12-310001739104us-gaap:MajorityShareholderMember2017-01-012017-12-3100017391042019-10-012019-12-3100017391042019-07-012019-09-3000017391042019-04-012019-06-3000017391042019-01-012019-03-3100017391042018-10-012018-12-3100017391042018-07-012018-09-3000017391042018-04-012018-06-3000017391042018-01-012018-03-310001739104us-gaap:SubsequentEventMemberelan:UnderwritingAgreementMemberus-gaap:CommonStockMember2020-01-222020-01-220001739104us-gaap:SubsequentEventMemberelan:UnderwritingAgreementMemberus-gaap:CommonStockMember2020-01-220001739104us-gaap:SubsequentEventMemberus-gaap:OverAllotmentOptionMemberus-gaap:CommonStockMember2020-01-232020-01-230001739104us-gaap:SubsequentEventMemberus-gaap:CommonStockMember2020-01-222020-01-230001739104us-gaap:SubsequentEventMemberus-gaap:CommonStockMember2020-01-272020-01-270001739104elan:TangibleEquityUnitMemberus-gaap:SubsequentEventMember2020-01-222020-01-220001739104elan:TangibleEquityUnitMemberus-gaap:SubsequentEventMember2020-01-220001739104elan:TangibleEquityUnitMemberus-gaap:SubsequentEventMember2020-01-272020-01-270001739104elan:TangibleEquityUnitMemberus-gaap:SubsequentEventMemberelan:A500SeniorAmortizingNotesMember2020-01-272020-01-270001739104elan:TangibleEquityUnitMemberus-gaap:SubsequentEventMembersrt:MinimumMember2020-01-222020-01-220001739104elan:TangibleEquityUnitMembersrt:MaximumMemberus-gaap:SubsequentEventMember2020-01-222020-01-220001739104elan:TangibleEquityUnitMemberus-gaap:SubsequentEventMembersrt:MinimumMember2020-01-220001739104elan:TangibleEquityUnitMembersrt:MaximumMemberus-gaap:SubsequentEventMember2020-01-220001739104us-gaap:SubsequentEventMemberus-gaap:LineOfCreditMemberelan:TermCreditFacilityMember2020-01-312020-01-310001739104us-gaap:SubsequentEventMemberelan:TermLoanBCreditFacilityMemberus-gaap:LineOfCreditMember2020-02-040001739104us-gaap:SubsequentEventMemberelan:TermLoanBCreditFacilityMemberus-gaap:LineOfCreditMember2020-02-042020-02-040001739104us-gaap:SubsequentEventMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2020-02-040001739104us-gaap:SubsequentEventMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2020-02-042020-02-040001739104us-gaap:SubsequentEventMemberus-gaap:LondonInterbankOfferedRateLIBORMemberelan:TermLoanBCreditFacilityMemberus-gaap:LineOfCreditMember2020-02-042020-02-040001739104us-gaap:SubsequentEventMemberus-gaap:RevolvingCreditFacilityMembersrt:MinimumMemberus-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:LineOfCreditMember2020-02-042020-02-040001739104srt:MaximumMemberus-gaap:SubsequentEventMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:LineOfCreditMember2020-02-042020-02-040001739104us-gaap:SubsequentEventMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberelan:OsurniaAndCapstarMember2020-01-012020-01-310001739104us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberelan:OsurniaAndCapstarMember2019-12-310001739104us-gaap:SubsequentEventMemberelan:VeocoxanMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2020-02-012020-02-28


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-K
ANNUAL REPORT UNDER SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2019

Commission file number 001-38661
Elanco Animal Health Incorporated
(Exact name of Registrant as specified in its charter)
INDIANA 82-5497352
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
2500 INNOVATION WAY, GREENFIELD, INDIANA 46140
(Address of principal executive offices)
Registrant’s telephone number, including area code (877) 352-6261
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, no par valueELANNew York Stock Exchange
5.00% Tangible Equity UnitsELATNew York Stock Exchange
Securities registered pursuant to Section 12(g) of the Act:
None.
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes x No o
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
Yes o No x
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
Yes ý No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ý No o



Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of a “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer ý
Accelerated filer o
Non-accelerated filer o
Smaller reporting company o
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes o No ý
Aggregate market value of the common equity held by non-affiliates computed by reference to the price at which the common equity was last sold as of June 30, 2019, the last business day of the Registrant’s most recently completed second fiscal quarter, was approximately $12.4 billion. The registrant has no non-voting common stock.
The number of shares of common stock outstanding as of February 25, 2020 were 398,532,256
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant's definitive proxy materials for its 2020 Annual Meeting of shareholders are incorporated by reference into Part III hereof.



Elanco Animal Health Incorporated
Form 10-K
For the Year Ended December 31, 2019
Table of Contents
Part I
Item 1.
Business
Item 1A.
Risk Factors
Item 1B.
Unresolved Staff Comments
Item 2.
Properties
Item 3.
Legal Proceedings
Item 4.
Mine Safety Disclosures
Part II
Item 5.
Market for the Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities
Item 6.
Selected Financial Data
Item 7.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 7A.
Quantitative and Qualitative Disclosures About Market Risk
Item 8.
Financial Statements and Supplementary Data
Item 9.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Item 9A.
Controls and Procedures
Item 9B.
Other Information
Part III
Item 10.
Directors, Executive Officers, and Corporate Governance
Item 11.
Executive Compensation
Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Item 13.
Certain Relationships and Related Transactions, and Director Independence
Item 14.
Principal Accountant Fees and Services
Part IV
Item 15.
Exhibits and Financial Statement Schedules
Item 16.
Form 10-K Summary

3

Forward-Looking Statements
This Annual Report on Form 10-K includes forward-looking statements within the meaning of the federal securities laws. This annual report contains forward-looking statements, including, without limitation, statements concerning our acquisition of the animal health business of Bayer Aktiengesellschaft (Bayer) and our estimated "stand up" costs as a result of our separation from Eli Lilly & Co. (Lilly), our estimated interest expense, our industry and our operations, performance and financial condition, including in particular, statements relating to our business, growth strategies, product development efforts and future expenses.
Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national, or global political, economic, business, competitive, market, and regulatory conditions, including but not limited to the following:
•heightened competition, including from innovation or generics;
•the impact of disruptive innovations and advances in veterinary medical practices, animal health technologies and alternatives to animal-derived protein;
•changes in regulatory restrictions on the use of antibiotics in food animals;
•our ability to implement our business strategies or achieve targeted cost efficiencies and gross margin improvements;
•consolidation of our customers and distributors;
•an outbreak of infectious disease carried by food animals;
•the success of our research and development (R&D) and licensing efforts;
•our ability to complete acquisitions and successfully integrate the businesses we acquire, including the animal health business of Bayer;
•misuse, off-label or counterfeiting use of our products;
•unanticipated safety, quality or efficacy concerns associated with our products;
•the impact of weather conditions and the availability of natural resources;
•disruption in our supply chain due to manufacturing issues experienced by our contract manufacturers;
•the impact of increased or decreased sales to our channel distributors resulting in higher or lower inventory levels held by them in advance of or trailing actual customer demand, which could lead to variations in quarterly revenue results;
•risks related to our presence in emerging markets;
•changes in United States (U.S.) foreign trade policy, imposition of tariffs or trade disputes;
•the impact of global macroeconomic conditions; and
•the effect on our business resulting from our separation from Lilly, including the various costs associated with transition to a standalone entity, including the ability to stand up our enterprise resource planning (ERP) system and other information technology systems.
See "Risk Factors" in Part I, Item 1A of this Annual Report on Form 10-K for a further description of these and other factors. Although we have attempted to identify important risk factors, there may be other risk factors not presently known to us or that we presently believe are not material that could cause actual results and developments to differ materially from those made in or suggested by the forward-looking statements contained in this annual report. If any of these risks materialize, or if any of the above assumptions underlying forward-looking statements prove incorrect, actual results and developments may differ materially from those made in or suggested by the forward-looking statements contained in this annual report. For the reasons described above, we caution you against relying on any forward-looking statements, which should also be read in conjunction with the other cautionary statements that are included elsewhere in this annual report. Any forward-looking statement made by us in this annual report speaks only as of the date hereof. Factors or events that could cause our actual results to differ
4

may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update or to revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless specifically expressed as such, and should be viewed as historical data.

Part I
Item 1. Business
Overview
Founded in 1954 as part of Lilly, Elanco Animal Health Incorporated (Elanco Parent) and its subsidiaries (collectively, Elanco, the Company, we, us, or our) is a premier animal health company that innovates, develops, manufactures and markets products for companion and food animals. Headquartered in Greenfield, Indiana, we are the fourth largest animal health company in the world, with revenue of $3.1 billion for the year ended December 31, 2019. Globally, we are #1 in medicinal feed additives, #2 in poultry, and #3 in other pharmaceuticals, which are mainly companion animal therapeutics, measured by 2018 revenue, according to Vetnosis. We also have one of the broadest portfolios of pet parasiticides in the companion animal sector. We offer a diverse portfolio of more than 125 brands that make us a trusted partner to veterinarians and food animal producers in more than 90 countries.
Elanco Parent was formed in 2018, as a wholly-owned subsidiary of Lilly, to serve as the ultimate parent company of substantially all of the animal health businesses of Lilly.
On September 20, 2018, our common stock began trading on the New York Stock Exchange (NYSE) under the symbol “ELAN.” On September 24, 2018, Elanco Parent completed an initial public offering (IPO), resulting in the issuance of 72.3 million shares of its common stock (including shares issued pursuant to the underwriters' option to purchase additional shares), which represented 19.8% of the outstanding shares, at $24.00 per share resulting in total net proceeds after underwriting discounts and commissions, of $1.7 billion. In connection with the completion of the IPO through a series of equity and other transactions, Lilly transferred to Elanco Parent the animal health businesses that form its business. In exchange, Elanco Parent has paid to Lilly approximately $4.2 billion, which included the net proceeds from the IPO, the net proceeds from the debt offering completed by Elanco Parent in August 2018 and the term loan entered into by Elanco Parent in September 2018 (see Note 9: Debt to our consolidated and combined financial statements). These transactions are collectively referred to herein as the "Separation."
On February 8, 2019, Lilly announced an exchange offer whereby Lilly shareholders could exchange all or a portion of Lilly common stock for shares of Elanco common stock owned by Lilly. The disposition of Elanco shares was completed on March 11, 2019, and resulted in the full separation of Elanco along with the disposal of Lilly's entire ownership and voting interest in Elanco.
We operate our business in a single segment directed at fulfilling our vision of enriching the lives of people through food, making protein more accessible and affordable, and through pet companionship, helping pets live longer, healthier lives. We advance our vision by offering products in four primary categories:
Companion Animal Disease Prevention (CA Disease Prevention): We have one of the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. Combining our parasiticide portfolio with our vaccines presence, we are a leader in the U.S. in the disease prevention category based on share of revenue.
Companion Animal Therapeutics (CA Therapeutics): We have a broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. Pet owners are increasingly treating osteoarthritis in their pets, and our Galliprant product is one of the fastest growing osteoarthritis treatments in the U.S. We also have treatments for otitis (ear infections), as well as cardiovascular and dermatology indications.
Food Animal Future Protein & Health (FA Future Protein & Health): Our portfolio in this category, which includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products
5

is outpacing overall industry growth. We are focused on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. We are a leader in providing vaccines as alternatives to antibiotics to promote animal health based on share of revenue.
Food Animal Ruminants & Swine (FA Ruminants & Swine): We have developed a range of food animal products used extensively in ruminant (e.g., cattle, sheep and goats) and swine production.
We have a top four presence in all four key industry geographic regions: North America (NA); Europe, the Middle East and Africa (EMEA); Latin America (LATAM); and Asia-Pacific (APAC), as measured by 2018 revenue, according to Vetnosis. The following graphs demonstrate our revenue for the year ended December 31, 2019 by product category and geography:
elan-20191231_g1.jpg
(1) Strategic Exits includes revenue from third-party manufacturing, distribution and other contractual arrangements, as well as products not core to our business, which we made the decision to exit.
6

elan-20191231_g2.jpg
(1) LATAM includes aquaculture in all regions
Through our global sales force of approximately 1,425 sales representatives, our veterinary consultants and our key distributors, we seek to build strong customer relationships and fulfill demand for our food animal products primarily with food animal producers, veterinarians and nutritionists, and for our companion animal products primarily with veterinarians and, in some markets, pet owners. We are also expanding into retail channels in order to meet pet owners where they want to purchase.
Our inclusive approach to sourcing innovation helps us identify, attract, fund and develop new ideas that enhance our pipeline and reduce risk as compared to an in-house only approach. Through this process we have launched or acquired 14 new products since 2015, including the additions of Entyce™, Nocita™ and Tanovea™ in 2019, that delivered $439.2 million of revenue in 2019.
We believe we have an experienced leadership team that fosters an adaptive, purpose-driven culture among approximately 6,080 employees worldwide as of December 31, 2019 and that our employees share a deep conviction for achieving our vision of food and companionship enriching life.
For the years ended December 31, 2019 and 2018, our revenue was $3.1 billion, and for the year ended December 31, 2017, our revenue was $2.9 billion. For the years ended December 31, 2019, 2018 and 2017, our net income (loss) was $67.9 million, $86.5 million and $(310.7) million, respectively.
Products
We have a diverse portfolio of products marketed under more than 125 brands, including products for both food animals and companion animals.
Our food animal products are designed to enable producers to keep animals healthy and deliver more food while using fewer resources. Our antibacterials, anticoccidials, vaccines and parasiticides aim to make food safer by preventing and controlling disease. We offer products and support to enhance the integrity of the food supply, while our productivity enhancers help make food more affordable and abundant by increasing the amount of meat or milk an animal can supply. Furthermore, our expertise and data analytics help our customers improve production efficiency and business performance. Food animal products represented approximately 60% of our revenue for the year ended December 31, 2019.
Our companion animal products help veterinarians better care for pets. We partner with pet owners and veterinarians for the purpose of providing a consistent flow of innovative and effective products and support. Our R&D focuses on products that prevent and treat disease, improve and extend quality of life and improve the type of care received by pets. We also partner closely with veterinarians to provide technical support and case
7

management for our products. Companion animal products represented approximately 37% of our revenue for the year ended December 31, 2019.
We group our products into four principal categories:
CA Disease Prevention: includes parasiticides and vaccine products for canines and felines.
CA Therapeutics: includes products for the treatment of pain, osteoarthritis, otitis, cardiovascular and dermatology indications in canines and felines.
FA Future Protein & Health: includes vaccines, antibiotics, parasiticides and other products used in poultry and aquaculture production, as well as functional nutritional health products, including enzymes, probiotics and prebiotics.
FA Ruminants & Swine: includes vaccines, antibiotics, implants, parasiticides and other products used in ruminants and swine production, as well as certain other food animal products.
We pursue the development of new chemical and biological molecules through our innovation strategy. Since 2015, we have launched or acquired the following 14 products:
In CA Disease Prevention, Credelio™ and Interceptor™ Plus.
In CA Therapeutics, Galliprant, Osurnia™, Tanovea, Entyce and Nocita.
In FA Future Protein & Health, Inteprity™, Imvixa™, Clynav™ and Correlink™.
In FA Ruminants & Swine, Imrestor™, Kavault™ and Prevacent™.
In the second quarter of 2018, we suspended commercialization of Imrestor and plan to pursue additional indications. In addition, as part of our antitrust strategy in connection with the acquisition of the animal health business of Bayer, we announced in January 2020 our plan to divest Osurnia and the U.S. rights to Capstar™ and in February 2020 our plan to divest Vecoxan™.
In 2016, we announced the creation of our Nutritional Health organization, which focuses on functional nutrition products, including enzymes, probiotics and prebiotics, which impact animal microbiomes and other dietary factors to reduce disease incidence, improve gut health and enhance feed digestibility. We first focused on nutritional health in 2012, with the acquisition of ChemGen and the Hemicell™ brand. In 2016, we entered into an agreement with Agro Biosciences, Inc. to commercialize Correlink - a novel direct-fed microbial (probiotic) product outside the U.S. In early 2018, we announced a new global, exclusive in-licensing agreement with Ab E Discovery to further develop and bring to the market an in feed antibody product focused on reducing and controlling coccidiosis. In late 2018, we entered into an R&D collaboration with Novozymes to develop nutritional health products in beef and dairy cattle. In 2019, we entered into an R&D collaboration agreement with AgBiome, Inc. to develop nutritional health products for swine.
Rumensin™, our top selling product, contributed approximately 10%, 11%, and 10% of our revenue in 2019, 2018, and 2017, respectively. No other product contributed 10% or more of our revenue. Our top five selling products, Rumensin, Trifexis™, Maxiban™, Interceptor Plus and Denagard™, collectively contributed approximately 31% of our 2019 revenue. Our top 10 products collectively contributed 43% of our 2019 revenue.
Set forth below is information regarding our principal products.
CA Disease Prevention Products
Primary
ProductDescriptionSpecies
Bronchi Shield™ III and Bronchi Shield Oral
(vaccines)
Bronchi Shield III - To protect against adenovirus, parainfluenza and Bordetella bronchiseptica (Bb) in dogs.
Bronchi Shield Oral - To protect against Bb in dogs.
Dogs
Comfortis™
(spinosad)
To kill fleas and prevent and treat flea infestations (Ctenocephalides felis) in cats 14 weeks of age or older and weighing at least 4.1 lbs. and dogs 14 weeks of age or older and weighing at least 5.0 lbs.
Cats, Dogs
8

Credelio
(lotilaner)
To kill adult fleas and to treat flea infestations (Ctenocephalides felis) and treat and control tick infestations (Amblyomma americanum (lone star tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black‑legged tick) and Rhipicephalus sanguineus (brown dog tick)) for one month in dogs and puppies 8 weeks of age or older and weighing at least 4.4 lbs.
Dogs
Duramune™
(vaccines)
Includes multiple products that collectively protect against distemper, adenovirus, parvovirus, corona, parainfluenza, leptospira canicola, and other diseases in dogs.Dogs
Rabvac™
(vaccines)
To protect against rabies, includes a 1-year and 3-year shot.Cats, Dogs
Fel-O-Vax™
(vaccines)
Includes multiple products that collectively protect against leukemia, rhinovirus, calicivirus, panleukopenia, and chlamydia in cats.Cats
Fel-O-Guard™
(vaccines)
Includes multiple products that collectively protect against leukemia, rhinovirus, calicivirus, panleukopenia, and chlamydia in cats.Cats
Interceptor Plus
(milbemycin oxime/praziquantel)
To prevent heartworm disease caused by Dirofilaria immitis and for the treatment and control of adult roundworm (Toxocara canis and Toxascaris leonina), adult hookworm (Ancylostoma caninum), adult whipworm (Trichuris vulpis), and adult tapeworm (Taenia pisiformis, Echinococcus multilocularis, and Echinococcus granulosus) infections in dogs and puppies weighing at least 2 lbs. and 6 weeks of age or older. Interceptor Plus is a relaunch of a previously approved formula.
Dogs
Milbemax™
(milbemycin
oxime +
praziquantel)
To treat and control parasitic infections due to adult hookworm, adult roundworm and adult tapeworm and to prevent heartworm disease caused by Dirofilaria immitis in cats and dogs.
Cats, Dogs
Trifexis
(spinosad +
milbemycin
oxime)
To prevent heartworm disease (Dirofilaria immitis) and to kill fleas. Trifexis is indicated for the prevention and treatment of flea infestations (Ctenocephalides felis), and the treatment and control of adult hookworm (Ancylostoma caninum), adult roundworm (Toxocara canis and Toxascaris leonina) and adult whipworm (Trichuris vulpis) infections in dogs and puppies 8 weeks of age or older and weighing at least 5 lbs.
Dogs
9

CA Therapeutics Products
Primary
ProductDescriptionSpecies
Atopica™
(cyclosporine A)
To control atopic dermatitis in dogs weighing at least 4 lbs.Dogs
Fortekor Plus™
(benazepril +
pimobendan)
To treat congestive heart failure due to atrioventricular valve insufficiency or dilated cardiomyopathy in dogs.Dogs
Galliprant
(grapiprant)
To control pain and inflammation associated with osteoarthritis in dogs.Dogs
Onsior™
(robenacoxib)
To control postoperative pain and inflammation associated with soft tissue surgery in dogs weighing at least 5.5 lbs. and 4 months of age or older and control postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy and castration in cats weighing at least 5.5 lbs. and 6 months of age or older; for up to a maximum of 3 days.Cats, Dogs
Osurnia(1)
(terbinafine +
florfenicol +
betamethasone
acetate)
To treat otitis externa in dogs associated with susceptible strains of bacteria (Staphylococcus pseudintermedius) and yeast (Malassezia pachydermatis).
Dogs
Entyce
(capromorelin)
To stimulate appetite in dogs.Dogs
Nocita
(bupivacaine liposome)
Local anesthetic to provide up to 72 hours of post-operative pain relief following cranial cruciate ligament surgery in dogs and onychectomy in cats.Cats, Dogs
(1) In January 2020, we announced our plan to divest Osurnia in connection with the pending acquisition of the animal health business of Bayer.
10

FA Future Protein & Health
Primary
ProductDescriptionSpecies
AviPro™
(vaccines)
Includes multiple products that collectively protect against Newcastle disease, infectious bronchitis, fowl cholera, paramyxovirus Type 3, Bursal Disease, other diseases and foodborne pathogens like Salmonella in poultry.Poultry
Clynav
(plasmid deoxyribonucleic acid vaccine)
To immunize Atlantic salmon to reduce impaired daily weight gain, and reduce mortality, and cardiac, pancreatic and skeletal muscle lesions caused by pancreas disease following infection with salmonid alphavirus subtype 3 (SAV3).Fish (Salmon)
Coban™ / Elancoban™
(monensin)
To aid in the prevention of coccidiosis in broiler and replacement chickens (caused by Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati, and E. maxima), in turkeys (caused by Eimeria adenoeides, E. meleagrimitis and E. gallopavonis) and in growing Bobwhite quail (caused by Eimeria dispersa and E. lettyae). Coban/Elancoban is an animal-only antibiotic and an ionophore.
Poultry
Hemicell
(endo-1, 4-â-mannanase)
Enzyme supplement for poultry and swine feeds that contain a source of â-mannanase, which hydrolyses the â-mannans present in soybean and corn meal.
Poultry, Swine
Imvixa
(lufenuron)
To prevent and control infestation caused by sea lice, Caligus reogercresseyi, in farmed salmon.
Fish (Salmon)
Maxiban
(narasin +
nicarbazin)
To prevent coccidiosis in broiler chickens caused by Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati and E. maxima. Maxiban is an animal-only antibiotic and an ionophore.
Poultry
Monteban™
(narasin)
To prevent coccidiosis in broiler chickens caused by Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati and E. maxima. Monteban is an animal-only antibiotic and an ionophore.
Poultry
Surmax™ / Maxus™ / Inteprity
(avilamycin)
To prevent mortality caused by necrotic enteritis associated with Clostridium perfringens in broiler chickens. Surmax, Maxis and Inteprity are animal-only antibiotics.
Poultry
11

FA Ruminants & Swine
Primary
ProductDescriptionSpecies
Denagard
(tiamulin)
To treat Swine Dysentery associated with Serpulina hyodysenteriae susceptible to tiamulin and for treatment of swine bacterial enteritis caused by Escherichia coli and Salmonella choleraesuis sensitive to chlortetracycline and treatment of bacterial pneumonia caused by Pasteurella multocida sensitive to chlortetracycline. Denagard is a shared-class antibiotic.
Swine
Pulmotil™
(tilmicosin)
For swine: To control swine respiratory disease associated with Actinobacillus pleuropneumoniae and Pasteurella multocida.
For cattle: To control bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni in groups of beef and non-lactating dairy cattle, where active BRD has been diagnosed in at least 10% of the animals in the group. Pulmotil is a shared-class antibiotic.
Cattle, Swine
Rumensin
(monensin)
For cattle fed in confinement for slaughter: To improve feed efficiency and prevent and control coccidiosis due to Eimeria bovis and Eimeria zuernii.
For dairy cows: To increase milk production efficiency (production of marketable solids-corrected milk per unit of feed intake).
Cattle
For growing cattle on pasture or in dry lot (stocker and feeder and dairy and beef replacement heifers): To increase rate of weight gain and to prevent and control coccidiosis due to Eimeria bovis and Eimeria zuernii.
For mature reproducing beef cows: To improve feed efficiency when receiving supplemental feed and to prevent and control coccidiosis due to Eimeria bovis and Eimeria zuernii.
For goats: To prevent coccidiosis due to Eimeria crandallis, Eimeria christenseni and Eimeria ninakohlyakimovae in goats maintained in confinement.
For calves (excluding veal calves): To prevent and control coccidiosis due to Eimeria bovis and Eimeria zuernii.
Rumensin is an animal-only antibiotic and an ionophore.
Tylan™ Premix
(tylosin phosphate)
To control porcine proliferative enteropathies associated with Lawsonia intracellularis and to control porcine proliferative enteropathies associated with Lawsonia intracellularis immediately after medicating with Tylan Soluble (tylosin tartrate) in drinking water. Tylan Premix is a shared-class antibiotic.
Swine, Cattle, Poultry
Vira Shield™
(vaccines)
Includes multiple products that protect against infection, bovine rhinotracheitis, bovine viral diarrhea, bovine respiratory syncytial virus, bovine respiratory disease, leptospira canicola and other diseases in cattle.Cattle
Antibiotics
Antimicrobial resistance in humans, or the risk that bacterial pathogens that cause infectious disease in humans evolve or otherwise emerge that are resistant to antibiotics or other antimicrobials, is a significant health concern, and animal agriculture can play a role in mitigating this risk. As a company dedicated to the health and well-being of animals, we seek to help veterinarians and farmers responsibly use antibiotics when treating animals. In our efforts to address antibiotic resistance while protecting animal health, we introduced a global antibiotic stewardship plan focused on increasing responsible antibiotic use; reducing the need for shared-class antibiotics; and replacing
12

antibiotics with alternatives to help livestock producers treat and prevent animal disease. Antibiotics, used responsibly, along with good animal care practices, help enhance food safety and animal well-being.
There are two classes of antibiotics used in animal health:
Animal-only antibiotics and ionophores: Not all pathogens that cause disease in animals are infectious in humans, and accordingly animal-only antibiotics are not used in human medicine (i.e., not medically important). Ionophores are a special class of animal-only antimicrobials uniquely developed only for use in animals. In Europe and certain other jurisdictions, ionophores are not currently classified as antibiotics. Because of their animal-only designation, mode of action, and spectrum of activity, their use is not considered to create the same risk of resistance in human pathogens.
Shared-class antibiotics: These are used in both humans and animals. Some antibiotics are used to treat infectious disease caused by pathogens that occur in both humans and animals. Of the 18 major antibiotic resistance threats that the Centers for Disease Control and Prevention tracks, two are associated with infectious disease in animals. As part of our global antibiotic stewardship plan and in compliance with the U.S. Food & Drug Administration (FDA) guidance, shared-class antibiotics are labeled only for the treatment of an established need in animals and only with veterinarian oversight.
We have intentionally shifted away from shared-class antibiotics, and are focusing on animal-only antibiotics, as well as antibiotic-free solutions. In 2019, 11% of our revenue was from products classified as shared-class antibiotics (4% from sales in the U.S. and 7% from sales outside the U.S.), which is down from 16% in 2015. Revenue from animal-only antibiotics and ionophores represented 24% of our total revenue in 2019 (21% from ionophores), which is up from 23% in 2015. Through our policies and efforts in this area, we seek to protect the benefits of antibiotics in human medicine, while responsibly protecting the health of food animals and the safety of our food supply.
Sales and Marketing
Our sales organization includes sales representatives, veterinary consultants and other value added specialists. In markets where we do not have a direct commercial presence, we generally contract with distributors that provide logistics and sales and marketing support for our products.
Our sales representatives visit our customers, including consultants, veterinarians, food animal producers, and resellers, to inform, promote and sell our products and to support customers. Our veterinary consultants are available to provide scientific consulting focused on disease management and herd management, training and education on diverse topics, including responsible product use, and generally have advanced degrees in veterinary medicine, veterinary nutrition or other agriculture-related fields. These direct relationships with customers allow us to understand their needs. Additionally, our sales representatives and veterinary consultants focus on collaborating with our customers to educate and support them on topics such as local disease awareness and to help them adopt new and more sophisticated animal health solutions, including through the use of our products. As a result of these relationships, our sales and consulting visits provide us with access to customer decision makers. In addition, our sales and marketing organization provides enhanced value by providing support to food animal producers to help maximize their yields and reduce costs. Our analytics help customers analyze large amounts of health and production data. As of December 31, 2019, we had approximately 1,425 sales representatives.
Customers
We primarily sell our food animal products to third-party distributors and directly to a diverse set of food animal producers, including beef and dairy farmers as well as pork, poultry and aquaculture operations. We primarily sell our companion animal products to third-party distributors, as well as directly to veterinarians that typically then sell our products to pet owners. We are also expanding into retail channels in order to meet pet owners where they want to purchase. Our largest customer, an affiliate of AmerisourceBergen Corp., is a third-party veterinary distributor and represented approximately 13% of our revenue for the year ended December 31, 2019. Our next two largest customers represented approximately 7% and 6% of our revenue for the year ended December 31, 2019. No other customer represented more than 5% of our revenue for the same period.

13

Research and Development
Our R&D organization is comprised of internal research, global development, global regulatory and external innovation collaborations and venture investing. As of December 31, 2019, we employed approximately 765 employees in our global R&D and Regulatory Affairs organizations. Our R&D headquarters is located in Greenfield, Indiana. We have R&D facilities in Basel, Switzerland; and Yarrandoo, Australia and R&D facilities co-located with manufacturing sites in Fort Dodge, Iowa; and Cuxhaven, Germany. Additional R&D operations are located in Sao Paulo, Brazil; Shanghai, China; and Bangalore, India. We incurred R&D expenses of $270.1 million in 2019, $246.6 million in 2018 and $251.7 million in 2017.
New product innovation is a core part of our business strategy. Our R&D investment is focused on projects that target novel product introductions, as well as new indications, presentations, combinations and species expansion. Our approach is a build, buy, or ally strategy to develop compelling targets and concepts that originate from our scientists and innovators, academia, agribusiness, or human pharmaceutical and biotechnology at all stages of R&D. The ability to source our concepts from different areas allows us to create a pipeline that can be competitive in the categories in which we have chosen to compete, while reducing our risk by not owning and funding all aspects of our R&D projects.
We seek to concentrate our resources in areas where we believe the science and our capabilities best match the opportunities in the animal health market. Specifically, our R&D focuses on six areas across companion animals and food animals. For companion animals, we have R&D activities in therapeutics, vaccines and parasiticides, while in food animals we are pursuing pharmaceuticals, vaccines and nutritional health.
Our R&D efforts consist of more than 100 active programs balanced across species and technology platforms. For both food animals and companion animals, we apply both large and small molecule approaches. In vaccines, our efforts encompass a full range of modified live, inactivated and nucleic acid strategies. In nutritional health, we focus on products based on enzymes, probiotics, prebiotics and other approaches that modulate biological activity in the animal digestive tract. Additionally, we employ various delivery strategies for products including in-feed, injectable, oral and topical formulations developed in conjunction with our manufacturing team to assure production that maximizes the capabilities within our internal and external manufacturing network.
We engage in licensing and business development to acquire assets for our pipeline and new R&D platforms and to establish strategic R&D collaborations. We make and maintain capital investments in venture capital vehicles that focus on agribusiness and animal health, and we engage in risk sharing collaborations to expand our external capital sources to augment internal investments. To support collaborations with innovation sources focused on human health we have developed capabilities to conduct translational comparative medical research trials in animals with naturally occurring conditions in animals that mimic a human disease or disorder. This type of collaboration de-risks unproven or less well-validated human hypotheses while potentially defining a clinically validated new approach in veterinary medicine.
Our R&D and commercial leadership allocate R&D investment annually with the goal of aligning near and long-term strategic opportunities and objectives. Portfolio investment decisions are made based on the probability of technical success and regulatory approval, timing of approval/launch and earlier milestones, feasibility and cost of development and manufacturing, intellectual property protection and market attractiveness/commercial forecast. R&D projects are supported by pharmaceutical project management approaches and we aim for all of our supporting R&D functional capabilities and capacities to be managed and matched to the evolving demands of the pipeline. We believe this overall R&D management system has enabled us to consistently gain product approvals while maintaining clear visibility to pipeline breadth and depth to support sustained launches into the future.
Manufacturing and Supply Chain
Prior to the separation, our products were manufactured at both sites operated by us and sites operated by third-party contract manufacturing organizations (CMOs).
14

We own and operate 12 internal manufacturing sites, four of which focus on vaccines, six of which focus on other animal health products and two of which are regional sites that focus on packaging:
SiteLocationSiteLocation
ClintonIndiana, U.S.Prince Edward IslandCanada
SpekeLiverpool, U.K.WinslowMaine, U.S.
Kansas CityKansas, U.S.Fort DodgeIowa, U.S.
HuningueFranceCuxhavenGermany
WusiChinaChungliTaiwan
Terre HauteIndiana, U.S.BarueriBrazil

We will continue to manufacture one product, human growth hormone, for Lilly at one of these sites until the end of 2020.
Our global manufacturing and supply chain is also supported by a network of CMOs. As of December 31, 2019, this network was comprised of approximately 90 CMOs. Our external manufacturing network centrally governs our global CMO relationships and provides oversight to these CMOs through four hubs.
We select CMOs based on several factors: (i) their ability to reliably supply products or materials that meet our quality standards at an optimized cost; (ii) their access to specialty products and technologies; (iii) capacity; and (iv) financial analyses. Our External Manufacturing Network seeks to ensure that all of the CMOs we use adhere to our standards of manufacturing quality.
We purchase certain raw materials necessary for the commercial production of our products from a variety of third-party suppliers. We utilize logistics service providers as a part of our global supply chain, primarily for shipping and logistics support.
We intend to continue our efficiency improvement programs in our manufacturing and supply chain organization. We have strong globally managed and coordinated quality control and quality assurance programs in place at all internal manufacturing sites and external manufacturing hubs, and we regularly inspect and audit our internal sites and CMO locations.
Competition
We face intense competition in the sectors and regions on which we focus. Principal methods of competition vary depending on the particular region, species, product category, or individual product. Some of these methods include new product development, quality, price, service and promotion.
Our primary competitors include animal health medicines and vaccines companies such as Zoetis Inc.; Boehringer Ingelheim Vetmedica, Inc., the animal health division of Boehringer Ingelheim GmbH; Merck Animal Health, the animal health division of Merck & Co., Inc.; and the animal health business of Bayer. In August 2019, we entered into an agreement to acquire the animal health business of Bayer (see Note 6: Acquisitions to our consolidated and combined financial statements). We also face competition globally from manufacturers of generic drugs, as well as from producers of nutritional health products, such as DSM Nutritional Products AG and Danisco Animal Nutrition, the animal health division of E.I. du Pont de Nemours and Company, a subsidiary of DowDuPont, Inc. There are also several new start-up companies working in the animal health area. In addition, we compete with numerous other producers of animal health products throughout the world.
Intellectual Property
Our technology, brands and other intellectual property are important elements of our business. We rely on patent, trademark, copyright and trade secret laws, as well as regulatory exclusivity periods and non-disclosure agreements to protect our intellectual property rights. Our policy is to vigorously protect, enforce and defend our rights to our intellectual property, as appropriate.
15

Our product portfolio and certain product candidates enjoy the protection of approximately 3,000 patents and applications, filed in over 50 countries, with concentration in our major market countries as well as other countries with strong patent systems, such as Australia, Brazil, Canada, Europe, Japan and the U.S. Many of the patents and patent applications in our portfolio are the result of our own work, while other patents and patent applications in our portfolio were at least partially developed, and licensed to us, by third parties. A subset of our current products or product candidates are covered by patents and patent applications in our portfolio.
Patents for individual products expire at different times based on the date of the patent filing (or sometimes the date of patent grant) and the legal term of patents in the countries where such patents are obtained. For example, Galliprant’s active ingredient, grapiprant, is encompassed by both compound and physical form patents in the U.S., Europe, Canada and other key markets, with terms that expire between October 2021 and March 2026. Various formulation and method of use patents encompass the spinosad pesticide products, Comfortis and Trifexis. The Comfortis formulation patent extends through August 2020 in the U.S., Canada and Australia, and, upon grant of applicable supplementing protection certificate (SPC), through August 2025 in Europe. The Trifexis formulation and method of use patents extend through September 2021 in the U.S., Canada and Australia, and, upon grant of applicable SPC, through September 2026 in Europe. We typically maintain all of our patents and assert our patent rights against third parties as appropriate.
Additionally, many of our vaccine products, including the Duramune family of vaccines, are based on proprietary or patented master seeds and formulations. We actively seek to protect our proprietary information, including our trade secrets and proprietary know-how, through a variety of means including by seeking to require our employees, consultants, advisors and partners to enter into confidentiality agreements and other arrangements upon the commencement of their employment or engagement.
In order to facilitate the Separation and allow Lilly's and our operations to continue with minimal interruption, Lilly licensed to us the right to use certain intellectual property rights in the animal health field. In addition, Lilly granted us a transitional license to use certain of Lilly’s trademarks for a period of time following the IPO.
We seek to file and maintain trademarks around the world based on commercial activities in most regions where we have, or desire to have, a business presence for a particular product. We currently maintain more than 9,000 trademark applications and registrations in major regions, primarily identifying products dedicated to the care of livestock and companion animals.
Regulatory
The sale of animal health products is governed by the laws and regulations specific to each country in which we sell our products. To maintain compliance with these regulatory requirements, we have established processes, systems and dedicated resources with end-to-end involvement from product concept to launch and maintenance in the market. Our regulatory function actively seeks to engage in dialogue with various global agencies regarding their policies that relate to animal health products. In the majority of our markets, the relevant health authority is separate from those governing human medicinal products.
United States
U.S. Food and Drug Administration. The regulatory body that is responsible for the regulation of animal health pharmaceuticals in the U.S. is the Center for Veterinary Medicine (CVM), a division of the FDA. All manufacturers of animal health pharmaceuticals must demonstrate their products to be safe, effective and produced by a consistent method of manufacture as defined under the Federal Food, Drug and Cosmetic Act (FFDCA). The FDA’s basis for approving a new animal drug application is documented in a Freedom of Information Summary. Post-approval monitoring of products is required by law, with reports being provided to the CVM’s Office of Surveillance and Compliance. Reports of product quality defects, adverse events or unexpected results are maintained and submitted in accordance with the law. Additionally, as part of the drug experience report, we are required to submit all new information pertaining to the safety or effectiveness of a product, regardless of the source.
U.S. Department of Agriculture. The regulatory body in the U.S. for veterinary biologicals is the U.S. Department of Agriculture (USDA). The Center for Veterinary Biologics within the Animal and Plant Health Inspection Service in the USDA is responsible for the regulation of animal health biologicals, which includes but is not limited to vaccines, bacterins, allergens, antibodies, antitoxins, toxoids, immunostimulants, certain cytokines, antigenic or immunizing components of live microorganisms, and diagnostic components of natural or synthetic origin, or that are derived
16

from synthesizing or altering various substances or components of substances such as microorganisms, genes or genetic sequences, carbohydrates, proteins, antigens, allergens or antibodies. All manufacturers of animal health biologicals must show their products to be pure, safe, effective and produced by a consistent method of manufacture as defined under the Virus Serum Toxin Act. Post-approval monitoring of products is required. Reports of product quality defects, adverse events or unexpected results are maintained and submitted in accordance with the agency requirements.
Environmental Protection Agency. The main regulatory body in the U.S. for veterinary pesticides is the Environmental Protection Agency (EPA). The EPA’s Office of Pesticide Programs is responsible for the regulation of most pesticide products applied to animals in accordance with a memorandum of understanding between the FDA and EPA for products that are subject to regulation under both the FFDCA and the Federal Insecticide, Fungicide and Rodenticide Act. All manufacturers of animal health pesticides must show their products will not cause unreasonable adverse effects to man or the environment as stated in the act. Within the U.S., individual state pesticide authorities must, before distribution in that state, also approve pesticide products that are approved by the EPA. Post-approval monitoring of products is required, with reports provided to the EPA and some state regulatory agencies.
Food Safety Inspection Service. The FDA is authorized to determine the safety of substances (including “generally recognized as safe” substances, food additives and color additives), as well as prescribe their safe conditions of use. However, although the FDA has the responsibility for determining the safety of substances, the Food Safety and Inspection Service, the public health agency in the USDA, still retains, under the tenets of the Federal Meat Inspection Act and the Poultry Products Inspection Act and their implementing regulations, the authority to determine that new substances and new uses of previously approved substances are suitable for use in meat and poultry products.
The Foreign Corrupt Practices Act (FCPA) prohibits U.S. corporations and their representatives from offering, promising, authorizing or making payments to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business abroad. The scope of the FCPA includes interactions with certain healthcare professionals in many countries. Other countries have enacted similar anti-corruption laws and/or regulations. In some countries in which we operate, the pharmaceutical and life sciences industries are exposed to a high risk of corruption associated with sales to healthcare professionals and institutions.
Outside of the United States
European Union (EU). We are governed by the following EU regulatory bodies:
The European Medicines Agency (EMA) is a centralized agency of the EU responsible for the scientific evaluation of Veterinary Medicinal Products (VMP) developed by pharmaceutical companies for use in the EU. The agency has a veterinary review section distinct from the medical review section for human products. The Committee for Veterinary Medicinal Products (CVMP) is responsible for scientific review of the submissions for VMP and Immunological Veterinary Medicinal Products. If the CVMP concludes that all requirements for quality, safety and efficacy are met, it issues a positive opinion that is forwarded to the European Commission, who takes the final decision following the European comitology procedure. The centralized marketing authorization (commission decision) of the European Commission is valid in all of the EU. All countries that are not part of the EU but belong to the European Economic Area (EEA), i.e., Norway, Iceland and Liechtenstein, have been part of the scientific assessment done by the CVMP. These countries issue a national marketing approval in accordance with the Commission decision. A series of regulations, directives, guidelines, EU Pharmacopeia Monographs and other legislation provide the requirements for approval in the EU. In general, these requirements are similar to those in the U.S., requiring demonstrated evidence of purity, safety, efficacy and consistency of manufacturing processes.
If approval is sought for products that either cannot or do not need to follow the centralized procedure, approval can also be achieved by national approval in an EEA country agency. This national authorization can be mutually recognized by other EEA countries/EU member states (Mutual Recognition Procedure). In addition, national and mutual recognition can be done in a combined procedure (Decentralized Procedure).
The European Food Safety Authority (EFSA) is the agency of the EU that provides scientific advice and communicates with respect to existing and emerging risks associated with the food chain. Based on EFSA’s mandate, the agency evaluates applications for feed additives, including enzymes and several nutritionals for animals.
17

The European Chemical Agency (ECHA) is the agency of the EU for the safe use of chemicals. Based on the ECHA’s mandate, the agency conducts the evaluation of biocides for the EU.
In regard to Brexit, the UK formally left the EU on January 31, 2020. A transition period is in effect from February 1, 2020 until December 31, 2020, during which the UK and the EU will negotiate a trade agreement. Post-separation, the UK has indicated it will look to continue working closely with the EMA, and that existing agreements between the EMA and other countries such as Switzerland, the U.S. and Canada provide a precedent on which the UK could build.
Brazil. The Ministry of Agriculture, Livestock Production and Supply (MAPA) is the regulatory body in Brazil that is responsible for the regulation and control of pharmaceuticals, biologicals and medicinal feed additives for animal use. MAPA’s regulatory activities are conducted through the Secretary of Agricultural Defense and its Livestock Products Inspection Department. In addition, regulatory activities are conducted at a local level through the Federal Agriculture Superintendence. These activities include the inspection and licensing of both manufacturing and commercial establishments for veterinary products, as well as the submission, review and approval of pharmaceuticals, biologicals and medicinal feed additives. MAPA is one of the most active regulatory agencies in Latin America, having permanent seats at several international animal health forums, such as Codex Alimentarius, World Organization for Animal Health and Committee of Veterinary Medicines for the Americas. MAPA was also recently invited to be a Latin American representative at International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH) meetings. Several normative instructions issued by MAPA have set regulatory trends in Latin America.
Japan. The Ministry of Agriculture, Forestry and Fishery (MAFF) is the regulatory body in Japan that is responsible for the regulation and control of pharmaceuticals (including biologicals and pesticide/disinfectant) and feed additive/feed for animal use. MAFF’s regulatory activities are conducted through the Livestock & Aquaculture Product Safety Control Division under Consumer Safety Bureau. The animal drug reviews and approvals, reexamination reviews, GxP compliance checks, GxP site inspections and product assay checks (including vaccine national assays) are done by National Veterinary Assay Laboratory (NVAL). MAFF coordinates with other agencies such as Ministry of Health, Labor and Welfare (MHLW) and Food Safety Commission (FSC) to perform various license compliance checks (e.g. marketing authorization holder, manufacturer and oversea site accreditation) and ensure good promotional activities. Routine inspections, antimicrobial feed additive national assays and manufacturing inspections are done by the Food & Agriculture Material Inspection Center. For food animal products, animal drug review is done by NVAL but the human food safety review is done by FSC (ADI establishment and antimicrobial risk assessment) and MHLW (MRL establishment). These three agencies (NVAL, FSC and MHLW) work together to approve food animal products. In addition to those central government agencies, various licenses are delegated to the local municipal government, such as animal drug wholesaler and retailer licenses and feed additive distributor licenses.
China. The Ministry of Agriculture (MOA) is the regulatory body that is responsible for the regulation and control of pharmaceuticals, biologicals, disinfectants, medicinal feed additives, pesticide and feed/feed additives for animal use. There are three organizations under the MOA that regulate animal health:
The Institute of Veterinary Drug Control is responsible for the evaluation of new applications, renewals, variations, manufacturers, quality methods and tissue residue methods for pharmaceuticals, biologicals, disinfectants and medicinal feed additives.
The feed/feed additive office is responsible for the registration and renewal of feed and feed additives.
The pesticide bureau is responsible for the registration and renewal of pesticide products.
Australia. The Australian Pesticides and Veterinary Medicines Authority (APVMA) is an Australian government statutory authority established in 1993 to centralize the registration of all agricultural and veterinary products into the Australian marketplace. Previously, each state and territory government had its own system of registration. The APVMA assesses applications from companies and individuals seeking registration so they can supply their product to the marketplace. Applications undergo rigorous assessment using the expertise of the APVMA’s scientific staff and drawing on the technical knowledge of other relevant scientific organizations, Commonwealth government departments and state agriculture departments. If the product works as intended and the scientific data confirms that when used as directed on the product label it will have no harmful or unintended effects on people, animals, the environment or international trade, the APVMA will register the product. As well as registering new agricultural and veterinary products, the APVMA reviews older products that have been on the market for a substantial period of
18

time to ensure they still do the job users expect and are safe to use. The APVMA also reviews registered products when particular concerns are raised about their safety and effectiveness. The review of a product may result in confirmation of its registration or it may see registration continue with some changes to the way the product can be used. In some cases, the review may result in the registration of a product being cancelled and the product taken off the market.
Rest of world. Country-specific regulatory laws typically have provisions that include requirements for certain labeling, safety, efficacy and manufacturers’ quality control procedures (to assure the consistency of the products), as well as company records and reports. Other countries’ regulatory agencies typically either refer to the FDA, USDA, EU and other international animal health entities, including the World Organization for Animal Health, Codex Alimentarius or VICH (see below), in establishing standards and regulations for veterinary pharmaceuticals and vaccines, or review the quality, safety and effectiveness of the products themselves according to their own national requirements.
Global policy and guidance
Joint FAO/WHO Expert Committee on Food Additives. The Joint FAO/WHO Expert Committee on Food Additives is an international expert scientific committee that is administered jointly by the Food and Agriculture Organization of the United Nations (FAO) and the World Health Organization (WHO). They provide a risk assessment/safety evaluation of residues of veterinary drugs in animal products, exposure and residue definition and maximum residue limit proposals for veterinary drugs. Similarly, the Joint FAO/WHO Meeting on Pesticide Residues (JMPR) is an international expert scientific group administered jointly by the FAO and WHO. JMPR reviews residues and analytical aspects of the pesticides, estimate the maximum residue levels, review toxicological data and estimate acceptable daily intakes for humans of the pesticides under consideration. Elanco works with these committees to establish acceptable safe levels of residual product in food-producing animals after treatment with veterinary drugs or pesticides. This in turn enables the calculation of appropriate withdrawal times for our products prior to an animal entering the food chain.
Advertising and promotion review. Promotion of ethical animal health products is controlled by regulations in many countries. These rules generally restrict advertising and promotion to those claims and uses that have been reviewed and endorsed by the applicable agency. We conduct a review of promotion material for compliance with the local and regional requirements in the markets where we sell animal health products.
Import and Export of Products. The importation and exportation of animal health products is controlled by regulations in many countries. In some jurisdictions this may include obtaining separate permits or licenses by product or by company or filing notices with applicable regulatory agencies prior to import or export of product. We ensure compliance with local and global regulations in the markets where we import/export our animal health products.
International Cooperation on Harmonization of Technical Requirements for Registration of Veterinary Medicinal Products. VICH is a trilateral (EU-Japan-USA) program launched in 1996 aimed at harmonizing technical requirements for veterinary product registration. Several other countries have obtained observer status, for example, Canada, New Zealand, Australia and South Africa, or are linked to VICH on basis of the VICH Outreach Forum, a VICH initiative with the main objective of providing a basis for wider international harmonization of technical requirements. In addition, the World Organization for Animal Health is an associate member of VICH.
The objectives of the VICH are as follows:
Establish and implement harmonized technical requirements for the registration of veterinary medicinal products in the VICH regions, which meet high quality, safety and efficacy standards and minimize the use of test animals and costs of product development.
Provide a basis for wider international harmonization of registration requirements through the VICH Outreach Forum.
Monitor and maintain existing VICH guidelines, taking particular note of the ICH work program and, where necessary, update these VICH guidelines.
Ensure efficient processes for maintaining and monitoring consistent interpretation of data requirements following the implementation of VICH guidelines.
19

By means of a constructive dialogue between regulatory authorities and industry, provide technical guidance enabling response to significant emerging global issues and science that impact regulatory requirements within the VICH regions.
Employees
As of December 31, 2019, we employed approximately 5,760 full time employees. In addition, we employed approximately 320 fixed-duration employees, which are individuals hired for a pre-defined length of time (one to four years). Together, they total approximately 6,080 worldwide. Of the 6,080 employees globally, approximately 2,560 are U.S.-based and approximately 3,520 are employed in other jurisdictions. Some of these employees are members of unions, works councils, trade associations or are otherwise subject to collective bargaining agreements, including approximately 150 union employees in the U.S. located at our Fort Dodge, Iowa manufacturing/R&D facility. Approximately 40% of our global population is in customer-facing roles, including but not limited to, traditional sales roles, technical consultants, account managers and commercial and general managers.
Environmental, Health and Safety
We are subject to various federal, state, local and foreign environmental, health and safety (EHS) laws and regulations. These laws and regulations govern matters such as the emission and discharge of hazardous materials into the ground, air or water; the generation, use, storage, handling, treatment, packaging, transportation, exposure to, and disposal of hazardous and biological materials, including recordkeeping, reporting and registration requirements; and the health and safety of our employees. Due to our operations, these laws and regulations also require us to obtain, and comply with, permits, registrations or other authorizations issued by governmental authorities. These authorities can modify or revoke our permits, registrations or other authorizations and can enforce compliance through fines and injunctions.
Certain environmental laws impose joint and several liability, without regard to fault, for cleanup costs on persons who have disposed of or released hazardous substances into the environment, including at third-party sites or offsite disposal locations, or that currently own or operate (or formerly owned or operated) sites where such a release occurred. We could be subject to liability for the investigation and remediation of legacy environmental contamination caused by historical industrial activity at sites that we own or on which we operate. In addition to clean-up actions brought by federal, state, local and foreign governmental entities, private parties could raise personal injury or other claims against us due to the presence of, or exposure to, hazardous materials on, from or otherwise relating to such a property.
We have made, and intend to continue to make, necessary expenditures for compliance with applicable EHS laws and regulations. We are also monitoring and investigating environmental contamination from past industrial activity at certain sites. As a result, we incurred capital and operational expenditures in 2019 for environmental compliance purposes and for the clean-up of certain past industrial activities. Environmental-related capital expenditures and other environmental-related expenditures were $0.0 million and $0.2 million in 2019, respectively.
In connection with past divestitures, we have undertaken certain indemnification obligations that may require us in the future, to conduct or finance environmental cleanups at sites that we no longer own or operate. In connection with certain of our acquisitions, we have also entered into indemnification agreements pursuant which we are or may be indemnified for various environmental cleanups; however, such indemnities are limited in both time and scope and may be further limited in the presence of new information, or may not be available at all.
Legal Proceedings
We are from time to time subject to claims and litigation arising in the ordinary course of business. These claims and litigation may include, among other things, allegations of violation of U.S. and foreign competition law, labor laws, consumer protection laws and environmental laws and regulations, as well as claims or litigation relating to product liability, intellectual property, securities, breach of contract and tort. We operate in multiple jurisdictions and, as a result, a claim in one jurisdiction may lead to claims or regulatory penalties in other jurisdictions. We intend to vigorously defend against any pending or future claims and litigation, as appropriate.
At this time, in the opinion of our management, the likelihood is remote that the impact of any such proceedings, either individually or in the aggregate, would have a material adverse effect on our consolidated results of operations, financial condition or cash flows. However, one or more unfavorable outcomes in any claim or litigation
20

against us could have a material adverse effect for the period in which they are resolved. In addition, regardless of their merits or their ultimate outcomes, such matters are costly, divert management’s attention and may materially adversely affect our reputation, even if resolved in our favor.
Available Information
Our website address is www.elanco.com. On our website, we make available, free of charge, our annual, quarterly and current reports, including amendments to such reports, as soon as reasonably practicable after we electronically file such material with, or furnish such material to, the SEC.
Information relating to corporate governance at Elanco, including our Corporate Governance Guidelines, Code of Conduct, Financial Code of Ethics, Articles of Incorporation, Bylaws, Committee Charters; information concerning our executive officers and members of our board of directors; and ways to communicate are available on our website. We will provide any of the foregoing information without charge upon written request to Elanco’s Corporate Secretary, Elanco, 2500 Innovation Way, Greenfield, Indiana 46140. Information relating to shareholder services is also available on our website.
Information contained on our website is not part of, or incorporated by reference, in this Annual Report on Form 10-K.
21

Item 1A. Risk Factors
Our business, financial condition and results of operations are subject to various risks, including but not limited to the risks described below. If any of such risks actually materializes, our business, financial condition and results of operations could be materially adversely affected.
Risks Related to Elanco
The animal health industry is highly competitive.
The animal health industry is highly competitive. Our competitors include standalone animal health businesses, the animal health businesses of large pharmaceutical companies, specialty animal health businesses and companies that mainly produce generic products. We believe many of our competitors are conducting R&D activities in areas served by our products and in areas in which we are developing products. Several new start-up companies also compete in the animal health industry. We also face competition from manufacturers of drugs globally, as well as producers of nutritional health products. These competitors may have access to greater financial, marketing, technical and other resources. As a result, they may be able to devote more resources to developing, manufacturing, marketing and selling their products, initiating or withstanding substantial price competition or more readily taking advantage of acquisitions or other opportunities. Further, consolidation in the animal health industry could result in existing competitors realizing additional efficiencies or improving portfolio bundling opportunities, thereby potentially increasing their market share and pricing power, which could lead to a decrease in our revenue and profitability and an increase in competition. For example, many of our competitors have relationships with key distributors and, because of their size, the ability to offer attractive pricing incentives, which may negatively impact or hinder our relationships with these distributors. In addition to competition from established market participants, new entrants to the animal health medicines and vaccines industry could substantially reduce our market share, render our products obsolete or disrupt our business model.
To the extent that any of our competitors are more successful with respect to any key competitive factor, or we are forced to reduce, or are unable to raise, the price of any of our products in order to remain competitive, our business, financial condition and results of operations could be materially adversely affected. Competitive pressure could arise from, among other things, more favorable safety and efficacy product profiles, limited demand growth or a significant number of additional competitive products being introduced into a particular market, price reductions by competitors, the ability of competitors to capitalize on their economies of scale, the ability of competitors to produce or otherwise procure animal health products at lower costs than us and the ability of competitors to access more or newer technology than us.
Disruptive innovation and advances in veterinary medical practices, animal health technologies and alternatives to animal-derived protein, could negatively affect the market for our products.
The markets for our products are regularly impacted by the introduction and/or broad market acceptance of newly-developed or alternative products that address the diseases and conditions for which we sell products, including “green” or “holistic” health products, specially bred disease-resistant animals or replacements for meat, milk, eggs or fish from alternative natural or synthetic sources. For example, the market for our companion animal therapeutics has been particularly affected by innovation in new molecules and delivery formulations in recent years. Technological breakthroughs by others may render obsolete our products and reduce or eliminate the market for our products. Introduction or acceptance of competing animal health products and innovation or disruptive protein alternatives could materially adversely affect our business, financial condition and results of operations.
Regulatory restrictions and bans on the use of antibiotics and productivity products in food animals, as well as changing market demand, may continue to negatively affect demand for certain of our food animal products.
Over the past few years, our operational results have been, and will continue to be, affected by regulations and changing market demand. In certain markets, including the U.S., sales of certain of our food animal products have been negatively affected by an increase in consumer sentiment for proteins and dairy products produced without the use of antibiotics or other products intended to increase animal production.
22

There are two classes of antibiotics used in animal health: shared-class, or medically important, antibiotics, which are used to treat infectious disease caused by pathogens that occur in both humans and animals; and animal-only antibiotics, which are used to treat infectious disease caused by pathogens that occur in animals only. See “Business of Elanco - Products - Antibiotics.” Concerns that the use of antibiotics in food animal production may lead to increased antibiotic resistance of human pathogens have resulted in increased regulation and changing market demand. In December 2013, the FDA announced final guidance establishing procedures for the voluntary phase-out in the U.S. over a three-year period of the use of shared-class antibiotics in animal feed or water for growth promotion in food animal production. The guidance allows for continued use of shared-class antibiotics in food-producing animals under the supervision of a veterinarian for treatment, control and, under certain circumstances, for prevention of disease. The FDA indicated that it took this action to help preserve the efficacy of shared-class antibiotics to treat infections in humans. As part of those efforts, stricter guidelines governing the administration of shared-class antibiotics have recently come into effect. As of January 1, 2017, under the FDA’s guidance and the related rule known as the Veterinary Feed Directive, the use of shared-class antibiotics in the water or feed of food-producing animals requires written authorization by a licensed veterinarian. In addition, other countries in which we sell or plan to sell our products, such as France and Vietnam, have passed restrictions or bans on antibiotic use. Other countries have placed restrictions or bans on the use of specific antibiotics in certain food-producing animals, regardless of the route of administration (in feed or injectable).
From 2015 to 2019, our revenue from shared-class antibiotics declined at a CAGR of 10%, excluding the impact of foreign exchange rates. This was driven primarily by changing regulations in many markets, including the Veterinary Feed Directive, as well as changing market demand and our tiered approach to antibiotic stewardship, which included removing growth promotion from labels and requiring veterinary oversight in the U.S. and other markets. Globally, during 2019, our revenue from shared-class antibiotics declined 13%, excluding the impact of foreign exchange rates, and represented 11% (4% from sales in the U.S. and 7% from sales outside the U.S.) of total revenue, down from 16% in 2015. From 2015 to 2019, our revenue from animal-only antibiotics grew at a CAGR of 4%, excluding the impact of foreign exchange rates, driven by sales outside the U.S., which offset a slight decline in the U.S. Globally, during 2019, our revenue from animal-only antibiotics declined 1%, excluding the impact of foreign exchange rates, and represented 24% of total revenue, up from 23% in 2015. In 2019, 87% of our revenue from animal-only antibiotics resulted from the sale of ionophores. Ionophores are a special class of animal-only antimicrobials, and because of their animal-only designation, mode of action and spectrum of activity, their use has not to date been impacted by regulations or changing market demand in many markets outside of the U.S.
The impact of changes in regulations and market preferences regarding the use of antibiotics in food animals could have a material adverse effect on our business, financial condition and results of operations. If there is an increased public perception that consumption of food derived from animals that utilize our products poses a risk to human health, there may be a further decline in the production of those food products and, in turn, demand for our products. In addition, antibiotic resistance concerns will likely result in additional restrictions or bans, expanded regulations or public pressure to further reduce the use of antibiotics in food animals, increased demand for antibiotic-free protein, or changes in the market acceptance or regulatory treatment of ionophores, any of which could materially adversely affect our business, financial condition and results of operations.
In addition, our revenue has been impacted by regulatory changes in China and other markets restricting the use of productivity products, such as those containing ractopamine, in food animals. This has resulted in many U.S. food producers who access such markets eliminating their use of ractopamine. Our FA Ruminants & Swine products Optaflexx™ and Paylean™ contain ractopamine. If more producers decide to access such markets or additional markets restrict the use of ractopamine or other productivity products, our business, financial condition and results of operations could be materially adversely affected.
Generic products may be viewed as more cost-effective than our products.
We face competition from products produced by other companies, including generic alternatives to our products. We depend on patents and regulatory data exclusivity periods to provide us with exclusive marketing rights for some of our products. Patents for individual products expire at different times based on the date of the patent filing (or sometimes the date of patent grant) and the legal term of patents in the jurisdictions where such patents are obtained. The extent of protection afforded by our patents varies from jurisdiction to jurisdiction and is limited by the scope of the claimed subject matter of our patents, the term of the patent and the availability and enforcement of legal remedies in the applicable jurisdiction. In 2019, approximately 67% of our revenue was from products that did not have patent protection, including revenue from some of our top products such as Rumensin, Maxiban, Denagard and Tylan Premix. Other products are protected by patents that expire over the next several years. As the
23

patents for a brand name product expire, competitors may begin to introduce generic or other alternatives, and as a result, we may face competition from lower-priced alternatives to many of our products. For example, we have experienced significant competitive headwinds from generic ractopamine in the U.S. In the third quarter of 2013, a large established animal health company received U.S. approval for generic ractopamine. U.S. revenue from Optaflexx, our ractopamine beef product, has declined at a compound annual growth rate of 21% from 2015 to 2019 as a result of generic competition and international regulatory restrictions. In the third quarter of 2019, an established animal health company received U.S. approval for generic monensin in cattle and goats for certain indications. U.S. revenue from Rumensin, our monensin product, may continue to decline as a result of the generic competition. We may face similar competition in the future for existing products that do not benefit from exclusivity or for existing products with material patents expiring in the future. See “Business of Elanco - Intellectual Property.”
Generic competitors are becoming more aggressive in terms of launching products before patent rights expire, and, because of attractive pricing, sales of generic products are an increasing percentage of overall animal health sales in certain regions. Although the impact of generic competition in the animal health industry to date has not typically mirrored that seen in human health, product pricing and the impact of generic competition in the future may more closely mirror human health as a result of changes in industry dynamics, such as channel expansion, consolidation, an increase in the availability and use of pet insurance and the potential for generic competition by established animal health businesses. If animal health customers increase their use of new or existing generic products, our business, financial condition and results of operations could be materially adversely affected.
We may not successfully implement our business strategies or achieve targeted cost efficiencies and gross margin improvements.
We are pursuing strategic initiatives that management considers critical to our long-term success, including, but not limited to: improving manufacturing processes, reducing our manufacturing footprint, achieving lean initiatives, consolidating our CMO network, strategically insourcing projects, pursuing cost savings opportunities with respect to raw materials through a new procurement process and improving the productivity of our sales force. We may pursue additional strategic initiatives in the future to improve gross margins and achieve our targeted cost efficiencies. We also have acquired or partnered with a number of smaller animal health businesses, and we intend to continue to do so in the future. There are significant risks involved with the execution of these initiatives, including significant business, economic and competitive uncertainties, many of which are outside of our control. Accordingly, we may not succeed in implementing these strategic initiatives. Realizing the anticipated benefits from these initiatives, if any benefits are achieved at all, may take several years. We may be unable to achieve our targeted cost efficiencies and gross margin improvements. Additionally, we may have insufficient access to capital to fund investments in strategic initiatives, or our business strategy may change from time to time, which could delay our ability to implement initiatives that we believe are important to our business.
Consolidation of our customers and distributors could negatively affect the pricing of our products.
Third-party distributors, veterinarians and food animal producers are our primary customers. In recent years, there has been a trend towards the concentration of veterinarians in large clinics and hospitals. In addition, food animal producers, particularly swine and poultry producers, and our distributors have seen recent consolidation in their industries. Furthermore, we have seen the expansion of larger cross-border corporate customers and an increase in the consolidation of buying groups (cooperatives of veterinary practices that leverage volume to pursue discounts from manufacturers). The pace of consolidation and structure of markets varies greatly across geographies. If these trends towards consolidation continue, our customers could attempt to improve their profitability by leveraging their buying power to obtain favorable pricing. The resulting decrease in our prices could have a material adverse effect on our business, financial condition and results of operations.
A general outbreak of infectious disease or viruses or an outbreak of infectious disease carried by food animals could negatively affect the demand for, and sale and production of, our food animal products.
Our global operations expose us to risks associated with public health crises, such as pandemics and epidemics, which could harm our business and have an adverse effect on our results of operations. For example, in December 2019, an outbreak of a new strain of coronavirus in Wuhan, China, has resulted in travel disruption globally and has affected certain companies' operations in China and other countries, including companies with which we do business. At this point, the extent to which the coronavirus may impact our results is uncertain.
24

Sales of our food animal products could be materially adversely affected by a general outbreak of infectious disease or an outbreak of disease carried by food animals, which could lead to the widespread death or precautionary destruction of food animals as well as the reduced consumption and demand for animal protein. In addition, outbreaks of disease carried by food animals may reduce regional or global sales of particular animal-derived food products or result in reduced exports of such products, either due to heightened export restrictions or import prohibitions, which may reduce demand for our food animal products due to reduced herd or flock sizes.
In recent years, outbreaks of various diseases, including African Swine Fever, avian influenza, foot-and-mouth disease, bovine spongiform encephalopathy (otherwise known as BSE or “mad cow” disease) and porcine epidemic diarrhea virus (otherwise known as PEDV) have negatively impacted sales of our animal health products. The discovery of additional cases of any of these, or new, diseases may result in additional restrictions on animal protein, reduced herd or flock sizes, or reduced demand for animal protein, any of which may have a material adverse effect on our business, financial condition and results of operations. In addition, the outbreak of any highly contagious disease near our main production sites could require us to immediately halt production of our products at such sites or force us to incur substantial expenses in procuring raw materials or products elsewhere.
Our R&D, acquisition and licensing efforts may fail to generate new products or expand the use of our existing products.
Our future success depends on both our existing product portfolio and our pipeline of new products, including new products that we may develop through joint ventures and products that we are able to obtain through license or acquisition, including the acquisition of the Bayer animal health business (see Note 6: Acquisitions to our consolidated and combined financial statements). We commit substantial effort, funds and other resources to R&D, both through our own dedicated resources and through collaborations with third parties.
We may be unable to determine with accuracy when or whether any of our products now under development will be approved or launched, or we may be unable to develop, license or otherwise acquire product candidates or products. In addition, we cannot predict whether any products, once launched, will be commercially successful or will achieve sales and revenue that are consistent with our expectations. The animal health industry is subject to regional and local trends and regulations and, as a result, products that are successful in some markets may not achieve similar success when introduced into other markets. Furthermore, the timing and cost of our R&D may increase, and our R&D may become less predictable as, among other things, regulations applicable to our industry may make it more time-consuming and/or costly to research, develop and register products. If we are unable to generate new products or expand the use of our existing products, our business, financial condition and results of operations will be materially adversely affected. For example, between 2015 and 2017, prior to our February 2018 launch of Credelio in the U.S., we experienced an innovation lag in the companion animal parasiticide space. In the absence of a competitive combined oral flea and tick product, our U.S. companion animal parasiticide portfolio revenue declined 15% in 2017, excluding the impact on revenue resulting from a reduction in inventory levels within our distribution channel.
In addition, some of our growth occurred through Lilly’s acquisitions, including Novartis Animal Health, Lohmann Animal Health, Janssen Animal Health and the BI Vetmedica U.S. vaccines portfolio. However, following the Separation, we no longer benefit from Lilly’s scale, capital base and financial strength.
We had losses in recent periods.
We have incurred net losses in recent periods. We could continue to incur asset impairment, restructuring and other special charges and could report losses in the future. We also expect to continue to incur substantial expenditures to develop, manufacture and market our products and implement our business strategies, transaction costs and integration expenses associated with acquisitions, additional amortization of intangible assets, and interest expense. We may encounter unforeseen expenses, difficulties, complications, delays, adverse events and other unknown factors that may materially adversely affect our business.
The misuse or off-label use of our products may harm our reputation or result in financial or other damages.
Our products have been approved for use under specific circumstances for the treatment of certain diseases and conditions in specific species. There may be increased risk of product liability claims if veterinarians, food animal producers, pet owners or others attempt to use our products off-label, including the use of our products in species
25

(including humans) for which they have not been approved. Furthermore, the use of our products for indications other than those for which our products have been approved may not be effective, which could harm our reputation and lead to an increased risk of litigation. If we are deemed by a governmental or regulatory agency to have engaged in the promotion of any of our products for off-label use, such agency could request that we modify our training or promotional materials and practices, and we could be subject to significant fines and penalties, and the imposition of these sanctions could also affect our reputation and position within the industry. Any of these events could materially adversely affect our business, financial condition and results of operations.
Animal health products are subject to unanticipated safety, quality or efficacy concerns, which may harm our reputation.
Unanticipated safety, quality or efficacy concerns arise from time to time with respect to animal health products, whether or not scientifically or clinically supported, leading to product recalls, withdrawals or suspended or declining sales, as well as product liability and other claims.
Regulatory actions based on these types of safety, quality or efficacy concerns could impact all, or a significant portion, of a product’s sales and could, depending on the circumstances, materially adversely affect our results of operations.
In addition, since we depend on positive perceptions of the safety, quality and efficacy of our products, and animal health products generally, by food producers, veterinarians and pet owners, any concern as to the safety, quality or efficacy of our products, whether actual or perceived, may harm our reputation. These concerns and the related harm to our reputation could materially adversely affect our business, financial condition and results of operations, regardless of whether such reports are accurate.
Our business may be negatively affected by weather conditions and the availability of natural resources.
The animal health industry and demand for many of our products in a particular region are affected by weather conditions, varying weather patterns and weather-related pressures from pests, such as ticks. As a result, we may experience regional and seasonal fluctuations in our results of operations.
Food animal producers depend on the availability of natural resources, including large supplies of fresh water. Their animals’ health and their ability to operate could be adversely affected if they experience a shortage of fresh water due to human population growth or floods, droughts or other weather conditions. In the event of adverse weather conditions or a shortage of fresh water, veterinarians or food animal producers may purchase less of our products.
Further, heat waves may cause stress in animals and lead to increased vulnerability to disease, reduced fertility rates and reduced milk production. Droughts may threaten pasture and feed supplies by reducing the quality and amount of forage available to grazing livestock, while climate change may increase the prevalence of parasites and diseases that affect food animals. Adverse weather conditions may also have a material impact on the aquaculture business. Changes in water temperatures could affect the timing of reproduction and growth of various fish species, as well as trigger the outbreak of certain water borne diseases.
In addition, veterinary hospitals and practitioners depend on visits from, and access to, the animals under their care. Veterinarians’ patient volume and ability to operate could be adversely affected if they experience prolonged snow, ice or other severe weather conditions, particularly in regions not accustomed to sustained inclement weather.
We may not be able to realize the expected benefits of our investments in emerging markets and are subject to certain risks due to our presence in emerging markets, including political or economic instability and failure to adequately comply with legal and regulatory requirements.
We have taken steps to increase our presence in select emerging markets, including by expanding our sales organization and product offerings in these markets. The acquisition of the Bayer animal health business is expected to further increase our presence in emerging markets (see Note 6: Acquisitions to our consolidated and combined financial statements). Failure to continue to maintain and expand our business in emerging markets could materially adversely affect our business, financial condition and results of operations.

26

In addition, certain emerging markets have legal systems that are less developed. Other jurisdictions in which we conduct business may have legal and regulatory regimes that differ materially from U.S. laws and regulations, are continuously evolving or do not include sufficient judicial or administrative guidance to interpret such laws and regulations. Compliance with diverse legal requirements is costly and time-consuming and requires significant resources. Violations or possible violations of applicable laws or regulations by our employees may result in investigation costs, potential penalties and other related costs, which in turn could negatively affect our reputation and our results of operations.
Some countries within emerging markets may be especially vulnerable to periods of local, regional or global economic, political or social instability or crisis. For example, our sales in certain emerging markets have suffered from extended periods of disruption due to natural disasters. Furthermore, we have also experienced lower than expected sales in certain emerging markets due to local, regional and global restrictions on banking and commercial activities in those countries. In addition, certain emerging markets have currencies that fluctuate substantially, which may impact our financial performance. For these reasons, among others, doing business within emerging markets carries significant risks.
Modification of foreign trade policy may harm our food animal product customers.
Changes in laws, agreements and policies governing foreign trade in the territories and countries where our customers do business could negatively impact such customers’ businesses and adversely affect our results of operations. A number of our customers, particularly U.S.-based food animal producers, benefit from free trade agreements, such as the North American Free Trade Agreement (NAFTA). In November 2018, the U.S. negotiated a new trade deal with Canada and Mexico known as the United States-Mexico-Canada-Agreement (USMCA), aimed at re-negotiating and updating the terms of NAFTA. The USMCA was revised by the parties on December 10, 2019. The USMCA still requires ratification by Canada before it can take effect. If the USMCA is not ratified and the U.S. were to withdraw from or materially modify NAFTA or other international trade agreements to which it is a party or if the U.S. were to engage in trade disputes or the imposition of tariffs, our customers could be harmed, and as a result, our business, financial condition and results of operations could be materially adversely affected.
Our business is subject to risk based on global economic conditions.
Macroeconomic business and financial disruptions could have a material adverse effect on our business, financial condition and results of operations. Certain of our customers and suppliers could be affected directly by an economic downturn and could face constraints on the availability of credit or decreased cash flow that could give rise to payment delays, increased credit risk, bankruptcies and other financial hardships that could decrease the demand for our products or hinder our ability to collect amounts due from our customers. If one or more of our large customers, including distributors, discontinues or modifies their relationship with us as a result of economic conditions or otherwise, our business, financial condition and results of operations may be materially adversely affected. In addition, economic concerns may cause some pet owners to forgo or defer visits to veterinary practices or could reduce their willingness to treat pet health conditions or to continue to own a pet. Furthermore, our exposure to credit and collectability risk is higher in certain international markets and our ability to mitigate such risks may be limited. Our procedures intended to monitor and limit our exposure to credit and collectability risk may not effectively limit such risk and avoid losses.
Our results of operations are dependent upon the success of our top products.
If any of our top products experience issues, such as disruptive innovations or the introduction of more effective competitive products, negative publicity, changes to veterinarian or customer preferences, loss of patent protection, material product liability litigation, new or unexpected side effects, manufacturing disruptions and/or regulatory proceedings, our revenue could be negatively impacted, perhaps significantly. Our top five products, Rumensin, Trifexis, Maxiban, Denagard and Interceptor Plus, contributed approximately 31% of our revenue in 2019. Any issues with these top products, particularly Rumensin, which contributed approximately 10% of our revenue in 2019 and is now subject to generic competition in the U.S., could have a material adverse effect on our business, financial condition and results of operations.

27

Our business is subject to risk based on customer exposure to rising costs and reduced customer income.
Feed, fuel, transportation and other key costs for food animal producers may increase or animal protein prices or sales may decrease. Either of these trends could cause deterioration in the financial condition of our food animal product customers, potentially inhibiting their ability to purchase our products or pay us for products delivered. Our food animal product customers may offset rising costs by reducing spending on our food animal products, including by switching to lower-cost alternatives to our products. In addition, concerns about the financial resources of pet owners could cause veterinarians to alter their treatment recommendations in favor of lower-cost alternatives to our products, which could result in a decrease in sales of our companion animal products, especially in developed countries where there is a higher rate of pet ownership. Rising costs or reduced income for our customers could have a material adverse effect on our business, financial condition and results of operations.
For our companion animal products, increased use of alternative distribution channels, or changes within existing distribution channels, could negatively impact our market share, margins and distribution of our products.
In most markets, pet owners typically purchase their animal health products directly from veterinarians. However, pet owners increasingly have the option to purchase animal health products from sources other than veterinarians, such as online retailers, “big-box” retail stores or other over-the-counter distribution channels. This trend has been demonstrated by the significant shift away from the veterinarian distribution channel in the sale of flea and tick products in recent years. Pet owners also could decrease their reliance on, and visits to, veterinarians as they rely more on internet-based animal health information. Because we market our companion animal prescription products primarily through the veterinarian distribution channel, any decrease in visits to veterinarians by pet owners could reduce our market share for such products and materially adversely affect our business, financial condition and results of operations. In addition, pet owners may substitute human health products for animal health products if human health products are deemed to be lower-cost alternatives.
Legislation has also been proposed in the U.S., and may be proposed in the U.S. or abroad in the future, that could impact the distribution channels for our companion animal products. For example, such legislation may require veterinarians to provide pet owners with written prescriptions and disclosure that the pet owner may fill prescriptions through a third party, which may further reduce the number of pet owners who purchase their animal health products directly from veterinarians. Such requirements may lead to increased use of generic alternatives to our products or the increased substitution of our companion animal products with other animal health products or human health products if such other products are deemed to be lower-cost alternatives. Many states already have regulations requiring veterinarians to provide prescriptions to pet owners upon request and the American Veterinary Medical Association has long-standing policies in place to encourage this practice.
Over time, these and other competitive conditions may increase our use of online retailers, “big-box” retail stores or other over-the-counter distribution channels to sell our companion animal products. We may not be adequately prepared or able to distribute our companion animal products if an increased portion of our sales occur through these channels. Also, we may realize lower margins on sales through these distribution channels than we do on sales through veterinarians. Any of these events could materially adversely affect our business, financial condition and results of operations.
In addition, if one or more of our companion animal distributors discontinues or modifies their relationship with us, our business, financial condition and results of operations may be materially adversely affected. For example, in 2017, a change in our U.S. inventory management practices resulted in a revenue lag as existing inventory was sold down, which management estimates decreased our revenue by approximately $35 million.
Supply chain continuity could be disrupted by a major catastrophic event or third party quality issue causing a loss of inventory and/or facility that could negatively impact the amount of product sold.

In our business, we have multiple warehouses in the supply chain that have a material amount of inventory. This could create excessive risk if a catastrophic event were to occur at one of these locations. As such, business continuity plans are critical to our manufacturing sites. Additionally, our contracts require that all CMOs and suppliers have business continuity plans. If business continuity plans are not in place, it could result in disruptions in our supply chain. While we work with our CMOs and suppliers to ensure continuity, no assurance can be given that these efforts will be successful. In addition, due to regulatory requirements relating to the qualification of CMOs and suppliers, we may not be able to establish additional or replacement CMOs or suppliers on a timely basis or without
28

excessive cost. The termination, reduction or interruption in our supply chain could adversely impact our ability to produce and sell certain of our products.

Increased or decreased inventory levels at our channel distributors can lead to fluctuations in our revenues and variations in payment terms extended to our distributors can impact our cash flows.

In addition to selling our products directly to veterinarians, we sell to distributors who, in turn, sell our products to third parties. Inventory levels at our distributors may increase or decrease as a result of various factors, including end customer demand, new customer contracts, heightened and generic competition, required minimum inventory levels, our ability to renew distribution contracts with expected terms, our ability to implement commercial strategies, regulatory restrictions, unexpected customer behavior, and procedures and environmental factors beyond our control, including weather conditions or an outbreak of infectious disease carried by food animals such as African Swine Fever. These increases and decreases can lead to variations in our quarterly and annual revenues. In addition, like all companies that manufacture and sell products, we have policies that govern the payment terms that we extend to our customers. Due to consolidation amongst our distributors, as well as changes in the buying habits of end customers or the need for certain inventory levels at our distributors to avoid supply disruptions, from time to time, our distributors have requested exceptions to the payment term policies that we extend to them. Extensions of customer payment terms can impact our cash flows, liquidity and results of operations.

Loss of our executive officers or other key personnel could disrupt our operations.
We depend on the efforts of our executive officers and other key personnel. Our executive officers and other key personnel are not currently, and are not expected to be, subject to non-compete provisions. In addition, we have not entered into employment agreements with our executive officers or other key personnel. Any unplanned turnover or our failure to develop an adequate succession plan for one or more of our executive officers or other key personnel positions could deplete our institutional knowledge base and erode our competitive advantage. The loss or limited availability of the services of one or more of our executive officers or other key personnel, or our inability to recruit and retain qualified executive officers or other key personnel in the future, could, at least temporarily, have a material adverse effect on our business, financial condition and results of operations.
We may be required to write down goodwill or identifiable intangible assets.
Under U.S. GAAP, if we determine goodwill or identifiable intangible assets are impaired, we will be required to write down these assets and record a non-cash impairment charge. As of December 31, 2019, we had recorded on our balance sheet goodwill of $3.0 billion and identifiable intangible assets of $2.5 billion. Identifiable intangible assets consist primarily of marketed products acquired or licensed from third parties, licensed platform technologies that have alternative future uses in R&D, manufacturing technologies, and customer relationships from business combinations. We also have indefinite-lived intangible assets, which consist of acquired in-process R&D projects from business combinations that are subject to impairment and non-cash impairment charges.
Determining whether an impairment exists and the amount of the potential impairment involves quantitative data and qualitative criteria that are based on estimates and assumptions requiring significant management judgment. Future events or new information may change management’s valuation of an intangible asset in a short amount of time. The timing and amount of impairment charges recorded in our consolidated and combined statements of operations and write-downs recorded in our consolidated balance sheets could vary if our management’s conclusions change. Any impairment of goodwill or identifiable intangible assets could have a material adverse effect on our business, financial condition and results of operations.
As a standalone public company, we may expend additional time and resources to comply with rules and regulations that did not previously apply to us, and failure to comply with such rules may lead investors to lose confidence in our financial data.
As a standalone public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act and regulations of the NYSE. Previously, we had established all of the procedures and practices required as a subsidiary of Lilly, but we must continue to implement others as a separate, standalone public company. Continuing to establish and expand such procedures and practices could increase our legal, accounting and financial compliance costs, will make some activities more difficult, time-consuming and costly and could be burdensome on our personnel, systems and resources. We have devoted and are continuing to devote resources to address these public company
29

requirements. As a result, we have and will continue to incur legal, accounting and other expenses that we did not previously incur while a subsidiary of Lilly to comply with these rules and regulations. Furthermore, continuing the need to establish the corporate infrastructure necessary for a standalone public company may divert some of our management’s attention from operating our business and implementing our strategy. However, the measures we take may not be sufficient to satisfy our obligations as a public company. In addition, we cannot predict or estimate the amount of additional costs we may incur in order to comply with these requirements.
Our R&D relies on evaluations of animals, which may become subject to bans, additional restrictive regulations or increased attention from activism movements.
As an animal health medicines and vaccines business, we are required to evaluate the effect of our existing and new products in animals in order to register such products. Animal testing in certain industries has been the subject of controversy and adverse publicity. Some organizations and individuals have attempted to ban animal testing or encourage the adoption of new regulations applicable to animal testing. To the extent that the activities of such organizations and individuals are successful, our R&D, and by extension our business, financial condition and results of operations, could be materially adversely affected. In addition, negative publicity about us or our industry could harm our reputation. For example, food animal producers may experience decreased demand for their products or reputational harm as a result of evolving consumer views of animal rights, nutrition, health-related or other concerns. Any reputational harm to the food animal industry may also extend to companies in related industries, including our company. Adverse consumer views related to the use of one or more of our products in food animals also may result in a decrease in the use of such products and could have a material adverse effect on our operating results and financial condition.

Manufacturing problems and capacity imbalances may cause product launch delays, inventory shortages, recalls or unanticipated costs.
In order to sell our products, we must be able to produce and ship sufficient quantities to our customers. We own and operate 12 internal manufacturing sites located in nine countries. We also employ a network of approximately 90 third-party CMOs. Many of our products involve complex manufacturing processes and are sole-sourced from certain manufacturing sites.
Minor deviations in our manufacturing or logistical processes, such as temperature excursions or improper package sealing, could result, and have in the past resulted in, delays, inventory shortages, unanticipated costs, product recalls, product liability and/or regulatory action. In addition, a number of factors could cause production interruptions, including:
•the failure of us or any of our vendors or suppliers, including logistical service providers, to comply with applicable regulations and quality assurance guidelines;
•mislabeling;
•construction delays;
•equipment malfunctions;
•shortages of materials;
•labor problems;
•natural disasters;
•power outages;
•criminal and terrorist activities;
•changes in manufacturing production sites and limits to manufacturing capacity due to regulatory requirements, changes in types of products produced, shipping distributions or physical limitations; and
•the outbreak of any highly contagious diseases near our production sites.
These interruptions could result in launch delays, inventory shortages, recalls, unanticipated costs or issues with our agreements under which we supply third parties, which may materially adversely affect our business, financial condition and results of operations.
30

Our manufacturing network may be unable to meet the demand for our products or we may have excess capacity if demand for our products changes. The unpredictability of a product’s regulatory or commercial success or failure, the lead time necessary to construct highly technical and complex manufacturing sites and shifting customer demand (including as a result of market conditions or entry of branded or generic competition) increase the potential for capacity imbalances. In addition, construction of sites is expensive, and our ability to recover costs will depend on the market acceptance and success of the products produced at the new sites, which is uncertain.
We rely on third parties to provide us with materials and services and are subject to increased labor and material costs and potential disruptions in supply.
The materials used to manufacture our products may be subject to availability constraints and price volatility caused by changes in demand, weather conditions, supply conditions, government regulations, economic climate and other factors. In addition, labor costs may be subject to volatility caused by the supply of labor, governmental regulations, economic climate and other factors. Increases in the demand for, availability or the price of, materials used to manufacture our products and increases in labor costs could increase the costs to manufacture our products, result in product delivery delays or shortages, and impact our ability to launch new products on a timely basis or at all. We may not be able to pass all or a material portion of any higher material or labor costs on to our customers, which could materially adversely affect our business, financial condition and results of operations.
We may be unable to meet demand for certain of our products if any of our third-party suppliers cease or interrupt operations, fail to renew contracts with us or otherwise fail to meet their obligations to us.
We may incur substantial costs and receive adverse outcomes in litigation and other legal matters.
Our business, financial condition and results of operations could be materially adversely affected by unfavorable results in pending or future litigation matters. If the acquisition of the Bayer animal health business is consummated, our business, financial condition and results of operations could also be materially adversely affected by pending or future litigation matters affecting the Bayer animal health business. These matters may include, among other things, allegations of violation of U.S. and foreign competition law, labor laws, consumer protection laws and environmental laws and regulations, as well as claims or litigation relating to product liability, intellectual property, securities, breach of contract and tort. In addition, changes in the interpretations of laws and regulations to which we are subject, or in legal standards in one or more of the jurisdictions in which we operate, could increase our exposure to liability. For example, in the U.S., attempts have been made to allow damages for emotional distress and pain and suffering in connection with the loss of, or injury to, a companion animal. If such attempts were successful, our exposure with respect to product liability claims could increase materially.
Litigation matters, regardless of their merits or their ultimate outcomes, are costly, divert management’s attention and may materially adversely affect our reputation and demand for our products. We cannot predict with certainty the eventual outcome of pending or future litigation matters. An adverse outcome of litigation or legal matters could result in us being responsible for significant damages. Any of these negative effects resulting from litigation matters could materially adversely affect our business, financial condition and results of operations.
Our business is subject to substantial regulation.
As a global company, we are subject to various state, federal and international laws and regulations, including regulations relating to the development, quality assurance, manufacturing, importation, distribution, marketing and sale of our products. Changes in applicable federal, state, local and foreign laws and regulations could have a material adverse effect on our business, financial condition and results of operations. In addition, our manufacturing facilities, including the manufacturing facilities operated by our CMOs, are subject to periodic inspections by regulatory agencies. An inspection may report conditions or practices that indicate possible violations of regulatory requirements. Our failure, or the failure of third parties we rely on, including CMOs, to comply with these regulatory requirements, allegations of such non-compliance or the discovery of previously unknown problems with a product or manufacturer could result in, among other things, inspection observation notices, warning letters or similar regulatory correspondence, fines, a partial or total shutdown of production in one or more of our facilities while an alleged violation is remediated, withdrawals or suspensions of current products from the market, and civil or criminal prosecution, as well as decreased sales as a result of negative publicity and product liability claims. Any one of these consequences could materially adversely affect our business, financial condition and results of operations.
31

In addition, we will not be able to market new products unless and until we have obtained all required regulatory approvals in each jurisdiction where we propose to market those products. Even after a product reaches market, we may be subject to re-review and may lose our approvals. Our failure to obtain approvals, delays in the approval process, or our failure to maintain approvals in any jurisdiction, may prevent us from selling products in that jurisdiction until approval or re-approval is obtained, if ever.
The illegal distribution and sale by third parties of counterfeit or illegally compounded versions of our products or of stolen, diverted or relabeled products could have a negative impact on our reputation and business.
Third parties may illegally distribute and sell counterfeit or illegally compounded versions of our products that do not meet the exacting standards of our development, manufacturing and distribution processes. Counterfeit or illegally compounded medicines pose a significant risk to animal health and safety because of the conditions under which they are manufactured and the lack of regulation of their contents. Counterfeit or illegally compounded products are frequently unsafe or ineffective and can be potentially life-threatening to animals. Our reputation and business could suffer harm as a result of counterfeit or illegally compounded products which are alleged to be equivalent and/or which are sold under our brand name. In addition, products stolen or unlawfully diverted from inventory, warehouses, plants or while in transit, which are not properly stored or which have an expired shelf life and which have been repackaged or relabeled and which are sold through unauthorized channels, could adversely impact animal health and safety, our reputation and our business. Public loss of confidence in the integrity of vaccines and/or pharmaceutical products as a result of counterfeiting, illegal compounding or theft could have a material adverse effect on our business, financial condition and results of operations.
We are subject to complex environmental, health and safety laws and regulations.
We are subject to various federal, state, local and foreign environmental, health and safety laws and regulations. These laws and regulations govern matters such as the emission and discharge of hazardous materials into the ground, air or water; the generation, use, storage, handling, treatment, packaging, transportation, exposure to and disposal of hazardous and biological materials, including recordkeeping, reporting and registration requirements; and the health and safety of our employees. Due to our operations, these laws and regulations also require us to obtain, and comply with, permits, registrations or other authorizations issued by governmental authorities. These authorities can modify or revoke our permits, registrations or other authorizations and can enforce compliance through fines and injunctions.
Given the nature of our business, we have incurred, are currently incurring and may in the future incur liabilities for the investigation and remediation of contaminated land under the U.S. Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended, or under other federal, state, local and foreign environmental cleanup laws, with respect to our current or former sites, adjacent or nearby third-party sites, or offsite disposal locations. We could be subject to liability for the investigation and remediation of legacy environmental contamination caused by historical industrial activity as sites that we own or on which we operate. The costs associated with future cleanup activities that we may be required to conduct or finance could be material. Additionally, we may become liable to third parties for damages, including personal injury, property damage and natural resource damages, resulting from the disposal or release of hazardous materials into the environment. Such liability could materially adversely affect our business, financial condition and results of operations.
Furthermore, regulatory agencies are showing increasing concern over the impact of animal health products and food animal operations on the environment. This increased regulatory scrutiny has in the past and may in the future necessitate that additional time and resources be spent to address these concerns in both new and existing products.
Our failure to comply with the environmental, health and safety laws and regulations to which we are subject, including any permits issued thereunder, may result in environmental remediation costs, loss of permits, fines, penalties or other adverse governmental or private actions, including regulatory or judicial orders enjoining or curtailing operations or requiring corrective measures, installation of pollution control equipment or remedial measures. We could also be held liable for any and all consequences arising out of human exposure to hazardous materials, environmental damage or significant environmental, health and safety issues that might arise at a manufacturing or R&D facility. Environmental laws and regulations are complex, change frequently, have tended to become more stringent and stringently enforced over time and may be subject to new interpretation. It is possible that our costs of complying with current and future environmental, health and safety laws, and our liabilities arising
32

from past or future releases of, or exposure to, hazardous materials could materially adversely affect our business, financial condition and results of operations.
The actual or purported intellectual property rights of third parties may negatively affect our business.
A third party may sue us, or our distributors or licensors, including Lilly, or otherwise make a claim, alleging infringement or other violation of such third-party’s patents, trademarks, trade dress, copyrights, trade secrets, domain names or other intellectual property rights. If our distributors, licensors or we do not prevail in this type of litigation, we may be required to:
•pay monetary damages;
•obtain a license in order to continue manufacturing or marketing the affected products, which may not be available on commercially reasonable terms, or at all; or
•stop activities, including any commercial activities, relating to the affected products, which could include a recall of the affected products and/or a cessation of sales in the future.
The costs of defending an intellectual property claim could be substantial and could materially adversely affect our business, financial condition and results of operations, even if we successfully defend such claim. Moreover, even if we believe that we do not infringe a validly existing third-party patent, we may choose to license such patent, which would result in associated costs and obligations. We may also incur costs in connection with an obligation to indemnify a distributor, licensor or other third party.
The intellectual property positions of animal health medicines and vaccines businesses frequently involve complex legal and factual questions, and an issued patent does not guarantee us the right to practice the patented technology or develop, manufacture or commercialize the patented product. For example, while we generally enter into proprietary information agreements with our employees and third parties, which assign intellectual property rights to us, these agreements may not be honored or may not effectively assign intellectual property rights to us under the local laws of some countries or jurisdictions. We cannot be certain that a competitor or other third party does not have or will not obtain rights to intellectual property that may prevent us from manufacturing, developing or marketing certain of our products, regardless of whether we believe such intellectual property rights are valid and enforceable or we believe we would otherwise be able to develop a more commercially successful product, which may materially adversely affect our business, financial condition and results of operations.
If our intellectual property rights are challenged or circumvented, competitors may be able to take advantage of our R&D efforts or harm the value of our brands.
Our long-term success depends on our ability to market innovative, competitive products. We rely and expect to continue to rely on a combination of intellectual property, including patent, trademark, trade dress, copyright, trade secret and domain name protection, as well as confidentiality and license agreements with our employees and others, to protect our intellectual property and proprietary rights. If we fail to obtain and maintain adequate intellectual property protection, we may not be able to prevent third parties from using our proprietary technologies or from marketing products that are very similar or identical to ours.
Our currently pending or future patent applications may not result in issued patents, or be approved on a timely basis, if at all. Similarly, any term extensions that we seek may not be approved on a timely basis, if at all. In addition, our issued patents, or any patents that may issue in the future, may not contain claims sufficiently broad to protect us against third parties with similar technologies or products or provide us with any competitive advantage, including exclusivity in a particular product area.
The validity and scope of our patent claims also may vary between countries, as individual countries have their own patent laws. For example, some countries only permit the issuance of patents covering a novel chemical compound itself, and its first use, and thus further methods of use for the same compound may not be patentable. The validity, enforceability, scope and effective term of patents can be highly uncertain and often involve complex legal and factual questions and proceedings that vary based on the local law of the relevant jurisdiction. Our ability to enforce our patents also depends on the laws of individual countries and each country’s practice with respect to enforcement of intellectual property rights. Patent protection must be obtained on a jurisdiction-by-jurisdiction basis, and we only pursue patent protection in countries where we think it makes commercial sense for the given product. In addition, if we are unable to maintain our existing license agreements or other agreements pursuant to which
33

third parties grant us rights to intellectual property, including because such agreements terminate, our financial condition and results of operations could be materially adversely affected.
Patent law reform in the U.S. and other countries may also weaken our ability to enforce our patent rights, or make such enforcement financially unattractive. For instance, in September 2011, the U.S. enacted the America Invents Act, which permits enhanced third-party actions for challenging patents and implements a first-to-invent system. These reforms could result in increased costs to protect our intellectual property or limit our ability to obtain and maintain patent protection for our products in these jurisdictions. Additionally, certain foreign governments have indicated that compulsory licenses to patents may be granted in the case of national emergencies, which could diminish or eliminate sales and profits from those regions and materially adversely affect our financial condition and results of operations.
Our trademarks and brands may provide us with a competitive advantage in the market as they may be known or trusted by consumers. In order to maintain the value of such brands, we must be able to enforce and defend our trademarks. We have pursued and will pursue the registration of trademarks and service marks in the U.S. and internationally; however, enforcing rights against those who knowingly or unknowingly dilute or infringe our brands can be difficult. Effective trademark, service mark, trade dress or related protections may not be available in every country in which our products and services are available. Enforcement is especially difficult in first-to-file countries where “trademark squatters” can prevent us from obtaining adequate protections for our brands. There can be no assurance that the steps we have taken and will take to protect our proprietary rights in our brands and trademarks will be adequate or that third parties will not infringe, dilute or misappropriate our brands, trademarks, trade dress or other similar proprietary rights.
Many of our products are based on or incorporate proprietary information. We actively seek to protect our proprietary information, including our trade secrets and proprietary know-how, by generally requiring our employees, consultants, other advisors and other third parties to execute proprietary information and confidentiality agreements upon the commencement of their employment, engagement or other relationship. Despite these efforts and precautions, we may be unable to prevent a third party from copying or otherwise obtaining and using our trade secrets or our other intellectual property without authorization and legal remedies may not adequately compensate us for the damages caused by such unauthorized use. Further, others may independently and lawfully develop substantially similar or identical products that circumvent our intellectual property by means of alternative designs or processes or otherwise.
We could be subject to changes in our tax rates, the adoption of new U.S. or foreign tax legislation or exposure to additional tax liabilities.
We are subject to income taxes in the U.S. and numerous foreign jurisdictions. Changes in the relevant tax laws, regulations, administrative practices, principles and interpretations could adversely affect our future effective tax rates. The U.S. recently enacted tax reform legislation significantly revising U.S. tax law, and a number of other countries are actively considering or enacting tax changes. Other organizations, such as the Organization for Economic Cooperation and Development and the European Commission, are also actively considering tax related matters, which could influence international tax policy in countries in which we operate. While outcomes of these initiatives continue to develop and remain uncertain, modifications to key elements of the U.S. or international tax framework could have a material adverse effect on our consolidated results of operations and cash flows.
In December 2017, the President of the United States signed into law the Tax Cuts and Jobs Act (the ‘‘2017 Tax Act’’). The 2017 Tax Act included significant changes to the U.S. corporate income tax system, such as the reduction in the corporate income tax rate, transition to a modified territorial tax system, changes to business related exclusions, deductions and credits, and modifications to international tax provisions. The U.S. Treasury Department and the IRS began to issue major proposed regulations related to the 2017 Tax Act during 2018 and are expected to continue issuing proposed and final regulations. Proposed regulations are generally subject to comment before being finalized; however, once finalized, these regulations may require Elanco to make adjustments, in particular, as a result of certain complex international provisions contained in the 2017 Tax Act. Such adjustments might materially impact Elanco’s provision for income taxes and effective tax rate in the period in which the adjustments are made and could also impact Elanco’s net income, earnings per share, consolidated cash flows and liquidity.
In addition, our effective tax rate is subject to potential risks that various taxing authorities may challenge the pricing of our cross border arrangements and subject us to additional tax, adversely impacting our effective tax rate and tax liability. We are also subject to the examination of our tax returns and other tax matters by the Internal
34

Revenue Service (IRS) and other tax authorities and governmental bodies. We regularly assess the likelihood of an adverse outcome resulting from these examinations to determine the adequacy of our provision for taxes. There can be no assurance as to the outcome of these examinations. If our effective tax rates were to increase, particularly in the U.S. or other material foreign jurisdictions, or if the ultimate determination of our taxes owed is for an amount in excess of amounts previously accrued, our business, financial condition and results of operations could be materially adversely affected.
Significant portions of our operations are conducted in foreign jurisdictions, including jurisdictions presenting a high risk of bribery and corruption, and are subject to the economic, political, legal and business environments of the countries in which we do business.
Our international operations could be limited or disrupted by any of the following:
•volatility in the international financial markets;
•compliance with governmental controls;
•difficulties enforcing contractual and intellectual property rights;
•parallel trade in our products (importation of our products from EU countries where our products are sold at lower prices into EU countries where the products are sold at higher prices);
•compliance with a wide variety of laws and regulations, such as the U.S. Foreign Corrupt Practices Act (the FCPA) and similar non-U.S. laws and regulations;
•compliance with foreign labor laws;
•burdens to comply with multiple and potentially conflicting foreign laws and regulations, including those relating to environmental, health and safety requirements;
•changes in laws, regulations, government controls or enforcement practices with respect to our business and the businesses of our customers, including the imposition of limits on our profitability;
•political and social instability, including crime, civil disturbance, terrorist activities and armed conflicts;
•trade restrictions and restrictions on direct investments by foreign entities, including restrictions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury and the EU, in relation to our products or the products of farmers and other customers;
•government limitations on foreign ownership;
•government takeover or nationalization of business;
•changes in tax laws and tariffs;
•imposition of anti-dumping and countervailing duties or other trade-related sanctions;
•costs and difficulties and compliance risks in staffing, managing and monitoring international operations, including in the use of overseas third-party goods and service providers;
•corruption risk inherent in business arrangements and regulatory contacts with foreign government entities;
•longer payment cycles and increased exposure to counterparty risk; and
•additional limitations on transferring personal information between countries or other restrictions on the processing of personal information.
In addition, international transactions may involve increased financial and legal risks due to differing legal systems and customs. Compliance with these requirements may prohibit the import or export of certain products and technologies or may require us to obtain a license before importing or exporting certain products or technologies. A failure to comply with any of these laws, regulations or requirements could result in civil or criminal legal proceedings, monetary or non-monetary penalties, or both, disruptions to our business, limitations on our ability to import and export products, and damage to our reputation. In addition, variations in the pricing of our products between jurisdictions may result in the unauthorized importation or unauthorized re-importation of our products between jurisdictions and may also result in the imposition of anti-dumping and countervailing duties or other trade-related sanctions. While the impact of these factors is difficult to predict, any of them could materially adversely affect our business, financial condition and results of operations.
35

Further, changes in any of these laws, regulations or requirements, or the political environment in a particular country, may affect our ability to engage in business transactions in certain markets, including investment, procurement and repatriation of earnings.
Significant portions of our operations are conducted in Europe and could be impacted by the withdrawal of the United Kingdom (UK) from the EU, commonly referred to as “Brexit.”
In June 2016, voters in the UK approved an advisory referendum to withdraw from the EU, commonly referred to as Brexit. On March 29, 2017, the UK Prime Minister formally notified the European Council of the UK's intention to withdraw from the EU under Article 50 of the Treaty of Lisbon. Brexit formally occurred on January 31, 2020. A transition period is in effect from February 1, 2020 until December 31, 2020, during which the UK and the EU will negotiate a trade agreement. During this period, EU rules and regulations will remain in effect for the UK. The referendum and notice created political, regulatory and economic uncertainty, particularly in the UK and the EU, and this uncertainty may persist for years if the UK and the EU are unable to reach an agreement by the end of the transition period.
Our business is subject to substantial regulation. If a trade agreement is not reached by the end of the transition period, we may not be able to market certain products that entered the EU market following marketing authorization by UK authorities in all the nations that are parties to free trade agreements with the EU unless and until we have obtained all required regulatory approvals in each jurisdiction where we proposed to market those products.
In addition, the uncertainty related to Brexit has caused foreign exchange rate fluctuations in the past, including the strengthening of the U.S. dollar relative to the Euro and British pound immediately following the announcement of Brexit. Further developments with respect to Brexit could further impact foreign exchange rates, which could materially adversely affect our business, financial condition and results of operations.
The end of the transition period with no agreement in place could significantly disrupt the free movement of goods, services, and people between the UK and the EU, and result in increased legal and regulatory complexities, as well as potential higher costs of conducting business in Europe and declining gross domestic product in many European markets. The UK's exit from the EU could also result in similar referendums or votes in other European countries in which we do business.
The uncertainty surrounding the terms of the UK's withdrawal and its consequences could adversely impact consumer and investor confidence, and could affect sales or regulation of our products. Any of these effects, among others, could materially adversely affect our business, financial condition and results of operations.
Foreign exchange rate fluctuations and potential currency controls affect our results of operations, as reported in our financial statements.
We conduct operations in many areas of the world, involving transactions denominated in a variety of currencies. In 2019, we generated approximately 44% of our revenue in currencies other than the U.S. dollar, principally the Euro, British pound, Canadian dollar, Australian dollar, Brazilian real, Japanese yen, and Chinese yuan. We are subject to currency exchange rate risk to the extent that our costs are denominated in currencies other than those in which we earn revenue. In addition, because our financial statements are reported in U.S. dollars, changes in currency exchange rates between the U.S. dollar and other currencies have had, and will continue to have, an impact on our results of operations.
We also face risks arising from currency devaluations and the imposition of cash repatriation restrictions and exchange controls. Currency devaluations result in a diminished value of funds denominated in the currency of the country instituting the devaluation. Cash repatriation restrictions and exchange controls may limit our ability to convert foreign currencies into U.S. dollars or to remit dividends and other payments by our foreign subsidiaries or businesses located in or conducted within a country imposing restrictions or controls. While we currently have no need and do not intend to repatriate or convert cash held in countries that have significant restrictions or controls in place, should we need to do so to fund our operations, we may be unable to repatriate or convert such cash, or may be unable to do so without incurring substantial costs.
We also bear foreign exchange risk associated with the future cash settlement of an existing net investment hedge. In October 2018, we entered into a fixed interest rate, 5-year, 750 million Swiss franc net investment hedge (NIH) against Swiss franc assets. The NIH is expected to generate approximately $25 million in cash and contra
36

interest expense per year; however, there is potential for significant 2023 settlement exposure on the 750 million Swiss franc notional if the U.S. dollar devalues versus the Swiss franc.
We depend on sophisticated information technology and infrastructure.
We rely on various information systems to manage our operations, and we increasingly depend on third parties to operate and support our information technology systems, including by way of virtual and cloud-based operations. These third parties include large established vendors as well as small, privately owned companies. Failure by any provider to adequately service our operations, or a change in control or insolvency of one or more providers, may materially adversely affect our business, financial condition and results of operations. Prior to the Separation, we relied on Lilly to negotiate and manage many of our relationships and contracts with these third parties.
In connection with the Separation, we are continuing to enhance a number of our business processes, including our financial reporting and supply chain processes and with respect to where and from whom we obtain information technology systems. In order to support the new business processes under the terms of our transitional services agreement with Lilly, we have made and will continue to make significant configuration, process and data changes within many of the information technology systems we use. If our information technology systems and processes are not sufficient to support our business and financial reporting functions, or if we fail to properly implement our new business processes, our financial reporting may be delayed or inaccurate and, as a result, our business, financial condition and results of operations may be materially adversely affected. Even if we are able to successfully configure and change our systems, all technology systems, even with implementation of security measures, are vulnerable to disability, failures or unauthorized access. If our information technology systems were to fail or be breached, this could materially adversely affect our reputation and our ability to perform critical business functions, and sensitive and confidential data could be compromised.
Breaches of our information technology systems or improper disclosure of confidential company or personal data could have a material adverse effect on our reputation and operations, or we may fail to comply with privacy laws, regulations and our contractual obligations.
We rely on information technology systems to process, transmit and store electronic information in our day-to-day operations, including customer, employee and company data. The secure processing, maintenance and transmission of this information is critical to our operations and the legal environment surrounding information security, storage, use, processing, disclosure and privacy is demanding with the frequent imposition of new and changing requirements. We also store certain information with third parties. Our information systems and those of our third-party vendors are subjected to computer viruses or other malicious codes, unauthorized access attempts, and cyber or phishing-attacks and also are vulnerable to an increasing threat of continually evolving cybersecurity risks and external hazards, as well as improper or inadvertent staff behavior, all of which could expose confidential company and personal data systems and information to security breaches. Any such breach could compromise our networks, and the information stored therein could be accessed, publicly disclosed, lost or stolen. Such attacks could result in our intellectual property and other confidential information being lost or stolen, disruption of our operations, and other negative consequences, such as increased costs for security measures or remediation costs, and diversion of management attention. Any actual or perceived access, disclosure or other loss of information or any significant breakdown, intrusion, interruption, cyber-attack or corruption of customer, employee or company data or our failure to comply with federal, state, local and foreign privacy laws or contractual obligations with customers, vendors, payment processors and other third parties, could result in legal claims or proceedings, liability under laws or contracts that protect the privacy of personal information, regulatory penalties, disruption of our operations, and damage to our reputation, all of which could materially adversely affect our business, revenue and competitive position. While we will continue to implement additional protective measures to reduce the risk of and detect cyber-incidents, cyber-attacks are becoming more sophisticated and frequent, and the techniques used in such attacks change rapidly. Our protective measures may not protect us against attacks and such attacks could have a significant impact on our business and reputation. In addition, prior to the Separation, we relied on Lilly for certain privacy and compliance functions and personnel and may experience difficulties maintaining and implementing all policies and practices following completion of the Separation.
Increased regulation or decreased governmental financial support relating to the raising, processing or consumption of food animals could reduce demand for our food animal products.
Companies in the food animal sector are subject to extensive and increasingly stringent regulations. See “Business of Elanco - Regulatory.” If food animal producers are adversely affected by new regulations or changes to
37

existing regulations, they may reduce herd or flock sizes or become less profitable and, as a result, they may reduce their use of our products, which may materially adversely affect our business, financial condition and results of operations. Also, many food animal producers benefit from governmental subsidies, and if such subsidies were to be reduced or eliminated, these companies may become less profitable and, as a result, may reduce their use of our food animal products. More stringent regulation of the food animal sector, including regarding the use of food animal products, could have a material adverse effect on our business, financial condition and results of operations.
Our business could be materially adversely affected by labor disputes, strikes or work stoppages.
Some of our employees are members of unions, works councils, trade associations or are otherwise subject to collective bargaining agreements in certain jurisdictions, including the U.S. As a result, we are subject to the risk of labor disputes, strikes, work stoppages and other labor-relations matters. We may be unable to negotiate new collective bargaining agreements on similar or more favorable terms and may experience work stoppages, higher ongoing labor costs or other labor problems in the future at our sites. We may also experience difficulty or delays in implementing changes to our workforce in certain markets. These risks may be increased by the Separation because we no longer benefit from Lilly’s prior relationships and negotiations relating to such agreements.
Further, labor-related issues, including at our suppliers or CMOs, could cause a disruption of our operations, which could have a material adverse effect on our business, financial condition and results of operations, potentially resulting in cancelled orders by customers, unanticipated inventory accumulation or shortages and reduced revenue and net income.
The anticipated benefits of the Separation from Lilly may not be achieved.
We may not be able to achieve the full strategic and financial benefits expected to result from the Separation from Lilly. Further, such benefits, if ultimately achieved, may be delayed. These benefits include the following:
•improving strategic and operational flexibility and streamlining decision-making by providing the flexibility to implement our strategic plan and to respond more effectively to different customer needs and the changing economic and industry environment;
•allowing us to adopt the investment policy and dividend policy best suited to our financial profile and business needs, and allowing us to raise capital as an independent business;
•creating an independent equity structure that makes possible future acquisitions utilizing our common stock as well as compensation arrangements; and
•facilitating incentive compensation arrangements for employees more directly tied to the performance of our business, and enhancing employee hiring and retention by, among other things, improving the alignment of management and employee incentives with performance and growth objectives of our business.
We may not achieve the anticipated benefits of the Separation from Lilly for a variety of reasons, which could materially adversely affect our business, financial condition and results of operations.
We have underfunded pension plan liabilities. We will require current and future operating cash flow to fund these shortfalls reducing the cash available for other uses.
We have certain defined benefit pension plans, predominantly outside of the U.S., that our employees participate in that are either dedicated to our employees or where the plan assets and liabilities that relate to our employees were legally required to transfer to us at the time of the Separation. The funded status and net periodic pension cost for these plans is materially affected by the discount rate used to measure pension obligations, the longevity and actuarial profile of our workforce, the level of plan assets available to fund those obligations and the actual and expected long-term rate of return on plan assets. Significant changes in investment performance or a change in the portfolio mix of invested assets can result in corresponding increases and decreases in the valuation of plan assets or in a change in the expected rate of return on plan assets. As of December 31, 2019, for pension plans with projected benefit obligations in excess of plan assets, the projected benefit obligation was $218.2 million with plan assets of $140.3 million. Any changes in the discount rate could result in a significant increase or decrease in the valuation of pension obligations, affecting the reported funded status of our pension plans as well as the net periodic pension cost in the following years. Similarly, changes in the expected return on plan assets can result in significant changes in the net periodic pension cost in the following years. The need to make additional cash contributions will
38

divert resources from our operations and may have a material adverse effect on our business, financial condition and results of operations.
We may not be able to successfully integrate acquired businesses when we pursue acquisitions, divestitures, joint ventures or other significant transactions, such as the acquisition of Aratana Therapeutics, Inc. and Prevtec Microbia Inc.
We finalized the acquisition of Aratana Therapeutics, Inc. on July 18, 2019 and the acquisition of Prevtec Microbia Inc. on July 31, 2019. Following the closing of the transactions, we are now required to devote significant management attention and resources to integrating the portfolio and operations of the target companies. Potential difficulties that we may encounter in the integration process, including as a result of distraction of our management, include the following:
•the inability to combine the businesses of the acquired companies with ours in a manner that permits us to achieve the cost savings or other synergies anticipated as a result of the transaction or to achieve such cost savings or other anticipated synergies in a timely manner, which could result in us not realizing some anticipated benefits of the transactions in the time frame anticipated, or at all;
•the inability to realize the anticipated value from various assets of the target companies;
•loss of key employees;
•potential unknown liabilities and unforeseen increased expenses, delays or unfavorable conditions in connection with the closing of the transactions and the subsequent integration; and
•performance shortfalls at our company or the target companies as a result of the diversion of management’s attention from ongoing business activities as a result of completing the transaction and integrating the companies’ operations.
Future acquisitions could also result in potentially dilutive issuances of equity securities, the incurrence of debt, contingent liabilities or amortization expenses related to intangible assets, and increased operating expenses, which could adversely affect our results of operations and financial condition. Furthermore, if we issue equity or debt securities to raise additional funds beyond the equity and debt issuances that have occurred in January and February 2020, our existing shareholders may experience significant dilution, and the new equity or debt securities may have rights, preferences and privileges senior to those of our existing shareholders. Furthermore, if we sell a substantial number of shares of common stock in the public markets, the availability of those shares for sale could adversely affect the market price of our common stock. Such sales, or the perception in the market that holders of a large number of shares intend to sell shares, could depress the market price of our common stock and impair our ability to raise capital through the sale of additional equity securities.
Our historical combined financial data prior to the Separation is not necessarily representative of the results we would have achieved as a standalone company and may not be a reliable indicator of our future results.

For periods prior to the Separation, our historical combined financial data included in this report does not reflect the financial condition, results of operations or cash flows we would have achieved as a standalone company during the periods presented or those we will achieve in the future. This is primarily the result of the following factors:

•our historical combined financial data does not reflect the Separation;
•our historical combined financial data for periods prior to the Separation reflects expense allocations for certain support functions that were provided on a centralized basis within Lilly, such as expenses for executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information technology and investor relations that may be higher or lower than the comparable expenses we would have actually incurred, or will incur in the future, as a standalone company;
•our cost of debt and our capital structure has been different from that reflected in our historical combined financial statements for periods prior to the Separation;
•significant increases have occurred in our cost structure as a result of the IPO, including costs related to public company reporting, investor relations and compliance with the Sarbanes-Oxley Act; and
39

•the IPO had a material effect on our customers and other business relationships, including supplier relationships, and resulted in the loss of preferred pricing available by virtue of our reduced relationship with Lilly.
Our financial condition and future results of operations, after giving effect to the Separation, have been materially different from the amounts for periods prior to the Separation reflected in our historical combined financial statements included in this report. As a result of the Separation, it may be difficult for investors to compare our 2019 and future results to historical results prior to the Separation or to evaluate our relative performance or trends in our business.
Risks Related to the Pending Acquisition of the Bayer Animal Health Business (the Acquisition)
The proposed acquisition of the Bayer animal health business may not be completed on the anticipated terms and there are uncertainties and risks related to consummating the Acquisition.
In August 2019, we entered into a share purchase agreement (Purchase Agreement) to purchase the animal health business of Bayer for approximately $5.3 billion in cash and approximately $2.3 billion of our common stock, subject to certain customary adjustments. Our obligation to consummate the Acquisition is subject to satisfaction or waiver, to the extent permitted under applicable law, of a number of conditions. Among other conditions, the Acquisition is subject to antitrust approvals in certain jurisdictions. We cannot provide any assurance that all required antitrust clearances will be obtained and what conditions will be imposed. There can be no assurance as to the cost, scope or impact of the actions that may be required, including divestiture actions, to obtain antitrust approval. If we are required to or otherwise decide to take such actions in order to close the Acquisition, it could be detrimental to the combined organization following the consummation of the Acquisition, including with respect to the synergies which we expect from the Acquisition. For example, in January 2020, we signed agreements to divest Osurnia, a treatment for otitis externa in dogs, and the U.S. rights to Capstar, an oral tablet that kills fleas in dogs and cats, for an aggregate of $230 million in all cash deals, with the intent to advance our efforts to secure the necessary regulatory clearances for the Acquisition. Furthermore, these actions, or the failure to effect any divestitures at an acceptable price or at all, could have the effect of delaying or preventing completion of the Acquisition or imposing additional costs on or limiting the revenues or cash of the combined organization following the consummation of the Acquisition.
Even if the parties receive antitrust approvals, the applicable domestic or international regulatory authorities could take action under the antitrust laws to prevent or rescind the Acquisition, require the divestiture of assets or seek other remedies. Additionally, state attorneys general could seek to block or challenge the Acquisition as they deem necessary or desirable in the public interest at any time, including after completion of the Acquisition. In addition, in some circumstances, a third party could initiate a private action under antitrust laws challenging or seeking to enjoin the Acquisition, before or after it is completed. We may not prevail and may incur significant costs in defending or settling any action under the antitrust laws.
We may be unable to integrate the Bayer animal health business successfully and realize the anticipated benefits of the Acquisition.
If the Acquisition is completed, the successful integration of the Bayer animal health business and operations into those of our own and our ability to realize the expected synergies and benefits of the Transactions are subject to a number of risks and uncertainties, many of which are outside of our control. We will also be required to devote significant management attention and resources to integrating business practices, cultures and operations of each business. The risks and uncertainties relating to integrating the two businesses and realizing the anticipated cost synergies include, among other things:
•the challenge of integrating complex organizations, systems, operating procedures, compliance programs, technology, networks and other assets of the Bayer animal health business;
•the difficulties harmonizing differences in the business cultures of our company and the Bayer animal health business;
•the inability to combine successfully our respective businesses in a manner that permits us to achieve the cost savings, synergies and other anticipated benefits from the Acquisition;
•the inability to minimize the diversion of management attention from ongoing business concerns during the process of integrating the Bayer animal health business into our businesses;
40

•the inability to resolve potential conflicts that may arise relating to customer, supplier and other important relationships of our business and the Bayer animal health business;
•difficulties in retaining key management and other key employees;
•the challenge of managing the expanded operations of a significantly larger and more complex company and coordinating geographically separate organizations; and
•difficulties in fully exploring intellectual property licensed from Bayer in connection with the acquisition, given Bayer's rights as licensor of such intellectual property.
We will incur substantial expenses to consummate the proposed Acquisition but may not realize the anticipated cost synergies and other benefits to the extent expected, on the timeline expected, or at all. In addition, even if we are able to integrate the Bayer animal health business successfully, the anticipated benefits of the Acquisition may not be realized fully, or at all, or may take longer to realize than expected. Moreover, competition in the animal health industry, including competition that has negatively impacted results in the companion animal parasiticide market, may also cause us not to fully realize the anticipated benefits of the Acquisition. Given the size and significance of the Acquisition, we may encounter difficulties in the integration of the operations of the Bayer animal health business and may fail to realize the full benefits and synergies of the Acquisition, which could adversely impact our business, results of operation and financial condition.
The Bayer animal health business may have liabilities that are not known to us.
The Bayer animal health business may have liabilities that we failed, or were unable, to discover in the course of performing our due diligence investigations of the Bayer animal health business. We cannot assure that the indemnification available to us under the Purchase Agreement in respect of the Acquisition in connection with such agreement will be sufficient in amount, scope or duration to fully offset the possible liabilities associated with the Bayer animal health business or property that we will assume upon consummation of the Acquisition. We may learn additional information about the Bayer animal health business that materially adversely affects us, such as unknown or contingent liabilities and liabilities related to compliance with applicable laws. Any such liabilities, individually or in the aggregate, could have a material adverse effect on our business, financial condition and results of operations.
Acquisition accounting adjustments could adversely affect our financial results.
We will account for the completion of the Acquisition using the acquisition method of accounting. We will allocate the total estimated purchase price to net tangible assets, amortizable intangible assets and indefinite-lived intangible assets, and based on their fair values as of the date of completion of the Acquisition record the excess, if any, of the purchase price over those fair values as goodwill. Differences between preliminary estimates and the final acquisition accounting may occur, and these differences could have a material impact on the consolidated and combined financial statements and the combined company’s future results of operations and financial position.
Failure to complete the Acquisition could impact our stock price and our future business and financial results.
If the Acquisition is not completed, our ongoing business and financial results may be adversely affected and we will be subject to a number of risks, including the following:
•depending on the reasons for the failure to complete the Acquisition, we could be liable to Bayer for monetary or other damages in connection with the termination or breach of the Purchase Agreement;
•we have dedicated significant time and resources, financial and otherwise, in planning for the Acquisition and the associated integration, of which we would lose the benefit if the Acquisition is not completed;
•we are responsible for certain transaction costs relating to the Acquisition, whether or not the Acquisition is completed;
•while the Purchase Agreement is in force, we are subject to certain restrictions on the conduct of our business, including taking any action that is reasonably likely to prevent, materially delay or materially impair the consummation of the Acquisition, which restrictions may adversely affect our ability to execute certain of our business strategies; and
41

•matters relating to the Acquisition (including integration planning) may require substantial commitments of time and resources by our management, whether or not the Acquisition is completed, which could otherwise have been devoted to other opportunities that may have been beneficial to us.
In addition, if the Acquisition is not completed, we may experience negative reactions from the financial markets and from our customers and employees. We also may be subject to litigation related to any failure to complete the Acquisition or to enforcement proceedings commenced against us to perform our obligations under the Purchase Agreement. If the Acquisition is not completed, these risks may materialize and may adversely affect our business, financial results and financial condition, as well as the price of our common stock.
While the Acquisition is pending, we and the Bayer animal health business will be subject to business uncertainties that could adversely affect our respective businesses.
Our success following the announcement of the Acquisition will depend in part upon the ability of us and the Bayer animal health business to maintain our respective business relationships. Uncertainty about the effect of the Acquisition on customers, suppliers, employees and other constituencies may have a material adverse effect on us and the Bayer animal health business. Customers, suppliers and others who deal with us or the Bayer animal health business may delay or defer business decisions, decide to terminate, modify or renegotiate their relationships or take other actions as a result of the Acquisition that could negatively affect the revenues, earnings and cash flows of our company or the Bayer animal health business. If we are unable to maintain these business and operational relationships, our financial position, results of operations or cash flows could be materially affected.
Our debt following the completion of the Acquisition will be significant and could adversely affect our business and our ability to meet our obligations.
In connection with the Acquisition, we priced a $4.3 billion term facility and a $750.0 million revolving credit facility (the New Credit Facilities) in February 2020, which will become effective at the closing of the Acquisition.
This significant amount of debt and other cash needs could have important consequences to us, including:
•requiring a substantial portion of our cash flow from operations to make payments on this debt, thereby limiting the cash we have available to fund future growth opportunities, such as R&D, capital expenditures and acquisitions;
•restrictive covenants in our debt arrangements, which could limit our operations and borrowing;
•the risk of a future credit ratings downgrade of our debt, increasing future debt costs and limiting the future availability of debt financing;
•increasing our vulnerability to general adverse economic and industry conditions and limiting our flexibility in planning for, or reacting to, changes in our business and industry, due to the need to use our cash to service our outstanding debt;
•placing us at a competitive disadvantage relative to our competitors that are not as highly leveraged with debt and that may therefore be more able to invest in their business or use their available cash to pursue other opportunities, including acquisitions; and
•limiting our ability to borrow additional funds as needed or take advantage of business opportunities as they arise.
In addition, our actual cash requirements in the future may be greater than expected. Our cash flow from operations may not be sufficient to repay all of our outstanding debt as it becomes due, and we may not be able to borrow money, sell assets or otherwise raise funds on acceptable terms, or at all, to refinance our debt.
The issuance of our common stock to Bayer under the Purchase Agreement will be dilutive to our shareholders and could depress the market price of our common stock.
Following the closing of the Acquisition, Bayer will own shares of our common stock valued at approximately $2.3 billion based on trading prices before the closing of the Acquisition, subject to a minimum and maximum number of shares as provided in the Purchase Agreement. The shares are subject to limited lock-up obligations and following the expiration of such lock-up obligations (the latest of which expire 12 months after the closing of the Acquisition), Bayer is free to sell the shares of our common stock received at the closing of the Acquisition. In addition, under the Purchase Agreement, we agreed to provide Bayer with customary shelf registration rights.
42

The market price of shares of our common stock may drop significantly as a result of the resale of the consideration shares, or when the lock-up restrictions on resale by Bayer lapse. In addition, this concentration of share ownership may adversely affect the trading price of our common stock because investors may perceive disadvantages in owning shares in a company with significant shareholders.
Risks Related to our Indebtedness
We have substantial indebtedness and expect to incur substantial additional indebtedness.
We have a significant amount of indebtedness, which could materially adversely affect our business, financial condition and results of operations. As of December 31, 2019, in addition to $2.4 billion of senior unsecured notes, we had $371.4 million of borrowings under a term loan, which was retired in January 2020 using the proceeds from our most recent equity offering. We have an additional $750.0 million of borrowing capacity ($1.0 billion if certain conditions are met) under our existing revolving facility. See Note 9: Debt to our consolidated and combined financial statements for further discussion.
We expect to incur substantial additional indebtedness in connection with the Acquisition under the New Credit Facilities. If we do so, the risks related to our high level of debt could intensify. Specifically, our high level of debt could have important consequences, including:
•making it more difficult for us to satisfy our obligations with respect to our debt and any failure to comply with the obligations of any of our debt instruments, including restrictive covenants and borrowing conditions, could result in an event of default under the agreements governing other indebtedness;
•requiring us to dedicate a substantial portion of our cash flow from operations to the payment of interest and the repayment of our indebtedness, thereby reducing funds available to us for other purposes;
•limiting our ability to obtain additional financing to fund future working capital, capital expenditures, business development or other general corporate requirements, including dividends;
•increasing our vulnerability to general adverse economic and industry conditions;
•making us more highly leveraged than some of our competitors, which may place us at a competitive disadvantage;
•restricting us from making strategic acquisitions, engaging in development activities or exploiting business opportunities;
•causing us to make non-strategic divestitures;
•exposing us to the risk of increased interest rates as certain of our borrowings are and may in the future be at variable rates of interest;
•limiting our flexibility in planning for and reacting to changes in the animal health industry;
•impacting our effective tax rate; and
•increasing our cost of borrowing.
In addition, the credit agreement expected to govern the New Credit Facilities is expected to contain restrictive covenants that will limit our ability to engage in activities that may be in our long-term best interest. Our failure to comply with those covenants could result in an event of default which, if not cured or waived, could result in the acceleration of substantially all of our indebtedness.
43

Despite our substantial indebtedness, we may still be able to incur significantly more debt, which could intensify the risks associated with our indebtedness.
We and our subsidiaries may be able to incur substantial indebtedness in the future, even following the incurrence of indebtedness in connection with the Acquisition. Although we expect that the terms of the credit agreement governing the New Credit Facilities will contain restrictions on our and our subsidiaries’ ability to incur additional indebtedness, these restrictions are expected to be subject to a number of important qualifications and exceptions, and the indebtedness incurred in compliance with these restrictions could be substantial. These restrictions are also not expected to prevent us from incurring obligations that do not constitute indebtedness. In addition to our borrowings under the New Credit Facilities, the covenants under the credit agreement governing the New Credit Facilities are expected to, and the covenants under any other of our existing or future debt instruments could, allow us to incur a significant amount of additional indebtedness and, subject to certain limitations, such additional indebtedness could be secured. The more leveraged we become, the more we, and in turn our security holders, will be exposed to certain risks described above under “—We have substantial indebtedness and expect to incur substantial additional indebtedness.”
We may not be able to generate sufficient cash to service all of our indebtedness and may be forced to take other actions to satisfy our obligations under our indebtedness, which may not be successful.
Our ability to make scheduled payments on or refinance our debt obligations depends on our financial condition and operating performance, which are subject to prevailing economic and competitive conditions and to certain financial, business, legislative, regulatory and other factors beyond our control. We may be unable to maintain a level of cash flows from operating activities sufficient to permit us to pay the principal and interest on our indebtedness.
If our cash flows and capital resources are insufficient to fund our debt service obligations, we could face substantial liquidity problems and could be forced to reduce or delay investments and capital expenditures, or to dispose of material assets or operations, alter our dividend policy, seek additional debt or equity capital or restructure or refinance our indebtedness. We may not be able to effect any such alternative measures on commercially reasonable terms or at all and, even if successful, those alternative actions may not allow us to meet our scheduled debt service obligations. The instruments that will govern our indebtedness may restrict our ability to dispose of assets and may restrict the use of proceeds from those dispositions and may also restrict our ability to raise debt or equity capital to be used to repay other indebtedness when it becomes due. We may not be able to consummate those dispositions or to obtain proceeds in an amount sufficient to meet any debt service obligations when due.
In addition, we conduct our operations through our subsidiaries. Accordingly, repayment of our indebtedness will depend on the generation of cash flow by our subsidiaries, including certain international subsidiaries, and their ability to make such cash available to us, by dividend, debt repayment or otherwise. Our subsidiaries may not have any obligation to pay amounts due on our indebtedness or to make funds available for that purpose. Our subsidiaries may not be able to, or may not be permitted to, make adequate distributions to enable us to make payments in respect of our indebtedness. Each subsidiary is a distinct legal entity and, under certain circumstances, legal, tax and contractual restrictions may limit our ability to obtain cash from our subsidiaries. In the event that we do not receive distributions from our subsidiaries, we may be unable to make required principal and interest payments on our indebtedness.
Our inability to generate sufficient cash flows to satisfy our debt obligations, or to refinance our indebtedness on commercially reasonable terms or at all, may materially adversely affect our business, financial condition and results of operations and our ability to satisfy our obligations under our indebtedness or pay dividends on our common stock.
44

Our debt agreements following the completion of the Acquisition are expected to contain restrictions that will limit our flexibility in operating our business.
Our existing term facility and revolving credit facility contain, and the New Credit Facilities are expected to contain, and any other existing or future indebtedness of ours would likely contain, a number of covenants that impose significant operating and financial restrictions on us, including restrictions on our and our subsidiaries’ ability to, among other things:
•incur additional debt, guarantee indebtedness or issue certain preferred shares;
•pay dividends on or make distributions in respect of, or repurchase or redeem, our capital stock or make other restricted payments;
•prepay, redeem or repurchase certain debt;
•make loans or certain investments;
•sell certain assets;
•create liens on certain assets;
•consolidate, merge, sell or otherwise dispose of all or substantially all of our assets;
•enter into certain transactions with our affiliates;
•substantially alter the businesses we conduct;
•enter into agreements restricting our subsidiaries’ ability to pay dividends; and
•designate our subsidiaries as unrestricted subsidiaries.
In addition, the New Credit Facilities are expected to require us to comply with a net total leverage ratio and a minimum fixed charge coverage ratio under certain circumstances.
As a result of these covenants, we will be limited in the manner in which we conduct our business, and we may be unable to engage in favorable business activities or finance future operations or capital needs.
A failure to comply with the covenants under the existing term facility, the existing revolving credit facility, the indenture that governs the senior unsecured notes, the New Credit Facilities, or any of our other existing or future indebtedness could result in an event of default, which, if not cured or waived, could have a material adverse effect on our business, financial condition and results of operations. In the event of an event of default under the New Credit Facilities, it is expected that the lenders:
•will not be required to lend any additional amounts to us;
•could elect to declare all borrowings outstanding, together with accrued and unpaid interest and fees, to be due and payable and terminate all commitments to extend further credit;
•could require us to apply all of our available cash to repay these borrowings; or
•could effectively prevent us from making debt service payments on the notes (due to a cash sweep feature).
Such actions by the lenders could cause cross defaults under our other indebtedness, including our senior unsecured notes. If we were unable to repay those amounts, the lenders under the New Credit Facilities and any of our other existing or future secured indebtedness could proceed against the collateral granted to them to secure the New Credit Facilities or such other indebtedness. We are expecting to pledge a significant portion of our assets as collateral under the New Credit Facilities.
The terms and conditions of the New Credit Facilities have not been finalized.
The credit agreement relating to the New Credit Facilities has not been finalized. Our entry into the New Credit Facilities is subject to market conditions, and we cannot assure you that the New Credit Facilities will be completed, in the manner, on the terms or on the timetable described herein, or at all. Future changes in market conditions may result in less favorable terms for the New Credit Facilities and any changes to the terms of the New Credit Facilities
45

may increase our interest expense and adversely affect our business. The terms of the New Credit Facilities could also change in a way that increases our indebtedness or makes it easier to incur debt in the future.
Changes in our credit rating could increase our interest expense and restrict our access to, and negatively impact the terms of, current or future financings or trade credit.
Credit rating agencies continually revise their ratings for the companies that they follow, including us. Credit rating agencies also evaluate our industry as a whole and may change their credit ratings for us based on their overall view of our industry. We cannot be sure that credit rating agencies will maintain their ratings on us and certain of our debt. As a result of the Acquisition, our credit ratings may be downgraded. Because the ratings of certain of our senior unsecured notes have been downgraded, we will be required to pay additional interest under the senior unsecured notes. Any further downgrades could result in requiring us to pay additional interest under the senior unsecured notes. Moreover, any decision to downgrade our ratings could restrict our access to, and negatively impact the terms of, current or future financings and trade credit extended by our suppliers of raw materials or other vendors.
Changes in interest rates may adversely affect our earnings and/or cash flows.
Our revolving credit facility bears interest at variable interest rates that use the London Inter-Bank Offered Rate (LIBOR) as a benchmark rate. On July 27, 2017, the United Kingdom’s Financial Conduct Authority (FCA), which regulates LIBOR, announced that it intends to stop persuading or compelling banks to submit LIBOR quotations after 2021 (the FCA Announcement). The FCA announcement indicates that the continuation of LIBOR on the current basis cannot and will not be assured after 2021, and LIBOR may cease to exist or otherwise be unsuitable for use as a benchmark. Recent proposals for LIBOR reforms may result in the establishment of new methods of calculating LIBOR or the establishment of one or more alternative benchmark rates. Although our revolving credit facility provides for successor base rates, the successor base rates may be related to LIBOR, and the consequences of any potential cessation, modification or other reform of LIBOR cannot be predicted at this time. If LIBOR ceases to exist, we may need to amend our existing or enter into a new revolving credit facility, and we cannot predict what alternative interest rate(s) will be negotiated with our counterparties. As a result, our interest expense may increase, our ability to refinance some or all of our existing indebtedness may be affected and our available cash flow may be adversely affected.
Risks Related to our Relationship with Lilly
As a result of the Separation, we no longer have access to Lilly’s brand, reputation, capital base and other resources.
We believe our association with Lilly has contributed to our building relationships with our customers due to Lilly’s globally recognized brand and perceived high-quality products. The Separation could adversely affect our ability to attract and retain customers, which could result in reduced sales of our products.
The loss of Lilly’s scale, capital base and financial strength may also prompt suppliers to reprice, modify or terminate their relationships with us. In addition, Lilly’s reduction of its ownership of our company could potentially cause some of our existing agreements and licenses to be terminated. We cannot predict with certainty the effect that the Separation will have on our business, our clients, vendors or other persons, or whether our brand will be accepted in the marketplace.
Further, because we have only operated as a standalone company for a limited period of time, we may have difficulty doing so. We may need to acquire assets and resources in addition to those provided by Lilly, and in connection with the Separation, may also face difficulty in separating our assets from Lilly’s assets and integrating newly acquired assets into our business. Our business, financial condition and results of operations could be materially adversely affected if we have difficulty operating as a standalone company, fail to acquire assets that prove to be important to our operations or incur unexpected costs in separating our assets from Lilly’s assets or integrating newly-acquired assets.
Lilly may compete with us.
Lilly is not restricted from competing with us in the animal health business. Although Lilly informed us it had no intention to compete with us in the animal health business, if Lilly in the future decides to engage in the type of
46

business we conduct, it may have a competitive advantage over us, which may cause our business, financial condition and results of operations to be materially adversely affected.
To preserve the tax-free treatment to Lilly and its shareholders of the Separation and certain related transactions, we may not be able to engage in certain transactions.
To preserve the tax-free treatment to Lilly and its shareholders of the Separation and certain related transactions, under a tax matters agreement with Lilly, we are restricted from taking any action that prevents such transactions from being tax-free for U.S. federal income tax purposes. These restrictions limit our ability to pursue certain strategic transactions or engage in other transactions, including using our common stock to make acquisitions and in connection with equity capital market transactions that might increase the value of our business. Because of these restrictions, following the issuance of our common stock and tangible equity units in public offerings completed in January 2020, and the issuance of the consideration shares to Bayer in connection with the Acquisition, we will have limited or no ability to issue shares of our common stock in the near term.
Lilly’s rights as licensor under the intellectual property and technology license agreement could limit our ability to develop and commercialize certain products.
Prior to the Separation, we had the ability to leverage certain of Lilly’s intellectual property. As part of the Separation, we entered into an intellectual property and technology license agreement. Pursuant to the intellectual property and technology license agreement, Lilly licenses to us certain of its intellectual property (excluding trademarks) related to the animal health business and also grants a license for us to use Lilly’s proprietary compound library for a period of two years plus up to three additional one-year periods, each such period to be granted under Lilly’s sole discretion. If we fail to comply with our obligations under this agreement and Lilly exercises its right to terminate it, our ability to continue to research, develop and commercialize products incorporating that intellectual property will be limited. In addition, this agreement includes limitations that affect our ability to develop and commercialize certain products, including in circumstances where Lilly has an interest in the licensed intellectual property in connection with its human health development programs. These limitations and termination rights may make it more difficult, time consuming or expensive for us to develop and commercialize certain new products, or may result in our products being later to market than those of our competitors. For a summary description of the terms of the intellectual property and technology license agreement, see Note 20: Related Party Agreements and Transactions to our consolidated and combined financial statements.
We have incurred and will continue to incur significant charges in connection with the Separation and incremental costs as a standalone public company.
We are currently replicating or replacing certain functions, systems and infrastructure to which we no longer have the same access after the Separation. We have also made and will continue to make investments or hire additional employees to operate without the same access to Lilly’s existing operational and administrative infrastructure. These initiatives may be costly to implement. Due to the scope and complexity of the underlying projects relative to these efforts, the amount of total costs could be materially higher than our estimates, and the timing of the incurrence of these costs is subject to change.
Prior to the Separation, Lilly performed or supported many important corporate functions for us. Our consolidated and combined financial statements prior to the Separation reflect charges for these services on an allocated basis. Following the Separation, many of these services are governed by our transitional services agreement with Lilly. Under the transitional services agreement we are able to use these Lilly services for a fixed term established on a service-by-service basis. Partial reduction in the provision of any service or termination of a service prior to the expiration of the applicable fixed term requires Lilly’s consent. In addition, either party is able to terminate the agreement due to a material breach of the other party, upon prior written notice, subject to limited cure periods or if the other party undergoes a change of control.
We pay Lilly mutually agreed-upon fees for these services, which are based on Lilly’s costs (including third-party costs) of providing the services through March 31, 2021 and subject to a mark-up of 7% thereafter, with additional inflation-based escalation beginning January 1, 2022. However, since our transitional services agreement was negotiated in the context of a parent-subsidiary relationship, the terms of the agreement, including the fees charged for the services, may be higher or lower than those that would be agreed to by parties bargaining at arm’s length for similar services and may be higher or lower than the costs reflected in the allocations in our historical consolidated and combined financial statements. In addition, while these services are being provided to us by Lilly, our
47

operational flexibility to modify or implement changes with respect to such services or the amounts we pay for them will be limited.
We may not be able to replace these services or enter into appropriate third-party agreements on terms and conditions, including cost, comparable to those that we receive from Lilly under the transitional services agreement. Additionally, after the transitional services agreement terminates, we may be unable to sustain the services at the same levels or obtain the same benefits as when we were receiving such services and benefits from Lilly. When we begin to operate these functions separately, if we do not have our own adequate systems and business functions in place, or are unable to obtain them from other providers, we may not be able to operate our business effectively or at comparable costs, and our profitability may decline. In addition, we have historically received informal support from Lilly, which may not be addressed in the transitional services agreement. The level of this informal support may diminish or be eliminated in the future.
Risks Related to Elanco Common Stock
Future sales or the possibility of future sales of a substantial amount of our common stock may depress the price of shares of our common stock.
Future sales or the availability for sale of substantial amounts of our common stock in the public market could adversely affect the prevailing market price of our common stock and could impair our ability to raise capital through future sales of equity securities.
As of December 31, 2019, there were 373 million shares of our common stock outstanding, approximately 3.5 million shares of our common stock issuable upon exercise or vesting of outstanding equity awards and an additional 8 million shares of common stock available for issuance under the 2018 Elanco Stock Plan and Elanco Animal Health Incorporated Directors’ Deferral Plan; issuances of these shares are registered on our Registration Statement on Form S-8. Accordingly, shares of our common stock registered under such registration statement will be available for sale in the open market upon exercise or vesting by the holders of such awards, subject to vesting restrictions and Rule 144 limitations applicable to our affiliates.
On January 27, 2020, we issued approximately 25 million shares of our common stock in a registered public offering. Additionally, we issued on such date 11 million tangible equity units in a registered public offering. Unless settled earlier, each purchase contract that is a component of a tangible equity unit will settle automatically on the mandatory settlement date into up to 1.5625 shares of our common stock, subject to certain anti-dilution adjustments. All of the shares of common stock and tangible equity units sold in the public offering, as well as the shares of common stock issuable upon settlement of the units, are and will be freely tradable without restriction or further registration under the Securities Act by persons other than our “affiliates” and sales of the shares of common stock, the units or the underlying common stock may depress the price of shares of our common stock.
Pursuant to the Purchase Agreement, we have agreed to issue the consideration shares to Bayer and to use our reasonable best efforts to file a shelf registration statement to register such shares within 60 days after the closing date of the Acquisition. The Purchase Agreement provides that, subject to certain lock-up restrictions with respect to the transfer of the consideration shares, Bayer may request that we complete underwritten offerings with respect the consideration shares, subject to limitations on minimum offering size. The completion of the Acquisition is subject to the satisfaction of certain customary closing conditions, including the receipt of antitrust approvals and the absence of any law or order enjoining or otherwise prohibiting the Acquisition in specified jurisdictions. Bayer will receive the consideration shares at the completion of the Acquisition.
Any shares of common stock sold by Bayer under the shelf registration statement in compliance with or following the expiration of the lock-up provisions under the Purchase Agreement will be freely tradable. In the event Bayer exercises its registration rights and sells a large number of shares of our common stock, such sales could reduce the trading price of our common stock. These sales or the prospects of these sales or any other sales also could impede our ability to raise future capital.
In addition, subject to compliance with our tax matters agreement with Lilly, we may also issue additional shares of common stock or convertible debt securities to finance future acquisitions or for other corporate purposes. We cannot predict the size of future issuances of our common stock or other securities or the effect, if any, that future issuances and sales of our common stock or other securities will have on the market price of our common stock . Sales of substantial amounts of common stock (including shares of common stock issued in connection with the
48

Acquisition or any future acquisition), or the perception that such sales could occur, may adversely affect prevailing market prices for our common stock.
The price of our common stock may fluctuate substantially.
Investors should consider an investment in our common stock to be risky, and should invest in our common stock only if the investor can withstand a significant loss and wide fluctuations in the market value of the investment. Some factors that may cause the market price of our common stock to fluctuate, in addition to the other risks mentioned in this section of the annual report on Form 10-K, are:
•our announcements or our competitors’ announcements regarding new products, enhancements, significant contracts, acquisitions or strategic investments;
•changes in earnings estimates or recommendations by securities analysts, if any, who cover our common stock;
•failures to meet external expectations or management guidance;
•fluctuations in our quarterly financial results or the quarterly financial results of companies perceived to be similar to us;
•changes in our capital structure or dividend policy future issuances of securities, sales of large blocks of common stock by our shareholders or our incurrence of additional debt;
•reputational issues;
•changes in general economic and market conditions in or any of the regions in which we conduct our business;
•changes in industry conditions or perceptions; and
•changes in applicable laws, rules or regulations and other dynamics.
In addition, if the market for stocks in our industry or related industries, or the stock market in general, experiences a loss of investor confidence, the trading price of our common stock could decline for reasons unrelated to our business, financial condition and results of operations. If any of the foregoing occurs, it could cause our stock price to fall and may expose us to lawsuits that, even if unsuccessful, could be costly to defend and a distraction to management.
The market price of our common stock is also likely to be influenced by the tangible equity units issued by us. For example, the market price of our common stock could become more volatile and could be depressed by:
•investors' anticipation of the potential resale in the market of a substantial number of additional shares of our common stock received upon settlement of the purchase contracts that are a component of the units;
•possible sales of our common stock by investors who view the units as a more attractive means of equity participation in us than owning shares of our common stock; and
•hedging or arbitrage trading activity that may develop involving the units and our common stock.
We do not anticipate paying dividends on our common stock in the foreseeable future.
We do not anticipate paying any dividends in the foreseeable future on our common stock. We intend to retain all future earnings for the operation and expansion of our business and the repayment of outstanding debt. The New Credit Facilities are expected to contain restrictive covenants that impose significant operating and financial restrictions on us, including restrictions on our ability to pay dividends and make other restricted payments. As a result, capital appreciation, if any, of our common stock may be your major source of gain for the foreseeable future. While we may change this policy at some point in the future, we cannot assure you that we will make such a change.
49

The distributions we pay on our common stock may not qualify as dividends for U.S. federal income tax purposes, which could adversely affect the U.S. federal income tax consequences to you of owning our common stock.
Generally, any distributions that we make to a stockholder with respect to its shares of our common stock will constitute a dividend for U.S. federal income tax purposes to the extent of our current or accumulated earnings and profits as determined for U.S. federal income tax purposes. While we expect that we will have accumulated earnings and profits, as determined for U.S. federal income tax purposes, allocated to us as a result of our separation from Lilly, this allocation has not yet been finalized. Furthermore, our ability to generate earnings and profits, as determined for U.S. federal income tax purposes, in any future year is subject to a number of variables that are uncertain and difficult to predict.
Generally, any distribution not constituting a dividend under the rules described above will be treated as first reducing the investor's adjusted basis in shares of our common stock and, to the extent that the distribution exceeds the adjusted basis in shares of our common stock, as gain from the sale or exchange of such shares, and if the investor is a domestic corporation, it will not be entitled to claim, with respect to such non-dividend distribution, a “dividends-received” deduction, which generally applies to dividends received from other domestic corporations.
Applicable laws and regulations, provisions of our amended and restated articles of incorporation and our amended and restated bylaws may discourage takeover attempts and business combinations that shareholders might consider in their best interests.
Applicable laws, provisions of our amended and restated articles of incorporation and our amended and restated bylaws and certain contractual rights that have been granted to Lilly under the master separation agreement may delay, deter, prevent or render more difficult a takeover attempt that our shareholders might consider in their best interests. For example, they may prevent our shareholders from receiving the benefit from any premium to the market price of our common stock offered by a bidder in a takeover context. Even in the absence of a takeover attempt, the existence of these provisions may adversely affect the prevailing market price of our common stock if they are viewed as discouraging takeover attempts in the future.
Our amended and restated articles of incorporation and our amended and restated bylaws contain provisions that are intended to encourage prospective acquirers to negotiate with our board of directors rather than to attempt a hostile takeover, which could deter coercive takeover practices and inadequate takeover bids. These provisions provide for:
•a board of directors divided into three classes with staggered terms;
•advance notice requirements regarding how our shareholders may present proposals or nominate directors for election at shareholder meetings;
•the right of our board of directors to issue one or more series of preferred stock with such powers, rights and preferences as the board of directors shall determine;
•only the board of directors to fill newly-created directorships or vacancies on our board of directors;
•limitations on the ability of shareholders to call special meetings of shareholders and require that all shareholder action be taken at a meeting rather than by written consent;
•a two-thirds shareholder vote requirement to amend our amended and restated articles of incorporation;
•the exclusive right of our board of directors to amend our amended and restated bylaws; and
•the requirement that a 66 2/3% vote is necessary to remove directors.
These limitations may adversely affect the prevailing market price and market for our common stock if they are viewed as limiting the liquidity of our stock or discouraging takeover attempts in the future.

Item 1B. Unresolved Staff Comments
None.
50

Item 2. Properties
Properties
The address of our principal executive offices is currently c/o Elanco, 2500 Innovation Way, Greenfield IN, 46140.
We have R&D operations co-located with certain of our manufacturing sites in the U.S. to facilitate the efficient transfer of production processes from our laboratories to manufacturing sites. In addition, we maintain R&D operations at non-manufacturing locations in the U.S., Switzerland, Australia, Brazil and China. As part of the Separation, Lilly transferred to us its interest in each of these R&D facilities. Our largest R&D facility is our U.S. R&D site located in Fort Dodge, Iowa, which has approximately 0.3 million square feet.
Our global manufacturing network is comprised of 12 manufacturing sites. The largest manufacturing site in our global manufacturing network is our manufacturing site located in Clinton, Indiana, which has approximately 0.7 million square feet. In addition, our global manufacturing network will continue to be supplemented by approximately 90 CMOs. See "Item 1. Business — Manufacturing and Supply Chain."
We own or lease various additional properties for other business purposes including office space, warehouses and logistics centers. In addition, under the TSA, Lilly provides us with continued access to certain of its premises currently occupied by our employees for up to two years from the date of the Separation.
We believe that our existing properties, as supplemented by CMOs and access to Lilly facilities that will be provided under the TSA, are adequate for our current requirements and for our operations in the near future.

Item 3. Legal Proceedings
We are from time to time subject to claims and litigation arising in the ordinary course of business. These claims and litigation may include, among other things, allegations of violation of U.S. and foreign competition law, labor laws, consumer protection laws and environmental laws and regulations, as well as claims or litigation relating to product liability, intellectual property, securities, breach of contract and tort. We operate in multiple jurisdictions and, as a result, a claim in one jurisdiction may lead to claims or regulatory penalties in other jurisdictions. We intend to vigorously defend against any pending or future claims and litigation, as appropriate.

At this time, in the opinion of our management, the likelihood is remote that the impact of such proceedings, either individually or in the aggregate, would have a material adverse effect on our consolidated and combined results of operations, financial condition or cash flows. However, one or more unfavorable outcomes in any claim or litigation against us could have a material adverse effect for the period in which they are resolved. In addition, regardless of their merits or their ultimate outcomes, such matters are costly, divert management’s attention and may materially adversely affect our reputation, even if resolved in our favor.

Item 4. Mine Safety Disclosures
Not applicable.
Part II
Item 5. Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
MARKET INFORMATION
On September 20, 2018, our common stock began trading on the New York Stock Exchange under the symbol “ELAN.”
51

HOLDERS
There were 313 holders of record of our common stock as of February 25, 2020. This does not include the number of stockholders who hold shares of our common stock through banks, brokers or other financial institutions.
DIVIDEND POLICY
We do not anticipate paying dividends on our common stock in the foreseeable future; however, we may change our dividend policy at any time.
PERFORMANCE GRAPH
This graph compares the return on Elanco's common stock with that of the S&P 500 Stock Index and the S&P 500 Pharmaceuticals Index from September 20, 2018 (the first day our common stock was traded in conjunction with our IPO) through December 31, 2019. The graph assumes that, on September 20, 2018, a person invested $100 each in Elanco common stock, the S&P 500 Index, and the S&P 500 Pharmaceuticals Index. The graph measures total shareholder return, which takes into account both stock price and dividends. It assumes that dividends paid by a company are reinvested in that company’s stock.
elan-20191231_g3.jpg
*$100 invested on 9/20/2018 in stock or index, including reinvestment of dividends. Fiscal year ending December 31.
9/20/189/30/1812/31/183/31/196/30/199/30/1912/31/19
Elanco Animal Health Inc.100.00  96.92  87.58  89.08  93.89  73.86  81.81  
S&P 500 Index100.00  100.57  86.97  98.84  103.10  104.85  114.36  
S&P 500 Pharmaceuticals Index100.00  102.91  98.62  104.60  104.66  100.45  113.50  

Item 6. Selected Financial Data
The following tables set forth our selected historical consolidated and combined financial data for the periods indicated below.
52

Our consolidated and combined financial statements include the attribution of certain assets and liabilities that have historically been held at the Lilly corporate level but which are specifically identifiable or attributable to us. Through the completion of the IPO, our consolidated and combined financial statements also include expense allocations related to certain Lilly corporate functions, including executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information technology and investor relations. These expenses were allocated to us based on direct usage or benefit where specifically identifiable, with the remainder allocated primarily on a pro rata basis of revenue, headcount or other measures. We believe that this expense methodology, and the results thereof, is reasonable for all periods presented. However, the allocations may not be indicative of the actual expense that would have been incurred if we would have operated as an independent, publicly traded company for the periods presented. It is impractical to estimate what our standalone costs would have been for the historical periods presented. After the IPO, a TSA between Lilly and Elanco went into effect. Under the terms of the TSA, we will be able to use certain services and resources related to corporate functions historically provided to us by Lilly, such as executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information technology and investor relations (Lilly Services) for a fixed term, established on a service-by-service basis. For those TSAs that remain in effect as of December 31, 2019, we are paying Lilly mutually agreed upon fees for the Lilly Services provided under the TSA. Our consolidated and combined financial statements reflect the charges for Lilly Services after the IPO.
The financial statements presented may not be indicative of our future performance and do not necessarily reflect what our financial position and results of operations would have been had we operated as an independent, publicly traded company for the periods presented prior to IPO.
ELANCO ANIMAL HEALTH INCORPORATED (Dollars in millions, except per-share data)
20192018201720162015
Operations
Revenue$3,071.0  $3,066.8  $2,889.0  $2,913.5  $2,909.1  
Cost of sales1,470.3  1,573.8  1,493.9  1,409.0  1,533.7  
Research and development270.1  246.6  251.7  265.8  291.0  
Marketing, selling and administrative760.2  735.2  779.8  784.8  916.0  
Amortization of intangible assets200.4  197.4  221.2  170.7  163.0  
Asset impairment, restructuring and other special charges185.5  128.8  375.1  308.4  263.3  
Interest expense, net of capitalized interest78.9  29.6  —  —  —  
Other–net, expense (income)
27.4  41.3  (0.1) (2.8) 1.6  
Income (loss) before income tax expense78.2  114.1  (232.6) (22.4) (259.5) 
Income tax expense (benefit)10.3  27.6  78.1  25.5  (48.7) 
Net income (loss)$67.9  $86.5  $(310.7) $(47.9) $(210.8) 
Net income (loss) as a percent of revenue2 %3 %(11)%(2)%(7)%
Net income (loss) per share - basic$0.18  $0.28  $(1.06) $(0.16) $(0.72) 
Net income (loss) per share - diluted0.18  0.28  (1.06) (0.16) (0.72) 
Weighted-average number of shares outstanding - basic369.0  313.7  293.3  293.3  293.3  
Weighted-average number of shares outstanding - diluted370.3  313.7  293.3  293.3  293.3  
Financial Position
Total assets$8,985.8  $8,956.7  $8,940.3  $8,099.7  $8,433.6  
Long-term debt2,330.5  2,443.3  —  —  —  
Total liabilities3,438.9  3,759.2  1,160.0  1,082.3  1,004.1  
Total equity5,546.9  5,197.5  7,780.3  7,017.4  7,429.5  

53

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Management’s discussion and analysis of financial condition and results of operations, is intended to assist the reader in understanding and assessing significant changes and trends related to our results of operations and financial position. This discussion and analysis should be read in conjunction with the consolidated and combined financial statements and accompanying footnotes in Item 8 of Part II of this Annual Report on Form 10-K. Certain statements in this Item 7 of Part II of this Annual Report on Form 10-K constitute forward-looking statements. Various risks and uncertainties, including those discussed in "Forward-Looking Statements" and Item 1A, “Risk Factors,” may cause our actual results, financial position, and cash generated from operations to differ materially from these forward-looking statements.
Overview
Founded in 1954 as part of Eli Lilly & Co. (Lilly), Elanco is a premier animal health company that innovates, develops, manufactures and markets products for companion and food animals. Headquartered in Greenfield, Indiana, we are the fourth largest animal health company in the world, with revenue of $3,071.0 million for the year ended December 31, 2019. Globally, we are #1 in medicinal feed additives, #2 in poultry, and #3 in other pharmaceuticals, which are mainly companion animal therapeutics, measured by 2018 revenue, according to Vetnosis.
We have one of the broadest portfolios of pet parasiticides in the companion animal sector. We offer a diverse portfolio of more than 125 brands that make us a trusted partner to veterinarians and food animal producers in more than 90 countries.
On September 24, 2018, we completed our initial public offering (IPO), pursuant to which we issued and sold 19.8% of our total outstanding shares. On September 20, 2018, our common stock began trading on the New York Stock Exchange (NYSE) under the symbol “ELAN.” On September 24, 2018, immediately preceding the completion of the IPO, Lilly transferred to us substantially all of its animal health businesses in exchange for (i) all of the net proceeds (approximately $1,659.7 million) we received from the sale of our common stock in the IPO, including the net proceeds we received as a result of the exercise in full of the underwriters’ option to purchase additional shares, (ii) all of the net proceeds (approximately $2,000 million) we received from the issuance of our senior notes; and (iii) all of the net proceeds ($498.6 million) we received from the entry into our term loan facility. In addition, immediately prior to the completion of the IPO, we entered into certain agreements with Lilly that provide a framework for our ongoing relationship with them.

On February 8, 2019, Lilly announced an exchange offer whereby Lilly shareholders could exchange all or a portion of Lilly common stock for shares of Elanco common stock owned by Lilly. On that date, we filed a Registration Statement on Form S-4 with the SEC in connection with that exchange offer. The disposition of Elanco shares was completed on March 11, 2019, and resulted in the full separation of Elanco along with the disposal of Lilly's entire ownership and voting interest in Elanco.

We operate our business in a single segment directed at fulfilling our vision of enriching the lives of people through food, making protein more accessible and affordable and through pet companionship, helping pets live longer, healthier lives. We advance our vision by offering products in four primary categories:
Companion Animal Disease Prevention (CA Disease Prevention): We have one of the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. Combining our parasiticide portfolio with our vaccines presence, we are a leader in the U.S. in the disease prevention category based on share of revenue.
Companion Animal Therapeutics (CA Therapeutics): We have a broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. Pet owners are increasingly treating osteoarthritis in their pets, and our Galliprant product is one of the fastest growing osteoarthritis treatments in the U.S. We also have treatments for otitis (ear infections), as well as cardiovascular and dermatology indications.
Food Animal Future Protein & Health (FA Future Protein & Health): Our portfolio in this category, which includes vaccines, nutritional enzymes and animal only antibiotics, serves the growing demand for
54

protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. We are focused on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. We are a leader in providing vaccines as alternatives to antibiotics to promote animal health based on share of revenue.
Food Animal Ruminants & Swine (FA Ruminants & Swine): We have developed a range of food animal products used extensively in ruminant (e.g., cattle, sheep and goats) and swine production.
For the years ended December 31, 2019, 2018 and 2017, our revenue was $3,071.0 million, $3,066.8 million and $2,889.0 million, respectively. For the years ended December 31, 2019, 2018 and 2017, our net income (loss) was $67.9 million, $86.5 million and $(310.7) million, respectively.
Increases or decreases in inventory levels at our channel distributors can positively or negatively impact our quarterly and annual revenue results, leading to variations in quarterly revenues. This can be a result of various factors, such as end customer demand, new customer contracts, heightened and generic competition, the need for certain inventory levels, our ability to renew distribution contracts with expected terms, our ability to implement commercial strategies, regulatory restrictions, unexpected customer behavior, payment terms we extend, which are subject to internal policies, and procedures and environmental factors beyond our control, including weather conditions.

Key Trends and Conditions Affecting Our Results of Operations
Industry Trends
The animal health industry, which focuses on both food animals and companion animals, is a growing industry that benefits billions of people worldwide.
As demand for animal protein grows, food animal health is becoming increasingly important. Factors influencing growth in demand for food animal medicines and vaccines include:
•one in three people need improved nutrition;
•increased global demand for protein, particularly poultry and aquaculture;
•natural resource constraints, such as scarcity of arable land, fresh water and increased competition for cultivated land, driving the need for more efficient food production;
•loss of productivity due to food animal disease and death;
•increased focus on food safety and food security; and
•human population growth, increased standards of living, particularly in many emerging markets, and increased urbanization.
Growth in food animal nutritional health products (enzymes, probiotics and prebiotics) is influenced, among other factors, by demand for antibiotic alternatives that can promote animal health and increase productivity.
Factors influencing growth in demand for companion animal medicines and vaccines include:
•increased pet ownership globally;
•pets living longer; and
•increased pet spending as pets are viewed as members of the family by owners.
Factors Affecting Our Results of Operations
Product Development and New Product Launches
A key element of our targeted value creation strategy is to drive growth through portfolio development and product innovation, primarily in our three targeted growth categories of CA Disease Prevention, CA Therapeutics and FA Future Protein & Health. Since 2015, we have launched or acquired 14 new products, including the additions of Entyce, Nocita and Tanovea in 2019. Revenue from these products contributed $439.2 million to revenue for the
55

year ended December 31, 2019. We continue to pursue the development of new chemical and biological molecules through our approach to innovation. Our future growth and success depends on both our pipeline of new products, including new products that we may develop through joint ventures and products that we are able to obtain through license or acquisition, and the expansion of the use of our existing products. We believe we are an industry leader in animal health R&D, with a track record of product innovation, business development and commercialization.
Impact of Changing Market Demand for Antibiotics
In recent years, our operational results have been, and will continue to be, affected by regulations and changing market demand relating to the use of antibiotics and other products intended to increase food animal production.
There are two classes of antibiotics used in animal health: (i) shared-class, or medically important, antibiotics; and (ii) animal-only antibiotics. Shared-class antibiotics are used to treat infectious disease caused by pathogens that occur in both humans and animals. As part of our antibiotic stewardship plan and in compliance with FDA guidance, shared-class antibiotics are labeled only for the treatment of an established need in animals and only with veterinarian oversight. However, not all pathogens that cause disease in animals are infectious in humans, and accordingly animal-only antibiotics are not used in human medicine (i.e., not medically important). From 2015 to 2019, our revenue from shared-class antibiotics declined at a CAGR of 10%, excluding the impact of foreign exchange. This was driven primarily by changing regulations in many markets, including the Veterinary Feed Directive, as well as changing market demand and Elanco’s tiered-approach to antibiotic stewardship, which included removing growth promotion from labels and requiring veterinary oversight in the U.S. and other markets.
Globally, during 2019, our revenue from shared-class antibiotics declined 13%, excluding the impact of foreign exchange, and represented 11% (4% from sales in the U.S. and 7% from sales outside of the U.S.) of our total revenue, down from 16% in 2015. From 2015 to 2019, our revenue from animal-only antibiotics grew at a CAGR of 4%, excluding the impact of foreign exchange, driven by sales outside the U.S., which offset a slight decline in the U.S. Globally, during 2019, our revenue from animal-only antibiotics declined 1%, excluding the impact of foreign exchange, and represented 24% of our total revenue, up from 23% in 2015. During 2019, 87% of our revenue from animal-only antibiotics resulted from the sale of ionophores. Ionophores are a special class of animal-only antimicrobials, and because of their animal-only designation, mode of action and spectrum of activity, their use, to date have not been impacted by regulations or changing market demand in many markets outside the U.S.
We have intentionally shifted away from shared-class antibiotics, and are focusing on animal-only antibiotics, as well as antibiotic-free solutions. When an animal-only antibiotic exists, we believe it should be the first, preferred antibiotic treatment. Antibiotic resistance concerns, or other health concerns regarding food animal products, may result in additional restrictions, expanded regulations or changes in market demand to further reduce the use of antibiotics in food animals. We believe it is important to protect the benefits of antibiotics in human medicine, while responsibly protecting the health of food animals and the safety of our food supply.
Impact of Competition
The animal health industry is competitive. Established animal health companies who consistently deliver high quality products enjoy brand loyalty from their customers, which often continues after the loss of patent-based or regulatory exclusivity. In 2019, approximately 67% of our revenue was from products that did not have patent protection. In animal health, while potentially significant, erosion from generic competition is often not as steep as in human health, with the originator often retaining a significant market share. However, generic competition can nevertheless significantly affect our results. While our largest product, Rumensin (monensin), has been subject to generic competition from monensin outside the U.S. for more than 10 years, our revenue from Rumensin sales outside the U.S. grew at a CAGR of 5% from 2015 to 2019. In the third quarter of 2019, an established animal health company received U.S. approval for generic monensin in cattle and goats for certain indications. U.S. revenue from Rumensin may decline as a result of the generic competition. We have experienced significant competitive headwinds from generic ractopamine in the U.S. In the third quarter of 2013, a large, established animal health company received U.S. approval for ractopamine (the generic to our drugs Paylean and Optaflexx). U.S. revenue for Paylean and Optaflexx, our ractopamine beef and swine products, has declined at a CAGR of 44% and 21%, respectively, from 2015 to 2019 as a result of generic competition and the impact of international regulatory restrictions. In 2019, we had an estimated 70% market share of all U.S. ractopamine-treated beef cattle based on management estimates.
56

Although we believe brand loyalty is an important contributor to a product's ongoing success, the animal health industry is also impacted by innovation. We experienced an innovation lag in the companion animal parasiticide space from 2015 to 2017. In the absence of a competitive combined oral flea and tick product, our U.S. companion animal parasiticide portfolio revenue declined 15% in 2017, excluding the impact on revenue resulting from a reduction in inventory levels within our distribution channel. In February 2018, we launched Credelio in the U.S. for the treatment of fleas and ticks. Since the launch of Credelio, our sales of parasiticides in the U.S. have begun to grow again.
Productivity
Our results during the periods presented have benefited from operational and productivity initiatives implemented following recent acquisitions and in response to changing market demand for antibiotics and other headwinds.
Our acquisitions within the last six years added in the aggregate $1.4 billion in revenue, 4,600 full-time employees, 12 manufacturing and eight R&D sites. In addition, from 2015 to 2019, changing market demand for antibiotics and other headwinds, such as competition with generics and innovation, affected some of our highest gross margin products, resulting in a change to our product mix and driving operating margin lower. In response, we implemented a number of initiatives across the manufacturing, R&D and selling, general and administrative (SG&A) functions. Our manufacturing cost savings strategies included improving manufacturing processes and headcount through lean manufacturing (minimizing waste while maintaining productivity), closing of three manufacturing sites, consolidating our CMO network, strategically insourcing certain projects, and pursuing cost savings opportunities with respect to raw materials via a new procurement process. Additional cost savings resulted from reducing the number of R&D sites from 16 to nine, SG&A savings from sales force consolidation, and reducing discretionary and other general and administrative (G&A) operating expense.
Foreign Exchange Rates
Significant portions of our revenue and costs are exposed to changes in foreign exchange rates. Our products are sold in more than 90 countries and, as a result, our revenue is influenced by changes in foreign exchange rates. For the years ended December 31, 2019 and 2018, approximately 44% and 52%, respectively, of our revenue was denominated in foreign currencies. As we operate in multiple foreign currencies, including the Euro, British pound, Swiss franc, Brazilian real, Australian dollar, Japanese yen, Canadian dollar, Chinese yuan, and other currencies, changes in those currencies relative to the U.S. dollar will impact our revenue, cost of sales and expenses, and consequently, net income. These fluctuations may also affect the ability to buy and sell our products between markets impacted by significant exchange rate variances. Currency movements decreased revenue by 2% during the year ended December 31, 2019. Currency movements had limited impact on revenue during the years ended December 31, 2018 and 2017.
General Economic Conditions
In addition to industry-specific factors, we, like other businesses, face challenges related to global economic conditions. Growth in both the food animal and companion animal sectors is driven in part by overall economic development and related growth, particularly in many emerging markets. In recent years, certain of our customers and suppliers have been affected directly by economic downturns, which decreased the demand for our products.
The cost of our products to food animal producers is small relative to their other production costs, including feed, and the use of our products is intended to improve economic outcomes for food animal producers. Similarly, industry sources have reported that pet owners indicated a preference for reducing spending on other aspects of their lifestyle, including entertainment, clothing and household goods, before reducing spending on pet care. While these factors have mitigated the impact of recent downturns in the global economy, further economic challenges could increase cost sensitivity among our customers, which may result in reduced demand for our products and could have a material adverse effect on our financial condition and results of operations.
Weather Conditions and the Availability of Natural Resources
The animal health industry and demand for many of our animal health products in a particular region are affected by weather conditions, varying weather patterns and weather-related pressures from pests, such as fleas and ticks. As a result, we may experience regional and seasonal fluctuations in our results of operations.
57

Food animal producers depend on the availability of natural resources, including large supplies of fresh water. Their animals' health and their ability to operate could be adversely affected if they experience a shortage of fresh water due to human population growth or floods, droughts or other weather conditions.
Drought conditions could negatively impact, among other things, the supply of corn and the availability of grazing pastures. A decrease in harvested corn results in higher corn prices, which could negatively impact the profitability of food animal producers of ruminants, pork and poultry. Higher corn prices and reduced availability of grazing pastures contribute to reductions in herd or flock sizes that in turn result in less spending on animal health products. As such, a prolonged drought could have a material adverse effect on our financial condition and results of operations. Factors influencing the magnitude and timing of effects of a drought on our performance include, but may not be limited to, weather patterns and herd management decisions.
In addition, veterinary hospitals and practitioners depend on visits from and access to the animals under their care. Veterinarians' patient volume and ability to operate could be adversely affected if they experience prolonged snow, ice or other severe weather conditions, particularly in regions not accustomed to sustained inclement weather. Adverse weather conditions or a shortage of fresh water may cause veterinarians and food animal producers to purchase less of our products.
Disease Outbreaks
Sales of our food animal products could be adversely affected by the outbreak of disease carried by animals, such as African Swine Fever. Outbreaks of disease may reduce regional or global sales of particular animal-derived food products or result in reduced exports of such products, either due to heightened export restrictions or import prohibitions, which may reduce demand for our products. Also, the outbreak of any highly contagious disease near our main production sites could require us to immediately halt production of our products at such sites or force us to incur substantial expenses in procuring raw materials or products elsewhere. Alternatively, sales of products that treat specific disease outbreaks may increase.
Manufacturing and Supply
In order to sell our products, we must be able to reliably produce and ship our products in sufficient quantities. Many of our products involve complex manufacturing processes and are sole-sourced from certain manufacturing sites.
Minor deviations in our manufacturing or logistical processes, unpredictability of a product's regulatory or commercial success or failure, the lead time necessary to construct highly technical and complex manufacturing sites, and shifting customer demand increase the potential for capacity imbalances.
Components of Revenue and Costs and Expenses
Revenue
Our revenue is primarily derived from sales of our products to third-party distributors, and directly to food producers and veterinarians. For additional information regarding our products, including descriptions of our products, see "Item 1. Business — Products."
We aggregate our products into five categories to understand revenue growth:
•CA Disease Prevention includes parasiticides and vaccine products for dogs and cats;
•CA Therapeutics includes products for the treatment of pain, osteoarthritis, otitis, cardiovascular and dermatology indications in dogs and cats;
•FA Future Protein & Health includes vaccines, antibiotics, parasiticides and other products used in poultry and aquaculture production, as well as functional nutritional health products, including enzymes, probiotics and prebiotics;
•FA Ruminants & Swine includes vaccines, antibiotics, implants, parasiticides, and other products used in ruminants and swine production, as well as certain other food animal products; and
58

•Strategic Exits includes business activities that we have either exited or made the strategic decision to exit, including the transitional contract manufacturing activity that we acquired in connection with our acquisition of the BI Vetmedica U.S. vaccines portfolio, two terminated legacy U.S. distribution agreements, a terminated distribution agreement outside the U.S., an equine product not core to our business and a transitional contract manufacturing activity associated with the supply to Lilly of human growth hormone.
Costs, Expenses and Other
Cost of sales consists primarily of cost of materials, facilities and other infrastructure used to manufacture our products, shipping and handling, inventory losses and expired products.
Marketing, selling and administrative expenses consist of, among other things, the costs of marketing, promotion and advertising and the costs of administration (business technology, facilities, legal, finance, human resources, business development, external affairs and procurement).
Amortization of intangible assets consists of the amortization expense for intangible assets that have been acquired through business combinations.
R&D expenses consist of project costs specific to new product R&D and product lifecycle management, overhead costs associated with R&D operations, regulatory, product registrations and investments that support local market clinical trials for approved indications. We manage overall R&D based on our strategic opportunities and do not disaggregate our R&D expenses incurred by nature or by product as we do not use or maintain such information in managing our business.
Asset impairment, restructuring and other special charges consist primarily of impairment of long-term assets, restructuring charges, costs associated with acquiring and integrating businesses, and certain non-recurring expenses, including costs related to the build out of processes and systems to support finance and global supply and logistics, among others, to stand our organization up as an independent company.
Interest expense, net of capitalized interest consists of interest incurred on our long-term debt.
Other-net, expense (income) consists primarily of realized or unrealized foreign exchange losses and loss or impairment on other investments.
Comparability of Historical Results
Our historical results of operations for the periods presented may not be comparable with prior periods or with our results of operations in the future, due to many factors, included but not limited to the factors identified in "Key Trends and Conditions Affecting Our Results of Operations."
Our Relationship with Lilly and Additional Standalone Costs
During the period prior to the IPO, our business operated solely as part of a division of Lilly. Our combined financial statements have been derived from Lilly’s consolidated financial statements and accounting records. Our consolidated and combined financial statements reflect our financial position, results of operations and cash flows of the business that was transferred at the time of the separation and do not purport to reflect what the results of operations, comprehensive income/(loss), financial position, equity or cash flows would have been had we operated as an independent, publicly traded company during the periods presented prior to the IPO.
Our historical results reflect an allocation of costs for certain Lilly corporate costs for periods prior to the IPO, including, among others, executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information technology and investor relations. These allocations are not necessarily indicative of the expenses we may incur as a standalone public company. Although we entered into certain agreements with Lilly in connection with the IPO and the Separation, the amount and composition of our expenses may vary from historical levels since the fees charged for the services under these agreements may be higher or lower than the costs reflected in the historical allocations. The total allocations included in our results for the years ended December 31, 2019, 2018 and 2017 were $0.0 million, $105.2 million, and $151.7 million, respectively. See Note 20: Related Party Agreements and Transactions to our consolidated and combined financial statements.
59

We are currently investing in expanding our own administrative functions, including, but not limited to, information technology, facilities management, distribution, human resources, and manufacturing, to replace services previously provided by Lilly. Because of initial stand-up costs and overlaps with services previously provided by Lilly, we have incurred and expect to continue to incur certain temporary, duplicative expenses in connection with the Separation. We have also incurred and expect to continue to incur costs related to the build out of processes and systems to support finance and global supply and logistics, among others. We currently estimate these costs taken together to be in a range from $240 million to $290 million, net of potential real estate dispositions and employee benefit changes, of which a portion will be capitalized and the remainder will be expensed.
Lilly utilizes a centralized treasury management system, of which we were a part until our IPO. For periods prior to the IPO, our consolidated and combined financial statements reflect cash held only in bank accounts in our legal name and no allocation of combined cash positions. Our consolidated and combined financial statements do not reflect an allocation of Lilly’s debt or any associated interest expense. In connection with the IPO, we incurred $2.5 billion of long-term borrowings. Our historical results reflect $29.6 million of interest expense during the year ended December 31, 2018 due to the timing of the borrowings, in comparison to our interest expense of $78.9 million during the year ended December 31, 2019.
For the periods prior to the IPO, our consolidated and combined financial statements reflect income tax expense (benefit) computed on a separate company basis, as if operating as a standalone entity or a separate consolidated group in each material jurisdiction in which we operate. Our consolidated and combined financial statements for the periods prior to the IPO also reflect certain deferred tax assets and liabilities and income taxes payable based on this approach that did not transfer to us upon the Separation, as the underlying tax attributes were used by Lilly or retained by Lilly. As a result of potential changes to our business model and the fact that certain deferred tax assets and liabilities and income taxes payable did not transfer to us, income tax expense (benefit) included in the consolidated and combined financial statements may not be indicative of our future expected tax rate. 
Our historical results prior to IPO also do not reflect the impact of costs we have incurred and expect to continue to incur as a consequence of becoming a standalone company, including incremental costs associated with being a publicly traded company.
Subsequent to the IPO, we have implemented competitive compensation policies and programs as a standalone public company. Our historical results prior to the IPO reflect compensation costs that were allocated by Lilly.
As a result of the IPO, we became subject to the reporting requirements of the Securities Exchange Act of 1934 and the Sarbanes-Oxley Act. We are continuing to establish or expand additional procedures and practices as a standalone public company. As a result, we will continue to incur additional costs as a standalone public company, including internal audit, external audit, investor relations, stock administration, stock exchange fees and regulatory compliance costs.
Recent Significant Acquisitions
Our financial results have been impacted by acquisitions and integrations. For the periods presented, these include primarily the acquisitions and integrations of Novartis Animal Health, which closed on January 1, 2015, Boehringer Ingelheim Vetmedica, Inc.'s U.S. feline, canine and rabies vaccine portfolio and other related assets (BIVIVP), which closed on January 3, 2017, Aratana Therapeutics, Inc., which closed on July 18, 2019, and Prevtec Microbia Inc., which closed on July 31, 2019. For more information, see Note 6: Acquisitions to our consolidated and combined financial statements.
Asset Impairment, Restructuring and Other Special Charges
During the years ended December 31, 2019, 2018 and 2017 including in connection with the productivity initiatives described above under "Key Trends and Conditions Affecting Our Results of Operations - Productivity," we incurred charges related to asset impairment, restructuring and other special charges, including integration of acquired businesses. These charges include severance costs resulting from actions taken to reduce our costs, asset impairment charges primarily related to competitive pressures for certain companion animal products, product rationalizations, site closures and integration costs related to acquired businesses, primarily Novartis Animal Health, and costs related to the build out of processes and systems to support finance and global supply and logistics, among others, as we stand our organization up as an independent company.
60

For more information on these charges, see Note 7: Asset Impairment, Restructuring and Other Special Charges to our consolidated and combined financial statements.
Results of Operations
The following discussion and analysis of our consolidated and combined statements of operations should be read along with our consolidated and combined financial statements and the notes thereto included elsewhere in this report. For more information, see Note 2: Basis of Presentation to our consolidated and combined financial statements.

(Dollars in millions)Year Ended December 31,% Change
20192018201719/1818/17
Revenue $3,071.0  $3,066.8  $2,889.0  —%  6%  
Costs, expenses and other:
Cost of sales1,470.3  1,573.8  1,493.9  (7)% 5%  
% of revenue48 %51 %52 %
Research and development270.1  246.6  251.7  10%  (2)% 
% of revenue9 %8 %9 %
Marketing, selling and administrative760.2  735.2  779.8  3%  (6)% 
% of revenue25 %24 %27 %
Amortization of intangible assets200.4  197.4  221.2  2%  (11)% 
% of revenue7 %6 %8 %
Asset impairment, restructuring and other special charges185.5  128.8  375.1  44%  (66)% 
Interest expense, net of capitalized interest78.9  29.6  —  167%  NM  
Other–net, expense (income)
27.4  41.3  (0.1) NM  NM  
Income (loss) before taxes78.2  114.1  (232.6) NM  NM  
% of revenue3 %4 %(8)%NM  NM  
Income tax expense10.3  27.6  78.1  (63)% (65)% 
Net income (loss)$67.9  $86.5  $(310.7) NM  NM  
Certain amounts and percentages may reflect rounding adjustments.
NM - Not meaningful
Revenue
On a global basis, our revenue within our product categories was as follows:
(Dollars in millions)Year Ended December 31,% Change
20192018201719/1818/17
CA Disease Prevention$787.9  $804.6  $660.2  (2)% 22%  
CA Therapeutics (1)
348.0  283.1  260.8  23%  9%  
FA Future Protein & Health745.1  711.2  649.2  5%  10%  
FA Ruminants & Swine1,110.3  1,174.0  1,175.0  (5)% —%  
Subtotal2,991.3  2,972.9  2,745.2  1%  8%  
Strategic Exits (1)
79.7  93.9  143.8  (15)% (35)% 
Total$3,071.0  $3,066.8  $2,889.0  —%  6%  
(1) Represents revenue from business activities we have either exited or made a strategic decision to exit. On June 30, 2018, Elanco made the decision to exit an equine product not core to its business. Revenue from this product is reflected in Strategic Exits for the years ended December 31, 2019 and 2018 and in CA Therapeutics for the year ended December 31, 2017. Revenue from this product was $0.4 million, $1.6 million and $3.4 million for the years ended December 31, 2019, 2018 and 2017, respectively.
61

On a global basis, the effect of price, foreign exchange rates and volumes on changes in revenue as compared to the prior year was as follows:
(Dollars in millions)
Full year 2019Revenue  Price  FX Rate  Volume  Total  CER*  
CA Disease Prevention$787.9  1%  (1)% (2)% (2)% (1)% 
CA Therapeutics348.0  5%  (2)% 20%  23%  25%  
FA Future Protein & Health745.1  4%  (3)% 4%  5%  8%  
FA Ruminants & Swine1,110.3  1%  (2)% (5)% (5)% (4)% 
Core Revenue$2,991.3  2%  (2)% 1%  1%  3%  
Strategic Exits79.7  —%  —%  (15)% (15)% (15)% 
Total Elanco$3,071.0  2%  (2)% —%  —%  2%  

(Dollars in millions)
Full year 2018Revenue  Price  FX Rate  Volume  Total  CER*  
CA Disease Prevention$804.6  8%  —%  14%  22%  22%  
CA Therapeutics283.1  7%  1%  —%  9%  7%  
FA Future Protein & Health711.2  4%  —%  6%  10%  10%  
FA Ruminants & Swine1,174.0  (1)% —%  1%  —%  —%  
Core Revenue$2,972.9  3%  —%  5%  8%  8%  
Strategic Exits93.9  —%  —%  (34)% (35)% (35)% 
Total Elanco$3,066.8  3%  —%  3%  6%  6%  
Note: Numbers may not add due to rounding
*CER = Constant exchange rate

Revenue
Total revenue
2019 vs. 2018
Total revenue increased $4.2 million or 0.1% in 2019 as compared to 2018, reflecting a 2% increase in price, offset by a 2% unfavorable impact from foreign exchange rates. Volume was flat as compared to prior year.
In summary, the total revenue increase was due primarily to:
•an increase in revenue of $72.0 million or 25% from CA Therapeutics products, excluding the impact of foreign exchange rates; and
•an increase in revenue of $59.5 million or 8% from FA Future Protein & Health products, excluding the impact of foreign exchange rates;
partially offset by:
•a decrease in revenue of $46.1 million or 4% from FA Ruminants & Swine products, excluding the impact of foreign exchange rates;
•a decrease in revenue of $7.3 million or 1% from CA Disease Prevention products, excluding the impact of foreign exchange rates;
•a decrease in revenue of $14.2 million or 15% from Strategic Exits, excluding the impact of foreign exchange rates; and
•a decrease in revenue of $59.7 million due to the negative impact of foreign exchange rates.
62

The detailed change in revenue by product category was as follows:
•CA Disease Prevention revenue decreased by $16.7 million or 2%, driven by a decline in volume and to a lesser extent the unfavorable impact of foreign exchange rates, partially offset by an increase in price. The revenue decrease was a result of several unfavorable comparisons to 2018. In 2018, vaccines benefited from the initial stocking of a new customer agreement, customers purchased higher than normal levels of parasiticides and vaccines to achieve desired incentive levels across companion animal, and all remaining inventory for Parastar was sold prior to rationalizing the product, all contributing to the unfavorable comparison for the year. The decrease was also driven by declines in sales of older generation parasiticides, partially offset by the continued growth of Credelio and Interceptor Plus, including the initial stocking of a new customer agreement in the third quarter of 2019.
•CA Therapeutics revenue increased by $64.9 million or 23%, driven by increased volume and to a lesser extent price, partially offset by the impact of foreign exchange rates. The revenue increase was driven by increased demand for products across the therapeutics portfolio, primarily Galliprant, initial stocking for a new customer agreement in the third quarter of 2019, and inclusion of sales of Entyce and Nocita, as a result of the acquisition of Aratana.
•FA Future Protein & Health revenue increased by $33.9 million or 5%, driven by both increased volume and price, partially offset by an unfavorable impact from foreign exchange rates. Growth was driven by the aqua portfolio, poultry vaccines and nutritional products, partially offset by the loss of sales for certain products in China as a result of changing antibiotic policies.
•FA Ruminants & Swine revenue decreased by $63.7 million or 5%, driven by a decline in volume and to a lesser extent the unfavorable impact of foreign exchange rates, partially offset by an increase in price. The decline in revenue was driven by softness in swine products due to African Swine Fever across Asia, a disruption in global supply of certain third-party produced injectable cattle products, reduced U.S. producer use of Paylean, decreased Rumensin sales as a result of the generic entrant, and the impact from the Australian drought. These decreases were partially offset by revenue generated from Posilac™ sales as a result of the revised commercial agreement entered into in the third quarter of 2019.
•Strategic Exits revenue decreased by $14.2 million to $79.7 million and represented 3% of total revenue.

2018 vs. 2017
Total revenue increased $177.8 million or 6% in 2018 as compared to 2017, reflecting a 3% increase due to higher realized prices and a 3% increase due to higher volumes.
In summary, the total revenue increase was due primarily to:
•an increase in revenue of $142.1 million or 22% from CA Disease Prevention products, excluding the impact of foreign exchange rates;
•an increase in revenue of $18.4 million or 7% from CA Therapeutics products, excluding the impact of foreign exchange rates;
•an increase in revenue of $63.8 million or 10% from FA Future Protein & Health products, excluding the impact of foreign exchange rates and
partially offset by:
•a decrease in revenue of $0.8 million or 0% from FA Ruminants & Swine, excluding the impact of foreign exchange rates and
•a decrease in revenue of $49.9 million or 35% from Strategic Exits, excluding the impact of foreign exchange rates.
The detailed change in revenue by product category was as follows:
•CA Disease Prevention revenue increased by $144.4 million or 22% due primarily to a reduction in channel inventory in 2017 providing a favorable year-on-year comparison, continued uptake of Credelio and Interceptor Plus, as well as realized price increases primarily impacting Trifexis, Capstar (a flea treatment) and Comfortis, partially offset by volume declines in certain parasiticides, primarily Trifexis and Comfortis volumes.
63

•CA Therapeutics revenue increased by $22.3 million or 9% due primarily to the continued uptake of Galliprant and Osurnia, as well as increased demand for Onsior, partially offset by a temporary supply shortage of Percorten™ V used for the treatment of canine Addison’s Disease.
•FA Future Protein & Health revenue increased by $62.0 million or 10% due primarily to the launch of Imvixa and the growth in poultry animal-only antibiotics and poultry vaccines.
•FA Ruminants & Swine revenue decreased by $1.0 million due primarily to competitive headwinds for ractopamine based products, offset by growth in animal-only antibiotics, primarily in cattle.
•Strategic Exits revenue decreased by $49.9 million or 35% due primarily to the termination of a legacy U.S. distribution agreement in the third quarter of 2017, partially offset by revenue from the contract manufacturing agreement to supply human growth hormone to Lilly.
Costs, Expenses and Other
Cost of sales
2019 vs. 2018
Cost of sales decreased $103.5 million in 2019 as compared to 2018 due primarily to manufacturing productivity improvements and charges recorded during the year ended December 30, 2018 for inventory adjustments related to the suspension of commercial activities of Imrestor and the closure of the Larchwood, Iowa facility, partially offset by unfavorable product mix and logistics costs.
2018 vs. 2017
Cost of sales increased $79.9 million in 2018 as compared to 2017 primarily due to increased volume of products sold and the write-off of inventory related to the suspension of activities for Imrestor in 2018, partially offset by non-recurring costs incurred in 2017 associated with fair value adjustments to inventory acquired in the BIVIVP acquisition and subsequently sold.
Research and development
2019 vs. 2018
R&D expenses increased $23.5 million for 2019 as compared to 2018 primarily due to additional costs from acquired businesses during the year, including Aratana and Prevtec, increased costs from R&D infrastructure investments, and project spend as a result of pipeline progression.
2018 vs. 2017
R&D expenses decreased $5.1 million in 2018 as compared to 2017 due primarily to cost control measures and timing of projects leading to lower spend in 2018.
Marketing, selling and administrative
2019 vs. 2018
Marketing, selling and administrative expenses increased $25.0 million for 2019 as compared to 2018 due primarily to additional costs from acquired businesses during the year, primarily Aratana, and increased marketing efforts for our companion animal portfolio, and increased expenses as a result of operating as a standalone public company, partially offset by slightly lower selling costs and lower costs due to continued productivity initiatives and cost control measures across the business.
2018 vs. 2017
Marketing, selling and administrative expenses decreased $44.6 million in 2018 as compared to 2017 due primarily to productivity initiatives in sales and administrative functions and reduced direct to consumer programs combined with new product launches in 2017.
64

Amortization of intangible assets
2019 vs. 2018
Amortization of intangible assets increased $3.0 million for 2019 as compared to 2018 primarily due to the addition of amortization of intangible assets recorded from the acquisitions of Aratana and Prevtec in 2019 and the acceleration of the amortization of certain software assets to be retired prior to the end of their previously estimated respective useful lives due to our separation from Lilly.
2018 vs. 2017
Amortization of intangible assets decreased $23.8 million in 2018 as compared to 2017 due primarily to the acceleration of amortization related to certain product exits in 2017.
Asset impairment, restructuring and other special charges
For additional information regarding our asset impairment, restructuring and other special charges, see Note 7: Asset Impairment, Restructuring and Other Special Charges to our consolidated and combined financial statements.
2019 vs. 2018
Asset impairment, restructuring and other special charges increased $56.7 million in 2019 as compared to 2018 primarily due to higher transaction costs directly related to business acquisitions, including the pending acquisition of the animal health business of Bayer, higher integration costs of acquisitions, and costs associated with the implementation of new systems, programs, and processes due to the Separation from Lilly as well as severance costs, exit costs, impairment charges, and write-down charges recorded in 2019, as more fully described in Note 7.
2018 vs. 2017
Asset impairment, restructuring and other special charges decreased $246.3 million in 2018 as compared to 2017 primarily due to a decrease in severance related to the U.S. voluntary early retirement program offered in 2017 as well as a decrease in integration costs related to the BIVIVP acquisition in 2017, partially offset by a gain on disposal of a site that was previously closed as part of the acquisition and integration of Novartis Animal Health in 2017.
Interest expense, net of capitalized interest
2019 vs. 2018
Interest expense increased $49.3 million for the year ended December 31, 2019 due to the timing of the issuance of debt in the third quarter of 2018.
2018 vs. 2017
Interest expense was $29.6 million for the year ended December 31, 2018 due to our issuance of debt in the third quarter of 2018. There was no interest expense in 2017 and prior years.
Other–net, expense (income)

2019 vs. 2018
Other–net, expense decreased $13.9 million from $41.3 million in 2018 to $27.4 million in 2019. The decrease in expense is primarily due to the increase in the Aratana contingent consideration liability of $37.6 million associated with the Galliprant acquisition recorded in 2018, partially offset by the impact of $8.3 million of expense recorded in 2019 due to the release of a tax indemnity asset related to the 2015 acquisition of Novartis and $13.0 million of unfavorable adjustments to the contingent consideration liabilities recorded for Galliprant during 2019.

65

2018 vs. 2017
Other–net, expense (income) was expense of $41.3 million in 2018 compared to income of $0.1 million in 2017. The increase in expense is primarily due to the increase in the Aratana contingent consideration liability of $37.6 million associated with the Galliprant acquisition.
Income tax expense
Elanco’s historical income tax expense may not be indicative of its future expected tax rate. See “Comparability of Historical Results, Our Relationship with Lilly and Additional Standalone Costs.”
2019 vs. 2018
Income tax expense decreased $17.3 million in 2019 as compared to 2018. The decrease is primarily attributable to lower pre-tax earnings primarily due to restructuring charges, in addition to the release of tax reserves related to final resolution of the Brazilian tax matter. See Note 15: Income Taxes to our consolidated and combined financial statements.
2018 vs. 2017
Income tax expense decreased $50.5 million in 2018 as compared to 2017. The decrease is primarily due to a decrease in the U.S. valuation allowance, which was recorded in 2017 based upon the pre-IPO separate return methodology. See Note 2: Basis of Presentation and Note 15: Income Taxes to our consolidated and combined financial statements.

Liquidity and Capital Resources
We historically participated in Lilly’s centralized treasury management system, including centralized cash pooling and overall financing arrangements. We have generated and expect to continue to generate positive cash flows from operations. In connection with the IPO, we entered into various long-term debt agreements as described below.
Our primary sources of liquidity are cash on hand, cash flows from operations and funds available under our Credit Facilities. As a significant portion of our business is conducted outside the U.S., we hold a significant portion of cash outside of the U.S. We monitor and adjust the amount of foreign cash based on projected cash flow requirements. Our ability to use foreign cash to fund cash flow requirements in the U.S. may be impacted by local regulations and, to a lesser extent, following U.S. tax reforms, the income taxes associated with transferring cash to the U.S. See Note 15: Income Taxes to our consolidated and combined financial statements. We currently intend to indefinitely reinvest foreign earnings for continued use in our foreign operations. As our structure evolves as a standalone company, we may change that strategy, particularly to the extent we identify tax efficient reinvestment alternatives for our foreign earnings or change our cash management strategy.
Our principal liquidity needs going forward include funding existing marketed and pipeline products, capital expenditures, business development in our targeted areas, interest expense and funding the acquisition of the animal health business of Bayer. We believe our cash and cash equivalents on hand, our operating cash flows, our existing financing arrangements and financing arrangements entered into in 2020 will be sufficient to support our cash needs for the foreseeable future, including for at least the next 12 months.
Our ability to meet future funding requirements may be impacted by macroeconomic, business and financial volatility. As markets change, we will continue to monitor our liquidity position. However, a challenging economic environment or an economic downturn may impact our liquidity or ability to obtain future financing. See "Item 1A. Risk Factors - We may not be able to generate sufficient cash to service all of our indebtedness and may be forced to take other actions to satisfy our obligations under our indebtedness, which may not be successful."
As of December 31, 2019, cash and cash equivalents was $334.0 million, a decrease of $140.8 million compared to $474.8 million at December 31, 2018. We also held $11.1 million of restricted cash at December 31, 2019, which is available solely to pay the remainder of the purchase for our businesses to Lilly. We have a corresponding liability recorded on our balance sheet and included in Payable to Lilly. Refer to the Consolidated and Combined
66

Statements of Cash Flows for additional details on the significant sources and uses of cash for the years ended December 31, 2019, 2018 and 2017.
Cash Flows
The following table provides a summary of cash flows from operating, investing and financing activities for the periods presented:
(Dollars in millions)Year Ended December 31,% Change
Net cash provided by (used for):20192018201719/1818/17
Operating activities$224.1  $487.3  $173.8  (54)%180 %
Investing activities(234.8) (127.0) (964.6) 85 %(87)%
Financing activities(304.8) (35.2) 847.5  766 %(104)%
Effect of exchange-rate changes on cash and cash equivalents(16.9) 29.0  7.9  (158)%267 %
Net (decrease) increase in cash, cash equivalents and restricted cash$(332.4) $354.1  $64.6  (194)%448 %
Operating activities
2019 vs. 2018
Our cash flow from operating activities decreased by $263.2 million from $487.3 million for the year ended December 31, 2018 to $224.1 million for the year ended December 31, 2019. The decrease in operating cash flows was primarily attributable to a decrease in net income, increases in accounts receivable and inventories, and changes in timing of payments in the ordinary course of business.
We have extended our payment terms in the past in certain customer situations and may need to continue this practice going forward as a result of competitive pressures and the need for certain inventory levels at our channel distributors to avoid supply disruptions. Further extensions of customer payment terms could result in additional uses of our cash flow.
2018 vs. 2017
Our cash flow from operating activities increased by $313.5 million from $173.8 million for the year ended December 31, 2017 to $487.3 million for the year ended December 31, 2018. The increase is a result of an increase in net income, which was partially offset by cash used to finance working capital, primarily focused on accounts receivable and inventory.
Investing activities
2019 vs. 2018
Our cash flow used for investing activities increased by $107.8 million, to $234.8 million for the year ended December 31, 2019 compared to $127.0 million for the year ended December 31, 2018. The change was primarily driven by cash paid for the acquisition of Prevtec during 2019 and increases in purchases of software from 2018 to 2019.
2018 vs. 2017
Our cash flow used for investing activities decreased from $964.6 million for the year ended December 31, 2017 to $127.0 million for the year ended December 31, 2018. Our cash used in investing activities for the year ended December 31, 2017 included $882.1 million related to the acquisition of BIVIVP. This decrease was offset by a net increase of $35.9 million in capital expenditures from 2017 to 2018.
67

Financing activities
2019 vs. 2018
Our cash used for financing activities increased by $269.6 million to $304.8 million in 2019 compared to $35.2 million in 2018. Cash used in financing activities during 2018 reflected the impact of our IPO and the issuance of long-term debt in connection with our Separation from Lilly during the period. $4.2 billion of cash was generated from those transactions, which was mostly offset by $4.1 billion of payments to Lilly in connection with local country asset purchases and other financing activities related to the Separation. During 2019, we made $121.1 million of payments on our term credit facility as well as $191.6 million of payments to Lilly in connection with local country asset purchases and other financing activities related to the Separation.
2018 vs. 2017
Our cash used for financing activities was a $35.2 million in 2018 compared to cash provided by financing activities of $847.5 million in 2017, a change of $882.7 million. The cash flows in 2017 relate to net cash provided by transactions with Lilly of $848.3 million compared to cash used in transactions with Lilly of $154.4 million in 2018, a reduction in financing of cash flows between periods of $1.0 billion. This, in addition to the consideration paid to Lilly in connection with the Separation, was partially offset by net cash provided from financing transactions related to the Separation including the proceeds from long-term debt and our IPO. The remainder of the proceeds from the financing related to the Separation will be paid to Lilly in future periods and is reflected as restricted cash in our consolidated balance sheet.
Capital Expenditures
Capital expenditures were $140.4 million during 2019, an increase of $5.9 million compared to 2018. We expect 2020 capital expenditures to be approximately $150 million.
Description of Indebtedness
For a complete description of our debt and available credit facilities as of December 31, 2019, see Note 9: Debt to our consolidated and combined financial statements.
Contractual Obligations
Payments due under contractual obligations as of December 31, 2019, are set forth below:
Years
(Dollars in millions)
Total(1)
Less Than 1 Year
1 - 3 Years
4 - 5 Years
More Than 5 Years
Long-term debt obligations, including interest payments(2)
$2,771.5  $77.6  $981.2  $1,578.2  $134.5  
Operating leases91.6  26.0  32.2  16.9  16.5  
Purchase obligations(3)
1,127.4  1,079.8  29.9  7.7  10.0  
Other long-term liabilities18.4  5.7  8.5  0.8  3.4  
Total$4,008.9  $1,189.1  $1,051.8  $1,603.6  $164.4  
(1) We excluded deferred taxes because we cannot reasonably estimate the timing of future cash outflows associated with those liabilities.
(2) Our long-term debt obligations include both our expected principal and interest obligations and our interest rate swaps. We used current period assumptions for interest rates to compute expected interest payments on variable rate debt instruments and swaps.
(3) Represents open purchase orders as of December 31, 2019 and contractual payment obligations with each of our significant vendors which are noncancelable and are not contingent.
In connection with our pending acquisition of the animal health business of Bayer as discussed in Note 6: Acquisitions, in August 2019, we entered into a commitment letter that provides for financing consisting of up to $750 million in a revolving facility, $3.0 billion in a term facility, and $2.75 billion in a senior secured bridge facility. In connection with the financing commitment letter, we will incur fixed commitment fees of $40.4 million that will become due and payable upon the closing of the pending acquisition or the termination of the Purchase Agreement
68

with Bayer. These fees have not been recorded on the consolidated balance sheet as of December 31, 2019. See Note 22: Subsequent Events to our consolidated and combined financial statements for updates regarding financing secured after the balance sheet date.
Critical Accounting Policies
The preparation of financial statements in accordance with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. Certain of our accounting policies are considered critical because these policies are the most important to the depiction of our financial statements and require significant, difficult or complex judgments by us, often requiring the use of estimates about the effects of matters that are inherently uncertain. Actual results that differ from our estimates could have an unfavorable effect on our financial position and results of operations. We apply estimation methodologies consistently from year to year. The following is a summary of accounting policies that we consider critical to the consolidated and combined financial statements.
Revenue Recognition
Our gross product revenue is subject to deductions that are generally estimated and recorded in the same period that the revenue is recognized and that primarily represent revenue incentives (rebates and discounts) and sales returns. For example:
•for revenue incentives, we use our historical experience with similar incentives programs and current sales data and estimates of inventory levels at our channel distributors to evaluate the impact of such programs on revenue and continually monitor the impact of this experience and adjust as necessary; and
•for sales returns, we consider items such as: local returns policies and practices; returns as a percentage of revenue; an understanding of the reasons for past returns; estimated shelf life by product; and estimate of the amount of time between shipment and return to estimate the impact of sales returns.
If any of our ratios, factors, assessments, experiences or judgments are not indicative or accurate predictors of our future experience, our results could be materially affected.
Although the amounts recorded for these revenue deductions are dependent on estimates and assumptions, historically our adjustments to actual results have not been material. The sensitivity of our estimates can vary by program, type of customer and geographic location. Amounts recorded for revenue deductions can result from a complex series of judgments about future events and uncertainties and can rely on estimates and assumptions.
See Note 4: Summary of Significant Accounting Policies to our consolidated and combined financial statements for further discussion regarding our revenue recognition policy.
Acquisitions and Fair Value
We account for the assets acquired and liabilities assumed in an acquisition based on their respective fair values as of the acquisition date. The excess of the purchase price over the fair value of the acquired net assets, where applicable, is recorded as goodwill.
The judgments made in determining estimated fair values assigned to assets acquired and liabilities assumed in a business combination, as well as estimated asset lives, can materially affect our consolidated results of operations. The fair values of intangible assets are re-determined using information available at the acquisition date based on expectations and assumptions that are deemed reasonable by management. These fair value estimates require significant judgment with respect to future volume and prices, use of working capital, the selection of appropriate discount rates, product mix, income tax rates and other assumptions and estimates. Such estimates and assumptions are determined based upon our business plans and when applicable, market participants' views of us and other similar companies. Depending on the facts and circumstances, we may deem it necessary to engage an independent valuation expert to assist in valuing significant assets and liabilities.
We determine fair value of any contingent consideration liability that results from a business combination by utilizing a market approach (i.e., based on quoted market values, significant other observable inputs for identical or comparable assets or liabilities) a discounted cash flow analysis, or a Monte Carlo simulation (i.e., based on multiple potential financial outcomes using estimated variables such as expected revenues, growth rates, and a
69

discount rate). Estimating the fair value of contingent consideration requires the use of significant estimates and judgments, including, but not limited to, revenue and the discount rate and will be remeasured every reporting period.
Impairment of Indefinite-Lived and Long-Lived Assets
We review the carrying value of long-lived assets (both intangible and tangible) for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset (or asset group) may not be recoverable. We identify impairment by comparing the projected undiscounted cash flows to be generated by the asset (or asset group) to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset's net book value over its fair value utilizing a discounted cash flow analysis, and the cost basis is adjusted.
Goodwill and indefinite-lived intangible assets are reviewed for impairment at least annually and when certain impairment indicators are present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment.
The estimated cash flows and fair values used in our impairment reviews require significant judgment with respect to future volume; use of working capital; foreign currency exchange rates; the selection of appropriate discount rates; product mix; income tax rates and other assumptions and estimates. Such estimates and assumptions are determined based upon our business plans and when applicable, market participants' views of us and other similar companies. We make these judgments based on our historical experience, relevant market size, historical pricing of similar products and expected industry trends. These assumptions are subject to change in future periods because of, among other things, additional information, financial information based on further historical experience, changes in competition, our investment decisions, volatility in foreign currency exchange rates, and results of research and development. A change in these assumptions or the use of alternative estimates and assumptions could have a significant impact on the estimated fair values of the assets, and may result in an impairment of the existing assets in a future period.
During the years ended December 31, 2019, 2018 and 2017, we recorded asset impairments of $15.4 million, $81.9 million and $110.6 million, respectively, primarily due to product rationalization or changes in business strategy. For more information related to our impairment charges, see Note 7: Asset Impairment, Restructuring and Other Special Charges to our consolidated and combined financial statements.
Deferred Tax Asset Valuation Allowances
We maintain valuation allowances unless it is more likely than not that all or a portion of the deferred tax asset will be realized. Changes in valuation allowances are included in our tax provision in the period of change. In determining whether a valuation allowance is warranted, we evaluate factors such as prior earnings history, expected future earnings, carryback and carryforward periods, and tax strategies that could potentially enhance the likelihood of realization of a deferred tax asset. The realizability assessments made at a given balance sheet date are subject to change in the future, particularly if earnings of a subsidiary are significantly higher or lower than expected, or if we take operational or tax planning actions that could impact the future taxable earnings of a subsidiary. A change in these assumptions may result in an increase or decrease in the realizability of our existing deferred tax assets, and therefore a change in the valuation allowance, in future periods. As of December 31, 2019 and 2018, we had valuation allowances of $32.7 million and $21.4 million, respectively.
Quantitative and Qualitative Disclosures About Market Risk
Foreign Exchange Risk
We operate on a global basis and are exposed to the risk that our earnings, cash flows and equity could be adversely impacted by fluctuations in foreign exchange rates. We are primarily exposed to foreign exchange risk with respect to net assets denominated in the Euro, Swiss franc, British pound, Canadian dollar, Australian dollar and Brazilian real. As part of the TSA, Lilly maintained a foreign currency risk management program through a central shared entity, which entered into derivative contracts to hedge foreign currency risk associated with forecasted transactions for the entire company, including historically for our operations. Gains and losses on derivative contracts entered into by Lilly were previously allocated to our results to the extent they were to cover exposure related to our business and offset gains and losses on underlying foreign currency exposures. We implemented our own foreign currency risk management program and assumed all hedging activities in the second
70

quarter of 2019.
We face foreign currency exchange exposures when we enter into transactions arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. We also face currency exposure that arises from translating the results of our global operations to the U.S. dollar at exchange rates that have fluctuated from the beginning of the period. We may enter into foreign currency forward or option derivative contracts to reduce the effect of fluctuating currency exchange rates in future periods, but our historical results prior to 2018 do not reflect the impact of any such derivatives related to our exposure to foreign currency impacts on translation.

We estimate that a hypothetical 10% adverse movement in all foreign currency exchange rates related to the translation of the results of our foreign operations would decrease our net income by approximately $7.4 million for the year ended December 31, 2019.
We also bear foreign exchange risk associated with the future cash settlement of an existing NIH. In October 2018, we entered into a fixed interest rate, 5-year, 750 million Swiss franc NIH against Swiss franc assets. The NIH is expected to generate approximately $25 million in cash and contra interest expense per year; however, there is potential for significant 2023 settlement exposure on the 750 million Swiss franc notional if the U.S. dollar devalues versus the Swiss franc.
Interest Risk
We are exposed to interest rate risk on the long-term debt we incurred in connection with our IPO. Prior to our IPO, we did not have any interest rate exposure. We have cash flow risk associated with our $371.4 million of borrowings under the Term Credit Facility that pay interest based on variable rates. We actively monitor our exposure and may enter into financial instruments to fix the interest rate based on our assessment of the risk.
Recently Issued Accounting Pronouncements
For discussion of our new accounting standards, see Note 4: Summary of Significant Accounting Policies - Implementation of New Financial Accounting Pronouncements to our consolidated and combined financial statements.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk
You can find quantitative and qualitative disclosures about market risk (e.g., interest rate risk) at Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources - Quantitative and Qualitative Disclosures About Market Risk.” That information is incorporated in this Item 7A by reference.
71

Item 8. Financial Statements and Supplementary Data

Report of Independent Registered Public Accounting Firm


To the Shareholders and the Board of Directors of Elanco Animal Health Incorporated

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Elanco Animal Health Incorporated (the Company) as of December 31, 2019 and 2018, the related consolidated and combined statements of operations, comprehensive income (loss), equity and cash flows for each of the three years in the period ended December 31, 2019, and the related notes (collectively referred to as the “consolidated and combined financial statements”). In our opinion, the consolidated and combined financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2019, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 28, 2020 expressed an unqualified opinion thereon.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated and combined financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.





72

Sales rebates and discounts
Description of the matterAt December 31, 2019, the Company’s US sales rebates and discounts liability totaled $150.4 million. As explained in Note 5 to the consolidated and combined financial statements, the Company estimates a sales rebates and discounts liability for direct customers and other indirect customers in the distribution chain under the terms of their arrangements using the expected value approach. The sales rebates and discounts are recorded as a deduction to revenue at the time the Company recognizes a sale to a customer.

Auditing the sales rebates and discounts liability in the US is complex because of the level of subjectivity involved in management’s assumptions used in the measurement process and the volume of rebate programs offered. For example, estimates of the expected rebate rates based on projected sales volumes derived from current sales data and recent trends, estimates of future rebates to be paid to indirect customers in the distribution chain based on inventory volumes and historical experience with similar rebate incentive programs.

How we addressed the matter in our audit

We tested the Company’s internal controls over the sales rebates and discounts liability process. This included testing controls over management’s review of the significant assumptions in the estimation of sales rebates and discounts, including rebate rates by product category, forecasted sales, and channel inventory levels.

To test the Company’s sales rebates and discounts liability, our audit procedures included, among others, evaluating the assumptions discussed above and testing the completeness and accuracy of the underlying data used in management’s expected value analysis. For example, we compared the significant assumptions to third-party reports used by the Company to estimate indirect sales volumes during the period. Furthermore, we confirmed product remaining in the distribution channel at period end. In addition, we inspected the underlying direct and indirect customer rebate programs and compared the rebate percentages used in the Company’s analyses with the program percentages. Additionally, on a sample basis, we assessed the historical accuracy of management’s sales rebates and discounts estimates by comparing the prior period sales rebates and discounts liability to the amount of actual payments made in subsequent periods. We also performed independent calculations of the rebate accruals and a sensitivity analysis of certain significant assumptions to evaluate the change in the sales rebates and discounts liability resulting from changes in the assumptions.


73

Acquisition of Aratana Therapeutics, Inc.
Description of the matterDuring 2019, the Company completed its acquisition of Aratana Therapeutics, Inc. (“Aratana”) for net consideration of $238.0 million, as disclosed in Note 6 to the consolidated and combined financial statements. The acquisition was accounted for as a business combination. Auditing the Company's accounting for its acquisition of Aratana was complex due to the significant estimation uncertainty in determining the fair value of identified intangible assets, which principally consisted of intellectual property related to marketed products and in-process research and development of $36.7 million and $31.9 million, respectively. The significant estimation uncertainty was primarily due to the sensitivity of the respective fair values to the significant underlying assumptions about the future performance of the acquired business. The Company used a discounted cash flow model to measure the intellectual property related to marketed products and in-process research and development intangible assets. The significant assumptions used to estimate the value of these intangible assets included discount rates and certain assumptions that form the basis of the forecasted results (e.g., revenue growth rates, gross margins and selling, general and administrative expenses). These significant assumptions are forward-looking and could be affected by future economic and market conditions.
How we addressed the matter in our auditWe tested the Company's controls over its accounting for acquisitions. This included testing controls over the recognition and measurement of consideration transferred and related intangible assets, including the valuation models and underlying assumptions discussed above used to develop such estimates.

To test the estimated fair value of the intellectual property related to marketed products and in-process research and development intangible assets our audit procedures included, among others, evaluating the Company’s use of the income approach and testing the significant assumptions discussed above used in the models, including the completeness and accuracy of the underlying data. For example, we compared the forecasted revenue, gross margins and selling, general and administrative expenses to current industry and economic trends as well as the historic financial performance of the acquired business. We also performed sensitivity analyses of the significant assumptions to evaluate the changes in the fair value of the intangible assets resulting from changes in the assumptions. We involved our valuation specialists to assist in our evaluation of the methodology used by the Company and significant assumptions included in the fair value estimates. For example, comparing the discount rate to the acquired business’s weighted average cost of capital and evaluating the relationship of the weighted average cost of capital, internal rate of return and weighted-average return on assets.


/s/ Ernst & Young LLP



We have served as the Company’s auditor since 2017.

Indianapolis, Indiana
February 28, 2020
74

Elanco Animal Health Incorporated
Consolidated and Combined Statements of Operations
(in millions, except per-share data)
 Year Ended December 31,
 201920182017
Revenue$3,071.0  $3,066.8  $2,889.0  
Costs, expenses and other:
Cost of sales1,470.3  1,573.8  1,493.9  
Research and development270.1  246.6  251.7  
Marketing, selling and administrative760.2  735.2  779.8  
Amortization of intangible assets
200.4  197.4  221.2  
Asset impairment, restructuring and other special charges (Note 7)
185.5  128.8  375.1  
Interest expense, net of capitalized interest78.9  29.6  —  
Other-net, expense (income)27.4  41.3  (0.1) 
2,992.8  2,952.7  3,121.6  
Income (loss) before income taxes78.2  114.1  (232.6) 
Income tax expense10.3  27.6  78.1  
Net income (loss)$67.9  $86.5  $(310.7) 
Earnings (loss) per share:
Basic$0.18  $0.28  $(1.06) 
Diluted$0.18  $0.28  $(1.06) 
Weighted average shares outstanding:
Basic369.0  313.7  293.3  
Diluted370.3  313.7  293.3  
See notes to consolidated and combined financial statements.
75

Elanco Animal Health Incorporated
Consolidated and Combined Statements of Comprehensive Income (Loss)
(in millions)
Year Ended December 31,
201920182017
Net income (loss)$67.9  $86.5  $(310.7) 
Other comprehensive income (loss):
Foreign currency translation19.8  (47.1) 210.1  
Defined benefit pension and retiree health benefit plans, net of taxes28.7  25.4  (9.8) 
Other comprehensive income (loss), net of taxes48.5  (21.7) 200.3  
Comprehensive income (loss)$116.4  $64.8  $(110.4) 
See notes to consolidated and combined financial statements.

76

Elanco Animal Health Incorporated
Consolidated Balance Sheets
(in millions)
December 31, 2019December 31, 2018
Assets 
Current Assets
Cash and cash equivalents$334.0  $474.8  
Accounts receivable, net of allowances of $6.2 (2019) and $8.4 (2018)
816.9  651.8  
Other receivables73.0  57.6  
Inventories (Note 8)1,050.7  1,004.1  
Prepaid expenses and other87.4  113.9  
Restricted cash (Note 20)11.1  202.7  
Total current assets2,373.1  2,504.9  
Noncurrent Assets
Goodwill (Note 11)2,989.6  2,958.0  
Other intangibles, net (Note 11)2,482.8  2,504.8  
Other noncurrent assets185.0  66.6  
Property and equipment, net (Note 12)955.3  922.4  
Total assets$8,985.8  $8,956.7  
Liabilities and Equity
Current Liabilities
Accounts payable$222.6  $205.2  
Employee compensation99.6  98.9  
Sales rebates and discounts211.0  169.9  
Current portion of long term debt (Note 9)24.5  29.0  
Other current liabilities244.4  199.0  
Payable to Lilly (Note 20)16.4  268.7  
Total current liabilities818.5  970.7  
Noncurrent Liabilities
Long-term debt (Note 9)2,330.5  2,443.3  
Accrued retirement benefits (Note 18)82.5  109.1  
Deferred taxes (Note 15)100.8  114.6  
Other noncurrent liabilities106.6  121.5  
Total liabilities3,438.9  3,759.2  
Commitments and Contingencies (Note 16)
Equity
Preferred stock, 1,000,000,000 shares authorized, no par value; none issued
—  —  
Common stock, 5,000,000,000 shares authorized, no par value; 373,011,513 and 365,643,911 shares issued and outstanding as of December 31, 2019 and 2018, respectively
—  —  
Additional paid-in capital5,636.3  5,403.3  
Retained earnings84.3  16.4  
Accumulated other comprehensive loss(173.7) (222.2) 
Total equity5,546.9  5,197.5  
Total liabilities and equity$8,985.8  $8,956.7  
See notes to consolidated and combined financial statements.
77

Elanco Animal Health Incorporated
Consolidated and Combined Statements of Equity
(in millions)
Common StockAccumulated Other Comprehensive Income (Loss)
SharesAmountAdditional Paid-in CapitalNet Parent Company InvestmentRetained EarningsForeign Currency TranslationDefined Benefit Pension and Retiree Health Benefit PlansTotalTotal Equity
January 1, 2017293.3  $—  $—  $7,474.3  $—  $(437.3) $(19.6) $(456.9) $7,017.4  
Net (loss)—  —  —  (310.7) —  —  —  —  (310.7) 
Other comprehensive income (loss), net of tax—  —  —  —  —  210.1  (9.8) 200.3  200.3  
Transfers (to)/from Lilly, net—  —  —  873.3  —  —  —  —  873.3  
December 31, 2017293.3  —  —  8,036.9  —  (227.2) (29.4) (256.6) 7,780.3  
Net income—  —  —  70.1  16.4  —  —  —  86.5  
Adoption of Accounting Standards Update 2016-16—  —  —  (0.3) —  —  —  —  (0.3) 
Other comprehensive income (loss), net of tax—  —  —  —  —  (47.1) 25.4  (21.7) (21.7) 
Transfers (to)/from Lilly, net—  —  —  (226.3) —  —  —  —  (226.3) 
Separation adjustments (1)
—  —  —  43.5  —  56.1  —  56.1  99.6  
Issuance of common stock72.3  —  1,659.7  —  —  —  —  —  1,659.7  
Consideration to Lilly in connection with Separation—  —  (4,194.9) —  —  —  —  —  (4,194.9) 
Reclassification of net parent company investment—  —  7,923.9  (7,923.9) —  —  —  —  —  
Stock compensation—  —  1.8  —  —  —  —  —  1.8  
Capital contribution from Lilly—  —  12.8  —  —  —  —  —  12.8  
December 31, 2018365.6  —  5,403.3  —  16.4  (218.2) (4.0) (222.2) 5,197.5  
Net income—  —  —  —  67.9  —  —  —  67.9  
Other comprehensive income, net of tax—  —  —  —  —  19.8  28.7  48.5  48.5  
Separation activities (2)
—  —  (51.2) —  —  —  —  —  (51.2) 
Stock compensation—  —  40.7  —  —  —  —  —  40.7  
Issuance of stock under employee stock plans, net0.1  —  —  —  —  —  —  —  —  
Issuances of stock in connection with Aratana acquisition: (3)
Issuance to Aratana shareholders for acquisition7.2  —  238.0  —  —  —  —  —  238.0  
Accelerated vesting of equity awards0.1  —  3.6  —  —  —  —  —  3.6  
Other—  —  1.9  —  —  —  —  —  1.9  
December 31, 2019373.0  $—  $5,636.3  $—  $84.3  $(198.4) $24.7  $(173.7) $5,546.9  
(1) See Note 3: Impact of Separation for further discussion.
(2) See Note 20: Related Party Agreements and Transactions for further discussion.
(3) See Note 6: Acquisitions for further discussion.
See notes to consolidated and combined financial statements.

78

Elanco Animal Health Incorporated
Consolidated and Combined Statement of Cash Flows
(in millions)
Year Ended December 31,
201920182017
Cash Flows from Operating Activities
Net income (loss)$67.9  $86.5  $(310.7) 
Adjustments to reconcile net income (loss) to cash flows from operating activities:
Depreciation and amortization314.5  296.0  318.4  
Change in deferred income taxes0.1  (60.7) (13.4) 
Stock-based compensation expense49.4  26.0  25.0  
Asset impairment charges32.6  120.5  110.6  
Gain on sale of assets—  (0.8) (19.6) 
Other non-cash operating activities, net(12.7) 49.0  10.0  
Other changes in operating assets and liabilities, net of acquisitions and divestitures:
Receivables(172.4) (122.0) 48.4  
Inventories(33.1) (20.1) (39.0) 
Other assets7.0  (3.2) 52.5  
Accounts payable and other liabilities(29.2) 116.1  (8.4) 
Net Cash Provided by Operating Activities224.1  487.3  173.8  
Cash Flows from Investing Activities
Purchases of property and equipment(140.4) (134.5) (98.6) 
Disposals of property and equipment0.3  9.4  37.6  
Purchases of software(57.0) (2.0) (18.5) 
Cash paid for acquisitions, net of cash acquired(32.8) —  (882.1) 
Other investing activities, net(4.9) 0.1  (3.0) 
Net Cash Used for Investing Activities(234.8) (127.0) (964.6) 
Cash Flows from Financing Activities
Proceeds from issuance of long-term debt (Note 9)—  2,500.0  —  
Repayments of borrowings (Note 9)(121.1) (7.5) —  
Proceeds from issuance of common stock (Note 1)—  1,659.7  —  
Debt issuance costs—  (24.5) —  
Consideration paid to Lilly in connection with the Separation (Note 1)(191.6) (3,991.3) —  
Other financing activities, net1.6  (17.2) (0.8) 
Other net transactions with Lilly6.3  (154.4) 848.3  
Net Cash Provided by (Used for) Financing Activities(304.8) (35.2) 847.5  
Effect of exchange rate changes on cash and cash equivalents(16.9) 29.0  7.9  
Net (decrease) increase in cash, cash equivalents and restricted cash(332.4) 354.1  64.6  
Cash, cash equivalents and restricted cash at January 1677.5  323.4  258.8  
Cash, cash equivalents and restricted cash at December 31$345.1  $677.5  $323.4  

December 31,
201920182017
Cash and cash equivalents$334.0  $474.8  $323.4  
Restricted cash (Note 20)11.1  202.7  —  
Cash, cash equivalents and restricted cash at December 31$345.1  $677.5  $323.4  
See notes to consolidated and combined financial statements.
79

Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements
(Tables present dollars in millions, except per-share data)
Note 1. Nature of Business and Organization
Nature of Business
Elanco was formed as a wholly-owned subsidiary of Lilly, and is a global animal health company that innovates, develops, manufactures and markets products for companion and food animals. We offer a diverse portfolio of more than 125 brands to veterinarians and food animal producers in more than 90 countries.
Organization
Elanco Parent was formed in 2018, as a wholly-owned subsidiary of Lilly, to serve as the ultimate parent company of substantially all of the animal health businesses of Lilly.
On September 24, 2018, Elanco Parent completed an IPO resulting in the issuance of 72.3 million shares of its common stock (including shares issued pursuant to the underwriters’ option to purchase additional shares), which represented 19.8% of the outstanding shares, at $24 per share resulting in total net proceeds, after underwriting discounts and commissions, of $1.7 billion.  In connection with the completion of the IPO, through a series of equity and other transactions, Lilly transferred to Elanco Parent the animal health businesses that form its business. In exchange, Elanco Parent has paid to Lilly approximately $4.2 billion, which included the net proceeds from the IPO, the net proceeds from the debt offering completed by Elanco Parent in August 2018 and the term loan facility entered into by Elanco Parent in September 2018 (see Note 9: Debt). These transactions are collectively referred to herein as the Separation.
On February 8, 2019, Lilly announced an exchange offer whereby Lilly shareholders could exchange all or a portion of Lilly common stock for shares of Elanco common stock owned by Lilly. The disposition of Elanco shares was completed on March 11, 2019 and resulted in the full separation of Elanco along with the disposal of Lilly's entire ownership and voting interest in Elanco.

Note 2. Basis of Presentation
We have prepared the accompanying consolidated and combined financial statements in accordance with accounting principles generally accepted in the United States (GAAP). In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for fair presentation of the results of operations for the periods shown. The accounts of all wholly-owned and majority-owned subsidiaries are included in the consolidated financial statements, and all intercompany balances and transactions have been eliminated.
Certain reclassifications have been made to prior periods in the unaudited condensed consolidated and combined financial statements and accompanying notes to conform with current presentation.
In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. We issued our financial statements by filing with the Securities and Exchange Commission and have evaluated subsequent events up to the time of the filing.
For the periods after Separation, the financial statements are prepared on a consolidated basis and reflect the results of operations, comprehensive income, financial position, equity and cash flows resulting from our operations as an independent company. For periods prior to Separation, our financial statements are combined, have been prepared on a standalone basis, and are derived from Lilly's consolidated financial statements and accounting records. The consolidated and combined financial statements reflect the financial position, results of operations and cash flows related to the animal health businesses that were transferred to Elanco Parent and are prepared in conformity with GAAP.
80

The combined financial statements include the attribution of certain assets and liabilities that historically have been held at the Lilly corporate level but which are specifically identifiable or attributable to the businesses that have been transferred to Elanco Parent. All intercompany transactions and accounts within Elanco have been eliminated. All transactions between us and Lilly are considered to be effectively settled in the combined financial statements at the time the intercompany transaction is recorded. The total net effect of the settlement of these intercompany transactions is reflected in the combined statements of cash flows as a financing activity and in the consolidated and combined statement of equity as net parent company investment.
Prior to Separation, these combined financial statements include an allocation of expenses related to certain Lilly corporate functions, including executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information technology and investor relations, prior to IPO. These expenses were allocated to us based on direct usage or benefit where specifically identifiable, with the remainder allocated primarily on a pro rata basis of revenue, headcount and other measures. We consider the expenses methodology and results to be reasonable for all periods presented. However, the allocations may not be indicative of the actual expense that would have been incurred had we operated as an independent, publicly traded company for the periods presented. It is impractical to estimate what the standalone costs of Elanco would have been in the historical periods. After the Separation, a TSA between Lilly and Elanco went into effect. Under the terms of the TSA, we will be able to use these Lilly services for a fixed term established on a service-by-service basis. We are paying Lilly mutually agreed upon fees for the Lilly services provided under the TSA. Our consolidated and combined financial statements reflect the charges for Lilly services after the IPO. See Note 20: Related Party Agreements and Transactions for additional details.
The income tax amounts in the combined financial statements have been calculated based on a separate return methodology and presented as if our operations were separate taxpayers in the respective jurisdictions. We file income tax returns in the U.S. federal jurisdiction and various state, local and non-U.S. jurisdictions. Prior to full separation, certain of these income tax returns were filed on a consolidated or combined basis with Eli Lilly and Company and/or its subsidiaries.
Prior to Separation, Lilly maintained various benefit and combined stock-based compensation plans at a corporate level and other benefit plans at a country level. Our employees participated in such programs and the portion of the cost of those plans related to our employees is included in our financial statements. However, the consolidated balance sheets do not include any equity issued related to stock-based compensation plans or any net benefit plan obligations unless the benefit plan covers only our dedicated employees or where the legal obligation associated with the benefit plan transferred to Elanco. Upon Lilly's full divestiture of Elanco in March 2019, all Lilly share-based awards held by our employees were converted into awards that will be settled in Elanco shares.
Prior to Separation, the equity balance in the combined financial statements represents the excess of total assets over liabilities, including intercompany balances between Elanco and Lilly (net parent company investment) and accumulated other comprehensive income (loss). Net parent company investment is primarily impacted by contributions from Lilly which are the result of treasury activities and net funding provided by or distributed to Lilly. See Note 20: Related Party Agreements and Transactions for further information.

Note 3. Impact of Separation
In connection with the Separation, we issued $2.0 billion aggregate principal amount of senior notes in a private placement, and we also entered into a $750.0 million senior unsecured revolving credit facility and $500.0 million senior unsecured term credit facility. See Note 9: Debt for further information. In connection with the Separation, we entered into various agreements with Lilly, including a master separation agreement, a tax matters agreement and the TSA.
In connection with the terms of the Separation, there were certain assets and liabilities included in the pre-Separation balance sheet that were retained by Lilly and there were certain assets not included in the pre-Separation balance sheet that were transferred to us. The cumulative adjustment to the historical balance sheet increased net assets and total equity by approximately $99.6 million. The impact on net assets primarily represents the elimination of certain income tax assets and liabilities and the contribution of additional assets.
We will also continue to have certain ongoing relationships with Lilly as described in Note 20: Related Party Agreements and Transactions.
81

Note 4. Summary of Significant Accounting Policies
Revenue recognition
Effective January 1, 2018, we adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (ASU 2014-09) and other related updates. The new standard has been applied to contracts for which performance had not been completed as of the date of adoption. Revenue presented for periods prior to 2018 was accounted for under previous standards and has not been adjusted. Revenue and net income for the years ended December 31, 2019 and 2018 do not differ materially from amounts that would have resulted from application of the previous standards.
Product Sales
We recognize revenue primarily from product sales to customers. Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which generally is at the time we ship the product to the customer. Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from 30 to 120 days from date of shipment. Revenue for our product sales has not been adjusted for the effects of a financing component as we expect, at contract inception, that the period between when we transfer control of the product and when we receive payment will be one year or less. Any exceptions are either not material or we collect interest for payments made after the due date. For arrangements with contract manufacturing organizations (CMO), we recognize revenue over time or at a point in time depending on our evaluation of when the customer obtains control of the promised goods or service. Revenue is recognized over time when we are creating or enhancing an asset that the customer controls. In this instance revenue is recognized as the asset is created or enhanced or our performance does not create an asset with an alternative use and we have an enforceable right to payment for performance completed.
Provisions for rebates and discounts, as well as returns are established in the same period the related sales are recognized. We generally ship product shortly after orders are received; therefore, we generally only have a few days of orders received but not yet shipped at the end of any reporting period. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are imposed on our sales of product and collected from a customer.
Significant judgments must be made in determining the transaction price for sales of products related to anticipated rebates and discounts, and returns. The following describe the most significant of these judgments:
Sales Rebates and Discounts - Background and Uncertainties
•Most of our products are sold to wholesale distributors. We initially invoice our customers contractual list prices. Contracts with direct and indirect customers may provide for various rebates and discounts that may differ in each contract. As a consequence, to determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we must estimate any rebates or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts. Judgments are required in making these estimates.
•The rebate and discount amounts are recorded as a deduction to arrive at our net product sales. We estimate these accruals using an expected value approach.
•In determining the appropriate accrual amount, we consider our historical experience with similar incentives programs and current sales data and estimates of inventory levels at our channel distributors to evaluate the impact of such programs on revenue and continually monitor the impact of this experience and adjust as necessary. Although we accrue a liability for rebates related to these programs at the time the sale is recorded, the rebate related to that sale is typically paid up to six months after the rebate or incentive period expires. Because of this time lag, in any particular period rebate adjustments may incorporate revisions of accruals for several periods.
Sales Returns - Background and Uncertainties
•We estimate a reserve for future product returns related to product sales using an expected value approach. This estimate is based on several factors, including: local returns policies and practices; returns as a
82

percentage of revenue; an understanding of the reasons for past returns; estimated shelf life by product; and estimate of the amount of time between shipment and return. Adjustments to the returns reserve have been and may in the future be required based on revised estimates to our assumptions, which would have an impact on our consolidated results of operations. We record the return amounts as a deduction to arrive at our net product sales.
Research and development expenses and acquired in-process research and development
Research and development expenses include the following:
•Research and development costs, which are expensed as incurred.
•Milestone payment obligations incurred prior to regulatory approval of the product, which are accrued when the event requiring payment of the milestone occurs.
•Acquired in-process research and development (IPR&D) expense, which includes the initial costs of IPR&D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use.
Foreign Currency Translation
Operations in our subsidiaries outside the U.S. are recorded in the functional currency of each subsidiary which is determined by a review of the environment where each subsidiary primarily generates and expends cash. The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted average currency rate for the period. Assets and liabilities are translated using the period end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries are recorded in other comprehensive income (loss).
Other significant accounting policies
Our other significant accounting policies are described in the remaining appropriate notes to the combined financial statements.
Implementation of New Financial Accounting Pronouncements
The following table provides a brief description of an accounting standard that was effective January 1, 2019 and was adopted on that date:
StandardDescriptionEffect on the financial statements or other significant matters
Accounting Standards Update 2016-02, Leases
This standard was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under previous GAAP, on the balance sheet and requiring additional disclosures about leasing arrangements.
We adopted the standard on January 1, 2019 using the modified retrospective approach, applied at the beginning of the period of adoption, and we elected the package of transition practical expedients. Upon adoption of the standard, we recorded $84.9 million of right-of-use assets and $85.3 million of operating lease liabilities on our consolidated balance sheet. Adoption of this standard did not have a material impact on our consolidated statement of operations for the year ended December 31, 2019. See Note 13: Leases for further information.

83

The following table provides a brief description of the accounting standards applicable to us that have not yet been adopted:
StandardDescriptionEffective DateEffect on the financial statements or other significant matters
Accounting Standards Update 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments
This standard modifies the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses.This standard is effective January 1, 2020, with early adoption permitted. We intend to adopt this standard on that date.We do not expect that the adoption of this standard will have a material impact on our consolidated financial statements based on financial instruments currently held.
Accounting Standards Update 2018-15, Intangibles - Goodwill and Other Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract
This guidance aligns the requirements for capitalizing implementation costs incurred in a cloud-based hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software.This standard is effective January 1, 2020, with early adoption permitted. We intend to adopt this standard on that date.Adoption of this standard is not expected to have a significant impact on our consolidated financial statements.
Accounting Standards Update 2019-12, Simplifying the Accounting for Income Taxes
The amendments in this update simplify the accounting for income taxes by removing certain exceptions and clarifying certain requirements regarding franchise taxes, goodwill, consolidated tax expenses, and annual effective tax rate calculations. This standard is effective January 1, 2021, with early adoption permitted. We intend to adopt this standard on that date.We are currently evaluating the impact of adoption of the new standard on our consolidated financial statements.

Note 5. Revenue
Our sales rebates and discounts are based on specific agreements and the majority relate to sales in the U.S. As of December 31, 2019 and 2018, the liability for sales rebates and discounts in the U.S. represents approximately 71% and 70%, respectively, of our total liability with the next largest country representing approximately 8% of our total liability for 2019 and 2018.
The following table summarizes the activity in the sales rebates and discounts liability in the U.S.:
Year Ended December 31,
20192018
Beginning balance$118.5  $114.8  
Reduction of revenue316.3  221.0  
Payments(284.4) (217.3) 
Ending balance$150.4  $118.5  
Adjustments to revenue recognized as a result of changes in estimates for the judgments described above during the years ended December 31, 2019 and 2018 for product shipped in previous periods were not material.
Actual product returns were 0.2% and 0.6% of net revenue for the years ended December 31, 2019 and 2018, respectively, and have not fluctuated significantly as a percentage of revenue.
84

Disaggregation of Revenue
The following table summarizes our revenue disaggregated by product category for the years ended December 31:
201920182017
Companion Animal Disease Prevention$787.9  $804.6  $660.2  
Companion Animal Therapeutics348.0  283.1  260.8  
Food Animal Future Protein & Health745.1  711.2  649.2  
Food Animal Ruminants Swine1,110.3  1,174.0  1,175.0  
Strategic Exits(1)
79.7  93.9  143.8  
Total Revenue$3,071.0  $3,066.8  $2,889.0  
(1) Represents revenue from business activities we have either exited or made a strategic decision to exit.

Note 6. Acquisitions
During the year ended December 31, 2019, we completed the acquisitions of all outstanding shares of Aratana Therapeutics, Inc. (Aratana) and Prevtec Microbia Inc. (Prevtec). During 2017, we completed the acquisition of BIVIVP. These transactions were accounted for as business combinations under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated and combined financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our consolidated and combined financial statements from the dates of acquisition.
Aratana Therapeutics, Inc.
On July 18, 2019, we acquired Aratana, a pet therapeutics company focused on innovative therapies for dogs and cats, for stock and cash-based contingent value rights. Aratana is the creator of the canine osteoarthritis medicine, Galliprant, the rights to which we acquired in 2016. The acquisition enhances our presence in the areas of appetite stimulants in dogs, pain relief in dogs and cats, and treatments of other conditions in the U.S. and internationally. In connection with the acquisition, we issued approximately 7.2 million shares with a value of $238.0 million to Aratana shareholders, based on our stock price on the last trading day immediately prior to the closing date. The purchase consideration also included up to $12 million in contingent value rights, which represent the rights of Aratana shareholders to receive a contingent payment of $0.25 per share in cash upon the achievement of a specified milestone as outlined in the merger agreement. We calculated an immaterial fair value for the contingent value rights using the Monte Carlo simulation model.
Contingent consideration liabilities that we previously recorded for future royalty and milestone payments in relation to the 2016 acquisition of rights to Galliprant were settled upon the closing of our acquisition of Aratana. The liabilities were valued at $84.7 million as of the acquisition date using the Monte Carlo simulation model. The resulting $7.5 million loss upon settlement was recorded in Other - net, expense in the consolidated and combined statement of operations for the year ended December 31, 2019.
85

The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:
Estimated Fair Value at July 18, 2019
Cash and cash equivalents$26.4  
Inventories10.3  
Acquired in-process research and development 31.9  
Marketed products (1)
36.7  
Other intangible assets (1)
13.2  
Other assets and liabilities - net 24.0  
Total identifiable net assets142.5  
Goodwill (2)
10.8  
Settlement of existing contingent consideration liabilities84.7  
Total consideration transferred$238.0  
(1) These intangible assets, which are being amortized on a straight-line basis over their estimated useful lives, are expected to have a weighted average useful life of approximately 12.5 years.
(2) The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of Aratana with our legacy business. The majority of goodwill associated with this acquisition is not deductible for tax purposes.
The accounting for this acquisition is substantially complete, with the exception of the finalization of the valuation of intangible assets, tax-related amounts and minor working capital adjustments. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date.
We issued 0.1 million shares and recorded $3.6 million of stock-based compensation expense for the vesting of Aratana equity awards that was accelerated upon the closing of the acquisition during the year ended December 31, 2019.
Our consolidated statement of operations for the year ended December 31, 2019 included revenues of $10.0 million from Aratana.
Had Aratana been acquired on January 1, 2018, the unaudited pro forma combined revenues of Elanco and Aratana would have been $3.1 billion for both the years ending December 31, 2019 and December 31, 2018, and income before income taxes would have been $63.2 million and $117.7 million for the years ending December 31, 2019 and December 31, 2018, respectively.
Prevtec Microbia Inc.
On July 31, 2019, we acquired Prevtec in a cash transaction for approximately $60.3 million, inclusive of certain post-closing adjustments. Prevtec is a Canadian biotechnology company specializing in the development of vaccines intended to help prevent bacterial diseases in food animals. The acquisition allows us to expand on our previous distribution arrangement for Coliprotec and is consistent with our efforts to explore innovative antibiotic alternatives.
The purchase consideration included up to $16.3 million in additional cash consideration, contingent upon the achievement of specific sales milestones by December 31, 2021. We have recorded a $4.7 million liability on the consolidated balance sheet as of the acquisition date based on the fair value of the contingent consideration as calculated using the Monte Carlo simulation model.
A previously existing $0.7 million receivable owed from Prevtec to Elanco Animal Health UK Limited was settled upon the closing of our acquisition of Prevtec. The resulting immaterial gain upon settlement was recorded in Other - net, expense in the consolidated and combined statement of operations for the year ended December 31, 2019.
86

The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:
Estimated Fair Value at July 31, 2019
Cash and cash equivalents$0.9  
Property and equipment0.5  
Acquired in-process research and development 2.8  
Marketed products(1)
58.9  
Other intangible assets1.1  
Other assets and liabilities - net(10.3) 
Total identifiable net assets53.9  
Goodwill (2)
11.1  
Total consideration transferred$65.0  
(1) These intangible assets, which are being amortized on a straight-line basis over their estimated useful lives, are expected to have a weighted average useful life of 10 years.
(2) The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of Prevtec with our legacy business and future unidentified projects and products. The goodwill associated with this acquisition is not deductible for tax purposes.
The accounting for this acquisition is substantially complete, with the exception of the finalization of the valuation of intangible assets, tax-related amounts and minor working capital adjustments. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date.
Boehringer Ingelheim Vetmedica, Inc. Vaccine Portfolio Acquisition
On January 3, 2017, we acquired BIVIVP in a cash transaction for $882.1 million. Under the terms of the agreement, we acquired a manufacturing and research and development site, a U.S. vaccine portfolio including vaccines used for the treatment of bordetella, Lyme disease, rabies and parvovirus, among others.
The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:
Estimated Fair Value at January 3, 2017
Inventories (1)
$108.6  
Marketed products (2)
297.0  
Property and equipment148.2  
Other assets and liabilities — net8.2  
Total identifiable net assets562.0  
Goodwill (3)
320.1  
Total consideration transferred — net of cash acquired$882.1  
(1) The fair value for inventories include a purchase accounting adjustment to write up the inventory value, which resulted in incremental cost of sales of $42.7 million in 2017. The fair value was determined by estimating the expected sales price of the inventories, reduced for all costs expected to the incurred and a profit on those costs.
(2) These intangible assets, which are being amortized on a straight-line basis over their estimated useful lives, were expected to have a weighted average useful life of 10 years.
(3) The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of BIVIVP with our legacy business, future unidentified projects and products, and the assembled workforce of BIVIVP. The goodwill associated with this acquisition is deductible for tax purposes.
Our combined statement of operations for the year ended December 31, 2017 included BIVIVP revenues of $216.7 million. We are unable to provide the results of operations attributable to BIVIVP as those operations were substantially integrated into our legacy business.
87

Pending Acquisition
Bayer Animal Health Business
In August 2019, we entered into the Purchase Agreement with Bayer, a German corporation, to acquire Bayer's animal health business. Bayer's animal health business is a provider of products intended to improve the health and well-being of pets and farm animals. This acquisition is expected to expand our Companion Animal product category, advance our planned intentional portfolio mix transformation and create a better balance between our Food Animal and Companion Animal product categories. Pursuant to the Purchase Agreement and subject to the satisfaction of certain customary closing conditions, including the receipt of antitrust approvals and the absence of any law or order enjoining or otherwise prohibiting the transaction in specified jurisdictions, we will purchase Bayer’s animal health business for approximately $5.3 billion in cash and approximately $2.3 billion of our common stock, subject to certain customary adjustments. Unless the parties agree otherwise, the transaction will close no earlier than July 1, 2020, per the terms of the Purchase Agreement. See Note 16: Commitments and Contingencies for discussion regarding certain commitments related to this transaction.

Note 7. Asset Impairment, Restructuring and Other Special Charges
In recent years, we have incurred substantial costs associated with restructuring programs and cost-reduction initiatives designed to achieve a flexible and competitive cost structure. Restructuring activities primarily include charges associated with facility rationalization and workforce reductions. In connection with our recent acquisitions, we have also incurred costs associated with executing transactions and integrating acquired operations, which may include expenditures for banking, legal, accounting, and other similar services. In addition, we have incurred costs to stand up our organization as an independent company. All operating functions can be impacted by these actions; therefore, non-cash expenses associated with our tangible and intangible assets can be incurred as a result of revised fair value projections and/or determinations to no longer utilize certain assets in the business on an ongoing basis.
For finite-lived intangible asset and other long-lived assets, whenever impairment indicators are present, we calculate the undiscounted value of projected cash flows associated with the asset, or group of assets, and compare it to the carrying amount. If the carrying amount is greater, we record an impairment loss for the excess of book value over fair value. Determinations of fair value can result from a complex series of judgments and rely on estimates and assumptions. See Note 2: Basis of Presentation for discussion regarding estimates and assumptions.
Components of asset impairment, restructuring and other special charges for the years ended December 31 are as follows:
201920182017
Restructuring charges: (1)
Severance and other costs$8.2  $15.5  $162.0  
Facility exit costs—  5.7  31.8  
Acquisition related charges:
Transaction and integration costs (2)
144.7  26.5  90.3  
Non-cash and other items:
Asset impairment (3)
15.4  81.9  110.6  
Asset write-down (4)
17.2  —  —  
Gain on sale of fixed assets (5)
—  (0.8) (19.6) 
Total expense$185.5  $128.8  $375.1  
(1)For the year ended December 31, 2019, these charges primarily relate to a new program that will eliminate certain positions across multiple locations and functions, including exiting R&D operations in Prince Edward Island, Canada, ceasing certain manufacturing operations in Wusi, China, and streamlining operations in Speke, England. We expect to substantially complete these restructuring activities by September 2020.
88

For the year ended December 31, 2018, these charges primarily relate to a program to streamline international operations, including  shifting focus and resources to priority areas. Among other actions, amounts reflect a change from having a physical location to a distribution model in certain countries in connection with the Separation. These activities were substantially complete as of December 31, 2019.
We historically participated in Lilly’s cost-reduction initiatives, which resulted in restructuring charges in the period prior to our IPO. These restructuring charges include severance and other costs associated with the reduction of our workforce, including special termination benefits recognized in 2017 associated with the U.S. voluntary early retirement program offered by Lilly, related to our employees and pension curtailment costs and facility exit costs. We also recorded certain impairment charges related to the activities as described below.
(2)Transaction costs represent external costs directly related to acquiring businesses and primarily include expenditures for banking, legal, accounting and other similar services. Integration costs represent external, incremental costs directly related to integrating acquired businesses (e.g., expenditures for consulting, system and process integration, and product transfers), as well as stand-up costs related to the implementation of new systems, programs, and processes due to the Separation from Lilly .
(3)Asset impairment charges are associated with the following:
•For the year ended December 31, 2019, write-off certain IPR&D and manufacturing assets in the US, Canada and Speke, resulting from the adjustment to fair value of property and equipment and intangible assets that were subject to product rationalization.
•For the year ended December 31, 2018, the decision to dispose of a manufacturing facility in the U.S., the suspension of commercial activities for Imrestor, the write-off of certain idle assets in a U.S. manufacturing facility and product rationalization.
•For the year ended December 31, 2017, intangible asset impairments related to revised projections of fair value due to product rationalization and to a lesser extent competitive pressures.
(4)Asset write-down expenses resulted from the adjustments recorded to write assets classified as held and used and held for sale down to their current fair values. These charges primarily related to fixed assets in Prince Edward Island, Canada; Wusi, China and Indianapolis, Indiana. $11.2 million of Property and equipment, net in Prince Edward Island, Canada and Indianapolis, Indiana are classified as held for sale.
(5)Represents a gain on the disposal of a site that was previously closed as part of the acquisition and integration of Novartis Animal Health beginning on January 1, 2015.
The following table summarizes the activity in our reserves established in connection with restructuring activities:
Exit costs SeveranceTotal
Balance at December 31, 2017$34.9  $43.1  $78.0  
Charges11.7  15.5  27.2  
Separation adjustment(5.9) —  (5.9) 
Reserve adjustment(6.0) —  (6.0) 
Cash paid(25.4) (23.5) (48.9) 
Balance at December 31, 20189.3  35.1  44.4  
Charges—  19.3  19.3  
Reserve adjustment (1)
—  (11.1) (11.1) 
Cash paid(3.9) (27.8) (31.7) 
Balance at December 31, 2019$5.4  $15.5  $20.9  
(1) Reserve adjustment represents the reversal of reserves for severance programs that are no longer active.

These reserves are included in other current liabilities in the consolidated balance sheets. Substantially all of the reserves are expected to be paid in the next twelve months. We believe that the reserves are adequate.

Note 8. Inventories
We state all inventories at the lower of cost or net realizable value. We use the last-in, first-out (LIFO) method for a portion of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost.

89

Inventories at December 31 consisted of the following:
20192018
Finished products$402.9  $400.7  
Work in process603.2  570.4  
Raw materials and supplies83.9  80.4  
Total (approximates replacement cost)1,090.0  1,051.5  
Decrease to LIFO cost(39.3) (47.4) 
Inventories$1,050.7  $1,004.1  
Inventories valued under the LIFO method comprised $197.2 million and $194.8 million of total inventories at December 31, 2019 and 2018, respectively.
During the year ended December 31, 2018, we recognized $38.6 million of inventory write-offs in cost of sales primarily related to the suspension of commercial activities for Imrestor.

Note 9. Debt
Long-term debt as of December 31 consisted of the following:
20192018
Term credit facility$371.4  $492.5  
3.912% Senior Notes due 2021
500.0  500.0  
4.272% Senior Notes due 2023
750.0  750.0  
4.900% Senior Notes due 2028
750.0  750.0  
Other obligations0.4  0.5  
Unamortized debt issuance costs(16.8) (20.7) 
2,355.0  2,472.3  
Less current portion of long-term debt(24.5) (29.0) 
Total long-term debt$2,330.5  $2,443.3  
Revolving and Term Credit Facilities
On September 5, 2018, we entered into a revolving credit agreement with a syndicate of banks providing for a five-year $750.0 million senior unsecured revolving credit facility (Revolving Facility). The Revolving Facility bears interest at a variable rate plus specified margin as defined in the agreement and is payable quarterly. There were no borrowings outstanding under the Revolving Facility at December 31, 2019 or 2018. The Revolving Facility is payable in full at the end of the term.
On September 5, 2018, we also entered into a $500.0 million three-year term loan under a term credit facility with a syndicate of banks (the Term Facility and collectively with the Revolving Facility, the Credit Facilities.) The Term Facility bears interest at a variable rate plus margin as defined in Term Facility (3.01% and 3.77% at December 31, 2019 and 2018, respectively) and is payable quarterly. The Term Facility also requires a quarterly principal payment equal to 1.5% of the aggregate initial principal less any prepayment. The Term Facility is payable in full at the end of the term.
The Credit Facilities are subject to various financial and other covenants, including restrictions on the level of borrowings based on a consolidated leverage ratio and a consolidated interest coverage ratio. We were in compliance with all such covenants as of December 31, 2019.
Senior Notes
On August 28, 2018, we issued $2.0 billion of senior notes (Senior Notes) in a private placement. The Senior Notes comprised of $500.0 million of 3.912% Senior Notes due August 27, 2021, $750.0 million of 4.272% Senior Notes due August 28, 2023, and $750.0 million of 4.900% Senior Notes due August 28, 2028. The interest rate
90

payable on each series of Senior Notes is subject to adjustment if Moody's Investor Services, Inc. or Standard & Poor's Financial Services LLC downgrades, or subsequently upgrades, its ratings on the respective series of Senior Notes.
The indenture that governs the Senior Notes contains covenants, including limitations on our ability, and certain of our subsidiaries, to incur liens or engage in sale-leaseback transactions. The indenture also contains restrictions on our ability to consolidate, merge or sell substantially all of our assets, in addition to other customary terms. We were in compliance with all such covenants under the indenture governing the Senior Notes as of December 31, 2019.

On June 26, 2019, we completed an exchange offer pursuant to which the privately issued Senior Notes were exchanged for publicly registered Senior Notes having substantially identical terms.

Note 10. Financial Instruments and Fair Value
Financial instruments that are potentially subject to credit risk consist principally of trade receivables. Collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures.
A large portion of our cash is held by a few major financial institutions. We monitor the exposure with these institutions and do not expect any of these institutions to fail to meet their obligations. All highly liquid investments with a maturity of three months or less from the date of purchase are considered to be cash equivalents. The cost of these investments approximates fair value. We also consider the carrying value of restricted cash balances to be representative of its fair value.
As of December 31, 2019 and 2018, we had $18.8 million and $15.3 million, respectively, primarily related to equity method investments included in other noncurrent assets in our consolidated balance sheet.
The following table summarizes the fair value information at December 31, 2019 and 2018 for contingent consideration liabilities, and net investment hedge assets/(liabilities) measured at fair value on a recurring basis in the respective balance sheet line items, as well as long-term debt for which fair value is disclosed on a recurring basis:
  Fair Value Measurements Using 
Financial statement line itemCarrying AmountQuoted Prices in Active Markets for Identical Assets (Level 1)Significant Other Observable Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)		Fair Value
December 31, 2019
Other noncurrent liabilities- contingent consideration$(4.7) $—  $—  $(4.7) $(4.7) 
Other noncurrent assets/(liabilities) - cross currency interest rate contracts designated as net investment hedges2.3  —  2.3  —  2.3  
Long-term debt - senior notes(2,000.0) —  (2,120.6) —  (2,120.6) 
Long-term debt - term credit facility(371.4) —  (371.4) —  (371.4) 
December 31, 2018
Other current liabilities- contingent consideration$(5.1) $—  $—  $(5.1) $(5.1) 
Other noncurrent liabilities- contingent consideration(69.0) —  —  (69.0) (69.0) 
Other noncurrent assets/(liabilities) - cross currency interest rate contracts designated as net investment hedges(7.4) —  (7.4) —  (7.4) 
Long-term debt - senior notes(2,000.0) —  (2,005.0) —  (2,005.0) 
Long-term debt - term credit facility(492.5) —  (492.5) —  (492.5) 
91

We determine our Level 2 fair value measurements based on a market approach using quoted market values or significant other observable inputs for identical or comparable assets or liabilities.

Contingent consideration liabilities as of December 31, 2019 related to contingent consideration associated with the acquisitions of Aratana and Prevtec during the period. For Aratana, we will pay up to $12 million in contingent value rights that are dependent on the achievement of a specified milestone as outlined in the merger agreement. For Prevtec, based on the terms of the purchase agreement, we will pay up to $16.3 million contingent upon the achievement of specific Coliprotec sales milestones by December 31, 2021. The fair value of both contingent consideration liabilities was estimated using the Monte Carlo simulation model and Level 3 inputs including historical revenue, discount rate, asset volatility, and revenue volatility. See Note 6: Acquisitions for further discussion.
Contingent consideration liabilities as of December 31, 2018 related to Galliprant for which the fair value was estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant view for the probability of achieving potential future payments to Aratana and an estimated discount rate. The amount to be paid as of December 31, 2018 was dependent upon certain development, success-based regulatory, and sales-based milestones. These liabilities were settled upon the closing of our acquisition of Aratana on July 18, 2019. See Note 6: Acquisitions for further discussion.

In October 2018, we entered into a five-year cross-currency fixed interest rate swap with a 750 million Swiss Franc (CHF) notional amount, which is designated as a NIH against CHF denominated assets for which the fair value was estimated based on quoted market values of similar hedges and is classified as Level 2. The NIH is expected to generate approximately $25 million in cash and an offset to interest expense on an annual basis. For the years ended December 31, 2019 and 2018, our interest expense was offset by $25.1 million and $5.6 million, respectively, as a result of the NIH. Over the life of the derivative, gains or losses due to spot rate fluctuations are recorded in cumulative translation adjustment in other comprehensive income. During the years ended December 31, 2019 and 2018, we recorded a gain of $7.7 million and a loss of $5.9 million, respectively, net of tax, on the NIH, which is included in the change in the cumulative translation adjustment. There is a potential for significant 2023 settlement exposure as the U.S. dollar fluctuates against the Swiss Franc. The risk management objective is to manage foreign currency risk relating to net investments in certain CHF denominated assets. Changes in fair value of the derivative instruments are recognized in a component of accumulated other comprehensive loss to offset the changes in the values of the net investments being hedged.

Note 11. Goodwill and Intangibles
Goodwill
Goodwill was $3.0 billion as of December 31, 2019 and 2018. Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually and when impairment indicators are present. Goodwill may be impaired if the carrying amount of a reporting unit exceeds the fair value of that reporting unit, calculated as based on discounted cash flows. An impairment charge would be recorded for the excess, if any, of the reporting unit's carrying amount over its fair value, but not to exceed the total amount of goodwill allocated to the reporting unit. The estimated fair value is based on a number of assumptions, including current market capitalization as corroboration of fair value. See Note 6: Acquisitions for further discussion of goodwill resulting from recent business combinations. The remaining change in goodwill is primarily the result of foreign exchange translation adjustments.
No impairments occurred with respect to the carrying value of goodwill for the years ended December 31, 2019, 2018 and 2017.
92

Other Intangibles
The components of intangible assets other than goodwill at December 31 were as follows:
20192018
Description
Carrying Amount, Gross
Accumulated Amortization
Carrying Amount, Net
Carrying Amount, Gross
Accumulated Amortization
Carrying Amount, Net
Finite-lived intangible assets:
Marketed products$3,302.7  $(980.6) $2,322.1  $3,193.5  $(779.2) $2,414.3  
Software159.2  (72.2) 87.0  101.3  (49.5) 51.8  
Other58.3  (34.0) 24.3  53.1  (34.0) 19.1  
Total finite-lived intangible assets3,520.2  (1,086.8) 2,433.4  3,347.9  (862.7) 2,485.2  
Indefinite-lived intangible assets:
Acquired in-process research and development49.4  —  49.4  19.6  —  19.6  
Other intangibles$3,569.6  $(1,086.8) $2,482.8  $3,367.5  $(862.7) $2,504.8  
Marketed products consist of the amortized cost of the rights to assets acquired in business combinations and approved for marketing in a significant global jurisdiction. For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing.
Software consists of certain costs incurred in connection with obtaining or developing internal-use software, including payroll and payroll-related costs for employees directly associated with the internal-use software projects and direct costs of external resources. These costs include software classified as "in process" until the project is substantially complete and the software is ready for its intended purpose, at which point the costs are amortized on a straight-line basis over the estimated useful life. Depreciation expense includes $20.4 million in 2019, $18.4 million in 2018, and $17.4 million in 2017 for amortization of software.
Other finite-lived intangibles consist primarily of the amortized cost of licensed platform technologies that have alternative future uses in research and development, manufacturing technologies and customer relationships from business combinations. Acquired IPR&D consists of the related costs capitalized, adjusted for subsequent impairments, if any. The costs of acquired IPR&D projects acquired directly in a transaction other than a business combination are capitalized if the projects have an alternative future use; otherwise, they are expensed immediately. The fair values of acquired IPR&D projects acquired in business combinations are capitalized as other intangible assets.
Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the "income method" for other intangibles. This method is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each group of assets independently. The acquired IPR&D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate.
See Note 6: Acquisitions for further discussion of intangible assets acquired in recent business combinations.
Other indefinite-lived intangible assets are reviewed for impairment at least annually and when impairment indicators are present. The fair value of the indefinite lived intangible assets (acquired IPR&D) is estimated using the same assumptions as used for goodwill and by applying a probability weighting that reflects the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is
93

present. We compare the carrying amounts of the assets with the estimated undiscounted future cash flows. In the event the carrying amount exceeds the undiscounted cash flows, an impairment charge is recorded for the amount by which the carrying amount of the asset exceeds the estimated fair value, which is determined based on discounted future cash flows.
During 2019, we recorded impairment charges of $11.4 million primarily related to indefinite-lived intangible assets which are included in asset impairment, restructuring and other special charges on the consolidated and combined statements of operations. The impairment of indefinite-lived intangible assets primarily related to product rationalization.
During 2018, we recorded impairment charges of $22.5 million (comprised of $9.5 million impairment of finite-lived intangible assets and $13.0 million impairment of indefinite-lived intangible assets) which are included in asset impairment, restructuring and other special charges on the consolidated and combined statements of operations. The impairment of finite-lived intangible assets primarily related to competitive pressures for a certain marketed product resulting in a reduction of projected cash flows. The impairment of indefinite-lived intangible assets primarily related to revised projections of fair value due to competitive pressures and to a lesser extent product rationalization. The increase in the carrying amount of finite intangibles is primarily due to the receipt of full commercialization rights outside the U.S. for Galliprant.
During 2017, we had impairment charges of $94.5 million (comprised of $56.5 million impairment of finite-lived intangible assets and $38.0 million impairment of indefinite-lived intangible assets) which are included in asset impairment, restructuring and other special charges on the consolidated and combined statements of operations. The impairment of finite-lived intangible assets primarily related to competitive pressures for a certain marketed product resulting in a reduction of projected cash flows. The impairment of indefinite-lived intangible assets primarily related to revised projections of fair value due to competitive pressures and to a lesser extent product rationalization.
Intangible assets with finite lives are capitalized and are amortized over their estimated useful lives, ranging from 3 to 20 years. As of December 31, 2019, the remaining weighted-average amortization periods for finite-lived intangible assets are as follows:
Weighted Average Life (Years)
Marketed products13
Software6
Other8
The estimated amortization expense for each of the next five years associated with our finite-lived intangible assets as of December 31, 2019 is as follows:
20202021202220232024
Estimated amortization expense$206.2  $205.4  $203.3  $203.0  $203.0  

Note 12. Property and Equipment
Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (12 to 50 years for buildings and 3 to 25 years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset's net book value over its fair value utilizing a discounted cash flow analysis, and the cost basis is adjusted.
94

At December 31, property and equipment consisted of the following:
20192018
Land$28.3  $27.6  
Buildings608.5  567.2  
Equipment1,109.4  1,025.1  
Construction in progress139.1  181.1  
Finance lease asset0.5  —  
1,885.8  1,801.0  
Less accumulated depreciation(930.5) (878.6) 
Property and equipment, net$955.3  $922.4  
Depreciation expense related to property and equipment was as follows:
201920182017
Depreciation expense$93.7  $81.3  $79.8  

Note 13. Leases
We determine if an arrangement is a lease at inception. We have operating leases for corporate offices, research and development facilities, vehicles, and equipment. Our leases have remaining lease terms of one to 12 years, some of which have options to extend or terminate the leases. Finance leases are included in property and equipment, current portion of long-term debt, and long-term debt in our consolidated balance sheet. Finance leases are not material to our consolidated statements of operations, consolidated balance sheet, or consolidated statement of cash flows. Beginning January 1, 2019, operating leases are included in noncurrent assets, other current liabilities, and other noncurrent liabilities in our consolidated balance sheet.
Right-of-use assets included in noncurrent assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Right-of-use assets and operating lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate if it is readily determinable. The right-of-use asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain and there is a significant economic incentive to exercise that option.
Operating lease expense for right-of-use assets is recognized on a straight-line basis over the lease term. Variable lease payments, which represent lease payments that vary due to changes in facts or circumstances occurring after the commencement date other than the passage of time, are expensed in the period in which the obligation for these payments was incurred.
We elected not to apply the recognition requirements of ASC 842, Leases, to short-term leases, which are deemed to be leases with a lease term of 12 months or less. Instead, we recognize lease payments in the consolidated statements of operations on a straight-line basis over the lease term and variable payments in the period in which the obligation for these payments are incurred. We elected this policy for all classes of underlying assets. We elected not to apply the practical expedient related to the separation of lease and non-lease components or the practical expedient which allows entities to use hindsight when determining lease term.
95

The impact of operating leases to our consolidated financial statements for the year ended December 31, 2019 was as follows:
2019
Lease cost
Operating lease cost$26.1  
Short-term lease cost0.5  
Variable lease cost2.5  
Total lease cost (1)
$29.1  
Other information
Operating cash outflows from operating leases$24.0  
Right-of-use assets obtained in exchange for new operating lease liabilities20.1  
Weighted-average remaining lease term - operating leases5.1 years
Weighted-average discount rate - operating leases3.6 %
(1) Rental expense for all leases was $47.5 million and $47.1 million for the years ended December 31, 2018 and 2017, respectively.
Supplemental balance sheet information related to our operating leases is as follows:
Balance Sheet ClassificationDecember 31, 2019
Right-of-use assetsOther noncurrent assets$85.0  
Current operating lease liabilitiesOther current liabilities23.7  
Non-current operating lease liabilitiesOther noncurrent liabilities61.7  
As of December 31, 2019, the annual minimum lease payments of our operating lease liabilities were as follows:
Year 1$26.0  
Year 220.3  
Year 311.9  
Year 49.7  
Year 57.2  
After Year 516.5  
Total lease payments91.6  
Less imputed interest(6.2) 
Total$85.4  

Note 14. Stock-Based Compensation
Elanco Stock Compensation Plans
The 2018 Elanco Stock Plan (Plan) provides long-term incentives to attract, motivate and retain employees and non-employee directors. The types of stock-based awards available include, but are not limited to, restricted stock units (RSUs), performance-based awards (PAs), and stock options. Our practices and policies specify that stock-based compensation awards are approved by the Compensation Committee of the Board of Directors. The Plan, initially authorized the issuance of up to 5.5 million common shares (subject to adjustments for certain events). Pursuant to the terms of the Plan, an additional 5.5 million common shares became automatically available for all awards upon completion of the Separation. The total number of shares authorized for stock-based compensation awards is 11 million as of December 31, 2019.
96

Stock-Based Compensation Expense

Components of stock-based compensation expense and related tax benefit for the years ended December 31 are as follows:
20192018
Stock-based compensation expense (1)
$40.7  $1.8  
Related tax benefit (9.8) (0.4) 
(1) We include the impact of estimated forfeitures when determining stock-based compensation expense.
Restricted Stock Units
RSUs are granted to certain employees and are settled in shares of our common stock. RSU shares are accounted for at fair value based upon the closing stock price on the date of the grant. The corresponding expense is amortized over the vesting period, typically three years. The number of shares ultimately issued for the RSU program remains constant with the exception of forfeitures.
RSUs granted to employees for the years ended December 31 are as follows:
(Units in millions)20192018
Granted units2.9  0.2  
Weighted-average fair value$31.22  $31.09  
Changes in nonvested portion of RSUs for 2019 is summarized below:
(Shares in millions)SharesWeighted-Average Fair Value
Nonvested units at January 1, 20190.2$31.09  
Granted2.931.22  
Vested(0.8)31.33  
Forfeited(0.1)31.25  
Nonvested units at December 31, 20192.230.42  

As of December 31, 2019, the total remaining unrecognized stock-based compensation expense related to nonvested RSUs was $25.5 million, which will amortize over the weighted-average remaining requisite service period of 19 months.
Performance-Based Awards
PAs, which are granted to eligible officers and management, represent the right to receive a share of our common stock and are subject to forfeiture until restrictions lapse (including continued employment through the end of the vesting period and achievement of certain pre-established metrics). Payouts can vary depending on achievement. PA shares are accounted for at fair value based upon the closing stock price on the date of grant and fully vest at the end of the measurement period.
97

PA activity during the year ended December 31, 2019 is summarized below:
(Shares in millions)SharesWeighted-Average Fair Value
Nonvested awards at January 1, 2019—  $—  
Granted0.8  25.75  
Vested—  —  
Forfeited—  —  
Nonvested awards at December 31, 20190.8  25.75  
As of December 31, 2019, the total remaining unrecognized stock-based compensation expense related to nonvested PAs was $11.0 million, which will amortize over the weighted-average remaining requisite service period of 13 months.
Stock Option Program
Stock options represent the right to purchase shares of our common stock within a specified period of time at a specified price. The exercise price for a stock option will be not less than 100% of the fair market value of the common stock on the date of the grant.
Stock options are accounted for using a fair-value based method at the date of the grant in the consolidated statement of operations. The values determined through this fair-value-based method generally are amortized on a straight-line basis over the vesting term.
Stock options were granted in 2018 to our officers, management and board members at exercise prices equal to the fair market value of our stock at the date of the grant. Options fully vest 3 years from the grant date and have a term of 10 years. No stock options were granted in 2019.
The fair-value-based method for valuing each Elanco stock option grant on the grant date uses the Black-Scholes-Merton option-pricing model, which incorporates a number of valuation assumptions noted in the following table, shown at their weighted-average values for the year ended December 31:
2018
Expected dividend yield(1)
0.70 %
Risk-free interest rate(2)
3.07 %
Expected stock price volatility(3)
28.25 %
Expected term(4) (years)
6.5
(1) Determined using the expected quarterly dividend divided by the available three-month average stock price as of the valuation date, annualized and continuously compounded.
(2) Determined using the term-matched, zero-coupon risk-free rate from the Treasury Constant Maturity yield curve, continuously compounded
(3) Determined using a leverage-adjusted historical volatility of peer companies
(4) Determined using SEC safe harbor approach, based on a 3-year cliff vesting schedule and 10-year contractual term.
98

Stock option activity during the year ended December 31, 2019 is summarized below:
(Shares in millions)Shares of Common Stock Attributable to OptionsWeighted-Average Exercise Price of OptionsWeighted-Average Remaining Contractual Term (Years)
Aggregate Intrinsic Value(1)
Outstanding at January 1, 20190.4  $31.61  
Granted—  —  
Exercised(0.1) 31.61  
Forfeited or expired—  —  
Outstanding at December 31, 20190.3  $31.61  8.8$—  
Exercisable at December 31, 2019—  —  —  —  
(1)Market price of underlying Elanco common stock less exercise price. Options do not have an intrinsic value unless the market price exceeds the exercise price.
As of December 31, 2019, there was approximately $2.2 million of unrecognized compensation costs related to nonvested stock options, which will be recognized over an expected remaining weighted-average period of 22 months.
The following table summarizes data related to stock option activity:
20192018
Weighted-average grant date fair value per stock option$10.21  $10.21  
Aggregate intrinsic value on exercise0.10  —  
Cash received upon exercise1.9  —  
Treatment of Lilly Equity Awards
Prior to the Separation, our employees participated in Lilly stock-based compensation plans, the cost of which was allocated to us and recorded in costs of sales, research and development, and marketing, selling and administrative expense in the consolidated and combined statements of operations. The cost of such plans related to our employees was $5.1 million, $26.0 million and $25.0 million for the years ended December 31, 2019, 2018 and 2017, respectively.
Following the IPO and until completion of the exchange offer, the equity awards previously granted to our employees by Lilly continued to vest with Elanco service counting toward the Lilly award's vesting provisions. On March 11, 2019, Elanco completed the exchange offer whereby Lilly disposed of all of its shares of Elanco common stock owned by Lilly. As a result, our employees' unvested Lilly equity awards were forfeited and replaced with Elanco RSUs (replacement awards), which were equivalent in value and vest on the same date as their forfeited Lilly equity awards. These replacement awards are included in the RSU activity described above.

Note 15. Income Taxes
Our income taxes for the year ended December 31, 2019 reflect the results on a stand-alone basis independent of Lilly, except for the period during which we were included in a combined tax return until full separation. In the jurisdictions in which we were included in a combined tax return, our income taxes were determined based on the tax matters agreement between us and Lilly. During the periods presented in the consolidated and combined financial statements for the year ended December 31, 2018 and December 31, 2017, our operations were generally included in the tax grouping of other Lilly entities within the respective entity's tax jurisdiction; however, in certain jurisdictions, we filed separate tax returns. Prior to the Separation, the income tax expense included in these financial statements has been calculated using the separate return basis as if Elanco filed separate tax returns.
99

2017 Tax Act
In 2017, the U.S. enacted the Tax Cuts and Jobs Act (2017 Tax Act), which significantly revised U.S. tax law. Guidance related to the 2017 Tax Act, including Notices, Proposed Regulations, and Final Regulations, has been issued, and we expect additional guidance will be issued in 2020. This additional guidance could materially impact our assumptions and estimates used to record our U.S. federal and state income tax expense resulting from the 2017 Tax Act.
We are included in Lilly's U.S. tax examinations by the Internal Revenue Service through the full separation date of March 11, 2019. Pursuant to the tax matters agreement we executed with Lilly in connection with the IPO, the potential liabilities or potential refunds attributable to pre-IPO periods in which Elanco was included in a Lilly consolidated or combined tax return remain with Lilly. Certain matters of Lilly’s U.S. examination of tax years 2013 - 2015 effectively settled during the second quarter of 2019 and the resulting adjustments will not require any cash tax payments by Elanco. During the fourth quarter of 2019, certain matters for tax year 2015 were effectively settled upon conclusion of the IRS' examination and the resulting adjustments will not require any cash tax payments by Elanco. In the fourth quarter of 2019, the IRS began its examination of tax years 2016 - 2018.
Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution.
Following is the composition of income (loss) before income tax expense (benefit):
201920182017
Federal$55.5  $12.2  $(133.2) 
Foreign22.7  101.9  (99.4) 
Income (loss) before income taxes$78.2  $114.1  $(232.6) 
Following is the composition of income tax expense (benefit):
201920182017
Current:
Federal$(5.5) $45.1  $—  
Foreign13.4  45.5  91.6  
State2.3  (2.3) (0.1) 
Total current tax expense10.2  88.3  91.5  
Deferred:
Federal14.5  (56.8) 42.6  
Foreign(7.5) (5.6) (16.6) 
State(6.9) 1.7  (6.3) 
2017 Tax Act—  —  (33.1) 
Total deferred tax expense (benefit)0.1  (60.7) (13.4) 
Income taxes$10.3  $27.6  $78.1  
100

Significant components of our deferred tax assets and liabilities as of December 31 are as follows:
20192018
Deferred tax assets:
Compensation and benefits$25.3  $32.2  
Accruals and reserves13.7  26.9  
Tax credit carryovers12.8  6.2  
Tax loss carryovers69.5  17.4  
Inventories20.1  18.3  
Restructuring and other reserves24.6  6.0  
Operating lease liabilities20.5  —  
Other2.3  20.1  
Total gross deferred tax assets188.8  127.1  
Valuation allowances(32.7) (21.4) 
Total deferred tax assets156.1  105.7  
Deferred tax liabilities:
Right-of-use assets(20.5) —  
Intangibles(134.5) (130.8) 
Property and equipment(56.4) (50.8) 
Other(0.6) (2.7) 
Total deferred tax liabilities(212.0) (184.3) 
Deferred tax liabilities - net$(55.9) $(78.6) 
Deferred tax assets and liabilities reflect the impact of re-measurement resulting from the 2017 Tax Act.
The deferred tax assets and related valuation allowance amounts for U.S. federal and state net operating losses and tax credits shown above have been reduced for differences between financial reporting and tax return filings.
At December 31, 2019, we have tax credit carryovers of $14.0 million available to reduce future income taxes. The amount is comprised of foreign, U.S. federal and state credits. The foreign credits total $5.1 million and if unused, will begin to expire in 2030. The U.S. federal credits total $3.2 million and if unused, will begin to expire in 2030. The state credits total $5.7 million and if unused, will begin to expire in 2020. The U.S. federal and state credits are subject to a full valuation allowance.
At December 31, 2019, we had net operating loss carryovers and other carryovers for foreign, U.S. federal and state income tax purposes of $348.4 million: $285.5 million will expire between 2020 and 2039; and $62.9 million of the carryovers have an indefinite carryforward period. Net operating losses and other carryovers for foreign and state income tax purposes are subject to a partial valuation allowance.
The movements in the valuation allowance are as follows:
20192018
January 1$(21.4) $(127.7) 
Adjustment related to Separation—  110.4  
January 1(21.4) (17.3) 
Increase (1)
(23.2) (5.8) 
Release11.9  1.7  
December 31$(32.7) $(21.4) 
(1) The increase in the valuation allowance during 2019 is primarily attributable to the acquisition of Aratana Therapeutics, Inc. and Prevtec Microbia Inc. (see Note 6: Acquisitions).

101

Prior to the IPO, we prepared the income tax amounts and balances based upon a separate return methodology, as if we were separate taxpayers from Lilly.  As a result, certain tax credits and net operating loss carryovers are not available for use in future periods as they were used in Lilly consolidated or combined tax return filings. Accordingly, as a result of the Separation, the tax credit and net operating loss carryovers and related valuation allowance have been adjusted to reflect the balance after Separation. These adjustments had no impact on income tax expense in the consolidated and combined financial statements. The separation entries related to the valuation allowance were offset by $133.7 million, prior to tax effect, of separation entries related to the removal of the net operating losses.
The 2017 Tax Act introduced international tax provisions that significantly change the U.S. taxation of foreign earnings.  At December 31, 2019, no U.S. taxes or foreign withholding taxes have been accrued with respect to the $496.7 million in unremitted earnings of our foreign subsidiaries as they are considered indefinitely reinvested for continued use in our foreign operations. It is not practicable to determine the unrecognized deferred tax liability related to these earnings.
Cash payments of income taxes were as follows:
201920182017
Cash payments of income taxes$42.5  $26.9  $35.7  
The following is a reconciliation of the income tax expense (benefit) applying the U.S. federal statutory rate to income before income taxes to reported income tax expense:
201920182017
Income tax at the U.S. federal statutory tax rate$16.4  $24.0  $(81.4) 
Add (deduct):
Taxation of international operations20.7  20.5  59.8  
State taxes2.9  4.4  5.4  
Income tax credits(9.8) (17.3) (1.8) 
Non-deductible employee compensation4.2  (1.9) —  
IPO and separation costs—  2.3  —  
Other permanent adjustments(4.2) (1.0) 0.8  
Change in uncertain tax positions(14.7) (1.7) 6.2  
Change in valuation allowance(5.2) (1.7) 122.2  
2017 Tax Act—  —  (33.1) 
Income taxes$10.3  $27.6  $78.1  
A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:
201920182017
Beginning balance at January 1$14.7  $29.6  $25.7  
Adjustments related to Separation(2.2) (17.6) —  
Adjusted beginning balance at January 112.5  12.0  25.7  
Additions based on tax positions related to the current year1.3  2.2  7.9  
Changes for tax positions of prior years(1.2) 4.0  —  
Settlements(4.3) (3.0) (4.0) 
Changes related to the impact of foreign currency translation(0.1) (0.5) —  
Ending balance at December 31$8.2  $14.7  $29.6  
The total amount of unrecognized tax benefits that, if recognized, would affect tax expense was $8.2 million and $12.8 million at December 31, 2019 and 2018, respectively. There were $1.9 million of 2018 unrecognized tax benefits which related to temporary differences which did not impact the effective tax rate. Adjustments related to the Separation represent unrecognized tax benefits assumed by Lilly in the Separation and have no impact on income tax expense in the consolidated and combined financial statements.
102

We file income tax returns in the U.S. federal jurisdiction and various state, local and non-U.S. jurisdictions. Prior to full separation, certain of these income tax returns were filed on a consolidated or combined basis with Lilly.
We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense (benefit). We recognized income tax expense (benefit) related to interest and penalties as follows:
201920182017
Income tax expense (benefit)$(10.6) $(2.5) $2.5  
At December 31, 2019 and 2018, our accruals for the payment of interest and penalties totaled $3.0 million and $13.3 million, respectively.

Note 16. Commitments and Contingencies
Legal matters
We are party to various legal actions in the normal course of business. In determining whether a pending matter is significant for financial reporting and disclosure purposes, we consider both quantitative and qualitative factors in order to assess materiality. We accrue for certain liability claims to the extent we can formulate a reasonable estimate of their costs and there is a reasonable probability of incurring significant costs or expenses. At December 31, 2019 and December 31, 2018, we had no liabilities established related to litigation as there were no significant claims which were probable and estimable. We have not historically had any significant litigation expense and are not currently subject to a significant claim.
Bayer Animal Health acquisition financing
In connection with our pending acquisition of the animal health business of Bayer as discussed in Note 6: Acquisitions, in August 2019, we entered into a commitment letter that provides for financing consisting of up to $750 million in a revolving facility, $3.0 billion in a term facility, and $2.75 billion in a senior secured bridge facility. In connection with the financing commitment letter, we will incur fixed commitment fees of $40.4 million that will become due and payable upon the closing of the pending acquisition or the termination of the Purchase Agreement with Bayer. These fees have not been recorded on the consolidated balance sheet as of December 31, 2019. See Note 22: Subsequent Events for updates regarding financing secured after the balance sheet date.

Note 17. Geographic Information
We operate as a single operating segment engaged in the development, manufacturing, marketing and sales of animal health products worldwide for both food animals and companion animals. Consistent with our operational structure, our President and Chief Executive Officer (CEO), as the chief operating decision maker, makes resource allocation and business process decisions globally across our consolidated business. Strategic decisions are managed globally with global functional leaders responsible for determining significant costs/investments and with regional leaders responsible for overseeing the execution of the global strategy. Our global research and development organization is responsible for development of new products. Our manufacturing organization is responsible for the manufacturing and supply of products and for the optimization of our supply chain. Regional leaders are responsible for the distribution and sale of our products and for local direct costs. The business is also supported by global corporate staff functions. Managing and allocating resources at the global corporate level enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, product types, regional commercial organizations and research and development projects in line with our overarching long-term corporate-wide strategic goals, rather than on a product or geographic basis. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, allocating resources, setting incentive compensation targets, as well as forecasting future period financial results.
Our products include Rumensin, Optaflexx, Denagard, Tylan, Maxiban and other products for livestock and poultry, as well as Trifexis, Interceptor, Comfortis, Galliprant and other products for companion animals.
103

We have a single customer that accounted for 12.9%, 11.9% and 12.9% of revenue for the years ended December 31, 2019, 2018 and 2017, respectively. The product sales resulted in accounts receivable with this customer of $90.5 million and $96.4 million as of December 31, 2019 and 2018, respectively.
We are exposed to the risk of changes in social, political and economic conditions inherent in foreign operations and our results of operations and the value of our foreign assets are affected by fluctuations in foreign currency exchange rates.
Selected geographic area information was as follows:
201920182017
Revenue — to unaffiliated customers(1):
United States$1,524.7  $1,483.2  $1,373.0  
International1,546.3  1,583.6  1,516.0  
Revenue$3,071.0  $3,066.8  $2,889.0  
Long-lived assets(2):
United States$709.8  $602.6  $604.7  
United Kingdom192.6  187.5  204.4  
Other foreign countries244.7  195.8  190.2  
Long-lived assets$1,147.1  $985.9  $999.3  
(1) Revenue is attributed to the countries based on the location of the customer.
(2) Long-lived assets consist of property and equipment, net, and certain noncurrent assets, including right-of-use assets.

Note 18. Retirement Benefits
Pension Plans
There are certain defined benefit pension plans that our employees participate in that are either dedicated to our employees or where the plan assets and liabilities that relate to our employees were legally required to transfer to Elanco at the time of our separation from Lilly. The plans in Switzerland represent approximately 80% of our global benefit obligation. We use a measurement date of December 31 to develop the change in benefit obligation, change in plan assets, funded status and amounts recognized in the consolidated balance sheets at December 31 for our defined benefit pension plans, which were as follows:
  20192018
Change in benefit obligation:
Benefit obligation at beginning of year$234.8  $258.6  
Service cost9.3  11.3  
Interest cost2.2  2.5  
Actuarial loss (gain)56.4  (44.7) 
Benefits paid(5.5) (2.7) 
Plan amendments(74.7) —  
Foreign currency exchange rate changes and other adjustments
1.9  9.8  
Benefit obligation at end of year224.4  234.8  

104

Change in plan assets:
Fair value of plan assets at beginning of year131.6  131.5  
Actual return on plan assets15.3  (10.2) 
Employer contribution5.3  5.7  
Benefits paid(5.5) (2.7) 
Foreign currency exchange rate changes and other adjustments
2.0  7.3  
Fair value of plan assets at end of year148.7  131.6  

Funded status(75.7) (103.2) 
Unrecognized net actuarial loss45.9  0.5  
Unrecognized prior service cost(74.1) 0.8  
Net amount recognized$(103.9) $(101.9) 

Amounts recognized in the consolidated balance sheet consisted of:
Noncurrent assets$2.1  $2.3  
Other current liabilities(0.3) (0.3) 
Accrued retirement benefits(77.5) (105.2) 
Accumulated other comprehensive (income) loss before income taxes
(28.2) 1.3  
Net amount recognized$(103.9) $(101.9) 
The unrecognized net actuarial loss and unrecognized prior service cost for these pension plans have not yet been recognized in net periodic pension costs and are included in accumulated other comprehensive loss at December 31, 2019.
Pension plan amendment
In September 2019, we signed agreements under which certain defined pension benefits in Switzerland transferred from the previous Lilly pension fund as of December 31, 2019 to a new Elanco pension fund effective January 1, 2020. This resulted in a plan amendment during the period. The plan amendment decreased our pension benefit obligation by approximately $21 million, consisting primarily of a decrease in prior service costs of approximately $75 million, partially offset by a loss of approximately $54 million driven by changes in certain assumptions. The net impact to accumulated other comprehensive income was a gain of approximately $21 million, which will be amortized over the average remaining service period of employees expected to receive benefits under the plans.
We do not expect any plan assets to be returned to us in 2020.
The following represents our weighted-average assumptions related to these pension plans as of December 31:
(Percents)201920182017
Discount rate for benefit obligation0.6%  1.5%  1.1%  
Discount rate for net benefit costs1.4  1.1  1.0  
Rate of compensation increase for benefit obligation2.3  2.2  2.1  
Rate of compensation increase for net benefit costs2.2  2.1  3.1  
Expected return on plan assets for net benefit costs4.0  4.0  4.4  
We annually evaluate the expected return on the plan assets in these pension plans. In evaluating the expected rate of return, we consider many factors, with a primary analysis of current and projected market conditions; asset returns and asset allocations; and the views of leading financial advisers and economists. We may also review our historical assumptions compared with actual results, as well as the assumptions and trend rates utilized by similar plans, where applicable.
105

The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:
202020212022202320242025-2029
Benefit payments$7.9  $8.6  $8.4  $8.0  $8.1  $48.4  
Amounts relating to these pension plans with projected benefit obligations in excess of plan assets were as follows at December 31:
 20192018
Projected benefit obligation$218.2  $229.2  
Fair value of plan assets140.3  124.1  
Amounts relating to these defined benefit pension plans with accumulated benefit obligations in excess of plan assets were as follows at December 31:
 20192018
Accumulated benefit obligation$203.9  $194.3  
Fair value of plan assets140.3  124.1  
The total accumulated benefit obligation for these defined benefit pension plans was $210.1 million and $199.9 million at December 31, 2019 and 2018, respectively.
Net pension expense related to these plans included the following components:
  201920182017
Service cost$9.3  $11.3  $10.5  
Interest cost2.2  2.5  1.8  
Expected return on plan assets(4.2) (6.2) (2.4) 
Amortization of prior service cost
(1.7) 0.2  0.1  
Amortization of net actuarial loss1.1  1.9  1.4  
Other—  0.5  —  
Net pension expense$6.7  $10.2  $11.4  
The following represents the amounts recognized for these plans in other comprehensive loss:
201920182017
Actuarial gain (loss) arising during period$(45.6) $28.3  $(17.0) 
Prior year service cost during the year74.7  —  —  
Amortization of prior service cost included in net loss(1.7) 0.2  0.1  
Amortization of net actuarial loss included in net loss1.1  1.9  1.4  
Foreign currency exchange rate changes and other1.0  (1.9) 3.5  
Total other comprehensive income (loss) during period$29.5  $28.5  $(12.0) 
Benefit Plan Investments
Our benefit plan investment policies are set with specific consideration of return and risk requirements in relationship to the respective liabilities. Our plan assets in our Switzerland pension plans represent approximately 87% of our plan assets for these pension plans. Given the long-term nature of our liabilities, these plans have the flexibility to manage an above-average degree of risk in the asset portfolios. At the investment-policy level, there are no specifically prohibited investments. However, within individual investment manager mandates, restrictions and limitations are contractually set to align with our investment objectives, ensure risk control and limit concentrations.
We manage our portfolio to minimize concentration of risk by allocating funds within asset categories. In addition, within a category we use different managers with various management objectives to eliminate any significant concentration of risk.
106

The investment strategy is to diversify in five major categories with a designated percentage invested in each including 5% liquidity, 36% fixed income securities, 32% equity securities, a share of 21% in real estate and 6% in other alternative investments. Each category is diversified and comprised of the following:
•Liquidity - cash and cash equivalents
•Fixed-income securities - Swiss bonds, global aggregates, global aggregate corporates, emerging market local currencies and emerging markets hard currencies.
•Equity investments - Swiss equities, global equities, low volatility equities (to reduce risk), and emerging market equities.
•Real estate - Swiss real estate and global real estate funds.
•Other investments - represents primarily investments in senior secured loans.
We determine the fair value of the investments based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analysis for all investments except hedge funds, private equity-like investments and real estate.
We determine the fair value of investments using the value reported by the partnership, adjusted for known cash flows and significant events through our reporting date. Values provided by the partnerships are primarily based on analysis of and judgments about the underlying investments. Inputs to these valuations include underlying NAVs, discounted cash flow valuations, comparable market valuations, and may also include adjustments for currency, credit, liquidity and other risks as applicable. The vast majority of these private partnerships provide us with annual financial statements including their compliance with fair valuation procedures consistent with applicable accounting standards.
We determine the fair value of real estate investments based on the NAV provided by the fund manager. These NAVs are developed with inputs including discounted cash flow, independent appraisal and market comparable analyses.
The fair values of these pension plan assets as of December 31, 2019 by asset category are as follows:
  Fair Value Measurements Using
Asset ClassTotalQuoted Prices in Active Markets for Identical Assets
(Level 1)		Significant Observable 
Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)
Investments Valued at Net Asset Value(1)
Cash and cash equivalents (2)
$129.0  $129.0  $—  $—  $—  
Public equity securities3.8  1.9  —  —  1.9  
Fixed income:
Developed markets2.5  2.1  —  —  0.4  
Emerging markets9.1  8.8  0.3  —  —  
Other4.3  0.9  3.4  —  —  
Total$148.7  $142.7  $3.7  $—  $2.3  
(1)Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.
(2)Switzerland plan assets were exiting the Lilly pension plan as of December 31, 2019. As a result, assets were converted to cash and transferred to the new Elanco pension fund effective January 1, 2020.

No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December 31, 2019. The activity in the Level 3 investments during the year ended December 31, 2019 was not material.
107

The fair values of these pension plan assets as of December 31, 2018 by asset category are as follows:
Fair Value Measurements Using
Asset ClassTotalQuoted Prices in Active Markets for Identical Assets
(Level 1)		Significant Observable Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)
Investments Valued at Net Asset Value(1)
Public equity securities$2.2  $1.0  $—  $—  $1.2  
Fixed income:
Developed markets29.9  7.8  0.1  —  22.0  
Emerging markets6.4  0.7  0.4  —  5.3  
Private alternative investments:
Hedge funds6.6  —  —  —  6.6  
Equity-like funds49.0  —  —  —  49.0  
Real estate20.1  0.1  —  —  20.0  
Other17.4  0.3  2.3  —  14.8  
Total$131.6  $9.9  $2.8  $—  $118.9  
(1)Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.
No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December 31, 2018. The activity in the Level 3 investments during the year ended December 31, 2018 was not material.
Contributions of $6.5 million to these pension plans are expected in 2020.
Retiree Health Benefit Plan
There are two retiree health benefit plan where the plan liabilities that relate to our employees were legally required to transfer to Elanco at the time of separation from Lilly. The accrued retirement benefits for these plans were $4.7 million and $3.9 million as of December 31, 2019 and 2018, respectively.
Defined Contribution Plans
Elanco has defined contribution savings plans that include certain employees worldwide. The purpose of these plans is generally to provide additional financial security during retirement by providing employees with an incentive to save. Our contributions to the plans are based on our employee contributions and the level of our match. Expenses related to our employees under the plans totaled $32.2 million, $20.9 million and $22.1 million for the years ended December 31, 2019, 2018, and 2017, respectively. The expense for our 401(k) plan increased in 2019 primarily due to an increase our match and participant headcount.
Treatment of Lilly Plans
Prior to the Separation, our employees participated in defined benefit pension and other postretirement plans sponsored by Lilly, which include participants of Lilly's other business. Such plans were accounted for as multiemployer plans in the combined financial statements and as a result, no asset or liability was recorded by us to recognize the funded status of these plans.
We recorded expense of $4.0 million and $73.7 million for the years ended December 31, 2018 and 2017, respectively, relating to our employees’ participation in Lilly sponsored plans. The expense recorded in 2017 included $67.0 million related to a curtailment loss and special termination benefits for early retirement incentives offered by Lilly to our employees as part of a voluntary early retirement program for the U.S. plan and which has been recorded in asset impairment, restructuring and other special charges.

108

Note 19. Earnings Per Share
Basic Earnings Per Share
As discussed in Note 1, Elanco Parent was formed for the purpose of facilitating the IPO. Lilly held all shares of Elanco Parent from the time of formation until the IPO.
Prior to IPO, there were an aggregate of 293,290,000 shares of our common stock held by Lilly (which represents the 100 shares held by Lilly prior to giving effect to the 2,932,900-for-1 stock split that occurred on September 19, 2018). In connection with the completion of the IPO, an additional 72,335,000 shares of our common stock were issued. Earnings per share was calculated based on the assumptions that the shares held by Lilly were outstanding for all periods prior to IPO.
We compute basic earnings per share by dividing net earnings available to common shareholders by the actual weighted average number of common shares outstanding for the reporting period. For the year ended December 31, 2019, weighted average number of common shares outstanding used to calculate basic earnings per share includes the impact of approximately 7.3 million shares that were issued during the period in connection with the acquisition of Aratana. See Note 6: Acquisitions for further discussion.
Diluted Earnings Per Share
Elanco has common stock equivalents related to certain equity awards in stock-based compensation arrangements. Diluted earnings per share reflects the potential dilution that could occur if holders of unvested RSUs, PAs and stock options converted their holdings into common stock. The weighted average number of potentially dilutive shares outstanding is calculated using the treasury stock method.
Weighted average diluted shares outstanding included common stock equivalents of 1.3 million for 2019. The dilutive impact for 2018 was immaterial.
Potential common shares that would have the effect of increasing diluted earnings per share are considered to be anti-dilutive and as such, these shares are not included in the calculation of diluted earnings per share. For the year ended December 31, 2019, approximately 0.1 million shares of potential common shares were excluded from the calculation of diluted earnings per share because their effect was anti-dilutive.
Note 20. Related Party Agreements and Transactions
Transactions with Lilly Subsequent to Separation and Related to the Separation
Amounts due from/(due to) Lilly in connection with the Separation and agreed upon services as of December 31 were as follows:
20192018
TSA$10.5  $(28.0) 
Other activities(15.8) (38.0) 
Local country asset purchases(11.1) (202.7) 
Total receivable from/(payable to) Lilly$(16.4) $(268.7) 

As described in Note 1, we completed an IPO in September 2018 and Lilly fully divested all ownership of Elanco in March 2019. In connection with the Separation, we entered into various agreements with Lilly related to the form of our separation and certain ongoing activities that will continue for a period of time. These included, among others, a master separation agreement (MSA), a TSA and a tax matters agreement. In addition, there was a portion of our operations for which the legal transfer of our net assets did not occur prior to the Separation due to certain regulatory requirements in each of these countries.
Transitional Services Agreement (TSA)
Historically, Lilly has provided us significant shared services and resources related to corporate functions such as executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information
109

technology and investor relations, which we refer to collectively as the "Lilly Services." Under the terms of the TSA, we will be able to use Lilly Services for a fixed term established on a service-by-service basis. We will pay Lilly mutually agreed-upon fees for the Lilly Services provided under the TSA, which will be based on Lilly's cost (including third-party costs) of providing the Lilly Services through March 31, 2021, and subject to a mark-up of 7% thereafter, with additional inflation-based escalation beginning January 1, 2022. The fees under the TSA became payable for all periods beginning after October 1, 2018.
Separation Activities
Subsequent to our IPO, there continue to be transactions between us and Lilly related primarily to the completion of the local country asset purchases and finalization of assets and liabilities associated with the legal separation from Lilly, combined income tax returns and the impact of the tax matters agreement, historical Lilly retirement benefits, and centralized cash management. The net impact of these activities of $51.2 million for the year ended December 31, 2019 has been reflected as Separation Activities within shareholders' equity. The most significant of these activities includes the finalization of the local country valuation of business and the resulting impact on deferred tax assets and the impact of combined tax returns.

Other Activities
We continue to share certain services and back office functions with Lilly, which in certain instances result in Lilly paying costs for Elanco (e.g., utilities, local country operating costs, etc.) that are then passed through to Elanco for reimbursement. These amounts are included in cash flows from operating activities in our consolidated and combined statements of cash flows. In addition, we operate through a single treasury settlement process and prior to the local country asset purchases (as described below) continued to transact through Lilly's processes in certain instances. As a result of these activities, there were certain amounts of financing that occurred between Lilly and Elanco during the year ended December 31, 2019. These amounts are included in cash flows from financing activities in our consolidated and combined statements of cash flows.

Local Country Asset Purchases
The legal transfer of certain of our net assets did not occur prior to the Separation due to certain regulatory requirements in each of these countries. The related assets, liabilities, and results of operations have been reported in our consolidated and combined financial statements, as we are responsible for the business activities conducted by Lilly on our behalf and are subject to the risks and entitled to the benefits generated by these operations and assets under the terms of the MSA. We held restricted cash, and the associated payable to Lilly, at the date of Separation to fund the acquisition of these assets. As of December 31, 2019, the majority of these assets have been legally acquired and the remainder are expected to be purchased during 2020. Restricted cash and Payable to Lilly of $11.1 million are recorded in the consolidated balance sheet for the remainder of the assets expected to be purchased by the end of 2020.
Intellectual Property and Technology License Agreement.
We entered into an intellectual property and technology license agreement with Lilly immediately prior to the completion of the IPO. Under the intellectual property and technology license agreement, Lilly granted Elanco an exclusive, perpetual license to exploit products in the animal health field that utilize or use certain of Lilly's intellectual property (excluding trademarks). In addition, Lilly granted Elanco non-exclusive, non-sublicensable license to screen certain compounds in Lilly's compound libraries to exploit products in the animal use certain of Lilly's intellectual property. This screening license has an initial term of two years, subject to three one-year extensions, each of which requires Lilly's consent.
We also entered into a tax matters agreement (TMA), an employee matters agreement, a toll manufacturing and supply agreement and a registration rights agreement with Lilly in connection with the Separation.
Our consolidated and combined financial statement of operations includes revenue related to a toll manufacturing agreement of $17.8 million and $7.0 million for the years ended December 31, 2019 and 2018, respectively. Also included are approximately $93.7 million and $28.1 million related to TSA charges for 2019 and 2018, respectively.
110

Transactions with Lilly Prior to Separation
Prior to the IPO, we did not operate as a standalone business and had various relationships with Lilly whereby Lilly provided services to us. The impact on our historical combined financial statements includes the following:
Transfers to/from Lilly, net
As discussed in Note 2: Basis of Presentation, net parent company investment is primarily impacted by contributions from Lilly, which are the result of treasury activity and net funding provided by or distributed to Lilly. For the years ended December 31, 2018 and 2017, net transfers (to)/from Lilly were $(226.3) million and $873.3 million, respectively. The most significant activity impacting the 2017 transfer was the financing by Lilly of our acquisition in the amount of $882.1 million for the acquisition of BIVIVP as described in Note 6: Acquisitions. Other activities that impacted the net transfers (to)/from Lilly include corporate overhead and other allocations, income taxes, retirement benefits, and centralized cash management.

Corporate Overhead and Other Allocations
Prior to full separation, Lilly provided us certain services, including executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information technology and investor relations. We provide Lilly certain services related to manufacturing support. Our financial statements reflect an allocation of these costs. When specific identification is not practicable, the remainder have been allocated primarily on a proportional cost method on a basis of revenue or headcount.
The allocations of services from Lilly, prior to IPO, to us were reflected as follows in the combined statements of operations:
2018(1)
2017
Cost of sales$21.8  $31.8  
Research and development 2.2  2.8  
Marketing, selling and administrative81.2  117.1  
Total$105.2  $151.7  
(1) Through September 30, 2018
There were no allocations from Lilly to us reflected in the consolidated and combined statement of operations for the year ended December 31, 2019.
We provided Lilly certain services related to manufacturing support. Allocations of manufacturing support from us to Lilly were $3.7 million and $6.2 million for the years ended December 31, 2018 and 2017, respectively, which reduced the cost of sales in the consolidated and combined statements of operations.
The financial information herein may not necessarily reflect our consolidated financial position, results of operations and cash flows in the future or what they would have been if we had been a separate, standalone entity during the periods presented. Management believes that the methods used to allocate expenses are reasonable.
Stock-based Compensation
As discussed in Note 14: Stock-based Compensation, prior to full separation, our employees participated in Lilly stock-based compensation plans, the costs of which were allocated to us and recorded in cost of sales, research and development, and marketing, selling and administrative expenses in the consolidated and combined statements of operations. The costs of such plans related to our employees were $5.1 million, $26.0 million and $25.0 million for the years ended December 31, 2019, 2018 and 2017, respectively.
Retirement Benefits
As discussed in Note 18: Retirement Benefits, prior to full separation, our employees participated in defined benefit pension and other post retirement plans sponsored by Lilly, the costs and benefits of which were recorded in the consolidated and combined statement of operations in cost of sales, research and development, and marketing, selling and administrative expenses. The costs/(benefits) of such plans related to our employees were $(6.3) million and $73.7 million for the years ended December 31, 2018 and 2017, respectively.
111

Centralized Cash Management
Lilly uses a centralized approach to cash management and financing of operations. Until Separation, the majority of our business was party to Lilly’s cash pooling arrangements to maximize Lilly's availability of cash for general operating and investing purposes. Under these cash pooling arrangements, cash balances were swept regularly from our accounts. Cash transfers to and from Lilly’s cash concentration accounts and the resulting balances at the end of each reporting period were reflected in net parent company investment in the consolidated balance sheets.
Debt
Lilly’s third-party debt and the related interest expense were not allocated to us for any of the periods presented as we were not the legal obligor of the debt and Lilly borrowings were not directly attributable to our business.

Note 21. Selected Quarterly Data (unaudited)
2019FourthThirdSecondFirst
Revenue$787.0  $771.3  $781.6  $731.1  
Cost of sales410.1  360.4  356.0  343.8  
Operating expenses(1)
253.2  262.2  269.7  245.2  
Asset impairment, restructuring, and other special charges51.6  77.2  31.8  24.9  
Interest expense, net of capitalized interest18.7  18.7  20.7  20.8  
Income (loss) before income taxes(4.3) (12.5) 50.2  44.8  
Income tax (benefit) expense5.2  (22.5) 14.3  13.3  
Net income (loss)(9.5) 10.0  35.9  31.5  
Earnings (loss) per share—basic and diluted(0.03) 0.03  0.10  0.09  

2018Fourth  Third  Second  First  
Revenue$799.3  $761.1  $770.2  $736.2  
Cost of sales412.5  369.8  431.5  360.0  
Operating expenses(1)
246.2  237.9  252.5  245.2  
Asset impairment, restructuring, and other special charges46.0  12.4  68.0  2.4  
Interest expense, net of capitalized interest21.0  8.6  —  —  
Income (loss) before income taxes(2.2) 78.8  (40.0) 77.5  
Income tax (benefit) expense(18.6) 18.6  22.8  4.8  
Net income (loss)16.4  60.2  (62.8) 72.7  
Earnings (loss) per share—basic and diluted0.04  0.20  (0.21) 0.25  
(1)Includes research and development and marketing, selling, and administrative expenses.
Numbers may not add up to totals for each year due to rounding.

Note 22. Subsequent Events
Bayer Animal Health acquisition financing
Equity offerings
On January 22, 2020, we entered into an underwriting agreement in which we agreed to sell approximately 22.7 million shares of our common stock at a public offering price of $32.00 per share. In connection with the offering, we granted the underwriters an option to purchase up to an additional 2.3 million shares, which was exercised in full on January 23, 2020. As a result, we issued and sold a total of approximately 25.0 million shares of our common stock. Total cash of $769.9 million was received upon closing on January 27, 2020.
112

In addition, on January 22, 2020, we issued $550 million in tangible equity units (TEUs). We offered 11 million 5.00% TEUs at the stated amount of $50 per unit, composed of a prepaid stock purchase contract and a senior amortizing note due February 1, 2023 (the mandatory settlement date). Total cash of $530.1 million was received upon closing on January 27, 2020, which was comprised of $453.8 million of prepaid stock purchase contracts and $76.3 million of senior amortizing notes, net of debt issuance costs. Unless the stock purchase contracts are redeemed by us or settled earlier at the unit holder’s option, they are mandatorily convertible into shares of our common stock at a minimum of 1.3021 shares per purchase contract or a maximum of 1.5625 shares per purchase contract on the mandatory settlement date. This corresponds to a minimum of 14.3 million shares and a maximum of 17.2 million shares.
Debt activity
On January 31, 2020, we used a portion of the proceeds from the common stock and TEU issuances to repay indebtedness outstanding under our existing term loan facility. We paid $372.4 million in cash, composed of $371.4 million of principal and $1.0 million of accrued interest, resulting in a debt extinguishment loss of $0.8 million, primarily related to the write-off of deferred debt issuance costs.
On February 4, 2020, we successfully priced our senior secured credit facilities, consisting of the following:
•Term loan B facility with an aggregate principal amount of $4,275.0 million and a maturity of seven years.
•Revolving loan facility providing up to $750.0 million and a maturity of five years.
The term loan B facility was priced at par at LIBOR plus 175 basis points, and the revolving loan facility is expected to bear interest at LIBOR plus an applicable margin ranging between 1.50% and 2.25% per annum based on our corporate family rating or corporate credit rating.
We intend to use the proceeds from the equity and debt activities to finance the cash portion of the pending acquisition of Bayer's animal health business and to pay related fees and expenses. As a result, we have obtained substantially all of the financing necessary to consummate the acquisition and do not currently intend to pursue any additional financing previously provided under the commitment letter obtained in August 2019 (see Note 16: Commitments and Contingencies).
Divestitures
Osurnia and Capstar
In January 2020, we signed agreements to divest the worldwide rights to Osurnia and the U.S. rights to Capstar for an aggregate of $230 million in all cash deals, with the intent to advance our efforts to secure the necessary regulatory clearances for the pending acquisition of the Bayer animal health business. The closing of these transactions is contingent on us entering into consent decrees with certain agencies in connection with the pending acquisition as well as customary closing conditions. Both divestitures are expected to close by the end of 2020.
The related assets met the assets held for sale criteria as of December 31, 2019. No adjustment was required to record the assets at the lower of their carrying amounts or fair values less costs to sell on the consolidated balance sheet. Assets and liabilities considered held for sale in connection with the divestitures as of December 31, 2019 were included in the respective line items in the consolidated balance sheet as follows:

Inventories$10.6  
Other intangibles, net61.2  
Property and equipment, net0.2  
Total assets held for sale72.0  
Deferred taxes(1.4) 
Total liabilities held for sale$(1.4) 

113

Other intangibles, net classified as held for sale primarily consist of marketed products. We determined that the disposal of these net assets does not qualify for reporting as a discontinued operation because it does not represent a strategic shift that has or will have a major effect on our operations and financial results.
Vecoxan
In February 2020, we signed an agreement to divest the worldwide rights to Vecoxan for $55 million in an all cash deal, with the intent to advance our efforts to secure the necessary regulatory clearances for the pending acquisition of the Bayer animal health business. The closing of this transaction is contingent on us entering into consent decrees with certain agencies in connection with the pending acquisition as well as customary closing conditions. This divestiture is expected to close by the end of 2020.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
None
Item 9A. Controls and Procedures
Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (“the Exchange Act”)) as of the end of the period covered by this report. Based on the evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period our disclosure controls and procedures are effective in recording, processing, summarizing, and reporting, on a timely basis, information required to be disclosed by us in the reports that we file or submit under the Exchange Act, and that information is accumulated and communicated to the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely discussions regarding required disclosure.
Management's Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f)). Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our internal control over financial reporting based on the Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). The Company acquired Aratana and Prevtec in July 2019, and management has excluded Aratana and Prevtec’s internal control over financial reporting from our assessment of the effectiveness of our internal control as of December 31, 2019. Aratana and Prevtec represent approximately 3 percent of consolidated total assets and less than 1 percent of consolidated net sales as of and for the year ended December 31, 2019. Based on this evaluation, our management has concluded that, as of December 31, 2019, our internal control over financial reporting was effective.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. In addition, projections of any evaluation of effectiveness to future periods are subject to risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Ernst & Young LLP, an independent registered public accounting firm, has audited our consolidated and combined financial statements and the effectiveness of internal controls over financial reporting as of December 31, 2019 as stated in their report which is included herein.
Changes in Internal Control
During the fourth quarter of 2019, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
114

Item 9B. Other Information

Report of Independent Registered Public Accounting Firm


To the Shareholders and the Board of Directors of Elanco Animal Health Incorporated

Opinion on Internal Control Over Financial Reporting

We have audited Elanco Animal Health Incorporated’s internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Elanco Animal Health Incorporated (the Company) maintained, in all material respects, effective control over financial reporting as of December 31, 2019, based on the COSO criteria.

As indicated in the accompanying Management’s Report on Internal Control over Financial Reporting, management’s assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of Aratana and Prevtec, which are included in the 2019 consolidated and combined financial statements of the Company and constituted 3% of total assets as of December 31, 2019 and less than 1% of net sales for the year then ended. Our audit of internal control over financial reporting of the Company also did not include an evaluation of the internal control over financial reporting of Aratana and Prevtec.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2019 and 2018, the related consolidated and combined statements of operations, comprehensive income (loss), equity and cash flows for each of the three years in the period ended December 31, 2019, and the related notes and our report dated February 28, 2020 expressed an unqualified opinion thereon.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.

Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control Over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable
115

assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.


/s/ Ernst & Young LLP



Indianapolis, Indiana
February 28, 2020

Part III
Item 10. Directors, Executive Officers, and Corporate Governance
Information on Directors, Executive Officers and Corporate Governance can be found in the Proxy Statement under "Governance." That information is incorporated in this report by reference. 
Item 11. Executive Compensation
Information on director compensation, executive compensation, and compensation committee matters can be found in the Proxy Statement under “Director Compensation,” "Committees of the Board of Directors - Compensation Committee," "Compensation Discussion and Analysis," and “Executive Compensation Tables.” That information is incorporated in this report by reference.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Security Ownership of Certain Beneficial Owners and Management
Information relating to ownership of the company’s common stock by management and by persons known by the company to be the beneficial owners of more than five percent of the outstanding shares of common stock is found in the Proxy Statement under “Ownership of Company Stock.” That information is incorporated in this report by reference.
Securities Authorized for Issuance Under Equity Compensation Plans
Information about our compensation plans under which shares of our common stock have been authorized for issuance as of December 31, 2019 can be found in the Proxy Statement under “Securities Authorized for Issuance Under Equity Compensation Plans” and is incorporated in this report by reference.

Item 13. Certain Relationships and Related Transactions, and Director Independence
Related Person Transactions
Information relating to related person transactions and the board’s policies and procedures for approval of related person transactions can be found in the Proxy Statement under “Transactions with Related Persons.” That information is incorporated in this report by reference.
116

Director Independence
Information relating to director independence can be found in the Proxy Statement under “Director Independence” and is incorporated in this report by reference.

Item 14. Principal Accountant Fees and Services
Information related to the fees and services of our principal independent accountants, Ernst & Young LLP, can be found in the Proxy Statement under “Proxy Item No. 2. Proposal to Ratify the Appointment of Principal Independent Auditor.” That information is incorporated in this report by reference.

Part IV
Item 15. Exhibits and Financial Statement Schedules
1. Financial Statements
The following consolidated combined financial statements of the company and its subsidiaries are found at Item 8:
•Consolidated and Combined Statements of Operations—Years Ended December 31, 2019, 2018, and 2017
•Consolidated and Combined Statements of Comprehensive Income—Years Ended December 31, 2019, 2018, and 2017
•Consolidated Balance Sheets—December 31, 2019 and 2018
•Consolidated and Combined Statements of Equity—Years Ended December 31, 2019, 2018, and 2017
•Consolidated and Combined Statements of Cash Flows—Years Ended December 31, 2019, 2018, and 2017
•Notes to Consolidated and Combined Financial Statements
2. Financial Statement Schedules
The consolidated and combined financial statement schedules of the company and its subsidiaries have been omitted because they are not required, are inapplicable, or are adequately explained in the financial statements.
Financial statements of interests of 50 percent or less, which are accounted for by the equity method, have been omitted because they do not, considered in the aggregate as a single subsidiary, constitute a significant subsidiary.
3. Exhibits
The following exhibits are either filed or furnished herewith (as applicable) or, if so indicated, incorporated by reference to the documents indicated in parentheses, which have previously been filed or furnished with the Securities and Exchange Commission.
Exhibit Number   Description
Agreement and Plan of Merger by and among Elanco Animal Health Incorporated, Elanco Athens Inc. and Aratana Therapeutics, Inc., dated April 26, 2019 (incorporated by reference to Exhibit 2.1 of the Current Report on Form 8-K filed with the SEC on April 26, 2019).
Share and Asset Purchase Agreement, dated as of August 20, 2019, between Bayer Aktiengesellschaft and Elanco Animal Health Incorporated (incorporated by reference to Exhibit 2.1 of the Current Report on Form 8-K filed with the SEC on August 20, 2019).
Amendment No. 1 to Share and Asset Purchase Agreement, dated as of October 15, 2019, between Bayer Aktiengesellschaft and Elanco Animal Health Incorporated (incorporated by reference to Exhibit 2.1 of the Current Report on Form 8-K filed with the SEC on October 17, 2019).
117

Amendment No. 2 to Share and Asset Purchase Agreement, dated as of January 17, 2020, between Bayer Aktiengesellschaft and Elanco Animal Health Incorporated (incorporated by reference to Exhibit 2.1 of the Current Report on Form 8-K filed with the SEC on January 17, 2020).
Annex 27 to the Share and Asset Purchase Agreement, dated as of August 20, 2019, between Bayer Aktiengesellschaft and Elanco Animal Health Incorporated (Incorporated by reference to Exhibit 4.3 of the Registration Statement on Form S-3 (File No. 333-235991) filed with the SEC on January 21, 2020).
 Amended and Restated Articles of Incorporation of Elanco Animal Health Incorporated, effective September 18, 2018 (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed with the SEC on September 26, 2018).
 Amended and Restated Bylaws of Elanco Animal Health Incorporated, effective August 8, 2019 (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed with the SEC on August 9, 2019).
 Form of Certificate of Common Stock (incorporated by reference to Exhibit 4.1 of Amendment No. 1 to Registration Statement on Form S-1 (Registration No. 333-226536) filed with the SEC on August 28, 2018).
 Indenture, dated August 28, 2018, between Elanco Animal Health Incorporated and Deutsche Bank Trust Company Americas, as trustee (incorporated by reference to Exhibit 4.2 of Amendment No. 1 to Registration Statement on Form S-1 (Registration No. 333-226536) filed with the SEC on August 28, 2018).
 First Supplemental Indenture, dated August 28, 2018, between Elanco Animal Health Incorporated and Deutsche Bank Trust Company Americas, as trustee (incorporated by reference to Exhibit 4.3 of Amendment No. 1 to Registration Statement on Form S-1 (Registration No. 333-226536) filed with the SEC on August 28, 2018).
Second Supplemental Indenture, dated as of January 27, 2020, between Elanco Animal Health Incorporated and Deutsche Bank Trust Company Americas, as trustee, including the form of amortizing note (incorporated by reference to Exhibit 4.4 of Current Report on Form 8-K filed with the SEC on January 27, 2020).
Purchase Contract Agreement, dated as of January 27, 2020, between Elanco Animal Health Incorporated and Deutsche Bank Trust Company Americas, as purchase contract agent, as attorney-in-fact for holders of the purchase contracts referred to therein and as trustee under the indenture referred to therein, including the form of unit and form of purchase contract (incorporated by reference to Exhibit 4.1 of Current Report on Form 8-K filed with the SEC on January 27, 2020).
Description of Securities (filed herewith)
 Master Separation Agreement, dated September 24, 2018, between Eli Lilly and Company and Elanco Animal Health Incorporated (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the SEC on September 26, 2018).
 Transitional Services Agreement, dated September 24, 2018, between Eli Lilly and Company and Elanco Animal Health Incorporated (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed with the SEC on September 26, 2018).
 Tax Matters Agreement, dated September 24, 2018, between Eli Lilly and Company and Elanco Animal Health Incorporated (incorporated by reference to Exhibit 10.3 of the Current Report on Form 8-K filed with the SEC on September 26, 2018).
 Employee Matters Agreement, dated September 24, 2018, between Eli Lilly and Company and Elanco Animal Health Incorporated (incorporated by reference to Exhibit 10.4 of the Current Report on Form 8-K filed with the SEC on September 26, 2018).
 Toll Manufacturing and Supply Agreement, dated September 24, 2018, between Eli Lilly Export S.A. and Elanco UK AH Limited (incorporated by reference to Exhibit 10.5 of the Current Report on Form 8-K filed with the SEC on September 26, 2018).
118

Transitional Trademark License Agreement, dated September 24, 2018, among Eli Lilly and Company, Elanco Animal Health Incorporated and Elanco US Inc. (incorporated by reference to Exhibit 10.7 of the Current Report on Form 8-K filed with the SEC on September 26, 2018).
Intellectual Property and Technology License Agreement, dated September 24, 2018, among Eli Lilly and Company, Elanco Animal Health Incorporated and Elanco US Inc. (incorporated by reference to Exhibit 10.8 of the Current Report on Form 8-K filed with the SEC on September 26, 2018).
Revolving Loan Credit Agreement, dated as of September 5, 2018, among Elanco Animal Health Incorporated, as borrower, JPMorgan Chase Bank, N.A., as administrative agent and the other Lenders party thereto (incorporated by reference to Exhibit 10.24 of Amendment No. 2 to Registration Statement on Form S-1 (Registration No. 333-226536) filed with the SEC on September 6, 2018).
First Amendment to Revolving Loan Credit Agreement, dated as of September 5, 2018, among Elanco Animal Health Incorporated, as borrower, JPMorgan Chase Bank, N.A., as administrative agent and the other Lenders party thereto (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the SEC on December 20, 2019).
Term Loan Credit Agreement, dated as of September 5, 2018, among Elanco Animal Health Incorporated, as borrower, JPMorgan Chase Bank, N.A., as administrative agent and the other Lenders party thereto (incorporated by reference to Exhibit 10.25 of Amendment No. 2 to Registration Statement on Form S-1 (Registration No. 333-226536) filed with the SEC on September 6, 2018).
First Amendment to Term Loan Credit Agreement, dated as of September 5, 2018, among Elanco Animal Health Incorporated, as borrower, JPMorgan Chase Bank, N.A., as administrative agent and the other Lenders party thereto (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed with the SEC on December 20, 2019).
2018 Elanco Stock Plan (incorporated by reference to Exhibit 4.3 of Registration Statement on Form S-8 (Registration No. 333-227447) filed with the SEC on September 20, 2018).*
Elanco Animal Health Incorporated Directors’ Deferral Plan as amended (incorporated by reference to Exhibit 10.1 of the Quarterly Report on Form 10-Q filed with the SEC on May 14, 2019)*
Director Letter Agreement between Emu Holdings Company and R. David Hoover, dated as of May 25, 2018 (incorporated by reference to Exhibit 10.19 of Elanco Animal Health Incorporated's registration statement on Form S-1 (File No. 333-226536) filed with the SEC on August 2, 2018)*
Form of 2018 Change in Control Severance Pay Plan for Select Employees (incorporated by reference to Exhibit 10.20 of Amendment No. 1 to Elanco Animal Health Incorporated's registration statement on Form S-1 (File No. 333-226536) filed with the SEC on August 28, 2018).*
Form of Elanco Animal Health Incorporated Restricted Stock Unit Awards Agreement (incorporated by reference to Exhibit 10.21 of Amendment No. 1 to Elanco Animal Health Incorporated's registration statement on Form S-1 (File No. 333-226536) filed with the SEC on August 28, 2018).*
Form of Elanco Animal Health Incorporated Nonqualified Stock Option Award Agreement (incorporated by reference to Exhibit 10.22 of Amendment No. 1 to Elanco Animal Health Incorporated's registration statement on Form S-1 (File No. 333-226536) filed with the SEC on August 28, 2018).*
Retention Bonus Agreement, dated October 18, 2018, by and between Elanco US Inc. and Todd S. Young (incorporated by reference to Exhibit 10.2 to Elanco Animal Health Incorporated's Report on Form 8-K filed with the SEC on October 30, 2018).*
Employment Offer Letter with Mr. Todd S. Young, dated October 15, 2018, by and between Elanco US Inc. and Todd S. Young (incorporated by reference to Exhibit 10.1 to Elanco Animal Health Incorporated's Report on Form 8-K filed with the SEC on October 30, 2018).*
119

Form of Performance Award Agreement (Incorporated by reference to Exhibit 10.1 to Form 8-K filed with the SEC on February 19, 2019)*
Form of Restricted Stock Unit Award Agreement (Incorporated by reference to Exhibit 10.2 to Form 8-K filed with the SEC on February 19, 2019)*
Form of Restricted Stock Unit Award Agreement (incorporated by reference to Exhibit 10.22 to Annual Reporting on Form 10-K filed with the SEC on February 20, 2019)*
Form of Replacement Performance Award Agreement for Certain Named Executive Officers (incorporated by reference to Exhibit 10.23 to Annual Report on Form 10-K filed with the SEC on February 20, 2019)*
Form of Replacement Performance Award Agreement for Jeffery N. Simmons (incorporated by reference to Exhibit 10.24 to Annual Report on Form 10-K filed with the SEC on February 20, 2019)*
Form of Replacement Restricted Stock Unit Award Agreement for Certain Named Executive Officers (incorporated by reference to Exhibit 10.25 to Annual Report on Form 10-K filed with the SEC on February 20, 2019)*
The Elanco Corporate Bonus Plan (incorporated by reference to Exhibit 10.16 of Elanco Animal Health Incorporated's registration statement on Form S-1 (File No. 333-226536))* 
Form of Elanco Animal Health Incorporated Restricted Stock Unit Award Agreement for non-employee directors with respect to annual awards (incorporated by reference to Exhibit 10.2 of the Quarterly Report on Form 10-Q with the SEC on May 14, 2019).*
Form of Elanco Animal Health Incorporated Restricted Stock Unit Award Agreement for non-employee directors with respect to one-time founder award (incorporated by reference to Exhibit 10.3 of the Quarterly Report on Form 10-Q filed with the SEC on May 14, 2019).*
Elanco Animal Health Incorporated Replacement Restricted Stock Unit Award Agreement, dated March 12, 2019, by Elanco Animal Health Incorporated (incorporated by reference to Exhibit 10.4 of the Quarterly Report on Form 10-Q filed with the SEC on May 14, 2019).*
Elanco Animal Health Incorporated Executive Deferral Plan (incorporated by reference to Exhibit 10.1 of the Quarterly Report on Form 10-Q filed with the SEC on August 13, 2019)
Subsidiaries of Elanco Animal Health Incorporated (filed herewith)
Consent of Ernst & Young LLP (filed herewith)
Section 302 Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
Section 302 Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith).
101  
Interactive Data Files.
*Management contracts or compensatory plans or arrangements

Item 16. Form 10-K Summary
Not applicable.

120

Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
ELANCO ANIMAL HEALTH INCORPORATED
(Registrant)
Date:February 28, 2020/s/ Jeffrey N. Simmons
Jeffrey N. Simmons
President and Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
121

/s/ Jeffrey N. SimmonsDate:February 28, 2020
Jeffrey N. Simmons
President and Chief Executive Officer (principal executive officer) and Director
/s/ Todd S. YoungDate:February 28, 2020
Todd S. Young
Executive Vice President, Chief Financial Officer (principal financial officer)
/s/ James M. MeerDate:February 28, 2020
James M. Meer
Vice President, Chief Accounting Officer (principal accounting officer)
/s/ R. David HooverDate:February 28, 2020
R. David Hoover
Chairman of the Board
/s/ Kapila Kapur AnandDate:February 28, 2020
Kapila Kapur Anand
Director
/s/ John P. BilbreyDate:February 28, 2020
John P. Bilbrey
Director
/s/ Art A. GarciaDate:February 28, 2020
Art A. Garcia
Director
/s/ Michael J. HarringtonDate:February 28, 2020
Michael J. Harrington
Director
/s/ Deborah T. KochevarDate:February 28, 2020
Deborah T. Kochevar
Director
/s/ Lawrence E. KurziusDate:February 28, 2020
Lawrence E. Kurzius
Director
/s/ Kirk McDonaldDate:February 28, 2020
Kirk McDonald
Director
/s/ Denise Scots-Knight Ph.D.Date:February 28, 2020
Denise Scots-Knight
Director

122
 EX-4.6 2 ex46elanco-20191231xde.htm EX-4.6 Document

EXHIBIT 4.6
Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities
Exchange Act of 1934
Elanco Animal Health Incorporated (“Elanco”) has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): (1) common stock, no par value, and (2) 5.00% tangible equity units.
Description of common stock
The following is a summary of Elanco common stock and important provisions of Elanco’s amended and restated articles of incorporation and amended and restated bylaws. This summary does not purport to be complete and is subject to and qualified by Elanco’s amended and restated articles of incorporation and amended and restated bylaws, each of which is an exhibit to the Annual Report on Form 10-K to which this description is an exhibit, and by the provisions of applicable law.
Elanco’s authorized capital stock is comprised of 6,000,000,000 shares, which are made up of (i) 5,000,000,000 shares of common stock, no par value and (ii) 1,000,000,000 shares of preferred stock, no par value, the rights and preferences of which may be established from time to time by Elanco’s board of directors. Holders of Elanco common stock are entitled to the rights set forth below.
Voting Rights
The holders of Elanco common stock are entitled to one vote per share on all matters submitted to a vote of Elanco’s shareholders (including the election or removal of directors), and do not have cumulative voting rights. Directors are elected by a plurality of the votes entitled to be cast. Except as otherwise provided in Elanco’s amended and restated articles of incorporation or as required by law, all matters to be voted on by Elanco’s shareholders other than matters relating to the election and removal of directors will be approved if votes cast in favor of the matter exceed the votes cast opposing the matter at a meeting at which a majority of the outstanding shares entitled to vote on such matter is represented in person or by proxy.
Dividend Rights
Holders of Elanco common stock will share equally in any dividends that may be declared by Elanco’s board of directors out of funds legally available therefor, subject to the rights of the holders of any outstanding preferred stock.
Liquidation Rights
In the event of any voluntary or involuntary liquidation, dissolution or winding up of Elanco’s affairs, holders of Elanco common stock would be entitled to share ratably in Elanco’s assets that are legally available for distribution to shareholders. If Elanco has any preferred stock outstanding at such time, holders of the preferred stock may be entitled to distribution and/or liquidation preferences. In either such case, Elanco must pay the applicable distribution to the holders of its preferred stock before it may pay distributions to the holders of Elanco common stock.
Other Rights
Holders of Elanco common stock do not have preemptive or other rights to subscribe for additional shares of Elanco’s stock. All outstanding shares of Elanco common stock are validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of Elanco common stock will be subject to those of the holders of any shares of preferred stock that Elanco may issue in the future.


Description of the units
Elanco has issued 11,000,000 5.00% tangible equity units (the “Units”), each with a stated amount of $50.00. Each Unit is comprised of a prepaid stock purchase contract (a “purchase contract”) issued by Elanco and a senior amortizing note (an “amortizing note”) issued by Elanco.
The following summary of the terms of the Units, the summary of the terms of the purchase contracts set forth under the caption “Description of the Purchase Contracts” and the summary of the terms of the amortizing notes set forth under the caption “Description of the Amortizing Notes” contain a description of certain terms of the Units and their components but are not complete and are subject to, and qualified in their entirety by reference to: (1) the Purchase Contract Agreement, dated as of January 27, 2020 (the “purchase contract agreement”), between Elanco and Deutsche Bank Trust Company Americas, as purchase contract agent (the “purchase contract agent”), attorney-in-fact for the holders of purchase contracts from time to time and as trustee (the “trustee”) under the indenture described below, (2) the Indenture, dated as of August 28, 2018, between Elanco, as issuer, and Deutsche Bank Trust Company Americas, as trustee, and (3) the Second Supplemental Indenture, dated as of January 27, 2020, between Elanco, as issuer and Deutsche Bank Trust Company Americas, as trustee, each of which is an exhibit to the Annual Report on Form 10-K to which this description is an exhibit.
Components of the Units
Each Unit was initially comprised of:
◦a prepaid stock purchase contract issued by Elanco pursuant to which Elanco will deliver to the holder, not later than 5:00 p.m., New York City time, on February 1, 2023 (subject to postponement in certain limited circumstances, the “mandatory settlement date”), unless earlier settled, a number of shares of Elanco common stock, no par value per share (the “Common Stock”), per purchase contract equal to the settlement rate described under “Description of the Purchase Contracts — Delivery of Common Stock;” and
◦a senior amortizing note issued by Elanco with an initial principal amount of $7.2007 that pays equal quarterly installments of $0.6250 per amortizing note (except for the May 1, 2020 installment payment, which will be $0.6528 per amortizing note), which cash payment in the aggregate will be equivalent to 5.00% per year with respect to the $50.00 stated amount per Unit.
Unless previously settled at the option of the holder as described in “Description of the Purchase Contracts — Early Settlement” or “Description of the Purchase Contracts — Early Settlement Upon a Fundamental Change” or settled at Elanco’s option as described in “Description of the Purchase Contracts — Early Mandatory Settlement at Elanco’s Election,” Elanco will deliver to each holder of the option not more than 1.5625 shares and not less than 1.3021 shares of Elanco common stock on the mandatory settlement date, based upon the applicable “settlement rate” (as defined under “Description of the Purchase Contracts — Delivery of Common Stock”), which is subject to adjustment as described herein, and the “applicable market value” (as defined under “Description of the Purchase Contracts — Delivery of Common Stock”) of Elanco common stock, as described under “Description of the Purchase Contracts — Delivery of Common Stock.”
Each amortizing note had an initial principal amount of $7.2007. On each February 1, May 1, August 1, and November 1, commencing on May 1, 2020, each amortizing note will pay equal cash installments of $0.6250 on each amortizing note (except for the May 1, 2020 installment payment, which will be $0.6528 per amortizing note), which cash payment in the aggregate per year will be equivalent to 5.00% per year with respect to each $50.00 stated amount of Units. Each installment payment will constitute a payment of interest (at a rate of 2.75% per annum) and a partial repayment of principal on the amortizing note, allocated as set forth on the amortization schedule set forth under “Description of the Amortizing Notes — Amortization Schedule.”
The initial stated amount of each Unit must be allocated between the amortizing note and the purchase contract based upon their relative fair market values. At initial issuance, Elanco determined that the fair market value
2

of each amortizing note is $7.2007 and the fair market value of each purchase contract is $42.7993, as set forth in the purchase contract agreement.
Separating and Recreating Units
Upon the conditions and under the circumstances described below, a holder of a Unit will have the right to separate a Unit into its component parts, and a holder of a separate purchase contract and a separate amortizing note will have the right to combine the two components to recreate a Unit.
Separating Units
At initial issuance, the purchase contracts and amortizing notes were purchased and transferred only as Units consisting of a “component purchase contract” and a “component amortizing note” and traded under the CUSIP number for the Units.
On any business day during the period beginning on, and including, the business day immediately following the date of initial issuance of the Units to, but excluding, the second scheduled trading day immediately preceding February 1, 2023 or, if earlier, the second scheduled trading day immediately preceding any “early mandatory settlement date” (as defined under “Description of the Purchase Contracts — Early Mandatory Settlement at Elanco’s Election”) and also excluding the business day immediately preceding any installment payment date (provided, the right to separate the Units shall resume after such business day), a holder will have the right to separate the holder’s Unit into its constituent purchase contract and amortizing note (which is referred to herein as a “separate purchase contract” and a “separate amortizing note,” respectively, and which will thereafter trade under their respective CUSIP numbers), in which case that Unit will cease to exist. If the holder beneficially owns a Unit, the holder may separate it into its component purchase contract and component amortizing note by delivering written instructions to the broker or other direct or indirect participant through which the holder holds an interest in such Unit (the “participant”) to notify the purchase contract agent, the trustee and The Depository Trust Company (“DTC”) through DTC’s Deposit/Withdrawal at Custodian (“DWAC”) system of the holder’s desire to separate the Unit. Holders who elect to separate a Unit into its constituent purchase contract and amortizing note shall be responsible for any fees or expenses payable in connection with such separation. “Business day” means any day other than a Saturday, Sunday or any day on which banking institutions in New York, New York are authorized or obligated by applicable law or executive order to close or be closed. Separate purchase contracts and separate amortizing notes will be transferable independently from each other.
Recreating Units
On any business day during the period beginning on, and including, the business day immediately following the date of initial issuance of the Units to, but excluding, the second scheduled trading day immediately preceding February 1, 2023 or, if earlier, the second scheduled trading day immediately preceding any early mandatory settlement date and also excluding the business day immediately preceding any installment payment date (provided, the right to recreate the Units shall resume after such business day), a holder may recreate a Unit from the holder’s separate purchase contract and separate amortizing note. If the holder beneficially owns a separate purchase contract and a separate amortizing note, the holder may recreate a Unit by delivering written instruction to the holder’s participant to notify the purchase contract agent, the trustee and DTC through DTC’s DWAC system of the holder’s desire to recreate the Unit. Holders who elect to recreate Units shall be responsible for any fees or expenses payable in connection with such recreation.
Global Securities
Each Unit, purchase contract and amortizing note is represented by global securities registered in the name of a nominee of DTC. Holders are not entitled to receive definitive physical certificates for the Units, purchase contracts or amortizing notes, except under the limited circumstances. Beneficial interests in a Unit and, after separation, the separate purchase contract and separate amortizing note will be represented through book-entry accounts of, and transfers will be effected through, direct or indirect participants in DTC.
3

Replacement of Unit Certificates
In the event that physical certificates evidencing the Units have been issued, any mutilated Unit certificate will be replaced by Elanco at the expense of the holder upon surrender of the certificate to the purchase contract agent. Unit certificates that become destroyed, lost or stolen will be replaced by Elanco at the expense of the holder upon delivery to Elanco and the purchase contract agent of evidence of their destruction, loss or theft satisfactory to Elanco and the purchase contract agent. In the case of a destroyed, lost or stolen Unit certificate, an indemnity satisfactory to Elanco and the purchase contract agent may be required at the expense of the holder of the Units before a replacement will be issued.
Notwithstanding the foregoing, Elanco will not be obligated to replace any Unit certificates on or after the second scheduled trading day immediately preceding February 1, 2023 or the second scheduled trading day immediately preceding any early mandatory settlement date. In those circumstances, the purchase contract agreement will provide that, in lieu of the delivery of a replacement Unit certificate, the purchase contract agent, upon delivery of the evidence and indemnity described above, will deliver or arrange for delivery of the shares of Elanco common stock issuable pursuant to the purchase contracts included in the Units evidenced by the Unit certificate.
Description of the purchase contracts
Each purchase contract initially formed a part of a Unit. Each Unit may be separated by a holder into its constituent purchase contract and amortizing note on any business day during the period beginning on, and including, the business day immediately following the date of initial issuance of the Units to, but excluding, the second scheduled trading day immediately preceding February 1, 2023 or, if earlier, the second scheduled trading day immediately preceding any “early mandatory settlement date,” and also excluding the business day immediately preceding any installment payment date (provided, the right to separate the Units shall resume after such business day). Following such separation, purchase contracts may be transferred separately from amortizing notes.
As used herein, unless the context otherwise requires, references to: (i) “close of business” refer to 5:00 p.m., New York City time, and (ii) “open of business” refer to 9:00 a.m., New York City time.
Delivery of Common Stock
Unless settled early at the holder’s or Elanco’s option, for each purchase contract Elanco will deliver to the holder on February 1, 2023 (subject to postponement in certain limited circumstances described below, the “mandatory settlement date”) a number of shares of Elanco common stock. The number of shares of Elanco common stock issuable upon settlement of each purchase contract (the “settlement rate”) will be determined as follows:
•if the “applicable market value” (as defined below) of Elanco common stock is greater than the “threshold appreciation price” (as defined below), then the holder will receive 1.3021 shares of Elanco common stock for each purchase contract (the “minimum settlement rate”);
•if the applicable market value of Elanco common stock is less than or equal to the threshold appreciation price but greater than or equal to the “reference price” (as defined below), then the holder will receive a number of shares of Elanco common stock for each purchase contract equal to the Unit stated amount of $50.00, divided by the applicable market value; and
•if the applicable market value of Elanco common stock is less than the reference price, then the holder will receive 1.5625 shares of Elanco common stock for each purchase contract (the “maximum settlement rate”).
4

The maximum settlement rate and the minimum settlement rate are each subject to adjustment as described under “— Adjustments to the Fixed Settlement Rates” below. Each of the minimum settlement rate and the maximum settlement rate is referred to as a “fixed settlement rate.”
The reference price is calculated by dividing $50.00 by the then applicable maximum settlement rate and initially was approximately equal to $32.00.
The threshold appreciation price is calculated by dividing $50.00 by the then applicable minimum settlement rate. The threshold appreciation price, which was initially approximately $38.40, represents a premium of approximately 20% over the reference price.
“Applicable market value” means the arithmetic average of the VWAP per share of Elanco common stock over the settlement period. The “settlement period” means the 20 consecutive trading day period beginning on, and including, the 21st scheduled trading day immediately preceding February 1, 2023.
“VWAP” per share of Elanco common stock on any trading day means the per share volume-weighted average price as displayed under the heading “Bloomberg VWAP” on Bloomberg (or any successor service) page “ELAN <Equity> AQR” (or its equivalent successor if such page is not available) in respect of the period from the scheduled open until the scheduled close of trading of the primary trading session on such trading day; or, if such price is not available, the market value per share of Elanco common stock on such trading day as determined, using a volume-weighted average method, by a nationally recognized independent investment banking firm retained by Elanco for this purpose. For the avoidance of doubt, “VWAP” will be determined without regard to after hours trading or any other trading outside of the regular trading session trading hours.
“Trading day” means a day on which:
•there is no “market disruption event” (as defined below); and
•trading in Elanco common stock (or other security for which a VWAP must be determined) generally occurs on the relevant stock exchange (as defined below);
provided, that if Elanco common stock (or such other security) is not so listed or traded, “trading day” means a “business day.”
“Relevant stock exchange” means the NYSE or, if Elanco common stock (or other security for which a VWAP or closing price must be determined) is not then listed on the NYSE, on the principal other U.S. national or regional securities exchange on which Elanco common stock (or such other security) is then listed or, if Elanco common stock (or such other security) is not then listed on a U.S. national or regional securities exchange, on the principal other market on which Elanco common stock (or such other security) is then listed or admitted for trading.
“Scheduled trading day” means a day that is scheduled to be a trading day on the relevant stock exchange. If Elanco common stock (or other such security) is not listed or admitted for trading on a relevant stock exchange, “scheduled trading day” means a “business day.”
“Market disruption event” means:
•a failure by the relevant stock exchange to open for trading during its regular trading session; or
•the occurrence or existence on the relevant stock exchange prior to 1:00 p.m., New York City time, on any scheduled trading day for Elanco common stock (or such other security) for more than one half-hour period in the aggregate during regular trading hours of any suspension or limitation imposed on trading (by reason of movements in price exceeding limits permitted by the relevant stock exchange or otherwise) in Elanco common stock (or such other security) or in any options contracts or futures contracts relating to Elanco common stock (or such other security).
5

On the mandatory settlement date, Elanco common stock will be issued and delivered to the holder or the holder’s designee, upon:
•surrender of certificates representing the purchase contracts, if such purchase contracts are held in certificated form; and
•payment by the holder of any transfer or similar taxes payable in connection with the issuance of Elanco common stock to any person other than you.
As long as the purchase contracts are evidenced by one or more global purchase contract certificates deposited with DTC, procedures for settlement will be governed by DTC’s applicable procedures.
If one or more of the 20 consecutive scheduled trading days in the settlement period is not a trading day, the mandatory settlement date will be postponed until the second scheduled trading day immediately following the last trading day of the settlement period.
Prior to the close of business on the last trading day of the settlement period, the shares of Elanco common stock underlying each purchase contract will not be outstanding, and the holder of such purchase contract will not have any voting rights, rights to dividends or other distributions or other rights of a holder of Elanco common stock by virtue of holding such purchase contract. The person in whose name any shares of Elanco common stock shall be issuable upon settlement of the purchase contract on the mandatory settlement date will be treated as the holder of record of such shares as of the close of business on the last trading day of the settlement period.
Elanco will pay any documentary, stamp or similar issue or transfer tax due on the issue of any shares of Elanco common stock upon settlement of the purchase contracts, unless the tax is due because the holder requests any shares to be issued in a name other than the holder’s name, in which case the holder will be obligated to pay that tax.
Hypothetical Settlement Values
For illustrative purposes only, the following table shows the number of shares of Elanco common stock issuable upon settlement of a purchase contract at assumed applicable market values. The table assumes that there will be no adjustments to the fixed settlement rates described under “— Adjustments to the Fixed Settlement Rates” below and that the purchase contracts have not been settled early at the option of holders or at Elanco’s option as described under “— Early Settlement,” “— Early Settlement Upon a Fundamental Change” or “— Early Mandatory Settlement at Elanco’s Election” below. The actual applicable market value may differ from those set forth in the table below. Based on a reference price of approximately $32.00 and a threshold appreciation price of approximately $38.40, a holder of a Unit or a separate purchase contract, as applicable, would receive on the mandatory settlement date the number of shares of Elanco common stock for each Unit or separate purchase contract set forth below:
6

Assumed Applicable Market Value  Number of Shares of Common Stock to be Received on the Mandatory Settlement Date  Assumed Settlement Value (Calculated as Applicable Market Value multiplied by the Number of Shares of Common Stock to be received on the Mandatory Settlement Date)
$10.00    1.5625 $15.63  
$15.00    1.5625 $23.44  
$20.00    1.5625 $31.25  
$25.00    1.5625 $39.06  
$30.00    1.5625 $46.88  
$32.00    1.5625 $50.00  
$34.00    1.4706 $50.00  
$36.00    1.3889 $50.00  
$38.40    1.3021 $50.00  
$40.00    1.3021 $52.08  
$50.00    1.3021 $65.11  
$60.00    1.3021 $78.13  
$70.00    1.3021 $91.15  
$80.00    1.3021 $104.17  
$90.00    1.3021 $117.19  
As the above table illustrates, if, on the mandatory settlement date, the applicable market value is greater than the threshold appreciation price, Elanco would be obligated to deliver 1.3021 shares of Elanco common stock for each purchase contract. As a result, if the applicable market value exceeds the threshold appreciation price, the holder will receive only a portion of the appreciation in the market value of the shares of Elanco common stock such holder would have received had the holder purchased $50.00 worth of shares of Elanco common stock at the reference price.
If, on the mandatory settlement date, the applicable market value is less than or equal to the threshold appreciation price but greater than or equal to the reference price of approximately $32.00, Elanco would be obligated to deliver a number of shares of Elanco common stock on the mandatory settlement date equal to $50.00, divided by the applicable market value. As a result, Elanco would retain all appreciation in the market value of Elanco common stock underlying each purchase contract between the reference price and the threshold appreciation price.
If, on the mandatory settlement date, the applicable market value is less than the reference price of approximately $32.00, Elanco would be obligated to deliver upon settlement of the purchase contract 1.5625 shares of Elanco common stock for each purchase contract, regardless of the market price of Elanco common stock. As a result, the holder would realize the entire loss on the decline in market value of the Elanco common stock underlying each purchase contract since the date of the pricing of Units.
Because the applicable market value of the common stock is determined over the settlement period, the number of shares of Elanco common stock delivered for each purchase contract may be greater than or less than the number that would have been delivered based on the closing price (or VWAP) per share of the common stock on the last trading day in the settlement period. In addition, the holder will bear the risk of fluctuations in the market price of the shares of Elanco common stock deliverable upon settlement of the purchase contracts between the last trading day in the settlement period and the date such shares are delivered.
Early Settlement
7

Prior to the close of business on the second scheduled trading day immediately preceding February 1, 2023, the holder, as a holder of Units or a holder of separate purchase contracts, may elect to settle the holder’s purchase contracts early, in whole or in part, and receive a number of shares of Elanco common stock per purchase contract equal to the “early settlement rate” (and any cash payable for fractional shares). The early settlement rate is equal to the minimum settlement rate in effect on the early settlement date unless the holder elects to settle the holder’s purchase contracts early in connection with a fundamental change, in which case the holder will receive upon settlement of the holder’s purchase contracts a number of shares of Elanco common stock based on the “fundamental change early settlement rate” as described under “— Early Settlement Upon a Fundamental Change.”
The holder’s right to receive Elanco common stock (and any cash payable for fractional shares) upon early settlement of a purchase contract is subject to:
•delivery of a written and signed notice of election (an “early settlement notice”) to the purchase contract agent electing early settlement of such purchase contract;
•if the Unit that includes such purchase contract or such purchase contract is held in certificated form, surrendering the certificates representing the purchase contract, or if held in global form, surrendering in accordance with DTC’s applicable procedures; and
•payment by the holder of any transfer or similar taxes payable in connection with the issuance of Elanco common stock to any person other than the holder.
As long as the purchase contracts or the Units are evidenced by one or more global certificates deposited with DTC, procedures for early settlement will be governed by DTC’s applicable procedures.
Upon surrender of the Unit or the separate purchase contract and payment of any applicable transfer or similar taxes due because of any issue of such shares in a name of a person other than the holder, the holder will receive the applicable number of shares of Elanco common stock (and any cash payable for fractional shares) due upon early settlement on the second business day following the “early settlement date” (as defined below).
If the holder complies with the requirements for effecting early settlement of the holder’s purchase contracts earlier than the close of business on any business day, then that day will be considered the “early settlement date.” If the holder complies with such requirements at or after the close of business on any business day or at any time on a day that is not a business day, then the next succeeding business day will be considered the “early settlement date.” Prior to the close of business on the early settlement date, the shares of Elanco common stock underlying each purchase contract will not be outstanding, and the holder of such purchase contract will not have any voting rights, rights to dividends or other distributions or other rights of a holder of Elanco common stock by virtue of holding such purchase contract. The person in whose name any shares of Elanco common stock shall be issuable upon such early settlement of the purchase contract will be treated as the holder of record of such shares as of the close of business on the relevant early settlement date.
Upon early settlement at the holder’s election of the purchase contract component of a Unit, the amortizing note underlying such Unit will remain outstanding and be beneficially owned by or registered in the name of, as the case may be, the holder who elected to settle the related purchase contract early and will no longer constitute a part of the Unit.
Early Settlement Upon a Fundamental Change
If a “fundamental change” occurs and the holder elects to settle the holder’s purchase contracts early in connection with such fundamental change, the holder will receive per purchase contract a number of shares of Elanco common stock (and any cash payable for fractional shares) (or, if a reorganization event has occurred, cash, securities or other property, as applicable) equal to the “fundamental change early settlement rate,” as described below. An early settlement will be deemed for these purposes to be “in connection with” such fundamental change if the holder delivers the holder’s early settlement notice to the purchase contract agent, and otherwise satisfies the
8

requirements for effecting early settlement of the holder’s purchase contracts, during the period beginning on, and including, the effective date of the fundamental change and ending at the close of business on the 35th business day thereafter (or, if earlier, the second scheduled trading day immediately preceding February 1, 2023) (the “fundamental change early settlement period”). This right is referred to as the “fundamental change early settlement right.”
A holder’s right to Elanco common stock (and any cash payable for fractional shares) (or, if a reorganization event has occurred, cash, securities or other property, as applicable) upon early settlement in connection with a fundamental change is subject to compliance with the conditions described under “— Early Settlement.”
Upon surrender of the Unit or the separate purchase contract and payment of any applicable transfer or similar taxes due because of any issue of such shares in a name of a person other than the holder, the holder will receive the applicable number of shares of Elanco common stock (and any cash payable for fractional shares) (or, if a reorganization event has occurred, cash, securities or other property, as applicable) issuable as a result of the holder’s exercise of the fundamental change early settlement right on the second business day following the “fundamental change early settlement date” (as defined below).
If the holder complies with the requirements for effecting early settlement of the holder’s purchase contracts in connection with a fundamental change prior to the close of business on any business day during the fundamental change early settlement period, then that day will be considered the “fundamental change early settlement date.” If the holder complies with such requirements at or after the close of business on any business day during the fundamental change early settlement period or at any time on a day during the fundamental change early settlement period that is not a business day, then the next succeeding business day will be considered the “fundamental change early settlement date.”
Elanco will provide the purchase contract agent, the trustee and the holders of Units and separate purchase contracts with a notice of a fundamental change within five business days after its effective date and issue a press release announcing such effective date. The notice will also set forth, among other things:
•the applicable fundamental change early settlement rate;
•if not Elanco common stock, the kind and amount of cash, securities and other property receivable by the holder upon settlement; and
•the deadline by which each holder’s fundamental change early settlement right must be exercised.
A “fundamental change” will be deemed to have occurred upon the occurrence of any of the following:
(1)any “person” or “group” within the meaning of Section 13(d) of the Exchange Act, other than Elanco, any of its subsidiaries or any of Elanco’s and their employee benefit plans, files a Schedule TO or any other schedule, form or report under the Exchange Act disclosing that such person or group has become the direct or indirect “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act) of Elanco common stock representing more than 50% of the voting power of Elanco common stock;
(2)the consummation of (A) any recapitalization, reclassification or change of Elanco common stock (other than changes resulting from a subdivision or combination) as a result of which Elanco common stock would be converted into, or exchanged for, stock, other securities, other property or assets; (B) any share exchange, consolidation or merger of Elanco pursuant to which Elanco common stock will be converted into cash, securities or other property or assets; or (C) any sale, lease or other transfer in one transaction or a series of transactions of all or substantially all of the consolidated assets of Elanco and its subsidiaries, taken as a whole, to any person or persons other than one of its wholly owned subsidiaries;
9

(3)Elanco’s stockholders approve any plan or proposal for the liquidation or dissolution of Elanco; or
(4)Elanco common stock (or other common stock receivable upon settlement of the holder’s purchase contracts, if applicable) ceases to be listed or quoted on any of the NYSE, the Nasdaq Global Select Market or the Nasdaq Global Market (or any of their respective successors).
A transaction or transactions described in clauses (1) or (2) above will not constitute a fundamental change, however, if (a) at least 90% of the consideration received or to be received by Elanco’s shareholders (excluding cash payments for fractional shares and cash payments made in respect of dissenters’ appraisal rights) in connection with such transaction or transactions consists of shares of Elanco common stock that are listed or quoted on any of the NYSE, the Nasdaq Global Select Market or the Nasdaq Global Market (or any of their respective successors), or will be so listed or quoted when issued or exchanged in connection with such transaction or transactions, and (b) as a result of such transaction or transactions such consideration becomes the consideration receivable upon settlement of the holder’s purchase contracts, if applicable, excluding cash payments for fractional shares.
Notwithstanding anything to the contrary herein, in no event shall the Acquisition (as defined in the purchase contract agreement) and related transactions constitute a fundamental change.
If any transaction in which Elanco common stock is replaced by the securities of another entity occurs, following completion of any related fundamental change early settlement period (or, in the case of a transaction that would have been a fundamental change but for the immediately preceding paragraph, following the effective date of such transaction), references to Elanco in the definition of “fundamental change” above shall instead be references to such other entity.
The “fundamental change early settlement rate” will be determined by Elanco by reference to the table below, based on the date on which the fundamental change occurs or becomes effective (the “effective date”) and the “stock price” in the fundamental change, which will be:
•in the case of a fundamental change described in clause (2) of the definition of “fundamental change” in which all holders of shares of Elanco common stock receive only cash in the fundamental change, the stock price will be the cash amount paid per share of Elanco common stock; and
•in all other cases, the stock price will be the arithmetic average of the VWAPs of Elanco common stock over the five consecutive trading day period ending on, and including, the trading day immediately preceding the effective date.
The stock prices set forth in the column headings of the table below will be adjusted as of any date on which the fixed settlement rates are adjusted. The adjusted stock prices will equal the stock prices applicable immediately prior to such adjustment, multiplied by a fraction, the numerator of which is the maximum settlement rate immediately prior to the adjustment giving rise to the stock price adjustment and the denominator of which is the maximum settlement rate as so adjusted. The fundamental change early settlement rates per purchase contract in the table below will be adjusted in the same manner and at the same time as the fixed settlement rates as set forth under “— Adjustments to the Fixed Settlement Rates.”
The following table sets forth the fundamental change early settlement rate per purchase contract for each stock price and effective date set forth below:
10



Stock Price
Effective Date

$10.00


$20.00


$25.00


$32.00


$35.00


$38.40


$45.00


$60.00


$70.00


$80.00


$90.00


$100.00
January 27, 2020

1.5327


1.4646


1.4202


1.3688


1.3519


1.3364


1.3149


1.2925


1.2871


1.2846


1.2835


1.2830
May 1, 2020

1.5365


1.4731


1.4279


1.3740


1.3562


1.3397


1.3171


1.2938


1.2884


1.2861


1.2851


1.2846
August 1, 2020

1.5399


1.4818


1.4359


1.3794


1.3604


1.3429


1.3190


1.2950


1.2897


1.2875


1.2866


1.2862
November 1, 2020

1.5430


1.4908


1.4445


1.3851


1.3649


1.3462


1.3208


1.2961


1.2909


1.2889


1.2881


1.2877
February 1, 2021

1.5458


1.5002


1.4539


1.3912


1.3695


1.3494


1.3223


1.2970


1.2920


1.2902


1.2895


1.2893
May 1, 2021

1.5482


1.5097


1.4637


1.3975


1.3742


1.3525


1.3236


1.2977


1.2931


1.2915


1.2910


1.2908
August 1, 2021

1.5505


1.5199


1.4750


1.4047


1.3793


1.3556


1.3245


1.2982


1.2941


1.2929


1.2925


1.2924
November 1, 2021

1.5527


1.5301


1.4875


1.4129


1.3847


1.3585


1.3248


1.2986


1.2952


1.2943


1.2941


1.2940
February 1, 2022

1.5547


1.5402


1.5018


1.4223


1.3906


1.3611


1.3242


1.2988


1.2963


1.2957


1.2956


1.2956
May 1, 2022

1.5566


1.5492


1.5176


1.4334


1.3969


1.3629


1.3222


1.2989


1.2974


1.2972


1.2972


1.2972
August 1, 2022

1.5586


1.5565


1.5361


1.4486


1.4045


1.3630


1.3177


1.2993


1.2989


1.2988


1.2988


1.2988
November 1, 2022

1.5605


1.5605


1.5547


1.4732


1.4139


1.3576


1.3090


1.3005


1.3005


1.3005


1.3005


1.3005
February 1, 2023

1.5625


1.5625


1.5625


1.5625


1.4286


1.3021


1.3021


1.3021


1.3021


1.3021


1.3021


1.3021
The exact stock price and effective date may not be set forth in the table above, in which case:
•if the applicable stock price is between two stock prices in the table or the applicable effective date is between two effective dates in the table, the fundamental change early settlement rate will be determined by straight line interpolation between the fundamental change early settlement rates set forth for the higher and lower stock prices and the earlier and later effective dates, as applicable, based on a 365-or 366-day year, as applicable;
•if the applicable stock price is greater than $100.00 per share (subject to adjustment in the same manner and at the same time as the stock prices set forth in the column headings of the table above), then the fundamental change early settlement rate will be the minimum settlement rate; or
•if the applicable stock price is less than $10.00 per share (subject to adjustment in the same manner and at the same time as the stock prices set forth in the column headings of the table above, the “minimum stock price”), the fundamental change early settlement rate will be determined as if the stock price equaled the minimum stock price, and using straight line interpolation, as described in the first bullet of this paragraph, if the effective date is between two effective dates in the table.
The maximum number of shares of Elanco common stock deliverable under a purchase contract is 1.5625, subject to adjustment in the same manner and at the same time as the fixed settlement rates as set forth under “— Adjustments to the Fixed Settlement Rates.”
Our obligation to settle the purchase contracts at the fundamental change early settlement rate could be considered a penalty, in which case the enforceability thereof would be subject to general principles of reasonableness of economic remedies.
We will deliver the shares of Elanco common stock (and any cash payable for fractional shares) (or, if a reorganization event has occurred, cash, securities or other property, as applicable) payable as a result of the holder’s exercise of the fundamental change early settlement right on the second business day following the fundamental change early settlement date.
Prior to the close of business on the fundamental change early settlement date, the shares of Elanco common stock or other securities, if applicable, underlying each purchase contract will not be outstanding, and the
11

holder of such purchase contract will not have any voting rights, rights to dividends or other distributions or other rights of a holder of Elanco common stock or such other securities by virtue of holding such purchase contract. The person in whose name any shares of Elanco common stock or such other securities shall be deliverable following exercise of a holder’s fundamental change early settlement right will be treated as the holder of record of such shares or such other securities as of the close of business on the fundamental change early settlement date.
Upon early settlement at the holder’s election upon a fundamental change of the purchase contract component of a Unit, the amortizing note underlying such Unit will remain outstanding and will be beneficially owned by or registered in the name of, as the case may be, the holder who elected to settle the related purchase contract early upon the fundamental change and will no longer constitute a part of the Unit.
If the holder does not elect to exercise their fundamental change early settlement right, the holder’s purchase contracts will remain outstanding and will be subject to normal settlement on any subsequent early settlement date, any subsequent fundamental change early settlement date, any subsequent early mandatory settlement date or the mandatory settlement date, as the case may be.
Early Mandatory Settlement at Elanco’s Election
Elanco has the right to settle the purchase contracts on or after November 1, 2020, in whole but not in part, on a date fixed by Elanco as described below at the “early mandatory settlement rate” described below. This right is referred to as Elanco “early mandatory settlement right.”
The “early mandatory settlement rate” will be the maximum settlement rate as of the date (the “notice date”) of the early mandatory settlement notice (as defined below).
The “closing price” per share of Elanco common stock (or any other security) on any day means:
•the closing sale price per share (or if no closing sale price is reported, the average of the bid and ask prices or, if more than one in either case, the average of the average bid and the average ask prices) on that date as reported in composite transactions for the relevant stock exchange;
•if Elanco common stock (or any other security) is not listed for trading on a relevant stock exchange on the relevant date, the last quoted bid price for Elanco common stock (or such other security) in the over-the-counter market on the relevant date as reported by OTC Markets Group Inc. or a similar organization; and
•if Elanco common stock (or any other security) is not so quoted, the average of the mid-point of the last bid and ask prices for Elanco common stock (or such other security) on the relevant date from each of at least three nationally recognized independent investment banking firms selected by Elanco for this purpose.
In the event Elanco elects to settle the purchase contracts early, holders of the amortizing notes (whether as components of Units or separate amortizing notes) will have the right to require Elanco to repurchase some or all of their amortizing notes on the repurchase date and at the repurchase price, as described under “Description of the Amortizing Notes — Repurchase of Amortizing Notes at the Option of the Holder.” If Elanco exercises its early mandatory settlement right and the holder of any Unit does not require Elanco to repurchase the amortizing note that is a component of such Unit, such amortizing note will remain outstanding and will be beneficially owned by or registered in the name of, as the case may be, such holder. If Elanco exercises its early mandatory settlement right and the holder of any Unit requires Elanco to repurchase the amortizing note that is a component of such Unit but the related repurchase date falls after the early mandatory settlement date, such amortizing note will remain outstanding (pending such repurchase date) and will be beneficially owned by or registered in the name of, as the case may be, such holder.
12

If Elanco elects to exercise its early mandatory settlement right, Elanco will provide the purchase contract agent and the holders of Units, separate purchase contracts and separate amortizing notes with a notice of Elanco’s election (the “early mandatory settlement notice”) and issue a press release announcing Elanco’s election. The early mandatory settlement notice will specify, among other things:
•the early mandatory settlement rate;
•the date on which Elanco will deliver shares of Elanco common stock (and any cash payable for fractional shares) following exercise of its early mandatory settlement right (the “early mandatory settlement date”), which will be on or after November 1, 2020 and at least five but not more than 20 business days following the notice date;
•that holders of Units and separate amortizing notes will have the right to require Elanco to repurchase their amortizing notes that are a component of the Units or their separate amortizing notes, as the case may be (subject to certain exceptions described under “Description of the Amortizing Notes — Repurchase of Amortizing Notes at the Option of the Holder”);
•if applicable, the “repurchase price” and “repurchase date” (each as defined below under “Description of the Amortizing Notes — Repurchase of Amortizing Notes at the Option of the Holder”);
•if applicable, the last date on which holders of amortizing notes may exercise their repurchase right; and
•if applicable, the procedures that holders of amortizing notes must follow to require Elanco to repurchase their amortizing notes.
Elanco will deliver the shares of Elanco common stock (and any cash payable for fractional shares) to the holder on the early mandatory settlement date.
Prior to the close of business on the notice date, the shares of Elanco common stock underlying each purchase contract will not be outstanding, and the holder of such purchase contract will not have any voting rights, rights to dividends or other distributions or other rights of a holder of Elanco common stock by virtue of holding such purchase contract. The person in whose name any shares of Elanco common stock shall be issuable following exercise of Elanco’s early mandatory settlement right will be treated as the holder of record of such shares as of the close of business on the notice date.
Adjustments to the Fixed Settlement Rates
The fixed settlement rates will be adjusted as described below, except that Elanco will not make any adjustments to the fixed settlement rates if holders of the purchase contracts participate (other than in the case of (x) a share split or share combination or (y) a tender or exchange offer), at the same time and upon the same terms as holders of Elanco common stock and solely as a result of holding the purchase contracts, in any of the transactions described below without having to settle their purchase contracts as if they held a number of shares of Elanco common stock equal to the maximum settlement rate, multiplied by the number of purchase contracts held by such holders.
(a)  If Elanco issues common stock to all or substantially all of the holders of Elanco common stock as a dividend or other distribution, or if Elanco effect a share split or share combination, then each fixed settlement rate will be adjusted based on the following formula:
image01.jpg
13

where,
SR0  =  the fixed settlement rate in effect immediately prior to the close of business on the record date (as defined below) for such dividend or distribution or immediately prior to the open of business on the effective date (as defined below) for such share split or share combination, as the case may be;
SR1  =  the fixed settlement rate in effect immediately after the close of business on such record date or immediately after the open of business on such effective date, as the case may be;
OS0  = the number of shares of Elanco common stock outstanding immediately prior to the close of business on such record date or immediately prior to the open of business on such effective date, as the case may be (in either case, prior to giving effect to such event); and
OS1  = the number of shares of Elanco common stock that would be outstanding immediately after, and solely as a result of, such dividend, distribution, share split or share combination.
Any adjustment made pursuant to this clause (a) will become effective immediately after the close of business on the record date for such dividend or distribution, or immediately after the open of business on the effective date for such share subdivision or share combination, as the case may be. If any dividend or distribution described in this clause (a) is declared but not so paid or made, each fixed settlement rate will be readjusted, effective as of the date Elanco’s board of directors (or a committee thereof) publicly announces its decision not to make such dividend or distribution, to such fixed settlement rate that would be in effect if such dividend or distribution had not been declared. For the purposes of this clause (a), the number of shares of Elanco common stock outstanding immediately prior to the close of business on the record date for such dividend or distribution or the open of business on the effective date for such share subdivision or share combination, as applicable, will not include shares held in treasury but will include any shares issuable in respect of any scrip certificates issued in lieu of fractions of shares of Elanco common stock. Elanco will not pay any such dividend or make any such distribution on shares of Elanco common stock held in treasury.
“Record date” means, when used with respect to any dividend, distribution or other transaction or event in which the holders of Elanco common stock (or other applicable security) have the right to receive any cash, securities or other property or in which Elanco common stock (or other applicable security) is exchanged for or converted into any combination of cash, securities or other property, the date fixed for determination of holders of Elanco common stock (or other applicable security) entitled to receive such cash, securities or other property (whether such date is fixed by Elanco’s board of directors or a committee thereof, or by statute, contract or otherwise).
“Effective date” means the first date on which the shares of Elanco common stock trade on the relevant stock exchange, regular way, reflecting the relevant share split or share combination, as applicable.
(b) If Elanco issues to all or substantially all holders of Elanco common stock rights, options or warrants (other than rights issued pursuant to a stockholder rights plan) entitling them, for a period of up to 45 calendar days from the date of issuance of such rights, options or warrants, to subscribe for or purchase Elanco’s shares of Elanco common stock at a price per share less than the average of the closing prices (as defined under “— Early Mandatory Settlement at Elanco’s Election”) per share of Elanco common stock for the 10 consecutive trading day (as defined below) period ending on, and including, the trading day immediately preceding the date of announcement for such distribution per share of Elanco common stock, then each fixed settlement rate will be adjusted based on the following formula:
image11.jpg
14

where,
SR0  = the fixed settlement rate in effect immediately prior to the close of business on the record date for such issuance;
SR1 = the fixed settlement rate in effect immediately after the close of business on such record date;
OS0  = the number of shares of Elanco common stock outstanding immediately prior to the close of business on such record date;
X = the total number of shares of Elanco common stock issuable pursuant to such rights, options or warrants; and
Y = the total number of shares of Elanco common stock equal to the aggregate price payable to exercise such rights, options or warrants, divided by the average of the closing prices per share of Elanco common stock for the 10 consecutive trading day period ending on, and including, the trading day immediately preceding the date of announcement for such distribution.
Any adjustment made pursuant to this clause (b) will be made successively whenever any such rights, options or warrants are issued and will become effective immediately after the close of business on the record date for such issuance. In the event that such rights, options or warrants described in this clause (b) are not so issued, each fixed settlement rate will be readjusted, effective as of the date Elanco’s board of directors (or a committee thereof) publicly announces its decision not to issue such rights, options or warrants, to such fixed settlement rate that would then be in effect if such issuance had not been declared. To the extent that such rights, options or warrants are not exercised prior to their expiration or shares of Elanco common stock are otherwise not delivered pursuant to such rights, options or warrants upon the exercise of such rights, options or warrants, each fixed settlement rate will be readjusted, effective as of the date of such expiration or the date it is determined such shares will not be delivered, as the case may be, to such fixed settlement rate that would then be in effect had the adjustment made upon the issuance of such rights, options or warrants been made on the basis of the delivery of only the number of shares of Elanco common stock actually delivered.
In determining whether any rights, options or warrants entitle the holders thereof to subscribe for or purchase shares of Elanco common stock at less than the average of the closing prices per share of Elanco common stock for the 10 consecutive trading day period ending on, and including, the trading day immediately preceding the date of announcement for such distribution, and in determining the aggregate price payable to exercise such rights, options or warrants, there will be taken into account any consideration received by Elanco for such rights, options or warrants and any amount payable on exercise or conversion thereof, the value of such consideration, if other than cash, to be determined by Elanco’s board of directors, or a committee thereof.
For the purposes of this clause (b), the number of shares of Elanco common stock at the time outstanding will not include shares held in treasury but will include any shares issuable in respect of any scrip certificates issued in lieu of fractions of shares of Elanco common stock. Elanco will not issue any such rights, options or warrants in respect of shares of Elanco common stock held in treasury.
(c)  (1) If Elanco distributes to all or substantially all holders of Elanco common stock shares of Elanco’s capital stock (other than Elanco common stock), evidences of Elanco’s indebtedness, assets or rights, options or warrants to acquire Elanco’s capital stock, indebtedness or assets, excluding:
•any dividend or distribution (including share splits or share combinations) as to which an adjustment was effected pursuant to clause (a) above;
15

•any rights, options or warrants as to which an adjustment was effected pursuant to clause (b) above;
•except as otherwise described below, rights issued pursuant to any stockholder rights plan of ours then in effect;
•any dividend or distribution described in clause (d) below;
•distributions of exchange property in a transaction described in “— Recapitalizations, Reclassifications and Changes of Our Common Stock;” and
•any spin-off (as defined below) to which the provisions set forth below in clause (c)(2) shall apply;
then each fixed settlement rate will be adjusted based on the following formula:
image21.jpg
where,
SR0  = the fixed settlement rate in effect immediately prior to the close of business on the record date for such dividend or distribution;
SR1  = the fixed settlement rate in effect immediately after the close of business on such record date;
SP0  = the average of the closing prices per share of Elanco common stock for the 10 consecutive trading day period ending on, and including, the trading day immediately preceding the ex-date for such dividend or distribution; and
FMV =  the fair market value (as determined by Elanco’s board of directors or a committee thereof) on the ex-date for such dividend or distribution, of the shares of Elanco’s capital stock, evidences of Elanco’s indebtedness, assets or rights, options or warrants so distributed, expressed as an amount per share of Elanco common stock.
Notwithstanding the foregoing, if FMV (as defined above) is equal to or greater than SP0 (as defined above) or if the difference between SP0 and FMV is less than $1.00, in lieu of the foregoing adjustment, provision shall be made for each holder of a Unit or separate purchase contract to receive, for each Unit or separate purchase contract, at the same time and upon the same terms as holders of Elanco common stock, the kind and amount of Elanco’s capital stock, evidences of Elanco’s indebtedness, assets or rights, options or warrants that such holder would have received if such holder owned a number of shares of Elanco common stock equal to the maximum settlement rate in effect on the record date for the dividend or distribution.
Any adjustment made pursuant to this clause (c)(1) will become effective immediately after the close of business on the record date for such dividend or distribution. In the event that such dividend or distribution is not so made, each fixed settlement rate will be readjusted, effective as of the date Elanco’s board of directors (or a committee thereof) publicly announces its decision not to make such dividend or distribution, to such fixed settlement rate that would then be in effect if such dividend or distribution had not been declared. Elanco will not make any such distribution on shares of Elanco common stock held in treasury.
“Ex-date,” when used with respect to any issuance or distribution, means the first date on which shares of Elanco common stock (or other applicable security) trade on the applicable exchange or in the applicable market, regular way, without the right to receive such issuance, dividend or distribution in question from Elanco or, if
16

applicable, from the seller of Elanco common stock (or other applicable security) on such exchange or market (in the form of due bills or otherwise) as determined by such exchange or market.
(c)  (2) In the event that Elanco makes a dividend or distribution to all or substantially all holders of Elanco common stock consisting of capital stock of, or similar equity interests in, or relating to, a subsidiary or other business unit of Elanco’s that, upon issuance, will be traded on a U.S. national securities exchange (herein referred to as a “spin-off”), each fixed settlement rate will be adjusted based on the following formula:
image31.jpg
where,
SR0  = the fixed settlement rate in effect immediately prior to the open of business on the ex-date for the spin-off;
SR1  = the fixed settlement rate in effect immediately after the open of business on the ex-date for the spin-off;
FMV0  =  the average of the closing prices (as defined above, as if references to “Elanco common stock” therein were references to such capital stock or similar equity interest distributed to the holders of Elanco common stock) per share of the capital stock or similar equity interests so distributed applicable to one share of Elanco common stock for the 10 consecutive trading day period commencing on, and including, the ex-date date for the spin-off (the “valuation period”); and
MP0  = the average of the closing prices per share of Elanco common stock for the valuation period.
Any adjustment made pursuant to this clause (c)(2) will become effective immediately after the close of business on the last trading day of the valuation period but will be given effect as of immediately after the open of business on the ex-date of the spin-off. Because Elanco will make the adjustment to each fixed settlement rate with retroactive effect, Elanco will delay any settlement of a Unit or separate purchase contract where any date for determining the number of shares of Elanco common stock issuable to a holder occurs during the valuation period until the second business day after the last date for determining the number of shares of Elanco common stock issuable to such holder with respect to such settlement occurs. In the event that such dividend or distribution described in this clause (c)(2) is not so made, each fixed settlement rate will be readjusted, effective as of the date Elanco’s board of directors (or a committee thereof) publicly announces its decision not to pay such dividend or distribution, to such fixed settlement rate that would then be in effect if such distribution had not been declared. Elanco will not make any such dividend or distribution on shares of Elanco common stock held in treasury.
(d) If Elanco makes a dividend or distribution consisting exclusively of cash to all or substantially all holders of Elanco common stock, excluding:
•any cash that is distributed in, and will constitute exchange property as a result of, a reorganization event (as defined below) in exchange for shares of Elanco common stock; and
•any dividend or distribution in connection with Elanco’s liquidation, dissolution or winding up;
then each fixed settlement rate will be adjusted based on the following formula:
17

image41.jpg
where,
SR0  =  the fixed settlement rate in effect immediately prior to the close of business on the record date for such dividend or distribution;
SR1  =  the fixed settlement rate in effect immediately after the close of business on the record date for such dividend or distribution;
SP0  =  the average of the closing prices per share of Elanco common stock over the 10 consecutive trading day period ending on, and including, the trading day immediately preceding the ex-date for such dividend or distribution; and
C =  the amount in cash per share Elanco distributes to holders of Elanco common stock.
If C (as defined above) is equal to or greater than SP0 (as defined above) or if the difference between SP0 and C is less than $1.00, in lieu of the foregoing adjustment, provision shall be made for each holder of a Unit or separate purchase contract to receive, for each Unit or separate purchase contract, at the same time and upon the same terms as holders of Elanco common stock, the amount of cash that such holder would have received if such holder owned a number of shares of Elanco common stock equal to the maximum settlement rate on the record date for such cash dividend or distribution.
Any adjustment made pursuant to this clause (d) will become effective immediately after the close of business on the record date for such dividend or distribution. In the event that any dividend or distribution described in this clause (d) is not so made, each fixed settlement rate will be readjusted, effective as of the date Elanco’s board of directors (or a committee thereof) publicly announces its decision not to pay such dividend or distribution, to such fixed settlement rate which would then be in effect if such dividend or distribution had not been declared. Elanco will not make any such dividend or distribution on shares of Elanco common stock held in treasury.
For the purposes of this clause (d), in no event shall the Acquisition (as defined in the purchase contract agreement) and related transactions be deemed to be a liquidation, dissolution or winding up.
(e)  If Elanco or any of its subsidiaries successfully complete a tender or exchange offer for Elanco common stock where the cash and the value of any other consideration included in the payment per share of Elanco common stock validly tendered or exchanged exceeds the average of the closing prices per share of Elanco common stock for the 10 consecutive trading day period (the “averaging period”) commencing on, and including, the trading day next succeeding the last date on which tenders or exchanges may be made pursuant to such tender offer or exchange offer (the “expiration date”), then each fixed settlement rate will be adjusted based on the following formula:
image51.jpg
where,
SR0 =  the fixed settlement rate in effect immediately prior to the close of business on the expiration date;
SR1  =  the fixed settlement rate in effect immediately after the close of business on the expiration date;
18

AC =  the aggregate value of all cash and the fair market value (as determined by Elanco’s board of directors, or a committee thereof) on the expiration date of any other consideration paid or payable for shares of Elanco common stock acquired pursuant to such tender offer or exchange offer;
OS1 =  the number of shares of Elanco common stock outstanding immediately after the expiration date, after giving effect to the purchase of all shares accepted for purchase or exchange in such tender or exchange offer;
OS0 =  the number of shares of Elanco common stock outstanding immediately prior to the expiration date, prior to giving effect to the purchase of any shares accepted for purchase or exchange in such tender or exchange offer; and
SP = the average of the closing prices per share of Elanco common stock over the averaging period.
Any adjustment made pursuant to this clause (e) will become effective immediately after the close of business on the expiration date. Because Elanco will make the adjustment to each fixed settlement rate with retroactive effect, Elanco will delay any settlement of a Unit or separate purchase contract where any date for determining the number of shares of Elanco common stock issuable to a holder occurs during the averaging period until the second business day after the last date for determining the number of shares of Elanco common stock issuable to such holder with respect to such settlement occurs. In the event that Elanco is, or one of its subsidiaries is, obligated to purchase shares of Elanco common stock pursuant to any such tender or exchange offer, but Elanco is, or such subsidiary is, permanently prevented by applicable law from effecting any such purchases, or all such purchases are rescinded, then each fixed settlement rate will be readjusted to be such fixed settlement rate that would then be in effect if such tender or exchange offer had not been made.
To the extent that Elanco has a rights plan in effect with respect to Elanco common stock on any date for determining the number of shares of Elanco common stock issuable to a holder, the holder will receive, in addition to Elanco common stock, the rights under the rights plan, unless, prior to such determination date, the rights have separated from Elanco common stock, in which case each fixed settlement rate will be adjusted at the time of separation as if Elanco made a distribution to all holders of Elanco common stock as described in clause (c)(1) above, subject to readjustment in the event of the expiration, termination or redemption of such rights.
For purposes of this “— Adjustments to the Fixed Settlement Rates” section, “trading day” means a day on which:
•trading in Elanco common stock (or other security for which a closing sale price must be determined) generally occurs on the relevant stock exchange, or, if Elanco common stock (or such other security) is not then listed on a relevant stock exchange, on the principal other market on which Elanco common stock (or such other security) is then listed or admitted for trading; and
•a closing price per share for Elanco common stock (or closing sale price for such other security) is available on such securities exchange or market.
If Elanco common stock (or such other security) is not so listed or traded, “trading day” means a “business day.”
In addition, subject to applicable law and the applicable listing standards of the NYSE (or any other securities exchange where Elanco common stock is listed) and in accordance with the provisions of the purchase contract agreement, Elanco may make such increases in each fixed settlement rate as Elanco determines to be in its best interests or Elanco deems advisable. Elanco may also (but is not required to) increase each fixed settlement rate in order to avoid or diminish any income tax to holders of Elanco common stock resulting from any dividend or distribution of shares of Elanco common stock (or issuance of rights, options or warrants to acquire shares of Elanco
19

common stock) or from any event treated as such for income tax purposes or for any other reason. Elanco may only make such a discretionary adjustment if Elanco makes the same proportionate adjustment to each fixed settlement rate.
Adjustments to each fixed settlement rate will be calculated to the nearest 1/10,000th of a share. No adjustment in the fixed settlement rates will be required unless the adjustment would require an increase or decrease of at least one percent. If any adjustment is not required to be made because it would not change the fixed settlement rates by at least one percent, then the adjustment will be carried forward and taken into account in any subsequent adjustment; provided that, on any date for determining the number of shares of Elanco common stock issuable to a holder, adjustments to the fixed settlement rates will be made with respect to any such adjustment carried forward and which has not been taken into account before such determination date.
The fixed settlement rates will only be adjusted as set forth above and will not be adjusted:
•upon the issuance of any shares of Elanco common stock pursuant to any present or future plan providing for the reinvestment of dividends or interest payable on Elanco’s securities and the investment of additional optional amounts in Elanco common stock under any plan;
•upon the issuance of any shares of Elanco common stock or rights, options or warrants to purchase those shares pursuant to any present or future employee, director or consultant benefit plan or program of or assumed by Elanco or any of its subsidiaries;
•upon the repurchase of any shares of Elanco common stock pursuant to an open market share repurchase program or other buy-back transaction, including structured or derivative transactions, that is not a tender offer or exchange offer of the nature described in clause (e) above;
•for the sale or issuance of shares of Elanco common stock, or securities convertible into or exercisable for shares of Elanco common stock, for cash, including at a price per share less than the fair market value thereof or otherwise or in an acquisition, including the Acquisition, except as described in one of clauses (a) through (e) above;
•for a third-party tender offer;
•upon the issuance of any shares of Elanco common stock pursuant to any option, warrant, right or exercisable, exchangeable or convertible security outstanding as of the date the Units were first issued;
•solely for a change in the par value of Elanco common stock;
•for accrued and unpaid interest, if any; or
•for any other issuance of shares of Elanco common stock or any securities convertible into or exchangeable for shares of Elanco common stock or the right to purchase shares of Elanco common stock or such convertible or exchangeable securities, except as described above, including in connection with the Acquisition and related transactions.
Whenever the fixed settlement rates are adjusted, Elanco will deliver to the purchase contract agent a certificate setting forth in reasonable detail the method by which the adjustment to each fixed settlement rate was determined and setting forth each adjusted fixed settlement rate. In addition, Elanco will, within five business days of any event requiring such adjustment, provide or cause to be provided written notice of the adjustment to the holders of the Units and separate purchase contracts and describe in reasonable detail the method by which each fixed settlement rate was adjusted.
20

Elanco will adjust the fundamental change early settlement rates at the time Elanco adjusts the fixed settlement rates. For the avoidance of doubt, if Elanco makes an adjustment to the fixed settlement rates, it will result in a corresponding adjustment to the early settlement rate and the early mandatory settlement rate. For the further avoidance of doubt, if Elanco makes an adjustment to the fixed settlement rates, no separate inversely proportionate adjustment will be made either to (i) the threshold appreciation price because it is equal to $50.00 divided by the minimum settlement rate as adjusted in the manner described herein (rounded to the nearest $0.0001) or (ii) the reference price because it is equal to $50.00 divided by the maximum settlement rate as adjusted in the manner described herein (rounded to the nearest $0.0001).
Whenever the terms of the purchase contracts require Elanco to calculate closing prices, VWAPs or any other prices or amounts over a span of multiple days (including, without limitation, the applicable market value or the “stock price”), Elanco will make appropriate adjustments, if any, to each to account for any adjustment to the fixed settlement rates if the related record date, ex-date, effective date or expiration date occurs during the period in which the closing prices, the VWAPs or such other prices or amounts are to be calculated.
Recapitalizations, Reclassifications and Changes of Elanco Common Stock
In the event of:
•any consolidation or merger of Elanco with or into another person (other than a merger or consolidation in which Elanco is the continuing or surviving corporation and in which the shares of Elanco common stock outstanding immediately prior to the merger or consolidation are not exchanged for cash, securities or other property of Elanco or another person;
•any direct or indirect sale, lease, assignment, transfer or conveyance of all or substantially all of Elanco’s consolidated property or assets;
•any reclassification of Elanco common stock into securities, including securities other than Elanco common stock (other than changes in par value or resulting from a subdivision or combination); or
•any statutory exchange of Elanco’s securities with another person (other than in connection with a merger or acquisition);
in each case, as a result of which Elanco common stock would be converted into, or exchanged for, securities, cash or other property (each, a “reorganization event”), each purchase contract outstanding immediately prior to such reorganization event will, without the consent of the holders of the purchase contracts, become a contract to purchase the kind of securities, cash and/or other property that a holder of Elanco common stock would have been entitled to receive in connection with such reorganization event (such securities, cash and other property, the “exchange property” with each unit of exchange property being the kind and amount of exchange property that a holder of one share of Elanco common stock would have received in such reorganization event) and, prior to or at the effective time of such reorganization event, Elanco or the successor or purchasing person, as the case may be, shall execute with the purchase contract agent and the trustee a supplemental agreement pursuant to the purchase contract agreement and the purchase contracts to provide for such change in the right to settle the purchase contracts. Notwithstanding anything to the contrary herein, in no event shall the Acquisition and related transactions constitute a reorganization event.
For purposes of the foregoing, the type and amount of exchange property in the case of any reorganization event that causes Elanco common stock to be converted into, or exchanged for, the right to receive more than a single type of consideration (determined based in part upon any form of shareholder election) will be deemed to be the weighted average of the types and amounts of consideration actually received by the holders of Elanco common stock.
The number of units of exchange property Elanco will deliver for each purchase contract settled following the effective date of such reorganization event will be equal to the number of shares of Elanco common stock Elanco
21

would otherwise be required to deliver as determined by the fixed settlement rates then in effect on the applicable settlement date, or such other settlement rates as provided herein (without interest thereon and without any right to dividends or distributions thereon which have a record date prior to the close of business such purchase contracts are actually settled). Each fixed settlement rate will be determined using the applicable market value of a unit of exchange property, and such value will be determined, on any date of determination, with respect to:
•in the case of any publicly traded securities that comprise all or part of the exchange property, based on the VWAP of such securities on such date;
•in the case of any cash that comprises all or part of the exchange property, based on the amount of such cash; and
•in the case of any other property that comprises all or part of the exchange property, based on the value of such property on such date, as determined by a nationally recognized independent investment banking firm retained by Elanco for this purpose.
In addition, if the exchange property in respect of any reorganization event includes, in whole or in part, securities of another entity, Elanco shall amend the terms of the purchase contract agreement and the purchase contracts, without the consent of holders thereof, to: (x) provide for anti-dilution and other adjustments that shall be as nearly equivalent as practicable, as determined by the officer executing such amendment, to the adjustments described above under the heading “— Adjustments to the Fixed Settlement Rates;” and (y) otherwise modify the terms of the purchase contract agreement and the purchase contracts to reflect the substitution of the applicable exchange property for Elanco common stock (or other exchange property then underlying the purchase contracts). In establishing such anti-dilution and other adjustments referenced in the immediately preceding sentence, such officer shall act in a commercially reasonable manner and in good faith.
Fractional Shares
No fractional shares of Elanco common stock will be issued to holders upon settlement of the purchase contracts. In lieu of fractional shares otherwise issuable, holders will be entitled to receive an amount in cash equal to the fraction of a share of Elanco common stock, calculated on an aggregate basis in respect of the purchase contracts being settled (provided that, so long as the Units are in global form, Elanco may elect to aggregate Units for purposes of these calculations on any basis permitted by the applicable procedures of DTC), multiplied by the VWAP of Elanco common stock on the trading day immediately preceding the mandatory settlement date, early settlement date, fundamental change early settlement date or early mandatory settlement date, as the case may be.
Legal Holidays
In any case where the mandatory settlement date, early settlement date, fundamental change early settlement date or early mandatory settlement date, as the case may be, shall not be a business day, notwithstanding any term to the contrary in the purchase contract agreement or purchase contract, the settlement of the purchase contracts shall not be effected on such date, but instead shall be effected on the next succeeding business day with the same force and effect as if made on such settlement date, and no interest or other amounts shall accrue or be payable by Elanco or to any holder in respect of such delay.
Consequences of Bankruptcy
Pursuant to the terms of the purchase contract agreement, the mandatory settlement date for each purchase contract, whether held separately or as part of a Unit, will automatically accelerate upon the occurrence of specified events of bankruptcy, insolvency or reorganization with respect to Elanco. Pursuant to the terms of the purchase contract agreement, upon acceleration, holders will be entitled under the terms of the purchase contracts to receive a number of shares of Elanco common stock per purchase contract equal to the maximum settlement rate in effect immediately prior to such acceleration (regardless of the market value of Elanco common stock at that time). If for any reason the accelerated purchase contracts are not settled by the delivery of Elanco common stock (for example, a
22

bankruptcy court may prevent Elanco from delivering Elanco common stock in settlement of the accelerated purchase contracts), a holder may have a damage claim against Elanco for the value of the common stock that Elanco would have otherwise been required to deliver upon settlement of the purchase contracts. Elanco expects that any such damage claim that holders have against Elanco following such acceleration would rank equally with the claims of holders of Elanco common stock in the relevant bankruptcy proceeding. As such, to the extent Elanco fails to deliver Elanco common stock to the holders upon such an acceleration, the holders will only be able to recover damages to the extent holders of Elanco common stock receive any recovery.
Modification
The purchase contract agreement will contain provisions permitting us, the purchase contract agent and the trustee to modify the purchase contract agreement or the purchase contracts without the consent of the holders of purchase contracts (whether held separately or as a component of Units) for any of the following purposes:
•to evidence the succession of another person to Elanco, and the assumption by any such successor of the covenants and obligations of Elanco’s in the purchase contract agreement and the units and separate purchase contracts, if any;
•to add to the covenants for the benefit of holders of purchase contracts or to surrender any of Elanco’s rights or powers under the agreement;
•to evidence and provide for the acceptance of appointment of a successor purchase contract agent;
•upon the occurrence of a reorganization event, solely: (i) to provide that each purchase contract will become a contract to purchase exchange property; and (ii) to effect the related changes to the terms of the purchase contracts, in each case, as required by the applicable provisions of the purchase contract agreement;
•to cure any ambiguity or manifest error, to correct or supplement any provisions that may be inconsistent; and
•to make any other provisions with respect to such matters or questions, so long as such action does not adversely affect the interest of the holders.
The purchase contract agreement will contain provisions permitting Elanco, the purchase contract agent and the trustee, with the consent of the holders of not less than a majority of the purchase contracts at the time outstanding, to modify the terms of the purchase contracts or the purchase contract agreement. However, no such modification may, without the consent of the holder of each outstanding purchase contract affected by the modification,
•reduce the number of shares of Elanco common stock deliverable upon settlement of the purchase contract (except to the extent expressly provided in the anti-dilution adjustments);
•change the mandatory settlement date, or adversely modify the right to settle purchase contracts early or the fundamental change early settlement right;
•impair the right to institute suit for the enforcement of the purchase contracts; or
•reduce the above-stated percentage of outstanding purchase contracts the consent of the holders of which is required for the modification or amendment of the provisions of the purchase contracts or the purchase contract agreement.
In executing any supplement, modification or amendment to the purchase contract agreement, the purchase contract agent and trustee shall be provided an officer’s certificate and an opinion of counsel stating that the
23

execution of such supplemental agreement is authorized or permitted by the purchase contract agreement, and that any and all conditions precedent to the execution and delivery of such supplemental agreement have been satisfied.
Consolidation, Merger, Conveyance, Transfer or Lease
The purchase contract agreement will provide that Elanco will not consolidate or merge with or into any other entity, or sell, transfer, lease or otherwise convey its properties and assets as an entirety or substantially as an entirety to any entity, unless:
•(i) it is the continuing entity (in the case of a merger), or (ii) the successor entity formed by such consolidation or into which it is merged or which acquires by sale, transfer, lease or other conveyance of its properties and assets, as an entirety or substantially as an entirety, is a corporation organized and existing under the laws of the United States of America or any State thereof, the District of Columbia or any territory thereof, and expressly assumes, by a supplement to the purchase contract agreement, all Elanco’s obligations under the purchase contract agreement; and
•immediately after giving effect to the transaction, no event of default, and no event which after notice or lapse of time or both would become an event of default under the purchase contract agreement or the purchase contracts, has or will have occurred and be continuing.
Notwithstanding anything to the contrary herein, in no event shall the Acquisition and related transactions be limited by this “— Consolidation, Merger, Conveyance, Transfer or Lease.”
Although there is a limited body of case law interpreting the phrase “substantially as an entirety,” there is no precise established definition of the phrase under applicable law. Accordingly, in certain circumstances there may be a degree of uncertainty as to whether a particular transaction would involve a disposition of Elanco’s properties and assets “substantially as an entirety.” As a result, it may be unclear as to whether the foregoing restrictions on mergers, consolidations, sales, conveyances, transfers, leases and other dispositions would apply to a particular transaction as described above absent a decision by a court of competent jurisdiction.
Reservation of Common Stock
Elanco will at all times reserve and keep available out of Elanco’s authorized and unissued common stock, solely for issuance upon settlement of the purchase contracts, the number of shares of common stock that would be issuable upon the settlement of all purchase contracts then outstanding, assuming settlement at the maximum settlement rate.
Governing Law
The purchase contract agreement, the Units, the purchase contracts and any claim, controversy or dispute arising under or related to the purchase contract agreement, the Units or the purchase contracts are governed by, and construed in accordance with, the laws of the State of New York.
Waiver of Jury Trial
The purchase contract agreement provides that Elanco, the purchase contract agent and the trustee will waive its respective rights to trial by jury in any action or proceeding arising out of or related to the purchase contracts, the purchase contract agreement or the transactions contemplated thereby, to the maximum extent permitted by law.
24

Information Concerning the Purchase Contract Agent
Deutsche Bank Trust Company Americas is the purchase contract agent. The purchase contract agent act as the agent for the holders of Units and separate purchase contracts from time to time but shall have no fiduciary relationship to the holder of the Units or any other party. The purchase contract agreement does not obligate the purchase contract agent to exercise any discretionary actions in connection with a default under the terms of the purchase contracts or the purchase contract agreement.
The purchase contract agreement contains provisions limiting the liability of the purchase contract agent. The purchase contract agreement contains provisions under which the purchase contract agent may resign or be replaced. This resignation or replacement would be effective upon the acceptance of appointment by a successor purchase contract agent.
Elanco maintains banking relationships in the ordinary course of business with the purchase contract agent and its affiliates.
Description of the amortizing notes
The amortizing notes were issued by Elanco pursuant to an indenture, between Elanco, as issuer, and Deutsche Bank Trust Company Americas, as trustee, dated August 28, 2018 and a related supplemental indenture, dated as of January 27, 2020, between Elanco and the trustee (collectively referred to herein as the “indenture”).
General
The amortizing notes were issued as a separate series of senior debt securities under the indenture. The amortizing notes were issued by Elanco in an aggregate initial principal amount of $79,207,700. The final installment payment date will be February 1, 2023. Elanco may not redeem the amortizing notes, and no sinking fund is provided for the amortizing notes.
Each amortizing note initially forms a part of a Unit. Each Unit may be separated by a holder into its constituent purchase contract and amortizing note on any business day during the period beginning on, and including, the business day immediately following the date of initial issuance of the Units to, but excluding, the second scheduled trading day immediately preceding February 1, 2023 or, if earlier, the second scheduled trading day immediately preceding any “early mandatory settlement date” and also excluding the business day immediately preceding any installment payment date (provided, the right to separate the Units shall resume after such business day). Following such separation, amortizing notes may be transferred separately from purchasing contracts.
Amortizing notes may only be issued in certificated form in exchange for a global security under the circumstances. In the event that amortizing notes are issued in certificated form, such amortizing notes may be transferred or exchanged at the offices described below.
Payments on amortizing notes issued as a global security will be made to DTC, or a successor depositary. In the event amortizing notes are issued in certificated form, installment payments will be made, at the corporate trust office of the trustee. Installment payments on certificated amortizing notes may be made at Elanco’s option by check mailed to the address of the persons entitled thereto. The amortizing notes are not guaranteed by any of Elanco’s subsidiaries.
There are no covenants or provisions in the indenture that would afford the holders of the amortizing notes protection in the event of a highly leveraged transaction, reorganization, restructuring, merger or similar transaction involving Elanco that may adversely affect such holders, except to the extent set forth under “— Consolidation, Merger, Conveyance, Transfer or Lease.”
The indenture does not limit the aggregate principal amount of indebtedness that may be issued thereunder and provides that debt securities may be issued thereunder from time to time in one or more series.
25

Ranking
The amortizing notes are Elanco’s general unsecured senior obligations and rank equally in right of payment with all of Elanco’s other existing and future unsecured senior indebtedness and guarantees and are structurally subordinated to the indebtedness and other liabilities of Elanco’s subsidiaries. The amortizing notes rank senior to all of Elanco’s existing and future indebtedness, if any, that is subordinated to the amortizing notes. The amortizing notes are effectively subordinated to any of Elanco’s secured indebtedness to the extent of the collateral securing that indebtedness.
The amortizing notes are Elanco ‘s obligations exclusively, and are not the obligations of any of Elanco’s subsidiaries.
Elanco conducts its operations through its subsidiaries. Accordingly, Elanco’s ability to meet its obligations under the amortizing notes will depend on the generation of cash flow by its subsidiaries, including its international subsidiaries, and their ability to make such cash available to Elanco, by dividend, debt repayment or otherwise. Elanco ‘s subsidiaries are not obligated to pay dividends or make loans or distributions to Elanco and each subsidiary is a distinct legal entity, and under certain circumstances, legal, tax and contractual restrictions may limit Elanco’s ability to obtain cash from its subsidiaries. As a result, Elanco may not be able to cause such subsidiaries to distribute funds or provide loans sufficient to enable Elanco to meet its debt and other obligations, including obligations under the amortizing notes.
Installment Payments
Each amortizing note had an initial principal amount of $7.2007. On each February 1, May 1, August 1 and November 1, commencing on May 1, 2020 (each, an “installment payment date”), Elanco will pay, in cash, equal quarterly installments of $0.6250 on each amortizing note (except for the May 1, 2020 installment payment, which will be $0.6528 per amortizing note). Each installment payment will constitute a payment of interest (at a rate of 2.75% per annum) and a partial repayment of principal on the amortizing note, allocated as set forth on the amortization schedule set forth under “— Amortization Schedule.”
Installments will be paid to the person in whose name an amortizing note is registered as of 5:00 p.m., New York City time, on January 15, April 15, July 15 and October 15, as applicable.
Each installment payment for any period will be computed on the basis of a 360-day year of twelve 30-day months. The installment payable for any period shorter or longer than a full installment payment period will be computed on the basis of the actual number of days elapsed per 30-day month. In the event that any date on which an installment is payable is not a business day, then payment of the installment on such date will be made on the next succeeding day that is a business day, and without any interest or other payment in respect of any such delay.
Amortization Schedule
The total installments of principal of and interest on the amortizing notes for each installment payment date are set forth below:
26

Installment Payment Date Amount of Principal Amount of Interest 
May 1, 2020 $0.6011 $0.0517 
August 1, 2020 $0.5796 $0.0454 
November 1, 2020 $0.5836 $0.0414 
February 1, 2021 $0.5876 $0.0374 
May 1, 2021 $0.5917 $0.0333 
August 1, 2021 $0.5957 $0.0293 
November 1, 2021 $0.5998 $0.0252 
February 1, 2022 $0.6040 $0.0210 
May 1, 2022 $0.6081 $0.0169 
August 1, 2022 $0.6123 $0.0127 
November 1, 2022 $0.6165 $0.0085 
February 1, 2023 $0.6207 $0.0043 

Repurchase of Amortizing Notes at the Option of the Holder
If Elanco elects to exercise its early mandatory settlement right with respect to the purchase contracts, then holders of the amortizing notes (whether as components of Units or separate amortizing notes) will have the right (the “repurchase right”) to require Elanco to repurchase some or all of their amortizing notes for cash at the repurchase price per amortizing note to be repurchased on the repurchase date, as described below. Holders may not require Elanco to repurchase a portion of an amortizing note. Holders will not have the right to require Elanco to repurchase any or all of such holder’s amortizing notes in connection with any early settlement of such holder’s purchase contracts at the holder’s option, as described above under “Description of the Purchase Contracts — Early Settlement” and “Description of the Purchase Contracts — Early Settlement Upon a Fundamental Change.”
The “repurchase date” will be a date specified by Elanco in the early mandatory settlement notice, which will be at least 20 but not more than 35 business days following the date of Elanco’s early mandatory settlement notice as described under “Description of the Purchase Contracts — Early Mandatory Settlement at Elanco’s Election” (and which may or may not fall on the early mandatory settlement date).
The “repurchase price” per amortizing note to be repurchased will be equal to the principal amount of such amortizing note as of the repurchase date, plus accrued and unpaid interest on such principal amount from, and including, the immediately preceding installment payment date to, but not including, the repurchase date, calculated at an annual rate of 2.75%; provided that, if the repurchase date falls after a regular record date for any installment payment and on or prior to the immediately succeeding installment payment date, the installment payment payable on such installment payment date will be paid on such installment payment date to the holder as of such regular record date and will not be included in the repurchase price per amortizing note.
To exercise the holder’s repurchase right, the holder must deliver, on or before 5:00 p.m., New York City time, on the business day immediately preceding the repurchase date, the amortizing notes to be repurchased (or the Units, if the early mandatory settlement date occurs on or after the repurchase date and the holder has not separated their Units into their constituent components), together with a duly completed written repurchase notice in the form entitled “Form of Repurchase Notice” on the reverse side of the amortizing notes (a “repurchase notice”), in each case, in accordance with appropriate DTC procedures, unless the holders holds certificated amortizing notes (or Units), in which case the holder must deliver the amortizing notes to be repurchased (or Units), duly endorsed for transfer, together with a repurchase notice, to the paying agent. The holder’s repurchase notice must state:
27

•if certificated amortizing notes (or Units) have been issued, the certificate numbers of the amortizing notes (or Units), or if not certificated, the holder’s repurchase notice must comply with appropriate DTC procedures;
•the number of amortizing notes to be repurchased; and
•that the amortizing notes are to be repurchased by Elanco pursuant to the applicable provisions of the amortizing notes and the indenture.
The holder may withdraw any repurchase notice (in whole or in part) by a written, irrevocable notice of withdrawal delivered (in the case of an amortizing note in global form, in accordance with the appropriate DTC procedures) on or before 5:00 p.m., New York City time, on the business day immediately preceding the repurchase date. The notice of withdrawal must state:
•if certificated amortizing notes (or Units) have been issued, the certificate numbers of the withdrawn amortizing notes (or Units), or if not certificated, the holder’s notice must comply with appropriate DTC procedures;
•the number of the withdrawn amortizing notes; and
•the number of amortizing notes, if any, that remain subject to the repurchase notice.
Elanco will be required to repurchase the amortizing notes on the repurchase date. The holder will receive payment of the repurchase price on the later of (i) the repurchase date and (ii) the time of book-entry transfer or the delivery of the amortizing notes. If the trustee holds money sufficient to pay the repurchase price of the amortizing notes to be purchased on the repurchase date, then:
•such amortizing notes will cease to be outstanding and interest will cease to accrue (whether or not book-entry transfer of the amortizing notes is made or whether or not the amortizing notes are delivered to the trustee); and
•all other rights of the holder will terminate (other than the right to receive the repurchase price and, if the repurchase date falls between a regular record date and the corresponding installment payment date, the related installment payment).
In connection with any repurchase offer pursuant to an early mandatory settlement notice, Elanco will, if required, comply with the provisions of the tender offer rules under the Exchange Act that may then be applicable.
No amortizing notes may be repurchased at the option of holders if the principal amount thereof has been accelerated, and such acceleration has not been rescinded, on or prior to the repurchase date (except in the case of an acceleration resulting from a default by Elanco of the payment of the repurchase price with respect to such amortizing notes).
Events of Default
Each of the following will be an “event of default” under the indenture with respect to the amortizing notes:
(1)default in the payment of any installment payment on any amortizing notes as and when the same shall become due and payable and continuance of such failure for a period of 30 days;
(2)default in the payment of the repurchase price of any amortizing notes when the same shall become due and payable;
28

(3)Elanco’s failure to give notice of a fundamental change as described under “Description of the Purchase Contracts — Early Settlement Upon a Fundamental Change” when due and continuance of such failure for a period of five business days;
(4)Elanco ‘s failure to perform for 90 days after notice any other covenant in the amortizing notes or the indenture; and
(5)certain events of bankruptcy or insolvency of Elanco, whether voluntary or not.
Notwithstanding anything to the contrary herein, in no event shall the consummation of the Acquisition and related transactions constitute an event of default under the indenture.
If an event of default (other than an event of default described in clause (5) above) occurs and is continuing, either the trustee or the holders of not less than 25% in the principal amount of outstanding amortizing notes may, by written notice to Elanco (and to the trustee if given by the holders), declare to be due and payable immediately the principal of and accrued and unpaid interest, if any, on the amortizing notes. In the case of an event of default described in clause (5) above, the principal amount of and accrued and unpaid interest, if any, on the amortizing notes will automatically become due and payable. Upon such a declaration of acceleration, such principal and accrued and unpaid interest, if any, will be due and payable immediately.
At any time after a declaration of acceleration with respect to the amortizing notes has been made, but before a judgment or decree for payment of the money due has been obtained by the trustee, the holders of a majority in principal amount of the outstanding amortizing notes, by written notice to Elanco and the trustee, may rescind and annul such declaration and its consequences if (1) Elanco has paid or deposited with the trustee a sum sufficient to pay (i) all overdue installments of interest on such amortizing notes, (ii) all principal of the amortizing notes which has become due otherwise than by such declaration of acceleration and any interest thereon, (iii) to the extent enforceable under applicable law, interest upon overdue installments of interest and principal, and (iv) amounts payable to the trustee and (2) all events of default, other than the non-payment of the principal with respect to the amortizing notes which have become due solely by such declaration of acceleration, have been cured or waived as provided in the indenture.
The indenture provides that the trustee will be under no obligation to exercise any of its rights or powers under the indenture unless the trustee receives security or indemnity reasonably satisfactory to it against any loss, liability or expense. Subject to certain rights of the trustee, the holders of a majority in principal amount of the amortizing notes will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee or exercising any trust or power conferred on the trustee with respect to the amortizing notes.
No holder of any amortizing notes will have any right to institute any proceeding, judicial or otherwise, with respect to the indenture or for the appointment of a receiver or trustee, or for any remedy under the indenture, unless:
•such holder has previously given to the trustee written notice of a continuing event of default with respect to the amortizing notes; and
•the holders of not less than 25% in principal amount of the outstanding amortizing notes have made written request, and offered reasonable indemnity, to the trustee to institute the proceeding as trustee, and after receipt of such request the trustee has not received from the holders of a majority in principal amount of the amortizing notes a direction inconsistent with that request and has failed to institute the proceeding within 60 days.
Notwithstanding the foregoing, the holder of any amortizing note will have an absolute and unconditional right to receive payment of the principal of and any interest on that amortizing note on or after the due dates
29

expressed in that amortizing note and to institute suit for the enforcement of any such payment, and such rights shall not be impaired without the consent of such holder.
The indenture requires Elanco to furnish to the trustee upon request a statement as to compliance with the indenture. The indenture provides that the trustee may withhold notice to the holders of the amortizing notes of any default or event of default (except in payment on any amortizing notes) with respect to the amortizing notes if it in good faith determines that withholding notice is in the interest of the holders of those amortizing notes.
Discharge and Defeasance of Indenture
After Elanco has deposited with the trustee, cash or government securities, in trust for the benefit of the holders of the amortizing notes, sufficient to pay the portion of all future scheduled installment payments constituting the payment of principal in respect of the amortizing notes and the portion of the repurchase price constituting the principal amount of the amortizing notes, and the portion of all future scheduled installment payments constituting the payment of interest in respect of the amortizing notes and the portion of the repurchase price constituting the accrued but unpaid interest on the amortizing notes when due, and satisfied certain other conditions, including (in the case of defeasance only) receipt of an opinion of counsel that holders of the amortizing notes will not recognize taxable gain or loss for United States federal income tax purposes, then:
•Elanco will be deemed to have paid and satisfied Elanco’s obligations on all outstanding amortizing notes, which is known as defeasance and discharge; or
•Elanco will cease to be under any obligation, other than to pay when due the principal of, premium, if any, and interest on amortizing notes, which is known as covenant defeasance.
When there is a defeasance and discharge, the indenture will no longer govern the amortizing notes, Elanco will no longer be liable for payments required by the terms of the amortizing notes and the holders thereof will be entitled only to the deposited funds. When there is a covenant defeasance, however, Elanco will continue to be obligated to make payments when due if the deposited funds are not sufficient.
Consolidation, Merger, Conveyance, Transfer or Lease
The indenture will provide that Elanco will not consolidate or merge with or into any other entity, or sell, transfer, lease or otherwise convey its properties and assets as an entirety or substantially as an entirety to any entity, unless:
•(i) it is the continuing entity (in the case of a merger), or (ii) the successor entity formed by such consolidation or into which it is merged or which acquires by sale, transfer, lease or other conveyance of its properties and assets, as an entirety or substantially as an entirety, is a corporation organized and existing under the laws of the United States of America or any State thereof, the District of Columbia or any territory thereof, and expressly assumes, by supplemental indenture, the due and punctual payment of the installment payments on all amortizing notes and the performance of all of the covenants under the indenture; and
•immediately after giving effect to the transaction, no event of default, and no event which after notice or lapse of time or both would become an event of default under the indenture, has or will have occurred and be continuing.
Notwithstanding anything to the contrary herein, in no event shall the Acquisition and related transactions be limited by this “— Consolidation, Merger, Conveyance, Transfer or Lease.”
Although there is a limited body of case law interpreting the phrase “substantially as an entirety,” there is no precise established definition of the phrase under applicable law. Accordingly, in certain circumstances there may be a degree of uncertainty as to whether a particular transaction would involve a disposition of Elanco’s properties
30

and assets “substantially as an entirety.” As a result, it may be unclear as to whether the foregoing restrictions on mergers, consolidations, sales, conveyances, transfers, leases and other dispositions would apply to a particular transaction as described above absent a decision by a court of competent jurisdiction.
Modifications and Amendments
Elanco and the trustee may amend or supplement the indenture or the amortizing notes without consent of the holders to:
•cure any ambiguity, omission, defect or inconsistency in the indenture;
•provide for the assumption by a successor corporation as set forth in “— Consolidation, Merger, Conveyance, Transfer or Lease;”
•comply with any requirements of the Securities and Exchange Commission in connection with the qualification of the indenture under the Trust Indenture Act;
•to evidence and provide for the acceptance of appointment with respect to the amortizing notes by a successor trustee in accordance with the indenture, and add or change any of the provisions of the indenture as shall be necessary to provide for or facilitate the administration of the trusts under the indenture by more than one trustee;
•secure the notes;
•add guarantees with respect to the notes;
•add covenants or events of default for the benefit of the holders or surrender any right or power conferred upon Elanco; and
•make any change that does not adversely affect the rights of any holder in any material respect.
In addition, Elanco may modify and amend the indenture or the amortizing notes as to all other matters with the consent of the holders of at least a majority in principal amount of the outstanding amortizing notes; provided, however, that Elanco may not make any modification or amendment to the indenture or the amortizing notes without the consent of each holder affected thereby if that modification or amendment will:
•change any installment payment date or reduce the amount owed on any installment payment date;
•reduce the repurchase price or amend or modify in any manner adverse to the holders of the amortizing notes Elanco’s obligation to make such payment;
•reduce the percentage in principal amount of amortizing notes whose holders must consent to an amendment of the indenture;
•make any change in the amendment provisions that require each holder’s consent or in the waiver provisions of the indenture; or
•impair the right of any holder to receive payment of principal and interest on such holder’s amortizing notes on or after the due dates therefor or the right to institute suit for the enforcement of any such payment on or after the due dates therefor.
31

Governing Law
The indenture and the amortizing notes are governed by and construed in accordance with the laws of the State of New York.
Waiver of Jury Trial
The indenture provides that Elanco and the trustee will waive their respective rights to trial by jury in any action or proceeding arising out of or related to the amortizing notes, the indenture or the transactions contemplated thereby, to the maximum extent permitted by law.
Information Concerning the Trustee
Deutsche Bank Trust Company Americas is the trustee under the indenture for the amortizing notes. Elanco and certain of its affiliates maintain deposit accounts and banking relationships with Deutsche Bank Trust Company Americas. Affiliates of Deutsche Bank Trust Company Americas have purchased, and are likely to purchase in the future, Elanco’s securities and securities of its affiliates.
As trustee under the indenture, Deutsche Bank Trust Company Americas will perform only those duties that are specifically described in the indenture unless an event of default under the indenture occurs and is continuing. It is under no obligation to exercise any of its powers under the indenture at the request of any holder of amortizing notes unless that holder offers reasonable indemnity to the trustee against the costs, expenses and liabilities which it might incur as a result.
Deutsche Bank Trust Company Americas administers its corporate trust business at 60 Wall Street, 24th Floor, New York, NY 10005 or such other address as it may notify to Elanco from time to time.
Book-Entry Procedures and Settlement
The Units, the separate purchase contracts and the separate amortizing notes have been issued under a book-entry system in the form of global securities. Elanco has registered the global securities in the name of The Depository Trust Company, New York, New York, or DTC, or its nominee and will deposit the global securities with that depositary.
Following the issuance of a global security in registered form, the depositary will credit the accounts of its participants with the Units, the separate purchase contracts and the separate amortizing notes, as the case may be, upon Elanco’s instructions. Only persons who hold directly or indirectly through financial institutions that are participants in the depositary can hold beneficial interests in the global securities. Because the laws of some jurisdictions require certain types of purchasers to take physical delivery of such securities in definitive form, a purchaser may encounter difficulties in its ability to own, transfer or pledge beneficial interests in a global security.
So long as the depositary or its nominee is the registered owner of a global security, Elanco, the trustee and the purchase contract agent will treat the depositary as the sole owner or holder of the Units, the separate purchase contracts and the separate amortizing notes, as the case may be. Therefore, except as set forth below, owners of beneficial interests will not be entitled to have Units, separate purchase contracts or separate amortizing notes registered in their name or to receive physical delivery of certificates representing the Units, the separate purchase contracts or the separate amortizing notes. Accordingly, owners of beneficial interests will have to rely on the procedures of the depositary and the participant in the depositary through whom they hold their beneficial interest in order to exercise any rights of a holder under the indenture or the purchase contract agreement, as the case may be. Elanco understands that under existing practices, the depositary would act upon the instructions of a participant or authorize that participant to take any action that a holder is entitled to take.
As long as the separate amortizing notes are represented by the global securities, Elanco will pay installments on those separate amortizing notes to or as directed by DTC as the registered holder of the global
32

securities. Payments to DTC will be in immediately available funds by wire transfer. DTC will credit the relevant accounts of their participants on the applicable date. Neither Elanco nor the trustee will be responsible for making any payments to participants or customers of participants or for maintaining any records relating to the holdings of participants and their customers, and beneficial owners will have to rely on the procedures of the depositary and its participants.
Settlement
Secondary market trading between DTC participants will occur in the ordinary way in accordance with DTC rules and will be settled in immediately available funds using DTC’s Same-Day Funds Settlement System.
Definitive Securities and Paying Agents
Book-entry securities represented by a global security will be exchanged for definitive (paper) securities only if:
•the depositary is at any time unwilling or unable to continue as depositary for such security or ceases to be a clearing agency registered under the Exchange Act, and a successor depositary registered as a clearing agency under the Exchange Act is not appointed by Elanco within 90 days; or
•an Event of Default with respect to the amortizing notes, or any failure on the part of Elanco to observe or perform any covenant or agreement in the purchase contracts, has occurred and is continuing and a beneficial owner requests that its amortizing notes and/or purchase contracts, as the case may be, be issued in physical, certificated form.
The global security will be exchangeable in whole for definitive securities in registered form, with the same terms and of an equal aggregate principal amount. Definitive Units, separate purchase contracts or separate amortizing notes, as the case may be, will be registered in the name or names of the person or persons specified by the depositary in a written instruction to the registrar of the securities. The depositary may base its written instruction upon directions it receives from its participants.
If any of the events described above occurs, then the beneficial owners will be notified through the chain of intermediaries that definitive securities are available and notice will be published as described below under “—Notices.” Beneficial owners of book-entry Units, separate purchase contracts or separate amortizing notes, as the case may be, will then be entitled (1) to receive physical delivery in certificated form of definitive Units, separate purchase contracts or separate amortizing notes, as the case may be, equal in aggregate amount of Units, separate purchase contracts or separate amortizing notes, as the case may be, to their beneficial interest and (2) to have the definitive securities registered in their names. Thereafter, the holders of the definitive Units, separate purchase contracts and separate amortizing notes, as the case may be, will be recognized as the “holders” of the Units, separate amortizing notes and separate purchase contracts for purposes of the purchase contract agreement and indenture, respectively.
Each of the purchase contract agreement and indenture provides for the replacement of a mutilated, lost, stolen or destroyed definitive security, so long as the applicant furnishes to Elanco and the trustee such security or indemnity and such evidence of ownership as Elanco and the trustee may require.
In the event definitive separate amortizing notes are issued, the holders thereof will be able to receive installment payments at the office of Elanco’s paying agent. The final installment payment of a definitive separate amortizing note may be made only against surrender of the separate amortizing note to one of Elanco’s paying agents. Elanco also has the option of making installment payments by mailing checks to the registered holders of the separate certificated amortizing notes.
33

In the event definitive Units, separate purchase contracts or separate amortizing notes are issued, the holders thereof will be able to transfer their securities, in whole or in part, by surrendering such securities for registration of transfer at the office specified in the purchase contract agreement or the indenture, as applicable. A form of such instrument of transfer will be obtainable at the relevant office. Upon surrender, Elanco will execute, and the purchase contract agent and the trustee will authenticate and deliver, new Units, separate purchase contracts or separate amortizing notes, as the case may be, to the designated transferee in the amount being transferred, and a new security for any amount not being transferred will be issued to the transferor. Such new securities will be delivered free of charge at the relevant office, as requested by the owner of such new Units, separate purchase contracts or separate amortizing notes. Elanco will not charge any fee for the registration of transfer or exchange, except that Elanco may require the payment of a sum sufficient to cover any applicable tax or other governmental charge payable in connection with the transfer.
Notices
So long as the global securities are held on behalf of DTC or any other clearing system, notices to holders of securities represented by a beneficial interest in the global securities may be given by delivery of the relevant notice to DTC or the alternative clearing system, as the case may be. So long as the amortizing notes are in the form of global securities, any notice will be deemed to have been given on the date given to DTC or the alternative clearing system, as the case may be.
34
 EX-21.1 3 ex211elanco-20191231su.htm EX-21.1 Document
SUBSIDIARIES OF THE COMPANY
EXHIBIT 21.1
The following is a list of subsidiaries of the company as of December 31, 2019, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary.



Subsidiary NameJurisdiction
Aratana Therapeutics, Inc.United States
ChemGen CorporationMassachusetts
Dista Products LimitedUnited Kingdom
Elanco (Shanghai) Animal Health Co., Ltd.China
Elanco (Taiwan) Animal Health Co. Ltd. (FKA: Lohmann Animal Health (Farmosa) Co. Ltd.)Taiwan
Elanco (Thailand) Ltd. (FKA: Lohmann Animal Health (Thailand) Co., Ltd.)Thailand
Elanco Animal Health (Pty) Ltd.South Africa
Elanco Animal Health UK Limited (FKA: Novartis Animal Health UK Limited)United Kingdom
Elanco Animal Health, Korea, Ltd.Korea
Elanco Animal Vaccines Limited (FKA: Novartis Animal Vaccines Limited)United Kingdom
Elanco Argentina S.R.L. (later Elanco S.R.L.)Argentina
Elanco Australasia Pty. Ltd.Australia
Elanco Australia Holding Pty LimitedAustralia
Elanco Bangladesh LimitedBangladesh
Elanco Belgium BVBABelgium
Elanco Brazil Holdings LtdaBrazil
Elanco Canada LimitedCanada
Elanco Centre de Recherche Sante Animale SASwitzerland
Elanco Chile SpAChile
Elanco Colombia S.A.S.Colombia
Elanco Denmark ApSDenmark
Elanco Denmark ApS -- Norway BranchNorway
Elanco Denmark ApS -- Sweden BranchSweden
Elanco Deutschland GmbHGermany
Elanco Europe GmbHSwitzerland
Elanco Europe Ltd.United Kingdom
Elanco Financing S.A.Switzerland
Elanco France S.A.S. (FKA: Novartis Sante Animale S.A.S.France
Elanco GmbHGermany
Elanco Hayvan Sağlığı Limited ŞirketiTurkey
Elanco India Private LimitedIndia
Elanco Innovation and Alliance Centre India LLPIndia
Elanco International, Inc.Indiana
Elanco Ireland LimitedIreland
Elanco Italia S.p.A. (FKA: Novartis Animal Health S.p.A.)Italy
Elanco Japan K.K .Japan
Elanco Malaysia Sdn BhdMalaysia
Elanco Nederland B.V.Netherlands
Elanco Netherlands Holding B.V.Netherlands
Elanco New ZealandNew Zealand

SUBSIDIARIES OF THE COMPANY
EXHIBIT 21.1
The following is a list of subsidiaries of the company as of December 31, 2019, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary.


Elanco Philippines Inc.Philippines
Elanco Polska spółka z ograniczoną odpowiedzialnościąPoland
Elanco Rus Ltd.Russia
Elanco Salud Animal S.A. de C.V.Mexico
Elanco Saude Animal Ltda. (FKA: Novartis Saude Animal Ltda)Brazil
Elanco Shanghai - Beijing BranchChina
Elanco Spain S.L. - Portugal BranchPortugal
Elanco Spain, S.L. (FKA: Novartis Sanidad Animal, S.L.U.)Spain
Elanco Tiergesundheit AG -- Austria BranchAustria
Elanco Tiergesundheit AG -- Czech BranchCzech
Elanco Tiergesundheit AG -- Egypt Representative OfficeEgypt
Elanco Tiergesundheit AG -- Hungary BranchHungary
Elanco Tiergesundheit AG -- Lebanon Representative OfficeLebanon
Elanco Tiergesundheit AG -- Poland BranchPoland
Elanco Tiergesundheit AG -- Saudi Arabia BranchSaudi Arabia
Elanco Tiergesundheit AG - South AfricaSouth Africa
Elanco Tiergesundheit AG -- Vietnam Representative OfficeVietnam
Elanco Tiergesundheit AG (FKA: Novartis Tiergesundheit AG)Switzerland
Elanco Tiergesundheit AG --Tunisia Representative OfficeTunisia
Elanco UK AH LimitedUnited Kingdom
Elanco US Inc.Delaware
Elanco Veterina SVN d.o.o. (FKA: Novartis Veterina d.o.o.)Slovenia
Immuno-Vet Services (Pty) Ltd. South AfricaSouth Africa
Immunovet Services Zambia Ltd.South Africa
Ivy Animal Health, Inc.Delaware
Lohmann Animal Health (Malaysia) Sdn. BhdMalaysia
Lohmann Animal Health Beteiligungs GmbHGermany
Lohmann Animal Health GmbHGermany
Lohmann Animal Health International Inc.Maine
Lohmann Animal Health Phils. Corp.Philippines
Lohmann Animal Health South Africa (Pty) Ltd.South Africa
Lohmann Asia Holding Co. Ltd.Thailand
Prevtec do BrasilBrazil
Prevtec Microbia GmbHGermany
Prevtec Microbia HK Ltd.China
Prevtec Microbia Inc.Canada
Pt. Lohmann Elanco Animal Health Indonesia (FKA: Pt. Lohmann Animal Health Indonesia)Indonesia
Vericore LimitedUnited Kingdom
Vet Therapeutics, Inc.United States



 EX-23.1 4 ex231elanco-20191231xe.htm EX-23.1 Document

EXHIBIT 23.1

Consent of Independent Registered Public Accounting Firm
 
We consent to the incorporation by reference in the Registration Statements (Form S-3 ASR No. 333-235991 and Form S-8 333-227447) of Elanco Animal Health Incorporated and in the related Prospectus of our reports dated February 28, 2020, with respect to the consolidated and combined financial statements of Elanco Animal Health Incorporated, and the effectiveness of internal control over financial reporting of Elanco Animal Health Incorporated, included in this Annual Report (Form 10-K) for the year ended December 31, 2019.

/s/ Ernst & Young LLP        
Indianapolis, Indiana
February 28, 2020

 EX-31.1 5 ex311elanco-20191231ce.htm EX-31.1 Document

EXHIBIT 31.1
CERTIFICATIONS
I, Jeffrey N. Simmons, certify that:
1. I have reviewed this report on Form 10-K of Elanco Animal Health Incorporated;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:February 28, 2020
By:/s/ Jeffrey N. Simmons
Jeffrey N. Simmons
President and Chief Executive Officer


 EX-31.2 6 ex312elanco-20191231ce.htm EX-31.2 Document

EXHIBIT 31.2
CERTIFICATIONS
I, Todd S. Young, certify that:
1. I have reviewed this report on Form 10-K of Elanco Animal Health Incorporated;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:February 28, 2020
By:/s/ Todd S. Young
Todd S. Young
Executive Vice President and Chief Financial Officer


 EX-32 7 ex32elanco-20191231x13.htm EX-32 Document

EXHIBIT 32

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Elanco Animal Health Incorporated, an Indiana corporation (the “Company”), does hereby certify that, to the best of their knowledge:

The Annual Report on Form 10-K for the year ended December 31, 2019 (the “Form 10-K”) of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.
 





Date:February 28, 2020 /s/Jeffrey N. Simmons
   Jeffrey N. Simmons
   President and Chief Executive Officer
    
    
   

Date:February 28, 2020 /s/Todd S. Young
   Todd S. Young
   Executive Vice President and Chief Financial Officer



 EX-101.SCH 8 elan-20191231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 000010001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010002 - Statement - Consolidated and Combined Statements of Operations link:presentationLink link:calculationLink link:definitionLink 100020003 - Statement - Consolidated and Combined Statements of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 100030004 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100040005 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100050006 - Statement - Consolidated and Combined Statement of Cash Flows link:presentationLink link:calculationLink link:definitionLink 100060007 - Statement - Consolidated and Combined Statements of Equity link:presentationLink link:calculationLink link:definitionLink 210011001 - Disclosure - Nature of Business and Organization link:presentationLink link:calculationLink link:definitionLink 240024001 - Disclosure - Nature of Business and Organization (Details) link:presentationLink link:calculationLink link:definitionLink 210031002 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 220042001 - Disclosure - Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 210051003 - Disclosure - Impact of Separation link:presentationLink link:calculationLink link:definitionLink 240064002 - Disclosure - Impact of Separation (Details) link:presentationLink link:calculationLink link:definitionLink 210071004 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 230083001 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 240094003 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 210101005 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 230113002 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 240124004 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 240134005 - Disclosure - Revenue - Summary of Activity in Sales Rebates and Discounts Liability (Details) link:presentationLink link:calculationLink link:definitionLink 240144006 - Disclosure - Revenue - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 210151006 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 230163003 - Disclosure - Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 240174007 - Disclosure - Acquisitions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 240184008 - Disclosure - Acquisitions - Summary of Amounts Recognized for Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 210191007 - Disclosure - Asset Impairment, Restructuring and Other Special Charges link:presentationLink link:calculationLink link:definitionLink 230203004 - Disclosure - Asset Impairment, Restructuring and Other Special Charges (Tables) link:presentationLink link:calculationLink link:definitionLink 240214009 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Total Charges Related to Asset Impairment, Restructuring and Other Special Charges (Details) link:presentationLink link:calculationLink link:definitionLink 240224010 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Summary of Activity in Reserves (Details) link:presentationLink link:calculationLink link:definitionLink 210231008 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 230243005 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 240254011 - Disclosure - Inventories - Schedule of Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 240264012 - Disclosure - Inventories - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 210271009 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 230283006 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 240294013 - Disclosure - Debt - Schedule of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 240294013 - Disclosure - Debt - Schedule of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 240304014 - Disclosure - Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 210311010 - Disclosure - Financial Instruments and Fair Value link:presentationLink link:calculationLink link:definitionLink 230323007 - Disclosure - Financial Instruments and Fair Value (Tables) link:presentationLink link:calculationLink link:definitionLink 240334015 - Disclosure - Financial Instruments and Fair Value - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 240344016 - Disclosure - Financial Instruments and Fair Value - Summary of Fair Value Information (Details) link:presentationLink link:calculationLink link:definitionLink 210351011 - Disclosure - Goodwill and Intangibles link:presentationLink link:calculationLink link:definitionLink 230363008 - Disclosure - Goodwill and Intangibles (Tables) link:presentationLink link:calculationLink link:definitionLink 240374017 - Disclosure - Goodwill and Intangibles - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 240384018 - Disclosure - Goodwill and Intangibles - Components of Intangible Assets Other Than Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 240384018 - Disclosure - Goodwill and Intangibles - Components of Intangible Assets Other Than Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 240394019 - Disclosure - Goodwill and Intangibles - Remaining Weighted Average Amortization Periods (Details) link:presentationLink link:calculationLink link:definitionLink 240404020 - Disclosure - Goodwill and Intangibles - Estimated Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 210411012 - Disclosure - Intangible Assets, Goodwill and Other link:presentationLink link:calculationLink link:definitionLink 230423009 - Disclosure - Intangible Assets, Goodwill and Other (Tables) link:presentationLink link:calculationLink link:definitionLink 240434021 - Disclosure - Intangible Assets, Goodwill and Other (Details) link:presentationLink link:calculationLink link:definitionLink 210441013 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 230453010 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 240464022 - Disclosure - Property and Equipment - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 240474023 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 240484024 - Disclosure - Property and Equipment - Depreciation Expense and Rental Expense for All Leases (Details) link:presentationLink link:calculationLink link:definitionLink 210491014 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 230503011 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 240514025 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 240524026 - Disclosure - Leases - Impact of Operating Leases to Condensed Consolidated Financial Statements (Details) link:presentationLink link:calculationLink link:definitionLink 240534027 - Disclosure - Leases - Supplemental Balance Sheet Information Related to Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 240544028 - Disclosure - Leases - Annual Minimum Lease Payments of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 240544028 - Disclosure - Leases - Annual Minimum Lease Payments of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 210551015 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 230563012 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 240574029 - Disclosure - Stock-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 240584030 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 240594031 - Disclosure - Stock-Based Compensation - Schedule of Restricted Stock Unit and Performance Award Activity (Details) link:presentationLink link:calculationLink link:definitionLink 240604032 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used (Details) link:presentationLink link:calculationLink link:definitionLink 240614033 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 210621016 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 230633013 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 240644034 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 240654035 - Disclosure - Income Taxes - Composition of Income (Loss) Before Income Tax Expense (Benefit) (Details) link:presentationLink link:calculationLink link:definitionLink 240664036 - Disclosure - Income Taxes - Composition of Income Tax Expense (Benefit) (Details) link:presentationLink link:calculationLink link:definitionLink 240674037 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 240684038 - Disclosure - Income Taxes - Movements in the Valuation Allowance (Details) link:presentationLink link:calculationLink link:definitionLink 240694039 - Disclosure - Income Taxes - Cash Payments of Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 240704040 - Disclosure - Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details) link:presentationLink link:calculationLink link:definitionLink 240714041 - Disclosure - Income Taxes - Reconciliation of Gross Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 240724042 - Disclosure - Income Taxes - Income Tax Expense (Benefit) Related to Interest and Penalties (Details) link:presentationLink link:calculationLink link:definitionLink 210731017 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 240744043 - Disclosure - Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 210751018 - Disclosure - Geographic Information link:presentationLink link:calculationLink link:definitionLink 230763014 - Disclosure - Geographic Information (Tables) link:presentationLink link:calculationLink link:definitionLink 240774044 - Disclosure - Geographic Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 240784045 - Disclosure - Geographic Information - Revenue and Long-lived Assets by Selected Geographic Area Information (Details) link:presentationLink link:calculationLink link:definitionLink 210791019 - Disclosure - Retirement Benefits link:presentationLink link:calculationLink link:definitionLink 230803015 - Disclosure - Retirement Benefits (Tables) link:presentationLink link:calculationLink link:definitionLink 240814046 - Disclosure - Retirement Benefits - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 240824047 - Disclosure - Retirement Benefits - Change in Benefit Obligation, Change in Plan Assets, and Funded Status (Details) link:presentationLink link:calculationLink link:definitionLink 240834048 - Disclosure - Retirement Benefits - Amounts Recognized in Combined Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 240844049 - Disclosure - Retirement Benefits - Weighted-Average Assumptions Related to Pension Plans (Details) link:presentationLink link:calculationLink link:definitionLink 240854050 - Disclosure - Retirement Benefits - Schedule of Expected Benefit Payments (Details) link:presentationLink link:calculationLink link:definitionLink 240864051 - Disclosure - Retirement Benefits - Projected Benefit Obligations in Excess of Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 240874052 - Disclosure - Retirement Benefits - Accumulated Benefit Obligations in Excess of Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 240884053 - Disclosure - Retirement Benefits - Net Pension Expense (Details) link:presentationLink link:calculationLink link:definitionLink 240894054 - Disclosure - Retirement Benefits - Amounts Recognized in Other Comprehensive Loss (Details) link:presentationLink link:calculationLink link:definitionLink 240904055 - Disclosure - Retirement Benefits - Fair Value of Pension Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 210911020 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 240924056 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 210931021 - Disclosure - Related Party Agreements and Transactions link:presentationLink link:calculationLink link:definitionLink 230943016 - Disclosure - Related Party Agreements and Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 240954057 - Disclosure - Related Party Agreements and Transactions - Amounts Due From/(Due To) Lilly (Details) link:presentationLink link:calculationLink link:definitionLink 240964058 - Disclosure - Related Party Agreements and Transactions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 240974059 - Disclosure - Related Party Agreements and Transactions - Allocation of Services (Details) link:presentationLink link:calculationLink link:definitionLink 210981022 - Disclosure - Selected Quarterly Data (unaudited) link:presentationLink link:calculationLink link:definitionLink 230993017 - Disclosure - Selected Quarterly Data (unaudited) (Tables) link:presentationLink link:calculationLink link:definitionLink 241004060 - Disclosure - Selected Quarterly Data (unaudited) (Details) link:presentationLink link:calculationLink link:definitionLink 211011023 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 231023018 - Disclosure - Subsequent Events (Tables) link:presentationLink link:calculationLink link:definitionLink 241034061 - Disclosure - Subsequent Events - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 241044062 - Disclosure - Subsequent Events - Divestitures (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 elan-20191231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 elan-20191231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 elan-20191231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Debt issuance costs Payments of Debt Issuance Costs Hedge funds Hedge Funds [Member] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Loss upon settlement of contingent consideration liability Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Lease cost Lease, Cost [Abstract] Stock compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition 2020 Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months Reduction of revenue Contract with Customer, Liability, Revenue Recognized Other net transactions with Lilly Proceeds From (Payments To) Transactions With Parent Proceeds From (Payments To) Transactions With Parent Real estate Defined Benefit Plan, Real Estate [Member] Public equity securities Defined Benefit Plan, Equity Securities [Member] Interest cost Defined Benefit Plan, Interest Cost Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Benefit payments Defined Benefit Plan, Expected Future Benefit Payment [Abstract] Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Type of Restructuring [Domain] Type of Restructuring [Domain] Decrease in pension benefit obligation Plan amendments Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment Proceeds from issuance of common stock (Note 1) Proceeds from Issuance of Common Stock Intellectual Property and Technology License Agreement Intellectual Property And Technology License Agreement [Member] Intellectual Property And Technology License Agreement [Member] Foreign currency exchange rate changes and other Other Comprehensive Income (Loss), Defined Benefit Plan, Foreign Currency Transaction And Translation Gain (Loss), Before Tax Other Comprehensive Income (Loss), Defined Benefit Plan, Foreign Currency Transaction And Translation Gain (Loss), Before Tax Current Fiscal Year End Date Current Fiscal Year End Date Fixed Income Securities Fixed Income Securities [Member] Carrying Amount Reported Value Measurement [Member] Outstanding at beginning of period (in shares) Outstanding at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Issuance of common stock Issuance of stock Stock Issued During Period, Value, New Issues Schedule of Selected Quarterly Data Quarterly Financial Information [Table Text Block] Accelerated stock based compensation Share-based Payment Arrangement, Accelerated Cost Property and equipment, net (Note 12) Property and equipment, net Property, Plant and Equipment, Net LIBOR London Interbank Offered Rate (LIBOR) [Member] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Basis points Debt Instrument, Basis Spread on Variable Rate Weighted-average remaining contractual term of the exercisable options Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Changes related to the impact of foreign currency translation Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation Cash and cash equivalents Defined Benefit Plan, Cash [Member] Repayments of debt Repayments of Long-term Debt Construction in progress Construction in Progress [Member] Contingent consideration liability Business Combination, Contingent Consideration, Liability Work in process Inventory, Work in Process, Gross Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Share-based Payment Arrangement [Abstract] Switzerland Foreign Plan [Member] Current Liabilities Liabilities, Current [Abstract] Purchase contract, shares issued upon conversion Purchase Contract, Shares Issued Upon Conversion Purchase Contract, Shares Issued Upon Conversion Credit Facility [Axis] Credit Facility [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Long-term debt - term credit facility Lines of Credit, Fair Value Disclosure Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Equity [Abstract] Equity [Abstract] Forfeited or expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Income Tax Authority [Domain] Income Tax Authority [Domain] Commitments and Contingencies (Note 16) Commitments and Contingencies Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Cash, cash equivalents and restricted cash at end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Debt extinguishment loss Gain (Loss) on Extinguishment of Debt Percentage of benefit obligation in Switzerland pension plans Defined Benefit Plan, Funded Percentage Debt Instrument [Line Items] Debt Instrument [Line Items] 5.00% Senior Amortizing Notes 5.00% Senior Amortizing Notes [Member] 5.00% Senior Amortizing Notes Noncash or Part Noncash Divestitures [Line Items] Noncash or Part Noncash Divestitures [Line Items] Expenses related to employees under Defined Contribution Plans Defined Contribution Plan, Cost Federal Income (Loss) from Continuing Operations before Income Taxes, Domestic 2022 Defined Benefit Plan, Expected Future Benefit Payment, Year Three Price per share (usd per share) Sale of Stock, Price Per Share Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Restricted cash (Note 20) Restricted cash Restricted Cash, Current Basis of Presentation Basis of Accounting [Text Block] Investments Valued at Net Asset Value Fair Value Measured at Net Asset Value Per Share [Member] Impairment of indefinite-lived intangible assets Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Unrecognized compensation cost Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Retirement Plan Type [Axis] Retirement Plan Type [Axis] Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Initial term Related Party Transaction, Term Of Contract Related Party Transaction, Term Of Contract Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Expenses Related to Certain Corporate Functions Selling, General and Administrative Expenses, Policy [Policy Text Block] Noncash or Part Noncash Divestitures [Table] Noncash or Part Noncash Divestitures [Table] 2023 Defined Benefit Plan, Expected Future Benefit Payment, Year Four Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Basic (usd per share) Earnings Per Share, Basic Inventories Inventory Disclosure [Text Block] Restatement [Domain] Restatement [Domain] Outstanding at beginning of period (usd per share) Outstanding at end of period (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Total Charges Related to Asset Impairment, Restructuring and Other Special Charges Restructuring and Related Costs [Table Text Block] Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Subsequent Event Type [Axis] Subsequent Event Type [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Year 1 Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months Consideration to Lilly in connection with Separation Stockholders' Equity, Consideration To Parent In Separation Stockholders' Equity, Consideration To Parent In Separation Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Weighted-Average Exercise Price of Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Other changes in operating assets and liabilities, net of acquisitions and divestitures: Increase (Decrease) in Operating Capital [Abstract] Customer [Axis] Customer [Axis] Actuarial gain (loss) arising during period Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax Interest expense, net of capitalized interest Interest Expense Class of Stock [Axis] Class of Stock [Axis] Plan Name [Domain] Plan Name [Domain] 2020 Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months Interest Expense Interest Expense [Member] Nature of Business and Organization Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Inventory write-offs Inventory Write-down Valuation Allowance, Deferred Tax Asset SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member] Expected stock price volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Other noncurrent assets/(liabilities) - cross currency interest rate contracts designated as net investment hedges Derivative Assets (Liabilities), at Fair Value, Net Accounts payable and other liabilities Increase (Decrease) in Accounts Payable and Other Operating Liabilities Percentage of total outstanding shares Sale of Stock, Percentage of Ownership before Transaction Consideration received for prepaid stock purchase contracts Sale of Stock, Consideration Received on Transaction, Prepaid Stock Purchase Contracts Sale of Stock, Consideration Received on Transaction, Prepaid Stock Purchase Contracts Document Type Document Type Marketed products Marketing-Related Intangible Assets [Member] Other-net, expense (income) Nonoperating Income (Expense) Entity Registrant Name Entity Registrant Name Amounts Recognized in Other Comprehensive Loss Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Total (approximates replacement cost) Inventory, Gross Prepaid expenses and other Prepaid Expense and Other Assets, Current Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Total other comprehensive income (loss) during period Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax Total current assets Assets, Current Net (decrease) increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Noncurrent Liabilities Liabilities, Noncurrent [Abstract] Net income (loss) Net income (loss) Net Income (Loss) Attributable to Parent Percentage of plan assets in Switzerland pension plans Defined Benefit Plan, Plan Assets, Concentration Of Risk, Percentage Defined Benefit Plan, Plan Assets, Concentration of Risk, Percentage Aggregate intrinsic value on exercise (usd per share) Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercised, Weighted Average Intrinsic Value Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercised, Weighted Average Intrinsic Value Current Assets Assets, Current [Abstract] Leases [Abstract] Debt Instrument [Axis] Debt Instrument [Axis] Other Defined Benefit Plan, Other Cost (Credit) Fair value of plan assets Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Benefits paid Defined Benefit Plan, Benefit Obligation, Benefits Paid Net Investment Hedging Net Investment Hedging [Member] Stock-based compensation Stock-based compensation expense Share-based Payment Arrangement, Expense Related Party Transaction [Domain] Related Party Transaction [Domain] After Year 5 Lessee, Operating Lease, Liability, Payments, Due after Year Five Noncurrent Assets Assets, Noncurrent [Abstract] Fair value of plan assets at beginning of year Fair value of plan assets at end of year Fair value of plan assets Defined Benefit Plan, Plan Assets, Amount Current portion of long term debt (Note 9) Less current portion of long-term debt Long-term Debt, Current Maturities Non-current operating lease liabilities Operating Lease, Liability, Noncurrent Property and equipment, net Property, Plant, And Equipment And Finance Lease Right-of-Use Asset, After Accumulated Depreciation And Amortization Property, Plant, And Equipment And Finance Lease Right-of-Use Asset, After Accumulated Depreciation And Amortization Preferred stock authorized (in shares) Preferred Stock, Shares Authorized Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Legal Entity [Axis] Legal Entity [Axis] Equity Stockholders' Equity Attributable to Parent [Abstract] Weighted-average grant date fair value per stock option (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Subsequent Events Subsequent Events [Text Block] Carrying Amount, Gross Intangible Assets, Gross (Excluding Goodwill) Estimated useful lives Finite-Lived Intangible Asset, Useful Life Severance and other costs Severance Costs Recurring Fair Value, Recurring [Member] Deferred tax assets: Components of Deferred Tax Assets [Abstract] Accounts receivable, net of allowances Accounts Receivable, Allowance for Credit Loss, Current Noncurrent assets Assets for Plan Benefits, Defined Benefit Plan Other foreign countries Other Foreign Countries Not Separately Disclosed [Member] Other Foreign Countries Not Separately Disclosed [Member] Subsequent Events [Abstract] Related Party Agreements and Transactions Related Party Transactions Disclosure [Text Block] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Operating cash outflows from operating leases Operating Lease, Payments Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Prevtec Prevtec Microbia, Inc. [Member] Prevtec Microbia, Inc. [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Foreign currency exchange rate changes and other adjustments Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Foreign Current Foreign Tax Expense (Benefit) Cash Payments of Income Taxes Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] State taxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Beginning balance Ending balance Contract with Customer, Liability Cash Flows from Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Service cost Defined Benefit Plan, Service Cost Designated as Hedging Instrument Designated as Hedging Instrument [Member] Related Party [Domain] Related Party [Domain] Underwriting Agreement Underwriting Agreement [Member] Underwriting Agreement Fair Value of Pension Plan Assets Schedule of Allocation of Plan Assets [Table Text Block] Weighted-average remaining contractual term of the outstanding options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Retained earnings Retained Earnings (Accumulated Deficit) Diluted (usd per share) Earnings Per Share, Diluted Net Pension Expense Schedule of Net Benefit Costs [Table Text Block] 4.272% Senior Notes due 2023 4.272% Senior Notes Due 2023 [Member] 4.272% Senior Notes Due 2023 [Member] Settlements Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Payable to Lilly (Note 20) Accounts Payable, Related Parties, Current Total receivable from/(payable to) Lilly Related Party Transaction, Due from (to) Related Party Minimum Minimum [Member] Accruals for payment of interest and penalties Income Tax Examination, Penalties and Interest Accrued Summary of Amounts Recognized for Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Veocoxan Veocoxan [Member] Veocoxan 2021 Finite-Lived Intangible Assets, Amortization Expense, Year Two Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Inventories Deferred Tax Assets, Inventory Balance Sheet Location [Domain] Balance Sheet Location [Domain] Reserve adjustment Restructuring Reserve, Accrual Adjustment Change in deferred income taxes Total deferred tax expense (benefit) Deferred Income Tax Expense (Benefit) Adjustments to reconcile net income (loss) to cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Asset write-down Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down Previously Reported Previously Reported [Member] Schedule of Stock Option Activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Net Cash Provided by (Used for) Financing Activities Net Cash Provided by (Used in) Financing Activities Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Reclassification of net parent company investment Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Income tax expense Income taxes Income tax (benefit) expense Income Tax Expense (Benefit) Inventories Disposal Group, Including Discontinued Operation, Inventory Year 2 Lessee, Operating Lease, Liability, Payments, Due Year Two Beginning balance Ending balance SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Multiemployer plans expense Multiemployer Plans, Cost Recognized Multiemployer Plans, Cost Recognized Property and equipment Deferred Tax Liabilities, Property, Plant and Equipment Deferred: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Other noncurrent liabilities Other Liabilities, Noncurrent Total assets held for sale Disposal Group, Including Discontinued Operation, Assets Decrease for plan amendment related to other costs and losses Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment, Changes In Certain Assumptions Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment, Changes In Certain Assumptions Consideration paid to Lilly in connection with the Separation (Note 1) Payments Of Separation Related Costs, Financing Activities Payments Of Separation Related Costs, Financing Activities Companion Animal Disease Prevention Companion Animal Disease Prevention [Member] Companion Animal Disease Prevention [Member] Other intangibles, net (Note 11) Carrying Amount, Net Intangible Assets, Net (Excluding Goodwill) Entity Well Known Seasoned Issuer Entity Well-known Seasoned Issuer Shares of common stock to be reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Gain (Loss) to AOCI, net of tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Net Of Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Net Of Tax Concentration Risk [Table] Concentration Risk [Table] BIVIVP Boehringer Ingelheim Vetmedica, Inc. Boehringer Ingelheim Vetmedica, Inc. [Member] Boehringer Ingelheim Vetmedica, Inc. [Member] Defined Benefit Pension and Retiree Health Benefit Plans Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Long-term debt, gross Borrowings outstanding Long-term Debt, Gross Assets Assets [Abstract] Receivables Increase (Decrease) in Accounts and Other Receivables Tax credit carryovers Deferred Tax Assets, Tax Credit Carryforwards Balance at beginning of period (in shares) Balance at end of period (in shares) Shares, Outstanding Number of operating segments Number of Operating Segments Total current tax expense Current Income Tax Expense (Benefit) Weighted-average remaining lease term - operating leases Operating Lease, Weighted Average Remaining Lease Term Stock split ratio Stockholders' Equity Note, Stock Split, Conversion Ratio Net proceeds from senior amortizing notes Proceeds from Issuance of Debt 2017 Tax Act Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount Less accumulated depreciation Property, Plant, And Equipment And Finance Lease Right-of-Use Asset, Accumulated Depreciation And Amortization Property, Plant, And Equipment And Finance Lease Right-of-Use Asset, Accumulated Depreciation And Amortization Purchases of software Payments to Acquire Software PAs Performance Shares [Member] Restructuring charges Restructuring, Settlement and Impairment Provisions [Abstract] Weighted average number diluted shares outstanding adjustment (in shares) Weighted Average Number Diluted Shares Outstanding Adjustment Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Extension term Related Party Transaction, Renewal Term Related Party Transaction, Renewal Term Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Measurement Basis [Axis] Measurement Basis [Axis] Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Carrying Amount, Net Finite-Lived Intangible Assets, Net Other assets and liabilities - net Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Assets And Other Liabilities, Net Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Assets And Other Liabilities, Net Customer [Domain] Customer [Domain] Derivative Instrument [Axis] Derivative Instrument [Axis] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Allocation of services Related Party Transaction, Expenses from Transactions with Related Party Range [Axis] Statistical Measurement [Axis] Total consideration transferred Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Income tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Amount Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Repayments of debt, principal Repayments Of Long-Term Debt, Principal Repayments Of Long-Term Debt, Principal Notional amount Derivative, Notional Amount Revenue recognition Revenue from Contract with Customer [Policy Text Block] Designated percentage invested Defined Benefit Plan, Plan Assets, Target Allocation, Percentage Prior year service cost during the year Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax Debt Debt Disclosure [Text Block] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] International, State and Federal Domestic, Foreign and State Tax Authorities [Member] Domestic, Foreign and State Tax Authorities [Member] Schedule of Weighted-Average Amortization Periods For Finite-Lived Intangible Assets Schedule of Intangible Assets and Goodwill [Table Text Block] Revenue by Selected Geographic Area Information Revenue from External Customers by Geographic Areas [Table Text Block] Variable lease cost Variable Lease, Cost Common stock authorized (in shares) Common Stock, Shares Authorized Accumulated Amortization Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Benefit and Combined Stock-Based Compensation Plans Compensation Related Costs, Policy [Policy Text Block] Derivative, term of contract Derivative, Term of Contract Beginning nonvested balance (in shares) Ending nonvested balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Marketing, selling and administrative Selling, General and Administrative Expense Other Related Party Activities Other Related Party Activities [Member] Other Related Party Activities [Member] Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense Long-term debt (Note 9) Total long-term debt Long-term Debt, Excluding Current Maturities Toll Manufacturing Arrangement Toll Manufacturing Arrangement [Member] Toll Manufacturing Arrangement [Member] State State and Local Jurisdiction [Member] Income Tax Income Tax, Policy [Policy Text Block] Proceeds from issuance of long-term debt (Note 9) Proceeds from Issuance of Senior Long-term Debt Rate of compensation increase for net benefit costs Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase Credit Facility [Domain] Credit Facility [Domain] Employee compensation Employee-related Liabilities, Current Decreased in prior service costs Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment, Prior Service Costs Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment, Prior Service Costs Significant Observable  Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Other permanent adjustments Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Amounts Recognized in Combined Balance Sheet Schedule of Amounts Recognized in Balance Sheet [Table Text Block] Preferred stock issued (in shares) Preferred Stock, Shares Issued Other Alternative Investments Other Alternative Investments [Member] Other Alternative Investments [Member] Net Revenue Revenue from Contract with Customer Benchmark [Member] Amendment Flag Amendment Flag Product Sales Product [Member] Fair value of plan assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets Non-cash and other items Asset Impairment Charges [Abstract] Liabilities and Equity Liabilities and Equity [Abstract] Other noncurrent assets Other Assets, Noncurrent Cash Flows from Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Other comprehensive income (loss), net of taxes Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax Derivative Contract [Domain] Derivative Contract [Domain] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Long-term debt Long-term Debt Over-Allotment Option Over-Allotment Option [Member] 2023 Finite-Lived Intangible Assets, Amortization Expense, Year Four Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Net operating loss carryforwards that expire Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration Purchase accounting adjustment Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory Retirement Plan Type [Domain] Retirement Plan Type [Domain] Gain on sale of fixed assets Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Summary of Activity in Sales Rebates and Discounts Liability Contract with Customer, Asset and Liability [Table Text Block] Other current liabilities Other Liabilities, Current Sale of Stock [Axis] Sale of Stock [Axis] Subsequent Event [Table] Subsequent Event [Table] Weighted-average remaining requisite service period Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Accounting Policies [Abstract] Accounting Policies [Abstract] Remaining lease terms Lessee, Operating Lease, Remaining Lease Term Lessee, Operating Lease, Remaining Lease Term Unrecognized tax benefits that, if recognized, would not affect effective tax rate Unrecognized Tax Benefits That Would Not Impact Effective Tax Rate Unrecognized Tax Benefits That Would Not Impact Effective Tax Rate Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document And Entity Information [Abstract] United States UNITED STATES Income tax at the U.S. federal statutory tax rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Operating lease liabilities Deferred Tax Assets, Operating Lease Right-Of-Use Liabilities Deferred Tax Assets, Operating Lease Right-Of-Use Liabilities Foreign Deferred Foreign Income Tax Expense (Benefit) Unrecognized prior service cost Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax Property and equipment, gross Property, Plant and Equipment, Gross Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Amounts recognized in the consolidated balance sheet consisted of: Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract] Geographical [Domain] Geographical [Domain] Composition of Income (Loss) Before Income Tax Expense (Benefit) Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Current: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Entity Voluntary Filers Entity Voluntary Filers Unrecognized net actuarial loss Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax Expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period IPO IPO [Member] Retirement Benefits [Abstract] Retirement Benefits [Abstract] Net Cash Used for Investing Activities Net Cash Provided by (Used in) Investing Activities Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Costs/(benefits) of defined benefit pension plan Pension Cost (Reversal of Cost) Separation entries related to the removal of the net operating losses Operating Loss Carryforwards, Separation Adjustments Operating Loss Carryforwards, Separation Adjustments Disposals of property and equipment Proceeds from Sale of Property, Plant, and Equipment Income Tax Authority [Axis] Income Tax Authority [Axis] Accounts payable Accounts Payable, Current Cash and cash equivalents Defined Benefit Plan, Cash and Cash Equivalents [Member] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Indefinite-lived Intangible Assets [Line Items] Indefinite-lived Intangible Assets [Line Items] Pro forma combined income before income taxes Business Combination, Pro Forma Information, Earnings or Loss Before Income Taxes of Acquiree since Acquisition Date, Actual Business Combination, Pro Forma Information, Earnings or Loss Before Income Taxes of Acquiree since Acquisition Date, Actual Geographic Concentration Risk Geographic Concentration Risk [Member] Common stock issued (in shares) Common Stock, Shares, Issued Food Animal Future Protein & Health Food Animal Future Protein And Health [Member] Food Animal Future Protein And Health [Member] Other obligations Notes Payable, Other Payables [Member] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Change in Benefit Obligation, Change in Plan Assets, and Funded Status Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block] Other receivables Other Receivables, Net, Current Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Revenue from related parties Revenue from Related Parties Other assets Increase (Decrease) in Other Operating Assets Granted (usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Issuance of common stock (in shares) Stock Issued During Period, Shares, New Issues Emerging markets Fixed Income Securities, Emerging Markets [Member] Fixed Income Securities, Emerging Markets [Member] Liabilities related to litigation Estimated Litigation Liability Accounting Standards Update 2016-02 Accounting Standards Update 2016-02 [Member] Revenue Revenue Benchmark [Member] Bridge Facility Bridge Facility [Member] Bridge Facility Cost of sales Cost of Sales [Member] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Benefit obligation at beginning of year Benefit obligation at end of year Defined Benefit Plan, Benefit Obligation Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Restatement [Axis] Restatement [Axis] Reconciliation of Income Tax Expense (Benefit) Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Common stock, 5,000,000,000 shares authorized, no par value; 373,011,513 and 365,643,911 shares issued and outstanding as of December 31, 2019 and 2018, respectively Common Stock, Value, Issued Schedule of Performance Awards Activity Share-based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block] Research and development Research and Development Expense Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Amortization of net actuarial loss Defined Benefit Plan, Amortization of Gain (Loss) Proceeds from divestiture Proceeds from Divestiture of Businesses Amortization of prior service cost included in net loss Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax Inventories Increase (Decrease) in Inventories Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Inventories valued under the LIFO method LIFO Inventory Amount Other Stockholders' Equity, Other Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Right-of-use assets Operating Lease, Right-of-Use Asset Stock Option Activity, Additional Disclosures Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Changes for tax positions of prior years Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Equity Components [Axis] Equity Components [Axis] Deferred tax liabilities - net Deferred Tax Liabilities, Net Foreign currency exchange rate changes and other adjustments Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) Property and equipment gross Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Entity Small Business Entity Small Business Single Customer Customer A [Member] Customer A [Member] Asset impairment charges Asset Impairment Charges, Including Inventory Write-Down Asset Impairment Charges, Including Inventory Write-Down Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Supplemental Balance Sheet Information Related to Operating Leases Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee Sales rebates and discounts Contract with Customer, Liability, Current Purchase contract conversion of stock ratio Purchase Contract Conversion Of Stock, Ratio Purchase Contract Conversion Of Stock, Ratio Components of Indefinite-Lived Intangible Assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Federal Current Federal Tax Expense (Benefit) Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] 2017 Tax Act Tax Cuts and Jobs Act, Incomplete Accounting, Provisional Income Tax Expense (Benefit) Impact of Operating Leases to Condensed Consolidated Financial Statements Lease, Cost [Table Text Block] Total identifiable net assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Depreciation and amortization Depreciation, Depletion and Amortization Variable Rate [Axis] Variable Rate [Axis] Contingent consideration Nonfinancial Liabilities Fair Value Disclosure Disposal Group Classification [Domain] Disposal Group Classification [Domain] Related Party Transaction [Axis] Related Party Transaction [Axis] Changes for tax positions of prior years Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Equity method investments Equity Method Investments Net Cash Provided by Operating Activities Net Cash Provided by (Used in) Operating Activities Outstanding Restricted Stock Units Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Asset impairment, restructuring and other special charges (Note 7) Total expense Asset impairment, restructuring, and other special charges Restructuring, Settlement and Impairment Provisions Other current liabilities- contingent consideration Other Current Liabilities [Member] Accumulated benefit obligation Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation Stock options Share-based Payment Arrangement, Option [Member] Unamortized debt issuance costs Debt Issuance Costs, Net Credit Facility Line of Credit [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] Restructuring and other reserves Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges Unaudited pro forma combined revenues Business Acquisition, Pro Forma Revenue Term Facility Term Loan [Member] Term Loan Income Statement [Abstract] Income Statement [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Accumulated Benefit Obligations in Excess of Plan Assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block] Related Party Transactions [Abstract] Related Party Transactions [Abstract] Valuation allowances Deferred Tax Assets, Valuation Allowance Land Land [Member] Release SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Foreign Currency Translation Foreign Currency Transactions and Translations Policy [Policy Text Block] Total current liabilities Liabilities, Current Deferred tax liabilities: Components of Deferred Tax Liabilities [Abstract] Amounts Due From/(Due To) Lilly and Allocations of Services Schedule of Related Party Transactions [Table Text Block] Add (deduct): Effective Income Tax Rate Reconciliation, Additions And Deductions [Abstract] Effective Income Tax Rate Reconciliation, Additions And Deductions [Abstract] Indefinite-lived intangible assets Indefinite-lived Intangible Assets (Excluding Goodwill) Discount rate for net benefit costs Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate Beginning balance Ending balance Unrecognized Tax Benefits Number of plans Defined Benefit Plan, Number Of Plans Defined Benefit Plan, Number Of Plans Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Concentration Risk [Line Items] Concentration Risk [Line Items] Implementation of New Financial Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Cost of sales Cost of Goods and Services Sold Elanco Stock Compensation Plans Elanco Stock Compensation Plans [Member] Elanco Stock Compensation Plans Net pension expense Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Repayments of borrowings (Note 9) Repayments of Senior Debt Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Property and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Unremitted earnings of foreign subsidiaries Undistributed Earnings of Foreign Subsidiaries Total assets Assets Foreign Exchange Contract Foreign Exchange Contract [Member] Exercised (usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Operating lease liabilities Total Operating Lease, Liability Manufacturing Support Manufacturing Support [Member] Manufacturing Support [Member] Common shares outstanding Noncontrolling Interest, Number Of Shares Owned By Parent Noncontrolling Interest, Number Of Shares Owned By Parent Subsequent Event Subsequent Event [Member] Schedule of Assumptions Used Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Impairment of finite-lived intangible assets Impairment of Intangible Assets, Finite-lived Variable Rate [Domain] Variable Rate [Domain] IPO and separation costs Effective Income Tax Rate Reconciliation, Nondeductible Expense, Stock Issuance Costs Effective Income Tax Rate Reconciliation, Nondeductible Expense, Stock Issuance Costs Accruals and reserves Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Other information Operating Lease, Other Information [Abstract] Operating Lease, Other Information Year 4 Lessee, Operating Lease, Liability, Payments, Due Year Four Right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Contributions expected in 2020 Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year Product Return Concentration Risk Product Return Concentration Risk [Member] Product Return Concentration Risk [Member] Geographic Information Segment Reporting Disclosure [Text Block] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Class of Stock [Domain] Class of Stock [Domain] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Total accumulated benefit obligation Defined Benefit Plan, Accumulated Benefit Obligation Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Lilly Majority Shareholder [Member] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Entity Public Float Entity Public Float Income Tax Expense (Benefit) Related to Interest and Penalties Summary of Income Tax Examinations [Table Text Block] Employer contribution Defined Benefit Plan, Plan Assets, Contributions by Employer Weighted average number of shares issued basic (in shares) Weighted Average Number of Shares Issued, Basic Other financing activities, net Proceeds from (Payments for) Other Financing Activities Adoption of Accounting Standards Update 2016-16 Cumulative Effect of New Accounting Principle in Period of Adoption TSA Transitional Services Agreement Transitional Services Agreement [Member] Transitional Services Agreement [Member] Foreign Foreign Tax Authority [Member] Tax credit carryovers Tax Credit Carryforward, Amount United Kingdom UNITED KINGDOM Significant Components of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Product and Service [Domain] Product and Service [Domain] Payments Contract With Customer, Liability, Increase From Cash Receipts Contract With Customer, Liability, Increase From Cash Receipts Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Bayer Animal Business Bayer Animal Business [Member] Bayer Animal Business Entity Filer Category Entity Filer Category Goodwill (Note 11) Goodwill Goodwill Schedule of Restricted Stock Unit Activity Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Statement [Line Items] Statement [Line Items] Hedging Designation [Domain] Hedging Designation [Domain] Total Revenue Revenue from Contract with Customer, Excluding Assessed Tax Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax [Abstract] Adjustment related to Separation Restatement Adjustment [Member] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Related tax benefit Share-based Payment Arrangement, Expense, Tax Benefit Projected benefit obligation Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation Plan Name [Axis] Plan Name [Axis] 4.900% Senior Notes due 2028 4.9% Senior Notes Due 2028 [Member] 4.9% Senior Notes Due 2028 [Member] Revenues Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual Components of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Amortization Amortization Common stock outstanding (in shares) Common Stock, Shares, Outstanding Weighted average shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Tax Period [Axis] Tax Period [Axis] Net Parent Company Investment Net Parent Company Investment [Member] Net Parent Company Investment [Member] Capital contribution from Lilly Stockholders' Equity, Capital Contribution From Parent Stockholders' Equity, Capital Contribution From Parent Impact of Separation Stockholders' Equity Note Disclosure [Text Block] Food Animal Ruminants Swine Food Animal Ruminants And Swine [Member] Food Animal Ruminants And Swine [Member] Equity Balance Stockholders' Equity, Policy [Policy Text Block] Term loan B credit facility Term Loan B Credit Facility [Member] Term Loan B Credit Facility Gain on sale of assets Gain (Loss) on Disposition of Assets Other Other Intangible Assets [Member] Amortization of net actuarial loss included in net loss Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Total lease payments Lessee, Operating Lease, Liability, Payments, Due Number of brands in diverse portfolio (more than) Number Of Brands In Entity's Portfolio Number Of Brands In Entity's Portfolio Property and Equipment and Depreciation Expense Property, Plant and Equipment [Table Text Block] Property, plant and equipment classified as held for sale Property and equipment, net Disposal Group, Including Discontinued Operation, Property, Plant and Equipment Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Accounts receivable, net of allowances of $6.2 (2019) and $8.4 (2018) Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Additional paid-in capital Additional Paid in Capital Schedule of Stock-Based Compensation Expenses Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Short-term lease cost Short-term Lease, Cost Change in uncertain tax positions Effective Income Tax Rate Reconciliation, Tax Contingency, Amount Stock options granted (in shares) Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Asset Impairment, Restructuring and Other Special Charges Restructuring, Impairment, and Other Activities Disclosure [Text Block] Defined benefit pension and retiree health benefit plans, net of taxes Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Marketed products Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles State Deferred State and Local Income Tax Expense (Benefit) Severance Employee Severance [Member] Other intangibles, net Disposal Group, Including Discontinued Operation, Intangible Assets Cash received upon exercise Proceeds from Stock Options Exercised Common Stock Common Stock [Member] 2024 Finite-Lived Intangible Assets, Amortization Expense, Year Five Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Commitments and Contingencies Legal Matters and Contingencies [Text Block] Product and Service [Axis] Product and Service [Axis] Entity Shell Company Entity Shell Company Operating lease cost Operating Lease, Cost Maximum aggregate contingent payment Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Total deferred tax liabilities Deferred Tax Liabilities, Gross Total liabilities and equity Liabilities and Equity Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Net amount recognized Defined Benefit Plan, Amounts For Asset (Liability) And Accumulated Other Comprehensive (Income) Loss, Before Tax, Recognized In Statement Of Financial Position Defined Benefit Plan, Amounts For Asset (Liability) And Accumulated Other Comprehensive (Income) Loss, Before Tax, Recognized In Statement Of Financial Position Marketing, selling and administrative Selling, General and Administrative Expenses [Member] Concentration risk Concentration Risk, Percentage Movements in the Valuation Allowance Summary of Valuation Allowance [Table Text Block] Separation adjustments Stockholders' Equity, Separation Adjustments Stockholders' Equity, Separation Adjustments Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Schedule of Expected Benefit Payments Schedule of Expected Benefit Payments [Table Text Block] Actual return on plan assets Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Rate of compensation increase for benefit obligation Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Consolidation Consolidation, Policy [Policy Text Block] Total net proceeds, after underwriting discounts and commissions Total cash received upon sale closing Sale of Stock, Consideration Received on Transaction State Current State and Local Tax Expense (Benefit) Number of shares issued (in shares) Sale of Stock, Number of Shares Issued in Transaction Retirement Benefits Pension and Other Postretirement Benefits Disclosure [Text Block] Accelerated vesting of equity awards APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Accelerated Vesting APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Accelerated Vesting Summary of Fair Value Information Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Award Type [Axis] Award Type [Axis] Discount rate for benefit obligation Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Total liabilities held for sale Disposal Group, Including Discontinued Operation, Liabilities Costs, expenses and other: Costs and Expenses [Abstract] Aratana Therapeutics, Inc. Aratana Therapeutics, Inc. [Member] Aratana Therapeutics, Inc. [Member] Geographical [Axis] Geographical [Axis] Strategic Exits Product Category Strategic Exits [Member] Product Category Strategic Exits Retained Earnings Retained Earnings [Member] Subsequent Event Type [Domain] Subsequent Event Type [Domain] New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Leases Lessee, Operating Leases [Text Block] Other Other Investments [Member] Statement [Table] Statement [Table] 2025-2029 Defined Benefit Plan, Expected Future Benefit Payment, Five Fiscal Years Thereafter Number of countries in which entity operates (more than) Number of Countries in which Entity Operates Estimated useful lives Property, Plant and Equipment, Useful Life Goodwill and Intangibles Goodwill and Intangible Assets Disclosure [Text Block] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Maximum Maximum [Member] Year 3 Lessee, Operating Lease, Liability, Payments, Due Year Three Ownership [Axis] Ownership [Axis] Domestic Tax Authority Domestic Tax Authority [Member] Next Largest Country International Non-US [Member] Deferred taxes Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities Repayments of debt, interest Repayments Of Long Term Debt, Accrued Interest Repayments Of Long Term Debt, Accrued Interest Unrecognized tax benefits that, if recognized, would affect effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Selected Quarterly Data (unaudited) Quarterly Financial Information [Text Block] Separation adjustment Restructuring Reserve, Separation Adjustment Restructuring Reserve, Separation Adjustment Companion Animal Therapeutics Companion Animal Therapeutics [Member] Companion Animal Therapeutics [Member] Aggregate principal amount Debt Instrument, Face Amount Long-lived assets Long-Lived Assets SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Foreign currency translation Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Debt maturity term Debt Instrument, Term Restructuring Type [Axis] Restructuring Type [Axis] Range [Domain] Statistical Measurement [Domain] Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Aggregate intrinsic value of exercisable options Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Stock-Based Compensation Share-based Payment Arrangement [Text Block] Issuance to Aratana shareholders for acquisition Stock Issued During Period, Value, Acquisitions Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Rebate period Contract With Customer, Rebate Period Contract With Customer, Rebate Period Non-deductible employee compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Employee Compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Employee Compensation Galliprant Galliprant [Member] Galliprant [Member] Other investing activities, net Payments for (Proceeds from) Other Investing Activities Related Party [Axis] Related Party [Axis] Exercisable (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Fair Value Estimate of Fair Value Measurement [Member] Earnings (loss) per share Earnings Per Share [Abstract] Retiree Health Benefit Plan Postretirement Health Coverage [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Other Deferred Tax Liabilities, Other Benefits paid Defined Benefit Plan, Plan Assets, Benefits Paid Annual Minimum Lease Payments of Operating Lease Liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Software Computer Software, Intangible Asset [Member] Income (loss) before income taxes Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Rent expense Operating Leases, Rent Expense Number of renewal terms Related Party Transaction, Number Of Renewal Terms Related Party Transaction, Number Of Renewal Terms Quarterly Financial Information Disclosure [Abstract] Quarterly Financial Information Disclosure [Abstract] Total lease cost Lease, Cost 2022 Finite-Lived Intangible Assets, Amortization Expense, Year Three Long-term debt - senior notes Notes Payable, Fair Value Disclosure Other current liabilities Liability, Defined Benefit Plan, Current Estimated Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Cash Flows from Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Operating expenses Operating Expenses Expected return on plan assets for net benefit costs Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets Expected cash and contra interest per year Derivative Instruments, Expected Annual Contra Interest Derivative Instruments, Expected Annual Contra Interest Osurnia and Capstar Osurnia and Capstar [Member] Osurnia and Capstar Segment Reporting [Abstract] Segment Reporting [Abstract] Right-of-use assets Deferred Tax Liabilities, Operating Lease Right-Of-Use Assets Deferred Tax Liabilities, Operating Lease Right-Of-Use Assets Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Earnings (loss) per share—basic and diluted (usd per share) Earnings Per Share, Basic and Diluted Entity Central Index Key Entity Central Index Key Change in benefit obligation: Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Net operating loss carryforwards with indefinite carryforward period Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration Income Statement Location [Domain] Income Statement Location [Domain] Weighted-average discount rate - operating leases Operating Lease, Weighted Average Discount Rate, Percent Revenue Revenue Revenue from Contract with Customer, Including Assessed Tax Contra interest expense Derivative, Excluded Component, Gain (Loss), Recognized in Earnings Payments made to date Separation Related Costs, Financing Activities, Payments Made To Date Separation Related Costs, Financing Activities, Payments Made To Date Aggregate intrinsic value of outstanding options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Federal Deferred Federal Income Tax Expense (Benefit) Shares of Common Stock Attributable to Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Cash payments of income taxes Income Taxes Paid, Net Balance at beginning of period Balance at end of period Restructuring Reserve Impairment charges Impairment of Intangible Assets (Excluding Goodwill) Settlement of accounts receivable Business Combination, Consideration Transferred, Settlement Of Accounts Receivable Business Combination, Consideration Transferred, Settlement Of Accounts Receivable Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Transfers (to)/from Lilly, net Net transfers (to)/from Lilly Stockholders' Equity, Transfers (To) From Parent Stockholders' Equity, Transfers (To) From Parent Change in plan assets: Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] Additions based on tax positions related to the current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Senior Notes Senior Notes [Member] Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan, Plan Assets, Category [Domain] Transaction and integration costs Business Combination, Integration Related Costs Sale of Stock [Domain] Sale of Stock [Domain] Current operating lease liabilities Operating Lease, Liability, Current Other Deferred Tax Assets, Other Local Country Asset Purchases Local Country Asset Purchases [Member] Local Country Asset Purchases [Member] Rental Expense for All Leases Schedule of Rent Expense [Table Text Block] Taxation of international operations Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Number of shares issued to previous shareholders upon closing (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Income Taxes Income Tax Disclosure [Text Block] Estimated Fair Value Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract] Buildings Building [Member] Disposal Group Name [Domain] Disposal Group Name [Domain] Document Fiscal Period Focus Document Fiscal Period Focus 3.912% Senior Notes due 2021 3.912% Senior Notes Due 2021 [Member] 3.912% Senior Notes Due 2021 [Member] Lilly Eli Lilly and Company [Member] Eli Lilly and Company [Member] Business Acquisition, Contingent Consideration [Line Items] Business Acquisition, Contingent Consideration [Line Items] Issuance of stock under employee stock plans, net (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Other intangibles Intangible Assets, Net (Excluding Goodwill) [Abstract] Type of Adoption [Domain] Type of Adoption [Domain] Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Line of credit facility, commitment fee amount Line of Credit Facility, Commitment Fee Amount Disclosure of Long Lived Assets Held-for-sale Disclosure of Long Lived Assets Held-for-sale [Table Text Block] Year 5 Lessee, Operating Lease, Liability, Payments, Due Year Five Lilly's Stock-Based Compensation Program Lilly's Stock-Based Compensation Program [Member] Lilly's Stock-Based Compensation Program [Member] Value of shares issued as consideration Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Additional Paid-in Capital Additional Paid-in Capital [Member] Revenue Revenue from Contract with Customer [Text Block] Decrease to LIFO cost Inventory, LIFO Reserve Disposal Group Name [Axis] Disposal Group Name [Axis] Net operating losses and other carryovers Tax loss carryovers Deferred Tax Assets, Operating Loss Carryforwards Issuance to Aratana shareholders for acquisition (in shares) Stock Issued During Period, Shares, Acquisitions Deferred taxes (Note 15) Deferred Income Tax Liabilities, Net Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Equity-like funds Defined Benefit Plan, Equity-Like Funds [Member] Defined Benefit Plan, Equity-Like Funds [Member] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Multiemployer plans, curtailment loss and special termination benefits Multiemployer Plans, Settlement And Curtailments Multiemployer Plans, Settlement And Curtailments Cash paid for acquisitions, net of cash acquired Acquisition amount Payments to Acquire Businesses, Net of Cash Acquired Elanco Elanco Animal Health Incorporated And Subsidiaries [Member] Elanco Animal Health Incorporated And Subsidiaries [Member] Accumulated other comprehensive (income) loss before income taxes Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax Interest rate Debt Instrument, Interest Rate, Stated Percentage Finished products Inventory, Finished Goods, Gross Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Business Combinations [Abstract] Business Combinations [Abstract] Reconciliation of Gross Unrecognized Tax Benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Other noncurrent liabilities- contingent consideration Other Noncurrent Liabilities [Member] Amount paid at closing Payments to Acquire Businesses, Gross Income Statement Location [Axis] Income Statement Location [Axis] Business acquisition (usd per share) Business Combination, Contingent Consideration, Amount Per Share Paid Upon Specified Merger Agreement Milestones Business Combination, Contingent Consideration, Amount Per Share Paid Upon Specified Merger Agreement Milestones Business Acquisition [Axis] Business Acquisition [Axis] Customer Concentration Risk Customer Concentration Risk [Member] Taxes accrued with respect to unremitted earnings of foreign subsidiaries Deferred Tax Liabilities, Undistributed Foreign Earnings Charges Restructuring Charges Exit costs Facility Closing [Member] Finance lease asset Finance Lease, Right-of-Use Asset, Before Accumulated Amortization Finance Lease, Right-of-Use Asset, Before Accumulated Amortization Total consideration transferred Business Combination, Consideration Transferred Other non-cash operating activities, net Other Operating Activities, Cash Flow Statement Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Intangibles Deferred Tax Liabilities, Goodwill and Intangible Assets Business Acquisition [Line Items] Business Acquisition [Line Items] Accrued retirement benefits (Note 18) Accrued retirement benefits Accrued retirement benefits Liability, Defined Benefit Plan, Noncurrent 2024 Defined Benefit Plan, Expected Future Benefit Payment, Year Five Costs, expenses and other Costs and Expenses Projected Benefit Obligations in Excess of Plan Assets Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block] Cash paid Payments for Restructuring Asset impairment Asset Impairment Charges Long-lived Assets by Selected Geographic Area Information Long-lived Assets by Geographic Areas [Table Text Block] Beginning nonvested balance (in dollars per share) Ending nonvested balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Inventories (Note 8) Inventories Inventory, Net Amortization of prior service cost Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Acquired in-process research and development Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Pension Plans Pension Plan [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] 2021 Defined Benefit Plan, Expected Future Benefit Payment, Year Two Summary of Activity in Reserves Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Earnings Per Share Earnings Per Share [Text Block] Equity Award [Domain] Award Type [Domain] Revolving credit facility Revolving credit facility Revolving Credit Facility [Member] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Change In Contract With Customer, Liability [Roll Forward] Change In Contract With Customer, Liability [Roll Forward] Change In Contract With Customer, Liability [Roll Forward] Term credit facility Term credit facility Term Credit Facility [Member] Term Credit Facility [Member] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] Hedging Designation [Axis] Hedging Designation [Axis] Ownership [Domain] Ownership [Domain] Settlement of existing contingent consideration liabilities Payment for Contingent Consideration Liability, Investing Activities RSUs Restricted Stock Units (RSUs) [Member] Research and development Research and Development Expense [Member] Schedule of Long-term Debt Schedule of Long-term Debt Instruments [Table Text Block] Research and development expenses and acquired in-process research and development Research, Development, and Computer Software, Policy [Policy Text Block] Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Income tax expense (benefit) Income Tax Examination, Penalties and Interest Expense Composition of Income Tax Expense (Benefit) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Total liabilities Liabilities Acquisitions Business Combination Disclosure [Text Block] 2020 To 2039 Tax Year 2020 To 2039 [Member] Tax Year 2020 To 2039 [Member] Facility exit costs Business Exit Costs Entity Current Reporting Status Entity Current Reporting Status Increase (1) SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Forfeited or expired (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Developed markets Fixed Income Securities, Developed Markets [Member] Fixed Income Securities, Developed Markets [Member] Funded status Defined Benefit Plan, Funded (Unfunded) Status of Plan Weighted-Average Restricted Stock Unit Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Total equity Balance at beginning of period Balance at end of period Stockholders' Equity Attributable to Parent Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Amortization of intangible assets Amortization of Intangible Assets Concentration Risk Type [Domain] Concentration Risk Type [Domain] Total deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Tangible Equity Unit Tangible Equity Unit [Member] Tangible Equity Unit Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Raw materials and supplies Inventory, Raw Materials and Supplies, Gross Accelerated vesting of equity awards (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture, Accelerated Vesting Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture, Accelerated Vesting Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Financial Instruments and Fair Value Fair Value Disclosures [Text Block] Remaining amortization period Finite-Lived Intangible Assets, Remaining Amortization Period Acquired in-process research and development In Process Research and Development [Member] Foreign Currency Translation Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Interest rate at period end Line of Credit Facility, Interest Rate at Period End Tax Period [Domain] Tax Period [Domain] Carrying Amount, Gross Finite-Lived Intangible Assets, Gross Preferred stock, 1,000,000,000 shares authorized, no par value; none issued Preferred Stock, Value, Issued Antidilutive shares not included in calculation diluted earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Accumulated other comprehensive income net impact Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Weighted-Average Assumptions Related to Pension Plans Defined Benefit Plan, Assumptions [Table Text Block] Depreciation expense Depreciation Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Equity Component [Domain] Equity Component [Domain] Expected term (years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Hedging Relationship [Domain] Hedging Relationship [Domain] Payment terms Revenue, Performance Obligation, Description of Timing Equipment Equipment [Member] Quarterly principal payments percentage Debt Instrument, Periodic Payment, Principal, Percentage Of Face Amount Less Prepayments Debt Instrument, Periodic Payment, Principal, Percentage Of Face Amount Less Prepayments Entity [Domain] Entity [Domain] Total gross deferred tax assets Deferred Tax Assets, Gross Impairments with respect to the carrying value of goodwill Goodwill, Impairment Loss Disposal group Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member] Sales rebates and discounts, liability Contract With Customer, Liability [Member] Contract With Customer, Liability [Member] Actuarial loss (gain) Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Weighted average useful life Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Description of Accounting Standards Adopted and Not Yet Adopted Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] Compensation and benefits Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits Balance Sheet Location [Axis] Balance Sheet Location [Axis] EX-101.PRE 12 elan-20191231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 13 elan-20191231_g1.jpg begin 644 elan-20191231_g1.jpg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elan-20191231_g2.jpg begin 644 elan-20191231_g2.jpg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elan-20191231_g3.jpg begin 644 elan-20191231_g3.jpg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end GRAPHIC 16 image01.jpg begin 644 image01.jpg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end GRAPHIC 17 image11.jpg begin 644 image11.jpg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end GRAPHIC 18 image21.jpg begin 644 image21.jpg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

O[!E47235GLW3+! I9]NVCSW?(XAHPUPF0P\6QA;SYY?X,JOE2[> MN[J@3\LY>]8VRG:[R,D-MU 59NR88>YG@2#(*NG"8X?8UI[RNW9;LR;COVG) MY1A%VBZ2!C5\8=&:C*6W[&2O6CM1!*N^>N?_V0$! ! $! end GRAPHIC 19 image31.jpg begin 644 image31.jpg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end GRAPHIC 20 image41.jpg begin 644 image41.jpg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end GRAPHIC 21 image51.jpg begin 644 image51.jpg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end XML 22 R76.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stock-Based Compensation - Schedule of Stock-Based Compensation Expenses (Details) - Elanco Stock Compensation Plans - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock-based compensation expense $ 40.7 $ 1.8
Related tax benefit $ (9.8) $ (0.4)

XML 23 R86.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Income Tax Disclosure [Abstract]                      
Income tax at the U.S. federal statutory tax rate                 $ 16.4 $ 24.0 $ (81.4)
Add (deduct):                      
Taxation of international operations                 20.7 20.5 59.8
State taxes                 2.9 4.4 5.4
Income tax credits                 (9.8) (17.3) (1.8)
Non-deductible employee compensation                 4.2 (1.9) 0.0
IPO and separation costs                 0.0 2.3 0.0
Other permanent adjustments                 (4.2) (1.0) 0.8
Change in uncertain tax positions                 (14.7) (1.7) 6.2
Change in valuation allowance                 (5.2) (1.7) 122.2
2017 Tax Act                 0.0 0.0 (33.1)
Income taxes $ 5.2 $ (22.5) $ 14.3 $ 13.3 $ (18.6) $ 18.6 $ 22.8 $ 4.8 $ 10.3 $ 27.6 $ 78.1
XML 24 R82.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Composition of Income Tax Expense (Benefit) (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Current:                      
Federal                 $ (5.5) $ 45.1 $ 0.0
Foreign                 13.4 45.5 91.6
State                 2.3 (2.3) (0.1)
Total current tax expense                 10.2 88.3 91.5
Deferred:                      
Federal                 14.5 (56.8) 42.6
Foreign                 (7.5) (5.6) (16.6)
State                 (6.9) 1.7 (6.3)
2017 Tax Act                 0.0 0.0 (33.1)
Total deferred tax expense (benefit)                 0.1 (60.7) (13.4)
Income taxes $ 5.2 $ (22.5) $ 14.3 $ 13.3 $ (18.6) $ 18.6 $ 22.8 $ 4.8 $ 10.3 $ 27.6 $ 78.1
XML 25 R72.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases - Impact of Operating Leases to Condensed Consolidated Financial Statements (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Lease cost      
Operating lease cost $ 26.1    
Short-term lease cost 0.5    
Variable lease cost 2.5    
Total lease cost 29.1    
Other information      
Operating cash outflows from operating leases 24.0    
Right-of-use assets obtained in exchange for new operating lease liabilities $ 20.1    
Weighted-average remaining lease term - operating leases 5 years 1 month 6 days    
Weighted-average discount rate - operating leases 3.60%    
Rent expense   $ 47.5 $ 47.1
XML 26 R59.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Inventories - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2019
Inventory Disclosure [Abstract]    
Inventories valued under the LIFO method $ 194.8 $ 197.2
Inventory write-offs $ 38.6  
XML 27 R51.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Revenue - Narrative (Details)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Concentration Risk [Line Items]    
Rebate period 6 months  
Geographic Concentration Risk | Sales rebates and discounts, liability | United States    
Concentration Risk [Line Items]    
Concentration risk 71.00% 70.00%
Geographic Concentration Risk | Sales rebates and discounts, liability | Next Largest Country    
Concentration Risk [Line Items]    
Concentration risk 8.00% 8.00%
Product Return Concentration Risk | Net Revenue    
Concentration Risk [Line Items]    
Concentration risk 0.20% 0.60%
XML 28 R55.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Acquisitions - Summary of Amounts Recognized for Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Millions
 12 Months Ended
Jul. 31, 2019
Jul. 18, 2019
Jan. 03, 2017
Dec. 31, 2017
Dec. 31, 2019
Dec. 31, 2018
Estimated Fair Value            
Goodwill         $ 2,989.6 $ 2,958.0
Aratana Therapeutics, Inc.            
Estimated Fair Value            
Cash and cash equivalents   $ 26.4        
Inventories   10.3        
Other assets and liabilities - net   24.0        
Total identifiable net assets   142.5        
Goodwill   10.8        
Settlement of existing contingent consideration liabilities   84.7        
Total consideration transferred   $ 238.0        
Weighted average useful life   12 years 6 months        
Aratana Therapeutics, Inc. | Acquired in-process research and development            
Estimated Fair Value            
Acquired in-process research and development   $ 31.9        
Aratana Therapeutics, Inc. | Marketed products            
Estimated Fair Value            
Marketed products   36.7        
Aratana Therapeutics, Inc. | Other            
Estimated Fair Value            
Marketed products   $ 13.2        
Prevtec            
Estimated Fair Value            
Cash and cash equivalents $ 0.9          
Property and equipment 0.5          
Other assets and liabilities - net (10.3)          
Total identifiable net assets 53.9          
Goodwill 11.1          
Total consideration transferred $ 65.0          
Weighted average useful life 10 years          
Prevtec | Acquired in-process research and development            
Estimated Fair Value            
Acquired in-process research and development $ 2.8          
Prevtec | Marketed products            
Estimated Fair Value            
Marketed products 58.9          
Prevtec | Other            
Estimated Fair Value            
Marketed products $ 1.1          
BIVIVP            
Estimated Fair Value            
Inventories     $ 108.6      
Property and equipment     148.2      
Marketed products     297.0      
Other assets and liabilities - net     8.2      
Total identifiable net assets     562.0      
Goodwill     320.1      
Total consideration transferred     $ 882.1      
Weighted average useful life     10 years      
BIVIVP | Marketed products            
Estimated Fair Value            
Purchase accounting adjustment       $ 42.7    
XML 29 R34.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Asset Impairment, Restructuring and Other Special Charges (Tables)
 12 Months Ended
Dec. 31, 2019
Restructuring and Related Activities [Abstract]  
Total Charges Related to Asset Impairment, Restructuring and Other Special Charges
Components of asset impairment, restructuring and other special charges for the years ended December 31 are as follows:
201920182017
Restructuring charges: (1)
Severance and other costs$8.2  $15.5  $162.0  
Facility exit costs—  5.7  31.8  
Acquisition related charges:
Transaction and integration costs (2)
144.7  26.5  90.3  
Non-cash and other items:
Asset impairment (3)
15.4  81.9  110.6  
Asset write-down (4)
17.2  —  —  
Gain on sale of fixed assets (5)
—  (0.8) (19.6) 
Total expense$185.5  $128.8  $375.1  
(1)For the year ended December 31, 2019, these charges primarily relate to a new program that will eliminate certain positions across multiple locations and functions, including exiting R&D operations in Prince Edward Island, Canada, ceasing certain manufacturing operations in Wusi, China, and streamlining operations in Speke, England. We expect to substantially complete these restructuring activities by September 2020.
For the year ended December 31, 2018, these charges primarily relate to a program to streamline international operations, including  shifting focus and resources to priority areas. Among other actions, amounts reflect a change from having a physical location to a distribution model in certain countries in connection with the Separation. These activities were substantially complete as of December 31, 2019.
We historically participated in Lilly’s cost-reduction initiatives, which resulted in restructuring charges in the period prior to our IPO. These restructuring charges include severance and other costs associated with the reduction of our workforce, including special termination benefits recognized in 2017 associated with the U.S. voluntary early retirement program offered by Lilly, related to our employees and pension curtailment costs and facility exit costs. We also recorded certain impairment charges related to the activities as described below.
(2)Transaction costs represent external costs directly related to acquiring businesses and primarily include expenditures for banking, legal, accounting and other similar services. Integration costs represent external, incremental costs directly related to integrating acquired businesses (e.g., expenditures for consulting, system and process integration, and product transfers), as well as stand-up costs related to the implementation of new systems, programs, and processes due to the Separation from Lilly .
(3)Asset impairment charges are associated with the following:
•For the year ended December 31, 2019, write-off certain IPR&D and manufacturing assets in the US, Canada and Speke, resulting from the adjustment to fair value of property and equipment and intangible assets that were subject to product rationalization.
•For the year ended December 31, 2018, the decision to dispose of a manufacturing facility in the U.S., the suspension of commercial activities for Imrestor, the write-off of certain idle assets in a U.S. manufacturing facility and product rationalization.
•For the year ended December 31, 2017, intangible asset impairments related to revised projections of fair value due to product rationalization and to a lesser extent competitive pressures.
(4)Asset write-down expenses resulted from the adjustments recorded to write assets classified as held and used and held for sale down to their current fair values. These charges primarily related to fixed assets in Prince Edward Island, Canada; Wusi, China and Indianapolis, Indiana. $11.2 million of Property and equipment, net in Prince Edward Island, Canada and Indianapolis, Indiana are classified as held for sale.
(5)Represents a gain on the disposal of a site that was previously closed as part of the acquisition and integration of Novartis Animal Health beginning on January 1, 2015.
Summary of Activity in Reserves
The following table summarizes the activity in our reserves established in connection with restructuring activities:
Exit costs SeveranceTotal
Balance at December 31, 2017$34.9  $43.1  $78.0  
Charges11.7  15.5  27.2  
Separation adjustment(5.9) —  (5.9) 
Reserve adjustment(6.0) —  (6.0) 
Cash paid(25.4) (23.5) (48.9) 
Balance at December 31, 20189.3  35.1  44.4  
Charges—  19.3  19.3  
Reserve adjustment (1)
—  (11.1) (11.1) 
Cash paid(3.9) (27.8) (31.7) 
Balance at December 31, 2019$5.4  $15.5  $20.9  
(1) Reserve adjustment represents the reversal of reserves for severance programs that are no longer active.
XML 30 R103.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Related Party Agreements and Transactions - Amounts Due From/(Due To) Lilly (Details) - Lilly - USD ($)
$ in Millions
Dec. 31, 2019
Dec. 31, 2018
Related Party Transaction [Line Items]    
Total receivable from/(payable to) Lilly $ (16.4) $ (268.7)
TSA    
Related Party Transaction [Line Items]    
Total receivable from/(payable to) Lilly 10.5 (28.0)
Other Related Party Activities    
Related Party Transaction [Line Items]    
Total receivable from/(payable to) Lilly (15.8) (38.0)
Local Country Asset Purchases    
Related Party Transaction [Line Items]    
Total receivable from/(payable to) Lilly $ (11.1) $ (202.7)
XML 31 R30.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Basis of Presentation (Policies)
 12 Months Ended
Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
We have prepared the accompanying consolidated and combined financial statements in accordance with accounting principles generally accepted in the United States (GAAP). In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for fair presentation of the results of operations for the periods shown. The accounts of all wholly-owned and majority-owned subsidiaries are included in the consolidated financial statements, and all intercompany balances and transactions have been eliminated.
Certain reclassifications have been made to prior periods in the unaudited condensed consolidated and combined financial statements and accompanying notes to conform with current presentation.
In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. We issued our financial statements by filing with the Securities and Exchange Commission and have evaluated subsequent events up to the time of the filing.
Consolidation For the periods after Separation, the financial statements are prepared on a consolidated basis and reflect the results of operations, comprehensive income, financial position, equity and cash flows resulting from our operations as an independent company. For periods prior to Separation, our financial statements are combined, have been prepared on a standalone basis, and are derived from Lilly's consolidated financial statements and accounting records. The consolidated and combined financial statements reflect the financial position, results of operations and cash flows related to the animal health businesses that were transferred to Elanco Parent and are prepared in conformity with GAAP. The combined financial statements include the attribution of certain assets and liabilities that historically have been held at the Lilly corporate level but which are specifically identifiable or attributable to the businesses that have been transferred to Elanco Parent. All intercompany transactions and accounts within Elanco have been eliminated. All transactions between us and Lilly are considered to be effectively settled in the combined financial statements at the time the intercompany transaction is recorded. The total net effect of the settlement of these intercompany transactions is reflected in the combined statements of cash flows as a financing activity and in the consolidated and combined statement of equity as net parent company investment.
Expenses Related to Certain Corporate Functions Prior to Separation, these combined financial statements include an allocation of expenses related to certain Lilly corporate functions, including executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information technology and investor relations, prior to IPO. These expenses were allocated to us based on direct usage or benefit where specifically identifiable, with the remainder allocated primarily on a pro rata basis of revenue, headcount and other measures. We consider the expenses methodology and results to be reasonable for all periods presented. However, the allocations may not be indicative of the actual expense that would have been incurred had we operated as an independent, publicly traded company for the periods presented. It is impractical to estimate what the standalone costs of Elanco would have been in the historical periods. After the Separation, a TSA between Lilly and Elanco went into effect. Under the terms of the TSA, we will be able to use these Lilly services for a fixed term established on a service-by-service basis. We are paying Lilly mutually agreed upon fees for the Lilly services provided under the TSA. Our consolidated and combined financial statements reflect the charges for Lilly services after the IPO. See Note 20: Related Party Agreements and Transactions for additional details.
Income Tax The income tax amounts in the combined financial statements have been calculated based on a separate return methodology and presented as if our operations were separate taxpayers in the respective jurisdictions. We file income tax returns in the U.S. federal jurisdiction and various state, local and non-U.S. jurisdictions. Prior to full separation, certain of these income tax returns were filed on a consolidated or combined basis with Eli Lilly and Company and/or its subsidiaries.
Benefit and Combined Stock-Based Compensation Plans Prior to Separation, Lilly maintained various benefit and combined stock-based compensation plans at a corporate level and other benefit plans at a country level. Our employees participated in such programs and the portion of the cost of those plans related to our employees is included in our financial statements. However, the consolidated balance sheets do not include any equity issued related to stock-based compensation plans or any net benefit plan obligations unless the benefit plan covers only our dedicated employees or where the legal obligation associated with the benefit plan transferred to Elanco. Upon Lilly's full divestiture of Elanco in March 2019, all Lilly share-based awards held by our employees were converted into awards that will be settled in Elanco shares.
Equity Balance Prior to Separation, the equity balance in the combined financial statements represents the excess of total assets over liabilities, including intercompany balances between Elanco and Lilly (net parent company investment) and accumulated other comprehensive income (loss). Net parent company investment is primarily impacted by contributions from Lilly which are the result of treasury activities and net funding provided by or distributed to Lilly.
Revenue recognition
Revenue recognition
Effective January 1, 2018, we adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (ASU 2014-09) and other related updates. The new standard has been applied to contracts for which performance had not been completed as of the date of adoption. Revenue presented for periods prior to 2018 was accounted for under previous standards and has not been adjusted. Revenue and net income for the years ended December 31, 2019 and 2018 do not differ materially from amounts that would have resulted from application of the previous standards.
Product Sales
We recognize revenue primarily from product sales to customers. Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which generally is at the time we ship the product to the customer. Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from 30 to 120 days from date of shipment. Revenue for our product sales has not been adjusted for the effects of a financing component as we expect, at contract inception, that the period between when we transfer control of the product and when we receive payment will be one year or less. Any exceptions are either not material or we collect interest for payments made after the due date. For arrangements with contract manufacturing organizations (CMO), we recognize revenue over time or at a point in time depending on our evaluation of when the customer obtains control of the promised goods or service. Revenue is recognized over time when we are creating or enhancing an asset that the customer controls. In this instance revenue is recognized as the asset is created or enhanced or our performance does not create an asset with an alternative use and we have an enforceable right to payment for performance completed.
Provisions for rebates and discounts, as well as returns are established in the same period the related sales are recognized. We generally ship product shortly after orders are received; therefore, we generally only have a few days of orders received but not yet shipped at the end of any reporting period. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are imposed on our sales of product and collected from a customer.
Significant judgments must be made in determining the transaction price for sales of products related to anticipated rebates and discounts, and returns. The following describe the most significant of these judgments:
Sales Rebates and Discounts - Background and Uncertainties
•Most of our products are sold to wholesale distributors. We initially invoice our customers contractual list prices. Contracts with direct and indirect customers may provide for various rebates and discounts that may differ in each contract. As a consequence, to determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we must estimate any rebates or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts. Judgments are required in making these estimates.
•The rebate and discount amounts are recorded as a deduction to arrive at our net product sales. We estimate these accruals using an expected value approach.
•In determining the appropriate accrual amount, we consider our historical experience with similar incentives programs and current sales data and estimates of inventory levels at our channel distributors to evaluate the impact of such programs on revenue and continually monitor the impact of this experience and adjust as necessary. Although we accrue a liability for rebates related to these programs at the time the sale is recorded, the rebate related to that sale is typically paid up to six months after the rebate or incentive period expires. Because of this time lag, in any particular period rebate adjustments may incorporate revisions of accruals for several periods.
Sales Returns - Background and Uncertainties
•We estimate a reserve for future product returns related to product sales using an expected value approach. This estimate is based on several factors, including: local returns policies and practices; returns as a
percentage of revenue; an understanding of the reasons for past returns; estimated shelf life by product; and estimate of the amount of time between shipment and return. Adjustments to the returns reserve have been and may in the future be required based on revised estimates to our assumptions, which would have an impact on our consolidated results of operations. We record the return amounts as a deduction to arrive at our net product sales.
Research and development expenses and acquired in-process research and development
Research and development expenses include the following:
•Research and development costs, which are expensed as incurred.
•Milestone payment obligations incurred prior to regulatory approval of the product, which are accrued when the event requiring payment of the milestone occurs.
•Acquired in-process research and development (IPR&D) expense, which includes the initial costs of IPR&D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use.
Foreign Currency Translation Operations in our subsidiaries outside the U.S. are recorded in the functional currency of each subsidiary which is determined by a review of the environment where each subsidiary primarily generates and expends cash. The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted average currency rate for the period. Assets and liabilities are translated using the period end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries are recorded in other comprehensive income (loss).
Implementation of New Financial Accounting Pronouncements
The following table provides a brief description of an accounting standard that was effective January 1, 2019 and was adopted on that date:
StandardDescriptionEffect on the financial statements or other significant matters
Accounting Standards Update 2016-02, Leases
This standard was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under previous GAAP, on the balance sheet and requiring additional disclosures about leasing arrangements.
We adopted the standard on January 1, 2019 using the modified retrospective approach, applied at the beginning of the period of adoption, and we elected the package of transition practical expedients. Upon adoption of the standard, we recorded $84.9 million of right-of-use assets and $85.3 million of operating lease liabilities on our consolidated balance sheet. Adoption of this standard did not have a material impact on our consolidated statement of operations for the year ended December 31, 2019. See Note 13: Leases for further information.

The following table provides a brief description of the accounting standards applicable to us that have not yet been adopted:
StandardDescriptionEffective DateEffect on the financial statements or other significant matters
Accounting Standards Update 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments
This standard modifies the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses.This standard is effective January 1, 2020, with early adoption permitted. We intend to adopt this standard on that date.We do not expect that the adoption of this standard will have a material impact on our consolidated financial statements based on financial instruments currently held.
Accounting Standards Update 2018-15, Intangibles - Goodwill and Other Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract
This guidance aligns the requirements for capitalizing implementation costs incurred in a cloud-based hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software.This standard is effective January 1, 2020, with early adoption permitted. We intend to adopt this standard on that date.Adoption of this standard is not expected to have a significant impact on our consolidated financial statements.
Accounting Standards Update 2019-12, Simplifying the Accounting for Income Taxes
The amendments in this update simplify the accounting for income taxes by removing certain exceptions and clarifying certain requirements regarding franchise taxes, goodwill, consolidated tax expenses, and annual effective tax rate calculations. This standard is effective January 1, 2021, with early adoption permitted. We intend to adopt this standard on that date.We are currently evaluating the impact of adoption of the new standard on our consolidated financial statements.
XML 32 R107.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Subsequent Events - Narrative (Details)
$ / shares in Units, shares in Thousands
 1 Months Ended 12 Months Ended
Feb. 04, 2020
USD ($)
Jan. 31, 2020
USD ($)
Jan. 27, 2020
USD ($)
Jan. 23, 2020
shares
Jan. 23, 2020
shares
Jan. 22, 2020
USD ($)
$ / shares
shares
Sep. 05, 2018
USD ($)
Feb. 28, 2020
USD ($)
Jan. 31, 2020
USD ($)
Dec. 31, 2018
USD ($)
Sep. 24, 2018
USD ($)
Subsequent Event [Line Items]                      
Issuance of stock                   $ 1,659,700,000  
Credit Facility | Term credit facility                      
Subsequent Event [Line Items]                      
Credit facility, maximum borrowing capacity             $ 500,000,000.0       $ 500,000,000.0
Debt maturity term             3 years        
Credit Facility | Revolving credit facility                      
Subsequent Event [Line Items]                      
Credit facility, maximum borrowing capacity             $ 750,000,000.0       $ 750,000,000.0
Debt maturity term             5 years        
Subsequent Event | Disposal group | Osurnia and Capstar                      
Subsequent Event [Line Items]                      
Proceeds from divestiture                 $ 230,000,000    
Subsequent Event | Disposal group | Veocoxan                      
Subsequent Event [Line Items]                      
Proceeds from divestiture               $ 55,000,000      
Subsequent Event | Credit Facility | Term credit facility                      
Subsequent Event [Line Items]                      
Repayments of debt   $ 372,400,000                  
Repayments of debt, principal   371,400,000                  
Repayments of debt, interest   1,000,000.0                  
Debt extinguishment loss   $ 800,000                  
Subsequent Event | Credit Facility | Term loan B credit facility                      
Subsequent Event [Line Items]                      
Credit facility, maximum borrowing capacity $ 4,275.0                    
Debt maturity term 7 years                    
Subsequent Event | Credit Facility | Revolving credit facility                      
Subsequent Event [Line Items]                      
Credit facility, maximum borrowing capacity $ 750,000,000.0                    
Debt maturity term 5 years                    
Subsequent Event | LIBOR | Credit Facility | Term loan B credit facility                      
Subsequent Event [Line Items]                      
Basis points 1.75%                    
Subsequent Event | Minimum | LIBOR | Credit Facility | Revolving credit facility                      
Subsequent Event [Line Items]                      
Basis points 1.50%                    
Subsequent Event | Maximum | LIBOR | Credit Facility | Revolving credit facility                      
Subsequent Event [Line Items]                      
Basis points 2.25%                    
Subsequent Event | Common Stock                      
Subsequent Event [Line Items]                      
Number of shares issued (in shares) | shares         25,000            
Total cash received upon sale closing     $ 769,900,000                
Subsequent Event | Tangible Equity Unit                      
Subsequent Event [Line Items]                      
Number of shares issued (in shares) | shares           11,000          
Price per share (usd per share) | $ / shares           $ 50          
Total cash received upon sale closing     530,100,000                
Issuance of stock           $ 550,000,000          
Interest rate           5.00%          
Consideration received for prepaid stock purchase contracts     453,800,000                
Subsequent Event | Tangible Equity Unit | 5.00% Senior Amortizing Notes                      
Subsequent Event [Line Items]                      
Net proceeds from senior amortizing notes     $ 76,300,000                
Subsequent Event | Tangible Equity Unit | Minimum                      
Subsequent Event [Line Items]                      
Purchase contract conversion of stock ratio           1.3021          
Purchase contract, shares issued upon conversion | shares           14,300          
Subsequent Event | Tangible Equity Unit | Maximum                      
Subsequent Event [Line Items]                      
Purchase contract conversion of stock ratio           1.5625          
Purchase contract, shares issued upon conversion | shares           17,200          
Subsequent Event | Underwriting Agreement | Common Stock                      
Subsequent Event [Line Items]                      
Number of shares issued (in shares) | shares           22,700          
Price per share (usd per share) | $ / shares           $ 32.00          
Subsequent Event | Over-Allotment Option | Common Stock                      
Subsequent Event [Line Items]                      
Number of shares issued (in shares) | shares       2,300              
XML 33 R38.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Goodwill and Intangibles (Tables)
 12 Months Ended
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Components of Finite-Lived Intangible Assets
The components of intangible assets other than goodwill at December 31 were as follows:
20192018
Description
Carrying Amount, Gross
Accumulated Amortization
Carrying Amount, Net
Carrying Amount, Gross
Accumulated Amortization
Carrying Amount, Net
Finite-lived intangible assets:
Marketed products$3,302.7  $(980.6) $2,322.1  $3,193.5  $(779.2) $2,414.3  
Software159.2  (72.2) 87.0  101.3  (49.5) 51.8  
Other58.3  (34.0) 24.3  53.1  (34.0) 19.1  
Total finite-lived intangible assets3,520.2  (1,086.8) 2,433.4  3,347.9  (862.7) 2,485.2  
Indefinite-lived intangible assets:
Acquired in-process research and development49.4  —  49.4  19.6  —  19.6  
Other intangibles$3,569.6  $(1,086.8) $2,482.8  $3,367.5  $(862.7) $2,504.8  
Components of Indefinite-Lived Intangible Assets
The components of intangible assets other than goodwill at December 31 were as follows:
20192018
Description
Carrying Amount, Gross
Accumulated Amortization
Carrying Amount, Net
Carrying Amount, Gross
Accumulated Amortization
Carrying Amount, Net
Finite-lived intangible assets:
Marketed products$3,302.7  $(980.6) $2,322.1  $3,193.5  $(779.2) $2,414.3  
Software159.2  (72.2) 87.0  101.3  (49.5) 51.8  
Other58.3  (34.0) 24.3  53.1  (34.0) 19.1  
Total finite-lived intangible assets3,520.2  (1,086.8) 2,433.4  3,347.9  (862.7) 2,485.2  
Indefinite-lived intangible assets:
Acquired in-process research and development49.4  —  49.4  19.6  —  19.6  
Other intangibles$3,569.6  $(1,086.8) $2,482.8  $3,367.5  $(862.7) $2,504.8  
Schedule of Weighted-Average Amortization Periods For Finite-Lived Intangible Assets As of December 31, 2019, the remaining weighted-average amortization periods for finite-lived intangible assets are as follows:
Weighted Average Life (Years)
Marketed products13
Software6
Other8
Estimated Amortization Expense
The estimated amortization expense for each of the next five years associated with our finite-lived intangible assets as of December 31, 2019 is as follows:
20202021202220232024
Estimated amortization expense$206.2  $205.4  $203.3  $203.0  $203.0  
XML 35 R8.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Nature of Business and Organization
 12 Months Ended
Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Business and Organization Nature of Business and Organization
Nature of Business
Elanco was formed as a wholly-owned subsidiary of Lilly, and is a global animal health company that innovates, develops, manufactures and markets products for companion and food animals. We offer a diverse portfolio of more than 125 brands to veterinarians and food animal producers in more than 90 countries.
Organization
Elanco Parent was formed in 2018, as a wholly-owned subsidiary of Lilly, to serve as the ultimate parent company of substantially all of the animal health businesses of Lilly.
On September 24, 2018, Elanco Parent completed an IPO resulting in the issuance of 72.3 million shares of its common stock (including shares issued pursuant to the underwriters’ option to purchase additional shares), which represented 19.8% of the outstanding shares, at $24 per share resulting in total net proceeds, after underwriting discounts and commissions, of $1.7 billion.  In connection with the completion of the IPO, through a series of equity and other transactions, Lilly transferred to Elanco Parent the animal health businesses that form its business. In exchange, Elanco Parent has paid to Lilly approximately $4.2 billion, which included the net proceeds from the IPO, the net proceeds from the debt offering completed by Elanco Parent in August 2018 and the term loan facility entered into by Elanco Parent in September 2018 (see Note 9: Debt). These transactions are collectively referred to herein as the Separation.
On February 8, 2019, Lilly announced an exchange offer whereby Lilly shareholders could exchange all or a portion of Lilly common stock for shares of Elanco common stock owned by Lilly. The disposition of Elanco shares was completed on March 11, 2019 and resulted in the full separation of Elanco along with the disposal of Lilly's entire ownership and voting interest in Elanco.
XML 36 R13.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Acquisitions
 12 Months Ended
Dec. 31, 2019
Business Combinations [Abstract]  
Acquisitions Acquisitions
During the year ended December 31, 2019, we completed the acquisitions of all outstanding shares of Aratana Therapeutics, Inc. (Aratana) and Prevtec Microbia Inc. (Prevtec). During 2017, we completed the acquisition of BIVIVP. These transactions were accounted for as business combinations under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated and combined financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our consolidated and combined financial statements from the dates of acquisition.
Aratana Therapeutics, Inc.
On July 18, 2019, we acquired Aratana, a pet therapeutics company focused on innovative therapies for dogs and cats, for stock and cash-based contingent value rights. Aratana is the creator of the canine osteoarthritis medicine, Galliprant, the rights to which we acquired in 2016. The acquisition enhances our presence in the areas of appetite stimulants in dogs, pain relief in dogs and cats, and treatments of other conditions in the U.S. and internationally. In connection with the acquisition, we issued approximately 7.2 million shares with a value of $238.0 million to Aratana shareholders, based on our stock price on the last trading day immediately prior to the closing date. The purchase consideration also included up to $12 million in contingent value rights, which represent the rights of Aratana shareholders to receive a contingent payment of $0.25 per share in cash upon the achievement of a specified milestone as outlined in the merger agreement. We calculated an immaterial fair value for the contingent value rights using the Monte Carlo simulation model.
Contingent consideration liabilities that we previously recorded for future royalty and milestone payments in relation to the 2016 acquisition of rights to Galliprant were settled upon the closing of our acquisition of Aratana. The liabilities were valued at $84.7 million as of the acquisition date using the Monte Carlo simulation model. The resulting $7.5 million loss upon settlement was recorded in Other - net, expense in the consolidated and combined statement of operations for the year ended December 31, 2019.
The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:
Estimated Fair Value at July 18, 2019
Cash and cash equivalents$26.4  
Inventories10.3  
Acquired in-process research and development 31.9  
Marketed products (1)
36.7  
Other intangible assets (1)
13.2  
Other assets and liabilities - net 24.0  
Total identifiable net assets142.5  
Goodwill (2)
10.8  
Settlement of existing contingent consideration liabilities84.7  
Total consideration transferred$238.0  
(1) These intangible assets, which are being amortized on a straight-line basis over their estimated useful lives, are expected to have a weighted average useful life of approximately 12.5 years.
(2) The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of Aratana with our legacy business. The majority of goodwill associated with this acquisition is not deductible for tax purposes.
The accounting for this acquisition is substantially complete, with the exception of the finalization of the valuation of intangible assets, tax-related amounts and minor working capital adjustments. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date.
We issued 0.1 million shares and recorded $3.6 million of stock-based compensation expense for the vesting of Aratana equity awards that was accelerated upon the closing of the acquisition during the year ended December 31, 2019.
Our consolidated statement of operations for the year ended December 31, 2019 included revenues of $10.0 million from Aratana.
Had Aratana been acquired on January 1, 2018, the unaudited pro forma combined revenues of Elanco and Aratana would have been $3.1 billion for both the years ending December 31, 2019 and December 31, 2018, and income before income taxes would have been $63.2 million and $117.7 million for the years ending December 31, 2019 and December 31, 2018, respectively.
Prevtec Microbia Inc.
On July 31, 2019, we acquired Prevtec in a cash transaction for approximately $60.3 million, inclusive of certain post-closing adjustments. Prevtec is a Canadian biotechnology company specializing in the development of vaccines intended to help prevent bacterial diseases in food animals. The acquisition allows us to expand on our previous distribution arrangement for Coliprotec and is consistent with our efforts to explore innovative antibiotic alternatives.
The purchase consideration included up to $16.3 million in additional cash consideration, contingent upon the achievement of specific sales milestones by December 31, 2021. We have recorded a $4.7 million liability on the consolidated balance sheet as of the acquisition date based on the fair value of the contingent consideration as calculated using the Monte Carlo simulation model.
A previously existing $0.7 million receivable owed from Prevtec to Elanco Animal Health UK Limited was settled upon the closing of our acquisition of Prevtec. The resulting immaterial gain upon settlement was recorded in Other - net, expense in the consolidated and combined statement of operations for the year ended December 31, 2019.
The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:
Estimated Fair Value at July 31, 2019
Cash and cash equivalents$0.9  
Property and equipment0.5  
Acquired in-process research and development 2.8  
Marketed products(1)
58.9  
Other intangible assets1.1  
Other assets and liabilities - net(10.3) 
Total identifiable net assets53.9  
Goodwill (2)
11.1  
Total consideration transferred$65.0  
(1) These intangible assets, which are being amortized on a straight-line basis over their estimated useful lives, are expected to have a weighted average useful life of 10 years.
(2) The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of Prevtec with our legacy business and future unidentified projects and products. The goodwill associated with this acquisition is not deductible for tax purposes.
The accounting for this acquisition is substantially complete, with the exception of the finalization of the valuation of intangible assets, tax-related amounts and minor working capital adjustments. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date.
Boehringer Ingelheim Vetmedica, Inc. Vaccine Portfolio Acquisition
On January 3, 2017, we acquired BIVIVP in a cash transaction for $882.1 million. Under the terms of the agreement, we acquired a manufacturing and research and development site, a U.S. vaccine portfolio including vaccines used for the treatment of bordetella, Lyme disease, rabies and parvovirus, among others.
The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:
Estimated Fair Value at January 3, 2017
Inventories (1)
$108.6  
Marketed products (2)
297.0  
Property and equipment148.2  
Other assets and liabilities — net8.2  
Total identifiable net assets562.0  
Goodwill (3)
320.1  
Total consideration transferred — net of cash acquired$882.1  
(1) The fair value for inventories include a purchase accounting adjustment to write up the inventory value, which resulted in incremental cost of sales of $42.7 million in 2017. The fair value was determined by estimating the expected sales price of the inventories, reduced for all costs expected to the incurred and a profit on those costs.
(2) These intangible assets, which are being amortized on a straight-line basis over their estimated useful lives, were expected to have a weighted average useful life of 10 years.
(3) The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of BIVIVP with our legacy business, future unidentified projects and products, and the assembled workforce of BIVIVP. The goodwill associated with this acquisition is deductible for tax purposes.
Our combined statement of operations for the year ended December 31, 2017 included BIVIVP revenues of $216.7 million. We are unable to provide the results of operations attributable to BIVIVP as those operations were substantially integrated into our legacy business.
Pending Acquisition
Bayer Animal Health Business
In August 2019, we entered into the Purchase Agreement with Bayer, a German corporation, to acquire Bayer's animal health business. Bayer's animal health business is a provider of products intended to improve the health and well-being of pets and farm animals. This acquisition is expected to expand our Companion Animal product category, advance our planned intentional portfolio mix transformation and create a better balance between our Food Animal and Companion Animal product categories. Pursuant to the Purchase Agreement and subject to the satisfaction of certain customary closing conditions, including the receipt of antitrust approvals and the absence of any law or order enjoining or otherwise prohibiting the transaction in specified jurisdictions, we will purchase Bayer’s animal health business for approximately $5.3 billion in cash and approximately $2.3 billion of our common stock, subject to certain customary adjustments. Unless the parties agree otherwise, the transaction will close no earlier than July 1, 2020, per the terms of the Purchase Agreement. See Note 16: Commitments and Contingencies for discussion regarding certain commitments related to this transaction.
XML 37 R17.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Financial Instruments and Fair Value
 12 Months Ended
Dec. 31, 2019
Fair Value Disclosures [Abstract]  
Financial Instruments and Fair Value Financial Instruments and Fair Value
Financial instruments that are potentially subject to credit risk consist principally of trade receivables. Collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures.
A large portion of our cash is held by a few major financial institutions. We monitor the exposure with these institutions and do not expect any of these institutions to fail to meet their obligations. All highly liquid investments with a maturity of three months or less from the date of purchase are considered to be cash equivalents. The cost of these investments approximates fair value. We also consider the carrying value of restricted cash balances to be representative of its fair value.
As of December 31, 2019 and 2018, we had $18.8 million and $15.3 million, respectively, primarily related to equity method investments included in other noncurrent assets in our consolidated balance sheet.
The following table summarizes the fair value information at December 31, 2019 and 2018 for contingent consideration liabilities, and net investment hedge assets/(liabilities) measured at fair value on a recurring basis in the respective balance sheet line items, as well as long-term debt for which fair value is disclosed on a recurring basis:
  Fair Value Measurements Using 
Financial statement line itemCarrying AmountQuoted Prices in Active Markets for Identical Assets (Level 1)Significant Other Observable Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)		Fair Value
December 31, 2019
Other noncurrent liabilities- contingent consideration$(4.7) $—  $—  $(4.7) $(4.7) 
Other noncurrent assets/(liabilities) - cross currency interest rate contracts designated as net investment hedges2.3  —  2.3  —  2.3  
Long-term debt - senior notes(2,000.0) —  (2,120.6) —  (2,120.6) 
Long-term debt - term credit facility(371.4) —  (371.4) —  (371.4) 
December 31, 2018
Other current liabilities- contingent consideration$(5.1) $—  $—  $(5.1) $(5.1) 
Other noncurrent liabilities- contingent consideration(69.0) —  —  (69.0) (69.0) 
Other noncurrent assets/(liabilities) - cross currency interest rate contracts designated as net investment hedges(7.4) —  (7.4) —  (7.4) 
Long-term debt - senior notes(2,000.0) —  (2,005.0) —  (2,005.0) 
Long-term debt - term credit facility(492.5) —  (492.5) —  (492.5) 
We determine our Level 2 fair value measurements based on a market approach using quoted market values or significant other observable inputs for identical or comparable assets or liabilities.

Contingent consideration liabilities as of December 31, 2019 related to contingent consideration associated with the acquisitions of Aratana and Prevtec during the period. For Aratana, we will pay up to $12 million in contingent value rights that are dependent on the achievement of a specified milestone as outlined in the merger agreement. For Prevtec, based on the terms of the purchase agreement, we will pay up to $16.3 million contingent upon the achievement of specific Coliprotec sales milestones by December 31, 2021. The fair value of both contingent consideration liabilities was estimated using the Monte Carlo simulation model and Level 3 inputs including historical revenue, discount rate, asset volatility, and revenue volatility. See Note 6: Acquisitions for further discussion.
Contingent consideration liabilities as of December 31, 2018 related to Galliprant for which the fair value was estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant view for the probability of achieving potential future payments to Aratana and an estimated discount rate. The amount to be paid as of December 31, 2018 was dependent upon certain development, success-based regulatory, and sales-based milestones. These liabilities were settled upon the closing of our acquisition of Aratana on July 18, 2019. See Note 6: Acquisitions for further discussion.

In October 2018, we entered into a five-year cross-currency fixed interest rate swap with a 750 million Swiss Franc (CHF) notional amount, which is designated as a NIH against CHF denominated assets for which the fair value was estimated based on quoted market values of similar hedges and is classified as Level 2. The NIH is expected to generate approximately $25 million in cash and an offset to interest expense on an annual basis. For the years ended December 31, 2019 and 2018, our interest expense was offset by $25.1 million and $5.6 million, respectively, as a result of the NIH. Over the life of the derivative, gains or losses due to spot rate fluctuations are recorded in cumulative translation adjustment in other comprehensive income. During the years ended December 31, 2019 and 2018, we recorded a gain of $7.7 million and a loss of $5.9 million, respectively, net of tax, on the NIH, which is included in the change in the cumulative translation adjustment. There is a potential for significant 2023 settlement exposure as the U.S. dollar fluctuates against the Swiss Franc. The risk management objective is to manage foreign currency risk relating to net investments in certain CHF denominated assets. Changes in fair value of the derivative instruments are recognized in a component of accumulated other comprehensive loss to offset the changes in the values of the net investments being hedged.
EXCEL 38 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

XML 40 R29.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Subsequent Events
 12 Months Ended
Dec. 31, 2019
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
Bayer Animal Health acquisition financing
Equity offerings
On January 22, 2020, we entered into an underwriting agreement in which we agreed to sell approximately 22.7 million shares of our common stock at a public offering price of $32.00 per share. In connection with the offering, we granted the underwriters an option to purchase up to an additional 2.3 million shares, which was exercised in full on January 23, 2020. As a result, we issued and sold a total of approximately 25.0 million shares of our common stock. Total cash of $769.9 million was received upon closing on January 27, 2020.
In addition, on January 22, 2020, we issued $550 million in tangible equity units (TEUs). We offered 11 million 5.00% TEUs at the stated amount of $50 per unit, composed of a prepaid stock purchase contract and a senior amortizing note due February 1, 2023 (the mandatory settlement date). Total cash of $530.1 million was received upon closing on January 27, 2020, which was comprised of $453.8 million of prepaid stock purchase contracts and $76.3 million of senior amortizing notes, net of debt issuance costs. Unless the stock purchase contracts are redeemed by us or settled earlier at the unit holder’s option, they are mandatorily convertible into shares of our common stock at a minimum of 1.3021 shares per purchase contract or a maximum of 1.5625 shares per purchase contract on the mandatory settlement date. This corresponds to a minimum of 14.3 million shares and a maximum of 17.2 million shares.
Debt activity
On January 31, 2020, we used a portion of the proceeds from the common stock and TEU issuances to repay indebtedness outstanding under our existing term loan facility. We paid $372.4 million in cash, composed of $371.4 million of principal and $1.0 million of accrued interest, resulting in a debt extinguishment loss of $0.8 million, primarily related to the write-off of deferred debt issuance costs.
On February 4, 2020, we successfully priced our senior secured credit facilities, consisting of the following:
•Term loan B facility with an aggregate principal amount of $4,275.0 million and a maturity of seven years.
•Revolving loan facility providing up to $750.0 million and a maturity of five years.
The term loan B facility was priced at par at LIBOR plus 175 basis points, and the revolving loan facility is expected to bear interest at LIBOR plus an applicable margin ranging between 1.50% and 2.25% per annum based on our corporate family rating or corporate credit rating.
We intend to use the proceeds from the equity and debt activities to finance the cash portion of the pending acquisition of Bayer's animal health business and to pay related fees and expenses. As a result, we have obtained substantially all of the financing necessary to consummate the acquisition and do not currently intend to pursue any additional financing previously provided under the commitment letter obtained in August 2019 (see Note 16: Commitments and Contingencies).
Divestitures
Osurnia and Capstar
In January 2020, we signed agreements to divest the worldwide rights to Osurnia and the U.S. rights to Capstar for an aggregate of $230 million in all cash deals, with the intent to advance our efforts to secure the necessary regulatory clearances for the pending acquisition of the Bayer animal health business. The closing of these transactions is contingent on us entering into consent decrees with certain agencies in connection with the pending acquisition as well as customary closing conditions. Both divestitures are expected to close by the end of 2020.
The related assets met the assets held for sale criteria as of December 31, 2019. No adjustment was required to record the assets at the lower of their carrying amounts or fair values less costs to sell on the consolidated balance sheet. Assets and liabilities considered held for sale in connection with the divestitures as of December 31, 2019 were included in the respective line items in the consolidated balance sheet as follows:

Inventories$10.6  
Other intangibles, net61.2  
Property and equipment, net0.2  
Total assets held for sale72.0  
Deferred taxes(1.4) 
Total liabilities held for sale$(1.4) 
Other intangibles, net classified as held for sale primarily consist of marketed products. We determined that the disposal of these net assets does not qualify for reporting as a discontinued operation because it does not represent a strategic shift that has or will have a major effect on our operations and financial results.
Vecoxan
In February 2020, we signed an agreement to divest the worldwide rights to Vecoxan for $55 million in an all cash deal, with the intent to advance our efforts to secure the necessary regulatory clearances for the pending acquisition of the Bayer animal health business. The closing of this transaction is contingent on us entering into consent decrees with certain agencies in connection with the pending acquisition as well as customary closing conditions. This divestiture is expected to close by the end of 2020.
XML 41 R21.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stock-Based Compensation
 12 Months Ended
Dec. 31, 2019
Share-based Payment Arrangement [Abstract]  
Stock-Based Compensation Stock-Based Compensation
Elanco Stock Compensation Plans
The 2018 Elanco Stock Plan (Plan) provides long-term incentives to attract, motivate and retain employees and non-employee directors. The types of stock-based awards available include, but are not limited to, restricted stock units (RSUs), performance-based awards (PAs), and stock options. Our practices and policies specify that stock-based compensation awards are approved by the Compensation Committee of the Board of Directors. The Plan, initially authorized the issuance of up to 5.5 million common shares (subject to adjustments for certain events). Pursuant to the terms of the Plan, an additional 5.5 million common shares became automatically available for all awards upon completion of the Separation. The total number of shares authorized for stock-based compensation awards is 11 million as of December 31, 2019.
Stock-Based Compensation Expense

Components of stock-based compensation expense and related tax benefit for the years ended December 31 are as follows:
20192018
Stock-based compensation expense (1)
$40.7  $1.8  
Related tax benefit (9.8) (0.4) 
(1) We include the impact of estimated forfeitures when determining stock-based compensation expense.
Restricted Stock Units
RSUs are granted to certain employees and are settled in shares of our common stock. RSU shares are accounted for at fair value based upon the closing stock price on the date of the grant. The corresponding expense is amortized over the vesting period, typically three years. The number of shares ultimately issued for the RSU program remains constant with the exception of forfeitures.
RSUs granted to employees for the years ended December 31 are as follows:
(Units in millions)20192018
Granted units2.9  0.2  
Weighted-average fair value$31.22  $31.09  
Changes in nonvested portion of RSUs for 2019 is summarized below:
(Shares in millions)SharesWeighted-Average Fair Value
Nonvested units at January 1, 20190.2$31.09  
Granted2.931.22  
Vested(0.8)31.33  
Forfeited(0.1)31.25  
Nonvested units at December 31, 20192.230.42  

As of December 31, 2019, the total remaining unrecognized stock-based compensation expense related to nonvested RSUs was $25.5 million, which will amortize over the weighted-average remaining requisite service period of 19 months.
Performance-Based Awards
PAs, which are granted to eligible officers and management, represent the right to receive a share of our common stock and are subject to forfeiture until restrictions lapse (including continued employment through the end of the vesting period and achievement of certain pre-established metrics). Payouts can vary depending on achievement. PA shares are accounted for at fair value based upon the closing stock price on the date of grant and fully vest at the end of the measurement period.
PA activity during the year ended December 31, 2019 is summarized below:
(Shares in millions)SharesWeighted-Average Fair Value
Nonvested awards at January 1, 2019—  $—  
Granted0.8  25.75  
Vested—  —  
Forfeited—  —  
Nonvested awards at December 31, 20190.8  25.75  
As of December 31, 2019, the total remaining unrecognized stock-based compensation expense related to nonvested PAs was $11.0 million, which will amortize over the weighted-average remaining requisite service period of 13 months.
Stock Option Program
Stock options represent the right to purchase shares of our common stock within a specified period of time at a specified price. The exercise price for a stock option will be not less than 100% of the fair market value of the common stock on the date of the grant.
Stock options are accounted for using a fair-value based method at the date of the grant in the consolidated statement of operations. The values determined through this fair-value-based method generally are amortized on a straight-line basis over the vesting term.
Stock options were granted in 2018 to our officers, management and board members at exercise prices equal to the fair market value of our stock at the date of the grant. Options fully vest 3 years from the grant date and have a term of 10 years. No stock options were granted in 2019.
The fair-value-based method for valuing each Elanco stock option grant on the grant date uses the Black-Scholes-Merton option-pricing model, which incorporates a number of valuation assumptions noted in the following table, shown at their weighted-average values for the year ended December 31:
2018
Expected dividend yield(1)
0.70 %
Risk-free interest rate(2)
3.07 %
Expected stock price volatility(3)
28.25 %
Expected term(4) (years)
6.5
(1) Determined using the expected quarterly dividend divided by the available three-month average stock price as of the valuation date, annualized and continuously compounded.
(2) Determined using the term-matched, zero-coupon risk-free rate from the Treasury Constant Maturity yield curve, continuously compounded
(3) Determined using a leverage-adjusted historical volatility of peer companies
(4) Determined using SEC safe harbor approach, based on a 3-year cliff vesting schedule and 10-year contractual term.
Stock option activity during the year ended December 31, 2019 is summarized below:
(Shares in millions)Shares of Common Stock Attributable to OptionsWeighted-Average Exercise Price of OptionsWeighted-Average Remaining Contractual Term (Years)
Aggregate Intrinsic Value(1)
Outstanding at January 1, 20190.4  $31.61  
Granted—  —  
Exercised(0.1) 31.61  
Forfeited or expired—  —  
Outstanding at December 31, 20190.3  $31.61  8.8$—  
Exercisable at December 31, 2019—  —  —  —  
(1)Market price of underlying Elanco common stock less exercise price. Options do not have an intrinsic value unless the market price exceeds the exercise price.
As of December 31, 2019, there was approximately $2.2 million of unrecognized compensation costs related to nonvested stock options, which will be recognized over an expected remaining weighted-average period of 22 months.
The following table summarizes data related to stock option activity:
20192018
Weighted-average grant date fair value per stock option$10.21  $10.21  
Aggregate intrinsic value on exercise0.10  —  
Cash received upon exercise1.9  —  
Treatment of Lilly Equity Awards
Prior to the Separation, our employees participated in Lilly stock-based compensation plans, the cost of which was allocated to us and recorded in costs of sales, research and development, and marketing, selling and administrative expense in the consolidated and combined statements of operations. The cost of such plans related to our employees was $5.1 million, $26.0 million and $25.0 million for the years ended December 31, 2019, 2018 and 2017, respectively.
Following the IPO and until completion of the exchange offer, the equity awards previously granted to our employees by Lilly continued to vest with Elanco service counting toward the Lilly award's vesting provisions. On March 11, 2019, Elanco completed the exchange offer whereby Lilly disposed of all of its shares of Elanco common stock owned by Lilly. As a result, our employees' unvested Lilly equity awards were forfeited and replaced with Elanco RSUs (replacement awards), which were equivalent in value and vest on the same date as their forfeited Lilly equity awards. These replacement awards are included in the RSU activity described above.
XML 42 R25.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Retirement Benefits
 12 Months Ended
Dec. 31, 2019
Retirement Benefits [Abstract]  
Retirement Benefits Retirement Benefits
Pension Plans
There are certain defined benefit pension plans that our employees participate in that are either dedicated to our employees or where the plan assets and liabilities that relate to our employees were legally required to transfer to Elanco at the time of our separation from Lilly. The plans in Switzerland represent approximately 80% of our global benefit obligation. We use a measurement date of December 31 to develop the change in benefit obligation, change in plan assets, funded status and amounts recognized in the consolidated balance sheets at December 31 for our defined benefit pension plans, which were as follows:
  20192018
Change in benefit obligation:
Benefit obligation at beginning of year$234.8  $258.6  
Service cost9.3  11.3  
Interest cost2.2  2.5  
Actuarial loss (gain)56.4  (44.7) 
Benefits paid(5.5) (2.7) 
Plan amendments(74.7) —  
Foreign currency exchange rate changes and other adjustments
1.9  9.8  
Benefit obligation at end of year224.4  234.8  
Change in plan assets:
Fair value of plan assets at beginning of year131.6  131.5  
Actual return on plan assets15.3  (10.2) 
Employer contribution5.3  5.7  
Benefits paid(5.5) (2.7) 
Foreign currency exchange rate changes and other adjustments
2.0  7.3  
Fair value of plan assets at end of year148.7  131.6  

Funded status(75.7) (103.2) 
Unrecognized net actuarial loss45.9  0.5  
Unrecognized prior service cost(74.1) 0.8  
Net amount recognized$(103.9) $(101.9) 

Amounts recognized in the consolidated balance sheet consisted of:
Noncurrent assets$2.1  $2.3  
Other current liabilities(0.3) (0.3) 
Accrued retirement benefits(77.5) (105.2) 
Accumulated other comprehensive (income) loss before income taxes
(28.2) 1.3  
Net amount recognized$(103.9) $(101.9) 
The unrecognized net actuarial loss and unrecognized prior service cost for these pension plans have not yet been recognized in net periodic pension costs and are included in accumulated other comprehensive loss at December 31, 2019.
Pension plan amendment
In September 2019, we signed agreements under which certain defined pension benefits in Switzerland transferred from the previous Lilly pension fund as of December 31, 2019 to a new Elanco pension fund effective January 1, 2020. This resulted in a plan amendment during the period. The plan amendment decreased our pension benefit obligation by approximately $21 million, consisting primarily of a decrease in prior service costs of approximately $75 million, partially offset by a loss of approximately $54 million driven by changes in certain assumptions. The net impact to accumulated other comprehensive income was a gain of approximately $21 million, which will be amortized over the average remaining service period of employees expected to receive benefits under the plans.
We do not expect any plan assets to be returned to us in 2020.
The following represents our weighted-average assumptions related to these pension plans as of December 31:
(Percents)201920182017
Discount rate for benefit obligation0.6%  1.5%  1.1%  
Discount rate for net benefit costs1.4  1.1  1.0  
Rate of compensation increase for benefit obligation2.3  2.2  2.1  
Rate of compensation increase for net benefit costs2.2  2.1  3.1  
Expected return on plan assets for net benefit costs4.0  4.0  4.4  
We annually evaluate the expected return on the plan assets in these pension plans. In evaluating the expected rate of return, we consider many factors, with a primary analysis of current and projected market conditions; asset returns and asset allocations; and the views of leading financial advisers and economists. We may also review our historical assumptions compared with actual results, as well as the assumptions and trend rates utilized by similar plans, where applicable.
The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:
202020212022202320242025-2029
Benefit payments$7.9  $8.6  $8.4  $8.0  $8.1  $48.4  
Amounts relating to these pension plans with projected benefit obligations in excess of plan assets were as follows at December 31:
 20192018
Projected benefit obligation$218.2  $229.2  
Fair value of plan assets140.3  124.1  
Amounts relating to these defined benefit pension plans with accumulated benefit obligations in excess of plan assets were as follows at December 31:
 20192018
Accumulated benefit obligation$203.9  $194.3  
Fair value of plan assets140.3  124.1  
The total accumulated benefit obligation for these defined benefit pension plans was $210.1 million and $199.9 million at December 31, 2019 and 2018, respectively.
Net pension expense related to these plans included the following components:
  201920182017
Service cost$9.3  $11.3  $10.5  
Interest cost2.2  2.5  1.8  
Expected return on plan assets(4.2) (6.2) (2.4) 
Amortization of prior service cost
(1.7) 0.2  0.1  
Amortization of net actuarial loss1.1  1.9  1.4  
Other—  0.5  —  
Net pension expense$6.7  $10.2  $11.4  
The following represents the amounts recognized for these plans in other comprehensive loss:
201920182017
Actuarial gain (loss) arising during period$(45.6) $28.3  $(17.0) 
Prior year service cost during the year74.7  —  —  
Amortization of prior service cost included in net loss(1.7) 0.2  0.1  
Amortization of net actuarial loss included in net loss1.1  1.9  1.4  
Foreign currency exchange rate changes and other1.0  (1.9) 3.5  
Total other comprehensive income (loss) during period$29.5  $28.5  $(12.0) 
Benefit Plan Investments
Our benefit plan investment policies are set with specific consideration of return and risk requirements in relationship to the respective liabilities. Our plan assets in our Switzerland pension plans represent approximately 87% of our plan assets for these pension plans. Given the long-term nature of our liabilities, these plans have the flexibility to manage an above-average degree of risk in the asset portfolios. At the investment-policy level, there are no specifically prohibited investments. However, within individual investment manager mandates, restrictions and limitations are contractually set to align with our investment objectives, ensure risk control and limit concentrations.
We manage our portfolio to minimize concentration of risk by allocating funds within asset categories. In addition, within a category we use different managers with various management objectives to eliminate any significant concentration of risk.
The investment strategy is to diversify in five major categories with a designated percentage invested in each including 5% liquidity, 36% fixed income securities, 32% equity securities, a share of 21% in real estate and 6% in other alternative investments. Each category is diversified and comprised of the following:
•Liquidity - cash and cash equivalents
•Fixed-income securities - Swiss bonds, global aggregates, global aggregate corporates, emerging market local currencies and emerging markets hard currencies.
•Equity investments - Swiss equities, global equities, low volatility equities (to reduce risk), and emerging market equities.
•Real estate - Swiss real estate and global real estate funds.
•Other investments - represents primarily investments in senior secured loans.
We determine the fair value of the investments based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analysis for all investments except hedge funds, private equity-like investments and real estate.
We determine the fair value of investments using the value reported by the partnership, adjusted for known cash flows and significant events through our reporting date. Values provided by the partnerships are primarily based on analysis of and judgments about the underlying investments. Inputs to these valuations include underlying NAVs, discounted cash flow valuations, comparable market valuations, and may also include adjustments for currency, credit, liquidity and other risks as applicable. The vast majority of these private partnerships provide us with annual financial statements including their compliance with fair valuation procedures consistent with applicable accounting standards.
We determine the fair value of real estate investments based on the NAV provided by the fund manager. These NAVs are developed with inputs including discounted cash flow, independent appraisal and market comparable analyses.
The fair values of these pension plan assets as of December 31, 2019 by asset category are as follows:
  Fair Value Measurements Using
Asset ClassTotalQuoted Prices in Active Markets for Identical Assets
(Level 1)		Significant Observable 
Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)
Investments Valued at Net Asset Value(1)
Cash and cash equivalents (2)
$129.0  $129.0  $—  $—  $—  
Public equity securities3.8  1.9  —  —  1.9  
Fixed income:
Developed markets2.5  2.1  —  —  0.4  
Emerging markets9.1  8.8  0.3  —  —  
Other4.3  0.9  3.4  —  —  
Total$148.7  $142.7  $3.7  $—  $2.3  
(1)Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.
(2)Switzerland plan assets were exiting the Lilly pension plan as of December 31, 2019. As a result, assets were converted to cash and transferred to the new Elanco pension fund effective January 1, 2020.

No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December 31, 2019. The activity in the Level 3 investments during the year ended December 31, 2019 was not material.
The fair values of these pension plan assets as of December 31, 2018 by asset category are as follows:
Fair Value Measurements Using
Asset ClassTotalQuoted Prices in Active Markets for Identical Assets
(Level 1)		Significant Observable Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)
Investments Valued at Net Asset Value(1)
Public equity securities$2.2  $1.0  $—  $—  $1.2  
Fixed income:
Developed markets29.9  7.8  0.1  —  22.0  
Emerging markets6.4  0.7  0.4  —  5.3  
Private alternative investments:
Hedge funds6.6  —  —  —  6.6  
Equity-like funds49.0  —  —  —  49.0  
Real estate20.1  0.1  —  —  20.0  
Other17.4  0.3  2.3  —  14.8  
Total$131.6  $9.9  $2.8  $—  $118.9  
(1)Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.
No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December 31, 2018. The activity in the Level 3 investments during the year ended December 31, 2018 was not material.
Contributions of $6.5 million to these pension plans are expected in 2020.
Retiree Health Benefit Plan
There are two retiree health benefit plan where the plan liabilities that relate to our employees were legally required to transfer to Elanco at the time of separation from Lilly. The accrued retirement benefits for these plans were $4.7 million and $3.9 million as of December 31, 2019 and 2018, respectively.
Defined Contribution Plans
Elanco has defined contribution savings plans that include certain employees worldwide. The purpose of these plans is generally to provide additional financial security during retirement by providing employees with an incentive to save. Our contributions to the plans are based on our employee contributions and the level of our match. Expenses related to our employees under the plans totaled $32.2 million, $20.9 million and $22.1 million for the years ended December 31, 2019, 2018, and 2017, respectively. The expense for our 401(k) plan increased in 2019 primarily due to an increase our match and participant headcount.
Treatment of Lilly Plans
Prior to the Separation, our employees participated in defined benefit pension and other postretirement plans sponsored by Lilly, which include participants of Lilly's other business. Such plans were accounted for as multiemployer plans in the combined financial statements and as a result, no asset or liability was recorded by us to recognize the funded status of these plans.
We recorded expense of $4.0 million and $73.7 million for the years ended December 31, 2018 and 2017, respectively, relating to our employees’ participation in Lilly sponsored plans. The expense recorded in 2017 included $67.0 million related to a curtailment loss and special termination benefits for early retirement incentives offered by Lilly to our employees as part of a voluntary early retirement program for the U.S. plan and which has been recorded in asset impairment, restructuring and other special charges.
XML 44 R63.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Financial Instruments and Fair Value - Summary of Fair Value Information (Details) - Recurring - USD ($)
$ in Millions
Dec. 31, 2019
Dec. 31, 2018
Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other noncurrent assets/(liabilities) - cross currency interest rate contracts designated as net investment hedges $ 0.0 $ 0.0
Long-term debt - senior notes 0.0 0.0
Long-term debt - term credit facility 0.0 0.0
Significant Observable  Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other noncurrent assets/(liabilities) - cross currency interest rate contracts designated as net investment hedges 2.3 (7.4)
Long-term debt - senior notes (2,120.6) (2,005.0)
Long-term debt - term credit facility (371.4) (492.5)
Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other noncurrent assets/(liabilities) - cross currency interest rate contracts designated as net investment hedges 0.0 0.0
Long-term debt - senior notes 0.0 0.0
Long-term debt - term credit facility 0.0 0.0
Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other noncurrent assets/(liabilities) - cross currency interest rate contracts designated as net investment hedges 2.3 (7.4)
Long-term debt - senior notes (2,000.0) (2,000.0)
Long-term debt - term credit facility (371.4) (492.5)
Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other noncurrent assets/(liabilities) - cross currency interest rate contracts designated as net investment hedges 2.3 (7.4)
Long-term debt - senior notes (2,120.6) (2,005.0)
Long-term debt - term credit facility (371.4) (492.5)
Other current liabilities- contingent consideration | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration   0.0
Other current liabilities- contingent consideration | Significant Observable  Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration   0.0
Other current liabilities- contingent consideration | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration   (5.1)
Other current liabilities- contingent consideration | Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration   (5.1)
Other current liabilities- contingent consideration | Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration   (5.1)
Other noncurrent liabilities- contingent consideration | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration 0.0 0.0
Other noncurrent liabilities- contingent consideration | Significant Observable  Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration 0.0 0.0
Other noncurrent liabilities- contingent consideration | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration (4.7) (69.0)
Other noncurrent liabilities- contingent consideration | Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration (4.7) (69.0)
Other noncurrent liabilities- contingent consideration | Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration $ (4.7) $ (69.0)
XML 45 R93.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Retirement Benefits - Change in Benefit Obligation, Change in Plan Assets, and Funded Status (Details) - USD ($)
$ in Millions
 1 Months Ended 12 Months Ended
Sep. 30, 2019
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Change in benefit obligation:        
Plan amendments $ (21.0)      
Pension Plans        
Change in benefit obligation:        
Benefit obligation at beginning of year   $ 234.8 $ 258.6  
Service cost   9.3 11.3 $ 10.5
Interest cost   2.2 2.5 1.8
Actuarial loss (gain)   56.4 (44.7)  
Benefits paid   (5.5) (2.7)  
Plan amendments   74.7 0.0  
Foreign currency exchange rate changes and other adjustments   1.9 9.8  
Benefit obligation at end of year   224.4 234.8 258.6
Change in plan assets:        
Fair value of plan assets at beginning of year   131.6 131.5  
Actual return on plan assets   15.3 (10.2)  
Employer contribution   5.3 5.7  
Benefits paid   (5.5) (2.7)  
Foreign currency exchange rate changes and other adjustments   2.0 7.3  
Fair value of plan assets at end of year   148.7 131.6 $ 131.5
Funded status   (75.7) (103.2)  
Unrecognized net actuarial loss   45.9 0.5  
Unrecognized prior service cost   (74.1) 0.8  
Net amount recognized   $ (103.9) $ (101.9)  
XML 46 R97.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Retirement Benefits - Projected Benefit Obligations in Excess of Plan Assets (Details) - Pension Plans - USD ($)
$ in Millions
Dec. 31, 2019
Dec. 31, 2018
Defined Benefit Plan Disclosure [Line Items]    
Projected benefit obligation $ 218.2 $ 229.2
Fair value of plan assets $ 140.3 $ 124.1
XML 47 R67.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Goodwill and Intangibles - Estimated Amortization Expense (Details)
$ in Millions
Dec. 31, 2019
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
2020 $ 206.2
2021 205.4
2022 203.3
2023 203.0
2024 $ 203.0
XML 48 R44.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Retirement Benefits (Tables)
 12 Months Ended
Dec. 31, 2019
Retirement Benefits [Abstract]  
Change in Benefit Obligation, Change in Plan Assets, and Funded Status We use a measurement date of December 31 to develop the change in benefit obligation, change in plan assets, funded status and amounts recognized in the consolidated balance sheets at December 31 for our defined benefit pension plans, which were as follows:
  20192018
Change in benefit obligation:
Benefit obligation at beginning of year$234.8  $258.6  
Service cost9.3  11.3  
Interest cost2.2  2.5  
Actuarial loss (gain)56.4  (44.7) 
Benefits paid(5.5) (2.7) 
Plan amendments(74.7) —  
Foreign currency exchange rate changes and other adjustments
1.9  9.8  
Benefit obligation at end of year224.4  234.8  
Change in plan assets:
Fair value of plan assets at beginning of year131.6  131.5  
Actual return on plan assets15.3  (10.2) 
Employer contribution5.3  5.7  
Benefits paid(5.5) (2.7) 
Foreign currency exchange rate changes and other adjustments
2.0  7.3  
Fair value of plan assets at end of year148.7  131.6  

Funded status(75.7) (103.2) 
Unrecognized net actuarial loss45.9  0.5  
Unrecognized prior service cost(74.1) 0.8  
Net amount recognized$(103.9) $(101.9) 
Amounts Recognized in Combined Balance Sheet
Amounts recognized in the consolidated balance sheet consisted of:
Noncurrent assets$2.1  $2.3  
Other current liabilities(0.3) (0.3) 
Accrued retirement benefits(77.5) (105.2) 
Accumulated other comprehensive (income) loss before income taxes
(28.2) 1.3  
Net amount recognized$(103.9) $(101.9) 
Weighted-Average Assumptions Related to Pension Plans
The following represents our weighted-average assumptions related to these pension plans as of December 31:
(Percents)201920182017
Discount rate for benefit obligation0.6%  1.5%  1.1%  
Discount rate for net benefit costs1.4  1.1  1.0  
Rate of compensation increase for benefit obligation2.3  2.2  2.1  
Rate of compensation increase for net benefit costs2.2  2.1  3.1  
Expected return on plan assets for net benefit costs4.0  4.0  4.4  
Schedule of Expected Benefit Payments
The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:
202020212022202320242025-2029
Benefit payments$7.9  $8.6  $8.4  $8.0  $8.1  $48.4  
Projected Benefit Obligations in Excess of Plan Assets
Amounts relating to these pension plans with projected benefit obligations in excess of plan assets were as follows at December 31:
 20192018
Projected benefit obligation$218.2  $229.2  
Fair value of plan assets140.3  124.1  
Accumulated Benefit Obligations in Excess of Plan Assets
Amounts relating to these defined benefit pension plans with accumulated benefit obligations in excess of plan assets were as follows at December 31:
 20192018
Accumulated benefit obligation$203.9  $194.3  
Fair value of plan assets140.3  124.1  
Net Pension Expense
Net pension expense related to these plans included the following components:
  201920182017
Service cost$9.3  $11.3  $10.5  
Interest cost2.2  2.5  1.8  
Expected return on plan assets(4.2) (6.2) (2.4) 
Amortization of prior service cost
(1.7) 0.2  0.1  
Amortization of net actuarial loss1.1  1.9  1.4  
Other—  0.5  —  
Net pension expense$6.7  $10.2  $11.4  
Amounts Recognized in Other Comprehensive Loss
The following represents the amounts recognized for these plans in other comprehensive loss:
201920182017
Actuarial gain (loss) arising during period$(45.6) $28.3  $(17.0) 
Prior year service cost during the year74.7  —  —  
Amortization of prior service cost included in net loss(1.7) 0.2  0.1  
Amortization of net actuarial loss included in net loss1.1  1.9  1.4  
Foreign currency exchange rate changes and other1.0  (1.9) 3.5  
Total other comprehensive income (loss) during period$29.5  $28.5  $(12.0) 
Fair Value of Pension Plan Assets
The fair values of these pension plan assets as of December 31, 2019 by asset category are as follows:
  Fair Value Measurements Using
Asset ClassTotalQuoted Prices in Active Markets for Identical Assets
(Level 1)		Significant Observable 
Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)
Investments Valued at Net Asset Value(1)
Cash and cash equivalents (2)
$129.0  $129.0  $—  $—  $—  
Public equity securities3.8  1.9  —  —  1.9  
Fixed income:
Developed markets2.5  2.1  —  —  0.4  
Emerging markets9.1  8.8  0.3  —  —  
Other4.3  0.9  3.4  —  —  
Total$148.7  $142.7  $3.7  $—  $2.3  
(1)Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.
(2)Switzerland plan assets were exiting the Lilly pension plan as of December 31, 2019. As a result, assets were converted to cash and transferred to the new Elanco pension fund effective January 1, 2020.
The fair values of these pension plan assets as of December 31, 2018 by asset category are as follows:
Fair Value Measurements Using
Asset ClassTotalQuoted Prices in Active Markets for Identical Assets
(Level 1)		Significant Observable Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)
Investments Valued at Net Asset Value(1)
Public equity securities$2.2  $1.0  $—  $—  $1.2  
Fixed income:
Developed markets29.9  7.8  0.1  —  22.0  
Emerging markets6.4  0.7  0.4  —  5.3  
Private alternative investments:
Hedge funds6.6  —  —  —  6.6  
Equity-like funds49.0  —  —  —  49.0  
Real estate20.1  0.1  —  —  20.0  
Other17.4  0.3  2.3  —  14.8  
Total$131.6  $9.9  $2.8  $—  $118.9  
(1)Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.
XML 49 R40.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases (Tables)
 12 Months Ended
Dec. 31, 2019
Leases [Abstract]  
Impact of Operating Leases to Condensed Consolidated Financial Statements
The impact of operating leases to our consolidated financial statements for the year ended December 31, 2019 was as follows:
2019
Lease cost
Operating lease cost$26.1  
Short-term lease cost0.5  
Variable lease cost2.5  
Total lease cost (1)
$29.1  
Other information
Operating cash outflows from operating leases$24.0  
Right-of-use assets obtained in exchange for new operating lease liabilities20.1  
Weighted-average remaining lease term - operating leases5.1 years
Weighted-average discount rate - operating leases3.6 %
(1) Rental expense for all leases was $47.5 million and $47.1 million for the years ended December 31, 2018 and 2017, respectively.
Supplemental Balance Sheet Information Related to Operating Leases
Supplemental balance sheet information related to our operating leases is as follows:
Balance Sheet ClassificationDecember 31, 2019
Right-of-use assetsOther noncurrent assets$85.0  
Current operating lease liabilitiesOther current liabilities23.7  
Non-current operating lease liabilitiesOther noncurrent liabilities61.7  
Annual Minimum Lease Payments of Operating Lease Liabilities
As of December 31, 2019, the annual minimum lease payments of our operating lease liabilities were as follows:
Year 1$26.0  
Year 220.3  
Year 311.9  
Year 49.7  
Year 57.2  
After Year 516.5  
Total lease payments91.6  
Less imputed interest(6.2) 
Total$85.4  
XML 50 R48.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Nature of Business and Organization (Details)
$ / shares in Units, $ in Billions
Sep. 24, 2018
USD ($)
$ / shares
shares
Dec. 31, 2019
USD ($)
country
brand
Subsidiary, Sale of Stock [Line Items]    
Number of brands in diverse portfolio (more than) | brand   125
Number of countries in which entity operates (more than) | country   90
IPO    
Subsidiary, Sale of Stock [Line Items]    
Number of shares issued (in shares) | shares 72,335,000  
Percentage of total outstanding shares 19.80%  
Price per share (usd per share) | $ / shares $ 24  
Total net proceeds, after underwriting discounts and commissions $ 1.7  
Payments made to date   $ 4.2
XML 51 R20.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases
 12 Months Ended
Dec. 31, 2019
Leases [Abstract]  
Leases Leases
We determine if an arrangement is a lease at inception. We have operating leases for corporate offices, research and development facilities, vehicles, and equipment. Our leases have remaining lease terms of one to 12 years, some of which have options to extend or terminate the leases. Finance leases are included in property and equipment, current portion of long-term debt, and long-term debt in our consolidated balance sheet. Finance leases are not material to our consolidated statements of operations, consolidated balance sheet, or consolidated statement of cash flows. Beginning January 1, 2019, operating leases are included in noncurrent assets, other current liabilities, and other noncurrent liabilities in our consolidated balance sheet.
Right-of-use assets included in noncurrent assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Right-of-use assets and operating lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate if it is readily determinable. The right-of-use asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain and there is a significant economic incentive to exercise that option.
Operating lease expense for right-of-use assets is recognized on a straight-line basis over the lease term. Variable lease payments, which represent lease payments that vary due to changes in facts or circumstances occurring after the commencement date other than the passage of time, are expensed in the period in which the obligation for these payments was incurred.
We elected not to apply the recognition requirements of ASC 842, Leases, to short-term leases, which are deemed to be leases with a lease term of 12 months or less. Instead, we recognize lease payments in the consolidated statements of operations on a straight-line basis over the lease term and variable payments in the period in which the obligation for these payments are incurred. We elected this policy for all classes of underlying assets. We elected not to apply the practical expedient related to the separation of lease and non-lease components or the practical expedient which allows entities to use hindsight when determining lease term.
The impact of operating leases to our consolidated financial statements for the year ended December 31, 2019 was as follows:
2019
Lease cost
Operating lease cost$26.1  
Short-term lease cost0.5  
Variable lease cost2.5  
Total lease cost (1)
$29.1  
Other information
Operating cash outflows from operating leases$24.0  
Right-of-use assets obtained in exchange for new operating lease liabilities20.1  
Weighted-average remaining lease term - operating leases5.1 years
Weighted-average discount rate - operating leases3.6 %
(1) Rental expense for all leases was $47.5 million and $47.1 million for the years ended December 31, 2018 and 2017, respectively.
Supplemental balance sheet information related to our operating leases is as follows:
Balance Sheet ClassificationDecember 31, 2019
Right-of-use assetsOther noncurrent assets$85.0  
Current operating lease liabilitiesOther current liabilities23.7  
Non-current operating lease liabilitiesOther noncurrent liabilities61.7  
As of December 31, 2019, the annual minimum lease payments of our operating lease liabilities were as follows:
Year 1$26.0  
Year 220.3  
Year 311.9  
Year 49.7  
Year 57.2  
After Year 516.5  
Total lease payments91.6  
Less imputed interest(6.2) 
Total$85.4  
XML 52 R24.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Geographic Information
 12 Months Ended
Dec. 31, 2019
Segment Reporting [Abstract]  
Geographic Information Geographic Information
We operate as a single operating segment engaged in the development, manufacturing, marketing and sales of animal health products worldwide for both food animals and companion animals. Consistent with our operational structure, our President and Chief Executive Officer (CEO), as the chief operating decision maker, makes resource allocation and business process decisions globally across our consolidated business. Strategic decisions are managed globally with global functional leaders responsible for determining significant costs/investments and with regional leaders responsible for overseeing the execution of the global strategy. Our global research and development organization is responsible for development of new products. Our manufacturing organization is responsible for the manufacturing and supply of products and for the optimization of our supply chain. Regional leaders are responsible for the distribution and sale of our products and for local direct costs. The business is also supported by global corporate staff functions. Managing and allocating resources at the global corporate level enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, product types, regional commercial organizations and research and development projects in line with our overarching long-term corporate-wide strategic goals, rather than on a product or geographic basis. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, allocating resources, setting incentive compensation targets, as well as forecasting future period financial results.
Our products include Rumensin, Optaflexx, Denagard, Tylan, Maxiban and other products for livestock and poultry, as well as Trifexis, Interceptor, Comfortis, Galliprant and other products for companion animals.
We have a single customer that accounted for 12.9%, 11.9% and 12.9% of revenue for the years ended December 31, 2019, 2018 and 2017, respectively. The product sales resulted in accounts receivable with this customer of $90.5 million and $96.4 million as of December 31, 2019 and 2018, respectively.
We are exposed to the risk of changes in social, political and economic conditions inherent in foreign operations and our results of operations and the value of our foreign assets are affected by fluctuations in foreign currency exchange rates.
Selected geographic area information was as follows:
201920182017
Revenue — to unaffiliated customers(1):
United States$1,524.7  $1,483.2  $1,373.0  
International1,546.3  1,583.6  1,516.0  
Revenue$3,071.0  $3,066.8  $2,889.0  
Long-lived assets(2):
United States$709.8  $602.6  $604.7  
United Kingdom192.6  187.5  204.4  
Other foreign countries244.7  195.8  190.2  
Long-lived assets$1,147.1  $985.9  $999.3  
(1) Revenue is attributed to the countries based on the location of the customer.
(2) Long-lived assets consist of property and equipment, net, and certain noncurrent assets, including right-of-use assets.
XML 53 R28.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Selected Quarterly Data (unaudited)
 12 Months Ended
Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]  
Selected Quarterly Data (unaudited) Selected Quarterly Data (unaudited)
2019FourthThirdSecondFirst
Revenue$787.0  $771.3  $781.6  $731.1  
Cost of sales410.1  360.4  356.0  343.8  
Operating expenses(1)
253.2  262.2  269.7  245.2  
Asset impairment, restructuring, and other special charges51.6  77.2  31.8  24.9  
Interest expense, net of capitalized interest18.7  18.7  20.7  20.8  
Income (loss) before income taxes(4.3) (12.5) 50.2  44.8  
Income tax (benefit) expense5.2  (22.5) 14.3  13.3  
Net income (loss)(9.5) 10.0  35.9  31.5  
Earnings (loss) per share—basic and diluted(0.03) 0.03  0.10  0.09  

2018Fourth  Third  Second  First  
Revenue$799.3  $761.1  $770.2  $736.2  
Cost of sales412.5  369.8  431.5  360.0  
Operating expenses(1)
246.2  237.9  252.5  245.2  
Asset impairment, restructuring, and other special charges46.0  12.4  68.0  2.4  
Interest expense, net of capitalized interest21.0  8.6  —  —  
Income (loss) before income taxes(2.2) 78.8  (40.0) 77.5  
Income tax (benefit) expense(18.6) 18.6  22.8  4.8  
Net income (loss)16.4  60.2  (62.8) 72.7  
Earnings (loss) per share—basic and diluted0.04  0.20  (0.21) 0.25  
(1)Includes research and development and marketing, selling, and administrative expenses.
Numbers may not add up to totals for each year due to rounding.
XML 54 R62.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Financial Instruments and Fair Value - Narrative (Details)
$ in Millions
 1 Months Ended 12 Months Ended
Oct. 31, 2018
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Jul. 31, 2019
USD ($)
Jul. 18, 2019
USD ($)
Oct. 31, 2018
CHF (SFr)
Business Acquisition, Contingent Consideration [Line Items]            
Equity method investments   $ 18.8 $ 15.3      
Aratana Therapeutics, Inc.            
Business Acquisition, Contingent Consideration [Line Items]            
Maximum aggregate contingent payment         $ 12.0  
Prevtec            
Business Acquisition, Contingent Consideration [Line Items]            
Maximum aggregate contingent payment       $ 16.3    
Net Investment Hedging | Designated as Hedging Instrument | Foreign Exchange Contract            
Business Acquisition, Contingent Consideration [Line Items]            
Derivative, term of contract 5 years          
Notional amount | SFr           SFr 750,000,000
Expected cash and contra interest per year $ 25.0          
Gain (Loss) to AOCI, net of tax   7.7 5.9      
Net Investment Hedging | Designated as Hedging Instrument | Foreign Exchange Contract | Interest Expense            
Business Acquisition, Contingent Consideration [Line Items]            
Contra interest expense   $ 25.1 $ 5.6      
XML 55 R92.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Retirement Benefits - Narrative (Details)
$ in Millions
 1 Months Ended 12 Months Ended
Sep. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
plan
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Defined Benefit Plan Disclosure [Line Items]        
Decrease in pension benefit obligation $ 21.0      
Decreased in prior service costs 75.0      
Decrease for plan amendment related to other costs and losses 54.0      
Accumulated other comprehensive income net impact $ 21.0      
Contributions expected in 2020   $ 6.5    
Accrued retirement benefits   82.5 $ 109.1  
Expenses related to employees under Defined Contribution Plans   32.2 20.9 $ 22.1
Multiemployer plans expense     4.0 73.7
Multiemployer plans, curtailment loss and special termination benefits       $ 67.0
Pension Plans        
Defined Benefit Plan Disclosure [Line Items]        
Decrease in pension benefit obligation   (74.7) 0.0  
Total accumulated benefit obligation   210.1 199.9  
Accrued retirement benefits   $ 77.5 105.2  
Pension Plans | Public equity securities        
Defined Benefit Plan Disclosure [Line Items]        
Designated percentage invested   32.00%    
Pension Plans | Cash and cash equivalents        
Defined Benefit Plan Disclosure [Line Items]        
Designated percentage invested   5.00%    
Pension Plans | Real estate        
Defined Benefit Plan Disclosure [Line Items]        
Designated percentage invested   21.00%    
Pension Plans | Other Alternative Investments        
Defined Benefit Plan Disclosure [Line Items]        
Designated percentage invested   6.00%    
Pension Plans | Fixed Income Securities        
Defined Benefit Plan Disclosure [Line Items]        
Designated percentage invested   36.00%    
Pension Plans | Switzerland        
Defined Benefit Plan Disclosure [Line Items]        
Percentage of benefit obligation in Switzerland pension plans   80.00%    
Percentage of plan assets in Switzerland pension plans   87.00%    
Retiree Health Benefit Plan        
Defined Benefit Plan Disclosure [Line Items]        
Number of plans | plan   2    
Accrued retirement benefits   $ 4.7 $ 3.9  
XML 56 R96.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Retirement Benefits - Schedule of Expected Benefit Payments (Details) - Pension Plans
$ in Millions
Dec. 31, 2019
USD ($)
Benefit payments  
2020 $ 7.9
2021 8.6
2022 8.4
2023 8.0
2024 8.1
2025-2029 $ 48.4
XML 57 R66.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Goodwill and Intangibles - Remaining Weighted Average Amortization Periods (Details)
 12 Months Ended
Dec. 31, 2019
Marketed products  
Finite-Lived Intangible Assets [Line Items]  
Remaining amortization period 13 years
Software  
Finite-Lived Intangible Assets [Line Items]  
Remaining amortization period 6 years
Other  
Finite-Lived Intangible Assets [Line Items]  
Remaining amortization period 8 years
XML 58 R49.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Impact of Separation (Details) - USD ($)
 12 Months Ended
Sep. 24, 2018
Dec. 31, 2019
 [1]
Dec. 31, 2018
 [2]
Sep. 05, 2018
Aug. 28, 2018
Debt Instrument [Line Items]          
Separation adjustments $ 99,600,000 $ (51,200,000) $ 99,600,000    
Senior Notes          
Debt Instrument [Line Items]          
Aggregate principal amount         $ 2,000,000,000.0
Credit Facility | Revolving credit facility          
Debt Instrument [Line Items]          
Credit facility, maximum borrowing capacity 750,000,000.0     $ 750,000,000.0  
Credit Facility | Term credit facility          
Debt Instrument [Line Items]          
Credit facility, maximum borrowing capacity $ 500,000,000.0     $ 500,000,000.0  
[1] See Note 20: Related Party Agreements and Transactions for further discussion.
[2] See Note 3: Impact of Separation for further discussion.
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Related Party Agreements and Transactions (Tables)
 12 Months Ended
Dec. 31, 2019
Related Party Transactions [Abstract]  
Amounts Due From/(Due To) Lilly and Allocations of Services
Amounts due from/(due to) Lilly in connection with the Separation and agreed upon services as of December 31 were as follows:
20192018
TSA$10.5  $(28.0) 
Other activities(15.8) (38.0) 
Local country asset purchases(11.1) (202.7) 
Total receivable from/(payable to) Lilly$(16.4) $(268.7) 
The allocations of services from Lilly, prior to IPO, to us were reflected as follows in the combined statements of operations:
2018(1)
2017
Cost of sales$21.8  $31.8  
Research and development 2.2  2.8  
Marketing, selling and administrative81.2  117.1  
Total$105.2  $151.7  
(1) Through September 30, 2018
XML 60 R41.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stock-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2019
Share-based Payment Arrangement [Abstract]  
Schedule of Stock-Based Compensation Expenses
Components of stock-based compensation expense and related tax benefit for the years ended December 31 are as follows:
20192018
Stock-based compensation expense (1)
$40.7  $1.8  
Related tax benefit (9.8) (0.4) 
(1) We include the impact of estimated forfeitures when determining stock-based compensation expense.
Schedule of Restricted Stock Unit Activity
RSUs granted to employees for the years ended December 31 are as follows:
(Units in millions)20192018
Granted units2.9  0.2  
Weighted-average fair value$31.22  $31.09  
Changes in nonvested portion of RSUs for 2019 is summarized below:
(Shares in millions)SharesWeighted-Average Fair Value
Nonvested units at January 1, 20190.2$31.09  
Granted2.931.22  
Vested(0.8)31.33  
Forfeited(0.1)31.25  
Nonvested units at December 31, 20192.230.42  
Schedule of Performance Awards Activity
PA activity during the year ended December 31, 2019 is summarized below:
(Shares in millions)SharesWeighted-Average Fair Value
Nonvested awards at January 1, 2019—  $—  
Granted0.8  25.75  
Vested—  —  
Forfeited—  —  
Nonvested awards at December 31, 20190.8  25.75  
Schedule of Assumptions Used
The fair-value-based method for valuing each Elanco stock option grant on the grant date uses the Black-Scholes-Merton option-pricing model, which incorporates a number of valuation assumptions noted in the following table, shown at their weighted-average values for the year ended December 31:
2018
Expected dividend yield(1)
0.70 %
Risk-free interest rate(2)
3.07 %
Expected stock price volatility(3)
28.25 %
Expected term(4) (years)
6.5
(1) Determined using the expected quarterly dividend divided by the available three-month average stock price as of the valuation date, annualized and continuously compounded.
(2) Determined using the term-matched, zero-coupon risk-free rate from the Treasury Constant Maturity yield curve, continuously compounded
(3) Determined using a leverage-adjusted historical volatility of peer companies
(4) Determined using SEC safe harbor approach, based on a 3-year cliff vesting schedule and 10-year contractual term.
Schedule of Stock Option Activity
Stock option activity during the year ended December 31, 2019 is summarized below:
(Shares in millions)Shares of Common Stock Attributable to OptionsWeighted-Average Exercise Price of OptionsWeighted-Average Remaining Contractual Term (Years)
Aggregate Intrinsic Value(1)
Outstanding at January 1, 20190.4  $31.61  
Granted—  —  
Exercised(0.1) 31.61  
Forfeited or expired—  —  
Outstanding at December 31, 20190.3  $31.61  8.8$—  
Exercisable at December 31, 2019—  —  —  —  
(1)Market price of underlying Elanco common stock less exercise price. Options do not have an intrinsic value unless the market price exceeds the exercise price.
The following table summarizes data related to stock option activity:
20192018
Weighted-average grant date fair value per stock option$10.21  $10.21  
Aggregate intrinsic value on exercise0.10  —  
Cash received upon exercise1.9  —  
XML 61 R77.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stock-Based Compensation - Schedule of Restricted Stock Unit and Performance Award Activity (Details) - $ / shares
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
RSUs    
Outstanding Restricted Stock Units    
Beginning nonvested balance (in shares) 200,000  
Granted (in shares) 2,900,000 200,000
Vested (in shares) (800,000)  
Forfeited (in shares) (100,000)  
Ending nonvested balance (in shares) 2,200,000 200,000
Weighted-Average Restricted Stock Unit Fair Value    
Beginning nonvested balance (in dollars per share) $ 31.09  
Granted (in dollars per share) 31.22 $ 31.09
Vested (in dollars per share) 31.33  
Forfeited (in dollars per share) 31.25  
Ending nonvested balance (in dollars per share) $ 30.42 $ 31.09
PAs    
Outstanding Restricted Stock Units    
Beginning nonvested balance (in shares) 0  
Granted (in shares) 800,000  
Vested (in shares) 0  
Forfeited (in shares) 0  
Ending nonvested balance (in shares) 800,000 0
Weighted-Average Restricted Stock Unit Fair Value    
Beginning nonvested balance (in dollars per share) $ 0  
Granted (in dollars per share) 25.75  
Vested (in dollars per share) 0  
Forfeited (in dollars per share) 0  
Ending nonvested balance (in dollars per share) $ 25.75 $ 0
XML 62 R87.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Reconciliation of Gross Unrecognized Tax Benefits (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Beginning balance $ 12.5 $ 12.0 $ 25.7
Additions based on tax positions related to the current year 1.3 2.2 7.9
Changes for tax positions of prior years (1.2)    
Changes for tax positions of prior years   4.0 0.0
Settlements (4.3) (3.0) (4.0)
Changes related to the impact of foreign currency translation (0.1) (0.5) 0.0
Ending balance 8.2 12.5 12.0
Previously Reported      
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Beginning balance 14.7 29.6 25.7
Ending balance   14.7 29.6
Adjustment related to Separation      
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Beginning balance $ (2.2) (17.6) 0.0
Ending balance   $ (2.2) $ (17.6)
XML 63 R83.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Millions
Dec. 31, 2019
Dec. 31, 2018
Deferred tax assets:    
Compensation and benefits $ 25.3 $ 32.2
Accruals and reserves 13.7 26.9
Tax credit carryovers 12.8 6.2
Tax loss carryovers 69.5 17.4
Inventories 20.1 18.3
Restructuring and other reserves 24.6 6.0
Operating lease liabilities 20.5  
Other 2.3 20.1
Total gross deferred tax assets 188.8 127.1
Valuation allowances (32.7) (21.4)
Total deferred tax assets 156.1 105.7
Deferred tax liabilities:    
Right-of-use assets (20.5)  
Intangibles (134.5) (130.8)
Property and equipment (56.4) (50.8)
Other (0.6) (2.7)
Total deferred tax liabilities (212.0) (184.3)
Deferred tax liabilities - net $ (55.9) $ (78.6)
XML 64 R73.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases - Supplemental Balance Sheet Information Related to Operating Leases (Details)
$ in Millions
Dec. 31, 2019
USD ($)
Leases [Abstract]  
Right-of-use assets $ 85.0
Current operating lease liabilities 23.7
Non-current operating lease liabilities $ 61.7
XML 65 R50.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Summary of Significant Accounting Policies (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Jan. 01, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Right-of-use assets $ 85.0  
Operating lease liabilities $ 85.4  
Payment terms Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from 30 to 120 days from date of shipment.  
Accounting Standards Update 2016-02    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Right-of-use assets   $ 84.9
Operating lease liabilities   $ 85.3
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Acquisitions - Narrative (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 12 Months Ended
Aug. 19, 2019
Jul. 31, 2019
Jul. 18, 2019
Jan. 03, 2017
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Aratana Therapeutics, Inc.              
Business Acquisition [Line Items]              
Number of shares issued to previous shareholders upon closing (in shares)     7.2        
Value of shares issued as consideration     $ 238.0        
Maximum aggregate contingent payment     $ 12.0        
Business acquisition (usd per share)     $ 0.25        
Accelerated vesting of equity awards (in shares)         0.1    
Accelerated stock based compensation         $ 3.6    
Revenues         10.0    
Unaudited pro forma combined revenues         3,100.0 $ 3,100.0  
Pro forma combined income before income taxes         63.2 $ 117.7  
Weighted average useful life     12 years 6 months        
Galliprant              
Business Acquisition [Line Items]              
Contingent consideration liability     $ 84.7        
Loss upon settlement of contingent consideration liability         $ 7.5    
Prevtec              
Business Acquisition [Line Items]              
Maximum aggregate contingent payment   $ 16.3          
Contingent consideration liability   4.7          
Settlement of accounts receivable   0.7          
Total consideration transferred   $ 60.3          
Weighted average useful life   10 years          
BIVIVP              
Business Acquisition [Line Items]              
Revenues             $ 216.7
Total consideration transferred       $ 882.1      
Weighted average useful life       10 years      
Bayer Animal Business              
Business Acquisition [Line Items]              
Value of shares issued as consideration $ 2,300.0            
Amount paid at closing $ 5,300.0            
XML 67 R58.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Inventories - Schedule of Inventories (Details) - USD ($)
$ in Millions
Dec. 31, 2019
Dec. 31, 2018
Inventory Disclosure [Abstract]    
Finished products $ 402.9 $ 400.7
Work in process 603.2 570.4
Raw materials and supplies 83.9 80.4
Total (approximates replacement cost) 1,090.0 1,051.5
Decrease to LIFO cost (39.3) (47.4)
Inventories $ 1,050.7 $ 1,004.1
XML 68 R39.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Property and Equipment (Tables)
 12 Months Ended
Dec. 31, 2019
Property, Plant and Equipment [Abstract]  
Property and Equipment and Depreciation Expense
At December 31, property and equipment consisted of the following:
20192018
Land$28.3  $27.6  
Buildings608.5  567.2  
Equipment1,109.4  1,025.1  
Construction in progress139.1  181.1  
Finance lease asset0.5  —  
1,885.8  1,801.0  
Less accumulated depreciation(930.5) (878.6) 
Property and equipment, net$955.3  $922.4  
Rental Expense for All Leases
Depreciation expense related to property and equipment was as follows:
201920182017
Depreciation expense$93.7  $81.3  $79.8  
XML 69 R35.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Inventories (Tables)
 12 Months Ended
Dec. 31, 2019
Inventory Disclosure [Abstract]  
Schedule of Inventories
Inventories at December 31 consisted of the following:
20192018
Finished products$402.9  $400.7  
Work in process603.2  570.4  
Raw materials and supplies83.9  80.4  
Total (approximates replacement cost)1,090.0  1,051.5  
Decrease to LIFO cost(39.3) (47.4) 
Inventories$1,050.7  $1,004.1  
XML 70 R102.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Earnings Per Share (Details)
 12 Months Ended
Sep. 24, 2018
shares
Sep. 19, 2018
Dec. 31, 2019
shares
Dec. 31, 2018
shares
Sep. 18, 2018
shares
Subsidiary, Sale of Stock [Line Items]          
Stock split ratio   2,932,900      
Weighted average number of shares issued basic (in shares)     7,300,000    
Weighted average number diluted shares outstanding adjustment (in shares)     1,300,000    
Antidilutive shares not included in calculation diluted earnings per share (in shares)     100,000    
IPO          
Subsidiary, Sale of Stock [Line Items]          
Number of shares issued (in shares) 72,335,000        
Elanco | Lilly          
Subsidiary, Sale of Stock [Line Items]          
Common shares outstanding       293,290,000 100
XML 71 R31.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
Description of Accounting Standards Adopted and Not Yet Adopted
The following table provides a brief description of an accounting standard that was effective January 1, 2019 and was adopted on that date:
StandardDescriptionEffect on the financial statements or other significant matters
Accounting Standards Update 2016-02, Leases
This standard was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under previous GAAP, on the balance sheet and requiring additional disclosures about leasing arrangements.
We adopted the standard on January 1, 2019 using the modified retrospective approach, applied at the beginning of the period of adoption, and we elected the package of transition practical expedients. Upon adoption of the standard, we recorded $84.9 million of right-of-use assets and $85.3 million of operating lease liabilities on our consolidated balance sheet. Adoption of this standard did not have a material impact on our consolidated statement of operations for the year ended December 31, 2019. See Note 13: Leases for further information.

The following table provides a brief description of the accounting standards applicable to us that have not yet been adopted:
StandardDescriptionEffective DateEffect on the financial statements or other significant matters
Accounting Standards Update 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments
This standard modifies the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses.This standard is effective January 1, 2020, with early adoption permitted. We intend to adopt this standard on that date.We do not expect that the adoption of this standard will have a material impact on our consolidated financial statements based on financial instruments currently held.
Accounting Standards Update 2018-15, Intangibles - Goodwill and Other Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract
This guidance aligns the requirements for capitalizing implementation costs incurred in a cloud-based hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software.This standard is effective January 1, 2020, with early adoption permitted. We intend to adopt this standard on that date.Adoption of this standard is not expected to have a significant impact on our consolidated financial statements.
Accounting Standards Update 2019-12, Simplifying the Accounting for Income Taxes
The amendments in this update simplify the accounting for income taxes by removing certain exceptions and clarifying certain requirements regarding franchise taxes, goodwill, consolidated tax expenses, and annual effective tax rate calculations. This standard is effective January 1, 2021, with early adoption permitted. We intend to adopt this standard on that date.We are currently evaluating the impact of adoption of the new standard on our consolidated financial statements.
XML 72 R106.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Selected Quarterly Data (unaudited) (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]                      
Revenue $ 787.0 $ 771.3 $ 781.6 $ 731.1 $ 799.3 $ 761.1 $ 770.2 $ 736.2 $ 3,071.0 $ 3,066.8 $ 2,889.0
Cost of sales 410.1 360.4 356.0 343.8 412.5 369.8 431.5 360.0 1,470.3 1,573.8 1,493.9
Operating expenses 253.2 262.2 269.7 245.2 246.2 237.9 252.5 245.2      
Asset impairment, restructuring, and other special charges 51.6 77.2 31.8 24.9 46.0 12.4 68.0 2.4 185.5 128.8 375.1
Interest expense, net of capitalized interest 18.7 18.7 20.7 20.8 21.0 8.6 0.0 0.0 78.9 29.6 0.0
Income (loss) before income taxes (4.3) (12.5) 50.2 44.8 (2.2) 78.8 (40.0) 77.5 78.2 114.1 (232.6)
Income tax (benefit) expense 5.2 (22.5) 14.3 13.3 (18.6) 18.6 22.8 4.8 10.3 27.6 78.1
Net income (loss) $ (9.5) $ 10.0 $ 35.9 $ 31.5 $ 16.4 $ 60.2 $ (62.8) $ 72.7 $ 67.9 $ 86.5 $ (310.7)
Earnings (loss) per share—basic and diluted (usd per share) $ (0.03) $ 0.03 $ 0.10 $ 0.09 $ 0.04 $ 0.20 $ (0.21) $ 0.25      
XML 73 R5.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Millions
Dec. 31, 2019
Dec. 31, 2018
Statement of Financial Position [Abstract]    
Accounts receivable, net of allowances $ 6.2 $ 8.4
Preferred stock authorized (in shares) 1,000,000,000 1,000,000,000
Preferred stock issued (in shares) 0 0
Common stock authorized (in shares) 5,000,000,000 5,000,000,000
Common stock issued (in shares) 373,011,513 365,643,911
Common stock outstanding (in shares) 373,011,513 365,643,911
XML 74 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Document and Entity Information - USD ($)
$ in Billions
 12 Months Ended
Dec. 31, 2019
Feb. 25, 2020
Jun. 30, 2019
Document And Entity Information [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2019    
Document Fiscal Year Focus 2019    
Document Fiscal Period Focus FY    
Entity Registrant Name Elanco Animal Health Inc.    
Entity Central Index Key 0001739104    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Well Known Seasoned Issuer Yes    
Current Fiscal Year End Date --12-31    
Entity Filer Category Large Accelerated Filer    
Entity Emerging Growth Company false    
Entity Small Business false    
Entity Shell Company false    
Entity Public Float     $ 12.4
Entity Common Stock, Shares Outstanding   398,532,256  
XML 75 R9.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Basis of Presentation
 12 Months Ended
Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation Basis of Presentation
We have prepared the accompanying consolidated and combined financial statements in accordance with accounting principles generally accepted in the United States (GAAP). In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for fair presentation of the results of operations for the periods shown. The accounts of all wholly-owned and majority-owned subsidiaries are included in the consolidated financial statements, and all intercompany balances and transactions have been eliminated.
Certain reclassifications have been made to prior periods in the unaudited condensed consolidated and combined financial statements and accompanying notes to conform with current presentation.
In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. We issued our financial statements by filing with the Securities and Exchange Commission and have evaluated subsequent events up to the time of the filing.
For the periods after Separation, the financial statements are prepared on a consolidated basis and reflect the results of operations, comprehensive income, financial position, equity and cash flows resulting from our operations as an independent company. For periods prior to Separation, our financial statements are combined, have been prepared on a standalone basis, and are derived from Lilly's consolidated financial statements and accounting records. The consolidated and combined financial statements reflect the financial position, results of operations and cash flows related to the animal health businesses that were transferred to Elanco Parent and are prepared in conformity with GAAP.
The combined financial statements include the attribution of certain assets and liabilities that historically have been held at the Lilly corporate level but which are specifically identifiable or attributable to the businesses that have been transferred to Elanco Parent. All intercompany transactions and accounts within Elanco have been eliminated. All transactions between us and Lilly are considered to be effectively settled in the combined financial statements at the time the intercompany transaction is recorded. The total net effect of the settlement of these intercompany transactions is reflected in the combined statements of cash flows as a financing activity and in the consolidated and combined statement of equity as net parent company investment.
Prior to Separation, these combined financial statements include an allocation of expenses related to certain Lilly corporate functions, including executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information technology and investor relations, prior to IPO. These expenses were allocated to us based on direct usage or benefit where specifically identifiable, with the remainder allocated primarily on a pro rata basis of revenue, headcount and other measures. We consider the expenses methodology and results to be reasonable for all periods presented. However, the allocations may not be indicative of the actual expense that would have been incurred had we operated as an independent, publicly traded company for the periods presented. It is impractical to estimate what the standalone costs of Elanco would have been in the historical periods. After the Separation, a TSA between Lilly and Elanco went into effect. Under the terms of the TSA, we will be able to use these Lilly services for a fixed term established on a service-by-service basis. We are paying Lilly mutually agreed upon fees for the Lilly services provided under the TSA. Our consolidated and combined financial statements reflect the charges for Lilly services after the IPO. See Note 20: Related Party Agreements and Transactions for additional details.
The income tax amounts in the combined financial statements have been calculated based on a separate return methodology and presented as if our operations were separate taxpayers in the respective jurisdictions. We file income tax returns in the U.S. federal jurisdiction and various state, local and non-U.S. jurisdictions. Prior to full separation, certain of these income tax returns were filed on a consolidated or combined basis with Eli Lilly and Company and/or its subsidiaries.
Prior to Separation, Lilly maintained various benefit and combined stock-based compensation plans at a corporate level and other benefit plans at a country level. Our employees participated in such programs and the portion of the cost of those plans related to our employees is included in our financial statements. However, the consolidated balance sheets do not include any equity issued related to stock-based compensation plans or any net benefit plan obligations unless the benefit plan covers only our dedicated employees or where the legal obligation associated with the benefit plan transferred to Elanco. Upon Lilly's full divestiture of Elanco in March 2019, all Lilly share-based awards held by our employees were converted into awards that will be settled in Elanco shares.
Prior to Separation, the equity balance in the combined financial statements represents the excess of total assets over liabilities, including intercompany balances between Elanco and Lilly (net parent company investment) and accumulated other comprehensive income (loss). Net parent company investment is primarily impacted by contributions from Lilly which are the result of treasury activities and net funding provided by or distributed to Lilly. See Note 20: Related Party Agreements and Transactions for further information.
XML 76 R12.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Revenue
 12 Months Ended
Dec. 31, 2019
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
Our sales rebates and discounts are based on specific agreements and the majority relate to sales in the U.S. As of December 31, 2019 and 2018, the liability for sales rebates and discounts in the U.S. represents approximately 71% and 70%, respectively, of our total liability with the next largest country representing approximately 8% of our total liability for 2019 and 2018.
The following table summarizes the activity in the sales rebates and discounts liability in the U.S.:
Year Ended December 31,
20192018
Beginning balance$118.5  $114.8  
Reduction of revenue316.3  221.0  
Payments(284.4) (217.3) 
Ending balance$150.4  $118.5  
Adjustments to revenue recognized as a result of changes in estimates for the judgments described above during the years ended December 31, 2019 and 2018 for product shipped in previous periods were not material.
Actual product returns were 0.2% and 0.6% of net revenue for the years ended December 31, 2019 and 2018, respectively, and have not fluctuated significantly as a percentage of revenue.
Disaggregation of Revenue
The following table summarizes our revenue disaggregated by product category for the years ended December 31:
201920182017
Companion Animal Disease Prevention$787.9  $804.6  $660.2  
Companion Animal Therapeutics348.0  283.1  260.8  
Food Animal Future Protein & Health745.1  711.2  649.2  
Food Animal Ruminants Swine1,110.3  1,174.0  1,175.0  
Strategic Exits(1)
79.7  93.9  143.8  
Total Revenue$3,071.0  $3,066.8  $2,889.0  
(1) Represents revenue from business activities we have either exited or made a strategic decision to exit.
XML 77 R16.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Debt
 12 Months Ended
Dec. 31, 2019
Debt Disclosure [Abstract]  
Debt Debt
Long-term debt as of December 31 consisted of the following:
20192018
Term credit facility$371.4  $492.5  
3.912% Senior Notes due 2021
500.0  500.0  
4.272% Senior Notes due 2023
750.0  750.0  
4.900% Senior Notes due 2028
750.0  750.0  
Other obligations0.4  0.5  
Unamortized debt issuance costs(16.8) (20.7) 
2,355.0  2,472.3  
Less current portion of long-term debt(24.5) (29.0) 
Total long-term debt$2,330.5  $2,443.3  
Revolving and Term Credit Facilities
On September 5, 2018, we entered into a revolving credit agreement with a syndicate of banks providing for a five-year $750.0 million senior unsecured revolving credit facility (Revolving Facility). The Revolving Facility bears interest at a variable rate plus specified margin as defined in the agreement and is payable quarterly. There were no borrowings outstanding under the Revolving Facility at December 31, 2019 or 2018. The Revolving Facility is payable in full at the end of the term.
On September 5, 2018, we also entered into a $500.0 million three-year term loan under a term credit facility with a syndicate of banks (the Term Facility and collectively with the Revolving Facility, the Credit Facilities.) The Term Facility bears interest at a variable rate plus margin as defined in Term Facility (3.01% and 3.77% at December 31, 2019 and 2018, respectively) and is payable quarterly. The Term Facility also requires a quarterly principal payment equal to 1.5% of the aggregate initial principal less any prepayment. The Term Facility is payable in full at the end of the term.
The Credit Facilities are subject to various financial and other covenants, including restrictions on the level of borrowings based on a consolidated leverage ratio and a consolidated interest coverage ratio. We were in compliance with all such covenants as of December 31, 2019.
Senior Notes
On August 28, 2018, we issued $2.0 billion of senior notes (Senior Notes) in a private placement. The Senior Notes comprised of $500.0 million of 3.912% Senior Notes due August 27, 2021, $750.0 million of 4.272% Senior Notes due August 28, 2023, and $750.0 million of 4.900% Senior Notes due August 28, 2028. The interest rate
payable on each series of Senior Notes is subject to adjustment if Moody's Investor Services, Inc. or Standard & Poor's Financial Services LLC downgrades, or subsequently upgrades, its ratings on the respective series of Senior Notes.
The indenture that governs the Senior Notes contains covenants, including limitations on our ability, and certain of our subsidiaries, to incur liens or engage in sale-leaseback transactions. The indenture also contains restrictions on our ability to consolidate, merge or sell substantially all of our assets, in addition to other customary terms. We were in compliance with all such covenants under the indenture governing the Senior Notes as of December 31, 2019.

On June 26, 2019, we completed an exchange offer pursuant to which the privately issued Senior Notes were exchanged for publicly registered Senior Notes having substantially identical terms.
XML 78 R9999.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Label Element Value
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ (300,000)
Net Parent Company Investment [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ (300,000)
XML 79 R22.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes
 12 Months Ended
Dec. 31, 2019
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes Our income taxes for the year ended December 31, 2019 reflect the results on a stand-alone basis independent of Lilly, except for the period during which we were included in a combined tax return until full separation. In the jurisdictions in which we were included in a combined tax return, our income taxes were determined based on the tax matters agreement between us and Lilly. During the periods presented in the consolidated and combined financial statements for the year ended December 31, 2018 and December 31, 2017, our operations were generally included in the tax grouping of other Lilly entities within the respective entity's tax jurisdiction; however, in certain jurisdictions, we filed separate tax returns. Prior to the Separation, the income tax expense included in these financial statements has been calculated using the separate return basis as if Elanco filed separate tax returns.
2017 Tax Act
In 2017, the U.S. enacted the Tax Cuts and Jobs Act (2017 Tax Act), which significantly revised U.S. tax law. Guidance related to the 2017 Tax Act, including Notices, Proposed Regulations, and Final Regulations, has been issued, and we expect additional guidance will be issued in 2020. This additional guidance could materially impact our assumptions and estimates used to record our U.S. federal and state income tax expense resulting from the 2017 Tax Act.
We are included in Lilly's U.S. tax examinations by the Internal Revenue Service through the full separation date of March 11, 2019. Pursuant to the tax matters agreement we executed with Lilly in connection with the IPO, the potential liabilities or potential refunds attributable to pre-IPO periods in which Elanco was included in a Lilly consolidated or combined tax return remain with Lilly. Certain matters of Lilly’s U.S. examination of tax years 2013 - 2015 effectively settled during the second quarter of 2019 and the resulting adjustments will not require any cash tax payments by Elanco. During the fourth quarter of 2019, certain matters for tax year 2015 were effectively settled upon conclusion of the IRS' examination and the resulting adjustments will not require any cash tax payments by Elanco. In the fourth quarter of 2019, the IRS began its examination of tax years 2016 - 2018.
Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution.
Following is the composition of income (loss) before income tax expense (benefit):
201920182017
Federal$55.5  $12.2  $(133.2) 
Foreign22.7  101.9  (99.4) 
Income (loss) before income taxes$78.2  $114.1  $(232.6) 
Following is the composition of income tax expense (benefit):
201920182017
Current:
Federal$(5.5) $45.1  $—  
Foreign13.4  45.5  91.6  
State2.3  (2.3) (0.1) 
Total current tax expense10.2  88.3  91.5  
Deferred:
Federal14.5  (56.8) 42.6  
Foreign(7.5) (5.6) (16.6) 
State(6.9) 1.7  (6.3) 
2017 Tax Act—  —  (33.1) 
Total deferred tax expense (benefit)0.1  (60.7) (13.4) 
Income taxes$10.3  $27.6  $78.1  
Significant components of our deferred tax assets and liabilities as of December 31 are as follows:
20192018
Deferred tax assets:
Compensation and benefits$25.3  $32.2  
Accruals and reserves13.7  26.9  
Tax credit carryovers12.8  6.2  
Tax loss carryovers69.5  17.4  
Inventories20.1  18.3  
Restructuring and other reserves24.6  6.0  
Operating lease liabilities20.5  —  
Other2.3  20.1  
Total gross deferred tax assets188.8  127.1  
Valuation allowances(32.7) (21.4) 
Total deferred tax assets156.1  105.7  
Deferred tax liabilities:
Right-of-use assets(20.5) —  
Intangibles(134.5) (130.8) 
Property and equipment(56.4) (50.8) 
Other(0.6) (2.7) 
Total deferred tax liabilities(212.0) (184.3) 
Deferred tax liabilities - net$(55.9) $(78.6) 
Deferred tax assets and liabilities reflect the impact of re-measurement resulting from the 2017 Tax Act.
The deferred tax assets and related valuation allowance amounts for U.S. federal and state net operating losses and tax credits shown above have been reduced for differences between financial reporting and tax return filings.
At December 31, 2019, we have tax credit carryovers of $14.0 million available to reduce future income taxes. The amount is comprised of foreign, U.S. federal and state credits. The foreign credits total $5.1 million and if unused, will begin to expire in 2030. The U.S. federal credits total $3.2 million and if unused, will begin to expire in 2030. The state credits total $5.7 million and if unused, will begin to expire in 2020. The U.S. federal and state credits are subject to a full valuation allowance.
At December 31, 2019, we had net operating loss carryovers and other carryovers for foreign, U.S. federal and state income tax purposes of $348.4 million: $285.5 million will expire between 2020 and 2039; and $62.9 million of the carryovers have an indefinite carryforward period. Net operating losses and other carryovers for foreign and state income tax purposes are subject to a partial valuation allowance.
The movements in the valuation allowance are as follows:
20192018
January 1$(21.4) $(127.7) 
Adjustment related to Separation—  110.4  
January 1(21.4) (17.3) 
Increase (1)
(23.2) (5.8) 
Release11.9  1.7  
December 31$(32.7) $(21.4) 
(1) The increase in the valuation allowance during 2019 is primarily attributable to the acquisition of Aratana Therapeutics, Inc. and Prevtec Microbia Inc. (see Note 6: Acquisitions).
Prior to the IPO, we prepared the income tax amounts and balances based upon a separate return methodology, as if we were separate taxpayers from Lilly.  As a result, certain tax credits and net operating loss carryovers are not available for use in future periods as they were used in Lilly consolidated or combined tax return filings. Accordingly, as a result of the Separation, the tax credit and net operating loss carryovers and related valuation allowance have been adjusted to reflect the balance after Separation. These adjustments had no impact on income tax expense in the consolidated and combined financial statements. The separation entries related to the valuation allowance were offset by $133.7 million, prior to tax effect, of separation entries related to the removal of the net operating losses.
The 2017 Tax Act introduced international tax provisions that significantly change the U.S. taxation of foreign earnings.  At December 31, 2019, no U.S. taxes or foreign withholding taxes have been accrued with respect to the $496.7 million in unremitted earnings of our foreign subsidiaries as they are considered indefinitely reinvested for continued use in our foreign operations. It is not practicable to determine the unrecognized deferred tax liability related to these earnings.
Cash payments of income taxes were as follows:
201920182017
Cash payments of income taxes$42.5  $26.9  $35.7  
The following is a reconciliation of the income tax expense (benefit) applying the U.S. federal statutory rate to income before income taxes to reported income tax expense:
201920182017
Income tax at the U.S. federal statutory tax rate$16.4  $24.0  $(81.4) 
Add (deduct):
Taxation of international operations20.7  20.5  59.8  
State taxes2.9  4.4  5.4  
Income tax credits(9.8) (17.3) (1.8) 
Non-deductible employee compensation4.2  (1.9) —  
IPO and separation costs—  2.3  —  
Other permanent adjustments(4.2) (1.0) 0.8  
Change in uncertain tax positions(14.7) (1.7) 6.2  
Change in valuation allowance(5.2) (1.7) 122.2  
2017 Tax Act—  —  (33.1) 
Income taxes$10.3  $27.6  $78.1  
A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:
201920182017
Beginning balance at January 1$14.7  $29.6  $25.7  
Adjustments related to Separation(2.2) (17.6) —  
Adjusted beginning balance at January 112.5  12.0  25.7  
Additions based on tax positions related to the current year1.3  2.2  7.9  
Changes for tax positions of prior years(1.2) 4.0  —  
Settlements(4.3) (3.0) (4.0) 
Changes related to the impact of foreign currency translation(0.1) (0.5) —  
Ending balance at December 31$8.2  $14.7  $29.6  
The total amount of unrecognized tax benefits that, if recognized, would affect tax expense was $8.2 million and $12.8 million at December 31, 2019 and 2018, respectively. There were $1.9 million of 2018 unrecognized tax benefits which related to temporary differences which did not impact the effective tax rate. Adjustments related to the Separation represent unrecognized tax benefits assumed by Lilly in the Separation and have no impact on income tax expense in the consolidated and combined financial statements.
We file income tax returns in the U.S. federal jurisdiction and various state, local and non-U.S. jurisdictions. Prior to full separation, certain of these income tax returns were filed on a consolidated or combined basis with Lilly.
We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense (benefit). We recognized income tax expense (benefit) related to interest and penalties as follows:
201920182017
Income tax expense (benefit)$(10.6) $(2.5) $2.5  
At December 31, 2019 and 2018, our accruals for the payment of interest and penalties totaled $3.0 million and $13.3 million, respectively.
XML 80 R26.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Earnings Per Share
 12 Months Ended
Dec. 31, 2019
Earnings Per Share [Abstract]  
Earnings Per Share Earnings Per Share
Basic Earnings Per Share
As discussed in Note 1, Elanco Parent was formed for the purpose of facilitating the IPO. Lilly held all shares of Elanco Parent from the time of formation until the IPO.
Prior to IPO, there were an aggregate of 293,290,000 shares of our common stock held by Lilly (which represents the 100 shares held by Lilly prior to giving effect to the 2,932,900-for-1 stock split that occurred on September 19, 2018). In connection with the completion of the IPO, an additional 72,335,000 shares of our common stock were issued. Earnings per share was calculated based on the assumptions that the shares held by Lilly were outstanding for all periods prior to IPO.
We compute basic earnings per share by dividing net earnings available to common shareholders by the actual weighted average number of common shares outstanding for the reporting period. For the year ended December 31, 2019, weighted average number of common shares outstanding used to calculate basic earnings per share includes the impact of approximately 7.3 million shares that were issued during the period in connection with the acquisition of Aratana. See Note 6: Acquisitions for further discussion.
Diluted Earnings Per Share
Elanco has common stock equivalents related to certain equity awards in stock-based compensation arrangements. Diluted earnings per share reflects the potential dilution that could occur if holders of unvested RSUs, PAs and stock options converted their holdings into common stock. The weighted average number of potentially dilutive shares outstanding is calculated using the treasury stock method.
Weighted average diluted shares outstanding included common stock equivalents of 1.3 million for 2019. The dilutive impact for 2018 was immaterial.
Potential common shares that would have the effect of increasing diluted earnings per share are considered to be anti-dilutive and as such, these shares are not included in the calculation of diluted earnings per share. For the year ended December 31, 2019, approximately 0.1 million shares of potential common shares were excluded from the calculation of diluted earnings per share because their effect was anti-dilutive.
ZIP 81 0001739104-20-000005-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001739104-20-000005-xbrl.zip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‹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�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�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�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�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¾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end XML 82 R47.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Subsequent Events (Tables)
 12 Months Ended
Dec. 31, 2019
Subsequent Events [Abstract]  
Disclosure of Long Lived Assets Held-for-sale Assets and liabilities considered held for sale in connection with the divestitures as of December 31, 2019 were included in the respective line items in the consolidated balance sheet as follows:
Inventories$10.6  
Other intangibles, net61.2  
Property and equipment, net0.2  
Total assets held for sale72.0  
Deferred taxes(1.4) 
Total liabilities held for sale$(1.4) 

XML 83 R43.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Geographic Information (Tables)
 12 Months Ended
Dec. 31, 2019
Segment Reporting [Abstract]  
Revenue by Selected Geographic Area Information
Selected geographic area information was as follows:
201920182017
Revenue — to unaffiliated customers(1):
United States$1,524.7  $1,483.2  $1,373.0  
International1,546.3  1,583.6  1,516.0  
Revenue$3,071.0  $3,066.8  $2,889.0  
Long-lived assets(2):
United States$709.8  $602.6  $604.7  
United Kingdom192.6  187.5  204.4  
Other foreign countries244.7  195.8  190.2  
Long-lived assets$1,147.1  $985.9  $999.3  
(1) Revenue is attributed to the countries based on the location of the customer.
(2) Long-lived assets consist of property and equipment, net, and certain noncurrent assets, including right-of-use assets.
Long-lived Assets by Selected Geographic Area Information
Selected geographic area information was as follows:
201920182017
Revenue — to unaffiliated customers(1):
United States$1,524.7  $1,483.2  $1,373.0  
International1,546.3  1,583.6  1,516.0  
Revenue$3,071.0  $3,066.8  $2,889.0  
Long-lived assets(2):
United States$709.8  $602.6  $604.7  
United Kingdom192.6  187.5  204.4  
Other foreign countries244.7  195.8  190.2  
Long-lived assets$1,147.1  $985.9  $999.3  
(1) Revenue is attributed to the countries based on the location of the customer.
(2) Long-lived assets consist of property and equipment, net, and certain noncurrent assets, including right-of-use assets.
XML 84 R68.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Property and Equipment - Narrative (Details)
 12 Months Ended
Dec. 31, 2019
Buildings | Minimum  
Property, Plant and Equipment [Line Items]  
Estimated useful lives 12 years
Buildings | Maximum  
Property, Plant and Equipment [Line Items]  
Estimated useful lives 50 years
Equipment | Minimum  
Property, Plant and Equipment [Line Items]  
Estimated useful lives 3 years
Equipment | Maximum  
Property, Plant and Equipment [Line Items]  
Estimated useful lives 25 years
XML 85 R98.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Retirement Benefits - Accumulated Benefit Obligations in Excess of Plan Assets (Details) - Pension Plans - USD ($)
$ in Millions
Dec. 31, 2019
Dec. 31, 2018
Defined Benefit Plan Disclosure [Line Items]    
Accumulated benefit obligation $ 203.9 $ 194.3
Fair value of plan assets $ 140.3 $ 124.1
XML 86 R60.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Debt - Schedule of Long-term Debt (Details) - USD ($)
$ in Millions
Dec. 31, 2019
Dec. 31, 2018
Aug. 28, 2018
Debt Instrument [Line Items]      
Unamortized debt issuance costs $ (16.8) $ (20.7)  
Long-term debt 2,355.0 2,472.3  
Less current portion of long-term debt (24.5) (29.0)  
Total long-term debt 2,330.5 2,443.3  
Credit Facility | Term credit facility      
Debt Instrument [Line Items]      
Long-term debt, gross 371.4 492.5  
Senior Notes | 3.912% Senior Notes due 2021      
Debt Instrument [Line Items]      
Interest rate     3.912%
Long-term debt, gross 500.0 500.0  
Senior Notes | 4.272% Senior Notes due 2023      
Debt Instrument [Line Items]      
Interest rate     4.272%
Long-term debt, gross 750.0 750.0  
Senior Notes | 4.900% Senior Notes due 2028      
Debt Instrument [Line Items]      
Interest rate     4.90%
Long-term debt, gross 750.0 750.0  
Other obligations      
Debt Instrument [Line Items]      
Long-term debt, gross $ 0.4 $ 0.5  
XML 87 R90.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Geographic Information - Narrative (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2019
USD ($)
segment
Dec. 31, 2018
USD ($)
Dec. 31, 2017
Segment Reporting [Abstract]      
Number of operating segments | segment 1    
Concentration Risk [Line Items]      
Accounts receivable $ 816.9 $ 651.8  
Product Sales      
Concentration Risk [Line Items]      
Accounts receivable $ 90.5 $ 96.4  
Customer Concentration Risk | Revenue | Single Customer      
Concentration Risk [Line Items]      
Concentration risk 12.90% 11.90% 12.90%
XML 88 R94.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Retirement Benefits - Amounts Recognized in Combined Balance Sheet (Details) - USD ($)
$ in Millions
Dec. 31, 2019
Dec. 31, 2018
Amounts recognized in the consolidated balance sheet consisted of:    
Accrued retirement benefits $ (82.5) $ (109.1)
Pension Plans    
Amounts recognized in the consolidated balance sheet consisted of:    
Noncurrent assets 2.1 2.3
Other current liabilities (0.3) (0.3)
Accrued retirement benefits (77.5) (105.2)
Accumulated other comprehensive (income) loss before income taxes (28.2) 1.3
Net amount recognized $ (103.9) $ (101.9)
XML 89 R64.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Goodwill and Intangibles - Narrative (Details) - USD ($)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]      
Goodwill $ 2,989,600,000 $ 2,958,000,000.0  
Impairments with respect to the carrying value of goodwill 0 0 $ 0
Impairment charges 11,400,000 22,500,000 94,500,000
Impairment of finite-lived intangible assets   9,500,000 56,500,000
Impairment of indefinite-lived intangible assets   13,000,000.0 38,000,000.0
Software      
Finite-Lived Intangible Assets [Line Items]      
Amortization $ 20,400,000 $ 18,400,000 $ 17,400,000
Minimum      
Finite-Lived Intangible Assets [Line Items]      
Estimated useful lives 3 years    
Maximum      
Finite-Lived Intangible Assets [Line Items]      
Estimated useful lives 20 years    
XML 90 R52.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Revenue - Summary of Activity in Sales Rebates and Discounts Liability (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Change In Contract With Customer, Liability [Roll Forward]    
Beginning balance $ 118.5 $ 114.8
Reduction of revenue 316.3 221.0
Payments (284.4) (217.3)
Ending balance $ 150.4 $ 118.5
XML 91 R56.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Asset Impairment, Restructuring and Other Special Charges - Total Charges Related to Asset Impairment, Restructuring and Other Special Charges (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Restructuring charges                      
Severance and other costs                 $ 8.2 $ 15.5 $ 162.0
Facility exit costs                 0.0 5.7 31.8
Transaction and integration costs                 144.7 26.5 90.3
Non-cash and other items                      
Asset impairment                 15.4 81.9 110.6
Asset write-down                 17.2 0.0 0.0
Gain on sale of fixed assets                 0.0 (0.8) (19.6)
Total expense $ 51.6 $ 77.2 $ 31.8 $ 24.9 $ 46.0 $ 12.4 $ 68.0 $ 2.4 185.5 $ 128.8 $ 375.1
Property, plant and equipment classified as held for sale $ 11.2               $ 11.2    
XML 92 R75.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stock-Based Compensation - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Feb. 28, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock options granted (in shares) 0      
PAs        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Unrecognized compensation cost $ 11.0      
Weighted-average remaining requisite service period 13 months      
RSUs        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Vesting period 3 years      
Unrecognized compensation cost $ 25.5      
Weighted-average remaining requisite service period 19 months      
Stock options        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Vesting period 3 years      
Unrecognized compensation cost $ 2.2      
Weighted-average remaining requisite service period 22 months      
Expiration period 10 years      
Elanco Stock Compensation Plans        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Shares of common stock to be reserved for future issuance (in shares) 11,000,000 5,500,000   5,500,000
Stock-based compensation $ 40.7 $ 1.8    
Lilly's Stock-Based Compensation Program        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation $ 5.1 $ 26.0 $ 25.0  
XML 93 R85.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Cash Payments of Income Taxes (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Income Tax Disclosure [Abstract]      
Cash payments of income taxes $ 42.5 $ 26.9 $ 35.7
XML 94 R81.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Composition of Income (Loss) Before Income Tax Expense (Benefit) (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Income Tax Disclosure [Abstract]                      
Federal                 $ 55.5 $ 12.2 $ (133.2)
Foreign                 22.7 101.9 (99.4)
Income (loss) before income taxes $ (4.3) $ (12.5) $ 50.2 $ 44.8 $ (2.2) $ 78.8 $ (40.0) $ 77.5 $ 78.2 $ 114.1 $ (232.6)
XML 95 R71.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases - Narrative (Details)
 12 Months Ended
Dec. 31, 2019
Minimum  
Lessee, Lease, Description [Line Items]  
Remaining lease terms 1 year
Maximum  
Lessee, Lease, Description [Line Items]  
Remaining lease terms 12 years
XML 96 R89.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Commitments and Contingencies - Narrative (Details) - USD ($)
Aug. 19, 2019
Dec. 31, 2019
Dec. 31, 2018
Business Acquisition [Line Items]      
Liabilities related to litigation   $ 0 $ 0
Bayer Animal Business      
Business Acquisition [Line Items]      
Line of credit facility, commitment fee amount $ 40,400,000    
Bayer Animal Business | Revolving credit facility      
Business Acquisition [Line Items]      
Credit facility, maximum borrowing capacity 750,000,000    
Bayer Animal Business | Term Facility      
Business Acquisition [Line Items]      
Credit facility, maximum borrowing capacity 3,000,000,000.0    
Bayer Animal Business | Bridge Facility      
Business Acquisition [Line Items]      
Credit facility, maximum borrowing capacity $ 2,750,000,000    
XML 97 R79.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stock-Based Compensation - Schedule of Stock Option Activity (Details) - USD ($)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Shares of Common Stock Attributable to Options    
Outstanding at beginning of period (in shares) 400,000  
Granted (in shares) 0  
Exercised (in shares) (100,000)  
Forfeited or expired (in shares) 0  
Outstanding at end of period (in shares) 300,000 400,000
Exercisable (in shares) 0  
Weighted-Average Exercise Price of Options    
Outstanding at beginning of period (usd per share) $ 31.61  
Granted (usd per share) 0  
Exercised (usd per share) 31.61  
Forfeited or expired (usd per share) 0  
Outstanding at end of period (usd per share) 31.61 $ 31.61
Exercisable (usd per share) $ 0  
Stock Option Activity, Additional Disclosures    
Weighted-average remaining contractual term of the outstanding options 8 years 9 months 18 days  
Weighted-average remaining contractual term of the exercisable options 0 years  
Aggregate intrinsic value of outstanding options $ 0  
Aggregate intrinsic value of exercisable options $ 0  
Weighted-average grant date fair value per stock option (usd per share) $ 10.21 10.21
Aggregate intrinsic value on exercise (usd per share) $ 0.10 $ 0
Cash received upon exercise $ 1,900,000 $ 0
XML 98 R7.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated and Combined Statements of Equity - USD ($)
shares in Millions, $ in Millions
Total
Aratana Therapeutics, Inc.
Common Stock
Common Stock
Aratana Therapeutics, Inc.
Additional Paid-in Capital
Additional Paid-in Capital
Aratana Therapeutics, Inc.
Net Parent Company Investment
Retained Earnings
Accumulated Other Comprehensive Income (Loss)
Foreign Currency Translation
Defined Benefit Pension and Retiree Health Benefit Plans
Balance at beginning of period (in shares) at Dec. 31, 2016     293.3                
Balance at beginning of period at Dec. 31, 2016 $ 7,017.4   $ 0.0   $ 0.0   $ 7,474.3 $ 0.0 $ (456.9) $ (437.3) $ (19.6)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net income (loss) (310.7)           (310.7)        
Other comprehensive income (loss), net of tax 200.3               200.3 210.1 (9.8)
Transfers (to)/from Lilly, net 873.3           873.3        
Balance at end of period (in shares) at Dec. 31, 2017     293.3                
Balance at end of period at Dec. 31, 2017 7,780.3   $ 0.0   0.0   8,036.9 0.0 (256.6) (227.2) (29.4)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net income (loss) 86.5           70.1 16.4      
Other comprehensive income (loss), net of tax (21.7)               (21.7) (47.1) 25.4
Transfers (to)/from Lilly, net (226.3)           (226.3)        
Separation adjustments [1] 99.6           43.5   56.1 56.1  
Issuance of common stock (in shares)     72.3                
Issuance of common stock 1,659.7       1,659.7            
Consideration to Lilly in connection with Separation (4,194.9)       (4,194.9)            
Reclassification of net parent company investment 0.0       7,923.9   (7,923.9)        
Stock compensation 1.8       1.8            
Capital contribution from Lilly 12.8       12.8            
Balance at end of period (in shares) at Dec. 31, 2018     365.6                
Balance at end of period at Dec. 31, 2018 5,197.5   $ 0.0   5,403.3   0.0 16.4 (222.2) (218.2) (4.0)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net income (loss) 67.9             67.9      
Other comprehensive income (loss), net of tax 48.5               48.5 19.8 28.7
Separation adjustments [2] (51.2)       (51.2)            
Stock compensation 40.7       40.7            
Issuance of stock under employee stock plans, net (in shares)     0.1                
Issuance to Aratana shareholders for acquisition (in shares) [3]       7.2              
Issuance to Aratana shareholders for acquisition [3]   $ 238.0       $ 238.0          
Accelerated vesting of equity awards (in shares)   0.1   0.1 [3]              
Accelerated vesting of equity awards [3]   $ 3.6       3.6          
Other [3]   1.9       $ 1.9          
Balance at end of period (in shares) at Dec. 31, 2019     373.0                
Balance at end of period at Dec. 31, 2019 $ 5,546.9 $ 5,546.9 $ 0.0   $ 5,636.3   $ 0.0 $ 84.3 $ (173.7) $ (198.4) $ 24.7
[1] See Note 3: Impact of Separation for further discussion.
[2] See Note 20: Related Party Agreements and Transactions for further discussion.
[3] See Note 6: Acquisitions for further discussion.
XML 99 R3.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated and Combined Statements of Comprehensive Income (Loss) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Statement of Comprehensive Income [Abstract]      
Net income (loss) $ 67.9 $ 86.5 $ (310.7)
Other comprehensive income (loss)      
Foreign currency translation 19.8 (47.1) 210.1
Defined benefit pension and retiree health benefit plans, net of taxes 28.7 25.4 (9.8)
Other comprehensive income (loss), net of taxes 48.5 (21.7) 200.3
Comprehensive income (loss) $ 116.4 $ 64.8 $ (110.4)
XML 100 R18.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Goodwill and Intangibles
 12 Months Ended
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangibles Goodwill and Intangibles
Goodwill
Goodwill was $3.0 billion as of December 31, 2019 and 2018. Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually and when impairment indicators are present. Goodwill may be impaired if the carrying amount of a reporting unit exceeds the fair value of that reporting unit, calculated as based on discounted cash flows. An impairment charge would be recorded for the excess, if any, of the reporting unit's carrying amount over its fair value, but not to exceed the total amount of goodwill allocated to the reporting unit. The estimated fair value is based on a number of assumptions, including current market capitalization as corroboration of fair value. See Note 6: Acquisitions for further discussion of goodwill resulting from recent business combinations. The remaining change in goodwill is primarily the result of foreign exchange translation adjustments.
No impairments occurred with respect to the carrying value of goodwill for the years ended December 31, 2019, 2018 and 2017.
Other Intangibles
The components of intangible assets other than goodwill at December 31 were as follows:
20192018
Description
Carrying Amount, Gross
Accumulated Amortization
Carrying Amount, Net
Carrying Amount, Gross
Accumulated Amortization
Carrying Amount, Net
Finite-lived intangible assets:
Marketed products$3,302.7  $(980.6) $2,322.1  $3,193.5  $(779.2) $2,414.3  
Software159.2  (72.2) 87.0  101.3  (49.5) 51.8  
Other58.3  (34.0) 24.3  53.1  (34.0) 19.1  
Total finite-lived intangible assets3,520.2  (1,086.8) 2,433.4  3,347.9  (862.7) 2,485.2  
Indefinite-lived intangible assets:
Acquired in-process research and development49.4  —  49.4  19.6  —  19.6  
Other intangibles$3,569.6  $(1,086.8) $2,482.8  $3,367.5  $(862.7) $2,504.8  
Marketed products consist of the amortized cost of the rights to assets acquired in business combinations and approved for marketing in a significant global jurisdiction. For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing.
Software consists of certain costs incurred in connection with obtaining or developing internal-use software, including payroll and payroll-related costs for employees directly associated with the internal-use software projects and direct costs of external resources. These costs include software classified as "in process" until the project is substantially complete and the software is ready for its intended purpose, at which point the costs are amortized on a straight-line basis over the estimated useful life. Depreciation expense includes $20.4 million in 2019, $18.4 million in 2018, and $17.4 million in 2017 for amortization of software.
Other finite-lived intangibles consist primarily of the amortized cost of licensed platform technologies that have alternative future uses in research and development, manufacturing technologies and customer relationships from business combinations. Acquired IPR&D consists of the related costs capitalized, adjusted for subsequent impairments, if any. The costs of acquired IPR&D projects acquired directly in a transaction other than a business combination are capitalized if the projects have an alternative future use; otherwise, they are expensed immediately. The fair values of acquired IPR&D projects acquired in business combinations are capitalized as other intangible assets.
Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the "income method" for other intangibles. This method is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each group of assets independently. The acquired IPR&D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate.
See Note 6: Acquisitions for further discussion of intangible assets acquired in recent business combinations.
Other indefinite-lived intangible assets are reviewed for impairment at least annually and when impairment indicators are present. The fair value of the indefinite lived intangible assets (acquired IPR&D) is estimated using the same assumptions as used for goodwill and by applying a probability weighting that reflects the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is
present. We compare the carrying amounts of the assets with the estimated undiscounted future cash flows. In the event the carrying amount exceeds the undiscounted cash flows, an impairment charge is recorded for the amount by which the carrying amount of the asset exceeds the estimated fair value, which is determined based on discounted future cash flows.
During 2019, we recorded impairment charges of $11.4 million primarily related to indefinite-lived intangible assets which are included in asset impairment, restructuring and other special charges on the consolidated and combined statements of operations. The impairment of indefinite-lived intangible assets primarily related to product rationalization.
During 2018, we recorded impairment charges of $22.5 million (comprised of $9.5 million impairment of finite-lived intangible assets and $13.0 million impairment of indefinite-lived intangible assets) which are included in asset impairment, restructuring and other special charges on the consolidated and combined statements of operations. The impairment of finite-lived intangible assets primarily related to competitive pressures for a certain marketed product resulting in a reduction of projected cash flows. The impairment of indefinite-lived intangible assets primarily related to revised projections of fair value due to competitive pressures and to a lesser extent product rationalization. The increase in the carrying amount of finite intangibles is primarily due to the receipt of full commercialization rights outside the U.S. for Galliprant.
During 2017, we had impairment charges of $94.5 million (comprised of $56.5 million impairment of finite-lived intangible assets and $38.0 million impairment of indefinite-lived intangible assets) which are included in asset impairment, restructuring and other special charges on the consolidated and combined statements of operations. The impairment of finite-lived intangible assets primarily related to competitive pressures for a certain marketed product resulting in a reduction of projected cash flows. The impairment of indefinite-lived intangible assets primarily related to revised projections of fair value due to competitive pressures and to a lesser extent product rationalization.
Intangible assets with finite lives are capitalized and are amortized over their estimated useful lives, ranging from 3 to 20 years. As of December 31, 2019, the remaining weighted-average amortization periods for finite-lived intangible assets are as follows:
Weighted Average Life (Years)
Marketed products13
Software6
Other8
The estimated amortization expense for each of the next five years associated with our finite-lived intangible assets as of December 31, 2019 is as follows:
20202021202220232024
Estimated amortization expense$206.2  $205.4  $203.3  $203.0  $203.0  
XML 101 R10.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Impact of Separation
 12 Months Ended
Dec. 31, 2019
Equity [Abstract]  
Impact of Separation Impact of Separation
In connection with the Separation, we issued $2.0 billion aggregate principal amount of senior notes in a private placement, and we also entered into a $750.0 million senior unsecured revolving credit facility and $500.0 million senior unsecured term credit facility. See Note 9: Debt for further information. In connection with the Separation, we entered into various agreements with Lilly, including a master separation agreement, a tax matters agreement and the TSA.
In connection with the terms of the Separation, there were certain assets and liabilities included in the pre-Separation balance sheet that were retained by Lilly and there were certain assets not included in the pre-Separation balance sheet that were transferred to us. The cumulative adjustment to the historical balance sheet increased net assets and total equity by approximately $99.6 million. The impact on net assets primarily represents the elimination of certain income tax assets and liabilities and the contribution of additional assets.
We will also continue to have certain ongoing relationships with Lilly as described in Note 20: Related Party Agreements and Transactions.
XML 102 R14.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Asset Impairment, Restructuring and Other Special Charges
 12 Months Ended
Dec. 31, 2019
Restructuring and Related Activities [Abstract]  
Asset Impairment, Restructuring and Other Special Charges Asset Impairment, Restructuring and Other Special Charges
In recent years, we have incurred substantial costs associated with restructuring programs and cost-reduction initiatives designed to achieve a flexible and competitive cost structure. Restructuring activities primarily include charges associated with facility rationalization and workforce reductions. In connection with our recent acquisitions, we have also incurred costs associated with executing transactions and integrating acquired operations, which may include expenditures for banking, legal, accounting, and other similar services. In addition, we have incurred costs to stand up our organization as an independent company. All operating functions can be impacted by these actions; therefore, non-cash expenses associated with our tangible and intangible assets can be incurred as a result of revised fair value projections and/or determinations to no longer utilize certain assets in the business on an ongoing basis.
For finite-lived intangible asset and other long-lived assets, whenever impairment indicators are present, we calculate the undiscounted value of projected cash flows associated with the asset, or group of assets, and compare it to the carrying amount. If the carrying amount is greater, we record an impairment loss for the excess of book value over fair value. Determinations of fair value can result from a complex series of judgments and rely on estimates and assumptions. See Note 2: Basis of Presentation for discussion regarding estimates and assumptions.
Components of asset impairment, restructuring and other special charges for the years ended December 31 are as follows:
201920182017
Restructuring charges: (1)
Severance and other costs$8.2  $15.5  $162.0  
Facility exit costs—  5.7  31.8  
Acquisition related charges:
Transaction and integration costs (2)
144.7  26.5  90.3  
Non-cash and other items:
Asset impairment (3)
15.4  81.9  110.6  
Asset write-down (4)
17.2  —  —  
Gain on sale of fixed assets (5)
—  (0.8) (19.6) 
Total expense$185.5  $128.8  $375.1  
(1)For the year ended December 31, 2019, these charges primarily relate to a new program that will eliminate certain positions across multiple locations and functions, including exiting R&D operations in Prince Edward Island, Canada, ceasing certain manufacturing operations in Wusi, China, and streamlining operations in Speke, England. We expect to substantially complete these restructuring activities by September 2020.
For the year ended December 31, 2018, these charges primarily relate to a program to streamline international operations, including  shifting focus and resources to priority areas. Among other actions, amounts reflect a change from having a physical location to a distribution model in certain countries in connection with the Separation. These activities were substantially complete as of December 31, 2019.
We historically participated in Lilly’s cost-reduction initiatives, which resulted in restructuring charges in the period prior to our IPO. These restructuring charges include severance and other costs associated with the reduction of our workforce, including special termination benefits recognized in 2017 associated with the U.S. voluntary early retirement program offered by Lilly, related to our employees and pension curtailment costs and facility exit costs. We also recorded certain impairment charges related to the activities as described below.
(2)Transaction costs represent external costs directly related to acquiring businesses and primarily include expenditures for banking, legal, accounting and other similar services. Integration costs represent external, incremental costs directly related to integrating acquired businesses (e.g., expenditures for consulting, system and process integration, and product transfers), as well as stand-up costs related to the implementation of new systems, programs, and processes due to the Separation from Lilly .
(3)Asset impairment charges are associated with the following:
•For the year ended December 31, 2019, write-off certain IPR&D and manufacturing assets in the US, Canada and Speke, resulting from the adjustment to fair value of property and equipment and intangible assets that were subject to product rationalization.
•For the year ended December 31, 2018, the decision to dispose of a manufacturing facility in the U.S., the suspension of commercial activities for Imrestor, the write-off of certain idle assets in a U.S. manufacturing facility and product rationalization.
•For the year ended December 31, 2017, intangible asset impairments related to revised projections of fair value due to product rationalization and to a lesser extent competitive pressures.
(4)Asset write-down expenses resulted from the adjustments recorded to write assets classified as held and used and held for sale down to their current fair values. These charges primarily related to fixed assets in Prince Edward Island, Canada; Wusi, China and Indianapolis, Indiana. $11.2 million of Property and equipment, net in Prince Edward Island, Canada and Indianapolis, Indiana are classified as held for sale.
(5)Represents a gain on the disposal of a site that was previously closed as part of the acquisition and integration of Novartis Animal Health beginning on January 1, 2015.
The following table summarizes the activity in our reserves established in connection with restructuring activities:
Exit costs SeveranceTotal
Balance at December 31, 2017$34.9  $43.1  $78.0  
Charges11.7  15.5  27.2  
Separation adjustment(5.9) —  (5.9) 
Reserve adjustment(6.0) —  (6.0) 
Cash paid(25.4) (23.5) (48.9) 
Balance at December 31, 20189.3  35.1  44.4  
Charges—  19.3  19.3  
Reserve adjustment (1)
—  (11.1) (11.1) 
Cash paid(3.9) (27.8) (31.7) 
Balance at December 31, 2019$5.4  $15.5  $20.9  
(1) Reserve adjustment represents the reversal of reserves for severance programs that are no longer active.

These reserves are included in other current liabilities in the consolidated balance sheets. Substantially all of the reserves are expected to be paid in the next twelve months. We believe that the reserves are adequate.
XML 103 R108.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Subsequent Events - Divestitures (Details)
$ in Millions
Dec. 31, 2019
USD ($)
Noncash or Part Noncash Divestitures [Line Items]  
Property and equipment, net $ 11.2
Disposal group | Osurnia and Capstar  
Noncash or Part Noncash Divestitures [Line Items]  
Inventories 10.6
Other intangibles, net 61.2
Property and equipment, net 0.2
Total assets held for sale 72.0
Deferred taxes 1.4
Total liabilities held for sale $ 1.4
XML 104 R100.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Retirement Benefits - Amounts Recognized in Other Comprehensive Loss (Details) - Pension Plans - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Defined Benefit Plan Disclosure [Line Items]      
Actuarial gain (loss) arising during period $ (45.6) $ 28.3 $ (17.0)
Prior year service cost during the year 74.7 0.0 0.0
Amortization of prior service cost included in net loss (1.7) 0.2 0.1
Amortization of net actuarial loss included in net loss 1.1 1.9 1.4
Foreign currency exchange rate changes and other 1.0 (1.9) 3.5
Total other comprehensive income (loss) during period $ 29.5 $ 28.5 $ (12.0)
XML 105 R37.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Financial Instruments and Fair Value (Tables)
 12 Months Ended
Dec. 31, 2019
Fair Value Disclosures [Abstract]  
Summary of Fair Value Information
The following table summarizes the fair value information at December 31, 2019 and 2018 for contingent consideration liabilities, and net investment hedge assets/(liabilities) measured at fair value on a recurring basis in the respective balance sheet line items, as well as long-term debt for which fair value is disclosed on a recurring basis:
  Fair Value Measurements Using 
Financial statement line itemCarrying AmountQuoted Prices in Active Markets for Identical Assets (Level 1)Significant Other Observable Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)		Fair Value
December 31, 2019
Other noncurrent liabilities- contingent consideration$(4.7) $—  $—  $(4.7) $(4.7) 
Other noncurrent assets/(liabilities) - cross currency interest rate contracts designated as net investment hedges2.3  —  2.3  —  2.3  
Long-term debt - senior notes(2,000.0) —  (2,120.6) —  (2,120.6) 
Long-term debt - term credit facility(371.4) —  (371.4) —  (371.4) 
December 31, 2018
Other current liabilities- contingent consideration$(5.1) $—  $—  $(5.1) $(5.1) 
Other noncurrent liabilities- contingent consideration(69.0) —  —  (69.0) (69.0) 
Other noncurrent assets/(liabilities) - cross currency interest rate contracts designated as net investment hedges(7.4) —  (7.4) —  (7.4) 
Long-term debt - senior notes(2,000.0) —  (2,005.0) —  (2,005.0) 
Long-term debt - term credit facility(492.5) —  (492.5) —  (492.5) 
XML 106 R104.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Related Party Agreements and Transactions - Narrative (Details)
$ in Millions
 12 Months Ended
Sep. 24, 2018
USD ($)
Dec. 31, 2019
USD ($)
renewal_term
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Related Party Transaction [Line Items]        
Separation adjustments $ 99.6 $ (51.2) [1] $ 99.6 [2]  
Restricted cash   11.1 202.7 $ 0.0
Net transfers (to)/from Lilly     (226.3) 873.3
Acquisition amount   32.8 0.0 882.1
Additional Paid-in Capital        
Related Party Transaction [Line Items]        
Separation adjustments [1]   (51.2)    
Boehringer Ingelheim Vetmedica, Inc.        
Related Party Transaction [Line Items]        
Acquisition amount       882.1
Lilly        
Related Party Transaction [Line Items]        
Stock-based compensation   5.1 26.0 25.0
Costs/(benefits) of defined benefit pension plan     (6.3) 73.7
Lilly | TSA        
Related Party Transaction [Line Items]        
Revenue from related parties   $ 93.7 28.1  
Lilly | Intellectual Property and Technology License Agreement        
Related Party Transaction [Line Items]        
Initial term   2 years    
Number of renewal terms | renewal_term   3    
Extension term   1 year    
Lilly | Toll Manufacturing Arrangement        
Related Party Transaction [Line Items]        
Revenue from related parties   $ 17.8 7.0  
Lilly | Manufacturing Support        
Related Party Transaction [Line Items]        
Revenue from related parties     $ 3.7 $ 6.2
[1] See Note 20: Related Party Agreements and Transactions for further discussion.
[2] See Note 3: Impact of Separation for further discussion.
XML 107 R33.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Acquisitions (Tables)
 12 Months Ended
Dec. 31, 2019
Business Combinations [Abstract]  
Summary of Amounts Recognized for Assets Acquired and Liabilities Assumed
The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:
Estimated Fair Value at July 18, 2019
Cash and cash equivalents$26.4  
Inventories10.3  
Acquired in-process research and development 31.9  
Marketed products (1)
36.7  
Other intangible assets (1)
13.2  
Other assets and liabilities - net 24.0  
Total identifiable net assets142.5  
Goodwill (2)
10.8  
Settlement of existing contingent consideration liabilities84.7  
Total consideration transferred$238.0  
(1) These intangible assets, which are being amortized on a straight-line basis over their estimated useful lives, are expected to have a weighted average useful life of approximately 12.5 years.
(2) The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of Aratana with our legacy business. The majority of goodwill associated with this acquisition is not deductible for tax purposes.
The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:
Estimated Fair Value at July 31, 2019
Cash and cash equivalents$0.9  
Property and equipment0.5  
Acquired in-process research and development 2.8  
Marketed products(1)
58.9  
Other intangible assets1.1  
Other assets and liabilities - net(10.3) 
Total identifiable net assets53.9  
Goodwill (2)
11.1  
Total consideration transferred$65.0  
(1) These intangible assets, which are being amortized on a straight-line basis over their estimated useful lives, are expected to have a weighted average useful life of 10 years.
(2) The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of Prevtec with our legacy business and future unidentified projects and products. The goodwill associated with this acquisition is not deductible for tax purposes.
The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:
Estimated Fair Value at January 3, 2017
Inventories (1)
$108.6  
Marketed products (2)
297.0  
Property and equipment148.2  
Other assets and liabilities — net8.2  
Total identifiable net assets562.0  
Goodwill (3)
320.1  
Total consideration transferred — net of cash acquired$882.1  
(1) The fair value for inventories include a purchase accounting adjustment to write up the inventory value, which resulted in incremental cost of sales of $42.7 million in 2017. The fair value was determined by estimating the expected sales price of the inventories, reduced for all costs expected to the incurred and a profit on those costs.
(2) These intangible assets, which are being amortized on a straight-line basis over their estimated useful lives, were expected to have a weighted average useful life of 10 years.
(3) The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of BIVIVP with our legacy business, future unidentified projects and products, and the assembled workforce of BIVIVP. The goodwill associated with this acquisition is deductible for tax purposes.
XML 108 R53.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Revenue - Disaggregation of Revenue (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Disaggregation of Revenue [Line Items]      
Total Revenue $ 3,071.0 $ 3,066.8 $ 2,889.0
Companion Animal Disease Prevention      
Disaggregation of Revenue [Line Items]      
Total Revenue 787.9 804.6 660.2
Companion Animal Therapeutics      
Disaggregation of Revenue [Line Items]      
Total Revenue 348.0 283.1 260.8
Food Animal Future Protein & Health      
Disaggregation of Revenue [Line Items]      
Total Revenue 745.1 711.2 649.2
Food Animal Ruminants Swine      
Disaggregation of Revenue [Line Items]      
Total Revenue 1,110.3 1,174.0 1,175.0
Strategic Exits      
Disaggregation of Revenue [Line Items]      
Total Revenue $ 79.7 $ 93.9 $ 143.8
XML 109 R57.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Asset Impairment, Restructuring and Other Special Charges - Summary of Activity in Reserves (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Restructuring Reserve [Roll Forward]    
Balance at beginning of period $ 44.4 $ 78.0
Charges 19.3 27.2
Separation adjustment   (5.9)
Reserve adjustment (11.1) (6.0)
Cash paid (31.7) (48.9)
Balance at end of period 20.9 44.4
Exit costs    
Restructuring Reserve [Roll Forward]    
Balance at beginning of period 9.3 34.9
Charges 0.0 11.7
Separation adjustment   (5.9)
Reserve adjustment 0.0 (6.0)
Cash paid (3.9) (25.4)
Balance at end of period 5.4 9.3
Severance    
Restructuring Reserve [Roll Forward]    
Balance at beginning of period 35.1 43.1
Charges 19.3 15.5
Separation adjustment   0.0
Reserve adjustment (11.1) 0.0
Cash paid (27.8) (23.5)
Balance at end of period $ 15.5 $ 35.1
XML 110 R88.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Income Tax Expense (Benefit) Related to Interest and Penalties (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Income Tax Disclosure [Abstract]      
Income tax expense (benefit) $ (10.6) $ (2.5) $ 2.5
XML 111 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 397 565 1 true 116 0 false 10 false false R1.htm 000010001 - Document - Document and Entity Information Sheet http://www.elanco.com/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010002 - Statement - Consolidated and Combined Statements of Operations Sheet http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations Consolidated and Combined Statements of Operations Statements 2 false false R3.htm 100020003 - Statement - Consolidated and Combined Statements of Comprehensive Income (Loss) Sheet http://www.elanco.com/role/ConsolidatedandCombinedStatementsofComprehensiveIncomeLoss Consolidated and Combined Statements of Comprehensive Income (Loss) Statements 3 false false R4.htm 100030004 - Statement - Consolidated Balance Sheets Sheet http://www.elanco.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 4 false false R5.htm 100040005 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.elanco.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 100050006 - Statement - Consolidated and Combined Statement of Cash Flows Sheet http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows Consolidated and Combined Statement of Cash Flows Statements 6 false false R7.htm 100060007 - Statement - Consolidated and Combined Statements of Equity Sheet http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity Consolidated and Combined Statements of Equity Statements 7 false false R8.htm 210011001 - Disclosure - Nature of Business and Organization Sheet http://www.elanco.com/role/NatureofBusinessandOrganization Nature of Business and Organization Notes 8 false false R9.htm 210031002 - Disclosure - Basis of Presentation Sheet http://www.elanco.com/role/BasisofPresentation Basis of Presentation Notes 9 false false R10.htm 210051003 - Disclosure - Impact of Separation Sheet http://www.elanco.com/role/ImpactofSeparation Impact of Separation Notes 10 false false R11.htm 210071004 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.elanco.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 11 false false R12.htm 210101005 - Disclosure - Revenue Sheet http://www.elanco.com/role/Revenue Revenue Notes 12 false false R13.htm 210151006 - Disclosure - Acquisitions Sheet http://www.elanco.com/role/Acquisitions Acquisitions Notes 13 false false R14.htm 210191007 - Disclosure - Asset Impairment, Restructuring and Other Special Charges Sheet http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialCharges Asset Impairment, Restructuring and Other Special Charges Notes 14 false false R15.htm 210231008 - Disclosure - Inventories Sheet http://www.elanco.com/role/Inventories Inventories Notes 15 false false R16.htm 210271009 - Disclosure - Debt Sheet http://www.elanco.com/role/Debt Debt Notes 16 false false R17.htm 210311010 - Disclosure - Financial Instruments and Fair Value Sheet http://www.elanco.com/role/FinancialInstrumentsandFairValue Financial Instruments and Fair Value Notes 17 false false R18.htm 210351011 - Disclosure - Goodwill and Intangibles Sheet http://www.elanco.com/role/GoodwillandIntangibles Goodwill and Intangibles Notes 18 false false R19.htm 210441013 - Disclosure - Property and Equipment Sheet http://www.elanco.com/role/PropertyandEquipment Property and Equipment Notes 19 false false R20.htm 210491014 - Disclosure - Leases Sheet http://www.elanco.com/role/Leases Leases Notes 20 false false R21.htm 210551015 - Disclosure - Stock-Based Compensation Sheet http://www.elanco.com/role/StockBasedCompensation Stock-Based Compensation Notes 21 false false R22.htm 210621016 - Disclosure - Income Taxes Sheet http://www.elanco.com/role/IncomeTaxes Income Taxes Notes 22 false false R23.htm 210731017 - Disclosure - Commitments and Contingencies Sheet http://www.elanco.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 23 false false R24.htm 210751018 - Disclosure - Geographic Information Sheet http://www.elanco.com/role/GeographicInformation Geographic Information Notes 24 false false R25.htm 210791019 - Disclosure - Retirement Benefits Sheet http://www.elanco.com/role/RetirementBenefits Retirement Benefits Notes 25 false false R26.htm 210911020 - Disclosure - Earnings Per Share Sheet http://www.elanco.com/role/EarningsPerShare Earnings Per Share Notes 26 false false R27.htm 210931021 - Disclosure - Related Party Agreements and Transactions Sheet http://www.elanco.com/role/RelatedPartyAgreementsandTransactions Related Party Agreements and Transactions Notes 27 false false R28.htm 210981022 - Disclosure - Selected Quarterly Data (unaudited) Sheet http://www.elanco.com/role/SelectedQuarterlyDataunaudited Selected Quarterly Data (unaudited) Notes 28 false false R29.htm 211011023 - Disclosure - Subsequent Events Sheet http://www.elanco.com/role/SubsequentEvents Subsequent Events Notes 29 false false R30.htm 220042001 - Disclosure - Basis of Presentation (Policies) Sheet http://www.elanco.com/role/BasisofPresentationPolicies Basis of Presentation (Policies) Policies http://www.elanco.com/role/SummaryofSignificantAccountingPolicies 30 false false R31.htm 230083001 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.elanco.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.elanco.com/role/SummaryofSignificantAccountingPolicies 31 false false R32.htm 230113002 - Disclosure - Revenue (Tables) Sheet http://www.elanco.com/role/RevenueTables Revenue (Tables) Tables http://www.elanco.com/role/Revenue 32 false false R33.htm 230163003 - Disclosure - Acquisitions (Tables) Sheet http://www.elanco.com/role/AcquisitionsTables Acquisitions (Tables) Tables http://www.elanco.com/role/Acquisitions 33 false false R34.htm 230203004 - Disclosure - Asset Impairment, Restructuring and Other Special Charges (Tables) Sheet http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables Asset Impairment, Restructuring and Other Special Charges (Tables) Tables http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialCharges 34 false false R35.htm 230243005 - Disclosure - Inventories (Tables) Sheet http://www.elanco.com/role/InventoriesTables Inventories (Tables) Tables http://www.elanco.com/role/Inventories 35 false false R36.htm 230283006 - Disclosure - Debt (Tables) Sheet http://www.elanco.com/role/DebtTables Debt (Tables) Tables http://www.elanco.com/role/Debt 36 false false R37.htm 230323007 - Disclosure - Financial Instruments and Fair Value (Tables) Sheet http://www.elanco.com/role/FinancialInstrumentsandFairValueTables Financial Instruments and Fair Value (Tables) Tables http://www.elanco.com/role/FinancialInstrumentsandFairValue 37 false false R38.htm 230363008 - Disclosure - Goodwill and Intangibles (Tables) Sheet http://www.elanco.com/role/GoodwillandIntangiblesTables Goodwill and Intangibles (Tables) Tables http://www.elanco.com/role/GoodwillandIntangibles 38 false false R39.htm 230453010 - Disclosure - Property and Equipment (Tables) Sheet http://www.elanco.com/role/PropertyandEquipmentTables Property and Equipment (Tables) Tables http://www.elanco.com/role/PropertyandEquipment 39 false false R40.htm 230503011 - Disclosure - Leases (Tables) Sheet http://www.elanco.com/role/LeasesTables Leases (Tables) Tables http://www.elanco.com/role/Leases 40 false false R41.htm 230563012 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.elanco.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.elanco.com/role/StockBasedCompensation 41 false false R42.htm 230633013 - Disclosure - Income Taxes (Tables) Sheet http://www.elanco.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.elanco.com/role/IncomeTaxes 42 false false R43.htm 230763014 - Disclosure - Geographic Information (Tables) Sheet http://www.elanco.com/role/GeographicInformationTables Geographic Information (Tables) Tables http://www.elanco.com/role/GeographicInformation 43 false false R44.htm 230803015 - Disclosure - Retirement Benefits (Tables) Sheet http://www.elanco.com/role/RetirementBenefitsTables Retirement Benefits (Tables) Tables http://www.elanco.com/role/RetirementBenefits 44 false false R45.htm 230943016 - Disclosure - Related Party Agreements and Transactions (Tables) Sheet http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsTables Related Party Agreements and Transactions (Tables) Tables http://www.elanco.com/role/RelatedPartyAgreementsandTransactions 45 false false R46.htm 230993017 - Disclosure - Selected Quarterly Data (unaudited) (Tables) Sheet http://www.elanco.com/role/SelectedQuarterlyDataunauditedTables Selected Quarterly Data (unaudited) (Tables) Tables http://www.elanco.com/role/SelectedQuarterlyDataunaudited 46 false false R47.htm 231023018 - Disclosure - Subsequent Events (Tables) Sheet http://www.elanco.com/role/SubsequentEventsTables Subsequent Events (Tables) Tables http://www.elanco.com/role/SubsequentEvents 47 false false R48.htm 240024001 - Disclosure - Nature of Business and Organization (Details) Sheet http://www.elanco.com/role/NatureofBusinessandOrganizationDetails Nature of Business and Organization (Details) Details http://www.elanco.com/role/NatureofBusinessandOrganization 48 false false R49.htm 240064002 - Disclosure - Impact of Separation (Details) Sheet http://www.elanco.com/role/ImpactofSeparationDetails Impact of Separation (Details) Details http://www.elanco.com/role/ImpactofSeparation 49 false false R50.htm 240094003 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.elanco.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.elanco.com/role/SummaryofSignificantAccountingPoliciesTables 50 false false R51.htm 240124004 - Disclosure - Revenue - Narrative (Details) Sheet http://www.elanco.com/role/RevenueNarrativeDetails Revenue - Narrative (Details) Details 51 false false R52.htm 240134005 - Disclosure - Revenue - Summary of Activity in Sales Rebates and Discounts Liability (Details) Sheet http://www.elanco.com/role/RevenueSummaryofActivityinSalesRebatesandDiscountsLiabilityDetails Revenue - Summary of Activity in Sales Rebates and Discounts Liability (Details) Details 52 false false R53.htm 240144006 - Disclosure - Revenue - Disaggregation of Revenue (Details) Sheet http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails Revenue - Disaggregation of Revenue (Details) Details 53 false false R54.htm 240174007 - Disclosure - Acquisitions - Narrative (Details) Sheet http://www.elanco.com/role/AcquisitionsNarrativeDetails Acquisitions - Narrative (Details) Details 54 false false R55.htm 240184008 - Disclosure - Acquisitions - Summary of Amounts Recognized for Assets Acquired and Liabilities Assumed (Details) Sheet http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails Acquisitions - Summary of Amounts Recognized for Assets Acquired and Liabilities Assumed (Details) Details 55 false false R56.htm 240214009 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Total Charges Related to Asset Impairment, Restructuring and Other Special Charges (Details) Sheet http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails Asset Impairment, Restructuring and Other Special Charges - Total Charges Related to Asset Impairment, Restructuring and Other Special Charges (Details) Details 56 false false R57.htm 240224010 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Summary of Activity in Reserves (Details) Sheet http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails Asset Impairment, Restructuring and Other Special Charges - Summary of Activity in Reserves (Details) Details 57 false false R58.htm 240254011 - Disclosure - Inventories - Schedule of Inventories (Details) Sheet http://www.elanco.com/role/InventoriesScheduleofInventoriesDetails Inventories - Schedule of Inventories (Details) Details 58 false false R59.htm 240264012 - Disclosure - Inventories - Narrative (Details) Sheet http://www.elanco.com/role/InventoriesNarrativeDetails Inventories - Narrative (Details) Details 59 false false R60.htm 240294013 - Disclosure - Debt - Schedule of Long-term Debt (Details) Sheet http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails Debt - Schedule of Long-term Debt (Details) Details 60 false false R61.htm 240304014 - Disclosure - Debt - Narrative (Details) Sheet http://www.elanco.com/role/DebtNarrativeDetails Debt - Narrative (Details) Details 61 false false R62.htm 240334015 - Disclosure - Financial Instruments and Fair Value - Narrative (Details) Sheet http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails Financial Instruments and Fair Value - Narrative (Details) Details 62 false false R63.htm 240344016 - Disclosure - Financial Instruments and Fair Value - Summary of Fair Value Information (Details) Sheet http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails Financial Instruments and Fair Value - Summary of Fair Value Information (Details) Details 63 false false R64.htm 240374017 - Disclosure - Goodwill and Intangibles - Narrative (Details) Sheet http://www.elanco.com/role/GoodwillandIntangiblesNarrativeDetails Goodwill and Intangibles - Narrative (Details) Details 64 false false R65.htm 240384018 - Disclosure - Goodwill and Intangibles - Components of Intangible Assets Other Than Goodwill (Details) Sheet http://www.elanco.com/role/GoodwillandIntangiblesComponentsofIntangibleAssetsOtherThanGoodwillDetails Goodwill and Intangibles - Components of Intangible Assets Other Than Goodwill (Details) Details 65 false false R66.htm 240394019 - Disclosure - Goodwill and Intangibles - Remaining Weighted Average Amortization Periods (Details) Sheet http://www.elanco.com/role/GoodwillandIntangiblesRemainingWeightedAverageAmortizationPeriodsDetails Goodwill and Intangibles - Remaining Weighted Average Amortization Periods (Details) Details 66 false false R67.htm 240404020 - Disclosure - Goodwill and Intangibles - Estimated Amortization Expense (Details) Sheet http://www.elanco.com/role/GoodwillandIntangiblesEstimatedAmortizationExpenseDetails Goodwill and Intangibles - Estimated Amortization Expense (Details) Details 67 false false R68.htm 240464022 - Disclosure - Property and Equipment - Narrative (Details) Sheet http://www.elanco.com/role/PropertyandEquipmentNarrativeDetails Property and Equipment - Narrative (Details) Details 68 false false R69.htm 240474023 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details) Sheet http://www.elanco.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails Property and Equipment - Schedule of Property and Equipment (Details) Details 69 false false R70.htm 240484024 - Disclosure - Property and Equipment - Depreciation Expense and Rental Expense for All Leases (Details) Sheet http://www.elanco.com/role/PropertyandEquipmentDepreciationExpenseandRentalExpenseforAllLeasesDetails Property and Equipment - Depreciation Expense and Rental Expense for All Leases (Details) Details 70 false false R71.htm 240514025 - Disclosure - Leases - Narrative (Details) Sheet http://www.elanco.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 71 false false R72.htm 240524026 - Disclosure - Leases - Impact of Operating Leases to Condensed Consolidated Financial Statements (Details) Sheet http://www.elanco.com/role/LeasesImpactofOperatingLeasestoCondensedConsolidatedFinancialStatementsDetails Leases - Impact of Operating Leases to Condensed Consolidated Financial Statements (Details) Details 72 false false R73.htm 240534027 - Disclosure - Leases - Supplemental Balance Sheet Information Related to Operating Leases (Details) Sheet http://www.elanco.com/role/LeasesSupplementalBalanceSheetInformationRelatedtoOperatingLeasesDetails Leases - Supplemental Balance Sheet Information Related to Operating Leases (Details) Details 73 false false R74.htm 240544028 - Disclosure - Leases - Annual Minimum Lease Payments of Operating Lease Liabilities (Details) Sheet http://www.elanco.com/role/LeasesAnnualMinimumLeasePaymentsofOperatingLeaseLiabilitiesDetails Leases - Annual Minimum Lease Payments of Operating Lease Liabilities (Details) Details 74 false false R75.htm 240574029 - Disclosure - Stock-Based Compensation - Narrative (Details) Sheet http://www.elanco.com/role/StockBasedCompensationNarrativeDetails Stock-Based Compensation - Narrative (Details) Details 75 false false R76.htm 240584030 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expenses (Details) Sheet http://www.elanco.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpensesDetails Stock-Based Compensation - Schedule of Stock-Based Compensation Expenses (Details) Details 76 false false R77.htm 240594031 - Disclosure - Stock-Based Compensation - Schedule of Restricted Stock Unit and Performance Award Activity (Details) Sheet http://www.elanco.com/role/StockBasedCompensationScheduleofRestrictedStockUnitandPerformanceAwardActivityDetails Stock-Based Compensation - Schedule of Restricted Stock Unit and Performance Award Activity (Details) Details 77 false false R78.htm 240604032 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used (Details) Sheet http://www.elanco.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails Stock-Based Compensation - Schedule of Assumptions Used (Details) Details 78 false false R79.htm 240614033 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity (Details) Sheet http://www.elanco.com/role/StockBasedCompensationScheduleofStockOptionActivityDetails Stock-Based Compensation - Schedule of Stock Option Activity (Details) Details 79 false false R80.htm 240644034 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.elanco.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 80 false false R81.htm 240654035 - Disclosure - Income Taxes - Composition of Income (Loss) Before Income Tax Expense (Benefit) (Details) Sheet http://www.elanco.com/role/IncomeTaxesCompositionofIncomeLossBeforeIncomeTaxExpenseBenefitDetails Income Taxes - Composition of Income (Loss) Before Income Tax Expense (Benefit) (Details) Details 81 false false R82.htm 240664036 - Disclosure - Income Taxes - Composition of Income Tax Expense (Benefit) (Details) Sheet http://www.elanco.com/role/IncomeTaxesCompositionofIncomeTaxExpenseBenefitDetails Income Taxes - Composition of Income Tax Expense (Benefit) (Details) Details 82 false false R83.htm 240674037 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details) Sheet http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details) Details 83 false false R84.htm 240684038 - Disclosure - Income Taxes - Movements in the Valuation Allowance (Details) Sheet http://www.elanco.com/role/IncomeTaxesMovementsintheValuationAllowanceDetails Income Taxes - Movements in the Valuation Allowance (Details) Details 84 false false R85.htm 240694039 - Disclosure - Income Taxes - Cash Payments of Income Taxes (Details) Sheet http://www.elanco.com/role/IncomeTaxesCashPaymentsofIncomeTaxesDetails Income Taxes - Cash Payments of Income Taxes (Details) Details 85 false false R86.htm 240704040 - Disclosure - Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details) Sheet http://www.elanco.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details) Details 86 false false R87.htm 240714041 - Disclosure - Income Taxes - Reconciliation of Gross Unrecognized Tax Benefits (Details) Sheet http://www.elanco.com/role/IncomeTaxesReconciliationofGrossUnrecognizedTaxBenefitsDetails Income Taxes - Reconciliation of Gross Unrecognized Tax Benefits (Details) Details 87 false false R88.htm 240724042 - Disclosure - Income Taxes - Income Tax Expense (Benefit) Related to Interest and Penalties (Details) Sheet http://www.elanco.com/role/IncomeTaxesIncomeTaxExpenseBenefitRelatedtoInterestandPenaltiesDetails Income Taxes - Income Tax Expense (Benefit) Related to Interest and Penalties (Details) Details 88 false false R89.htm 240744043 - Disclosure - Commitments and Contingencies - Narrative (Details) Sheet http://www.elanco.com/role/CommitmentsandContingenciesNarrativeDetails Commitments and Contingencies - Narrative (Details) Details 89 false false R90.htm 240774044 - Disclosure - Geographic Information - Narrative (Details) Sheet http://www.elanco.com/role/GeographicInformationNarrativeDetails Geographic Information - Narrative (Details) Details 90 false false R91.htm 240784045 - Disclosure - Geographic Information - Revenue and Long-lived Assets by Selected Geographic Area Information (Details) Sheet http://www.elanco.com/role/GeographicInformationRevenueandLonglivedAssetsbySelectedGeographicAreaInformationDetails Geographic Information - Revenue and Long-lived Assets by Selected Geographic Area Information (Details) Details 91 false false R92.htm 240814046 - Disclosure - Retirement Benefits - Narrative (Details) Sheet http://www.elanco.com/role/RetirementBenefitsNarrativeDetails Retirement Benefits - Narrative (Details) Details 92 false false R93.htm 240824047 - Disclosure - Retirement Benefits - Change in Benefit Obligation, Change in Plan Assets, and Funded Status (Details) Sheet http://www.elanco.com/role/RetirementBenefitsChangeinBenefitObligationChangeinPlanAssetsandFundedStatusDetails Retirement Benefits - Change in Benefit Obligation, Change in Plan Assets, and Funded Status (Details) Details 93 false false R94.htm 240834048 - Disclosure - Retirement Benefits - Amounts Recognized in Combined Balance Sheet (Details) Sheet http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinCombinedBalanceSheetDetails Retirement Benefits - Amounts Recognized in Combined Balance Sheet (Details) Details 94 false false R95.htm 240844049 - Disclosure - Retirement Benefits - Weighted-Average Assumptions Related to Pension Plans (Details) Sheet http://www.elanco.com/role/RetirementBenefitsWeightedAverageAssumptionsRelatedtoPensionPlansDetails Retirement Benefits - Weighted-Average Assumptions Related to Pension Plans (Details) Details 95 false false R96.htm 240854050 - Disclosure - Retirement Benefits - Schedule of Expected Benefit Payments (Details) Sheet http://www.elanco.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsDetails Retirement Benefits - Schedule of Expected Benefit Payments (Details) Details 96 false false R97.htm 240864051 - Disclosure - Retirement Benefits - Projected Benefit Obligations in Excess of Plan Assets (Details) Sheet http://www.elanco.com/role/RetirementBenefitsProjectedBenefitObligationsinExcessofPlanAssetsDetails Retirement Benefits - Projected Benefit Obligations in Excess of Plan Assets (Details) Details 97 false false R98.htm 240874052 - Disclosure - Retirement Benefits - Accumulated Benefit Obligations in Excess of Plan Assets (Details) Sheet http://www.elanco.com/role/RetirementBenefitsAccumulatedBenefitObligationsinExcessofPlanAssetsDetails Retirement Benefits - Accumulated Benefit Obligations in Excess of Plan Assets (Details) Details 98 false false R99.htm 240884053 - Disclosure - Retirement Benefits - Net Pension Expense (Details) Sheet http://www.elanco.com/role/RetirementBenefitsNetPensionExpenseDetails Retirement Benefits - Net Pension Expense (Details) Details 99 false false R100.htm 240894054 - Disclosure - Retirement Benefits - Amounts Recognized in Other Comprehensive Loss (Details) Sheet http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinOtherComprehensiveLossDetails Retirement Benefits - Amounts Recognized in Other Comprehensive Loss (Details) Details 100 false false R101.htm 240904055 - Disclosure - Retirement Benefits - Fair Value of Pension Plan Assets (Details) Sheet http://www.elanco.com/role/RetirementBenefitsFairValueofPensionPlanAssetsDetails Retirement Benefits - Fair Value of Pension Plan Assets (Details) Details 101 false false R102.htm 240924056 - Disclosure - Earnings Per Share (Details) Sheet http://www.elanco.com/role/EarningsPerShareDetails Earnings Per Share (Details) Details http://www.elanco.com/role/EarningsPerShare 102 false false R103.htm 240954057 - Disclosure - Related Party Agreements and Transactions - Amounts Due From/(Due To) Lilly (Details) Sheet http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAmountsDueFromDueToLillyDetails Related Party Agreements and Transactions - Amounts Due From/(Due To) Lilly (Details) Details 103 false false R104.htm 240964058 - Disclosure - Related Party Agreements and Transactions - Narrative (Details) Sheet http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails Related Party Agreements and Transactions - Narrative (Details) Details 104 false false R105.htm 240974059 - Disclosure - Related Party Agreements and Transactions - Allocation of Services (Details) Sheet http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAllocationofServicesDetails Related Party Agreements and Transactions - Allocation of Services (Details) Details 105 false false R106.htm 241004060 - Disclosure - Selected Quarterly Data (unaudited) (Details) Sheet http://www.elanco.com/role/SelectedQuarterlyDataunauditedDetails Selected Quarterly Data (unaudited) (Details) Details http://www.elanco.com/role/SelectedQuarterlyDataunauditedTables 106 false false R107.htm 241034061 - Disclosure - Subsequent Events - Narrative (Details) Sheet http://www.elanco.com/role/SubsequentEventsNarrativeDetails Subsequent Events - Narrative (Details) Details 107 false false R108.htm 241044062 - Disclosure - Subsequent Events - Divestitures (Details) Sheet http://www.elanco.com/role/SubsequentEventsDivestituresDetails Subsequent Events - Divestitures (Details) Details 108 false false R9999.htm Uncategorized Items - elan-20191231.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - elan-20191231.htm Cover 109 false false All Reports Book All Reports elan-20191231.htm elan-20191231.xsd elan-20191231_cal.xml elan-20191231_def.xml elan-20191231_lab.xml elan-20191231_pre.xml ex211elanco-20191231su.htm ex231elanco-20191231xe.htm ex311elanco-20191231ce.htm ex312elanco-20191231ce.htm ex32elanco-20191231x13.htm ex46elanco-20191231xde.htm elan-20191231_g1.jpg elan-20191231_g2.jpg elan-20191231_g3.jpg http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2019-01-31 true true XML 112 R78.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stock-Based Compensation - Schedule of Assumptions Used (Details) - Stock options
 12 Months Ended
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Expected dividend yield 0.70%
Risk-free interest rate 3.07%
Expected stock price volatility 28.25%
Expected term (years) 6 years 6 months
XML 113 R74.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases - Annual Minimum Lease Payments of Operating Lease Liabilities (Details)
$ in Millions
Dec. 31, 2019
USD ($)
Leases [Abstract]  
Year 1 $ 26.0
Year 2 20.3
Year 3 11.9
Year 4 9.7
Year 5 7.2
After Year 5 16.5
Total lease payments 91.6
Less imputed interest (6.2)
Total $ 85.4
XML 114 R84.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Movements in the Valuation Allowance (Details) - Valuation Allowance, Deferred Tax Asset - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]    
Beginning balance $ (21.4) $ (17.3)
Increase (1) (23.2) (5.8)
Release 11.9 1.7
Ending balance (32.7) (21.4)
Previously Reported    
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]    
Beginning balance (21.4) (127.7)
Ending balance   (21.4)
Adjustment related to Separation    
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]    
Beginning balance $ 0.0 110.4
Ending balance   $ 0.0
XML 115 R80.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Narrative (Details) - USD ($)
Sep. 24, 2018
Dec. 31, 2019
Dec. 31, 2018
Operating Loss Carryforwards [Line Items]      
Tax credit carryovers   $ 14,000,000.0  
Net operating losses and other carryovers   69,500,000 $ 17,400,000
Separation entries related to the removal of the net operating losses $ 133,700,000    
Taxes accrued with respect to unremitted earnings of foreign subsidiaries   0  
Unremitted earnings of foreign subsidiaries   496,700,000  
Unrecognized tax benefits that, if recognized, would affect effective tax rate   8,200,000 12,800,000
Unrecognized tax benefits that, if recognized, would not affect effective tax rate     1,900,000
Accruals for payment of interest and penalties   3,000,000.0 $ 13,300,000
Foreign      
Operating Loss Carryforwards [Line Items]      
Tax credit carryovers   5,100,000  
Domestic Tax Authority      
Operating Loss Carryforwards [Line Items]      
Tax credit carryovers   3,200,000  
State      
Operating Loss Carryforwards [Line Items]      
Tax credit carryovers   5,700,000  
International, State and Federal      
Operating Loss Carryforwards [Line Items]      
Net operating losses and other carryovers   348,400,000  
Net operating loss carryforwards with indefinite carryforward period   62,900,000  
International, State and Federal | 2020 To 2039      
Operating Loss Carryforwards [Line Items]      
Net operating loss carryforwards that expire   $ 285,500,000  
XML 116 R70.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Property and Equipment - Depreciation Expense and Rental Expense for All Leases (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Property, Plant and Equipment [Abstract]      
Depreciation expense $ 93.7 $ 81.3 $ 79.8
XML 117 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 118 R11.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Revenue recognition
Effective January 1, 2018, we adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (ASU 2014-09) and other related updates. The new standard has been applied to contracts for which performance had not been completed as of the date of adoption. Revenue presented for periods prior to 2018 was accounted for under previous standards and has not been adjusted. Revenue and net income for the years ended December 31, 2019 and 2018 do not differ materially from amounts that would have resulted from application of the previous standards.
Product Sales
We recognize revenue primarily from product sales to customers. Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which generally is at the time we ship the product to the customer. Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from 30 to 120 days from date of shipment. Revenue for our product sales has not been adjusted for the effects of a financing component as we expect, at contract inception, that the period between when we transfer control of the product and when we receive payment will be one year or less. Any exceptions are either not material or we collect interest for payments made after the due date. For arrangements with contract manufacturing organizations (CMO), we recognize revenue over time or at a point in time depending on our evaluation of when the customer obtains control of the promised goods or service. Revenue is recognized over time when we are creating or enhancing an asset that the customer controls. In this instance revenue is recognized as the asset is created or enhanced or our performance does not create an asset with an alternative use and we have an enforceable right to payment for performance completed.
Provisions for rebates and discounts, as well as returns are established in the same period the related sales are recognized. We generally ship product shortly after orders are received; therefore, we generally only have a few days of orders received but not yet shipped at the end of any reporting period. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are imposed on our sales of product and collected from a customer.
Significant judgments must be made in determining the transaction price for sales of products related to anticipated rebates and discounts, and returns. The following describe the most significant of these judgments:
Sales Rebates and Discounts - Background and Uncertainties
•Most of our products are sold to wholesale distributors. We initially invoice our customers contractual list prices. Contracts with direct and indirect customers may provide for various rebates and discounts that may differ in each contract. As a consequence, to determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we must estimate any rebates or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts. Judgments are required in making these estimates.
•The rebate and discount amounts are recorded as a deduction to arrive at our net product sales. We estimate these accruals using an expected value approach.
•In determining the appropriate accrual amount, we consider our historical experience with similar incentives programs and current sales data and estimates of inventory levels at our channel distributors to evaluate the impact of such programs on revenue and continually monitor the impact of this experience and adjust as necessary. Although we accrue a liability for rebates related to these programs at the time the sale is recorded, the rebate related to that sale is typically paid up to six months after the rebate or incentive period expires. Because of this time lag, in any particular period rebate adjustments may incorporate revisions of accruals for several periods.
Sales Returns - Background and Uncertainties
•We estimate a reserve for future product returns related to product sales using an expected value approach. This estimate is based on several factors, including: local returns policies and practices; returns as a
percentage of revenue; an understanding of the reasons for past returns; estimated shelf life by product; and estimate of the amount of time between shipment and return. Adjustments to the returns reserve have been and may in the future be required based on revised estimates to our assumptions, which would have an impact on our consolidated results of operations. We record the return amounts as a deduction to arrive at our net product sales.
Research and development expenses and acquired in-process research and development
Research and development expenses include the following:
•Research and development costs, which are expensed as incurred.
•Milestone payment obligations incurred prior to regulatory approval of the product, which are accrued when the event requiring payment of the milestone occurs.
•Acquired in-process research and development (IPR&D) expense, which includes the initial costs of IPR&D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use.
Foreign Currency Translation
Operations in our subsidiaries outside the U.S. are recorded in the functional currency of each subsidiary which is determined by a review of the environment where each subsidiary primarily generates and expends cash. The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted average currency rate for the period. Assets and liabilities are translated using the period end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries are recorded in other comprehensive income (loss).
Other significant accounting policies
Our other significant accounting policies are described in the remaining appropriate notes to the combined financial statements.
Implementation of New Financial Accounting Pronouncements
The following table provides a brief description of an accounting standard that was effective January 1, 2019 and was adopted on that date:
StandardDescriptionEffect on the financial statements or other significant matters
Accounting Standards Update 2016-02, Leases
This standard was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under previous GAAP, on the balance sheet and requiring additional disclosures about leasing arrangements.
We adopted the standard on January 1, 2019 using the modified retrospective approach, applied at the beginning of the period of adoption, and we elected the package of transition practical expedients. Upon adoption of the standard, we recorded $84.9 million of right-of-use assets and $85.3 million of operating lease liabilities on our consolidated balance sheet. Adoption of this standard did not have a material impact on our consolidated statement of operations for the year ended December 31, 2019. See Note 13: Leases for further information.

The following table provides a brief description of the accounting standards applicable to us that have not yet been adopted:
StandardDescriptionEffective DateEffect on the financial statements or other significant matters
Accounting Standards Update 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments
This standard modifies the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses.This standard is effective January 1, 2020, with early adoption permitted. We intend to adopt this standard on that date.We do not expect that the adoption of this standard will have a material impact on our consolidated financial statements based on financial instruments currently held.
Accounting Standards Update 2018-15, Intangibles - Goodwill and Other Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract
This guidance aligns the requirements for capitalizing implementation costs incurred in a cloud-based hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software.This standard is effective January 1, 2020, with early adoption permitted. We intend to adopt this standard on that date.Adoption of this standard is not expected to have a significant impact on our consolidated financial statements.
Accounting Standards Update 2019-12, Simplifying the Accounting for Income Taxes
The amendments in this update simplify the accounting for income taxes by removing certain exceptions and clarifying certain requirements regarding franchise taxes, goodwill, consolidated tax expenses, and annual effective tax rate calculations. This standard is effective January 1, 2021, with early adoption permitted. We intend to adopt this standard on that date.We are currently evaluating the impact of adoption of the new standard on our consolidated financial statements.
XML 119 R15.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Inventories
 12 Months Ended
Dec. 31, 2019
Inventory Disclosure [Abstract]  
Inventories Inventories We state all inventories at the lower of cost or net realizable value. We use the last-in, first-out (LIFO) method for a portion of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost.
Inventories at December 31 consisted of the following:
20192018
Finished products$402.9  $400.7  
Work in process603.2  570.4  
Raw materials and supplies83.9  80.4  
Total (approximates replacement cost)1,090.0  1,051.5  
Decrease to LIFO cost(39.3) (47.4) 
Inventories$1,050.7  $1,004.1  
Inventories valued under the LIFO method comprised $197.2 million and $194.8 million of total inventories at December 31, 2019 and 2018, respectively.
During the year ended December 31, 2018, we recognized $38.6 million of inventory write-offs in cost of sales primarily related to the suspension of commercial activities for Imrestor.
XML 120 R6.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated and Combined Statement of Cash Flows - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Cash Flows from Operating Activities      
Net income (loss) $ 67.9 $ 86.5 $ (310.7)
Adjustments to reconcile net income (loss) to cash flows from operating activities:      
Depreciation and amortization 314.5 296.0 318.4
Change in deferred income taxes 0.1 (60.7) (13.4)
Stock-based compensation expense 49.4 26.0 25.0
Asset impairment charges 32.6 120.5 110.6
Gain on sale of assets 0.0 (0.8) (19.6)
Other non-cash operating activities, net (12.7) 49.0 10.0
Other changes in operating assets and liabilities, net of acquisitions and divestitures:      
Receivables (172.4) (122.0) 48.4
Inventories (33.1) (20.1) (39.0)
Other assets 7.0 (3.2) 52.5
Accounts payable and other liabilities (29.2) 116.1 (8.4)
Net Cash Provided by Operating Activities 224.1 487.3 173.8
Cash Flows from Investing Activities      
Purchases of property and equipment (140.4) (134.5) (98.6)
Disposals of property and equipment 0.3 9.4 37.6
Purchases of software (57.0) (2.0) (18.5)
Cash paid for acquisitions, net of cash acquired (32.8) 0.0 (882.1)
Other investing activities, net (4.9) 0.1 (3.0)
Net Cash Used for Investing Activities (234.8) (127.0) (964.6)
Cash Flows from Financing Activities      
Proceeds from issuance of long-term debt (Note 9) 0.0 2,500.0 0.0
Repayments of borrowings (Note 9) (121.1) (7.5) 0.0
Proceeds from issuance of common stock (Note 1) 0.0 1,659.7 0.0
Debt issuance costs 0.0 (24.5) 0.0
Consideration paid to Lilly in connection with the Separation (Note 1) (191.6) (3,991.3) 0.0
Other financing activities, net 1.6 (17.2) (0.8)
Other net transactions with Lilly 6.3 (154.4) 848.3
Net Cash Provided by (Used for) Financing Activities (304.8) (35.2) 847.5
Effect of exchange rate changes on cash and cash equivalents (16.9) 29.0 7.9
Net (decrease) increase in cash, cash equivalents and restricted cash (332.4) 354.1 64.6
Cash, cash equivalents and restricted cash at beginning of period 677.5 323.4 258.8
Cash, cash equivalents and restricted cash at end of period 345.1 677.5 323.4
Cash, cash equivalents and restricted cash at end of period $ 677.5 $ 323.4 $ 323.4
XML 121 R2.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated and Combined Statements of Operations - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Income Statement [Abstract]      
Revenue $ 3,071.0 $ 3,066.8 $ 2,889.0
Costs, expenses and other:      
Cost of sales 1,470.3 1,573.8 1,493.9
Research and development 270.1 246.6 251.7
Marketing, selling and administrative 760.2 735.2 779.8
Amortization of intangible assets 200.4 197.4 221.2
Asset impairment, restructuring and other special charges (Note 7) 185.5 128.8 375.1
Interest expense, net of capitalized interest 78.9 29.6 0.0
Other-net, expense (income) 27.4 41.3 (0.1)
Costs, expenses and other 2,992.8 2,952.7 3,121.6
Income (loss) before income taxes 78.2 114.1 (232.6)
Income tax expense 10.3 27.6 78.1
Net income (loss) $ 67.9 $ 86.5 $ (310.7)
Earnings (loss) per share      
Basic (usd per share) $ 0.18 $ 0.28 $ (1.06)
Diluted (usd per share) $ 0.18 $ 0.28 $ (1.06)
Weighted average shares outstanding      
Basic (in shares) 369.0 313.7 293.3
Diluted (in shares) 370.3 313.7 293.3
XML 122 R19.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Property and Equipment
 12 Months Ended
Dec. 31, 2019
Property, Plant and Equipment [Abstract]  
Property and Equipment Property and Equipment Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (12 to 50 years for buildings and 3 to 25 years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset's net book value over its fair value utilizing a discounted cash flow analysis, and the cost basis is adjusted.
At December 31, property and equipment consisted of the following:
20192018
Land$28.3  $27.6  
Buildings608.5  567.2  
Equipment1,109.4  1,025.1  
Construction in progress139.1  181.1  
Finance lease asset0.5  —  
1,885.8  1,801.0  
Less accumulated depreciation(930.5) (878.6) 
Property and equipment, net$955.3  $922.4  
Depreciation expense related to property and equipment was as follows:
201920182017
Depreciation expense$93.7  $81.3  $79.8  
XML 123 R101.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Retirement Benefits - Fair Value of Pension Plan Assets (Details) - Pension Plans - USD ($)
$ in Millions
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 148.7 $ 131.6 $ 131.5
Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 129.0    
Public equity securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 3.8 2.2  
Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2.5 29.9  
Emerging markets      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 9.1 6.4  
Hedge funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   6.6  
Equity-like funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   49.0  
Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   20.1  
Other      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 4.3 17.4  
Quoted Prices in Active Markets for Identical Assets (Level 1)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 142.7 9.9  
Quoted Prices in Active Markets for Identical Assets (Level 1) | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 129.0    
Quoted Prices in Active Markets for Identical Assets (Level 1) | Public equity securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1.9 1.0  
Quoted Prices in Active Markets for Identical Assets (Level 1) | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2.1 7.8  
Quoted Prices in Active Markets for Identical Assets (Level 1) | Emerging markets      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 8.8 0.7  
Quoted Prices in Active Markets for Identical Assets (Level 1) | Hedge funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   0.0  
Quoted Prices in Active Markets for Identical Assets (Level 1) | Equity-like funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   0.0  
Quoted Prices in Active Markets for Identical Assets (Level 1) | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   0.1  
Quoted Prices in Active Markets for Identical Assets (Level 1) | Other      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.9 0.3  
Significant Observable  Inputs (Level 2)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 3.7 2.8  
Significant Observable  Inputs (Level 2) | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0    
Significant Observable  Inputs (Level 2) | Public equity securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
Significant Observable  Inputs (Level 2) | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.1  
Significant Observable  Inputs (Level 2) | Emerging markets      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.3 0.4  
Significant Observable  Inputs (Level 2) | Hedge funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   0.0  
Significant Observable  Inputs (Level 2) | Equity-like funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   0.0  
Significant Observable  Inputs (Level 2) | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   0.0  
Significant Observable  Inputs (Level 2) | Other      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 3.4 2.3  
Significant Unobservable Inputs (Level 3)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
Significant Unobservable Inputs (Level 3) | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0    
Significant Unobservable Inputs (Level 3) | Public equity securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
Significant Unobservable Inputs (Level 3) | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
Significant Unobservable Inputs (Level 3) | Emerging markets      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
Significant Unobservable Inputs (Level 3) | Hedge funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   0.0  
Significant Unobservable Inputs (Level 3) | Equity-like funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   0.0  
Significant Unobservable Inputs (Level 3) | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   0.0  
Significant Unobservable Inputs (Level 3) | Other      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
Investments Valued at Net Asset Value      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2.3 118.9  
Investments Valued at Net Asset Value | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0    
Investments Valued at Net Asset Value | Public equity securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1.9 1.2  
Investments Valued at Net Asset Value | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.4 22.0  
Investments Valued at Net Asset Value | Emerging markets      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 5.3  
Investments Valued at Net Asset Value | Hedge funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   6.6  
Investments Valued at Net Asset Value | Equity-like funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   49.0  
Investments Valued at Net Asset Value | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   20.0  
Investments Valued at Net Asset Value | Other      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 0.0 $ 14.8  
XML 124 R36.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Debt (Tables)
 12 Months Ended
Dec. 31, 2019
Debt Disclosure [Abstract]  
Schedule of Long-term Debt
Long-term debt as of December 31 consisted of the following:
20192018
Term credit facility$371.4  $492.5  
3.912% Senior Notes due 2021
500.0  500.0  
4.272% Senior Notes due 2023
750.0  750.0  
4.900% Senior Notes due 2028
750.0  750.0  
Other obligations0.4  0.5  
Unamortized debt issuance costs(16.8) (20.7) 
2,355.0  2,472.3  
Less current portion of long-term debt(24.5) (29.0) 
Total long-term debt$2,330.5  $2,443.3  
XML 125 R105.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Related Party Agreements and Transactions - Allocation of Services (Details) - Lilly - Transitional Services Agreement - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Related Party Transaction [Line Items]    
Allocation of services $ 105.2 $ 151.7
Cost of sales    
Related Party Transaction [Line Items]    
Allocation of services 21.8 31.8
Research and development    
Related Party Transaction [Line Items]    
Allocation of services 2.2 2.8
Marketing, selling and administrative    
Related Party Transaction [Line Items]    
Allocation of services $ 81.2 $ 117.1
XML 126 R32.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Revenue (Tables)
 12 Months Ended
Dec. 31, 2019
Revenue from Contract with Customer [Abstract]  
Summary of Activity in Sales Rebates and Discounts Liability
The following table summarizes the activity in the sales rebates and discounts liability in the U.S.:
Year Ended December 31,
20192018
Beginning balance$118.5  $114.8  
Reduction of revenue316.3  221.0  
Payments(284.4) (217.3) 
Ending balance$150.4  $118.5  
Disaggregation of Revenue
The following table summarizes our revenue disaggregated by product category for the years ended December 31:
201920182017
Companion Animal Disease Prevention$787.9  $804.6  $660.2  
Companion Animal Therapeutics348.0  283.1  260.8  
Food Animal Future Protein & Health745.1  711.2  649.2  
Food Animal Ruminants Swine1,110.3  1,174.0  1,175.0  
Strategic Exits(1)
79.7  93.9  143.8  
Total Revenue$3,071.0  $3,066.8  $2,889.0  
(1) Represents revenue from business activities we have either exited or made a strategic decision to exit.
XML 127 elan-20191231_htm.xml IDEA: XBRL DOCUMENT 0001739104 2019-01-01 2019-12-31 0001739104 2019-06-30 0001739104 2020-02-25 0001739104 2018-01-01 2018-12-31 0001739104 2017-01-01 2017-12-31 0001739104 2019-12-31 0001739104 2018-12-31 0001739104 us-gaap:CommonStockMember 2016-12-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001739104 elan:NetParentCompanyInvestmentMember 2016-12-31 0001739104 us-gaap:RetainedEarningsMember 2016-12-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2016-12-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-12-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0001739104 2016-12-31 0001739104 elan:NetParentCompanyInvestmentMember 2017-01-01 2017-12-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2017-01-01 2017-12-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-01-01 2017-12-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0001739104 us-gaap:CommonStockMember 2017-12-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001739104 elan:NetParentCompanyInvestmentMember 2017-12-31 0001739104 us-gaap:RetainedEarningsMember 2017-12-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-12-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001739104 2017-12-31 0001739104 elan:NetParentCompanyInvestmentMember 2018-01-01 2018-12-31 0001739104 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001739104 elan:NetParentCompanyInvestmentMember 2018-01-01 0001739104 2018-01-01 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-12-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-12-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001739104 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001739104 us-gaap:CommonStockMember 2018-12-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001739104 elan:NetParentCompanyInvestmentMember 2018-12-31 0001739104 us-gaap:RetainedEarningsMember 2018-12-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001739104 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-12-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-12-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001739104 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001739104 elan:AratanaTherapeuticsInc.Member us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001739104 elan:AratanaTherapeuticsInc.Member us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001739104 elan:AratanaTherapeuticsInc.Member 2019-01-01 2019-12-31 0001739104 us-gaap:CommonStockMember 2019-12-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001739104 elan:NetParentCompanyInvestmentMember 2019-12-31 0001739104 us-gaap:RetainedEarningsMember 2019-12-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001739104 elan:AratanaTherapeuticsInc.Member 2019-12-31 0001739104 us-gaap:IPOMember 2018-09-24 2018-09-24 0001739104 us-gaap:IPOMember 2018-09-24 0001739104 us-gaap:IPOMember 2019-12-31 0001739104 us-gaap:SeniorNotesMember 2018-08-28 0001739104 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2018-09-24 0001739104 elan:TermCreditFacilityMember us-gaap:LineOfCreditMember 2018-09-24 0001739104 2018-09-24 2018-09-24 0001739104 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001739104 country:US elan:ContractWithCustomerLiabilityMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-12-31 0001739104 country:US elan:ContractWithCustomerLiabilityMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-12-31 0001739104 us-gaap:NonUsMember elan:ContractWithCustomerLiabilityMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-12-31 0001739104 us-gaap:NonUsMember elan:ContractWithCustomerLiabilityMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-12-31 0001739104 us-gaap:RevenueFromContractWithCustomerMember elan:ProductReturnConcentrationRiskMember 2019-01-01 2019-12-31 0001739104 us-gaap:RevenueFromContractWithCustomerMember elan:ProductReturnConcentrationRiskMember 2018-01-01 2018-12-31 0001739104 elan:CompanionAnimalDiseasePreventionMember 2019-01-01 2019-12-31 0001739104 elan:CompanionAnimalDiseasePreventionMember 2018-01-01 2018-12-31 0001739104 elan:CompanionAnimalDiseasePreventionMember 2017-01-01 2017-12-31 0001739104 elan:CompanionAnimalTherapeuticsMember 2019-01-01 2019-12-31 0001739104 elan:CompanionAnimalTherapeuticsMember 2018-01-01 2018-12-31 0001739104 elan:CompanionAnimalTherapeuticsMember 2017-01-01 2017-12-31 0001739104 elan:FoodAnimalFutureProteinAndHealthMember 2019-01-01 2019-12-31 0001739104 elan:FoodAnimalFutureProteinAndHealthMember 2018-01-01 2018-12-31 0001739104 elan:FoodAnimalFutureProteinAndHealthMember 2017-01-01 2017-12-31 0001739104 elan:FoodAnimalRuminantsAndSwineMember 2019-01-01 2019-12-31 0001739104 elan:FoodAnimalRuminantsAndSwineMember 2018-01-01 2018-12-31 0001739104 elan:FoodAnimalRuminantsAndSwineMember 2017-01-01 2017-12-31 0001739104 elan:ProductCategoryStrategicExitsMember 2019-01-01 2019-12-31 0001739104 elan:ProductCategoryStrategicExitsMember 2018-01-01 2018-12-31 0001739104 elan:ProductCategoryStrategicExitsMember 2017-01-01 2017-12-31 0001739104 elan:AratanaTherapeuticsInc.Member 2019-07-18 2019-07-18 0001739104 elan:AratanaTherapeuticsInc.Member 2019-07-18 0001739104 elan:GalliprantMember 2019-07-18 0001739104 elan:GalliprantMember 2019-01-01 2019-12-31 0001739104 elan:AratanaTherapeuticsInc.Member us-gaap:InProcessResearchAndDevelopmentMember 2019-07-18 0001739104 elan:AratanaTherapeuticsInc.Member us-gaap:MarketingRelatedIntangibleAssetsMember 2019-07-18 0001739104 elan:AratanaTherapeuticsInc.Member us-gaap:OtherIntangibleAssetsMember 2019-07-18 0001739104 elan:AratanaTherapeuticsInc.Member 2018-01-01 2018-12-31 0001739104 elan:PrevtecMicrobiaInc.Member 2019-07-31 2019-07-31 0001739104 elan:PrevtecMicrobiaInc.Member 2019-07-31 0001739104 elan:PrevtecMicrobiaInc.Member us-gaap:InProcessResearchAndDevelopmentMember 2019-07-31 0001739104 elan:PrevtecMicrobiaInc.Member us-gaap:MarketingRelatedIntangibleAssetsMember 2019-07-31 0001739104 elan:PrevtecMicrobiaInc.Member us-gaap:OtherIntangibleAssetsMember 2019-07-31 0001739104 elan:BoehringerIngelheimVetmedicaInc.Member 2017-01-03 2017-01-03 0001739104 elan:BoehringerIngelheimVetmedicaInc.Member 2017-01-03 0001739104 elan:BoehringerIngelheimVetmedicaInc.Member us-gaap:MarketingRelatedIntangibleAssetsMember 2017-01-01 2017-12-31 0001739104 elan:BoehringerIngelheimVetmedicaInc.Member 2017-01-01 2017-12-31 0001739104 elan:BayerAnimalBusinessMember 2019-08-19 2019-08-19 0001739104 us-gaap:FacilityClosingMember 2017-12-31 0001739104 us-gaap:EmployeeSeveranceMember 2017-12-31 0001739104 us-gaap:FacilityClosingMember 2018-01-01 2018-12-31 0001739104 us-gaap:EmployeeSeveranceMember 2018-01-01 2018-12-31 0001739104 us-gaap:FacilityClosingMember 2018-12-31 0001739104 us-gaap:EmployeeSeveranceMember 2018-12-31 0001739104 us-gaap:FacilityClosingMember 2019-01-01 2019-12-31 0001739104 us-gaap:EmployeeSeveranceMember 2019-01-01 2019-12-31 0001739104 us-gaap:FacilityClosingMember 2019-12-31 0001739104 us-gaap:EmployeeSeveranceMember 2019-12-31 0001739104 elan:TermCreditFacilityMember us-gaap:LineOfCreditMember 2019-12-31 0001739104 elan:TermCreditFacilityMember us-gaap:LineOfCreditMember 2018-12-31 0001739104 elan:A3.912SeniorNotesDue2021Member us-gaap:SeniorNotesMember 2018-08-28 0001739104 elan:A3.912SeniorNotesDue2021Member us-gaap:SeniorNotesMember 2019-12-31 0001739104 elan:A3.912SeniorNotesDue2021Member us-gaap:SeniorNotesMember 2018-12-31 0001739104 elan:A4.272SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2018-08-28 0001739104 elan:A4.272SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2019-12-31 0001739104 elan:A4.272SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2018-12-31 0001739104 elan:A4.9SeniorNotesDue2028Member us-gaap:SeniorNotesMember 2018-08-28 0001739104 elan:A4.9SeniorNotesDue2028Member us-gaap:SeniorNotesMember 2019-12-31 0001739104 elan:A4.9SeniorNotesDue2028Member us-gaap:SeniorNotesMember 2018-12-31 0001739104 us-gaap:NotesPayableOtherPayablesMember 2019-12-31 0001739104 us-gaap:NotesPayableOtherPayablesMember 2018-12-31 0001739104 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2018-09-05 2018-09-05 0001739104 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2018-09-05 0001739104 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2019-12-31 0001739104 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2018-12-31 0001739104 elan:TermCreditFacilityMember us-gaap:LineOfCreditMember 2018-09-05 0001739104 elan:TermCreditFacilityMember us-gaap:LineOfCreditMember 2018-09-05 2018-09-05 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001739104 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001739104 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001739104 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001739104 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001739104 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-10-01 2018-10-31 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-10-31 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-01-01 2019-12-31 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-01-01 2018-12-31 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-12-31 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-01-01 2018-12-31 0001739104 us-gaap:MarketingRelatedIntangibleAssetsMember 2019-12-31 0001739104 us-gaap:MarketingRelatedIntangibleAssetsMember 2018-12-31 0001739104 us-gaap:ComputerSoftwareIntangibleAssetMember 2019-12-31 0001739104 us-gaap:ComputerSoftwareIntangibleAssetMember 2018-12-31 0001739104 us-gaap:OtherIntangibleAssetsMember 2019-12-31 0001739104 us-gaap:OtherIntangibleAssetsMember 2018-12-31 0001739104 us-gaap:InProcessResearchAndDevelopmentMember 2019-12-31 0001739104 us-gaap:InProcessResearchAndDevelopmentMember 2018-12-31 0001739104 us-gaap:ComputerSoftwareIntangibleAssetMember 2019-01-01 2019-12-31 0001739104 us-gaap:ComputerSoftwareIntangibleAssetMember 2018-01-01 2018-12-31 0001739104 us-gaap:ComputerSoftwareIntangibleAssetMember 2017-01-01 2017-12-31 0001739104 srt:MinimumMember 2019-01-01 2019-12-31 0001739104 srt:MaximumMember 2019-01-01 2019-12-31 0001739104 us-gaap:MarketingRelatedIntangibleAssetsMember 2019-01-01 2019-12-31 0001739104 us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-12-31 0001739104 srt:MinimumMember us-gaap:BuildingMember 2019-01-01 2019-12-31 0001739104 srt:MaximumMember us-gaap:BuildingMember 2019-01-01 2019-12-31 0001739104 srt:MinimumMember us-gaap:EquipmentMember 2019-01-01 2019-12-31 0001739104 srt:MaximumMember us-gaap:EquipmentMember 2019-01-01 2019-12-31 0001739104 us-gaap:LandMember 2019-12-31 0001739104 us-gaap:LandMember 2018-12-31 0001739104 us-gaap:BuildingMember 2019-12-31 0001739104 us-gaap:BuildingMember 2018-12-31 0001739104 us-gaap:EquipmentMember 2019-12-31 0001739104 us-gaap:EquipmentMember 2018-12-31 0001739104 us-gaap:ConstructionInProgressMember 2019-12-31 0001739104 us-gaap:ConstructionInProgressMember 2018-12-31 0001739104 elan:ElancoStockCompensationPlansMember 2018-12-31 0001739104 elan:ElancoStockCompensationPlansMember 2019-02-28 0001739104 elan:ElancoStockCompensationPlansMember 2019-12-31 0001739104 elan:ElancoStockCompensationPlansMember 2019-01-01 2019-12-31 0001739104 elan:ElancoStockCompensationPlansMember 2018-01-01 2018-12-31 0001739104 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001739104 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0001739104 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001739104 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001739104 us-gaap:PerformanceSharesMember 2018-12-31 0001739104 us-gaap:PerformanceSharesMember 2019-01-01 2019-12-31 0001739104 us-gaap:PerformanceSharesMember 2019-12-31 0001739104 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001739104 us-gaap:EmployeeStockOptionMember 2019-12-31 0001739104 elan:LillysStockBasedCompensationProgramMember 2019-01-01 2019-12-31 0001739104 elan:LillysStockBasedCompensationProgramMember 2018-01-01 2018-12-31 0001739104 elan:LillysStockBasedCompensationProgramMember 2017-01-01 2017-12-31 0001739104 us-gaap:ForeignCountryMember 2019-12-31 0001739104 us-gaap:DomesticCountryMember 2019-12-31 0001739104 us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0001739104 elan:DomesticForeignAndStateTaxAuthoritiesMember 2019-12-31 0001739104 elan:DomesticForeignAndStateTaxAuthoritiesMember elan:TaxYear2020To2039Member 2019-12-31 0001739104 srt:ScenarioPreviouslyReportedMember us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-12-31 0001739104 srt:ScenarioPreviouslyReportedMember us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2017-12-31 0001739104 srt:RestatementAdjustmentMember us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-12-31 0001739104 srt:RestatementAdjustmentMember us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2017-12-31 0001739104 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-12-31 0001739104 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2017-12-31 0001739104 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2019-01-01 2019-12-31 0001739104 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-01-01 2018-12-31 0001739104 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2019-12-31 0001739104 srt:ScenarioPreviouslyReportedMember 2018-12-31 0001739104 srt:ScenarioPreviouslyReportedMember 2017-12-31 0001739104 srt:ScenarioPreviouslyReportedMember 2016-12-31 0001739104 srt:RestatementAdjustmentMember 2018-12-31 0001739104 srt:RestatementAdjustmentMember 2017-12-31 0001739104 srt:RestatementAdjustmentMember 2016-12-31 0001739104 elan:BayerAnimalBusinessMember us-gaap:RevolvingCreditFacilityMember 2019-08-19 0001739104 elan:BayerAnimalBusinessMember elan:TermLoanMember 2019-08-19 0001739104 elan:BayerAnimalBusinessMember elan:BridgeFacilityMember 2019-08-19 0001739104 elan:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001739104 elan:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001739104 elan:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001739104 us-gaap:ProductMember 2019-12-31 0001739104 us-gaap:ProductMember 2018-12-31 0001739104 country:US 2019-01-01 2019-12-31 0001739104 country:US 2018-01-01 2018-12-31 0001739104 country:US 2017-01-01 2017-12-31 0001739104 us-gaap:NonUsMember 2019-01-01 2019-12-31 0001739104 us-gaap:NonUsMember 2018-01-01 2018-12-31 0001739104 us-gaap:NonUsMember 2017-01-01 2017-12-31 0001739104 country:US 2019-12-31 0001739104 country:US 2018-12-31 0001739104 country:US 2017-12-31 0001739104 country:GB 2019-12-31 0001739104 country:GB 2018-12-31 0001739104 country:GB 2017-12-31 0001739104 elan:OtherForeignCountriesNotSeparatelyDisclosedMember 2019-12-31 0001739104 elan:OtherForeignCountriesNotSeparatelyDisclosedMember 2018-12-31 0001739104 elan:OtherForeignCountriesNotSeparatelyDisclosedMember 2017-12-31 0001739104 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0001739104 us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-12-31 0001739104 us-gaap:PensionPlansDefinedBenefitMember 2018-01-01 2018-12-31 0001739104 us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 2019-09-01 2019-09-30 0001739104 us-gaap:PensionPlansDefinedBenefitMember 2017-01-01 2017-12-31 0001739104 us-gaap:DefinedBenefitPlanCashMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 us-gaap:FixedIncomeSecuritiesMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 elan:OtherAlternativeInvestmentsMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 elan:FixedIncomeSecuritiesDevelopedMarketsMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 elan:FixedIncomeSecuritiesDevelopedMarketsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 elan:FixedIncomeSecuritiesDevelopedMarketsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 elan:FixedIncomeSecuritiesDevelopedMarketsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 elan:FixedIncomeSecuritiesDevelopedMarketsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 elan:FixedIncomeSecuritiesEmergingMarketsMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 elan:FixedIncomeSecuritiesEmergingMarketsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 elan:FixedIncomeSecuritiesEmergingMarketsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 elan:FixedIncomeSecuritiesEmergingMarketsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 elan:FixedIncomeSecuritiesEmergingMarketsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 us-gaap:OtherInvestmentsMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001739104 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 elan:FixedIncomeSecuritiesDevelopedMarketsMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 elan:FixedIncomeSecuritiesDevelopedMarketsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 elan:FixedIncomeSecuritiesDevelopedMarketsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 elan:FixedIncomeSecuritiesDevelopedMarketsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 elan:FixedIncomeSecuritiesDevelopedMarketsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 elan:FixedIncomeSecuritiesEmergingMarketsMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 elan:FixedIncomeSecuritiesEmergingMarketsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 elan:FixedIncomeSecuritiesEmergingMarketsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 elan:FixedIncomeSecuritiesEmergingMarketsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 elan:FixedIncomeSecuritiesEmergingMarketsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 us-gaap:HedgeFundsMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 us-gaap:HedgeFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 us-gaap:HedgeFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 us-gaap:HedgeFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 us-gaap:HedgeFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 elan:DefinedBenefitPlanEquityLikeFundsMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 elan:DefinedBenefitPlanEquityLikeFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 elan:DefinedBenefitPlanEquityLikeFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 elan:DefinedBenefitPlanEquityLikeFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 elan:DefinedBenefitPlanEquityLikeFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 us-gaap:OtherInvestmentsMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001739104 us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2019-12-31 0001739104 us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0001739104 elan:ElancoAnimalHealthIncorporatedAndSubsidiariesMember elan:EliLillyandCompanyMember 2018-12-31 0001739104 elan:ElancoAnimalHealthIncorporatedAndSubsidiariesMember elan:EliLillyandCompanyMember 2018-09-18 0001739104 2018-09-19 2018-09-19 0001739104 elan:TransitionalServicesAgreementMember us-gaap:MajorityShareholderMember 2019-12-31 0001739104 elan:TransitionalServicesAgreementMember us-gaap:MajorityShareholderMember 2018-12-31 0001739104 elan:OtherRelatedPartyActivitiesMember us-gaap:MajorityShareholderMember 2019-12-31 0001739104 elan:OtherRelatedPartyActivitiesMember us-gaap:MajorityShareholderMember 2018-12-31 0001739104 elan:LocalCountryAssetPurchasesMember us-gaap:MajorityShareholderMember 2019-12-31 0001739104 elan:LocalCountryAssetPurchasesMember us-gaap:MajorityShareholderMember 2018-12-31 0001739104 us-gaap:MajorityShareholderMember 2019-12-31 0001739104 us-gaap:MajorityShareholderMember 2018-12-31 0001739104 elan:IntellectualPropertyAndTechnologyLicenseAgreementMember us-gaap:MajorityShareholderMember 2019-01-01 2019-12-31 0001739104 elan:IntellectualPropertyAndTechnologyLicenseAgreementMember us-gaap:MajorityShareholderMember 2019-12-31 0001739104 elan:TollManufacturingArrangementMember us-gaap:MajorityShareholderMember 2019-01-01 2019-12-31 0001739104 elan:TollManufacturingArrangementMember us-gaap:MajorityShareholderMember 2018-01-01 2018-12-31 0001739104 elan:TransitionalServicesAgreementMember us-gaap:MajorityShareholderMember 2019-01-01 2019-12-31 0001739104 elan:TransitionalServicesAgreementMember us-gaap:MajorityShareholderMember 2018-01-01 2018-12-31 0001739104 us-gaap:CostOfSalesMember elan:TransitionalServicesAgreementMember us-gaap:MajorityShareholderMember 2018-01-01 2018-12-31 0001739104 us-gaap:CostOfSalesMember elan:TransitionalServicesAgreementMember us-gaap:MajorityShareholderMember 2017-01-01 2017-12-31 0001739104 us-gaap:ResearchAndDevelopmentExpenseMember elan:TransitionalServicesAgreementMember us-gaap:MajorityShareholderMember 2018-01-01 2018-12-31 0001739104 us-gaap:ResearchAndDevelopmentExpenseMember elan:TransitionalServicesAgreementMember us-gaap:MajorityShareholderMember 2017-01-01 2017-12-31 0001739104 us-gaap:SellingGeneralAndAdministrativeExpensesMember elan:TransitionalServicesAgreementMember us-gaap:MajorityShareholderMember 2018-01-01 2018-12-31 0001739104 us-gaap:SellingGeneralAndAdministrativeExpensesMember elan:TransitionalServicesAgreementMember us-gaap:MajorityShareholderMember 2017-01-01 2017-12-31 0001739104 elan:TransitionalServicesAgreementMember us-gaap:MajorityShareholderMember 2017-01-01 2017-12-31 0001739104 elan:ManufacturingSupportMember us-gaap:MajorityShareholderMember 2018-01-01 2018-12-31 0001739104 elan:ManufacturingSupportMember us-gaap:MajorityShareholderMember 2017-01-01 2017-12-31 0001739104 us-gaap:MajorityShareholderMember 2019-01-01 2019-12-31 0001739104 us-gaap:MajorityShareholderMember 2018-01-01 2018-12-31 0001739104 us-gaap:MajorityShareholderMember 2017-01-01 2017-12-31 0001739104 2019-10-01 2019-12-31 0001739104 2019-07-01 2019-09-30 0001739104 2019-04-01 2019-06-30 0001739104 2019-01-01 2019-03-31 0001739104 2018-10-01 2018-12-31 0001739104 2018-07-01 2018-09-30 0001739104 2018-04-01 2018-06-30 0001739104 2018-01-01 2018-03-31 0001739104 us-gaap:CommonStockMember us-gaap:SubsequentEventMember elan:UnderwritingAgreementMember 2020-01-22 2020-01-22 0001739104 us-gaap:CommonStockMember us-gaap:SubsequentEventMember elan:UnderwritingAgreementMember 2020-01-22 0001739104 us-gaap:CommonStockMember us-gaap:SubsequentEventMember us-gaap:OverAllotmentOptionMember 2020-01-23 2020-01-23 0001739104 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2020-01-22 2020-01-23 0001739104 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2020-01-27 2020-01-27 0001739104 elan:TangibleEquityUnitMember us-gaap:SubsequentEventMember 2020-01-22 2020-01-22 0001739104 elan:TangibleEquityUnitMember us-gaap:SubsequentEventMember 2020-01-22 0001739104 elan:TangibleEquityUnitMember us-gaap:SubsequentEventMember 2020-01-27 2020-01-27 0001739104 elan:A500SeniorAmortizingNotesMember elan:TangibleEquityUnitMember us-gaap:SubsequentEventMember 2020-01-27 2020-01-27 0001739104 srt:MinimumMember elan:TangibleEquityUnitMember us-gaap:SubsequentEventMember 2020-01-22 2020-01-22 0001739104 srt:MaximumMember elan:TangibleEquityUnitMember us-gaap:SubsequentEventMember 2020-01-22 2020-01-22 0001739104 srt:MinimumMember elan:TangibleEquityUnitMember us-gaap:SubsequentEventMember 2020-01-22 0001739104 srt:MaximumMember elan:TangibleEquityUnitMember us-gaap:SubsequentEventMember 2020-01-22 0001739104 elan:TermCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2020-01-31 2020-01-31 0001739104 elan:TermLoanBCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2020-02-04 0001739104 elan:TermLoanBCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2020-02-04 2020-02-04 0001739104 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2020-02-04 0001739104 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2020-02-04 2020-02-04 0001739104 elan:TermLoanBCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-02-04 2020-02-04 0001739104 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-02-04 2020-02-04 0001739104 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-02-04 2020-02-04 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:OsurniaAndCapstarMember us-gaap:SubsequentEventMember 2020-01-01 2020-01-31 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:OsurniaAndCapstarMember 2019-12-31 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:VeocoxanMember us-gaap:SubsequentEventMember 2020-02-01 2020-02-28 iso4217:USD shares iso4217:USD shares elan:brand elan:country pure iso4217:CHF elan:segment elan:plan elan:renewal_term 10-K false 2019-12-31 2019 FY Elanco Animal Health Inc. 0001739104 Yes No Yes Large Accelerated Filer false false false 12400000000 398532256 --12-31 P5Y P3Y P5Y P1Y P0Y 1 P1Y 3071000000.0 3066800000 2889000000.0 1470300000 1573800000 1493900000 270100000 246600000 251700000 760200000 735200000 779800000 200400000 197400000 221200000 185500000 128800000 375100000 78900000 29600000 0 -27400000 -41300000 100000 2992800000 2952700000 3121600000 78200000 114100000 -232600000 10300000 27600000 78100000 67900000 86500000 -310700000 0.18 0.28 -1.06 0.18 0.28 -1.06 369000000.0 313700000 293300000 370300000 313700000 293300000 67900000 86500000 -310700000 19800000 -47100000 210100000 -28700000 -25400000 9800000 48500000 -21700000 200300000 116400000 64800000 -110400000 334000000.0 474800000 6200000 8400000 816900000 651800000 73000000.0 57600000 1050700000 1004100000 87400000 113900000 11100000 202700000 2373100000 2504900000 2989600000 2958000000.0 2482800000 2504800000 185000000.0 66600000 955300000 922400000 8985800000 8956700000 222600000 205200000 99600000 98900000 211000000.0 169900000 24500000 29000000.0 244400000 199000000.0 16400000 268700000 818500000 970700000 2330500000 2443300000 82500000 109100000 100800000 114600000 106600000 121500000 3438900000 3759200000 1000000000 1000000000 0 0 0 0 5000000000 5000000000 373011513 373011513 365643911 365643911 0 0 5636300000 5403300000 84300000 16400000 -173700000 -222200000 5546900000 5197500000 8985800000 8956700000 293300000 0 0 7474300000 0 -437300000 -19600000 -456900000 7017400000 -310700000 -310700000 210100000 -9800000 200300000 200300000 873300000 873300000 293300000 0 0 8036900000 0 -227200000 -29400000 -256600000 7780300000 70100000 16400000 86500000 -300000 -300000 -47100000 25400000 -21700000 -21700000 -226300000 -226300000 43500000 56100000 56100000 99600000 72300000 1659700000 1659700000 -4194900000 -4194900000 -7923900000 7923900000 0 1800000 1800000 12800000 12800000 365600000 0 5403300000 0 16400000 -218200000 -4000000.0 -222200000 5197500000 67900000 67900000 19800000 28700000 48500000 48500000 -51200000 -51200000 40700000 40700000 100000 7200000 238000000.0 238000000.0 100000 3600000 3600000 -1900000 -1900000 373000000.0 0 5636300000 0 84300000 -198400000 24700000 -173700000 5546900000 67900000 86500000 -310700000 314500000 296000000.0 318400000 100000 -60700000 -13400000 49400000 26000000.0 25000000.0 32600000 120500000 110600000 0 800000 19600000 -12700000 49000000.0 10000000.0 172400000 122000000.0 -48400000 33100000 20100000 39000000.0 -7000000.0 3200000 -52500000 -29200000 116100000 -8400000 224100000 487300000 173800000 140400000 134500000 98600000 300000 9400000 37600000 57000000.0 2000000.0 18500000 32800000 0 882100000 4900000 -100000 3000000.0 -234800000 -127000000.0 -964600000 0 2500000000.0 0 121100000 7500000 0 0 1659700000 0 0 24500000 0 191600000 3991300000 0 1600000 -17200000 -800000 6300000 -154400000 848300000 -304800000 -35200000 847500000 -16900000 29000000.0 7900000 -332400000 354100000 64600000 677500000 323400000 258800000 345100000 677500000 323400000 334000000.0 474800000 323400000 11100000 202700000 0 345100000 677500000 323400000 Nature of Business and Organization <div style="text-align:justify;margin-top:6pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Nature of Business </span></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Elanco was formed as a wholly-owned subsidiary of Lilly, and is a global animal health company that innovates, develops, manufactures and markets products for companion and food animals. We offer a diverse portfolio of more than 125 brands to veterinarians and food animal producers in more than 90 countries.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Organization</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"> </span></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Elanco Parent was formed in 2018, as a wholly-owned subsidiary of Lilly, to serve as the ultimate parent company of substantially all of the animal health businesses of Lilly.</span></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September 24, 2018, Elanco Parent completed an IPO resulting in the issuance of 72.3 million shares of its common stock (including shares issued pursuant to the underwriters’ option to purchase additional shares), which represented 19.8% of the outstanding shares, at $24 per share resulting in total net proceeds, after underwriting discounts and commissions, of $1.7 billion.  In connection with the completion of the IPO, through a series of equity and other transactions, Lilly transferred to Elanco Parent the animal health businesses that form its business. In exchange, Elanco Parent has paid to Lilly approximately $4.2 billion, which included the net proceeds from the IPO, the net proceeds from the debt offering completed by Elanco Parent in August 2018 and the term loan facility entered into by Elanco Parent in September 2018 (see Note 9: Debt). These transactions are collectively referred to herein as the Separation.</span></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 8, 2019, Lilly announced an exchange offer whereby Lilly shareholders could exchange all or a portion of Lilly common stock for shares of Elanco common stock owned by Lilly. The disposition of Elanco shares was completed on March 11, 2019 and resulted in the full separation of Elanco along with the disposal of Lilly's entire ownership and voting interest in Elanco.</span></div> 125 90 72300000 0.198 24 1700000000 4200000000 Basis of Presentation <div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have prepared the accompanying consolidated and combined financial statements in accordance with accounting principles generally accepted in the United States (GAAP). In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for fair presentation of the results of operations for the periods shown. The accounts of all wholly-owned and majority-owned subsidiaries are included in the consolidated financial statements, and all intercompany balances and transactions have been eliminated. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain reclassifications have been made to prior periods in the unaudited condensed consolidated and combined financial statements and accompanying notes to conform with current presentation.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. We issued our financial statements by filing with the Securities and Exchange Commission and have evaluated subsequent events up to the time of the filing. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the periods after Separation, the financial statements are prepared on a consolidated basis and reflect the results of operations, comprehensive income, financial position, equity and cash flows resulting from our operations as an independent company. For periods prior to Separation, our financial statements are combined, have been prepared on a standalone basis, and are derived from Lilly's consolidated financial statements and accounting records. The consolidated and combined financial statements reflect the financial position, results of operations and cash flows related to the animal health businesses that were transferred to Elanco Parent and are prepared in conformity with GAAP. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The combined financial statements include the attribution of certain assets and liabilities that historically have been held at the Lilly corporate level but which are specifically identifiable or attributable to the businesses that have been transferred to Elanco Parent. All intercompany transactions and accounts within Elanco have been eliminated. All transactions between us and Lilly are considered to be effectively settled in the combined financial statements at the time the intercompany transaction is recorded. The total net effect of the settlement of these intercompany transactions is reflected in the combined statements of cash flows as a financing activity and in the consolidated and combined statement of equity as net parent company investment.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to Separation, these combined financial statements include an allocation of expenses related to certain Lilly corporate functions, including executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information technology and investor relations, prior to IPO. These expenses were allocated to us based on direct usage or benefit where specifically identifiable, with the remainder allocated primarily on a pro rata basis of revenue, headcount and other measures. We consider the expenses methodology and results to be reasonable for all periods presented. However, the allocations may not be indicative of the actual expense that would have been incurred had we operated as an independent, publicly traded company for the periods presented. It is impractical to estimate what the standalone costs of Elanco would have been in the historical periods. After the Separation, a TSA between Lilly and Elanco went into effect. Under the terms of the TSA, we will be able to use these Lilly services for a fixed term established on a service-by-service basis. We are paying Lilly mutually agreed upon fees for the Lilly services provided under the TSA. Our consolidated and combined financial statements reflect the charges for Lilly services after the IPO. See Note 20: Related Party Agreements and Transactions for additional details.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The income tax amounts in the combined financial statements have been calculated based on a separate return methodology and presented as if our operations were separate taxpayers in the respective jurisdictions. We file income tax returns in the U.S. federal jurisdiction and various state, local and non-U.S. jurisdictions. Prior to full separation, certain of these income tax returns were filed on a consolidated or combined basis with Eli Lilly and Company and/or its subsidiaries.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to Separation, Lilly maintained various benefit and combined stock-based compensation plans at a corporate level and other benefit plans at a country level. Our employees participated in such programs and the portion of the cost of those plans related to our employees is included in our financial statements. However, the consolidated balance sheets do not include any equity issued related to stock-based compensation plans or any net benefit plan obligations unless the benefit plan covers only our dedicated employees or where the legal obligation associated with the benefit plan transferred to Elanco. Upon Lilly's full divestiture of Elanco in March 2019, all Lilly share-based awards held by our employees were converted into awards that will be settled in Elanco shares.</span></div><div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to Separation, the equity balance in the combined financial statements represents the excess of total assets over liabilities, including intercompany balances between Elanco and Lilly (net parent company investment) and accumulated other comprehensive income (loss). Net parent company investment is primarily impacted by contributions from Lilly which are the result of treasury activities and net funding provided by or distributed to Lilly. See Note 20: Related Party Agreements and Transactions for further information.</span></div> <div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have prepared the accompanying consolidated and combined financial statements in accordance with accounting principles generally accepted in the United States (GAAP). In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for fair presentation of the results of operations for the periods shown. The accounts of all wholly-owned and majority-owned subsidiaries are included in the consolidated financial statements, and all intercompany balances and transactions have been eliminated. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain reclassifications have been made to prior periods in the unaudited condensed consolidated and combined financial statements and accompanying notes to conform with current presentation.</span></div>In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. We issued our financial statements by filing with the Securities and Exchange Commission and have evaluated subsequent events up to the time of the filing. For the periods after Separation, the financial statements are prepared on a consolidated basis and reflect the results of operations, comprehensive income, financial position, equity and cash flows resulting from our operations as an independent company. For periods prior to Separation, our financial statements are combined, have been prepared on a standalone basis, and are derived from Lilly's consolidated financial statements and accounting records. The consolidated and combined financial statements reflect the financial position, results of operations and cash flows related to the animal health businesses that were transferred to Elanco Parent and are prepared in conformity with GAAP. The combined financial statements include the attribution of certain assets and liabilities that historically have been held at the Lilly corporate level but which are specifically identifiable or attributable to the businesses that have been transferred to Elanco Parent. All intercompany transactions and accounts within Elanco have been eliminated. All transactions between us and Lilly are considered to be effectively settled in the combined financial statements at the time the intercompany transaction is recorded. The total net effect of the settlement of these intercompany transactions is reflected in the combined statements of cash flows as a financing activity and in the consolidated and combined statement of equity as net parent company investment. Prior to Separation, these combined financial statements include an allocation of expenses related to certain Lilly corporate functions, including executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information technology and investor relations, prior to IPO. These expenses were allocated to us based on direct usage or benefit where specifically identifiable, with the remainder allocated primarily on a pro rata basis of revenue, headcount and other measures. We consider the expenses methodology and results to be reasonable for all periods presented. However, the allocations may not be indicative of the actual expense that would have been incurred had we operated as an independent, publicly traded company for the periods presented. It is impractical to estimate what the standalone costs of Elanco would have been in the historical periods. After the Separation, a TSA between Lilly and Elanco went into effect. Under the terms of the TSA, we will be able to use these Lilly services for a fixed term established on a service-by-service basis. We are paying Lilly mutually agreed upon fees for the Lilly services provided under the TSA. Our consolidated and combined financial statements reflect the charges for Lilly services after the IPO. See Note 20: Related Party Agreements and Transactions for additional details. The income tax amounts in the combined financial statements have been calculated based on a separate return methodology and presented as if our operations were separate taxpayers in the respective jurisdictions. We file income tax returns in the U.S. federal jurisdiction and various state, local and non-U.S. jurisdictions. Prior to full separation, certain of these income tax returns were filed on a consolidated or combined basis with Eli Lilly and Company and/or its subsidiaries. Prior to Separation, Lilly maintained various benefit and combined stock-based compensation plans at a corporate level and other benefit plans at a country level. Our employees participated in such programs and the portion of the cost of those plans related to our employees is included in our financial statements. However, the consolidated balance sheets do not include any equity issued related to stock-based compensation plans or any net benefit plan obligations unless the benefit plan covers only our dedicated employees or where the legal obligation associated with the benefit plan transferred to Elanco. Upon Lilly's full divestiture of Elanco in March 2019, all Lilly share-based awards held by our employees were converted into awards that will be settled in Elanco shares. Prior to Separation, the equity balance in the combined financial statements represents the excess of total assets over liabilities, including intercompany balances between Elanco and Lilly (net parent company investment) and accumulated other comprehensive income (loss). Net parent company investment is primarily impacted by contributions from Lilly which are the result of treasury activities and net funding provided by or distributed to Lilly. Impact of Separation<div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the Separation, we issued $2.0 billion aggregate principal amount of senior notes in a private placement, and we also entered into a $750.0 million senior unsecured revolving credit facility and $500.0 million senior unsecured term credit facility. See Note 9: Debt for further information. In connection with the Separation, we entered into various agreements with Lilly, including a master separation agreement, a tax matters agreement and the TSA.</span></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the terms of the Separation, there were certain assets and liabilities included in the pre-Separation balance sheet that were retained by Lilly and there were certain assets not included in the pre-Separation balance sheet that were transferred to us. The cumulative adjustment to the historical balance sheet increased net assets and total equity by approximately $99.6 million. The impact on net assets primarily represents the elimination of certain income tax assets and liabilities and the contribution of additional assets.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will also continue to have certain ongoing relationships with Lilly as described in Note 20: Related Party Agreements and Transactions.</span></div> 2000000000.0 750000000.0 500000000.0 99600000 Summary of Significant Accounting Policies<div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Revenue recognition </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Effective January 1, 2018, we adopted Accounting Standards Update 2014-09, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (ASU 2014-09) and other related updates. The new standard has been applied to contracts for which performance had not been completed as of the date of adoption. Revenue presented for periods prior to 2018 was accounted for under previous standards and has not been adjusted. Revenue and net income for the years ended December 31, 2019 and 2018 do not differ materially from amounts that would have resulted from application of the previous standards.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Product Sales </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize revenue primarily from product sales to customers. Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which generally is at the time we ship the product to the customer. Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from 30 to 120 days from date of shipment. Revenue for our product sales has not been adjusted for the effects of a financing component as we expect, at contract inception, that the period between when we transfer control of the product and when we receive payment will be one year or less. Any exceptions are either not material or we collect interest for payments made after the due date. For arrangements with contract manufacturing organizations (CMO), we recognize revenue over time or at a point in time depending on our evaluation of when the customer obtains control of the promised goods or service. Revenue is recognized over time when we are creating or enhancing an asset that the customer controls. In this instance revenue is recognized as the asset is created or enhanced or our performance does not create an asset with an alternative use and we have an enforceable right to payment for performance completed.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Provisions for rebates and discounts, as well as returns are established in the same period the related sales are recognized. We generally ship product shortly after orders are received; therefore, we generally only have a few days of orders received but not yet shipped at the end of any reporting period. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are imposed on our sales of product and collected from a customer.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Significant judgments must be made in determining the transaction price for sales of products related to anticipated rebates and discounts, and returns. The following describe the most significant of these judgments:</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Sales Rebates and Discounts - Background and Uncertainties</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Most of our products are sold to wholesale distributors. We initially invoice our customers contractual list prices. Contracts with direct and indirect customers may provide for various rebates and discounts that may differ in each contract. As a consequence, to determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we must estimate any rebates or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts. Judgments are required in making these estimates.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The rebate and discount amounts are recorded as a deduction to arrive at our net product sales. We estimate these accruals using an expected value approach.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">In determining the appropriate accrual amount, we consider our historical experience with similar incentives programs and current sales data and estimates of inventory levels at our channel distributors to evaluate the impact of such programs on revenue and continually monitor the impact of this experience and adjust as necessary. Although we accrue a liability for rebates related to these programs at the time the sale is recorded, the rebate related to that sale is typically paid up to six months after the rebate or incentive period expires. Because of this time lag, in any particular period rebate adjustments may incorporate revisions of accruals for several periods.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Sales Returns - Background and Uncertainties</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We estimate a reserve for future product returns related to product sales using an expected value approach. This estimate is based on several factors, including: local returns policies and practices; returns as a </span></div><div style="padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">percentage of revenue; an understanding of the reasons for past returns; estimated shelf life by product; and estimate of the amount of time between shipment and return. Adjustments to the returns reserve have been and may in the future be required based on revised estimates to our assumptions, which would have an impact on our consolidated results of operations. We record the return amounts as a deduction to arrive at our net product sales.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Research and development expenses and acquired in-process research and development</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses include the following:</span></div><div style="text-indent:13.5pt;padding-left:4.5pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Research and development costs, which are expensed as incurred.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Milestone payment obligations incurred prior to regulatory approval of the product, which are accrued when the event requiring payment of the milestone occurs.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Acquired in-process research and development (IPR&amp;D) expense, which includes the initial costs of IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Foreign Currency Translation</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operations in our subsidiaries outside the U.S. are recorded in the functional currency of each subsidiary which is determined by a review of the environment where each subsidiary primarily generates and expends cash. The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted average currency rate for the period. Assets and liabilities are translated using the period end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries are recorded in other comprehensive income (loss).</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Other significant accounting policies</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our other significant accounting policies are described in the remaining appropriate notes to the combined financial statements.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Implementation of New Financial Accounting Pronouncements </span></div><div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a brief description of an accounting standard that was effective January 1, 2019 and was adopted on that date:</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:24.900%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:33.964%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:33.968%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Standard</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect on the financial statements or other significant matters</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Accounting Standards Update 2016-02, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Leases</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">This standard was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under previous GAAP, on the balance sheet and requiring additional disclosures about leasing arrangements.</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">We adopted the standard on January 1, 2019 using the modified retrospective approach, applied at the beginning of the period of adoption, and we elected the package of transition practical expedients. Upon adoption of the standard, we recorded $84.9 million of right-of-use assets and $85.3 million of operating lease liabilities on our consolidated balance sheet. Adoption of this standard did not have a material impact on our consolidated statement of operations for the year ended December 31, 2019. See Note 13: Leases for further information.</span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a brief description of the accounting standards applicable to us that have not yet been adopted:</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:24.900%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:26.216%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:22.419%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Standard</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effective Date</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect on the financial statements or other significant matters</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Accounting Standards Update 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">This standard modifies the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses.</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">This standard is effective January 1, 2020, with early adoption permitted. We intend to adopt this standard on that date.</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">We do not expect that the adoption of this standard will have a material impact on our consolidated financial statements based on financial instruments currently held.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Accounting Standards Update 2018-15, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Intangibles - Goodwill and Other Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">This guidance aligns the requirements for capitalizing implementation costs incurred in a cloud-based hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software.</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">This standard is effective January 1, 2020, with early adoption permitted. We intend to adopt this standard on that date.</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adoption of this standard is not expected to have a significant impact on our consolidated financial statements.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Accounting Standards Update 2019-12,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;"> Simplifying the Accounting for Income Taxes</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The amendments in this update simplify the accounting for income taxes by removing certain exceptions and clarifying certain requirements regarding franchise taxes, goodwill, consolidated tax expenses, and annual effective tax rate calculations. </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">This standard is effective January 1, 2021, with early adoption permitted. We intend to adopt this standard on that date.</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">We are currently evaluating the impact of adoption of the new standard on our consolidated financial statements.</span></td></tr></table></div> <div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Revenue recognition </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Effective January 1, 2018, we adopted Accounting Standards Update 2014-09, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (ASU 2014-09) and other related updates. The new standard has been applied to contracts for which performance had not been completed as of the date of adoption. Revenue presented for periods prior to 2018 was accounted for under previous standards and has not been adjusted. Revenue and net income for the years ended December 31, 2019 and 2018 do not differ materially from amounts that would have resulted from application of the previous standards.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Product Sales </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize revenue primarily from product sales to customers. Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which generally is at the time we ship the product to the customer. Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from 30 to 120 days from date of shipment. Revenue for our product sales has not been adjusted for the effects of a financing component as we expect, at contract inception, that the period between when we transfer control of the product and when we receive payment will be one year or less. Any exceptions are either not material or we collect interest for payments made after the due date. For arrangements with contract manufacturing organizations (CMO), we recognize revenue over time or at a point in time depending on our evaluation of when the customer obtains control of the promised goods or service. Revenue is recognized over time when we are creating or enhancing an asset that the customer controls. In this instance revenue is recognized as the asset is created or enhanced or our performance does not create an asset with an alternative use and we have an enforceable right to payment for performance completed.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Provisions for rebates and discounts, as well as returns are established in the same period the related sales are recognized. We generally ship product shortly after orders are received; therefore, we generally only have a few days of orders received but not yet shipped at the end of any reporting period. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are imposed on our sales of product and collected from a customer.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Significant judgments must be made in determining the transaction price for sales of products related to anticipated rebates and discounts, and returns. The following describe the most significant of these judgments:</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Sales Rebates and Discounts - Background and Uncertainties</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Most of our products are sold to wholesale distributors. We initially invoice our customers contractual list prices. Contracts with direct and indirect customers may provide for various rebates and discounts that may differ in each contract. As a consequence, to determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we must estimate any rebates or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts. Judgments are required in making these estimates.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The rebate and discount amounts are recorded as a deduction to arrive at our net product sales. We estimate these accruals using an expected value approach.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">In determining the appropriate accrual amount, we consider our historical experience with similar incentives programs and current sales data and estimates of inventory levels at our channel distributors to evaluate the impact of such programs on revenue and continually monitor the impact of this experience and adjust as necessary. Although we accrue a liability for rebates related to these programs at the time the sale is recorded, the rebate related to that sale is typically paid up to six months after the rebate or incentive period expires. Because of this time lag, in any particular period rebate adjustments may incorporate revisions of accruals for several periods.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Sales Returns - Background and Uncertainties</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We estimate a reserve for future product returns related to product sales using an expected value approach. This estimate is based on several factors, including: local returns policies and practices; returns as a </span></div>percentage of revenue; an understanding of the reasons for past returns; estimated shelf life by product; and estimate of the amount of time between shipment and return. Adjustments to the returns reserve have been and may in the future be required based on revised estimates to our assumptions, which would have an impact on our consolidated results of operations. We record the return amounts as a deduction to arrive at our net product sales. Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from 30 to 120 days from date of shipment. P6M <div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses include the following:</span></div><div style="text-indent:13.5pt;padding-left:4.5pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Research and development costs, which are expensed as incurred.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Milestone payment obligations incurred prior to regulatory approval of the product, which are accrued when the event requiring payment of the milestone occurs.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Acquired in-process research and development (IPR&amp;D) expense, which includes the initial costs of IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use.</span></div> Operations in our subsidiaries outside the U.S. are recorded in the functional currency of each subsidiary which is determined by a review of the environment where each subsidiary primarily generates and expends cash. The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted average currency rate for the period. Assets and liabilities are translated using the period end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries are recorded in other comprehensive income (loss). <div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a brief description of an accounting standard that was effective January 1, 2019 and was adopted on that date:</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:24.900%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:33.964%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:33.968%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Standard</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect on the financial statements or other significant matters</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Accounting Standards Update 2016-02, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Leases</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">This standard was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under previous GAAP, on the balance sheet and requiring additional disclosures about leasing arrangements.</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">We adopted the standard on January 1, 2019 using the modified retrospective approach, applied at the beginning of the period of adoption, and we elected the package of transition practical expedients. Upon adoption of the standard, we recorded $84.9 million of right-of-use assets and $85.3 million of operating lease liabilities on our consolidated balance sheet. Adoption of this standard did not have a material impact on our consolidated statement of operations for the year ended December 31, 2019. See Note 13: Leases for further information.</span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a brief description of the accounting standards applicable to us that have not yet been adopted:</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:24.900%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:26.216%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:22.419%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Standard</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effective Date</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect on the financial statements or other significant matters</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Accounting Standards Update 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">This standard modifies the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses.</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">This standard is effective January 1, 2020, with early adoption permitted. We intend to adopt this standard on that date.</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">We do not expect that the adoption of this standard will have a material impact on our consolidated financial statements based on financial instruments currently held.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Accounting Standards Update 2018-15, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Intangibles - Goodwill and Other Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">This guidance aligns the requirements for capitalizing implementation costs incurred in a cloud-based hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software.</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">This standard is effective January 1, 2020, with early adoption permitted. We intend to adopt this standard on that date.</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adoption of this standard is not expected to have a significant impact on our consolidated financial statements.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Accounting Standards Update 2019-12,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;"> Simplifying the Accounting for Income Taxes</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The amendments in this update simplify the accounting for income taxes by removing certain exceptions and clarifying certain requirements regarding franchise taxes, goodwill, consolidated tax expenses, and annual effective tax rate calculations. </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">This standard is effective January 1, 2021, with early adoption permitted. We intend to adopt this standard on that date.</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">We are currently evaluating the impact of adoption of the new standard on our consolidated financial statements.</span></td></tr></table></div> <div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a brief description of an accounting standard that was effective January 1, 2019 and was adopted on that date:</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:24.900%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:33.964%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:33.968%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Standard</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect on the financial statements or other significant matters</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Accounting Standards Update 2016-02, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Leases</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">This standard was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under previous GAAP, on the balance sheet and requiring additional disclosures about leasing arrangements.</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">We adopted the standard on January 1, 2019 using the modified retrospective approach, applied at the beginning of the period of adoption, and we elected the package of transition practical expedients. Upon adoption of the standard, we recorded $84.9 million of right-of-use assets and $85.3 million of operating lease liabilities on our consolidated balance sheet. Adoption of this standard did not have a material impact on our consolidated statement of operations for the year ended December 31, 2019. See Note 13: Leases for further information.</span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a brief description of the accounting standards applicable to us that have not yet been adopted:</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:24.900%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:26.216%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:22.419%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Standard</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effective Date</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect on the financial statements or other significant matters</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Accounting Standards Update 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">This standard modifies the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses.</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">This standard is effective January 1, 2020, with early adoption permitted. We intend to adopt this standard on that date.</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">We do not expect that the adoption of this standard will have a material impact on our consolidated financial statements based on financial instruments currently held.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Accounting Standards Update 2018-15, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Intangibles - Goodwill and Other Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">This guidance aligns the requirements for capitalizing implementation costs incurred in a cloud-based hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software.</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">This standard is effective January 1, 2020, with early adoption permitted. We intend to adopt this standard on that date.</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adoption of this standard is not expected to have a significant impact on our consolidated financial statements.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Accounting Standards Update 2019-12,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;"> Simplifying the Accounting for Income Taxes</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The amendments in this update simplify the accounting for income taxes by removing certain exceptions and clarifying certain requirements regarding franchise taxes, goodwill, consolidated tax expenses, and annual effective tax rate calculations. </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">This standard is effective January 1, 2021, with early adoption permitted. We intend to adopt this standard on that date.</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">We are currently evaluating the impact of adoption of the new standard on our consolidated financial statements.</span></td></tr></table></div> 84900000 85300000 Revenue <div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our sales rebates and discounts are based on specific agreements and the majority relate to sales in the U.S. As of December 31, 2019 and 2018, the liability for sales rebates and discounts in the U.S. represents approximately 71% and 70%, respectively, of our total liability with the next largest country representing approximately 8% of our total liability for 2019 and 2018.</span></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the activity in the sales rebates and discounts liability in the U.S.:</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:69.637%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.599%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">118.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">114.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reduction of revenue</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">316.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">221.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(284.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(217.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">118.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Adjustments to revenue recognized as a result of changes in estimates for the judgments described above during the years ended December 31, 2019 and 2018 for product shipped in previous periods were not material.</span></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Actual product returns were 0.2% and 0.6% of net revenue for the years ended December 31, 2019 and 2018, respectively, and have not fluctuated significantly as a percentage of revenue.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Disaggregation of Revenue </span></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our revenue disaggregated by product category for the years ended December 31: </span></div><div style="text-align:justify;margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.228%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.676%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Companion Animal Disease Prevention</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">787.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">804.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">660.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Companion Animal Therapeutics</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">348.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">283.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">260.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Food Animal Future Protein &amp; Health</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">745.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">711.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">649.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Food Animal Ruminants Swine</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,110.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,174.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,175.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Strategic Exits</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">143.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Revenue</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,071.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,066.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,889.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">(1) Represents revenue from business activities we have either exited or made a strategic decision to exit.</span></div> 0.71 0.70 0.08 0.08 <div style="text-indent:9pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the activity in the sales rebates and discounts liability in the U.S.:</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:69.637%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.599%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">118.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">114.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reduction of revenue</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">316.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">221.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(284.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(217.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">118.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 118500000 114800000 316300000 221000000.0 284400000 217300000 150400000 118500000 0.002 0.006 <div style="text-indent:9pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our revenue disaggregated by product category for the years ended December 31: </span></div><div style="text-align:justify;margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.228%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.676%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Companion Animal Disease Prevention</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">787.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">804.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">660.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Companion Animal Therapeutics</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">348.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">283.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">260.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Food Animal Future Protein &amp; Health</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">745.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">711.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">649.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Food Animal Ruminants Swine</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,110.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,174.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,175.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Strategic Exits</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">143.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Revenue</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,071.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,066.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,889.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">(1) Represents revenue from business activities we have either exited or made a strategic decision to exit.</span></div> 787900000 804600000 660200000 348000000.0 283100000 260800000 745100000 711200000 649200000 1110300000 1174000000.0 1175000000.0 79700000 93900000 143800000 3071000000.0 3066800000 2889000000.0 Acquisitions<div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the year ended December 31, 2019, we completed the acquisitions of all outstanding shares of Aratana Therapeutics, Inc. (Aratana) and Prevtec Microbia Inc. (Prevtec). During 2017, we completed the acquisition of BIVIVP. These transactions were accounted for as business combinations under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated and combined financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our consolidated and combined financial statements from the dates of acquisition.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Aratana Therapeutics, Inc. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On July 18, 2019, we acquired Aratana, a pet therapeutics company focused on innovative therapies for dogs and cats, for stock and cash-based contingent value rights. Aratana is the creator of the canine osteoarthritis medicine,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Galliprant</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, the rights to which we acquired in 2016. The acquisition enhances our presence in the areas of appetite stimulants in dogs, pain relief in dogs and cats, and treatments of other conditions in the U.S. and internationally. In connection with the acquisition, we issued approximately 7.2 million shares with a value of $238.0 million to Aratana shareholders, based on our stock price on the last trading day immediately prior to the closing date. The purchase consideration also included up to $12 million in contingent value rights, which represent the rights of Aratana shareholders to receive a contingent payment of $0.25 per share in cash upon the achievement of a specified milestone as outlined in the merger agreement. We calculated an immaterial fair value for the contingent value rights using the Monte Carlo simulation model.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Contingent consideration liabilities that we previously recorded for future royalty and milestone payments in relation to the 2016 acquisition of rights to </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Galliprant</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> were settled upon the closing of our acquisition of Aratana. The liabilities were valued at $84.7 million as of the acquisition date using the Monte Carlo simulation model. The resulting $7.5 million loss upon settlement was recorded in Other - net, expense in the consolidated and combined statement of operations for the year ended December 31, 2019.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:84.403%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.597%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value at July 18, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventories</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired in-process research and development </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Marketed products </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Other intangible assets </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets and liabilities - net </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total identifiable net assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">142.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Goodwill </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Settlement of existing contingent consideration liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total consideration transferred</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">238.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:-9pt;padding-left:9pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">(1) These intangible assets, which are being amortized on a straight-line basis over their estimated useful lives, are expected to have a weighted average useful life of approximately 12.5 years.</span></div><div style="text-indent:-9pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">(2) The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of Aratana with our legacy business. The majority of goodwill associated with this acquisition is not deductible for tax purposes.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accounting for this acquisition is substantially complete, with the exception of the finalization of the valuation of intangible assets, tax-related amounts and minor working capital adjustments. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We issued 0.1 million shares and recorded $3.6 million of stock-based compensation expense for the vesting of Aratana equity awards that was accelerated upon the closing of the acquisition during the year ended December 31, 2019.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our consolidated statement of operations for the year ended December 31, 2019 included revenues of $10.0 million from Aratana. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Had Aratana been acquired on January 1, 2018, the unaudited pro forma combined revenues of Elanco and Aratana would have been $3.1 billion for both the years ending December 31, 2019 and December 31, 2018, and income before income taxes would have been $63.2 million and $117.7 million for the years ending December 31, 2019 and December 31, 2018, respectively. </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Prevtec Microbia Inc. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On July 31, 2019, we acquired Prevtec in a cash transaction for approximately $60.3 million, inclusive of certain post-closing adjustments. Prevtec is a Canadian biotechnology company specializing in the development of vaccines intended to help prevent bacterial diseases in food animals. The acquisition allows us to expand on our previous distribution arrangement for </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Coliprotec</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"> </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and is consistent with our efforts to explore innovative antibiotic alternatives.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The purchase consideration included up to $16.3 million in additional cash consideration, contingent upon the achievement of specific sales milestones by December 31, 2021. We have recorded a $4.7 million liability on the consolidated balance sheet as of the acquisition date based on the fair value of the contingent consideration as calculated using the Monte Carlo simulation model.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A previously existing $0.7 million receivable owed from Prevtec to Elanco Animal Health UK Limited was settled upon the closing of our acquisition of Prevtec. The resulting immaterial gain upon settlement was recorded in Other - net, expense in the consolidated and combined statement of operations for the year ended December 31, 2019.</span></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date: </span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:84.403%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.597%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value at July 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired in-process research and development </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Marketed products</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets and liabilities - net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total identifiable net assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Goodwill </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total consideration transferred</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:-9pt;padding-left:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">(1) These intangible assets, which are being amortized on a straight-line basis over their estimated useful lives, are expected to have a weighted average useful life of 10 years.</span></div><div style="text-indent:-9pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">(2) The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of Prevtec with our legacy business and future unidentified projects and products. The goodwill associated with this acquisition is not deductible for tax purposes.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accounting for this acquisition is substantially complete, with the exception of the finalization of the valuation of intangible assets, tax-related amounts and minor working capital adjustments. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Boehringer Ingelheim Vetmedica, Inc. Vaccine Portfolio Acquisition </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 3, 2017, we acquired BIVIVP in a cash transaction for $882.1 million. Under the terms of the agreement, we acquired a manufacturing and research and development site, a U.S. vaccine portfolio including vaccines used for the treatment of bordetella, Lyme disease, rabies and parvovirus, among others. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date: </span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:84.403%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.597%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value at January 3, 2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Inventories </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">108.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Marketed products </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">297.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">148.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets and liabilities — net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total identifiable net assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">562.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Goodwill </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(3)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">320.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total consideration transferred — net of cash acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">882.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:-9pt;padding-left:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">(1) The fair value for inventories include a purchase accounting adjustment to write up the inventory value, which resulted in incremental cost of sales of $42.7 million in 2017. The fair value was determined by estimating the expected sales price of the inventories, reduced for all costs expected to the incurred and a profit on those costs. </span></div><div style="text-indent:-9pt;padding-left:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">(2) These intangible assets, which are being amortized on a straight-line basis over their estimated useful lives, were expected to have a weighted average useful life of 10 years. </span></div><div style="text-indent:-9pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">(3) The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of BIVIVP with our legacy business, future unidentified projects and products, and the assembled workforce of BIVIVP. The goodwill associated with this acquisition is deductible for tax purposes. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our combined statement of operations for the year ended December 31, 2017 included BIVIVP revenues of $216.7 million. We are unable to provide the results of operations attributable to BIVIVP as those operations were substantially integrated into our legacy business. </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Pending Acquisition</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Bayer Animal Health Business</span></div><div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2019, we entered into the Purchase Agreement with Bayer, a German corporation, to acquire Bayer's animal health business. Bayer's animal health business is a provider of products intended to improve the health and well-being of pets and farm animals. This acquisition is expected to expand our Companion Animal product category, advance our planned intentional portfolio mix transformation and create a better balance between our Food Animal and Companion Animal product categories. Pursuant to the Purchase Agreement and subject to the satisfaction of certain customary closing conditions, including the receipt of antitrust approvals and the absence of any law or order enjoining or otherwise prohibiting the transaction in specified jurisdictions, we will purchase Bayer’s animal health business for approximately $5.3 billion in cash and approximately $2.3 billion of our common stock, subject to certain customary adjustments. Unless the parties agree otherwise, the transaction will close no earlier than July 1, 2020, per the terms of the Purchase Agreement. See Note 16: Commitments and Contingencies for discussion regarding certain commitments related to this transaction.</span></div> 7200000 238000000.0 12000000 0.25 84700000 7500000 <div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:84.403%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.597%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value at July 18, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventories</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired in-process research and development </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Marketed products </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Other intangible assets </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets and liabilities - net </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total identifiable net assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">142.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Goodwill </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Settlement of existing contingent consideration liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total consideration transferred</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">238.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:-9pt;padding-left:9pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">(1) These intangible assets, which are being amortized on a straight-line basis over their estimated useful lives, are expected to have a weighted average useful life of approximately 12.5 years.</span></div><div style="text-indent:-9pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">(2) The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of Aratana with our legacy business. The majority of goodwill associated with this acquisition is not deductible for tax purposes.</span></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date: </span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:84.403%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.597%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value at July 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired in-process research and development </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Marketed products</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets and liabilities - net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total identifiable net assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Goodwill </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total consideration transferred</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:-9pt;padding-left:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">(1) These intangible assets, which are being amortized on a straight-line basis over their estimated useful lives, are expected to have a weighted average useful life of 10 years.</span></div><div style="text-indent:-9pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">(2) The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of Prevtec with our legacy business and future unidentified projects and products. The goodwill associated with this acquisition is not deductible for tax purposes.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date: </span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:84.403%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.597%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value at January 3, 2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Inventories </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">108.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Marketed products </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">297.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">148.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets and liabilities — net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total identifiable net assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">562.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Goodwill </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(3)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">320.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total consideration transferred — net of cash acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">882.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:-9pt;padding-left:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">(1) The fair value for inventories include a purchase accounting adjustment to write up the inventory value, which resulted in incremental cost of sales of $42.7 million in 2017. The fair value was determined by estimating the expected sales price of the inventories, reduced for all costs expected to the incurred and a profit on those costs. </span></div><div style="text-indent:-9pt;padding-left:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">(2) These intangible assets, which are being amortized on a straight-line basis over their estimated useful lives, were expected to have a weighted average useful life of 10 years. </span></div>(3) The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of BIVIVP with our legacy business, future unidentified projects and products, and the assembled workforce of BIVIVP. The goodwill associated with this acquisition is deductible for tax purposes. 26400000 10300000 31900000 36700000 13200000 24000000.0 142500000 10800000 84700000 238000000.0 P12Y6M 100000 3600000 10000000.0 3100000000 3100000000 63200000 117700000 60300000 16300000 4700000 700000 900000 500000 2800000 58900000 1100000 -10300000 53900000 11100000 65000000.0 P10Y 882100000 108600000 297000000.0 148200000 8200000 562000000.0 320100000 882100000 42700000 P10Y 216700000 5300000000 2300000000 Asset Impairment, Restructuring and Other Special Charges<div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In recent years, we have incurred substantial costs associated with restructuring programs and cost-reduction initiatives designed to achieve a flexible and competitive cost structure. Restructuring activities primarily include charges associated with facility rationalization and workforce reductions. In connection with our recent acquisitions, we have also incurred costs associated with executing transactions and integrating acquired operations, which may include expenditures for banking, legal, accounting, and other similar services. In addition, we have incurred costs to stand up our organization as an independent company. All operating functions can be impacted by these actions; therefore, non-cash expenses associated with our tangible and intangible assets can be incurred as a result of revised fair value projections and/or determinations to no longer utilize certain assets in the business on an ongoing basis.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For finite-lived intangible asset and other long-lived assets, whenever impairment indicators are present, we calculate the undiscounted value of projected cash flows associated with the asset, or group of assets, and compare it to the carrying amount. If the carrying amount is greater, we record an impairment loss for the excess of book value over fair value. Determinations of fair value can result from a complex series of judgments and rely on estimates and assumptions. See Note 2: Basis of Presentation for discussion regarding estimates and assumptions.</span></div><div style="text-indent:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">Components of asset impairment, restructuring and other special charges for the years ended December 31 are as follows:</span></div><div style="margin-top:6pt;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:56.040%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.600%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Restructuring charges: </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Severance and other costs</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">162.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Facility exit costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquisition related charges:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Transaction and integration costs </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">144.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash and other items:</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Asset impairment </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(3)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">110.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Asset write-down </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Gain on sale of fixed assets </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(5)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(19.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">185.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">128.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">375.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%;padding-left:10.07pt;">For the year ended December 31, 2019, these charges primarily relate to a new program that will eliminate certain positions across multiple locations and functions, including exiting R&amp;D operations in Prince Edward Island, Canada, ceasing certain manufacturing operations in Wusi, China, and streamlining operations in Speke, England. We expect to substantially complete these restructuring activities by September 2020.</span></div><div style="padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%;">For the year ended December 31, 2018, these charges primarily relate to a program to streamline international operations, including  shifting focus and resources to priority areas. Among other actions, amounts reflect a change from having a physical location to a distribution model in certain countries in connection with the Separation. These activities were substantially complete as of December 31, 2019.</span></div><div style="padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%;">We historically participated in Lilly’s cost-reduction initiatives, which resulted in restructuring charges in the period prior to our IPO. These restructuring charges include severance and other costs associated with the reduction of our workforce, including special termination benefits recognized in 2017 associated with the U.S. voluntary early retirement program offered by Lilly, related to our employees and pension curtailment costs and facility exit costs. We also recorded certain impairment charges related to the activities as described below. </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;vertical-align:top;">(2)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%;padding-left:10.07pt;">Transaction costs represent external costs directly related to acquiring businesses and primarily include expenditures for banking, legal, accounting and other similar services. Integration costs represent external, incremental costs directly related to integrating acquired businesses (e.g., expenditures for consulting, system and process integration, and product transfers), as well as stand-up costs related to the implementation of new systems, programs, and processes due to the Separation from Lilly .</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;vertical-align:top;">(3)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%;padding-left:10.07pt;">Asset impairment charges are associated with the following:</span><span style="background-color:rgb(255,255,255, 0.0);color:#ee2724;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%;"> </span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%;padding-left:15.2pt;">For the year ended December 31, 2019, write-off certain IPR&amp;D and manufacturing assets in the US, Canada and Speke, resulting from the adjustment to fair value of property and equipment and intangible assets that were subject to product rationalization. </span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%;padding-left:15.2pt;">For the year ended December 31, 2018, the decision to dispose of a manufacturing facility in the U.S., the suspension of commercial activities for </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:107%;">Imrestor</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%;">, the write-off of certain idle assets in a U.S. manufacturing facility and product rationalization. </span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%;padding-left:15.2pt;">For the year ended December 31, 2017, intangible asset impairments related to revised projections of fair value due to product rationalization and to a lesser extent competitive pressures. </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;vertical-align:top;">(4)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%;padding-left:10.07pt;">Asset write-down expenses resulted from the adjustments recorded to write assets classified as held and used and held for sale down to their current fair values. These charges primarily related to fixed assets in Prince Edward Island, Canada; Wusi, China and Indianapolis, Indiana. $11.2 million of Property and equipment, net in Prince Edward Island, Canada and Indianapolis, Indiana are classified as held for sale.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;vertical-align:top;">(5)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%;padding-left:10.07pt;">Represents a gain on the disposal of a site that was previously closed as part of the acquisition and integration of Novartis Animal Health beginning on January 1, 2015.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the activity in our reserves established in connection with restructuring activities: </span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:56.040%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.600%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exit costs </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Severance</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2017</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13.5pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Charges</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13.5pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Separation adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13.5pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reserve adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13.5pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(25.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(23.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(48.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13.5pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Charges</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Reserve adjustment </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13.5pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(27.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(31.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(1) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Reserve adjustment represents the reversal of reserves for severance programs that are no longer active.</span></div><div style="text-indent:9pt;text-align:justify;"><span><br/></span></div><div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These reserves are included in other current liabilities in the consolidated balance sheets. Substantially all of the reserves are expected to be paid in the next twelve months. We believe that the reserves are adequate.</span></div> <div style="text-indent:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">Components of asset impairment, restructuring and other special charges for the years ended December 31 are as follows:</span></div><div style="margin-top:6pt;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:56.040%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.600%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Restructuring charges: </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Severance and other costs</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">162.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Facility exit costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquisition related charges:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Transaction and integration costs </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">144.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash and other items:</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Asset impairment </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(3)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">110.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Asset write-down </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Gain on sale of fixed assets </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(5)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(19.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">185.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">128.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">375.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%;padding-left:10.07pt;">For the year ended December 31, 2019, these charges primarily relate to a new program that will eliminate certain positions across multiple locations and functions, including exiting R&amp;D operations in Prince Edward Island, Canada, ceasing certain manufacturing operations in Wusi, China, and streamlining operations in Speke, England. We expect to substantially complete these restructuring activities by September 2020.</span></div><div style="padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%;">For the year ended December 31, 2018, these charges primarily relate to a program to streamline international operations, including  shifting focus and resources to priority areas. Among other actions, amounts reflect a change from having a physical location to a distribution model in certain countries in connection with the Separation. These activities were substantially complete as of December 31, 2019.</span></div><div style="padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%;">We historically participated in Lilly’s cost-reduction initiatives, which resulted in restructuring charges in the period prior to our IPO. These restructuring charges include severance and other costs associated with the reduction of our workforce, including special termination benefits recognized in 2017 associated with the U.S. voluntary early retirement program offered by Lilly, related to our employees and pension curtailment costs and facility exit costs. We also recorded certain impairment charges related to the activities as described below. </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;vertical-align:top;">(2)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%;padding-left:10.07pt;">Transaction costs represent external costs directly related to acquiring businesses and primarily include expenditures for banking, legal, accounting and other similar services. Integration costs represent external, incremental costs directly related to integrating acquired businesses (e.g., expenditures for consulting, system and process integration, and product transfers), as well as stand-up costs related to the implementation of new systems, programs, and processes due to the Separation from Lilly .</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;vertical-align:top;">(3)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%;padding-left:10.07pt;">Asset impairment charges are associated with the following:</span><span style="background-color:rgb(255,255,255, 0.0);color:#ee2724;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%;"> </span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%;padding-left:15.2pt;">For the year ended December 31, 2019, write-off certain IPR&amp;D and manufacturing assets in the US, Canada and Speke, resulting from the adjustment to fair value of property and equipment and intangible assets that were subject to product rationalization. </span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%;padding-left:15.2pt;">For the year ended December 31, 2018, the decision to dispose of a manufacturing facility in the U.S., the suspension of commercial activities for </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:107%;">Imrestor</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%;">, the write-off of certain idle assets in a U.S. manufacturing facility and product rationalization. </span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%;padding-left:15.2pt;">For the year ended December 31, 2017, intangible asset impairments related to revised projections of fair value due to product rationalization and to a lesser extent competitive pressures. </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;vertical-align:top;">(4)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%;padding-left:10.07pt;">Asset write-down expenses resulted from the adjustments recorded to write assets classified as held and used and held for sale down to their current fair values. These charges primarily related to fixed assets in Prince Edward Island, Canada; Wusi, China and Indianapolis, Indiana. $11.2 million of Property and equipment, net in Prince Edward Island, Canada and Indianapolis, Indiana are classified as held for sale.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;vertical-align:top;">(5)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%;padding-left:10.07pt;">Represents a gain on the disposal of a site that was previously closed as part of the acquisition and integration of Novartis Animal Health beginning on January 1, 2015.</span></div> 8200000 15500000 162000000.0 0 5700000 31800000 144700000 26500000 90300000 15400000 81900000 110600000 17200000 0 0 0 800000 19600000 185500000 128800000 375100000 11200000 <div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the activity in our reserves established in connection with restructuring activities: </span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:56.040%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.600%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exit costs </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Severance</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2017</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13.5pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Charges</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13.5pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Separation adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13.5pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reserve adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13.5pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(25.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(23.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(48.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13.5pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Charges</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Reserve adjustment </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13.5pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(27.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(31.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(1) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Reserve adjustment represents the reversal of reserves for severance programs that are no longer active.</span></div> 34900000 43100000 78000000.0 11700000 15500000 27200000 -5900000 0 -5900000 -6000000.0 0 -6000000.0 25400000 23500000 48900000 9300000 35100000 44400000 0 19300000 19300000 0 -11100000 -11100000 3900000 27800000 31700000 5400000 15500000 20900000 Inventories We state all inventories at the lower of cost or net realizable value. We use the last-in, first-out (LIFO) method for a portion of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost.<div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inventories at December 31 consisted of the following:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.222%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished products</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">402.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">400.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">603.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">570.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials and supplies</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">83.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total (approximates replacement cost)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,090.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,051.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Decrease to LIFO cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(39.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(47.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventories</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,050.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,004.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inventories valued under the LIFO method comprised $197.2 million and $194.8 million of total inventories at December 31, 2019 and 2018, respectively. </span></div><div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the year ended December 31, 2018, we recognized $38.6 million of inventory write-offs in cost of sales primarily related to the suspension of commercial activities for </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Imrestor</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</span></div> <div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inventories at December 31 consisted of the following:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.222%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished products</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">402.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">400.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">603.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">570.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials and supplies</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">83.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total (approximates replacement cost)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,090.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,051.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Decrease to LIFO cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(39.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(47.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventories</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,050.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,004.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 402900000 400700000 603200000 570400000 83900000 80400000 1090000000.0 1051500000 39300000 47400000 1050700000 1004100000 197200000 194800000 38600000 Debt <div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Long-term debt as of December 31 consisted of the following:</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.222%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Term credit facility</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">371.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">492.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">3.912% Senior Notes due 2021</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">500.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">500.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">4.272% Senior Notes due 2023</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">750.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">750.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">4.900% Senior Notes due 2028</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">750.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">750.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other obligations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unamortized debt issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,355.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,472.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less current portion of long-term debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(24.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(29.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total long-term debt</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,330.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,443.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-align:justify;margin-top:6pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Revolving and Term Credit Facilities</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September 5, 2018, we entered into a revolving credit agreement with a syndicate of banks providing for a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg0ZmI4ZDkyMzYxZDQyYWRiNTcyOGY3MjAxYzVmMGM1L3NlYzo4NGZiOGQ5MjM2MWQ0MmFkYjU3MjhmNzIwMWM1ZjBjNV8xMjEvZnJhZzozZDdhZDM2NmM5MTc0OTBiYWZhZTBjMGU3YzgxYjdiOS90ZXh0cmVnaW9uOjNkN2FkMzY2YzkxNzQ5MGJhZmFlMGMwZTdjODFiN2I5XzI5MQ_5c019814-21df-44fb-a5b8-9cfa2062a5fa">five</span>-year $750.0 million senior unsecured revolving credit facility (Revolving Facility). The Revolving Facility bears interest at a variable rate plus specified margin as defined in the agreement and is payable quarterly. There were no borrowings outstanding under the Revolving Facility at December 31, 2019 or 2018. The Revolving Facility is payable in full at the end of the term. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September 5, 2018, we also entered into a $500.0 million <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg0ZmI4ZDkyMzYxZDQyYWRiNTcyOGY3MjAxYzVmMGM1L3NlYzo4NGZiOGQ5MjM2MWQ0MmFkYjU3MjhmNzIwMWM1ZjBjNV8xMjEvZnJhZzozZDdhZDM2NmM5MTc0OTBiYWZhZTBjMGU3YzgxYjdiOS90ZXh0cmVnaW9uOjNkN2FkMzY2YzkxNzQ5MGJhZmFlMGMwZTdjODFiN2I5XzcwMg_8e88d283-a8e8-4c4c-9fcd-b5ff7d997d9c">three</span>-year term loan under a term credit facility with a syndicate of banks (the Term Facility and collectively with the Revolving Facility, the Credit Facilities.) The Term Facility bears interest at a variable rate plus margin as defined in Term Facility (3.01% and 3.77% at December 31, 2019 and 2018, respectively) and is payable quarterly. The Term Facility also requires a quarterly principal payment equal to 1.5% of the aggregate initial principal less any prepayment. The Term Facility is payable in full at the end of the term. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Credit Facilities are subject to various financial and other covenants, including restrictions on the level of borrowings based on a consolidated leverage ratio and a consolidated interest coverage ratio. We were in compliance with all such covenants as of December 31, 2019.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Senior Notes</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On August 28, 2018, we issued $2.0 billion of senior notes (Senior Notes) in a private placement. The Senior Notes comprised of $500.0 million of 3.912% Senior Notes due August 27, 2021, $750.0 million of 4.272% Senior Notes due August 28, 2023, and $750.0 million of 4.900% Senior Notes due August 28, 2028. The interest rate </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">payable on each series of Senior Notes is subject to adjustment if Moody's Investor Services, Inc. or Standard &amp; Poor's Financial Services LLC downgrades, or subsequently upgrades, its ratings on the respective series of Senior Notes.</span></div><div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The indenture that governs the Senior Notes contains covenants, including limitations on our ability, and certain of our subsidiaries, to incur liens or engage in sale-leaseback transactions. The indenture also contains restrictions on our ability to consolidate, merge or sell substantially all of our assets, in addition to other customary terms. We were in compliance with all such covenants under the indenture governing the Senior Notes as of December 31, 2019.</span></div><div style="text-indent:9pt;text-align:justify;"><span><br/></span></div><div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June 26, 2019, we completed an exchange offer pursuant to which the privately issued Senior Notes were exchanged for publicly registered Senior Notes having substantially identical terms.</span></div> <div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Long-term debt as of December 31 consisted of the following:</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.222%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Term credit facility</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">371.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">492.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">3.912% Senior Notes due 2021</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">500.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">500.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">4.272% Senior Notes due 2023</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">750.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">750.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">4.900% Senior Notes due 2028</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">750.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">750.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other obligations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unamortized debt issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,355.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,472.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less current portion of long-term debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(24.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(29.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total long-term debt</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,330.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,443.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div> 371400000 492500000 0.03912 500000000.0 500000000.0 0.04272 750000000.0 750000000.0 0.04900 750000000.0 750000000.0 400000 500000 16800000 20700000 2355000000.0 2472300000 24500000 29000000.0 2330500000 2443300000 750000000.0 0 0 500000000.0 0.0301 0.0377 0.015 2000000000.0 500000000.0 0.03912 750000000.0 0.04272 750000000.0 0.04900 Financial Instruments and Fair Value <div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that are potentially subject to credit risk consist principally of trade receivables. Collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A large portion of our cash is held by a few major financial institutions. We monitor the exposure with these institutions and do not expect any of these institutions to fail to meet their obligations. All highly liquid investments with a maturity of three months or less from the date of purchase are considered to be cash equivalents. The cost of these investments approximates fair value. We also consider the carrying value of restricted cash balances to be representative of its fair value.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2019 and 2018, we had $18.8 million and $15.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, respectively, primarily related to equity method investments included in other noncurrent assets in our consolidated balance sheet. </span></div><div style="text-indent:9pt;text-align:justify;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the fair value information at December 31, 2019 and 2018 for contingent consideration liabilities, and net investment hedge assets/(liabilities) measured at fair value on a recurring basis in the respective balance sheet line items, as well as long-term debt for which fair value is disclosed on a recurring basis: </span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:30.456%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.679%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements Using</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financial statement line item</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted Prices in Active Markets for Identical Assets (Level 1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Other Observable Inputs <br/>(Level 2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Unobservable Inputs <br/>(Level 3)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other noncurrent liabilities- contingent consideration</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other noncurrent assets/(liabilities) - cross currency interest rate contracts designated as net investment hedges</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term debt - senior notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,000.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,120.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,120.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term debt - term credit facility</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(371.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(371.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(371.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities- contingent consideration</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other noncurrent liabilities- contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(69.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(69.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(69.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other noncurrent assets/(liabilities) - cross currency interest rate contracts designated as net investment hedges</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term debt - senior notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,000.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,005.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,005.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term debt - term credit facility</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(492.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(492.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(492.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We determine our Level 2 fair value measurements based on a market approach using quoted market values or significant other observable inputs for identical or comparable assets or liabilities. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Contingent consideration liabilities as of December 31, 2019 related to contingent consideration associated with the acquisitions of Aratana and Prevtec during the period. For Aratana, we will pay up to $12 million in contingent value rights that are dependent on the achievement of a specified milestone as outlined in the merger agreement. For Prevtec, based on the terms of the purchase agreement, we will pay up to $16.3 million contingent upon the achievement of specific </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Coliprotec </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">sales milestones by December 31, 2021. The fair value of both contingent consideration liabilities was estimated using the Monte Carlo simulation model and Level 3 inputs including historical revenue, discount rate, asset volatility, and revenue volatility. See Note 6: Acquisitions for further discussion. </span></div><div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Contingent consideration liabilities as of December 31, 2018 related to </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Galliprant </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">for which the fair value was estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant view for the probability of achieving potential future payments to Aratana and an estimated discount rate. The amount to be paid as of December 31, 2018 was dependent upon certain development, success-based regulatory, and sales-based milestones. These liabilities were settled upon the closing of our acquisition of Aratana on July 18, 2019. See Note 6: Acquisitions for further discussion.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2018, we entered into a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg0ZmI4ZDkyMzYxZDQyYWRiNTcyOGY3MjAxYzVmMGM1L3NlYzo4NGZiOGQ5MjM2MWQ0MmFkYjU3MjhmNzIwMWM1ZjBjNV8xMjcvZnJhZzoyMjE2MDA0MjMyMDU0NDk3OTEzMTM5OTJiMWRjMTFiNS90ZXh0cmVnaW9uOjIyMTYwMDQyMzIwNTQ0OTc5MTMxMzk5MmIxZGMxMWI1XzEwOTk1MTE2MzQ4Mjc_6e4cc0ec-a413-492d-a46c-56204432e91f">five</span>-year cross-currency fixed interest rate swap with a 750 million Swiss Franc (CHF) notional amount, which is designated as a NIH against CHF denominated assets for which the fair value was estimated based on quoted market values of similar hedges and is classified as Level 2. The NIH is expected to generate approximately $25 million in cash and an offset to interest expense on an annual basis. For the years ended December 31, 2019 and 2018, our interest expense was offset by $25.1 million and $5.6 million, respectively, as a result of the NIH. Over the life of the derivative, gains or losses due to spot rate fluctuations are recorded in cumulative translation adjustment in other comprehensive income. During the years ended December 31, 2019 and 2018, we recorded a gain of $7.7 million and a loss of $5.9 million, respectively, net of tax, on the NIH, which is included in the change in the cumulative translation adjustment. There is a potential for significant 2023 settlement exposure as the U.S. dollar fluctuates against the Swiss Franc. The risk management objective is to manage foreign currency risk relating to net investments in certain CHF denominated assets. Changes in fair value of the derivative instruments are recognized in a component of accumulated other comprehensive loss to offset the changes in the values of the net investments being hedged.</span></div> 18800000 15300000 <div style="text-indent:9pt;text-align:justify;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the fair value information at December 31, 2019 and 2018 for contingent consideration liabilities, and net investment hedge assets/(liabilities) measured at fair value on a recurring basis in the respective balance sheet line items, as well as long-term debt for which fair value is disclosed on a recurring basis: </span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:30.456%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.679%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements Using</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financial statement line item</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted Prices in Active Markets for Identical Assets (Level 1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Other Observable Inputs <br/>(Level 2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Unobservable Inputs <br/>(Level 3)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other noncurrent liabilities- contingent consideration</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other noncurrent assets/(liabilities) - cross currency interest rate contracts designated as net investment hedges</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term debt - senior notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,000.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,120.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,120.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term debt - term credit facility</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(371.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(371.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(371.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities- contingent consideration</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other noncurrent liabilities- contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(69.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(69.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(69.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other noncurrent assets/(liabilities) - cross currency interest rate contracts designated as net investment hedges</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term debt - senior notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,000.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,005.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,005.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term debt - term credit facility</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(492.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(492.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(492.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 4700000 0 0 4700000 4700000 2300000 0 2300000 0 2300000 2000000000.0 0 2120600000 0 2120600000 371400000 0 371400000 0 371400000 5100000 0 0 5100000 5100000 69000000.0 0 0 69000000.0 69000000.0 -7400000 0 -7400000 0 -7400000 2000000000.0 0 2005000000.0 0 2005000000.0 492500000 0 492500000 0 492500000 12000000 16300000 750000000 25000000 25100000 5600000 7700000 5900000 Goodwill and Intangibles<div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Goodwill </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill was $3.0 billion as of December 31, 2019 and 2018. Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually and when impairment indicators are present. Goodwill may be impaired if the carrying amount of a reporting unit exceeds the fair value of that reporting unit, calculated as based on discounted cash flows. An impairment charge would be recorded for the excess, if any, of the reporting unit's carrying amount over its fair value, but not to exceed the total amount of goodwill allocated to the reporting unit. The estimated fair value is based on a number of assumptions, including current market capitalization as corroboration of fair value. See Note 6: Acquisitions for further discussion of goodwill resulting from recent business combinations. The remaining change in goodwill is primarily the result of foreign exchange translation adjustments. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">No impairments occurred with respect to the carrying value of goodwill for the years ended December 31, 2019, 2018 and 2017. </span><span style="background-color:rgb(255,255,255, 0.0);color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Other Intangibles </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of intangible assets other than goodwill at December 31 were as follows: </span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:26.947%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.426%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.426%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.681%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Carrying Amount, Gross</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Accumulated Amortization</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Carrying Amount, Net</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Carrying Amount, Gross</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Accumulated Amortization</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Carrying Amount, Net</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketed products</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,302.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(980.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,322.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,193.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(779.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,414.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Software</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">159.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(72.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(49.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(34.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(34.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,520.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,086.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,433.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,347.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(862.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,485.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired in-process research and development</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other intangibles</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,569.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,086.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,482.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,367.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(862.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,504.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Marketed products consist of the amortized cost of the rights to assets acquired in business combinations and approved for marketing in a significant global jurisdiction. For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Software consists of certain costs incurred in connection with obtaining or developing internal-use software, including payroll and payroll-related costs for employees directly associated with the internal-use software projects and direct costs of external resources. These costs include software classified as "in process" until the project is substantially complete and the software is ready for its intended purpose, at which point the costs are amortized on a straight-line basis over the estimated useful life. Depreciation expense includes $20.4 million in 2019, $18.4 million in 2018, and $17.4 million in 2017 for amortization of software. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other finite-lived intangibles consist primarily of the amortized cost of licensed platform technologies that have alternative future uses in research and development, manufacturing technologies and customer relationships from business combinations. Acquired IPR&amp;D consists of the related costs capitalized, adjusted for subsequent impairments, if any. The costs of acquired IPR&amp;D projects acquired directly in a transaction other than a business combination are capitalized if the projects have an alternative future use; otherwise, they are expensed immediately. The fair values of acquired IPR&amp;D projects acquired in business combinations are capitalized as other intangible assets. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the "income method" for other intangibles. This method is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each group of assets independently. The acquired IPR&amp;D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See Note 6: Acquisitions for further discussion of intangible assets acquired in recent business combinations. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other indefinite-lived intangible assets are reviewed for impairment at least annually and when impairment indicators are present. The fair value of the indefinite lived intangible assets (acquired IPR&amp;D) is estimated using the same assumptions as used for goodwill and by applying a probability weighting that reflects the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">present. We compare the carrying amounts of the assets with the estimated undiscounted future cash flows. In the event the carrying amount exceeds the undiscounted cash flows, an impairment charge is recorded for the amount by which the carrying amount of the asset exceeds the estimated fair value, which is determined based on discounted future cash flows. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During 2019, we recorded impairment charges of $11.4 million primarily related to indefinite-lived intangible assets which are included in asset impairment, restructuring and other special charges on the consolidated and combined statements of operations. The impairment of indefinite-lived intangible assets primarily related to product rationalization. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During 2018, we recorded impairment charges of $22.5 million (comprised of $9.5 million impairment of finite-lived intangible assets and $13.0 million impairment of indefinite-lived intangible assets) which are included in asset impairment, restructuring and other special charges on the consolidated and combined statements of operations. The impairment of finite-lived intangible assets primarily related to competitive pressures for a certain marketed product resulting in a reduction of projected cash flows. The impairment of indefinite-lived intangible assets primarily related to revised projections of fair value due to competitive pressures and to a lesser extent product rationalization. The increase in the carrying amount of finite intangibles is primarily due to the receipt of full commercialization rights outside the U.S. for </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Galliprant</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During 2017, we had impairment charges of $94.5 million (comprised of $56.5 million impairment of finite-lived intangible assets and $38.0 million impairment of indefinite-lived intangible assets) which are included in asset impairment, restructuring and other special charges on the consolidated and combined statements of operations. The impairment of finite-lived intangible assets primarily related to competitive pressures for a certain marketed product resulting in a reduction of projected cash flows. The impairment of indefinite-lived intangible assets primarily related to revised projections of fair value due to competitive pressures and to a lesser extent product rationalization.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Intangible assets with finite lives are capitalized and are amortized over their estimated useful lives, ranging from 3 to 20 years. As of December 31, 2019, the remaining weighted-average amortization periods for finite-lived intangible assets are as follows:</span></div><div style="margin-top:6pt;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.818%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Life (Years)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketed products</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Software</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8</span></td></tr></table></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The estimated amortization expense for each of the next five years associated with our finite-lived intangible assets as of December 31, 2019 is as follows:</span></div><div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.216%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.771%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.771%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.771%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.771%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.780%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated amortization expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">206.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">205.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">203.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">203.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">203.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 3000000000.0 3000000000.0 0 0 0 <div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of intangible assets other than goodwill at December 31 were as follows: </span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:26.947%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.426%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.426%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.681%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Carrying Amount, Gross</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Accumulated Amortization</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Carrying Amount, Net</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Carrying Amount, Gross</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Accumulated Amortization</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Carrying Amount, Net</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketed products</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,302.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(980.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,322.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,193.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(779.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,414.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Software</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">159.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(72.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(49.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(34.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(34.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,520.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,086.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,433.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,347.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(862.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,485.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired in-process research and development</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other intangibles</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,569.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,086.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,482.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,367.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(862.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,504.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> <div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of intangible assets other than goodwill at December 31 were as follows: </span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:26.947%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.426%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.426%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.681%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Carrying Amount, Gross</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Accumulated Amortization</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Carrying Amount, Net</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Carrying Amount, Gross</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Accumulated Amortization</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Carrying Amount, Net</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketed products</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,302.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(980.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,322.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,193.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(779.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,414.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Software</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">159.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(72.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(49.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(34.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(34.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,520.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,086.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,433.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,347.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(862.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,485.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired in-process research and development</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other intangibles</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,569.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,086.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,482.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,367.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(862.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,504.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 3302700000 980600000 2322100000 3193500000 779200000 2414300000 159200000 72200000 87000000.0 101300000 49500000 51800000 58300000 34000000.0 24300000 53100000 34000000.0 19100000 3520200000 1086800000 2433400000 3347900000 862700000 2485200000 49400000 49400000 19600000 19600000 3569600000 1086800000 2482800000 3367500000 862700000 2504800000 20400000 18400000 17400000 11400000 11400000 22500000 9500000 13000000.0 94500000 56500000 38000000.0 P3Y P20Y As of December 31, 2019, the remaining weighted-average amortization periods for finite-lived intangible assets are as follows:<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.818%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Life (Years)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketed products</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Software</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8</span></td></tr></table> P13Y P6Y P8Y <div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The estimated amortization expense for each of the next five years associated with our finite-lived intangible assets as of December 31, 2019 is as follows:</span></div><div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.216%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.771%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.771%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.771%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.771%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.780%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated amortization expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">206.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">205.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">203.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">203.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">203.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 206200000 205400000 203300000 203000000.0 203000000.0 Property and Equipment Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (12 to 50 years for buildings and 3 to 25 years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset's net book value over its fair value utilizing a discounted cash flow analysis, and the cost basis is adjusted. <div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At December 31, property and equipment consisted of the following: </span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:69.637%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.599%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Land</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Buildings</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">608.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">567.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equipment</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,109.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,025.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">139.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">181.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance lease asset</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,885.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,801.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(930.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(878.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">955.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">922.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Depreciation expense related to property and equipment was as follows: </span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.228%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.676%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div> P12Y P50Y P3Y P25Y <div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At December 31, property and equipment consisted of the following: </span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:69.637%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.599%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Land</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Buildings</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">608.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">567.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equipment</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,109.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,025.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">139.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">181.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance lease asset</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,885.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,801.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(930.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(878.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">955.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">922.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 28300000 27600000 608500000 567200000 1109400000 1025100000 139100000 181100000 500000 1885800000 1801000000.0 930500000 878600000 955300000 922400000 <div style="text-indent:9pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Depreciation expense related to property and equipment was as follows: </span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.228%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.676%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div> 93700000 81300000 79800000 Leases<div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We determine if an arrangement is a lease at inception. We have operating leases for corporate offices, research and development facilities, vehicles, and equipment. Our leases have remaining lease terms of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg0ZmI4ZDkyMzYxZDQyYWRiNTcyOGY3MjAxYzVmMGM1L3NlYzo4NGZiOGQ5MjM2MWQ0MmFkYjU3MjhmNzIwMWM1ZjBjNV8yMDE2L2ZyYWc6NmM5MmNkYWI5ZGVhNDY4MTgyOGM3MTAyNjYxMmRjN2IvdGV4dHJlZ2lvbjo2YzkyY2RhYjlkZWE0NjgxODI4YzcxMDI2NjEyZGM3Yl8zMjk4NTM0ODg2NTEy_e25695ca-93f3-4e7c-aef3-d2dd572a6e33">one</span> to 12 years, some of which have options to extend or terminate the leases. Finance leases are included in property and equipment, current portion of long-term debt, and long-term debt in our consolidated balance sheet. Finance leases are not material to our consolidated statements of operations, consolidated balance sheet, or consolidated statement of cash flows. Beginning January 1, 2019, operating leases are included in noncurrent assets, other current liabilities, and other noncurrent liabilities in our consolidated balance sheet. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Right-of-use assets included in noncurrent assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Right-of-use assets and operating lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate if it is readily determinable. The right-of-use asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain and there is a significant economic incentive to exercise that option. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating lease expense for right-of-use assets is recognized on a straight-line basis over the lease term. Variable lease payments, which represent lease payments that vary due to changes in facts or circumstances occurring after the commencement date other than the passage of time, are expensed in the period in which the obligation for these payments was incurred. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We elected not to apply the recognition requirements of ASC 842, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, to short-term leases, which are deemed to be leases with a lease term of 12 months or less. Instead, we recognize lease payments in the consolidated statements of operations on a straight-line basis over the lease term and variable payments in the period in which the obligation for these payments are incurred. We elected this policy for all classes of underlying assets. We elected not to apply the practical expedient related to the separation of lease and non-lease components or the practical expedient which allows entities to use hindsight when determining lease term.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The impact of operating leases to our consolidated financial statements for the year ended December 31, 2019 was as follows: </span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease cost</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term lease cost</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Variable lease cost</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total lease cost </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:8pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other information</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating cash outflows from operating leases</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average remaining lease term - operating leases</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.1 years</span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average discount rate - operating leases</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-align:justify;margin-bottom:12pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(1) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Rental expense for all leases was $47.5 million and $47.1 million for the years ended December 31, 2018 and 2017, respectively.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Supplemental balance sheet information related to our operating leases is as follows:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:43.614%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:38.204%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Classification</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">85.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current operating lease liabilities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current operating lease liabilities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2019, the annual minimum lease payments of our operating lease liabilities were as follows:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:84.403%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.597%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year 1</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year 2</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year 3</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year 4</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year 5</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">After Year 5</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less imputed interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">85.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> P12Y <div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The impact of operating leases to our consolidated financial statements for the year ended December 31, 2019 was as follows: </span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease cost</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term lease cost</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Variable lease cost</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total lease cost </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:8pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other information</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating cash outflows from operating leases</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average remaining lease term - operating leases</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.1 years</span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average discount rate - operating leases</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-align:justify;margin-bottom:12pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(1) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Rental expense for all leases was $47.5 million and $47.1 million for the years ended December 31, 2018 and 2017, respectively.</span></div> 26100000 500000 2500000 29100000 24000000.0 20100000 P5Y1M6D 0.036 47500000 47100000 <div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Supplemental balance sheet information related to our operating leases is as follows:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:43.614%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:38.204%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Classification</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">85.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current operating lease liabilities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current operating lease liabilities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div> 85000000.0 23700000 61700000 <div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2019, the annual minimum lease payments of our operating lease liabilities were as follows:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:84.403%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.597%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year 1</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year 2</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year 3</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year 4</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year 5</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">After Year 5</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less imputed interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">85.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 26000000.0 20300000 11900000 9700000 7200000 16500000 91600000 6200000 85400000 Stock-Based Compensation<div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Elanco Stock Compensation Plans</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The 2018 Elanco Stock Plan (Plan) provides long-term incentives to attract, motivate and retain employees and non-employee directors. The types of stock-based awards available include, but are not limited to, restricted stock units (RSUs), performance-based awards (PAs), and stock options. Our practices and policies specify that stock-based compensation awards are approved by the Compensation Committee of the Board of Directors. The Plan, initially authorized the issuance of up to 5.5 million common shares (subject to adjustments for certain events). Pursuant to the terms of the Plan, an additional 5.5 million common shares became automatically available for all awards upon completion of the Separation. The total number of shares authorized for stock-based compensation awards is 11 million as of December 31, 2019. </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Stock-Based Compensation Expense</span></div><div><span><br/></span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Components of stock-based compensation expense and related tax benefit for the years ended December 31 are as follows:</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.222%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Stock-based compensation expense </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Related tax benefit </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:-9pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(1) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">We include the impact of estimated forfeitures when determining stock-based compensation expense.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Restricted Stock Units</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">RSUs are granted to certain employees and are settled in shares of our common stock. RSU shares are accounted for at fair value based upon the closing stock price on the date of the grant. The corresponding expense is amortized over the vesting period, typically three years. The number of shares ultimately issued for the RSU program remains constant with the exception of forfeitures.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">RSUs granted to employees for the years ended December 31 are as follows:</span></div><div style="margin-top:6pt;margin-bottom:15pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:69.802%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.381%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.517%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.381%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.519%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Units in millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted units</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average fair value</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.22 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.09 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Changes in nonvested portion of RSUs for 2019 is summarized below:</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:69.637%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.599%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Shares in millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nonvested units at January 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.09 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.9</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.22 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.33 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.25 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nonvested units at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30.42 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2019, the total remaining unrecognized stock-based compensation expense related to nonvested RSUs was $25.5 million, which will amortize over the weighted-average remaining requisite service period of 19 months.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Performance-Based Awards</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">PAs, which are granted to eligible officers and management, represent the right to receive a share of our common stock and are subject to forfeiture until restrictions lapse (including continued employment through the end of the vesting period and achievement of certain pre-established metrics). Payouts can vary depending on achievement. PA shares are accounted for at fair value based upon the closing stock price on the date of grant and fully vest at the end of the measurement period.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">PA activity during the year ended December 31, 2019 is summarized below:</span></div><div style="margin-top:6pt;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:69.637%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.599%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Shares in millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nonvested awards at January 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25.75 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nonvested awards at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25.75 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2019, the total remaining unrecognized stock-based compensation expense related to nonvested PAs was $11.0 million, which will amortize over the weighted-average remaining requisite service period of 13 months.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Stock Option Program</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock options represent the right to purchase shares of our common stock within a specified period of time at a specified price. The exercise price for a stock option will be not less than 100% of the fair market value of the common stock on the date of the grant. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock options are accounted for using a fair-value based method at the date of the grant in the consolidated statement of operations. The values determined through this fair-value-based method generally are amortized on a straight-line basis over the vesting term. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock options were granted in 2018 to our officers, management and board members at exercise prices equal to the fair market value of our stock at the date of the grant. Options fully vest 3 years from the grant date and have a term of 10 years. No stock options were granted in 2019.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair-value-based method for valuing each Elanco stock option grant on the grant date uses the Black-Scholes-Merton option-pricing model, which incorporates a number of valuation assumptions noted in the following table, shown at their weighted-average values for the year ended December 31:</span></div><div style="text-align:center;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:42.397%;"><tr><td style="width:1.0%;"/><td style="width:64.551%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.179%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:30.070%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Expected dividend yield</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.70 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Risk-free interest rate</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.07 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Expected stock price volatility</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(3)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28.25 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Expected term</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> (years)</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.5</span></td></tr></table></div><div style="text-indent:-9pt;padding-left:9pt;text-align:justify;margin-bottom:6pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(1) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Determined using the expected quarterly dividend divided by the available three-month average stock price as of the valuation date, annualized and continuously compounded.</span></div><div style="text-align:justify;margin-bottom:6pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(2)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"> Determined using the term-matched, zero-coupon risk-free rate from the Treasury Constant Maturity yield curve, continuously compounded</span></div><div style="text-align:justify;margin-bottom:6pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(3)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Determined using a leverage-adjusted historical volatility of peer companies</span></div><div style="text-align:justify;margin-bottom:12pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(4)</sup><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;"> </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Determined using SEC safe harbor approach, based on a 3-year cliff vesting schedule and 10-year contractual term.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock option activity during the year ended December 31, 2019 is summarized below:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:37.181%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.626%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Shares in millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares of Common Stock Attributable to Options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Exercise Price of Options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Aggregate Intrinsic Value</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at January 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.61 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.61 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited or expired</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.61 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.8</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable at December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt;">Market price of underlying Elanco common stock less exercise price. Options do not have an intrinsic value unless the market price exceeds the exercise price. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2019, there was approximately $2.2 million of unrecognized compensation costs related to nonvested stock options, which will be recognized over an expected remaining weighted-average period of 22 months. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes data related to stock option activity:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:69.637%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.599%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average grant date fair value per stock option</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.21 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.21 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate intrinsic value on exercise</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.10 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash received upon exercise</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Treatment of Lilly Equity Awards</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to the Separation, our employees participated in Lilly stock-based compensation plans, the cost of which was allocated to us and recorded in costs of sales, research and development, and marketing, selling and administrative expense in the consolidated and combined statements of operations. The cost of such plans related to our employees was $5.1 million, $26.0 million and $25.0 million for the years ended December 31, 2019, 2018 and 2017, respectively.</span></div><div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following the IPO and until completion of the exchange offer, the equity awards previously granted to our employees by Lilly continued to vest with Elanco service counting toward the Lilly award's vesting provisions. On March 11, 2019, Elanco completed the exchange offer whereby Lilly disposed of all of its shares of Elanco common stock owned by Lilly. As a result, our employees' unvested Lilly equity awards were forfeited and replaced with Elanco RSUs (replacement awards), which were equivalent in value and vest on the same date as their forfeited Lilly equity awards. These replacement awards are included in the RSU activity described above.</span></div> 5500000 5500000 11000000 <div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Components of stock-based compensation expense and related tax benefit for the years ended December 31 are as follows:</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.222%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Stock-based compensation expense </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Related tax benefit </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:-9pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(1) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">We include the impact of estimated forfeitures when determining stock-based compensation expense.</span></div> 40700000 1800000 9800000 400000 P3Y <div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">RSUs granted to employees for the years ended December 31 are as follows:</span></div><div style="margin-top:6pt;margin-bottom:15pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:69.802%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.381%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.517%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.381%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.519%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Units in millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted units</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average fair value</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.22 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.09 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Changes in nonvested portion of RSUs for 2019 is summarized below:</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:69.637%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.599%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Shares in millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nonvested units at January 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.09 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.9</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.22 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.33 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.25 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nonvested units at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30.42 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 2900000 200000 31.22 31.09 200000 31.09 2900000 31.22 800000 31.33 100000 31.25 2200000 30.42 25500000 P19M <div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">PA activity during the year ended December 31, 2019 is summarized below:</span></div><div style="margin-top:6pt;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:69.637%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.599%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Shares in millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nonvested awards at January 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25.75 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nonvested awards at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25.75 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 0 0 800000 25.75 0 0 0 0 800000 25.75 11000000.0 P13M P3Y P10Y <div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair-value-based method for valuing each Elanco stock option grant on the grant date uses the Black-Scholes-Merton option-pricing model, which incorporates a number of valuation assumptions noted in the following table, shown at their weighted-average values for the year ended December 31:</span></div><div style="text-align:center;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:42.397%;"><tr><td style="width:1.0%;"/><td style="width:64.551%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.179%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:30.070%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Expected dividend yield</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.70 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Risk-free interest rate</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.07 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Expected stock price volatility</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(3)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28.25 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Expected term</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> (years)</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.5</span></td></tr></table></div><div style="text-indent:-9pt;padding-left:9pt;text-align:justify;margin-bottom:6pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(1) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Determined using the expected quarterly dividend divided by the available three-month average stock price as of the valuation date, annualized and continuously compounded.</span></div><div style="text-align:justify;margin-bottom:6pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(2)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"> Determined using the term-matched, zero-coupon risk-free rate from the Treasury Constant Maturity yield curve, continuously compounded</span></div><div style="text-align:justify;margin-bottom:6pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(3)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Determined using a leverage-adjusted historical volatility of peer companies</span></div><div style="text-align:justify;margin-bottom:12pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(4)</sup><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;"> </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Determined using SEC safe harbor approach, based on a 3-year cliff vesting schedule and 10-year contractual term.</span></div> 0.0070 0.0307 0.2825 P6Y6M P3Y P10Y <div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock option activity during the year ended December 31, 2019 is summarized below:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:37.181%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.626%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Shares in millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares of Common Stock Attributable to Options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Exercise Price of Options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Aggregate Intrinsic Value</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at January 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.61 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.61 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited or expired</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.61 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.8</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable at December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt;">Market price of underlying Elanco common stock less exercise price. Options do not have an intrinsic value unless the market price exceeds the exercise price. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes data related to stock option activity:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:69.637%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.599%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average grant date fair value per stock option</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.21 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.21 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate intrinsic value on exercise</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.10 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash received upon exercise</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div> 400000 31.61 0 0 100000 31.61 0 0 300000 31.61 P8Y9M18D 0 0 0 0 2200000 P22M 10.21 10.21 0.10 0 1900000 0 5100000 26000000.0 25000000.0 Income Taxes Our income taxes for the year ended December 31, 2019 reflect the results on a stand-alone basis independent of Lilly, except for the period during which we were included in a combined tax return until full separation. In the jurisdictions in which we were included in a combined tax return, our income taxes were determined based on the tax matters agreement between us and Lilly. During the periods presented in the consolidated and combined financial statements for the year ended December 31, 2018 and December 31, 2017, our operations were generally included in the tax grouping of other Lilly entities within the respective entity's tax jurisdiction; however, in certain jurisdictions, we filed separate tax returns. Prior to the Separation, the income tax expense included in these financial statements has been calculated using the separate return basis as if Elanco filed separate tax returns. <div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">2017 Tax Act</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2017, the U.S. enacted the Tax Cuts and Jobs Act (2017 Tax Act), which significantly revised U.S. tax law. Guidance related to the 2017 Tax Act, including Notices, Proposed Regulations, and Final Regulations, has been issued, and we expect additional guidance will be issued in 2020. This additional guidance could materially impact our assumptions and estimates used to record our U.S. federal and state income tax expense resulting from the 2017 Tax Act.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are included in Lilly's U.S. tax examinations by the Internal Revenue Service through the full separation date of March 11, 2019. Pursuant to the tax matters agreement we executed with Lilly in connection with the IPO, the potential liabilities or potential refunds attributable to pre-IPO periods in which Elanco was included in a Lilly consolidated or combined tax return remain with Lilly. Certain matters of Lilly’s U.S. examination of tax years 2013 - 2015 effectively settled during the second quarter of 2019 and the resulting adjustments will not require any cash tax payments by Elanco. During the fourth quarter of 2019, certain matters for tax year 2015 were effectively settled upon conclusion of the IRS' examination and the resulting adjustments will not require any cash tax payments by Elanco. In the fourth quarter of 2019, the IRS began its examination of tax years 2016 - 2018.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following is the composition of income (loss) before income tax expense (benefit):</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.812%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.676%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(133.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(99.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) before income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">114.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(232.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following is the composition of income tax expense (benefit):</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.812%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.676%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current tax expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">88.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(56.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017 Tax Act</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(33.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total deferred tax expense (benefit)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(60.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Significant components of our deferred tax assets and liabilities as of December 31 are as follows:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.222%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Compensation and benefits</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accruals and reserves</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax credit carryovers</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax loss carryovers</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventories</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restructuring and other reserves</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total gross deferred tax assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">188.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">127.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation allowances</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(32.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total deferred tax assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">156.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangibles</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(134.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(130.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(56.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(50.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total deferred tax liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(212.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(184.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liabilities - net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(55.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(78.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deferred tax assets and liabilities reflect the impact of re-measurement resulting from the 2017 Tax Act.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The deferred tax assets and related valuation allowance amounts for U.S. federal and state net operating losses and tax credits shown above have been reduced for differences between financial reporting and tax return filings.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At December 31, 2019, we have tax credit carryovers of $14.0 million available to reduce future income taxes. The amount is comprised of foreign, U.S. federal and state credits. The foreign credits total $5.1 million and if unused, will begin to expire in 2030. The U.S. federal credits total $3.2 million and if unused, will begin to expire in 2030. The state credits total $5.7 million and if unused, will begin to expire in 2020. The U.S. federal and state credits are subject to a full valuation allowance.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At December 31, 2019, we had net operating loss carryovers and other carryovers for foreign, U.S. federal and state income tax purposes of $348.4 million: $285.5 million will expire between 2020 and 2039; and $62.9 million of the carryovers have an indefinite carryforward period. Net operating losses and other carryovers for foreign and state income tax purposes are subject to a partial valuation allowance. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The movements in the valuation allowance are as follows:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.222%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 1</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(127.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustment related to Separation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">110.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 1</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Increase </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(23.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Release</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(32.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:-9pt;padding-left:9pt;text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;"> The increase in the valuation allowance during 2019 is primarily attributable to the acquisition of Aratana Therapeutics, Inc. and Prevtec Microbia Inc. (see Note 6: Acquisitions).</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to the IPO, we prepared the income tax amounts and balances based upon a separate return methodology, as if we were separate taxpayers from Lilly.  As a result, certain tax credits and net operating loss carryovers are not available for use in future periods as they were used in Lilly consolidated or combined tax return filings. Accordingly, as a result of the Separation, the tax credit and net operating loss carryovers and related valuation allowance have been adjusted to reflect the balance after Separation. These adjustments had no impact on income tax expense in the consolidated and combined financial statements. The separation entries related to the valuation allowance were offset by $133.7 million, prior to tax effect, of separation entries related to the removal of the net operating losses.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2017 Tax Act introduced international tax provisions that significantly change the U.S. taxation of foreign earnings.  At December 31, 2019, no U.S. taxes or foreign withholding taxes have been accrued with respect to the $496.7 million in unremitted earnings of our foreign subsidiaries as they are considered indefinitely reinvested for continued use in our foreign operations. It is not practicable to determine the unrecognized deferred tax liability related to these earnings. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash payments of income taxes were as follows:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.812%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.676%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payments of income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is a reconciliation of the income tax expense (benefit) applying the U.S. federal statutory rate to income before income taxes to reported income tax expense:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.228%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.964%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.964%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.676%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax at the U.S. federal statutory tax rate</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(81.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Add (deduct):</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Taxation of international operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-deductible employee compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IPO and separation costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other permanent adjustments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in uncertain tax positions</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017 Tax Act</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(33.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.812%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.676%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Beginning balance at January 1</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments related to Separation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjusted beginning balance at January 1</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions based on tax positions related to the current year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes for tax positions of prior years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Settlements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes related to the impact of foreign currency translation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ending balance at December 31</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The total amount of unrecognized tax benefits that, if recognized, would affect tax expense was $8.2 million and $12.8 million at December 31, 2019</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and 2018, respectively. There were $1.9 million of 2018 unrecognized tax benefits which related to temporary differences which did not impact the effective tax rate. Adjustments related to the Separation represent unrecognized tax benefits assumed by Lilly in the Separation and have no impact on income tax expense in the consolidated and combined financial statements.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We file income tax returns in the U.S. federal jurisdiction and various state, local and non-U.S. jurisdictions. Prior to full separation, certain of these income tax returns were filed on a consolidated or combined basis with Lilly. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense (benefit). We recognized income tax expense (benefit) related to interest and penalties as follows:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.812%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.676%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax expense (benefit)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At December 31, 2019 and 2018, our accruals for the payment of interest and penalties totaled $3.0 million and $13.3 million, respectively.</span></div> <div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following is the composition of income (loss) before income tax expense (benefit):</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.812%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.676%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(133.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(99.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) before income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">114.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(232.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 55500000 12200000 -133200000 22700000 101900000 -99400000 78200000 114100000 -232600000 <div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following is the composition of income tax expense (benefit):</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.812%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.676%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current tax expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">88.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(56.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017 Tax Act</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(33.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total deferred tax expense (benefit)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(60.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> -5500000 45100000 0 13400000 45500000 91600000 2300000 -2300000 -100000 10200000 88300000 91500000 14500000 -56800000 42600000 -7500000 -5600000 -16600000 -6900000 1700000 -6300000 0 0 -33100000 100000 -60700000 -13400000 10300000 27600000 78100000 <div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Significant components of our deferred tax assets and liabilities as of December 31 are as follows:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.222%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Compensation and benefits</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accruals and reserves</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax credit carryovers</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax loss carryovers</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventories</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restructuring and other reserves</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total gross deferred tax assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">188.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">127.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation allowances</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(32.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total deferred tax assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">156.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangibles</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(134.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(130.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(56.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(50.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total deferred tax liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(212.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(184.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liabilities - net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(55.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(78.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 25300000 32200000 13700000 26900000 12800000 6200000 69500000 17400000 20100000 18300000 24600000 6000000.0 20500000 2300000 20100000 188800000 127100000 32700000 21400000 156100000 105700000 20500000 134500000 130800000 56400000 50800000 600000 2700000 212000000.0 184300000 55900000 78600000 14000000.0 5100000 3200000 5700000 348400000 285500000 62900000 <div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The movements in the valuation allowance are as follows:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.222%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 1</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(127.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustment related to Separation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">110.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 1</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Increase </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(23.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Release</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(32.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:-9pt;padding-left:9pt;text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;"> The increase in the valuation allowance during 2019 is primarily attributable to the acquisition of Aratana Therapeutics, Inc. and Prevtec Microbia Inc. (see Note 6: Acquisitions).</span></div> 21400000 127700000 0 -110400000 21400000 17300000 23200000 5800000 11900000 1700000 32700000 21400000 133700000 0 496700000 <div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash payments of income taxes were as follows:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.812%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.676%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payments of income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 42500000 26900000 35700000 <div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is a reconciliation of the income tax expense (benefit) applying the U.S. federal statutory rate to income before income taxes to reported income tax expense:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.228%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.964%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.964%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.676%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax at the U.S. federal statutory tax rate</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(81.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Add (deduct):</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Taxation of international operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-deductible employee compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IPO and separation costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other permanent adjustments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in uncertain tax positions</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017 Tax Act</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(33.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 16400000 24000000.0 -81400000 20700000 20500000 59800000 2900000 4400000 5400000 9800000 17300000 1800000 4200000 -1900000 0 0 2300000 0 -4200000 -1000000.0 800000 -14700000 -1700000 6200000 -5200000 -1700000 122200000 0 0 -33100000 10300000 27600000 78100000 <div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.812%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.676%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Beginning balance at January 1</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments related to Separation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjusted beginning balance at January 1</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions based on tax positions related to the current year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes for tax positions of prior years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Settlements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes related to the impact of foreign currency translation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ending balance at December 31</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 14700000 29600000 25700000 -2200000 -17600000 0 12500000 12000000.0 25700000 1300000 2200000 7900000 1200000 4000000.0 0 4300000 3000000.0 4000000.0 100000 500000 0 8200000 14700000 29600000 8200000 12800000 1900000 We recognized income tax expense (benefit) related to interest and penalties as follows:<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.812%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.676%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax expense (benefit)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table> -10600000 -2500000 2500000 3000000.0 13300000 Commitments and Contingencies <div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Legal matters</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are party to various legal actions in the normal course of business. In determining whether a pending matter is significant for financial reporting and disclosure purposes, we consider both quantitative and qualitative factors in order to assess materiality. We accrue for certain liability claims to the extent we can formulate a reasonable estimate of their costs and there is a reasonable probability of incurring significant costs or expenses. At December 31, 2019 and December 31, 2018, we had no liabilities established related to litigation as there were no significant claims which were probable and estimable. We have not historically had any significant litigation expense and are not currently subject to a significant claim.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Bayer Animal Health acquisition financing</span></div>In connection with our pending acquisition of the animal health business of Bayer as discussed in Note 6: Acquisitions, in August 2019, we entered into a commitment letter that provides for financing consisting of up to $750 million in a revolving facility, $3.0 billion in a term facility, and $2.75 billion in a senior secured bridge facility. In connection with the financing commitment letter, we will incur fixed commitment fees of $40.4 million that will become due and payable upon the closing of the pending acquisition or the termination of the Purchase Agreement with Bayer. These fees have not been recorded on the consolidated balance sheet as of December 31, 2019. See Note 22: Subsequent Events for updates regarding financing secured after the balance sheet date. 0 0 750000000 3000000000.0 2750000000 40400000 Geographic Information <div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We operate as a single operating segment engaged in the development, manufacturing, marketing and sales of animal health products worldwide for both food animals and companion animals. Consistent with our operational structure, our President and Chief Executive Officer (CEO), as the chief operating decision maker, makes resource allocation and business process decisions globally across our consolidated business. Strategic decisions are managed globally with global functional leaders responsible for determining significant costs/investments and with regional leaders responsible for overseeing the execution of the global strategy. Our global research and development organization is responsible for development of new products. Our manufacturing organization is responsible for the manufacturing and supply of products and for the optimization of our supply chain. Regional leaders are responsible for the distribution and sale of our products and for local direct costs. The business is also supported by global corporate staff functions. Managing and allocating resources at the global corporate level enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, product types, regional commercial organizations and research and development projects in line with our overarching long-term corporate-wide strategic goals, rather than on a product or geographic basis. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, allocating resources, setting incentive compensation targets, as well as forecasting future period financial results. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our products include </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Rumensin</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Optaflexx</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Denagard</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Tylan</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Maxiban</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and other products for livestock and poultry, as well as </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Trifexis</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Intercepto</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">r, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Comfortis</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Galliprant</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and other products for companion animals. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have a single customer that accounted for 12.9%, 11.9% and 12.9% of revenue for the years ended December 31, 2019, 2018 and 2017, respectively. The product sales resulted in accounts receivable with this customer of $90.5 million and $96.4 million as of December 31, 2019 and 2018, respectively. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are exposed to the risk of changes in social, political and economic conditions inherent in foreign operations and our results of operations and the value of our foreign assets are affected by fluctuations in foreign currency exchange rates. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Selected geographic area information was as follows: </span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.228%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.676%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Revenue — to unaffiliated customers</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United States</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,524.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,483.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,373.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">International</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,546.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,583.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,516.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,071.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,066.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,889.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Long-lived assets</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">:</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United States</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">709.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">602.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">604.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United Kingdom</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">192.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">187.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">204.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other foreign countries</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">244.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">195.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-lived assets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,147.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">985.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">999.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">(1) Revenue is attributed to the countries based on the location of the customer. </span></div>(2) Long-lived assets consist of property and equipment, net, and certain noncurrent assets, including right-of-use assets. 0.129 0.119 0.129 90500000 96400000 <div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Selected geographic area information was as follows: </span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.228%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.676%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Revenue — to unaffiliated customers</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United States</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,524.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,483.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,373.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">International</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,546.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,583.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,516.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,071.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,066.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,889.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Long-lived assets</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">:</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United States</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">709.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">602.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">604.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United Kingdom</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">192.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">187.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">204.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other foreign countries</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">244.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">195.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-lived assets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,147.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">985.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">999.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">(1) Revenue is attributed to the countries based on the location of the customer. </span></div>(2) Long-lived assets consist of property and equipment, net, and certain noncurrent assets, including right-of-use assets. <div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Selected geographic area information was as follows: </span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.228%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.676%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Revenue — to unaffiliated customers</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United States</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,524.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,483.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,373.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">International</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,546.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,583.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,516.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,071.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,066.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,889.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Long-lived assets</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">:</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United States</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">709.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">602.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">604.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United Kingdom</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">192.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">187.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">204.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other foreign countries</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">244.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">195.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-lived assets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,147.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">985.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">999.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">(1) Revenue is attributed to the countries based on the location of the customer. </span></div>(2) Long-lived assets consist of property and equipment, net, and certain noncurrent assets, including right-of-use assets. 1524700000 1483200000 1373000000.0 1546300000 1583600000 1516000000.0 3071000000.0 3066800000 2889000000.0 709800000 602600000 604700000 192600000 187500000 204400000 244700000 195800000 190200000 1147100000 985900000 999300000 Retirement Benefits<div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Pension Plans</span></div><div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There are certain defined benefit pension plans that our employees participate in that are either dedicated to our employees or where the plan assets and liabilities that relate to our employees were legally required to transfer to Elanco at the time of our separation from Lilly. The plans in Switzerland represent approximately 80% </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">of our global benefit obligation. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We use a measurement date of December 31 to develop the change in benefit obligation, change in plan assets, funded status and amounts recognized in the consolidated balance sheets at December 31 for our defined benefit pension plans, which were as follows:</span></div><div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.222%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">  </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in benefit obligation:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit obligation at beginning of year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">234.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">258.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Service cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Actuarial loss (gain)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(44.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefits paid</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Plan amendments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(74.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:15.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Foreign currency exchange rate changes and other adjustments</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit obligation at end of year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">224.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">234.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:70.099%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.656%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.387%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.658%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in plan assets:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of plan assets at beginning of year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">131.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">131.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Actual return on plan assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employer contribution</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefits paid</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:15.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Foreign currency exchange rate changes and other adjustments</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of plan assets at end of year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">148.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">131.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.222%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Funded status</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(75.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(103.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrecognized net actuarial loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrecognized prior service cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(74.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net amount recognized</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(103.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(101.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.222%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Amounts recognized in the consolidated balance sheet consisted of:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncurrent assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued retirement benefits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(77.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(105.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:15.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Accumulated other comprehensive (income) loss before income taxes</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(28.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net amount recognized</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(103.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(101.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The unrecognized net actuarial loss and unrecognized prior service cost for these pension plans have not yet been recognized in net periodic pension costs and are included in accumulated other comprehensive loss at December 31, 2019.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Pension plan amendment</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In September 2019, we signed agreements under which certain defined pension benefits in Switzerland transferred from the previous Lilly pension fund as of December 31, 2019 to a new Elanco pension fund effective January 1, 2020. This resulted in a plan amendment during the period. The plan amendment decreased our pension benefit obligation by approximately $21 million, consisting primarily of a decrease in prior service costs of approximately $75 million, partially offset by a loss of approximately $54 million driven by changes in certain assumptions. The net impact to accumulated other comprehensive income was a gain of approximately $21 million, which will be amortized over the average remaining service period of employees expected to receive benefits under the plans.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not expect any plan assets to be returned to us in 2020.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following represents our weighted-average assumptions related to these pension plans as of December 31:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.228%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.676%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Percents)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rate for benefit obligation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6% </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5% </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1% </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rate for net benefit costs</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rate of compensation increase for benefit obligation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rate of compensation increase for net benefit costs</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected return on plan assets for net benefit costs</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We annually evaluate the expected return on the plan assets in these pension plans. In evaluating the expected rate of return, we consider many factors, with a primary analysis of current and projected market conditions; asset returns and asset allocations; and the views of leading financial advisers and economists. We may also review our historical assumptions compared with actual results, as well as the assumptions and trend rates utilized by similar plans, where applicable. </span></div><div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:31.040%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.680%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2025-2029</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit payments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amounts relating to these pension plans with projected benefit obligations in excess of plan assets were as follows at December 31:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.222%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Projected benefit obligation</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">218.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">229.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of plan assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">140.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">124.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amounts relating to these defined benefit pension plans with accumulated benefit obligations in excess of plan assets were as follows at December 31:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.222%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated benefit obligation</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">203.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">194.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of plan assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">140.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">124.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The total accumulated benefit obligation for these defined benefit pension plans was $210.1 million and $199.9 million at December 31, 2019 and 2018, respectively.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net pension expense related to these plans included the following components:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.812%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.676%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">  </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Service cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected return on plan assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:15.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Amortization of prior service cost</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of net actuarial loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net pension expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following represents the amounts recognized for these plans in other comprehensive loss:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.812%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.676%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Actuarial gain (loss) arising during period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(45.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prior year service cost during the year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of prior service cost included in net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of net actuarial loss included in net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency exchange rate changes and other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other comprehensive income (loss) during period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Benefit Plan Investments</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our benefit plan investment policies are set with specific consideration of return and risk requirements in relationship to the respective liabilities. Our plan assets in our Switzerland pension plans represent approximately 87% of our plan assets for these pension plans. Given the long-term nature of our liabilities, these plans have the flexibility to manage an above-average degree of risk in the asset portfolios. At the investment-policy level, there are no specifically prohibited investments. However, within individual investment manager mandates, restrictions and limitations are contractually set to align with our investment objectives, ensure risk control and limit concentrations.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We manage our portfolio to minimize concentration of risk by allocating funds within asset categories. In addition, within a category we use different managers with various management objectives to eliminate any significant concentration of risk.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The investment strategy is to diversify in five major categories with a designated percentage invested in each including 5% liquidity, 36% fixed income securities, 32% equity securities, a share of 21% in real estate and 6% in other alternative investments. Each category is diversified and comprised of the following: </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Liquidity - cash and cash equivalents</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Fixed-income securities - Swiss bonds, global aggregates, global aggregate corporates, emerging market local currencies and emerging markets hard currencies. </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Equity investments - Swiss equities, global equities, low volatility equities (to reduce risk), and emerging market equities.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Real estate - Swiss real estate and global real estate funds.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Other investments - represents primarily investments in senior secured loans.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We determine the fair value of the investments based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analysis for all investments except hedge funds, private equity-like investments and real estate. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We determine the fair value of investments using the value reported by the partnership, adjusted for known cash flows and significant events through our reporting date. Values provided by the partnerships are primarily based on analysis of and judgments about the underlying investments. Inputs to these valuations include underlying NAVs, discounted cash flow valuations, comparable market valuations, and may also include adjustments for currency, credit, liquidity and other risks as applicable. The vast majority of these private partnerships provide us with annual financial statements including their compliance with fair valuation procedures consistent with applicable accounting standards.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We determine the fair value of real estate investments based on the NAV provided by the fund manager. These NAVs are developed with inputs including discounted cash flow, independent appraisal and market comparable analyses.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair values of these pension plan assets as of December 31, 2019 by asset category are as follows:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:27.411%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.388%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.764%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.388%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.705%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.388%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.705%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.388%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.705%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.388%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.770%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements Using</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset Class</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted Prices in Active Markets for Identical Assets <br/>(Level 1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Investments Valued at Net Asset Value</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Cash and cash equivalents </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">129.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">129.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Public equity securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fixed income:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Developed markets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Emerging markets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">148.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">142.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-bottom:12pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt;">Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.</span></div><div style="text-indent:-18pt;padding-left:18pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;vertical-align:top;">(2)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:11.65pt;">Switzerland plan assets were exiting the Lilly pension plan as of December 31, 2019. As a result, assets were converted to cash and transferred to the new Elanco pension fund effective January 1, 2020. </span></div><div><span><br/></span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December 31, 2019. The activity in the Level 3 investments during the year ended December 31, 2019 was not material.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair values of these pension plan assets as of December 31, 2018 by asset category are as follows:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:27.411%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.388%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.764%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.388%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.705%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.388%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.705%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.388%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.705%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.388%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.770%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements Using</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset Class</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted Prices in Active Markets for Identical Assets <br/>(Level 1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Investments Valued at Net Asset Value</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Public equity securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fixed income:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Developed markets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Emerging markets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private alternative investments:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Hedge funds</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity-like funds</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Real estate</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">131.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">118.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-bottom:12pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt;">Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December 31, 2018. The activity in the Level 3 investments during the year ended December 31, 2018 was not material.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Contributions of $6.5 million to these pension plans are expected in 2020.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Retiree Health Benefit Plan</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There are two retiree health benefit plan where the plan liabilities that relate to our employees were legally required to transfer to Elanco at the time of separation from Lilly. The accrued retirement benefits for these plans were $4.7 million and $3.9 million as of December 31, 2019 and 2018, respectively.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Defined Contribution Plans</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Elanco has defined contribution savings plans that include certain employees worldwide. The purpose of these plans is generally to provide additional financial security during retirement by providing employees with an incentive to save. Our contributions to the plans are based on our employee contributions and the level of our match. Expenses related to our employees under the plans totaled</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">$32.2 million,</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">$20.9 million and $22.1 million for the years ended December 31, 2019, 2018, and 2017, respectively. The expense for our 401(k) plan increased in 2019 primarily due to an increase our match and participant headcount.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Treatment of Lilly Plans</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to the Separation, our employees participated in defined benefit pension and other postretirement plans sponsored by Lilly, which include participants of Lilly's other business. Such plans were accounted for as multiemployer plans in the combined financial statements and as a result, no asset or liability was recorded by us to recognize the funded status of these plans.</span></div>We recorded expense of $4.0 million and $73.7 million for the years ended December 31, 2018 and 2017, respectively, relating to our employees’ participation in Lilly sponsored plans. The expense recorded in 2017 included $67.0 million related to a curtailment loss and special termination benefits for early retirement incentives offered by Lilly to our employees as part of a voluntary early retirement program for the U.S. plan and which has been recorded in asset impairment, restructuring and other special charges. 0.80 We use a measurement date of December 31 to develop the change in benefit obligation, change in plan assets, funded status and amounts recognized in the consolidated balance sheets at December 31 for our defined benefit pension plans, which were as follows:<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.222%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">  </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in benefit obligation:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit obligation at beginning of year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">234.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">258.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Service cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Actuarial loss (gain)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(44.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefits paid</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Plan amendments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(74.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:15.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Foreign currency exchange rate changes and other adjustments</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit obligation at end of year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">224.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">234.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table><div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:70.099%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.656%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.387%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.658%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in plan assets:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of plan assets at beginning of year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">131.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">131.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Actual return on plan assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employer contribution</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefits paid</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:15.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Foreign currency exchange rate changes and other adjustments</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of plan assets at end of year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">148.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">131.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.222%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Funded status</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(75.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(103.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrecognized net actuarial loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrecognized prior service cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(74.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net amount recognized</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(103.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(101.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div> 234800000 258600000 9300000 11300000 2200000 2500000 -56400000 44700000 5500000 2700000 74700000 0 -1900000 -9800000 224400000 234800000 131600000 131500000 15300000 -10200000 5300000 5700000 5500000 2700000 2000000.0 7300000 148700000 131600000 -75700000 -103200000 -45900000 -500000 -74100000 800000 -103900000 -101900000 <table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.222%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Amounts recognized in the consolidated balance sheet consisted of:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncurrent assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued retirement benefits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(77.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(105.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:15.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Accumulated other comprehensive (income) loss before income taxes</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(28.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net amount recognized</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(103.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(101.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table> 2100000 2300000 300000 300000 77500000 105200000 -28200000 1300000 -103900000 -101900000 -21000000 -75000000 -54000000 -21000000 <div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following represents our weighted-average assumptions related to these pension plans as of December 31:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.228%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.676%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Percents)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rate for benefit obligation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6% </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5% </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1% </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rate for net benefit costs</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rate of compensation increase for benefit obligation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rate of compensation increase for net benefit costs</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected return on plan assets for net benefit costs</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div> 0.006 0.015 0.011 0.014 0.011 0.010 0.023 0.022 0.021 0.022 0.021 0.031 0.040 0.040 0.044 <div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:31.040%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.680%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2025-2029</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit payments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div> 7900000 8600000 8400000 8000000.0 8100000 48400000 <div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amounts relating to these pension plans with projected benefit obligations in excess of plan assets were as follows at December 31:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.222%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Projected benefit obligation</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">218.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">229.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of plan assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">140.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">124.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 218200000 229200000 140300000 124100000 <div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amounts relating to these defined benefit pension plans with accumulated benefit obligations in excess of plan assets were as follows at December 31:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.222%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated benefit obligation</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">203.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">194.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of plan assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">140.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">124.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div> 203900000 194300000 140300000 124100000 210100000 199900000 <div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net pension expense related to these plans included the following components:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.812%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.676%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">  </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Service cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected return on plan assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:15.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Amortization of prior service cost</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of net actuarial loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net pension expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div> 9300000 11300000 10500000 2200000 2500000 1800000 4200000 6200000 2400000 -1700000 200000 100000 -1100000 -1900000 -1400000 0 500000 0 6700000 10200000 11400000 <div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following represents the amounts recognized for these plans in other comprehensive loss:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.812%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.676%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Actuarial gain (loss) arising during period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(45.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prior year service cost during the year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of prior service cost included in net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of net actuarial loss included in net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency exchange rate changes and other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other comprehensive income (loss) during period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div> -45600000 28300000 -17000000.0 -74700000 0 0 -1700000 200000 100000 -1100000 -1900000 -1400000 1000000.0 -1900000 3500000 -29500000 -28500000 12000000.0 0.87 0.05 0.36 0.32 0.21 0.06 <div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair values of these pension plan assets as of December 31, 2019 by asset category are as follows:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:27.411%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.388%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.764%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.388%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.705%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.388%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.705%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.388%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.705%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.388%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.770%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements Using</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset Class</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted Prices in Active Markets for Identical Assets <br/>(Level 1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Investments Valued at Net Asset Value</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Cash and cash equivalents </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">129.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">129.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Public equity securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fixed income:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Developed markets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Emerging markets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">148.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">142.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-bottom:12pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt;">Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.</span></div><div style="text-indent:-18pt;padding-left:18pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;vertical-align:top;">(2)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:11.65pt;">Switzerland plan assets were exiting the Lilly pension plan as of December 31, 2019. As a result, assets were converted to cash and transferred to the new Elanco pension fund effective January 1, 2020. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair values of these pension plan assets as of December 31, 2018 by asset category are as follows:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:27.411%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.388%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.764%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.388%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.705%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.388%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.705%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.388%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.705%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.388%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.770%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements Using</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset Class</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted Prices in Active Markets for Identical Assets <br/>(Level 1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Investments Valued at Net Asset Value</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Public equity securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fixed income:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Developed markets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Emerging markets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private alternative investments:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Hedge funds</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity-like funds</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Real estate</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">131.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">118.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-bottom:12pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt;">Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.</span></div> 129000000.0 129000000.0 0 0 0 3800000 1900000 0 0 1900000 2500000 2100000 0 0 400000 9100000 8800000 300000 0 0 4300000 900000 3400000 0 0 148700000 142700000 3700000 0 2300000 2200000 1000000.0 0 0 1200000 29900000 7800000 100000 0 22000000.0 6400000 700000 400000 0 5300000 6600000 0 0 0 6600000 49000000.0 0 0 0 49000000.0 20100000 100000 0 0 20000000.0 17400000 300000 2300000 0 14800000 131600000 9900000 2800000 0 118900000 6500000 2 4700000 3900000 32200000 20900000 22100000 4000000.0 73700000 67000000.0 Earnings Per Share<div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Basic Earnings Per Share</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As discussed in Note 1, Elanco Parent was formed for the purpose of facilitating the IPO. Lilly held all shares of Elanco Parent from the time of formation until the IPO.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to IPO, there were an aggregate of 293,290,000 shares of our common stock held by Lilly (which represents the 100 shares held by Lilly prior to giving effect to the 2,932,900-for-1 stock split that occurred on September 19, 2018). In connection with the completion of the IPO, an additional 72,335,000 shares of our common stock were issued. Earnings per share was calculated based on the assumptions that the shares held by Lilly were outstanding for all periods prior to IPO. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We compute basic earnings per share by dividing net earnings available to common shareholders by the actual weighted average number of common shares outstanding for the reporting period. For the year ended December 31, 2019, weighted average number of common shares outstanding used to calculate basic earnings per share includes the impact of approximately 7.3 million shares that were issued during the period in connection with the acquisition of Aratana. See Note 6: Acquisitions for further discussion.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Diluted Earnings Per Share</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Elanco has common stock equivalents related to certain equity awards in stock-based compensation arrangements. Diluted earnings per share reflects the potential dilution that could occur if holders of unvested RSUs, PAs and stock options converted their holdings into common stock. The weighted average number of potentially dilutive shares outstanding is calculated using the treasury stock method.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average diluted shares outstanding included common stock equivalents of 1.3 million for 2019. The dilutive impact for 2018 was immaterial. </span></div><div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Potential common shares that would have the effect of increasing diluted earnings per share are considered to be anti-dilutive and as such, these shares are not included in the calculation of diluted earnings per share. For the year ended December 31, 2019, approximately 0.1 million shares of potential common shares were excluded from the calculation of diluted earnings per share because their effect was anti-dilutive.</span></div> 293290000 100 2932900 72335000 7300000 1300000 100000 Related Party Agreements and Transactions <div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Transactions with Lilly Subsequent to Separation and Related to the Separation</span></div><div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amounts due from/(due to) Lilly in connection with the Separation and agreed upon services as of December 31 were as follows:</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.222%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TSA</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(28.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(38.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Local country asset purchases</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(202.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total receivable from/(payable to) Lilly</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(268.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As described in Note 1, we completed an IPO in September 2018 and Lilly fully divested all ownership of Elanco in March 2019. In connection with the Separation, we entered into various agreements with Lilly related to the form of our separation and certain ongoing activities that will continue for a period of time. These included, among others, a master separation agreement (MSA), a TSA and a tax matters agreement. In addition, there was a portion of our operations for which the legal transfer of our net assets did not occur prior to the Separation due to certain regulatory requirements in each of these countries. </span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Transitional Services Agreement (TSA)</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Historically, Lilly has provided us significant shared services and resources related to corporate functions such as executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">technology and investor relations, which we refer to collectively as the "Lilly Services." Under the terms of the TSA, we will be able to use Lilly Services for a fixed term established on a service-by-service basis. We will pay Lilly mutually agreed-upon fees for the Lilly Services provided under the TSA, which will be based on Lilly's cost (including third-party costs) of providing the Lilly Services through March 31, 2021, and subject to a mark-up of 7% thereafter, with additional inflation-based escalation beginning January 1, 2022. The fees under the TSA became payable for all periods beginning after October 1, 2018.</span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Separation Activities</span></div><div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subsequent to our IPO, there continue to be transactions between us and Lilly related primarily to the completion of the local country asset purchases and finalization of assets and liabilities associated with the legal separation from Lilly, combined income tax returns and the impact of the tax matters agreement, historical Lilly retirement benefits, and centralized cash management. The net impact of these activities of $51.2 million for the year ended December 31, 2019 has been reflected as Separation Activities within shareholders' equity. The most significant of these activities includes the finalization of the local country valuation of business and the resulting impact on deferred tax assets and the impact of combined tax returns.</span></div><div style="text-indent:9pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other Activities</span></div><div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We continue to share certain services and back office functions with Lilly, which in certain instances result in Lilly paying costs for Elanco (e.g., utilities, local country operating costs, etc.) that are then passed through to Elanco for reimbursement. These amounts are included in cash flows from operating activities in our consolidated and combined statements of cash flows. In addition, we operate through a single treasury settlement process and prior to the local country asset purchases (as described below) continued to transact through Lilly's processes in certain instances. As a result of these activities, there were certain amounts of financing that occurred between Lilly and Elanco during the year ended December 31, 2019. These amounts are included in cash flows from financing activities in our consolidated and combined statements of cash flows.</span></div><div style="text-indent:9pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Local Country Asset Purchases</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The legal transfer of certain of our net assets did not occur prior to the Separation due to certain regulatory requirements in each of these countries. The related assets, liabilities, and results of operations have been reported in our consolidated and combined financial statements, as we are responsible for the business activities conducted by Lilly on our behalf and are subject to the risks and entitled to the benefits generated by these operations and assets under the terms of the MSA. We held restricted cash, and the associated payable to Lilly, at the date of Separation to fund the acquisition of these assets. As of December 31, 2019, the majority of these assets have been legally acquired and the remainder are expected to be purchased during 2020. Restricted cash and Payable to Lilly of $11.1 million are recorded in the consolidated balance sheet for the remainder of the assets expected to be purchased by the end of 2020.</span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Intellectual Property and Technology License Agreement.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> We entered into an intellectual property and technology license agreement with Lilly immediately prior to the completion of the IPO. Under the intellectual property and technology license agreement, Lilly granted Elanco an exclusive, perpetual license to exploit products in the animal health field that utilize or use certain of Lilly's intellectual property (excluding trademarks). In addition, Lilly granted Elanco non-exclusive, non-sublicensable license to screen certain compounds in Lilly's compound libraries to exploit products in the animal use certain of Lilly's intellectual property. This screening license has an initial term of two years, subject to three <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg0ZmI4ZDkyMzYxZDQyYWRiNTcyOGY3MjAxYzVmMGM1L3NlYzo4NGZiOGQ5MjM2MWQ0MmFkYjU3MjhmNzIwMWM1ZjBjNV8xNjkvZnJhZzo1ZWRlOGJiZTBjY2Y0NzExYjY2YWI2YjlkNzBiOTIyYS90ZXh0cmVnaW9uOjVlZGU4YmJlMGNjZjQ3MTFiNjZhYjZiOWQ3MGI5MjJhXzMyNjM_3369d2a8-da4b-40e3-a2fe-23c939ba03c9">one</span>-year extensions, each of which requires Lilly's consent.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We also entered into a tax matters agreement (TMA), an employee matters agreement, a toll manufacturing and supply agreement and a registration rights agreement with Lilly in connection with the Separation.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our consolidated and combined financial statement of operations includes revenue related to a toll manufacturing agreement of $17.8 million and $7.0 million for the years ended December 31, 2019 and 2018, respectively. Also included are approximately $93.7 million and $28.1 million related to TSA charges for 2019 and 2018, respectively.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Transactions with Lilly Prior to Separation</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to the IPO, we did not operate as a standalone business and had various relationships with Lilly whereby Lilly provided services to us. The impact on our historical combined financial statements includes the following:</span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Transfers to/from Lilly, net</span></div><div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As discussed in Note 2: Basis of Presentation, net parent company investment is primarily impacted by contributions from Lilly, which are the result of treasury activity and net funding provided by or distributed to Lilly. For the years ended December 31, 2018 and 2017, net transfers (to)/from Lilly were $(226.3) million and $873.3 million, respectively. The most significant activity impacting the 2017 transfer was the financing by Lilly of our acquisition in the amount of $882.1 million for the acquisition of BIVIVP as described in Note 6: Acquisitions. Other activities that impacted the net transfers (to)/from Lilly include corporate overhead and other allocations, income taxes, retirement benefits, and centralized cash management.</span></div><div style="text-indent:9pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Corporate Overhead and Other Allocations</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to full separation, Lilly provided us certain services, including executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information technology and investor relations. We provide Lilly certain services related to manufacturing support. Our financial statements reflect an allocation of these costs. When specific identification is not practicable, the remainder have been allocated primarily on a proportional cost method on a basis of revenue or headcount.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The allocations of services from Lilly, prior to IPO, to us were reflected as follows in the combined statements of operations:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.076%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">2018</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of sales</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketing, selling and administrative</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">117.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">151.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr></table></div><div style="text-align:justify;margin-bottom:6pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">(1) Through September 30, 2018</sup></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were no allocations from Lilly to us reflected in the consolidated and combined statement of operations for the year ended December 31, 2019.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We provided Lilly certain services related to manufacturing support. Allocations of manufacturing support from us to Lilly were $3.7 million and $6.2 million for the years ended December 31, 2018 and 2017, respectively, which reduced the cost of sales in the consolidated and combined statements of operations.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The financial information herein may not necessarily reflect our consolidated financial position, results of operations and cash flows in the future or what they would have been if we had been a separate, standalone entity during the periods presented. Management believes that the methods used to allocate expenses are reasonable.</span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Stock-based Compensation</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As discussed in Note 14: Stock-based Compensation, prior to full separation, our employees participated in Lilly stock-based compensation plans, the costs of which were allocated to us and recorded in cost of sales, research and development, and marketing, selling and administrative expenses in the consolidated and combined statements of operations. The costs of such plans related to our employees were $5.1 million, $26.0 million and $25.0 million for the years ended December 31, 2019, 2018 and 2017, respectively.</span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Retirement Benefits</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As discussed in Note 18: Retirement Benefits, prior to full separation, our employees participated in defined benefit pension and other post retirement plans sponsored by Lilly, the costs and benefits of which were recorded in the consolidated and combined statement of operations in cost of sales, research and development, and marketing, selling and administrative expenses. The costs/(benefits) of such plans related to our employees were $(6.3) million and $73.7 million for the years ended December 31, 2018 and 2017, respectively.</span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Centralized Cash Management</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lilly uses a centralized approach to cash management and financing of operations. Until Separation, the majority of our business was party to Lilly’s cash pooling arrangements to maximize Lilly's availability of cash for general operating and investing purposes. Under these cash pooling arrangements, cash balances were swept regularly from our accounts. Cash transfers to and from Lilly’s cash concentration accounts and the resulting balances at the end of each reporting period were reflected in net parent company investment in the consolidated balance sheets.</span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Debt</span></div><div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lilly’s third-party debt and the related interest expense were not allocated to us for any of the periods presented as we were not the legal obligor of the debt and Lilly borrowings were not directly attributable to our business.</span></div> <div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amounts due from/(due to) Lilly in connection with the Separation and agreed upon services as of December 31 were as follows:</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.222%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TSA</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(28.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(38.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Local country asset purchases</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(202.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total receivable from/(payable to) Lilly</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(268.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The allocations of services from Lilly, prior to IPO, to us were reflected as follows in the combined statements of operations:</span></div><div style="text-align:justify;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.076%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">2018</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of sales</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketing, selling and administrative</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">117.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">151.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr></table></div><div style="text-align:justify;margin-bottom:6pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">(1) Through September 30, 2018</sup></div> 10500000 -28000000.0 -15800000 -38000000.0 -11100000 -202700000 -16400000 -268700000 -51200000 11100000 P2Y 3 17800000 7000000.0 93700000 28100000 -226300000 873300000 882100000 21800000 31800000 2200000 2800000 81200000 117100000 105200000 151700000 3700000 6200000 5100000 26000000.0 25000000.0 -6300000 73700000 Selected Quarterly Data (unaudited) <div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:52.970%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.678%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fourth</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Third</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Second</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">First</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">787.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">771.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">781.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">731.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of sales</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">410.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">360.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">356.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">343.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Operating expenses</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">253.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">262.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">269.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">245.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset impairment, restructuring, and other special charges</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense, net of capitalized interest</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) before income taxes</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax (benefit) expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(22.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Earnings (loss) per share—basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.03)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.03 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.10 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.09 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:52.970%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.678%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fourth </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Third </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Second </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">First </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">799.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">761.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">770.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">736.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of sales</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">412.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">369.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">431.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">360.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Operating expenses</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">246.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">237.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">252.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">245.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset impairment, restructuring, and other special charges</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense, net of capitalized interest</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) before income taxes</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(40.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax (benefit) expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(62.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Earnings (loss) per share—basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.04 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.20 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.21)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.25 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;margin-bottom:6pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.07pt;">Includes research and development and marketing, selling, and administrative expenses.</span></div><div style="text-indent:-31.5pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Numbers may not add up to totals for each year due to rounding.</span></div> <div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:52.970%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.678%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fourth</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Third</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Second</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">First</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">787.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">771.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">781.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">731.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of sales</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">410.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">360.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">356.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">343.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Operating expenses</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">253.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">262.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">269.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">245.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset impairment, restructuring, and other special charges</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense, net of capitalized interest</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) before income taxes</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax (benefit) expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(22.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Earnings (loss) per share—basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.03)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.03 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.10 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.09 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:52.970%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.678%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fourth </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Third </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Second </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">First </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">799.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">761.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">770.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">736.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of sales</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">412.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">369.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">431.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">360.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Operating expenses</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">246.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">237.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">252.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">245.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset impairment, restructuring, and other special charges</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense, net of capitalized interest</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) before income taxes</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(40.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax (benefit) expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(62.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Earnings (loss) per share—basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.04 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.20 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.21)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.25 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:12pt;margin-bottom:6pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.07pt;">Includes research and development and marketing, selling, and administrative expenses.</span></div><div style="text-indent:-31.5pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Numbers may not add up to totals for each year due to rounding.</span></div> 787000000.0 771300000 781600000 731100000 410100000 360400000 356000000.0 343800000 253200000 262200000 269700000 245200000 51600000 77200000 31800000 24900000 18700000 18700000 20700000 20800000 -4300000 -12500000 50200000 44800000 5200000 -22500000 14300000 13300000 -9500000 10000000.0 35900000 31500000 -0.03 0.03 0.10 0.09 799300000 761100000 770200000 736200000 412500000 369800000 431500000 360000000.0 246200000 237900000 252500000 245200000 46000000.0 12400000 68000000.0 2400000 21000000.0 8600000 0 0 -2200000 78800000 -40000000.0 77500000 -18600000 18600000 22800000 4800000 16400000 60200000 -62800000 72700000 0.04 0.20 -0.21 0.25 Subsequent Events <div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Bayer Animal Health acquisition financing</span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Equity offerings</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 22, 2020, we entered into an underwriting agreement in which we agreed to sell approximately 22.7 million shares of our common stock at a public offering price of $32.00 per share. In connection with the offering, we granted the underwriters an option to purchase up to an additional 2.3 million shares, which was exercised in full on January 23, 2020. As a result, we issued and sold a total of approximately 25.0 million shares of our common stock. Total cash of $769.9 million was received upon closing on January 27, 2020. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, on January 22, 2020, we issued $550 million in tangible equity units (TEUs). We offered 11 million 5.00% TEUs at the stated amount of $50 per unit, composed of a prepaid stock purchase contract and a senior amortizing note due February 1, 2023 (the mandatory settlement date). Total cash of $530.1 million was received upon closing on January 27, 2020, which was comprised of $453.8 million of prepaid stock purchase contracts and $76.3 million of senior amortizing notes, net of debt issuance costs. Unless the stock purchase contracts are redeemed by us or settled earlier at the unit holder’s option, they are mandatorily convertible into shares of our common stock at a minimum of 1.3021 shares per purchase contract or a maximum of 1.5625 shares per purchase contract on the mandatory settlement date. This corresponds to a minimum of 14.3 million shares and a maximum of 17.2 million shares.</span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Debt activity</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 31, 2020, we used a portion of the proceeds from the common stock and TEU issuances to repay indebtedness outstanding under our existing term loan facility. We paid $372.4 million in cash, composed of $371.4 million of principal and $1.0 million of accrued interest, resulting in a debt extinguishment loss of $0.8 million, primarily related to the write-off of deferred debt issuance costs. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 4, 2020, we successfully priced our senior secured credit facilities, consisting of the following: </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Term loan B facility with an aggregate principal amount of $4,275.0 million and a maturity of seven years.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Revolving loan facility providing up to $750.0 million and a maturity of five years. </span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The term loan B facility was priced at par at LIBOR plus 175 basis points, and the revolving loan facility is expected to bear interest at LIBOR plus an applicable margin ranging between 1.50% and 2.25% per annum based on our corporate family rating or corporate credit rating.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We intend to use the proceeds from the equity and debt activities to finance the cash portion of the pending acquisition of Bayer's animal health business and to pay related fees and expenses. As a result, we have obtained substantially all of the financing necessary to consummate the acquisition and do not currently intend to pursue any additional financing previously provided under the commitment letter obtained in August 2019 (see Note 16: Commitments and Contingencies).</span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Divestitures</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Osurnia and Capstar</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2020, we signed agreements to divest the worldwide rights to </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Osurnia</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and the U.S. rights to </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Capstar</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for an aggregate of $230 million in all cash deals, with the intent to advance our efforts to secure the necessary regulatory clearances for the pending acquisition of the Bayer animal health business. The closing of these transactions is contingent on us entering into consent decrees with certain agencies in connection with the pending acquisition as well as customary closing conditions. Both divestitures are expected to close by the end of 2020.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The related assets met the assets held for sale criteria as of December 31, 2019. No adjustment was required to record the assets at the lower of their carrying amounts or fair values less costs to sell on the consolidated balance sheet. Assets and liabilities considered held for sale in connection with the divestitures as of December 31, 2019 were included in the respective line items in the consolidated balance sheet as follows:</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:60.526%;"><tr><td style="width:1.0%;"/><td style="width:55.729%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:40.271%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventories</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other intangibles, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets held for sale</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities held for sale</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:9pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other intangibles, net classified as held for sale primarily consist of marketed products. We determined that the disposal of these net assets does not qualify for reporting as a discontinued operation because it does not represent a strategic shift that has or will have a major effect on our operations and financial results.</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Vecoxan</span></div><div style="text-indent:9pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2020, we signed an agreement to divest the worldwide rights to </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Vecoxan</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for $55 million in an all cash deal, with the intent to advance our efforts to secure the necessary regulatory clearances for the pending acquisition of the Bayer animal health business. The closing of this transaction is contingent on us entering into consent decrees with certain agencies in connection with the pending acquisition as well as customary closing conditions. This divestiture is expected to close by the end of 2020.</span></div> 22700000 32.00 2300000 25000000.0 769900000 550000000 11000000 0.0500 50 530100000 453800000 76300000 1.3021 1.5625 14300000 17200000 372400000 371400000 1000000.0 -800000 4275.0 P7Y 750000000.0 P5Y 0.0175 0.0150 0.0225 230000000 Assets and liabilities considered held for sale in connection with the divestitures as of December 31, 2019 were included in the respective line items in the consolidated balance sheet as follows:<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:60.526%;"><tr><td style="width:1.0%;"/><td style="width:55.729%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:40.271%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventories</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other intangibles, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets held for sale</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities held for sale</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table> 10600000 61200000 200000 72000000.0 1400000 1400000 55000000 See Note 6: Acquisitions for further discussion. See Note 3: Impact of Separation for further discussion. See Note 20: Related Party Agreements and Transactions for further discussion. XML 128 R23.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Legal matters
We are party to various legal actions in the normal course of business. In determining whether a pending matter is significant for financial reporting and disclosure purposes, we consider both quantitative and qualitative factors in order to assess materiality. We accrue for certain liability claims to the extent we can formulate a reasonable estimate of their costs and there is a reasonable probability of incurring significant costs or expenses. At December 31, 2019 and December 31, 2018, we had no liabilities established related to litigation as there were no significant claims which were probable and estimable. We have not historically had any significant litigation expense and are not currently subject to a significant claim.
Bayer Animal Health acquisition financing
In connection with our pending acquisition of the animal health business of Bayer as discussed in Note 6: Acquisitions, in August 2019, we entered into a commitment letter that provides for financing consisting of up to $750 million in a revolving facility, $3.0 billion in a term facility, and $2.75 billion in a senior secured bridge facility. In connection with the financing commitment letter, we will incur fixed commitment fees of $40.4 million that will become due and payable upon the closing of the pending acquisition or the termination of the Purchase Agreement with Bayer. These fees have not been recorded on the consolidated balance sheet as of December 31, 2019. See Note 22: Subsequent Events for updates regarding financing secured after the balance sheet date.
XML 129 R27.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Related Party Agreements and Transactions
 12 Months Ended
Dec. 31, 2019
Related Party Transactions [Abstract]  
Related Party Agreements and Transactions Related Party Agreements and Transactions
Transactions with Lilly Subsequent to Separation and Related to the Separation
Amounts due from/(due to) Lilly in connection with the Separation and agreed upon services as of December 31 were as follows:
20192018
TSA$10.5  $(28.0) 
Other activities(15.8) (38.0) 
Local country asset purchases(11.1) (202.7) 
Total receivable from/(payable to) Lilly$(16.4) $(268.7) 

As described in Note 1, we completed an IPO in September 2018 and Lilly fully divested all ownership of Elanco in March 2019. In connection with the Separation, we entered into various agreements with Lilly related to the form of our separation and certain ongoing activities that will continue for a period of time. These included, among others, a master separation agreement (MSA), a TSA and a tax matters agreement. In addition, there was a portion of our operations for which the legal transfer of our net assets did not occur prior to the Separation due to certain regulatory requirements in each of these countries.
Transitional Services Agreement (TSA)
Historically, Lilly has provided us significant shared services and resources related to corporate functions such as executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information
technology and investor relations, which we refer to collectively as the "Lilly Services." Under the terms of the TSA, we will be able to use Lilly Services for a fixed term established on a service-by-service basis. We will pay Lilly mutually agreed-upon fees for the Lilly Services provided under the TSA, which will be based on Lilly's cost (including third-party costs) of providing the Lilly Services through March 31, 2021, and subject to a mark-up of 7% thereafter, with additional inflation-based escalation beginning January 1, 2022. The fees under the TSA became payable for all periods beginning after October 1, 2018.
Separation Activities
Subsequent to our IPO, there continue to be transactions between us and Lilly related primarily to the completion of the local country asset purchases and finalization of assets and liabilities associated with the legal separation from Lilly, combined income tax returns and the impact of the tax matters agreement, historical Lilly retirement benefits, and centralized cash management. The net impact of these activities of $51.2 million for the year ended December 31, 2019 has been reflected as Separation Activities within shareholders' equity. The most significant of these activities includes the finalization of the local country valuation of business and the resulting impact on deferred tax assets and the impact of combined tax returns.

Other Activities
We continue to share certain services and back office functions with Lilly, which in certain instances result in Lilly paying costs for Elanco (e.g., utilities, local country operating costs, etc.) that are then passed through to Elanco for reimbursement. These amounts are included in cash flows from operating activities in our consolidated and combined statements of cash flows. In addition, we operate through a single treasury settlement process and prior to the local country asset purchases (as described below) continued to transact through Lilly's processes in certain instances. As a result of these activities, there were certain amounts of financing that occurred between Lilly and Elanco during the year ended December 31, 2019. These amounts are included in cash flows from financing activities in our consolidated and combined statements of cash flows.

Local Country Asset Purchases
The legal transfer of certain of our net assets did not occur prior to the Separation due to certain regulatory requirements in each of these countries. The related assets, liabilities, and results of operations have been reported in our consolidated and combined financial statements, as we are responsible for the business activities conducted by Lilly on our behalf and are subject to the risks and entitled to the benefits generated by these operations and assets under the terms of the MSA. We held restricted cash, and the associated payable to Lilly, at the date of Separation to fund the acquisition of these assets. As of December 31, 2019, the majority of these assets have been legally acquired and the remainder are expected to be purchased during 2020. Restricted cash and Payable to Lilly of $11.1 million are recorded in the consolidated balance sheet for the remainder of the assets expected to be purchased by the end of 2020.
Intellectual Property and Technology License Agreement.
We entered into an intellectual property and technology license agreement with Lilly immediately prior to the completion of the IPO. Under the intellectual property and technology license agreement, Lilly granted Elanco an exclusive, perpetual license to exploit products in the animal health field that utilize or use certain of Lilly's intellectual property (excluding trademarks). In addition, Lilly granted Elanco non-exclusive, non-sublicensable license to screen certain compounds in Lilly's compound libraries to exploit products in the animal use certain of Lilly's intellectual property. This screening license has an initial term of two years, subject to three one-year extensions, each of which requires Lilly's consent.
We also entered into a tax matters agreement (TMA), an employee matters agreement, a toll manufacturing and supply agreement and a registration rights agreement with Lilly in connection with the Separation.
Our consolidated and combined financial statement of operations includes revenue related to a toll manufacturing agreement of $17.8 million and $7.0 million for the years ended December 31, 2019 and 2018, respectively. Also included are approximately $93.7 million and $28.1 million related to TSA charges for 2019 and 2018, respectively.
Transactions with Lilly Prior to Separation
Prior to the IPO, we did not operate as a standalone business and had various relationships with Lilly whereby Lilly provided services to us. The impact on our historical combined financial statements includes the following:
Transfers to/from Lilly, net
As discussed in Note 2: Basis of Presentation, net parent company investment is primarily impacted by contributions from Lilly, which are the result of treasury activity and net funding provided by or distributed to Lilly. For the years ended December 31, 2018 and 2017, net transfers (to)/from Lilly were $(226.3) million and $873.3 million, respectively. The most significant activity impacting the 2017 transfer was the financing by Lilly of our acquisition in the amount of $882.1 million for the acquisition of BIVIVP as described in Note 6: Acquisitions. Other activities that impacted the net transfers (to)/from Lilly include corporate overhead and other allocations, income taxes, retirement benefits, and centralized cash management.

Corporate Overhead and Other Allocations
Prior to full separation, Lilly provided us certain services, including executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information technology and investor relations. We provide Lilly certain services related to manufacturing support. Our financial statements reflect an allocation of these costs. When specific identification is not practicable, the remainder have been allocated primarily on a proportional cost method on a basis of revenue or headcount.
The allocations of services from Lilly, prior to IPO, to us were reflected as follows in the combined statements of operations:
2018(1)
2017
Cost of sales$21.8  $31.8  
Research and development 2.2  2.8  
Marketing, selling and administrative81.2  117.1  
Total$105.2  $151.7  
(1) Through September 30, 2018
There were no allocations from Lilly to us reflected in the consolidated and combined statement of operations for the year ended December 31, 2019.
We provided Lilly certain services related to manufacturing support. Allocations of manufacturing support from us to Lilly were $3.7 million and $6.2 million for the years ended December 31, 2018 and 2017, respectively, which reduced the cost of sales in the consolidated and combined statements of operations.
The financial information herein may not necessarily reflect our consolidated financial position, results of operations and cash flows in the future or what they would have been if we had been a separate, standalone entity during the periods presented. Management believes that the methods used to allocate expenses are reasonable.
Stock-based Compensation
As discussed in Note 14: Stock-based Compensation, prior to full separation, our employees participated in Lilly stock-based compensation plans, the costs of which were allocated to us and recorded in cost of sales, research and development, and marketing, selling and administrative expenses in the consolidated and combined statements of operations. The costs of such plans related to our employees were $5.1 million, $26.0 million and $25.0 million for the years ended December 31, 2019, 2018 and 2017, respectively.
Retirement Benefits
As discussed in Note 18: Retirement Benefits, prior to full separation, our employees participated in defined benefit pension and other post retirement plans sponsored by Lilly, the costs and benefits of which were recorded in the consolidated and combined statement of operations in cost of sales, research and development, and marketing, selling and administrative expenses. The costs/(benefits) of such plans related to our employees were $(6.3) million and $73.7 million for the years ended December 31, 2018 and 2017, respectively.
Centralized Cash Management
Lilly uses a centralized approach to cash management and financing of operations. Until Separation, the majority of our business was party to Lilly’s cash pooling arrangements to maximize Lilly's availability of cash for general operating and investing purposes. Under these cash pooling arrangements, cash balances were swept regularly from our accounts. Cash transfers to and from Lilly’s cash concentration accounts and the resulting balances at the end of each reporting period were reflected in net parent company investment in the consolidated balance sheets.
Debt
Lilly’s third-party debt and the related interest expense were not allocated to us for any of the periods presented as we were not the legal obligor of the debt and Lilly borrowings were not directly attributable to our business.
XML 130 R46.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Selected Quarterly Data (unaudited) (Tables)
 12 Months Ended
Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]  
Schedule of Selected Quarterly Data
2019FourthThirdSecondFirst
Revenue$787.0  $771.3  $781.6  $731.1  
Cost of sales410.1  360.4  356.0  343.8  
Operating expenses(1)
253.2  262.2  269.7  245.2  
Asset impairment, restructuring, and other special charges51.6  77.2  31.8  24.9  
Interest expense, net of capitalized interest18.7  18.7  20.7  20.8  
Income (loss) before income taxes(4.3) (12.5) 50.2  44.8  
Income tax (benefit) expense5.2  (22.5) 14.3  13.3  
Net income (loss)(9.5) 10.0  35.9  31.5  
Earnings (loss) per share—basic and diluted(0.03) 0.03  0.10  0.09  

2018Fourth  Third  Second  First  
Revenue$799.3  $761.1  $770.2  $736.2  
Cost of sales412.5  369.8  431.5  360.0  
Operating expenses(1)
246.2  237.9  252.5  245.2  
Asset impairment, restructuring, and other special charges46.0  12.4  68.0  2.4  
Interest expense, net of capitalized interest21.0  8.6  —  —  
Income (loss) before income taxes(2.2) 78.8  (40.0) 77.5  
Income tax (benefit) expense(18.6) 18.6  22.8  4.8  
Net income (loss)16.4  60.2  (62.8) 72.7  
Earnings (loss) per share—basic and diluted0.04  0.20  (0.21) 0.25  
(1)Includes research and development and marketing, selling, and administrative expenses.
Numbers may not add up to totals for each year due to rounding.
XML 131 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} JSON 132 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "elan-20191231.htm": { "axisCustom": 0, "axisStandard": 43, "contextCount": 397, "dts": { "calculationLink": { "local": [ "elan-20191231_cal.xml" ] }, "definitionLink": { "local": [ "elan-20191231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "elan-20191231.htm" ] }, "labelLink": { "local": [ "elan-20191231_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2018/dei-doc-2018-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "elan-20191231_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2018/dei-ref-2018-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml" ] }, "schema": { "local": [ "elan-20191231.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd" ] } }, "elementCount": 815, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 5, "http://www.elanco.com/20191231": 2, "http://xbrl.sec.gov/dei/2018-01-31": 17, "total": 24 }, "keyCustom": 51, "keyStandard": 514, "memberCustom": 43, "memberStandard": 72, "nsprefix": "elan", "nsuri": "http://www.elanco.com/20191231", "report": { "R1": { "firstAnchor": null, "groupType": "document", "isDefault": "true", "longName": "000010001 - Document - Document and Entity Information", "role": "http://www.elanco.com/role/DocumentandEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": null }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210051003 - Disclosure - Impact of Separation", "role": "http://www.elanco.com/role/ImpactofSeparation", "shortName": "Impact of Separation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "ic82889430c4f4e129a2c2edb096de70f_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240894054 - Disclosure - Retirement Benefits - Amounts Recognized in Other Comprehensive Loss (Details)", "role": "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinOtherComprehensiveLossDetails", "shortName": "Retirement Benefits - Amounts Recognized in Other Comprehensive Loss (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "ic82889430c4f4e129a2c2edb096de70f_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "ib07144fba0c94e348b70475a49935437_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240904055 - Disclosure - Retirement Benefits - Fair Value of Pension Plan Assets (Details)", "role": "http://www.elanco.com/role/RetirementBenefitsFairValueofPensionPlanAssetsDetails", "shortName": "Retirement Benefits - Fair Value of Pension Plan Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i4650c4640c0149bab2e0b7394a1e99a2_I20191231", "decimals": "-5", "lang": null, "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R102": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6dbdbc28858c464ea30e8e0241960a7f_D20180919-20180919", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240924056 - Disclosure - Earnings Per Share (Details)", "role": "http://www.elanco.com/role/EarningsPerShareDetails", "shortName": "Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6dbdbc28858c464ea30e8e0241960a7f_D20180919-20180919", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R103": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i4e4f13741c3b4e17beadfec40ac29dee_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionDueFromToRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240954057 - Disclosure - Related Party Agreements and Transactions - Amounts Due From/(Due To) Lilly (Details)", "role": "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAmountsDueFromDueToLillyDetails", "shortName": "Related Party Agreements and Transactions - Amounts Due From/(Due To) Lilly (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i4e4f13741c3b4e17beadfec40ac29dee_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionDueFromToRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R104": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i4ee2ebf3c504426789a0f0c24ae84e74_D20180924-20180924", "decimals": "-5", "first": true, "lang": null, "name": "elan:StockholdersEquitySeparationAdjustments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240964058 - Disclosure - Related Party Agreements and Transactions - Narrative (Details)", "role": "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails", "shortName": "Related Party Agreements and Transactions - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "ie16f4c6fd2b9477b985e260a37f70494_D20170101-20171231", "decimals": "-5", "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R105": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i3d82053b8a52401c880681f0f75f75c2_D20180101-20181231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240974059 - Disclosure - Related Party Agreements and Transactions - Allocation of Services (Details)", "role": "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAllocationofServicesDetails", "shortName": "Related Party Agreements and Transactions - Allocation of Services (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i3d82053b8a52401c880681f0f75f75c2_D20180101-20181231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R106": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i32b346713216428cbe7cfbddbe71cd5e_D20191001-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241004060 - Disclosure - Selected Quarterly Data (unaudited) (Details)", "role": "http://www.elanco.com/role/SelectedQuarterlyDataunauditedDetails", "shortName": "Selected Quarterly Data (unaudited) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i32b346713216428cbe7cfbddbe71cd5e_D20191001-20191231", "decimals": "-5", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R107": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i4283f0014c0c41e09d51f540cead1695_D20180101-20181231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241034061 - Disclosure - Subsequent Events - Narrative (Details)", "role": "http://www.elanco.com/role/SubsequentEventsNarrativeDetails", "shortName": "Subsequent Events - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i434d3ff8ef774f69b6094ff2adc49b1c_D20200101-20200131", "decimals": "-6", "lang": null, "name": "us-gaap:ProceedsFromDivestitureOfBusinesses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R108": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241044062 - Disclosure - Subsequent Events - Divestitures (Details)", "role": "http://www.elanco.com/role/SubsequentEventsDivestituresDetails", "shortName": "Subsequent Events - Divestitures (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i4de6a271282a45408d2548690fdf34e4_I20191231", "decimals": "-5", "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210071004 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.elanco.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210101005 - Disclosure - Revenue", "role": "http://www.elanco.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210151006 - Disclosure - Acquisitions", "role": "http://www.elanco.com/role/Acquisitions", "shortName": "Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210191007 - Disclosure - Asset Impairment, Restructuring and Other Special Charges", "role": "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialCharges", "shortName": "Asset Impairment, Restructuring and Other Special Charges", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210231008 - Disclosure - Inventories", "role": "http://www.elanco.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210271009 - Disclosure - Debt", "role": "http://www.elanco.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210311010 - Disclosure - Financial Instruments and Fair Value", "role": "http://www.elanco.com/role/FinancialInstrumentsandFairValue", "shortName": "Financial Instruments and Fair Value", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210351011 - Disclosure - Goodwill and Intangibles", "role": "http://www.elanco.com/role/GoodwillandIntangibles", "shortName": "Goodwill and Intangibles", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210441013 - Disclosure - Property and Equipment", "role": "http://www.elanco.com/role/PropertyandEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010002 - Statement - Consolidated and Combined Statements of Operations", "role": "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations", "shortName": "Consolidated and Combined Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": "-5", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210491014 - Disclosure - Leases", "role": "http://www.elanco.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210551015 - Disclosure - Stock-Based Compensation", "role": "http://www.elanco.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210621016 - Disclosure - Income Taxes", "role": "http://www.elanco.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210731017 - Disclosure - Commitments and Contingencies", "role": "http://www.elanco.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210751018 - Disclosure - Geographic Information", "role": "http://www.elanco.com/role/GeographicInformation", "shortName": "Geographic Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210791019 - Disclosure - Retirement Benefits", "role": "http://www.elanco.com/role/RetirementBenefits", "shortName": "Retirement Benefits", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210911020 - Disclosure - Earnings Per Share", "role": "http://www.elanco.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210931021 - Disclosure - Related Party Agreements and Transactions", "role": "http://www.elanco.com/role/RelatedPartyAgreementsandTransactions", "shortName": "Related Party Agreements and Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210981022 - Disclosure - Selected Quarterly Data (unaudited)", "role": "http://www.elanco.com/role/SelectedQuarterlyDataunaudited", "shortName": "Selected Quarterly Data (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "211011023 - Disclosure - Subsequent Events", "role": "http://www.elanco.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020003 - Statement - Consolidated and Combined Statements of Comprehensive Income (Loss)", "role": "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofComprehensiveIncomeLoss", "shortName": "Consolidated and Combined Statements of Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": "-5", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "220042001 - Disclosure - Basis of Presentation (Policies)", "role": "http://www.elanco.com/role/BasisofPresentationPolicies", "shortName": "Basis of Presentation (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230083001 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.elanco.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230113002 - Disclosure - Revenue (Tables)", "role": "http://www.elanco.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230163003 - Disclosure - Acquisitions (Tables)", "role": "http://www.elanco.com/role/AcquisitionsTables", "shortName": "Acquisitions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230203004 - Disclosure - Asset Impairment, Restructuring and Other Special Charges (Tables)", "role": "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables", "shortName": "Asset Impairment, Restructuring and Other Special Charges (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230243005 - Disclosure - Inventories (Tables)", "role": "http://www.elanco.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230283006 - Disclosure - Debt (Tables)", "role": "http://www.elanco.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230323007 - Disclosure - Financial Instruments and Fair Value (Tables)", "role": "http://www.elanco.com/role/FinancialInstrumentsandFairValueTables", "shortName": "Financial Instruments and Fair Value (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230363008 - Disclosure - Goodwill and Intangibles (Tables)", "role": "http://www.elanco.com/role/GoodwillandIntangiblesTables", "shortName": "Goodwill and Intangibles (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230453010 - Disclosure - Property and Equipment (Tables)", "role": "http://www.elanco.com/role/PropertyandEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030004 - Statement - Consolidated Balance Sheets", "role": "http://www.elanco.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "-5", "lang": null, "name": "us-gaap:OtherReceivablesNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230503011 - Disclosure - Leases (Tables)", "role": "http://www.elanco.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230563012 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://www.elanco.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230633013 - Disclosure - Income Taxes (Tables)", "role": "http://www.elanco.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230763014 - Disclosure - Geographic Information (Tables)", "role": "http://www.elanco.com/role/GeographicInformationTables", "shortName": "Geographic Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230803015 - Disclosure - Retirement Benefits (Tables)", "role": "http://www.elanco.com/role/RetirementBenefitsTables", "shortName": "Retirement Benefits (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230943016 - Disclosure - Related Party Agreements and Transactions (Tables)", "role": "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsTables", "shortName": "Related Party Agreements and Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230993017 - Disclosure - Selected Quarterly Data (unaudited) (Tables)", "role": "http://www.elanco.com/role/SelectedQuarterlyDataunauditedTables", "shortName": "Selected Quarterly Data (unaudited) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "231023018 - Disclosure - Subsequent Events (Tables)", "role": "http://www.elanco.com/role/SubsequentEventsTables", "shortName": "Subsequent Events (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "0", "first": true, "lang": null, "name": "elan:NumberOfBrandsInEntitysPortfolio", "reportCount": 1, "unique": true, "unitRef": "brand", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240024001 - Disclosure - Nature of Business and Organization (Details)", "role": "http://www.elanco.com/role/NatureofBusinessandOrganizationDetails", "shortName": "Nature of Business and Organization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "0", "first": true, "lang": null, "name": "elan:NumberOfBrandsInEntitysPortfolio", "reportCount": 1, "unique": true, "unitRef": "brand", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i4ee2ebf3c504426789a0f0c24ae84e74_D20180924-20180924", "decimals": "-5", "first": true, "lang": null, "name": "elan:StockholdersEquitySeparationAdjustments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240064002 - Disclosure - Impact of Separation (Details)", "role": "http://www.elanco.com/role/ImpactofSeparationDetails", "shortName": "Impact of Separation (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R5": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040005 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.elanco.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "elan:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240094003 - Disclosure - Summary of Significant Accounting Policies (Details)", "role": "http://www.elanco.com/role/SummaryofSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "lang": "en-US", "name": "us-gaap:RevenuePerformanceObligationDescriptionOfTiming", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "elan:ContractWithCustomerRebatePeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240124004 - Disclosure - Revenue - Narrative (Details)", "role": "http://www.elanco.com/role/RevenueNarrativeDetails", "shortName": "Revenue - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "elan:ContractWithCustomerRebatePeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i88c2f373d5e4446db3412109d97163c7_I20181231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240134005 - Disclosure - Revenue - Summary of Activity in Sales Rebates and Discounts Liability (Details)", "role": "http://www.elanco.com/role/RevenueSummaryofActivityinSalesRebatesandDiscountsLiabilityDetails", "shortName": "Revenue - Summary of Activity in Sales Rebates and Discounts Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i300c5d6588df449f837c1722eb93c190_I20171231", "decimals": "-5", "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240144006 - Disclosure - Revenue - Disaggregation of Revenue (Details)", "role": "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails", "shortName": "Revenue - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "ic673b6e145f44faeaa7079327d55018f_D20190718-20190718", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240174007 - Disclosure - Acquisitions - Narrative (Details)", "role": "http://www.elanco.com/role/AcquisitionsNarrativeDetails", "shortName": "Acquisitions - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "ic673b6e145f44faeaa7079327d55018f_D20190718-20190718", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240184008 - Disclosure - Acquisitions - Summary of Amounts Recognized for Assets Acquired and Liabilities Assumed (Details)", "role": "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "shortName": "Acquisitions - Summary of Amounts Recognized for Assets Acquired and Liabilities Assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "ie9a52f8b3b644f4d8c1740a81c929abd_I20190718", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240214009 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Total Charges Related to Asset Impairment, Restructuring and Other Special Charges (Details)", "role": "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails", "shortName": "Asset Impairment, Restructuring and Other Special Charges - Total Charges Related to Asset Impairment, Restructuring and Other Special Charges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i88c2f373d5e4446db3412109d97163c7_I20181231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240224010 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Summary of Activity in Reserves (Details)", "role": "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails", "shortName": "Asset Impairment, Restructuring and Other Special Charges - Summary of Activity in Reserves (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i300c5d6588df449f837c1722eb93c190_I20171231", "decimals": "-5", "lang": null, "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240254011 - Disclosure - Inventories - Schedule of Inventories (Details)", "role": "http://www.elanco.com/role/InventoriesScheduleofInventoriesDetails", "shortName": "Inventories - Schedule of Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i88c2f373d5e4446db3412109d97163c7_I20181231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LIFOInventoryAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240264012 - Disclosure - Inventories - Narrative (Details)", "role": "http://www.elanco.com/role/InventoriesNarrativeDetails", "shortName": "Inventories - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i88c2f373d5e4446db3412109d97163c7_I20181231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LIFOInventoryAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050006 - Statement - Consolidated and Combined Statement of Cash Flows", "role": "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows", "shortName": "Consolidated and Combined Statement of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": "-5", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240294013 - Disclosure - Debt - Schedule of Long-term Debt (Details)", "role": "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "shortName": "Debt - Schedule of Long-term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "ic4cd05d50830474da4d7b2df20891a2f_I20180905", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240304014 - Disclosure - Debt - Narrative (Details)", "role": "http://www.elanco.com/role/DebtNarrativeDetails", "shortName": "Debt - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "id5cd701ac68f4353b8ca2cfc1a7b298a_I20191231", "decimals": "INF", "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240334015 - Disclosure - Financial Instruments and Fair Value - Narrative (Details)", "role": "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "shortName": "Financial Instruments and Fair Value - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i14089d7eacd349caa7b4de33320be374_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240344016 - Disclosure - Financial Instruments and Fair Value - Summary of Fair Value Information (Details)", "role": "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails", "shortName": "Financial Instruments and Fair Value - Summary of Fair Value Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i14089d7eacd349caa7b4de33320be374_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240374017 - Disclosure - Goodwill and Intangibles - Narrative (Details)", "role": "http://www.elanco.com/role/GoodwillandIntangiblesNarrativeDetails", "shortName": "Goodwill and Intangibles - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillImpairmentLoss", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": "INF", "lang": null, "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240384018 - Disclosure - Goodwill and Intangibles - Components of Intangible Assets Other Than Goodwill (Details)", "role": "http://www.elanco.com/role/GoodwillandIntangiblesComponentsofIntangibleAssetsOtherThanGoodwillDetails", "shortName": "Goodwill and Intangibles - Components of Intangible Assets Other Than Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i0799fe0af09d4823b03e02088e2e23be_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240394019 - Disclosure - Goodwill and Intangibles - Remaining Weighted Average Amortization Periods (Details)", "role": "http://www.elanco.com/role/GoodwillandIntangiblesRemainingWeightedAverageAmortizationPeriodsDetails", "shortName": "Goodwill and Intangibles - Remaining Weighted Average Amortization Periods (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i0799fe0af09d4823b03e02088e2e23be_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240404020 - Disclosure - Goodwill and Intangibles - Estimated Amortization Expense (Details)", "role": "http://www.elanco.com/role/GoodwillandIntangiblesEstimatedAmortizationExpenseDetails", "shortName": "Goodwill and Intangibles - Estimated Amortization Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i9a38f73b89874c32befe802d8ffbb191_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240464022 - Disclosure - Property and Equipment - Narrative (Details)", "role": "http://www.elanco.com/role/PropertyandEquipmentNarrativeDetails", "shortName": "Property and Equipment - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i9a38f73b89874c32befe802d8ffbb191_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i88c2f373d5e4446db3412109d97163c7_I20181231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240474023 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)", "role": "http://www.elanco.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails", "shortName": "Property and Equipment - Schedule of Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i88c2f373d5e4446db3412109d97163c7_I20181231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "idc35a1bd28a34ea1b80645ca7177cdd6_I20161231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060007 - Statement - Consolidated and Combined Statements of Equity", "role": "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity", "shortName": "Consolidated and Combined Statements of Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "idc35a1bd28a34ea1b80645ca7177cdd6_I20161231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRentExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240484024 - Disclosure - Property and Equipment - Depreciation Expense and Rental Expense for All Leases (Details)", "role": "http://www.elanco.com/role/PropertyandEquipmentDepreciationExpenseandRentalExpenseforAllLeasesDetails", "shortName": "Property and Equipment - Depreciation Expense and Rental Expense for All Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRentExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i17d977a9db084403b0283885c1b8a22a_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "elan:LesseeOperatingLeaseRemainingLeaseTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240514025 - Disclosure - Leases - Narrative (Details)", "role": "http://www.elanco.com/role/LeasesNarrativeDetails", "shortName": "Leases - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i17d977a9db084403b0283885c1b8a22a_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "elan:LesseeOperatingLeaseRemainingLeaseTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240524026 - Disclosure - Leases - Impact of Operating Leases to Condensed Consolidated Financial Statements (Details)", "role": "http://www.elanco.com/role/LeasesImpactofOperatingLeasestoCondensedConsolidatedFinancialStatementsDetails", "shortName": "Leases - Impact of Operating Leases to Condensed Consolidated Financial Statements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "elan:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240534027 - Disclosure - Leases - Supplemental Balance Sheet Information Related to Operating Leases (Details)", "role": "http://www.elanco.com/role/LeasesSupplementalBalanceSheetInformationRelatedtoOperatingLeasesDetails", "shortName": "Leases - Supplemental Balance Sheet Information Related to Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "elan:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "-5", "lang": null, "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240544028 - Disclosure - Leases - Annual Minimum Lease Payments of Operating Lease Liabilities (Details)", "role": "http://www.elanco.com/role/LeasesAnnualMinimumLeasePaymentsofOperatingLeaseLiabilitiesDetails", "shortName": "Leases - Annual Minimum Lease Payments of Operating Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240574029 - Disclosure - Stock-Based Compensation - Narrative (Details)", "role": "http://www.elanco.com/role/StockBasedCompensationNarrativeDetails", "shortName": "Stock-Based Compensation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6f941d0f8ceb484a83722c8ef2e5552a_I20191231", "decimals": "-5", "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i1337913f4b2e4445881a9c717aaabe78_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240584030 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expenses (Details)", "role": "http://www.elanco.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpensesDetails", "shortName": "Stock-Based Compensation - Schedule of Stock-Based Compensation Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i1337913f4b2e4445881a9c717aaabe78_D20190101-20191231", "decimals": "-5", "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i144a7277eaf64e82be1f9edf2b60b915_I20181231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240594031 - Disclosure - Stock-Based Compensation - Schedule of Restricted Stock Unit and Performance Award Activity (Details)", "role": "http://www.elanco.com/role/StockBasedCompensationScheduleofRestrictedStockUnitandPerformanceAwardActivityDetails", "shortName": "Stock-Based Compensation - Schedule of Restricted Stock Unit and Performance Award Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "ie9607a3cfbb048588b2bed72667501b5_D20190101-20191231", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "ibaaeef4cb8ae4f1bbbf6c36406fbf5cd_D20190101-20191231", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240604032 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used (Details)", "role": "http://www.elanco.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails", "shortName": "Stock-Based Compensation - Schedule of Assumptions Used (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "ibaaeef4cb8ae4f1bbbf6c36406fbf5cd_D20190101-20191231", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i88c2f373d5e4446db3412109d97163c7_I20181231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240614033 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity (Details)", "role": "http://www.elanco.com/role/StockBasedCompensationScheduleofStockOptionActivityDetails", "shortName": "Stock-Based Compensation - Schedule of Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210011001 - Disclosure - Nature of Business and Organization", "role": "http://www.elanco.com/role/NatureofBusinessandOrganization", "shortName": "Nature of Business and Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:TaxCreditCarryforwardAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240644034 - Disclosure - Income Taxes - Narrative (Details)", "role": "http://www.elanco.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:TaxCreditCarryforwardAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240654035 - Disclosure - Income Taxes - Composition of Income (Loss) Before Income Tax Expense (Benefit) (Details)", "role": "http://www.elanco.com/role/IncomeTaxesCompositionofIncomeLossBeforeIncomeTaxExpenseBenefitDetails", "shortName": "Income Taxes - Composition of Income (Loss) Before Income Tax Expense (Benefit) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240664036 - Disclosure - Income Taxes - Composition of Income Tax Expense (Benefit) (Details)", "role": "http://www.elanco.com/role/IncomeTaxesCompositionofIncomeTaxExpenseBenefitDetails", "shortName": "Income Taxes - Composition of Income Tax Expense (Benefit) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240674037 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)", "role": "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails", "shortName": "Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfValuationAllowanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "iec5ba68c443b44ba81fb4e301b387ac2_I20181231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240684038 - Disclosure - Income Taxes - Movements in the Valuation Allowance (Details)", "role": "http://www.elanco.com/role/IncomeTaxesMovementsintheValuationAllowanceDetails", "shortName": "Income Taxes - Movements in the Valuation Allowance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfValuationAllowanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i35350df1abda4021a443a32c26b1b4dc_I20171231", "decimals": "-5", "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeTaxesPaidNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240694039 - Disclosure - Income Taxes - Cash Payments of Income Taxes (Details)", "role": "http://www.elanco.com/role/IncomeTaxesCashPaymentsofIncomeTaxesDetails", "shortName": "Income Taxes - Cash Payments of Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeTaxesPaidNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240704040 - Disclosure - Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details)", "role": "http://www.elanco.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails", "shortName": "Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i88c2f373d5e4446db3412109d97163c7_I20181231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240714041 - Disclosure - Income Taxes - Reconciliation of Gross Unrecognized Tax Benefits (Details)", "role": "http://www.elanco.com/role/IncomeTaxesReconciliationofGrossUnrecognizedTaxBenefitsDetails", "shortName": "Income Taxes - Reconciliation of Gross Unrecognized Tax Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i86db48712a6440a7b78225e446224a6b_I20161231", "decimals": "-5", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240724042 - Disclosure - Income Taxes - Income Tax Expense (Benefit) Related to Interest and Penalties (Details)", "role": "http://www.elanco.com/role/IncomeTaxesIncomeTaxExpenseBenefitRelatedtoInterestandPenaltiesDetails", "shortName": "Income Taxes - Income Tax Expense (Benefit) Related to Interest and Penalties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LitigationReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240744043 - Disclosure - Commitments and Contingencies - Narrative (Details)", "role": "http://www.elanco.com/role/CommitmentsandContingenciesNarrativeDetails", "shortName": "Commitments and Contingencies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LitigationReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210031002 - Disclosure - Basis of Presentation", "role": "http://www.elanco.com/role/BasisofPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i6adb113754c34bb285522b938ceb1a0c_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240774044 - Disclosure - Geographic Information - Narrative (Details)", "role": "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "shortName": "Geographic Information - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i61676e6bd3364776975824de12f9291d_I20191231", "decimals": "-5", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i32b346713216428cbe7cfbddbe71cd5e_D20191001-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240784045 - Disclosure - Geographic Information - Revenue and Long-lived Assets by Selected Geographic Area Information (Details)", "role": "http://www.elanco.com/role/GeographicInformationRevenueandLonglivedAssetsbySelectedGeographicAreaInformationDetails", "shortName": "Geographic Information - Revenue and Long-lived Assets by Selected Geographic Area Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i300c5d6588df449f837c1722eb93c190_I20171231", "decimals": "-5", "lang": null, "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "ia177b1560d2748399acd6cd9b54a36d8_D20190901-20190930", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanPlanAmendments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240814046 - Disclosure - Retirement Benefits - Narrative (Details)", "role": "http://www.elanco.com/role/RetirementBenefitsNarrativeDetails", "shortName": "Retirement Benefits - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "ia177b1560d2748399acd6cd9b54a36d8_D20190901-20190930", "decimals": "-6", "lang": null, "name": "elan:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForPlanAmendmentPriorServiceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "ia177b1560d2748399acd6cd9b54a36d8_D20190901-20190930", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanPlanAmendments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240824047 - Disclosure - Retirement Benefits - Change in Benefit Obligation, Change in Plan Assets, and Funded Status (Details)", "role": "http://www.elanco.com/role/RetirementBenefitsChangeinBenefitObligationChangeinPlanAssetsandFundedStatusDetails", "shortName": "Retirement Benefits - Change in Benefit Obligation, Change in Plan Assets, and Funded Status (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "ic82889430c4f4e129a2c2edb096de70f_D20190101-20191231", "decimals": "-5", "lang": null, "name": "us-gaap:DefinedBenefitPlanActuarialGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240834048 - Disclosure - Retirement Benefits - Amounts Recognized in Combined Balance Sheet (Details)", "role": "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinCombinedBalanceSheetDetails", "shortName": "Retirement Benefits - Amounts Recognized in Combined Balance Sheet (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "ib07144fba0c94e348b70475a49935437_I20191231", "decimals": "-5", "lang": null, "name": "us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240844049 - Disclosure - Retirement Benefits - Weighted-Average Assumptions Related to Pension Plans (Details)", "role": "http://www.elanco.com/role/RetirementBenefitsWeightedAverageAssumptionsRelatedtoPensionPlansDetails", "shortName": "Retirement Benefits - Weighted-Average Assumptions Related to Pension Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i2ba28da1dba044be87fe5fc95eb69168_I20191231", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "ib07144fba0c94e348b70475a49935437_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240854050 - Disclosure - Retirement Benefits - Schedule of Expected Benefit Payments (Details)", "role": "http://www.elanco.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsDetails", "shortName": "Retirement Benefits - Schedule of Expected Benefit Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "ib07144fba0c94e348b70475a49935437_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "ib07144fba0c94e348b70475a49935437_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240864051 - Disclosure - Retirement Benefits - Projected Benefit Obligations in Excess of Plan Assets (Details)", "role": "http://www.elanco.com/role/RetirementBenefitsProjectedBenefitObligationsinExcessofPlanAssetsDetails", "shortName": "Retirement Benefits - Projected Benefit Obligations in Excess of Plan Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "ib07144fba0c94e348b70475a49935437_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "ib07144fba0c94e348b70475a49935437_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240874052 - Disclosure - Retirement Benefits - Accumulated Benefit Obligations in Excess of Plan Assets (Details)", "role": "http://www.elanco.com/role/RetirementBenefitsAccumulatedBenefitObligationsinExcessofPlanAssetsDetails", "shortName": "Retirement Benefits - Accumulated Benefit Obligations in Excess of Plan Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "ib07144fba0c94e348b70475a49935437_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "ic82889430c4f4e129a2c2edb096de70f_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240884053 - Disclosure - Retirement Benefits - Net Pension Expense (Details)", "role": "http://www.elanco.com/role/RetirementBenefitsNetPensionExpenseDetails", "shortName": "Retirement Benefits - Net Pension Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "ic82889430c4f4e129a2c2edb096de70f_D20190101-20191231", "decimals": "-5", "lang": null, "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9999": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20191231.htm", "contextRef": "i05a04894235647cebe6e10309c9c985a_I20180101", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - elan-20191231.htm", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - elan-20191231.htm", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 116, "tag": { "country_GB": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED KINGDOM", "terseLabel": "United Kingdom" } } }, "localname": "GB", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationRevenueandLonglivedAssetsbySelectedGeographicAreaInformationDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationRevenueandLonglivedAssetsbySelectedGeographicAreaInformationDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "If the value is true, then the document is an amendment to previously-filed/accepted document.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.elanco.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.elanco.com/role/DocumentandEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.elanco.com/role/DocumentandEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.elanco.com/role/DocumentandEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.elanco.com/role/DocumentandEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.elanco.com/role/DocumentandEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r554" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.elanco.com/role/DocumentandEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.elanco.com/role/DocumentandEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.elanco.com/role/DocumentandEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.elanco.com/role/EarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r554" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.elanco.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r554" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.elanco.com/role/DocumentandEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.elanco.com/role/DocumentandEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r554" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.elanco.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r554" ], "lang": { "en-US": { "role": { "documentation": "Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.elanco.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r554" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.elanco.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.elanco.com/role/DocumentandEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well Known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.elanco.com/role/DocumentandEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.elanco.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "elan_A3.912SeniorNotesDue2021Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "3.912% Senior Notes Due 2021 [Member]", "label": "3.912% Senior Notes Due 2021 [Member]", "terseLabel": "3.912% Senior Notes due 2021" } } }, "localname": "A3.912SeniorNotesDue2021Member", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "elan_A4.272SeniorNotesDue2023Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "4.272% Senior Notes Due 2023 [Member]", "label": "4.272% Senior Notes Due 2023 [Member]", "terseLabel": "4.272% Senior Notes due 2023" } } }, "localname": "A4.272SeniorNotesDue2023Member", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "elan_A4.9SeniorNotesDue2028Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "4.9% Senior Notes Due 2028 [Member]", "label": "4.9% Senior Notes Due 2028 [Member]", "terseLabel": "4.900% Senior Notes due 2028" } } }, "localname": "A4.9SeniorNotesDue2028Member", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "elan_A500SeniorAmortizingNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "5.00% Senior Amortizing Notes", "label": "5.00% Senior Amortizing Notes [Member]", "terseLabel": "5.00% Senior Amortizing Notes" } } }, "localname": "A500SeniorAmortizingNotesMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_APICShareBasedPaymentArrangementIncreaseForCostRecognitionAcceleratedVesting": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Accelerated Vesting", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Accelerated Vesting", "terseLabel": "Accelerated vesting of equity awards" } } }, "localname": "APICShareBasedPaymentArrangementIncreaseForCostRecognitionAcceleratedVesting", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "elan_AratanaTherapeuticsInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Aratana Therapeutics, Inc. [Member]", "label": "Aratana Therapeutics, Inc. [Member]", "terseLabel": "Aratana Therapeutics, Inc." } } }, "localname": "AratanaTherapeuticsInc.Member", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/AcquisitionsNarrativeDetails", "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_AssetImpairmentChargesIncludingInventoryWriteDown": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Asset Impairment Charges, Including Inventory Write-Down", "label": "Asset Impairment Charges, Including Inventory Write-Down", "verboseLabel": "Asset impairment charges" } } }, "localname": "AssetImpairmentChargesIncludingInventoryWriteDown", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "elan_AssetsAndLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assets And Liabilities, Lessee", "label": "Assets And Liabilities, Lessee [Table Text Block]", "terseLabel": "Supplemental Balance Sheet Information Related to Operating Leases" } } }, "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "elan_BayerAnimalBusinessMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bayer Animal Business", "label": "Bayer Animal Business [Member]", "terseLabel": "Bayer Animal Business" } } }, "localname": "BayerAnimalBusinessMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/AcquisitionsNarrativeDetails", "http://www.elanco.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_BoehringerIngelheimVetmedicaInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boehringer Ingelheim Vetmedica, Inc. [Member]", "label": "Boehringer Ingelheim Vetmedica, Inc. [Member]", "terseLabel": "BIVIVP", "verboseLabel": "Boehringer Ingelheim Vetmedica, Inc." } } }, "localname": "BoehringerIngelheimVetmedicaInc.Member", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/AcquisitionsNarrativeDetails", "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_BridgeFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bridge Facility", "label": "Bridge Facility [Member]", "terseLabel": "Bridge Facility" } } }, "localname": "BridgeFacilityMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_BusinessCombinationConsiderationTransferredSettlementOfAccountsReceivable": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Consideration Transferred, Settlement Of Accounts Receivable", "label": "Business Combination, Consideration Transferred, Settlement Of Accounts Receivable", "terseLabel": "Settlement of accounts receivable" } } }, "localname": "BusinessCombinationConsiderationTransferredSettlementOfAccountsReceivable", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_BusinessCombinationContingentConsiderationAmountPerSharePaidUponSpecifiedMergerAgreementMilestones": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Combination, Contingent Consideration, Amount Per Share Paid Upon Specified Merger Agreement Milestones", "label": "Business Combination, Contingent Consideration, Amount Per Share Paid Upon Specified Merger Agreement Milestones", "terseLabel": "Business acquisition (usd per share)" } } }, "localname": "BusinessCombinationContingentConsiderationAmountPerSharePaidUponSpecifiedMergerAgreementMilestones", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "elan_BusinessCombinationProFormaInformationEarningsOrLossBeforeIncomeTaxesOfAcquireeSinceAcquisitionDateActual": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Pro Forma Information, Earnings or Loss Before Income Taxes of Acquiree since Acquisition Date, Actual", "label": "Business Combination, Pro Forma Information, Earnings or Loss Before Income Taxes of Acquiree since Acquisition Date, Actual", "terseLabel": "Pro forma combined income before income taxes" } } }, "localname": "BusinessCombinationProFormaInformationEarningsOrLossBeforeIncomeTaxesOfAcquireeSinceAcquisitionDateActual", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsAndOtherLiabilitiesNet": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Assets And Other Liabilities, Net", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Assets And Other Liabilities, Net", "terseLabel": "Other assets and liabilities - net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsAndOtherLiabilitiesNet", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "elan_ChangeInContractWithCustomerLiabilityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Change In Contract With Customer, Liability [Roll Forward]", "label": "Change In Contract With Customer, Liability [Roll Forward]", "terseLabel": "Change In Contract With Customer, Liability [Roll Forward]" } } }, "localname": "ChangeInContractWithCustomerLiabilityRollForward", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/RevenueSummaryofActivityinSalesRebatesandDiscountsLiabilityDetails" ], "xbrltype": "stringItemType" }, "elan_CompanionAnimalDiseasePreventionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Companion Animal Disease Prevention [Member]", "label": "Companion Animal Disease Prevention [Member]", "terseLabel": "Companion Animal Disease Prevention" } } }, "localname": "CompanionAnimalDiseasePreventionMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "elan_CompanionAnimalTherapeuticsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Companion Animal Therapeutics [Member]", "label": "Companion Animal Therapeutics [Member]", "terseLabel": "Companion Animal Therapeutics" } } }, "localname": "CompanionAnimalTherapeuticsMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "elan_ContractWithCustomerLiabilityIncreaseFromCashReceipts": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contract With Customer, Liability, Increase From Cash Receipts", "label": "Contract With Customer, Liability, Increase From Cash Receipts", "negatedTerseLabel": "Payments" } } }, "localname": "ContractWithCustomerLiabilityIncreaseFromCashReceipts", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/RevenueSummaryofActivityinSalesRebatesandDiscountsLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "elan_ContractWithCustomerLiabilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contract With Customer, Liability [Member]", "label": "Contract With Customer, Liability [Member]", "terseLabel": "Sales rebates and discounts, liability" } } }, "localname": "ContractWithCustomerLiabilityMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_ContractWithCustomerRebatePeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contract With Customer, Rebate Period", "label": "Contract With Customer, Rebate Period", "terseLabel": "Rebate period" } } }, "localname": "ContractWithCustomerRebatePeriod", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "durationItemType" }, "elan_CustomerAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer A [Member]", "label": "Customer A [Member]", "terseLabel": "Single Customer" } } }, "localname": "CustomerAMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_DebtInstrumentPeriodicPaymentPrincipalPercentageOfFaceAmountLessPrepayments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Periodic Payment, Principal, Percentage Of Face Amount Less Prepayments", "label": "Debt Instrument, Periodic Payment, Principal, Percentage Of Face Amount Less Prepayments", "terseLabel": "Quarterly principal payments percentage" } } }, "localname": "DebtInstrumentPeriodicPaymentPrincipalPercentageOfFaceAmountLessPrepayments", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "elan_DeferredTaxAssetsOperatingLeaseRightOfUseLiabilities": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred Tax Assets, Operating Lease Right-Of-Use Liabilities", "label": "Deferred Tax Assets, Operating Lease Right-Of-Use Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "DeferredTaxAssetsOperatingLeaseRightOfUseLiabilities", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "elan_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Deferred Tax Liabilities, Operating Lease Right-Of-Use Assets", "label": "Deferred Tax Liabilities, Operating Lease Right-Of-Use Assets", "negatedLabel": "Right-of-use assets" } } }, "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "elan_DefinedBenefitPlanAmountsForAssetLiabilityAndAccumulatedOtherComprehensiveIncomeLossBeforeTaxRecognizedInStatementOfFinancialPosition": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinCombinedBalanceSheetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.elanco.com/role/RetirementBenefitsChangeinBenefitObligationChangeinPlanAssetsandFundedStatusDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Defined Benefit Plan, Amounts For Asset (Liability) And Accumulated Other Comprehensive (Income) Loss, Before Tax, Recognized In Statement Of Financial Position", "label": "Defined Benefit Plan, Amounts For Asset (Liability) And Accumulated Other Comprehensive (Income) Loss, Before Tax, Recognized In Statement Of Financial Position", "totalLabel": "Net amount recognized" } } }, "localname": "DefinedBenefitPlanAmountsForAssetLiabilityAndAccumulatedOtherComprehensiveIncomeLossBeforeTaxRecognizedInStatementOfFinancialPosition", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinCombinedBalanceSheetDetails", "http://www.elanco.com/role/RetirementBenefitsChangeinBenefitObligationChangeinPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "elan_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForPlanAmendmentChangesInCertainAssumptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment, Changes In Certain Assumptions", "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment, Changes In Certain Assumptions", "negatedLabel": "Decrease for plan amendment related to other costs and losses" } } }, "localname": "DefinedBenefitPlanBenefitObligationIncreaseDecreaseForPlanAmendmentChangesInCertainAssumptions", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForPlanAmendmentPriorServiceCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment, Prior Service Costs", "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment, Prior Service Costs", "negatedLabel": "Decreased in prior service costs" } } }, "localname": "DefinedBenefitPlanBenefitObligationIncreaseDecreaseForPlanAmendmentPriorServiceCosts", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_DefinedBenefitPlanEquityLikeFundsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Defined Benefit Plan, Equity-Like Funds [Member]", "label": "Defined Benefit Plan, Equity-Like Funds [Member]", "terseLabel": "Equity-like funds" } } }, "localname": "DefinedBenefitPlanEquityLikeFundsMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "elan_DefinedBenefitPlanNumberOfPlans": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Defined Benefit Plan, Number Of Plans", "label": "Defined Benefit Plan, Number Of Plans", "terseLabel": "Number of plans" } } }, "localname": "DefinedBenefitPlanNumberOfPlans", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "integerItemType" }, "elan_DefinedBenefitPlanPlanAssetsConcentrationOfRiskPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Defined Benefit Plan, Plan Assets, Concentration of Risk, Percentage", "label": "Defined Benefit Plan, Plan Assets, Concentration Of Risk, Percentage", "terseLabel": "Percentage of plan assets in Switzerland pension plans" } } }, "localname": "DefinedBenefitPlanPlanAssetsConcentrationOfRiskPercentage", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "percentItemType" }, "elan_DerivativeInstrumentsExpectedAnnualContraInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Derivative Instruments, Expected Annual Contra Interest", "label": "Derivative Instruments, Expected Annual Contra Interest", "terseLabel": "Expected cash and contra interest per year" } } }, "localname": "DerivativeInstrumentsExpectedAnnualContraInterest", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_DocumentAndEntityInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Document And Entity Information [Abstract]", "label": "Document And Entity Information [Abstract]", "terseLabel": "Document And Entity Information [Abstract]" } } }, "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.elanco.com/20191231", "xbrltype": "stringItemType" }, "elan_DomesticForeignAndStateTaxAuthoritiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Domestic, Foreign and State Tax Authorities [Member]", "label": "Domestic, Foreign and State Tax Authorities [Member]", "terseLabel": "International, State and Federal" } } }, "localname": "DomesticForeignAndStateTaxAuthoritiesMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_EffectiveIncomeTaxRateReconciliationAdditionsAndDeductionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Additions And Deductions [Abstract]", "label": "Effective Income Tax Rate Reconciliation, Additions And Deductions [Abstract]", "terseLabel": "Add (deduct):" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAdditionsAndDeductionsAbstract", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" ], "xbrltype": "stringItemType" }, "elan_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseEmployeeCompensation": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Employee Compensation", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Employee Compensation", "terseLabel": "Non-deductible employee compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseEmployeeCompensation", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "elan_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStockIssuanceCosts": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": { "order": 10.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Stock Issuance Costs", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Stock Issuance Costs", "terseLabel": "IPO and separation costs" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseStockIssuanceCosts", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "elan_ElancoAnimalHealthIncorporatedAndSubsidiariesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Elanco Animal Health Incorporated And Subsidiaries [Member]", "label": "Elanco Animal Health Incorporated And Subsidiaries [Member]", "terseLabel": "Elanco" } } }, "localname": "ElancoAnimalHealthIncorporatedAndSubsidiariesMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/EarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "elan_ElancoStockCompensationPlansMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Elanco Stock Compensation Plans", "label": "Elanco Stock Compensation Plans [Member]", "terseLabel": "Elanco Stock Compensation Plans" } } }, "localname": "ElancoStockCompensationPlansMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationNarrativeDetails", "http://www.elanco.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpensesDetails" ], "xbrltype": "domainItemType" }, "elan_EliLillyandCompanyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Eli Lilly and Company [Member]", "label": "Eli Lilly and Company [Member]", "terseLabel": "Lilly" } } }, "localname": "EliLillyandCompanyMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/EarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "elan_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": { "order": 1.0, "parentTag": "elan_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Finance Lease, Right-of-Use Asset, Before Accumulated Amortization", "label": "Finance Lease, Right-of-Use Asset, Before Accumulated Amortization", "terseLabel": "Finance lease asset" } } }, "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "elan_FixedIncomeSecuritiesDevelopedMarketsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fixed Income Securities, Developed Markets [Member]", "label": "Fixed Income Securities, Developed Markets [Member]", "terseLabel": "Developed markets" } } }, "localname": "FixedIncomeSecuritiesDevelopedMarketsMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "elan_FixedIncomeSecuritiesEmergingMarketsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fixed Income Securities, Emerging Markets [Member]", "label": "Fixed Income Securities, Emerging Markets [Member]", "terseLabel": "Emerging markets" } } }, "localname": "FixedIncomeSecuritiesEmergingMarketsMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "elan_FoodAnimalFutureProteinAndHealthMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Food Animal Future Protein And Health [Member]", "label": "Food Animal Future Protein And Health [Member]", "terseLabel": "Food Animal Future Protein & Health" } } }, "localname": "FoodAnimalFutureProteinAndHealthMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "elan_FoodAnimalRuminantsAndSwineMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Food Animal Ruminants And Swine [Member]", "label": "Food Animal Ruminants And Swine [Member]", "terseLabel": "Food Animal Ruminants Swine" } } }, "localname": "FoodAnimalRuminantsAndSwineMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "elan_GalliprantMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Galliprant [Member]", "label": "Galliprant [Member]", "terseLabel": "Galliprant" } } }, "localname": "GalliprantMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_IntellectualPropertyAndTechnologyLicenseAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intellectual Property And Technology License Agreement [Member]", "label": "Intellectual Property And Technology License Agreement [Member]", "terseLabel": "Intellectual Property and Technology License Agreement" } } }, "localname": "IntellectualPropertyAndTechnologyLicenseAgreementMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Remaining Lease Term", "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Remaining lease terms" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "elan_LillysStockBasedCompensationProgramMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lilly's Stock-Based Compensation Program [Member]", "label": "Lilly's Stock-Based Compensation Program [Member]", "terseLabel": "Lilly's Stock-Based Compensation Program" } } }, "localname": "LillysStockBasedCompensationProgramMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_LocalCountryAssetPurchasesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local Country Asset Purchases [Member]", "label": "Local Country Asset Purchases [Member]", "terseLabel": "Local Country Asset Purchases" } } }, "localname": "LocalCountryAssetPurchasesMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAmountsDueFromDueToLillyDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_ManufacturingSupportMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Manufacturing Support [Member]", "label": "Manufacturing Support [Member]", "terseLabel": "Manufacturing Support" } } }, "localname": "ManufacturingSupportMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_MultiemployerPlansCostRecognized": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Multiemployer Plans, Cost Recognized", "label": "Multiemployer Plans, Cost Recognized", "terseLabel": "Multiemployer plans expense" } } }, "localname": "MultiemployerPlansCostRecognized", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_MultiemployerPlansSettlementAndCurtailments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Multiemployer Plans, Settlement And Curtailments", "label": "Multiemployer Plans, Settlement And Curtailments", "terseLabel": "Multiemployer plans, curtailment loss and special termination benefits" } } }, "localname": "MultiemployerPlansSettlementAndCurtailments", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_NetParentCompanyInvestmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Net Parent Company Investment [Member]", "label": "Net Parent Company Investment [Member]", "terseLabel": "Net Parent Company Investment" } } }, "localname": "NetParentCompanyInvestmentMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity" ], "xbrltype": "domainItemType" }, "elan_NoncontrollingInterestNumberOfSharesOwnedByParent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Noncontrolling Interest, Number Of Shares Owned By Parent", "label": "Noncontrolling Interest, Number Of Shares Owned By Parent", "terseLabel": "Common shares outstanding" } } }, "localname": "NoncontrollingInterestNumberOfSharesOwnedByParent", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "elan_NumberOfBrandsInEntitysPortfolio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number Of Brands In Entity's Portfolio", "label": "Number Of Brands In Entity's Portfolio", "terseLabel": "Number of brands in diverse portfolio (more than)" } } }, "localname": "NumberOfBrandsInEntitysPortfolio", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/NatureofBusinessandOrganizationDetails" ], "xbrltype": "integerItemType" }, "elan_OperatingLeaseOtherInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating Lease, Other Information", "label": "Operating Lease, Other Information [Abstract]", "terseLabel": "Other information" } } }, "localname": "OperatingLeaseOtherInformationAbstract", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/LeasesImpactofOperatingLeasestoCondensedConsolidatedFinancialStatementsDetails" ], "xbrltype": "stringItemType" }, "elan_OperatingLossCarryforwardsSeparationAdjustments": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating Loss Carryforwards, Separation Adjustments", "label": "Operating Loss Carryforwards, Separation Adjustments", "terseLabel": "Separation entries related to the removal of the net operating losses" } } }, "localname": "OperatingLossCarryforwardsSeparationAdjustments", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_OsurniaAndCapstarMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Osurnia and Capstar", "label": "Osurnia and Capstar [Member]", "terseLabel": "Osurnia and Capstar" } } }, "localname": "OsurniaAndCapstarMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/SubsequentEventsDivestituresDetails", "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_OtherAlternativeInvestmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Alternative Investments [Member]", "label": "Other Alternative Investments [Member]", "terseLabel": "Other Alternative Investments" } } }, "localname": "OtherAlternativeInvestmentsMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyTransactionAndTranslationGainLossBeforeTax": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinOtherComprehensiveLossDetails": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Other Comprehensive Income (Loss), Defined Benefit Plan, Foreign Currency Transaction And Translation Gain (Loss), Before Tax", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Foreign Currency Transaction And Translation Gain (Loss), Before Tax", "terseLabel": "Foreign currency exchange rate changes and other" } } }, "localname": "OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyTransactionAndTranslationGainLossBeforeTax", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "elan_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossNetOfTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Net Of Tax", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Net Of Tax", "terseLabel": "Gain (Loss) to AOCI, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossNetOfTax", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_OtherForeignCountriesNotSeparatelyDisclosedMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Foreign Countries Not Separately Disclosed [Member]", "label": "Other Foreign Countries Not Separately Disclosed [Member]", "terseLabel": "Other foreign countries" } } }, "localname": "OtherForeignCountriesNotSeparatelyDisclosedMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/GeographicInformationRevenueandLonglivedAssetsbySelectedGeographicAreaInformationDetails" ], "xbrltype": "domainItemType" }, "elan_OtherRelatedPartyActivitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Related Party Activities [Member]", "label": "Other Related Party Activities [Member]", "terseLabel": "Other Related Party Activities" } } }, "localname": "OtherRelatedPartyActivitiesMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAmountsDueFromDueToLillyDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_PaymentsOfSeparationRelatedCostsFinancingActivities": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments Of Separation Related Costs, Financing Activities", "label": "Payments Of Separation Related Costs, Financing Activities", "negatedLabel": "Consideration paid to Lilly in connection with the Separation (Note 1)" } } }, "localname": "PaymentsOfSeparationRelatedCostsFinancingActivities", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "elan_PrevtecMicrobiaInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Prevtec Microbia, Inc. [Member]", "label": "Prevtec Microbia, Inc. [Member]", "terseLabel": "Prevtec" } } }, "localname": "PrevtecMicrobiaInc.Member", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/AcquisitionsNarrativeDetails", "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_ProceedsFromPaymentsToTransactionsWithParent": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds From (Payments To) Transactions With Parent", "label": "Proceeds From (Payments To) Transactions With Parent", "terseLabel": "Other net transactions with Lilly" } } }, "localname": "ProceedsFromPaymentsToTransactionsWithParent", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "elan_ProductCategoryStrategicExitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product Category Strategic Exits", "label": "Product Category Strategic Exits [Member]", "terseLabel": "Strategic Exits" } } }, "localname": "ProductCategoryStrategicExitsMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "elan_ProductReturnConcentrationRiskMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product Return Concentration Risk [Member]", "label": "Product Return Concentration Risk [Member]", "terseLabel": "Product Return Concentration Risk" } } }, "localname": "ProductReturnConcentrationRiskMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": { "order": 2.0, "parentTag": "elan_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Property, Plant, And Equipment And Finance Lease Right-of-Use Asset, Accumulated Depreciation And Amortization", "label": "Property, Plant, And Equipment And Finance Lease Right-of-Use Asset, Accumulated Depreciation And Amortization", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "elan_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Property, Plant, And Equipment And Finance Lease Right-of-Use Asset, After Accumulated Depreciation And Amortization", "label": "Property, Plant, And Equipment And Finance Lease Right-of-Use Asset, After Accumulated Depreciation And Amortization", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "elan_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization", "totalLabel": "Property and equipment gross" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "elan_PurchaseContractConversionOfStockRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchase Contract Conversion Of Stock, Ratio", "label": "Purchase Contract Conversion Of Stock, Ratio", "terseLabel": "Purchase contract conversion of stock ratio" } } }, "localname": "PurchaseContractConversionOfStockRatio", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "pureItemType" }, "elan_PurchaseContractSharesIssuedUponConversion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchase Contract, Shares Issued Upon Conversion", "label": "Purchase Contract, Shares Issued Upon Conversion", "terseLabel": "Purchase contract, shares issued upon conversion" } } }, "localname": "PurchaseContractSharesIssuedUponConversion", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "elan_RelatedPartyTransactionNumberOfRenewalTerms": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Related Party Transaction, Number Of Renewal Terms", "label": "Related Party Transaction, Number Of Renewal Terms", "terseLabel": "Number of renewal terms" } } }, "localname": "RelatedPartyTransactionNumberOfRenewalTerms", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "integerItemType" }, "elan_RelatedPartyTransactionRenewalTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Related Party Transaction, Renewal Term", "label": "Related Party Transaction, Renewal Term", "terseLabel": "Extension term" } } }, "localname": "RelatedPartyTransactionRenewalTerm", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "durationItemType" }, "elan_RelatedPartyTransactionTermOfContract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Related Party Transaction, Term Of Contract", "label": "Related Party Transaction, Term Of Contract", "terseLabel": "Initial term" } } }, "localname": "RelatedPartyTransactionTermOfContract", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "durationItemType" }, "elan_RepaymentsOfLongTermDebtAccruedInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Repayments Of Long Term Debt, Accrued Interest", "label": "Repayments Of Long Term Debt, Accrued Interest", "terseLabel": "Repayments of debt, interest" } } }, "localname": "RepaymentsOfLongTermDebtAccruedInterest", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_RepaymentsOfLongTermDebtPrincipal": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Repayments Of Long-Term Debt, Principal", "label": "Repayments Of Long-Term Debt, Principal", "terseLabel": "Repayments of debt, principal" } } }, "localname": "RepaymentsOfLongTermDebtPrincipal", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_RestructuringReserveSeparationAdjustment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Restructuring Reserve, Separation Adjustment", "label": "Restructuring Reserve, Separation Adjustment", "terseLabel": "Separation adjustment" } } }, "localname": "RestructuringReserveSeparationAdjustment", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "monetaryItemType" }, "elan_SaleOfStockConsiderationReceivedOnTransactionPrepaidStockPurchaseContracts": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sale of Stock, Consideration Received on Transaction, Prepaid Stock Purchase Contracts", "label": "Sale of Stock, Consideration Received on Transaction, Prepaid Stock Purchase Contracts", "terseLabel": "Consideration received for prepaid stock purchase contracts" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransactionPrepaidStockPurchaseContracts", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_SeparationRelatedCostsFinancingActivitiesPaymentsMadeToDate": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Separation Related Costs, Financing Activities, Payments Made To Date", "label": "Separation Related Costs, Financing Activities, Payments Made To Date", "terseLabel": "Payments made to date" } } }, "localname": "SeparationRelatedCostsFinancingActivitiesPaymentsMadeToDate", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/NatureofBusinessandOrganizationDetails" ], "xbrltype": "monetaryItemType" }, "elan_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageIntrinsicValue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercised, Weighted Average Intrinsic Value", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercised, Weighted Average Intrinsic Value", "terseLabel": "Aggregate intrinsic value on exercise (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageIntrinsicValue", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "elan_SharesIssuedSharesShareBasedPaymentArrangementAfterForfeitureAcceleratedVesting": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture, Accelerated Vesting", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture, Accelerated Vesting", "terseLabel": "Accelerated vesting of equity awards (in shares)" } } }, "localname": "SharesIssuedSharesShareBasedPaymentArrangementAfterForfeitureAcceleratedVesting", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/AcquisitionsNarrativeDetails", "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity" ], "xbrltype": "sharesItemType" }, "elan_StockholdersEquityCapitalContributionFromParent": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Stockholders' Equity, Capital Contribution From Parent", "label": "Stockholders' Equity, Capital Contribution From Parent", "terseLabel": "Capital contribution from Lilly" } } }, "localname": "StockholdersEquityCapitalContributionFromParent", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "elan_StockholdersEquityConsiderationToParentInSeparation": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Stockholders' Equity, Consideration To Parent In Separation", "label": "Stockholders' Equity, Consideration To Parent In Separation", "terseLabel": "Consideration to Lilly in connection with Separation" } } }, "localname": "StockholdersEquityConsiderationToParentInSeparation", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "elan_StockholdersEquitySeparationAdjustments": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Stockholders' Equity, Separation Adjustments", "label": "Stockholders' Equity, Separation Adjustments", "terseLabel": "Separation adjustments" } } }, "localname": "StockholdersEquitySeparationAdjustments", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity", "http://www.elanco.com/role/ImpactofSeparationDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_StockholdersEquityTransfersToFromParent": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Stockholders' Equity, Transfers (To) From Parent", "label": "Stockholders' Equity, Transfers (To) From Parent", "terseLabel": "Transfers (to)/from Lilly, net", "verboseLabel": "Net transfers (to)/from Lilly" } } }, "localname": "StockholdersEquityTransfersToFromParent", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_TangibleEquityUnitMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible Equity Unit", "label": "Tangible Equity Unit [Member]", "terseLabel": "Tangible Equity Unit" } } }, "localname": "TangibleEquityUnitMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_TaxYear2020To2039Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tax Year 2020 To 2039 [Member]", "label": "Tax Year 2020 To 2039 [Member]", "terseLabel": "2020 To 2039" } } }, "localname": "TaxYear2020To2039Member", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_TermCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term Credit Facility [Member]", "label": "Term Credit Facility [Member]", "terseLabel": "Term credit facility", "verboseLabel": "Term credit facility" } } }, "localname": "TermCreditFacilityMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/ImpactofSeparationDetails", "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_TermLoanBCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term Loan B Credit Facility", "label": "Term Loan B Credit Facility [Member]", "terseLabel": "Term loan B credit facility" } } }, "localname": "TermLoanBCreditFacilityMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_TermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term Loan", "label": "Term Loan [Member]", "terseLabel": "Term Facility" } } }, "localname": "TermLoanMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_TollManufacturingArrangementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Toll Manufacturing Arrangement [Member]", "label": "Toll Manufacturing Arrangement [Member]", "terseLabel": "Toll Manufacturing Arrangement" } } }, "localname": "TollManufacturingArrangementMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_TransitionalServicesAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Transitional Services Agreement [Member]", "label": "Transitional Services Agreement [Member]", "terseLabel": "TSA", "verboseLabel": "Transitional Services Agreement" } } }, "localname": "TransitionalServicesAgreementMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAllocationofServicesDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAmountsDueFromDueToLillyDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_UnderwritingAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Underwriting Agreement", "label": "Underwriting Agreement [Member]", "terseLabel": "Underwriting Agreement" } } }, "localname": "UnderwritingAgreementMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Unrecognized Tax Benefits That Would Not Impact Effective Tax Rate", "label": "Unrecognized Tax Benefits That Would Not Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits that, if recognized, would not affect effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_VeocoxanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Veocoxan", "label": "Veocoxan [Member]", "terseLabel": "Veocoxan" } } }, "localname": "VeocoxanMember", "nsuri": "http://www.elanco.com/20191231", "presentation": [ "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r175", "r255", "r260", "r546" ], "lang": { "en-US": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangiblesNarrativeDetails", "http://www.elanco.com/role/LeasesNarrativeDetails", "http://www.elanco.com/role/PropertyandEquipmentNarrativeDetails", "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangiblesNarrativeDetails", "http://www.elanco.com/role/LeasesNarrativeDetails", "http://www.elanco.com/role/PropertyandEquipmentNarrativeDetails", "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.elanco.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.elanco.com/role/EarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r170", "r255", "r258", "r543", "r544" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangiblesNarrativeDetails", "http://www.elanco.com/role/LeasesNarrativeDetails", "http://www.elanco.com/role/PropertyandEquipmentNarrativeDetails", "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangiblesNarrativeDetails", "http://www.elanco.com/role/LeasesNarrativeDetails", "http://www.elanco.com/role/PropertyandEquipmentNarrativeDetails", "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAdjustmentMember": { "auth_ref": [ "r138", "r140", "r141", "r142" ], "lang": { "en-US": { "role": { "label": "Restatement Adjustment [Member]", "terseLabel": "Adjustment related to Separation" } } }, "localname": "RestatementAdjustmentMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesMovementsintheValuationAllowanceDetails", "http://www.elanco.com/role/IncomeTaxesReconciliationofGrossUnrecognizedTaxBenefitsDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restatement [Axis]", "terseLabel": "Restatement [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesMovementsintheValuationAllowanceDetails", "http://www.elanco.com/role/IncomeTaxesReconciliationofGrossUnrecognizedTaxBenefitsDetails" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restatement [Domain]", "terseLabel": "Restatement [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesMovementsintheValuationAllowanceDetails", "http://www.elanco.com/role/IncomeTaxesReconciliationofGrossUnrecognizedTaxBenefitsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioPreviouslyReportedMember": { "auth_ref": [ "r140", "r141", "r142" ], "lang": { "en-US": { "role": { "label": "Previously Reported [Member]", "terseLabel": "Previously Reported" } } }, "localname": "ScenarioPreviouslyReportedMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesMovementsintheValuationAllowanceDetails", "http://www.elanco.com/role/IncomeTaxesReconciliationofGrossUnrecognizedTaxBenefitsDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationRevenueandLonglivedAssetsbySelectedGeographicAreaInformationDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r174", "r255", "r259", "r545", "r550", "r552" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationRevenueandLonglivedAssetsbySelectedGeographicAreaInformationDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesMovementsintheValuationAllowanceDetails", "http://www.elanco.com/role/IncomeTaxesReconciliationofGrossUnrecognizedTaxBenefitsDetails" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureTable": { "auth_ref": [ "r135" ], "lang": { "en-US": { "role": { "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureTable", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesMovementsintheValuationAllowanceDetails", "http://www.elanco.com/role/IncomeTaxesReconciliationofGrossUnrecognizedTaxBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r474" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "Accounting Standards Update 2016-02" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrent": { "auth_ref": [ "r44", "r132", "r492", "r493", "r494" ], "calculation": { "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Related Parties, Current", "terseLabel": "Payable to Lilly (Note 20)" } } }, "localname": "AccountsPayableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r7", "r26", "r177", "r178", "r256" ], "calculation": { "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net of allowances of $6.2 (2019) and $8.4 (2018)", "verboseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets", "http://www.elanco.com/role/GeographicInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r66", "r72", "r75", "r294", "r427" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Defined Benefit Pension and Retiree Health Benefit Plans" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r41", "r216" ], "calculation": { "http://www.elanco.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r70", "r71", "r72" ], "calculation": { "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r69", "r72", "r75", "r427" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r64", "r72", "r75", "r427" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign Currency Translation" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r196" ], "lang": { "en-US": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Weighted average useful life" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsNarrativeDetails", "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r27" ], "calculation": { "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r114", "r202" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization", "terseLabel": "Amortization" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangiblesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r137" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r317", "r319", "r353", "r354" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "verboseLabel": "Stock compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income (loss) to cash flows from operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r319", "r347", "r352" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense", "verboseLabel": "Stock-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails", "http://www.elanco.com/role/StockBasedCompensationNarrativeDetails", "http://www.elanco.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r32", "r179", "r182" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net of allowances" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r114", "r194", "r202" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r150" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive shares not included in calculation diluted earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r114", "r212" ], "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "order": 1.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Asset impairment" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetImpairmentChargesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Asset Impairment Charges [Abstract]", "terseLabel": "Non-cash and other items" } } }, "localname": "AssetImpairmentChargesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Assets": { "auth_ref": [ "r168", "r519", "r534" ], "calculation": { "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r8", "r9", "r62" ], "calculation": { "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current Assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "Noncurrent Assets" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r0", "r1", "r2", "r3", "r220" ], "calculation": { "http://www.elanco.com/role/SubsequentEventsDivestituresDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Assets", "totalLabel": "Total assets held for sale" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SubsequentEventsDivestituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r320", "r349" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationNarrativeDetails", "http://www.elanco.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails", "http://www.elanco.com/role/StockBasedCompensationScheduleofRestrictedStockUnitandPerformanceAwardActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r436", "r439" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccounting": { "auth_ref": [ "r136" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccounting", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/BasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Buildings" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/PropertyandEquipmentNarrativeDetails", "http://www.elanco.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsNarrativeDetails", "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r404", "r405" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsNarrativeDetails", "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition, Contingent Consideration [Line Items]", "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]" } } }, "localname": "BusinessAcquisitionContingentConsiderationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r418" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Number of shares issued to previous shareholders upon closing (in shares)" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsNarrativeDetails", "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r402", "r403" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Unaudited pro forma combined revenues" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r413", "r414", "r416" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Total consideration transferred" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r413", "r414" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "terseLabel": "Value of shares issued as consideration" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r113", "r422" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Loss upon settlement of contingent consideration liability" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r420" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Maximum aggregate contingent payment" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r412", "r415", "r419" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Contingent consideration liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r423" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisitions" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/Acquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationIntegrationRelatedCosts": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "order": 3.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.", "label": "Business Combination, Integration Related Costs", "terseLabel": "Transaction and integration costs" } } }, "localname": "BusinessCombinationIntegrationRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": { "auth_ref": [ "r401" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.", "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual", "terseLabel": "Revenues" } } }, "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory": { "auth_ref": [ "r409" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to inventory acquired in connection with a business combination for which the initial accounting was incomplete.", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory", "terseLabel": "Purchase accounting adjustment" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r407" ], "calculation": { "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "auth_ref": [ "r407" ], "calculation": { "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets", "terseLabel": "Acquired in-process research and development" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r406", "r407" ], "calculation": { "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Marketed products" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r406", "r407" ], "calculation": { "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventories" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r406", "r407" ], "calculation": { "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Total identifiable net assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r406", "r407" ], "calculation": { "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r407" ], "calculation": { "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Total consideration transferred" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]", "terseLabel": "Estimated Fair Value" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]", "terseLabel": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessExitCosts1": { "auth_ref": [ "r114", "r223", "r227", "r232" ], "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "order": 5.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Business Exit Costs", "terseLabel": "Facility exit costs" } } }, "localname": "BusinessExitCosts1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r459", "r460" ], "lang": { "en-US": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Amount" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r5", "r38", "r116" ], "calculation": { "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets", "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r111", "r116", "r121" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "totalLabel": "Cash, cash equivalents and restricted cash at end of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r111", "r465" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock": { "auth_ref": [ "r273" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the change in the benefit obligation, fair value of plan assets, and funded status of pension plans or other employee benefit plans.", "label": "Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]", "terseLabel": "Change in Benefit Obligation, Change in Plan Assets, and Funded Status" } } }, "localname": "ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r54", "r233", "r524", "r539" ], "calculation": { "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies (Note 16)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r55" ], "lang": { "en-US": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares of common stock to be reserved for future issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity", "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r25" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r25" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r25", "r242" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r25" ], "calculation": { "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, 5,000,000,000 shares authorized, no par value; 373,011,513 and 365,643,911 shares issued and outstanding as of December 31, 2019 and 2018, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Retirement Benefits [Abstract]", "terseLabel": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r122", "r324" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Compensation Related Costs, Policy [Policy Text Block]", "terseLabel": "Benefit and Combined Stock-Based Compensation Plans" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Components of Deferred Tax Assets [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "ComponentsOfDeferredTaxAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Components of Deferred Tax Liabilities [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r78", "r80", "r81" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r195", "r200", "r411" ], "lang": { "en-US": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Software, Intangible Asset [Member]", "terseLabel": "Software" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangiblesComponentsofIntangibleAssetsOtherThanGoodwillDetails", "http://www.elanco.com/role/GoodwillandIntangiblesNarrativeDetails", "http://www.elanco.com/role/GoodwillandIntangiblesRemainingWeightedAverageAmortizationPeriodsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r162", "r163", "r461", "r462" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r162", "r163", "r461", "r462", "r548" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r162", "r163", "r461", "r462", "r548" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r162", "r163", "r461", "r462" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r159", "r162", "r163", "r164", "r461", "r463" ], "lang": { "en-US": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r162", "r163", "r461", "r462" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r123", "r425", "r428", "r429" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r252" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of contract balances and changes in contract balances.", "label": "Contract with Customer, Asset and Liability [Table Text Block]", "terseLabel": "Summary of Activity in Sales Rebates and Discounts Liability" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r250", "r251", "r256" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RevenueSummaryofActivityinSalesRebatesandDiscountsLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r250", "r251", "r256" ], "calculation": { "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Sales rebates and discounts" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r257" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Reduction of revenue" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RevenueSummaryofActivityinSalesRebatesandDiscountsLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r92" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations", "http://www.elanco.com/role/SelectedQuarterlyDataunauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAllocationofServicesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r90" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Costs, expenses and other" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs, expenses and other:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/ImpactofSeparationDetails", "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/ImpactofSeparationDetails", "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Cumulative Effect of New Accounting Principle in Period of Adoption", "terseLabel": "Adoption of Accounting Standards Update 2016-16" } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r127", "r391", "r395" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesCompositionofIncomeTaxExpenseBenefitDetails": { "order": 3.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesCompositionofIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r131", "r393" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesCompositionofIncomeTaxExpenseBenefitDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesCompositionofIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r127", "r391", "r395" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesCompositionofIncomeTaxExpenseBenefitDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total current tax expense" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesCompositionofIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesCompositionofIncomeTaxExpenseBenefitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r127", "r391", "r395" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesCompositionofIncomeTaxExpenseBenefitDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesCompositionofIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r160" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r240" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r17", "r18", "r19", "r520", "r522", "r532" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis points" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r19", "r236", "r522", "r532" ], "calculation": { "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails_1": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Long-term debt, gross", "verboseLabel": "Borrowings outstanding" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r470", "r472" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Aggregate principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/ImpactofSeparationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r51" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/ImpactofSeparationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r52" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r52", "r129", "r243", "r244", "r245", "r246", "r469", "r470", "r472", "r529" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/ImpactofSeparationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt maturity term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r127", "r392", "r395" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesCompositionofIncomeTaxExpenseBenefitDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesCompositionofIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r43", "r471" ], "calculation": { "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails_1": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedTerseLabel": "Unamortized debt issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r127", "r392", "r395" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesCompositionofIncomeTaxExpenseBenefitDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesCompositionofIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r114", "r127", "r392", "r395" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.elanco.com/role/IncomeTaxesCompositionofIncomeTaxExpenseBenefitDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Change in deferred income taxes", "totalLabel": "Total deferred tax expense (benefit)" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows", "http://www.elanco.com/role/IncomeTaxesCompositionofIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Deferred:" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesCompositionofIncomeTaxExpenseBenefitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r21", "r22", "r381", "r521", "r531" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r367", "r385" ], "calculation": { "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred taxes (Note 15)" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r127", "r392", "r395" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesCompositionofIncomeTaxExpenseBenefitDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesCompositionofIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r382" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total gross deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInventory": { "auth_ref": [ "r360", "r389", "r390" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.", "label": "Deferred Tax Assets, Inventory", "terseLabel": "Inventories" } } }, "localname": "DeferredTaxAssetsInventory", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r383" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r358", "r389", "r390" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating losses and other carryovers", "verboseLabel": "Tax loss carryovers" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesNarrativeDetails", "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration", "terseLabel": "Net operating loss carryforwards with indefinite carryforward period" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration", "terseLabel": "Net operating loss carryforwards that expire" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r360", "r389", "r390" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r387", "r389", "r390" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Tax credit carryovers" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "auth_ref": [ "r358", "r389", "r390" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits", "terseLabel": "Compensation and benefits" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "auth_ref": [ "r359", "r389", "r390" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals", "terseLabel": "Accruals and reserves" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges": { "auth_ref": [ "r358", "r389", "r390" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from restructuring reserve.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges", "terseLabel": "Restructuring and other reserves" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r384" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedTerseLabel": "Valuation allowances" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r367", "r385" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Deferred tax liabilities - net" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": { "auth_ref": [ "r360", "r389", "r390" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Liabilities, Goodwill and Intangible Assets", "negatedTerseLabel": "Intangibles" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r360", "r389", "r390" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liabilities, Other", "negatedTerseLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r360", "r389", "r390" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedTerseLabel": "Property and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": { "auth_ref": [ "r389" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.", "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings", "terseLabel": "Taxes accrued with respect to unremitted earnings of foreign subsidiaries" } } }, "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": { "auth_ref": [ "r284" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.", "label": "Defined Benefit Plan, Accumulated Benefit Obligation", "terseLabel": "Total accumulated benefit obligation" } } }, "localname": "DefinedBenefitPlanAccumulatedBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax": { "auth_ref": [ "r67", "r72" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinCombinedBalanceSheetDetails": { "order": 4.0, "parentTag": "elan_DefinedBenefitPlanAmountsForAssetLiabilityAndAccumulatedOtherComprehensiveIncomeLossBeforeTaxRecognizedInStatementOfFinancialPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax", "terseLabel": "Accumulated other comprehensive (income) loss before income taxes" } } }, "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinCombinedBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax": { "auth_ref": [ "r72", "r294" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsChangeinBenefitObligationChangeinPlanAssetsandFundedStatusDetails": { "order": 3.0, "parentTag": "elan_DefinedBenefitPlanAmountsForAssetLiabilityAndAccumulatedOtherComprehensiveIncomeLossBeforeTaxRecognizedInStatementOfFinancialPosition", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.", "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax", "negatedTerseLabel": "Unrecognized net actuarial loss" } } }, "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsChangeinBenefitObligationChangeinPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": { "auth_ref": [ "r72", "r294" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsChangeinBenefitObligationChangeinPlanAssetsandFundedStatusDetails": { "order": 2.0, "parentTag": "elan_DefinedBenefitPlanAmountsForAssetLiabilityAndAccumulatedOtherComprehensiveIncomeLossBeforeTaxRecognizedInStatementOfFinancialPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax", "terseLabel": "Unrecognized prior service cost" } } }, "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsChangeinBenefitObligationChangeinPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": { "auth_ref": [ "r275", "r313" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)", "terseLabel": "Actual return on plan assets" } } }, "localname": "DefinedBenefitPlanActualReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsChangeinBenefitObligationChangeinPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "auth_ref": [ "r269" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "negatedTerseLabel": "Actuarial loss (gain)" } } }, "localname": "DefinedBenefitPlanActuarialGainLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsChangeinBenefitObligationChangeinPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "auth_ref": [ "r291", "r310", "r313" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsNetPensionExpenseDetails": { "order": 5.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "negatedTerseLabel": "Amortization of net actuarial loss" } } }, "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsNetPensionExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "auth_ref": [ "r292", "r311", "r313" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsNetPensionExpenseDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "terseLabel": "Amortization of prior service cost" } } }, "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsNetPensionExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]", "terseLabel": "Amounts recognized in the consolidated balance sheet consisted\u00a0of:" } } }, "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinCombinedBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": { "auth_ref": [ "r16", "r264", "r265", "r279", "r518", "r533" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinCombinedBalanceSheetDetails": { "order": 1.0, "parentTag": "elan_DefinedBenefitPlanAmountsForAssetLiabilityAndAccumulatedOtherComprehensiveIncomeLossBeforeTaxRecognizedInStatementOfFinancialPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.", "label": "Assets for Plan Benefits, Defined Benefit Plan", "terseLabel": "Noncurrent assets" } } }, "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinCombinedBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": { "auth_ref": [ "r296" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate", "terseLabel": "Discount rate for benefit obligation" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsWeightedAverageAssumptionsRelatedtoPensionPlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": { "auth_ref": [ "r297" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase", "terseLabel": "Rate of compensation increase for benefit obligation" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsWeightedAverageAssumptionsRelatedtoPensionPlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": { "auth_ref": [ "r296" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate", "terseLabel": "Discount rate for net benefit costs" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsWeightedAverageAssumptionsRelatedtoPensionPlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": { "auth_ref": [ "r298" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets", "terseLabel": "Expected return on plan assets for net benefit costs" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsWeightedAverageAssumptionsRelatedtoPensionPlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": { "auth_ref": [ "r297" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase", "terseLabel": "Rate of compensation increase for net benefit costs" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsWeightedAverageAssumptionsRelatedtoPensionPlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "auth_ref": [ "r266" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsChangeinBenefitObligationChangeinPlanAssetsandFundedStatusDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation", "periodEndLabel": "Benefit obligation at end of year", "periodStartLabel": "Benefit obligation at beginning of year" } } }, "localname": "DefinedBenefitPlanBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsChangeinBenefitObligationChangeinPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": { "auth_ref": [ "r271", "r314" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "negatedTerseLabel": "Benefits paid" } } }, "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsChangeinBenefitObligationChangeinPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": { "auth_ref": [ "r282", "r283", "r299", "r313" ], "lang": { "en-US": { "role": { "documentation": "Information by defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Axis]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]" } } }, "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsFairValueofPensionPlanAssetsDetails", "http://www.elanco.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "Cash and cash equivalent in which defined benefit plan asset is invested.", "label": "Defined Benefit Plan, Cash and Cash Equivalents [Member]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "DefinedBenefitPlanCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanCashMember": { "auth_ref": [ "r282", "r283", "r313" ], "lang": { "en-US": { "role": { "documentation": "Cash in which defined benefit plan asset is invested.", "label": "Defined Benefit Plan, Cash [Member]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "DefinedBenefitPlanCashMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]", "terseLabel": "Change in benefit obligation:" } } }, "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsChangeinBenefitObligationChangeinPlanAssetsandFundedStatusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]", "terseLabel": "Change in plan assets:" } } }, "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsChangeinBenefitObligationChangeinPlanAssetsandFundedStatusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "auth_ref": [ "r277", "r282", "r283", "r312", "r313" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "terseLabel": "Employer contribution" } } }, "localname": "DefinedBenefitPlanContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsChangeinBenefitObligationChangeinPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsAccumulatedBenefitObligationsinExcessofPlanAssetsDetails", "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinCombinedBalanceSheetDetails", "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinOtherComprehensiveLossDetails", "http://www.elanco.com/role/RetirementBenefitsChangeinBenefitObligationChangeinPlanAssetsandFundedStatusDetails", "http://www.elanco.com/role/RetirementBenefitsFairValueofPensionPlanAssetsDetails", "http://www.elanco.com/role/RetirementBenefitsNarrativeDetails", "http://www.elanco.com/role/RetirementBenefitsNetPensionExpenseDetails", "http://www.elanco.com/role/RetirementBenefitsProjectedBenefitObligationsinExcessofPlanAssetsDetails", "http://www.elanco.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsDetails", "http://www.elanco.com/role/RetirementBenefitsWeightedAverageAssumptionsRelatedtoPensionPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanEquitySecuritiesMember": { "auth_ref": [ "r282", "r313" ], "lang": { "en-US": { "role": { "documentation": "Security representing ownership in corporation or other legal entity for which ownership is represented by share of stock, in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.", "label": "Defined Benefit Plan, Equity Securities [Member]", "terseLabel": "Public equity securities" } } }, "localname": "DefinedBenefitPlanEquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsFairValueofPensionPlanAssetsDetails", "http://www.elanco.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Defined Benefit Plan, Expected Future Benefit Payment [Abstract]", "terseLabel": "Benefit payments" } } }, "localname": "DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": { "auth_ref": [ "r285" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of benefits for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following latest fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Five Fiscal Years Thereafter", "terseLabel": "2025-2029" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": { "auth_ref": [ "r285" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of benefits for defined benefit plan expected to be paid in next fiscal year following latest fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months", "terseLabel": "2020" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": { "auth_ref": [ "r285" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of benefits for defined benefit plan expected to be paid in fifth fiscal year following latest fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five", "terseLabel": "2024" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": { "auth_ref": [ "r285" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of benefits for defined benefit plan expected to be paid in fourth fiscal year following latest fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four", "terseLabel": "2023" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": { "auth_ref": [ "r285" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of benefits for defined benefit plan expected to be paid in third fiscal year following latest fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three", "terseLabel": "2022" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": { "auth_ref": [ "r285" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of benefits for defined benefit plan expected to be paid in second fiscal year following latest fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two", "terseLabel": "2021" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": { "auth_ref": [ "r286" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of contributions expected to be received by defined benefit plan from employer in next fiscal year following latest fiscal year.", "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year", "terseLabel": "Contributions expected in 2020" } } }, "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r290", "r309", "r313" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsNetPensionExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedTerseLabel": "Expected return on plan assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsNetPensionExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "auth_ref": [ "r274", "r282", "r283", "r313" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsChangeinBenefitObligationChangeinPlanAssetsandFundedStatusDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.", "label": "Defined Benefit Plan, Plan Assets, Amount", "periodEndLabel": "Fair value of plan assets at end of year", "periodStartLabel": "Fair value of plan assets at beginning of year", "terseLabel": "Fair value of plan assets" } } }, "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsChangeinBenefitObligationChangeinPlanAssetsandFundedStatusDetails", "http://www.elanco.com/role/RetirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": { "auth_ref": [ "r270" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)", "negatedTerseLabel": "Foreign currency exchange rate changes and other adjustments" } } }, "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsChangeinBenefitObligationChangeinPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFundedPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of plan assets to benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Funded Percentage", "terseLabel": "Percentage of benefit obligation in Switzerland pension plans" } } }, "localname": "DefinedBenefitPlanFundedPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": { "auth_ref": [ "r264", "r279" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsChangeinBenefitObligationChangeinPlanAssetsandFundedStatusDetails": { "order": 1.0, "parentTag": "elan_DefinedBenefitPlanAmountsForAssetLiabilityAndAccumulatedOtherComprehensiveIncomeLossBeforeTaxRecognizedInStatementOfFinancialPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.", "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan", "totalLabel": "Funded status" } } }, "localname": "DefinedBenefitPlanFundedStatusOfPlan", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsChangeinBenefitObligationChangeinPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r268", "r289", "r308", "r313" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsNetPensionExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsChangeinBenefitObligationChangeinPlanAssetsandFundedStatusDetails", "http://www.elanco.com/role/RetirementBenefitsNetPensionExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r287", "r306", "r313" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsNetPensionExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Net pension expense" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsNetPensionExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanOtherCosts": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/RetirementBenefitsNetPensionExpenseDetails": { "order": 6.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of defined benefit plan cost (credit), classified as other.", "label": "Defined Benefit Plan, Other Cost (Credit)", "terseLabel": "Other" } } }, "localname": "DefinedBenefitPlanOtherCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsNetPensionExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets": { "auth_ref": [ "r302" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of plan asset for defined benefit pension plan with projected benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets", "terseLabel": "Fair value of plan assets" } } }, "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsProjectedBenefitObligationsinExcessofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation": { "auth_ref": [ "r302" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of projected benefit obligation for defined benefit pension plan with projected benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation", "terseLabel": "Projected benefit obligation" } } }, "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsProjectedBenefitObligationsinExcessofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": { "auth_ref": [ "r302", "r303", "r313" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation", "terseLabel": "Accumulated benefit obligation" } } }, "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsAccumulatedBenefitObligationsinExcessofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": { "auth_ref": [ "r302", "r303", "r313" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets", "terseLabel": "Fair value of plan assets" } } }, "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsAccumulatedBenefitObligationsinExcessofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAmendments": { "auth_ref": [ "r272" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.", "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment", "negatedLabel": "Decrease in pension benefit obligation", "terseLabel": "Plan amendments" } } }, "localname": "DefinedBenefitPlanPlanAmendments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsChangeinBenefitObligationChangeinPlanAssetsandFundedStatusDetails", "http://www.elanco.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": { "auth_ref": [ "r278", "r314" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Plan Assets, Benefits Paid", "negatedTerseLabel": "Benefits paid" } } }, "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsChangeinBenefitObligationChangeinPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r276" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign currency exchange rate changes and other adjustments" } } }, "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsChangeinBenefitObligationChangeinPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": { "auth_ref": [ "r281", "r313" ], "lang": { "en-US": { "role": { "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.", "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage", "terseLabel": "Designated percentage invested" } } }, "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanRealEstateMember": { "auth_ref": [ "r282", "r313" ], "lang": { "en-US": { "role": { "documentation": "Property composed of building, land and land improvement; in which defined benefit plan asset is invested.", "label": "Defined Benefit Plan, Real Estate [Member]", "terseLabel": "Real estate" } } }, "localname": "DefinedBenefitPlanRealEstateMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsFairValueofPensionPlanAssetsDetails", "http://www.elanco.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r267", "r288", "r307", "r313" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsNetPensionExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Service cost" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsChangeinBenefitObligationChangeinPlanAssetsandFundedStatusDetails", "http://www.elanco.com/role/RetirementBenefitsNetPensionExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPostretirementHealthCoverageMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan designed to provide postretirement health benefits to retiree or beneficiary. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Postretirement Health Coverage [Member]", "terseLabel": "Retiree Health Benefit Plan" } } }, "localname": "DefinedBenefitPostretirementHealthCoverageMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r315" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Expenses related to employees under Defined Contribution Plans" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r114", "r214" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/PropertyandEquipmentDepreciationExpenseandRentalExpenseforAllLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r114", "r166" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": { "auth_ref": [ "r431" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.", "label": "Derivative Assets (Liabilities), at Fair Value, Net", "terseLabel": "Other noncurrent assets/(liabilities) - cross currency interest rate contracts designated as net investment hedges" } } }, "localname": "DerivativeAssetsLiabilitiesAtFairValueNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings": { "auth_ref": [ "r440", "r446" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.", "label": "Derivative, Excluded Component, Gain (Loss), Recognized in Earnings", "terseLabel": "Contra interest expense" } } }, "localname": "DerivativeExcludedComponentGainLossRecognizedInEarnings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r437", "r438", "r441", "r444" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r435", "r437", "r441" ], "lang": { "en-US": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r432", "r433" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTermOfContract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Derivative, Term of Contract", "terseLabel": "Derivative, term of contract" } } }, "localname": "DerivativeTermOfContract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r435" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r255" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r355" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock": { "auth_ref": [ "r221" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss).", "label": "Disclosure of Long Lived Assets Held-for-sale [Table Text Block]", "terseLabel": "Disclosure of Long Lived Assets Held-for-sale" } } }, "localname": "DisclosureOfLongLivedAssetsHeldForSaleTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SubsequentEventsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r320", "r349" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]", "terseLabel": "Schedule of Assumptions Used" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SubsequentEventsDivestituresDetails", "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SubsequentEventsDivestituresDetails", "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r211", "r213", "r221" ], "lang": { "en-US": { "role": { "documentation": "Disposal group that either has been sold or is classified as held-for-sale. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member]", "terseLabel": "Disposal group" } } }, "localname": "DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SubsequentEventsDivestituresDetails", "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities": { "auth_ref": [ "r0", "r1", "r2", "r220" ], "calculation": { "http://www.elanco.com/role/SubsequentEventsDivestituresDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities", "terseLabel": "Deferred taxes" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SubsequentEventsDivestituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets": { "auth_ref": [ "r0", "r1", "r2", "r220" ], "calculation": { "http://www.elanco.com/role/SubsequentEventsDivestituresDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Intangible Assets", "terseLabel": "Other intangibles, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SubsequentEventsDivestituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": { "auth_ref": [ "r0", "r1", "r2", "r220" ], "calculation": { "http://www.elanco.com/role/SubsequentEventsDivestituresDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Inventory", "terseLabel": "Inventories" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SubsequentEventsDivestituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": { "auth_ref": [ "r0", "r1", "r2", "r220" ], "calculation": { "http://www.elanco.com/role/SubsequentEventsDivestituresDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment", "terseLabel": "Property, plant and equipment classified as held for sale", "verboseLabel": "Property and equipment, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails", "http://www.elanco.com/role/SubsequentEventsDivestituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown": { "auth_ref": [ "r114", "r213", "r218" ], "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "order": 6.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.", "label": "Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down", "terseLabel": "Asset write-down" } } }, "localname": "DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SubsequentEventsDivestituresDetails", "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Domestic Tax Authority" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings (loss) per share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r89", "r138", "r146", "r147", "r148", "r149", "r152", "r527", "r541" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r148" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "verboseLabel": "Earnings (loss) per share\u2014basic and diluted (usd per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SelectedQuarterlyDataunauditedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r89", "r138", "r146", "r147", "r148", "r149", "r152", "r527", "r541" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r153" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r465" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Employee compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r348" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-average remaining requisite service period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r348" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r347" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expense, Tax Benefit", "negatedLabel": "Related tax benefit" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Severance" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r345" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationNarrativeDetails", "http://www.elanco.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/PropertyandEquipmentNarrativeDetails", "http://www.elanco.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r39", "r169", "r181" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity method investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r458" ], "lang": { "en-US": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Fair Value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FacilityClosingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Facility Closing [Member]", "terseLabel": "Exit costs" } } }, "localname": "FacilityClosingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r448", "r449", "r450", "r454" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r282", "r283", "r313", "r449", "r500" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails", "http://www.elanco.com/role/RetirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r448", "r455" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r448", "r449", "r451", "r452", "r456" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r453" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Financial Instruments and Fair Value" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValue" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r282", "r283", "r313", "r449", "r501" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted\u00a0Prices in Active Markets\u00a0for Identical Assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails", "http://www.elanco.com/role/RetirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r282", "r283", "r313", "r449", "r502" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Observable\u00a0 Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails", "http://www.elanco.com/role/RetirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r282", "r283", "r313", "r449", "r503" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails", "http://www.elanco.com/role/RetirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r448", "r449" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.", "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Fair Value Information" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": { "auth_ref": [ "r283", "r447", "r456" ], "lang": { "en-US": { "role": { "documentation": "Fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Measured at Net Asset Value Per Share [Member]", "terseLabel": "Investments Valued at Net Asset Value" } } }, "localname": "FairValueMeasuredAtNetAssetValuePerShareMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails", "http://www.elanco.com/role/RetirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r453", "r456" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Estimated useful lives" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangiblesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r201" ], "calculation": { "http://www.elanco.com/role/GoodwillandIntangiblesComponentsofIntangibleAssetsOtherThanGoodwillDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated Amortization", "negatedTerseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangiblesComponentsofIntangibleAssetsOtherThanGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r203" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "terseLabel": "2020" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangiblesEstimatedAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r203" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangiblesEstimatedAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r203" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangiblesEstimatedAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r203" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangiblesEstimatedAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r203" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangiblesEstimatedAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r195", "r198", "r201", "r205", "r504" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/GoodwillandIntangiblesComponentsofIntangibleAssetsOtherThanGoodwillDetails", "http://www.elanco.com/role/GoodwillandIntangiblesNarrativeDetails", "http://www.elanco.com/role/GoodwillandIntangiblesRemainingWeightedAverageAmortizationPeriodsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r201", "r504" ], "calculation": { "http://www.elanco.com/role/GoodwillandIntangiblesComponentsofIntangibleAssetsOtherThanGoodwillDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Carrying Amount, Gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangiblesComponentsofIntangibleAssetsOtherThanGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangiblesComponentsofIntangibleAssetsOtherThanGoodwillDetails", "http://www.elanco.com/role/GoodwillandIntangiblesNarrativeDetails", "http://www.elanco.com/role/GoodwillandIntangiblesRemainingWeightedAverageAmortizationPeriodsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r195", "r200" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/GoodwillandIntangiblesComponentsofIntangibleAssetsOtherThanGoodwillDetails", "http://www.elanco.com/role/GoodwillandIntangiblesNarrativeDetails", "http://www.elanco.com/role/GoodwillandIntangiblesRemainingWeightedAverageAmortizationPeriodsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r201" ], "calculation": { "http://www.elanco.com/role/GoodwillandIntangiblesComponentsofIntangibleAssetsOtherThanGoodwillDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.elanco.com/role/GoodwillandIntangiblesComponentsofIntangibleAssetsOtherThanGoodwillDetails_1": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Carrying Amount, Net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangiblesComponentsofIntangibleAssetsOtherThanGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Remaining amortization period" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangiblesRemainingWeightedAverageAmortizationPeriodsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FixedIncomeSecuritiesMember": { "auth_ref": [ "r282", "r313" ], "lang": { "en-US": { "role": { "documentation": "Investment that provides a return in the form of fixed periodic payments and eventual return of principal at maturity.", "label": "Fixed Income Securities [Member]", "terseLabel": "Fixed Income Securities" } } }, "localname": "FixedIncomeSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r123", "r464", "r467" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r282", "r442" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign Exchange Contract" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignPlanMember": { "auth_ref": [ "r301" ], "lang": { "en-US": { "role": { "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Foreign Plan [Member]", "terseLabel": "Switzerland" } } }, "localname": "ForeignPlanMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets": { "auth_ref": [ "r114", "r213", "r218" ], "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "order": 4.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property", "negatedTerseLabel": "Gain on sale of fixed assets" } } }, "localname": "GainLossOnDispositionOfAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r114" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedTerseLabel": "Gain on sale of assets" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r114", "r238", "r239" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Debt extinguishment loss" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r161" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]", "terseLabel": "Geographic Concentration Risk" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r187", "r189" ], "calculation": { "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill", "verboseLabel": "Goodwill (Note 11)" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/ConsolidatedBalanceSheets", "http://www.elanco.com/role/GoodwillandIntangiblesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r210" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangibles" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangibles" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r114", "r188", "r190", "r192" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Impairments with respect to the carrying value of goodwill" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangiblesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgeFundsMember": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "Investments in registered hedge funds.", "label": "Hedge Funds [Member]", "terseLabel": "Hedge funds" } } }, "localname": "HedgeFundsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r435", "r445" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r435" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r435" ], "lang": { "en-US": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "IPO" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/EarningsPerShareDetails", "http://www.elanco.com/role/NatureofBusinessandOrganizationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r114", "r206" ], "calculation": { "http://www.elanco.com/role/GoodwillandIntangiblesNarrativeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "totalLabel": "Impairment charges" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangiblesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r114", "r206" ], "calculation": { "http://www.elanco.com/role/GoodwillandIntangiblesNarrativeDetails": { "order": 1.0, "parentTag": "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-lived", "terseLabel": "Impairment of finite-lived intangible assets" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangiblesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r114", "r206" ], "calculation": { "http://www.elanco.com/role/GoodwillandIntangiblesNarrativeDetails": { "order": 2.0, "parentTag": "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)", "terseLabel": "Impairment of indefinite-lived intangible assets" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangiblesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "Acquired in-process research and development" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/GoodwillandIntangiblesComponentsofIntangibleAssetsOtherThanGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r130" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesCompositionofIncomeLossBeforeIncomeTaxExpenseBenefitDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "Federal" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesCompositionofIncomeLossBeforeIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r87", "r138", "r517", "r525", "r542" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.elanco.com/role/IncomeTaxesCompositionofIncomeLossBeforeIncomeTaxExpenseBenefitDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Income (loss) before income taxes", "totalLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations", "http://www.elanco.com/role/IncomeTaxesCompositionofIncomeLossBeforeIncomeTaxExpenseBenefitDetails", "http://www.elanco.com/role/SelectedQuarterlyDataunauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r130" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesCompositionofIncomeLossBeforeIncomeTaxExpenseBenefitDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesCompositionofIncomeLossBeforeIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SubsequentEventsDivestituresDetails", "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r219" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAllocationofServicesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAllocationofServicesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r371" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r400" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": { "auth_ref": [ "r370" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.", "label": "Income Tax Examination, Penalties and Interest Accrued", "terseLabel": "Accruals for payment of interest and penalties" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": { "auth_ref": [ "r370" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.", "label": "Income Tax Examination, Penalties and Interest Expense", "terseLabel": "Income tax expense (benefit)" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesIncomeTaxExpenseBenefitRelatedtoInterestandPenaltiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r127", "r167", "r397" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://www.elanco.com/role/IncomeTaxesCompositionofIncomeTaxExpenseBenefitDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.elanco.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense", "totalLabel": "Income taxes", "verboseLabel": "Income tax (benefit) expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations", "http://www.elanco.com/role/IncomeTaxesCompositionofIncomeTaxExpenseBenefitDetails", "http://www.elanco.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails", "http://www.elanco.com/role/SelectedQuarterlyDataunauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r82", "r123", "r365", "r366", "r379", "r380", "r386", "r398", "r551" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Tax" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r364", "r368", "r369" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r363", "r368", "r369" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": { "order": 8.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount", "terseLabel": "2017 Tax Act" } } }, "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r125", "r368", "r369" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount", "terseLabel": "Taxation of international operations" } } }, "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r126", "r368", "r369" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "Income tax at the U.S. federal statutory tax rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": { "auth_ref": [ "r368", "r369" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": { "order": 9.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount", "terseLabel": "Other permanent adjustments" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r126", "r368", "r369" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "terseLabel": "State taxes" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxContingencies": { "auth_ref": [ "r368", "r369" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.", "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount", "terseLabel": "Change in uncertain tax positions" } } }, "localname": "IncomeTaxReconciliationTaxContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCredits": { "auth_ref": [ "r368", "r369" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount", "negatedTerseLabel": "Income tax credits" } } }, "localname": "IncomeTaxReconciliationTaxCredits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r117" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash payments of income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesCashPaymentsofIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": { "auth_ref": [ "r113" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.", "label": "Increase (Decrease) in Accounts and Other Receivables", "negatedTerseLabel": "Receivables" } } }, "localname": "IncreaseDecreaseInAccountsAndOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": { "auth_ref": [ "r113" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.", "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities", "terseLabel": "Accounts payable and other liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r113" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Other changes in operating assets and liabilities, net of acquisitions and divestitures:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r113" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedTerseLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r197", "r204" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/GoodwillandIntangiblesComponentsofIntangibleAssetsOtherThanGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Indefinite-lived Intangible Assets [Line Items]", "terseLabel": "Indefinite-lived Intangible Assets [Line Items]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangiblesComponentsofIntangibleAssetsOtherThanGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r204" ], "calculation": { "http://www.elanco.com/role/GoodwillandIntangiblesComponentsofIntangibleAssetsOtherThanGoodwillDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0 }, "http://www.elanco.com/role/GoodwillandIntangiblesComponentsofIntangibleAssetsOtherThanGoodwillDetails_1": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite-lived intangible assets" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangiblesComponentsofIntangibleAssetsOtherThanGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r197", "r204" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/GoodwillandIntangiblesComponentsofIntangibleAssetsOtherThanGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/GoodwillandIntangiblesComponentsofIntangibleAssetsOtherThanGoodwillDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "totalLabel": "Carrying Amount, Gross" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangiblesComponentsofIntangibleAssetsOtherThanGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r193", "r199" ], "calculation": { "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.elanco.com/role/GoodwillandIntangiblesComponentsofIntangibleAssetsOtherThanGoodwillDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.elanco.com/role/GoodwillandIntangiblesComponentsofIntangibleAssetsOtherThanGoodwillDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Other intangibles, net (Note 11)", "totalLabel": "Carrying Amount, Net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets", "http://www.elanco.com/role/GoodwillandIntangiblesComponentsofIntangibleAssetsOtherThanGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]", "terseLabel": "Other intangibles" } } }, "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangiblesComponentsofIntangibleAssetsOtherThanGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r85", "r165", "r468", "r471", "r528" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations": { "order": 7.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "verboseLabel": "Interest expense, net of capitalized interest" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations", "http://www.elanco.com/role/SelectedQuarterlyDataunauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r443" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest Expense" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r186" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r57" ], "calculation": { "http://www.elanco.com/role/InventoriesScheduleofInventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished products" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r60" ], "calculation": { "http://www.elanco.com/role/InventoriesScheduleofInventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory, Gross", "totalLabel": "Total (approximates replacement cost)" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLIFOReserve": { "auth_ref": [ "r61" ], "calculation": { "http://www.elanco.com/role/InventoriesScheduleofInventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.", "label": "Inventory, LIFO Reserve", "negatedTerseLabel": "Decrease to LIFO cost" } } }, "localname": "InventoryLIFOReserve", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r6", "r60", "r184" ], "calculation": { "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.elanco.com/role/InventoriesScheduleofInventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories (Note 8)", "totalLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets", "http://www.elanco.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsAndSupplies": { "auth_ref": [ "r59" ], "calculation": { "http://www.elanco.com/role/InventoriesScheduleofInventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.", "label": "Inventory, Raw Materials and Supplies, Gross", "terseLabel": "Raw materials and supplies" } } }, "localname": "InventoryRawMaterialsAndSupplies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r58" ], "calculation": { "http://www.elanco.com/role/InventoriesScheduleofInventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r185" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory Write-down", "terseLabel": "Inventory write-offs" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/InventoriesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LIFOInventoryAmount": { "auth_ref": [ "r12" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of LIFO (last in first out) inventory present at the reporting date when inventory is also valued using different valuation methods.", "label": "LIFO Inventory Amount", "terseLabel": "Inventories valued under the LIFO method" } } }, "localname": "LIFOInventoryAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/InventoriesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r258" ], "lang": { "en-US": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Operating Leases, Rent Expense", "terseLabel": "Rent expense" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/LeasesImpactofOperatingLeasestoCondensedConsolidatedFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r486", "r488" ], "calculation": { "http://www.elanco.com/role/LeasesImpactofOperatingLeasestoCondensedConsolidatedFinancialStatementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/LeasesImpactofOperatingLeasestoCondensedConsolidatedFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Lease cost" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/LeasesImpactofOperatingLeasestoCondensedConsolidatedFinancialStatementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r486" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Impact of Operating Leases to Condensed Consolidated Financial Statements" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r234" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters and Contingencies [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r478" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r487" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Annual Minimum Lease Payments of Operating Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r487" ], "calculation": { "http://www.elanco.com/role/LeasesAnnualMinimumLeasePaymentsofOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.elanco.com/role/LeasesAnnualMinimumLeasePaymentsofOperatingLeaseLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/LeasesAnnualMinimumLeasePaymentsofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r487" ], "calculation": { "http://www.elanco.com/role/LeasesAnnualMinimumLeasePaymentsofOperatingLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "After Year 5" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/LeasesAnnualMinimumLeasePaymentsofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r487" ], "calculation": { "http://www.elanco.com/role/LeasesAnnualMinimumLeasePaymentsofOperatingLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "Year 1" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/LeasesAnnualMinimumLeasePaymentsofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r487" ], "calculation": { "http://www.elanco.com/role/LeasesAnnualMinimumLeasePaymentsofOperatingLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "Year 5" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/LeasesAnnualMinimumLeasePaymentsofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r487" ], "calculation": { "http://www.elanco.com/role/LeasesAnnualMinimumLeasePaymentsofOperatingLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "Year 4" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/LeasesAnnualMinimumLeasePaymentsofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r487" ], "calculation": { "http://www.elanco.com/role/LeasesAnnualMinimumLeasePaymentsofOperatingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "Year 3" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/LeasesAnnualMinimumLeasePaymentsofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r487" ], "calculation": { "http://www.elanco.com/role/LeasesAnnualMinimumLeasePaymentsofOperatingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "Year 2" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/LeasesAnnualMinimumLeasePaymentsofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r487" ], "calculation": { "http://www.elanco.com/role/LeasesAnnualMinimumLeasePaymentsofOperatingLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/LeasesAnnualMinimumLeasePaymentsofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r489" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r48" ], "calculation": { "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r31", "r523", "r537" ], "calculation": { "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Noncurrent Liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r0", "r1", "r2", "r3", "r220" ], "calculation": { "http://www.elanco.com/role/SubsequentEventsDivestituresDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "totalLabel": "Total liabilities held for sale" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SubsequentEventsDivestituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeeAmount": { "auth_ref": [ "r45" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the fee for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Commitment Fee Amount", "terseLabel": "Line of credit facility, commitment fee amount" } } }, "localname": "LineOfCreditFacilityCommitmentFeeAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "auth_ref": [ "r45" ], "lang": { "en-US": { "role": { "documentation": "The effective interest rate at the end of the reporting period.", "label": "Line of Credit Facility, Interest Rate at Period End", "terseLabel": "Interest rate at period end" } } }, "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r45" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Credit facility, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/ImpactofSeparationDetails", "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Credit Facility" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/ImpactofSeparationDetails", "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LinesOfCreditFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time.", "label": "Lines of Credit, Fair Value Disclosure", "negatedLabel": "Long-term debt - term credit facility" } } }, "localname": "LinesOfCreditFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationReserve": { "auth_ref": [ "r54", "r233" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.", "label": "Estimated Litigation Liability", "terseLabel": "Liabilities related to litigation" } } }, "localname": "LitigationReserve", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "LIBOR" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": { "auth_ref": [ "r173" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.", "label": "Long-lived Assets by Geographic Areas [Table Text Block]", "terseLabel": "Long-lived Assets by Selected Geographic Area Information" } } }, "localname": "LongLivedAssetsByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r19", "r237", "r522", "r535" ], "calculation": { "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Long-term debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "negatedLabel": "Less current portion of long-term debt", "verboseLabel": "Current portion of long term debt (Note 9)" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r52" ], "calculation": { "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt (Note 9)", "verboseLabel": "Total long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r52" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/ImpactofSeparationDetails", "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r52", "r235" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/ImpactofSeparationDetails", "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MajorityShareholderMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Owner that controls more than 50 percent of the voting interest in the entity through direct or indirect ownership.", "label": "Majority Shareholder [Member]", "terseLabel": "Lilly" } } }, "localname": "MajorityShareholderMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAllocationofServicesDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAmountsDueFromDueToLillyDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketingRelatedIntangibleAssetsMember": { "auth_ref": [ "r410" ], "lang": { "en-US": { "role": { "documentation": "Marketing-related asset, including, but not limited to, internet domain name, newspaper mast head, and trademark.", "label": "Marketing-Related Intangible Assets [Member]", "terseLabel": "Marketed products" } } }, "localname": "MarketingRelatedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/GoodwillandIntangiblesComponentsofIntangibleAssetsOtherThanGoodwillDetails", "http://www.elanco.com/role/GoodwillandIntangiblesRemainingWeightedAverageAmortizationPeriodsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]" } } }, "localname": "MovementInValuationAllowancesAndReservesRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesMovementsintheValuationAllowanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r111" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash Provided by (Used for) Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows from Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r111" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net Cash Used for Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows from Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r111", "r112", "r115" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash Provided by Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows from Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r76", "r79", "r88", "r115", "r151", "r526", "r540" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows", "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofComprehensiveIncomeLoss", "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity", "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations", "http://www.elanco.com/role/SelectedQuarterlyDataunauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentHedgingMember": { "auth_ref": [ "r434" ], "lang": { "en-US": { "role": { "documentation": "Hedges of a net investment in a foreign operation.", "label": "Net Investment Hedging [Member]", "terseLabel": "Net Investment Hedging" } } }, "localname": "NetInvestmentHedgingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r137", "r139" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Implementation of New Financial Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "Next Largest Country", "verboseLabel": "International" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationRevenueandLonglivedAssetsbySelectedGeographicAreaInformationDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncashOrPartNoncashDivestituresLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Noncash or Part Noncash Divestitures [Line Items]", "terseLabel": "Noncash or Part Noncash Divestitures [Line Items]" } } }, "localname": "NoncashOrPartNoncashDivestituresLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SubsequentEventsDivestituresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashOrPartNoncashDivestituresTable": { "auth_ref": [ "r118", "r119", "r120" ], "lang": { "en-US": { "role": { "documentation": "A table that contains information regarding the sale of an asset or business through a noncash (or part noncash) transaction. At a minimum, the table includes sufficient information to provide an understanding of the nature and purpose of the divesture, as well as the asset divested of and the noncash consideration received (that is, debt, stock, and so forth.) Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Divestitures [Table]", "terseLabel": "Noncash or Part Noncash Divestitures [Table]" } } }, "localname": "NoncashOrPartNoncashDivestituresTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SubsequentEventsDivestituresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r171" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long-Lived Assets", "terseLabel": "Long-lived assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationRevenueandLonglivedAssetsbySelectedGeographicAreaInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonfinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of obligations not classified as financial liabilities. Includes, but is not limited to, accounts payable and accrued liabilities, commitments, obligations, and other liabilities.", "label": "Nonfinancial Liabilities Fair Value Disclosure", "negatedLabel": "Contingent consideration" } } }, "localname": "NonfinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r95" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations": { "order": 6.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedLabel": "Other-net, expense (income)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableFairValueDisclosure": { "auth_ref": [ "r47" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of notes payable.", "label": "Notes Payable, Fair Value Disclosure", "negatedLabel": "Long-term debt - senior notes" } } }, "localname": "NotesPayableFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableOtherPayablesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "Notes Payable, Other Payables [Member]", "terseLabel": "Other obligations" } } }, "localname": "NotesPayableOtherPayablesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfCountriesInWhichEntityOperates": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of countries in which the entity operates as of balance sheet date.", "label": "Number of Countries in which Entity Operates", "terseLabel": "Number of countries in which entity operates (more than)" } } }, "localname": "NumberOfCountriesInWhichEntityOperates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/NatureofBusinessandOrganizationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SelectedQuarterlyDataunauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r479", "r488" ], "calculation": { "http://www.elanco.com/role/LeasesImpactofOperatingLeasestoCondensedConsolidatedFinancialStatementsDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/LeasesImpactofOperatingLeasestoCondensedConsolidatedFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r476" ], "calculation": { "http://www.elanco.com/role/LeasesAnnualMinimumLeasePaymentsofOperatingLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total", "verboseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/LeasesAnnualMinimumLeasePaymentsofOperatingLeaseLiabilitiesDetails", "http://www.elanco.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r476" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/LeasesSupplementalBalanceSheetInformationRelatedtoOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r476" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Non-current operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/LeasesSupplementalBalanceSheetInformationRelatedtoOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r477", "r482" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash outflows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/LeasesImpactofOperatingLeasestoCondensedConsolidatedFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r475" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/LeasesSupplementalBalanceSheetInformationRelatedtoOperatingLeasesDetails", "http://www.elanco.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r485", "r488" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/LeasesImpactofOperatingLeasestoCondensedConsolidatedFinancialStatementsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r484", "r488" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/LeasesImpactofOperatingLeasestoCondensedConsolidatedFinancialStatementsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r388" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r4", "r430" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Nature of Business and Organization" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/NatureofBusinessandOrganization" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "verboseLabel": "Other noncurrent assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax": { "auth_ref": [ "r68", "r70", "r293" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinOtherComprehensiveLossDetails": { "order": 5.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax", "negatedLabel": "Prior year service cost during the year" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r67", "r70", "r424", "r426" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "negatedLabel": "Accumulated other comprehensive income net impact" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": { "auth_ref": [ "r70", "r73", "r74", "r293" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinOtherComprehensiveLossDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax", "terseLabel": "Amortization of prior service cost included in net loss" } } }, "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r63", "r466" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r77", "r80", "r83", "r242" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income (loss), net of tax", "totalLabel": "Other comprehensive income (loss), net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofComprehensiveIncomeLoss", "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax": { "auth_ref": [ "r67", "r70" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinOtherComprehensiveLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax", "negatedTotalLabel": "Total other comprehensive income (loss) during period" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "auth_ref": [ "r67", "r70" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "negatedLabel": "Defined benefit pension and retiree health benefit plans, net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": { "auth_ref": [ "r65", "r70", "r293" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinOtherComprehensiveLossDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax", "terseLabel": "Actuarial gain (loss) arising during period" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax": { "auth_ref": [ "r70", "r73", "r74", "r293" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinOtherComprehensiveLossDetails": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax", "negatedTerseLabel": "Amortization of net actuarial loss included in net loss" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other current liabilities- contingent consideration" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/GoodwillandIntangiblesComponentsofIntangibleAssetsOtherThanGoodwillDetails", "http://www.elanco.com/role/GoodwillandIntangiblesRemainingWeightedAverageAmortizationPeriodsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherInvestmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other investments.", "label": "Other Investments [Member]", "terseLabel": "Other" } } }, "localname": "OtherInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r10", "r11", "r49" ], "calculation": { "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other noncurrent liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other noncurrent liabilities- contingent consideration" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other Operating Activities, Cash Flow Statement", "terseLabel": "Other non-cash operating activities, net" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.", "label": "Other Receivables, Net, Current", "terseLabel": "Other receivables" } } }, "localname": "OtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "Over-Allotment Option" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities": { "auth_ref": [ "r102" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability.", "label": "Payment for Contingent Consideration Liability, Investing Activities", "terseLabel": "Settlement of existing contingent consideration liabilities" } } }, "localname": "PaymentForContingentConsiderationLiabilityInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r99", "r103", "r133" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other investing activities, net" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r110", "r224" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedTerseLabel": "Cash paid" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r108" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r100", "r417" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Amount paid at closing" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r100" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Cash paid for acquisitions, net of cash acquired", "terseLabel": "Acquisition amount" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r101" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireSoftware": { "auth_ref": [ "r101" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition from vendors of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.", "label": "Payments to Acquire Software", "negatedLabel": "Purchases of software" } } }, "localname": "PaymentsToAcquireSoftware", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r316" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for pension and other postretirement benefits.", "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]", "terseLabel": "Retirement Benefits" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefits" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": { "auth_ref": [ "r18", "r264", "r265", "r279" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinCombinedBalanceSheetDetails": { "order": 2.0, "parentTag": "elan_DefinedBenefitPlanAmountsForAssetLiabilityAndAccumulatedOtherComprehensiveIncomeLossBeforeTaxRecognizedInStatementOfFinancialPosition", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.", "label": "Liability, Defined Benefit Plan, Current", "negatedTerseLabel": "Other current liabilities" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinCombinedBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "auth_ref": [ "r20", "r264", "r265", "r279" ], "calculation": { "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinCombinedBalanceSheetDetails": { "order": 3.0, "parentTag": "elan_DefinedBenefitPlanAmountsForAssetLiabilityAndAccumulatedOtherComprehensiveIncomeLossBeforeTaxRecognizedInStatementOfFinancialPosition", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.", "label": "Liability, Defined Benefit Plan, Noncurrent", "negatedTerseLabel": "Accrued retirement benefits", "terseLabel": "Accrued retirement benefits (Note 18)", "verboseLabel": "Accrued retirement benefits" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets", "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinCombinedBalanceSheetDetails", "http://www.elanco.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost (reversal of cost) for pension benefits. Excludes other postretirement benefits.", "label": "Pension Cost (Reversal of Cost)", "terseLabel": "Costs/(benefits) of defined benefit pension plan" } } }, "localname": "PensionExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionPlansDefinedBenefitMember": { "auth_ref": [ "r262", "r300", "r301", "r315" ], "lang": { "en-US": { "role": { "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.", "label": "Pension Plan [Member]", "verboseLabel": "Pension Plans" } } }, "localname": "PensionPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsAccumulatedBenefitObligationsinExcessofPlanAssetsDetails", "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinCombinedBalanceSheetDetails", "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinOtherComprehensiveLossDetails", "http://www.elanco.com/role/RetirementBenefitsChangeinBenefitObligationChangeinPlanAssetsandFundedStatusDetails", "http://www.elanco.com/role/RetirementBenefitsFairValueofPensionPlanAssetsDetails", "http://www.elanco.com/role/RetirementBenefitsNarrativeDetails", "http://www.elanco.com/role/RetirementBenefitsNetPensionExpenseDetails", "http://www.elanco.com/role/RetirementBenefitsProjectedBenefitObligationsinExcessofPlanAssetsDetails", "http://www.elanco.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsDetails", "http://www.elanco.com/role/RetirementBenefitsWeightedAverageAssumptionsRelatedtoPensionPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "PAs" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationNarrativeDetails", "http://www.elanco.com/role/StockBasedCompensationScheduleofRestrictedStockUnitandPerformanceAwardActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanAssetCategoriesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Domain]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]" } } }, "localname": "PlanAssetCategoriesDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsFairValueofPensionPlanAssetsDetails", "http://www.elanco.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r320", "r349" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationNarrativeDetails", "http://www.elanco.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationNarrativeDetails", "http://www.elanco.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r457" ], "lang": { "en-US": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r24" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r24" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r24" ], "calculation": { "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, 1,000,000,000 shares authorized, no par value; none issued" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r8", "r36", "r37" ], "calculation": { "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r97" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds from Divestiture of Businesses", "terseLabel": "Proceeds from divestiture" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r104" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock (Note 1)" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r105" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "terseLabel": "Net proceeds from senior amortizing notes" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": { "auth_ref": [ "r105" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).", "label": "Proceeds from Issuance of Senior Long-term Debt", "terseLabel": "Proceeds from issuance of long-term debt (Note 9)" } } }, "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r106", "r109", "r133" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other financing activities, net" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r98" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Disposals of property and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r104", "r350" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Cash received upon exercise" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r258" ], "lang": { "en-US": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product Sales" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r41", "r217" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/PropertyandEquipmentNarrativeDetails", "http://www.elanco.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r222" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/PropertyandEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r40", "r215" ], "calculation": { "http://www.elanco.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": { "order": 2.0, "parentTag": "elan_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/PropertyandEquipmentNarrativeDetails", "http://www.elanco.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r14", "r15", "r217", "r538" ], "calculation": { "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.elanco.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net (Note 12)", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets", "http://www.elanco.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r14", "r217" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property and Equipment and Depreciation Expense" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/PropertyandEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r14", "r215" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/PropertyandEquipmentNarrativeDetails", "http://www.elanco.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful lives" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/PropertyandEquipmentNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Quarterly Financial Information Disclosure [Abstract]", "terseLabel": "Quarterly Financial Information Disclosure [Abstract]" } } }, "localname": "QuarterlyFinancialInformationDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r158" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Quarterly Financial Information [Text Block]", "terseLabel": "Selected Quarterly Data (unaudited)" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SelectedQuarterlyDataunaudited" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r72", "r83" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "negatedLabel": "Reclassification of net parent company investment" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]" } } }, "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesReconciliationofGrossUnrecognizedTaxBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r497" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAllocationofServicesDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAmountsDueFromDueToLillyDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r299", "r492", "r493" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAllocationofServicesDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAmountsDueFromDueToLillyDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAllocationofServicesDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAmountsDueFromDueToLillyDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionDueFromToRelatedParty": { "auth_ref": [ "r132", "r491" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.", "label": "Related Party Transaction, Due from (to) Related Party", "terseLabel": "Total receivable from/(payable to) Lilly" } } }, "localname": "RelatedPartyTransactionDueFromToRelatedParty", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAmountsDueFromDueToLillyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r490" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Expenses from Transactions with Related Party", "verboseLabel": "Allocation of services" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAllocationofServicesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAllocationofServicesDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAmountsDueFromDueToLillyDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r299", "r492", "r493", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAllocationofServicesDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAmountsDueFromDueToLillyDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r497" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Agreements and Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r107" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "terseLabel": "Repayments of debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfSeniorDebt": { "auth_ref": [ "r107" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.", "label": "Repayments of Senior Debt", "negatedLabel": "Repayments of borrowings (Note 9)" } } }, "localname": "RepaymentsOfSeniorDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r357", "r553" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAllocationofServicesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": { "auth_ref": [ "r42", "r123", "r208", "r209", "r553" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.", "label": "Research, Development, and Computer Software, Policy [Policy Text Block]", "terseLabel": "Research and development expenses and acquired in-process research and development" } } }, "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r5", "r13", "r121" ], "calculation": { "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash", "verboseLabel": "Restricted cash (Note 20)" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets", "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationNarrativeDetails", "http://www.elanco.com/role/StockBasedCompensationScheduleofRestrictedStockUnitandPerformanceAwardActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring and Related Activities [Abstract]", "terseLabel": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r114", "r223", "r227", "r232" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring, Impairment, and Other Activities Disclosure [Text Block]", "terseLabel": "Asset Impairment, Restructuring and Other Special Charges" } } }, "localname": "RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialCharges" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r224", "r229" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveAccrualAdjustment1": { "auth_ref": [ "r223", "r228" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.", "label": "Restructuring Reserve, Accrual Adjustment", "terseLabel": "Reserve adjustment" } } }, "localname": "RestructuringReserveAccrualAdjustment1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringSettlementAndImpairmentProvisions": { "auth_ref": [ "r93" ], "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of restructuring charges, remediation cost, and asset impairment loss.", "label": "Restructuring, Settlement and Impairment Provisions", "terseLabel": "Asset impairment, restructuring and other special charges (Note 7)", "totalLabel": "Total expense", "verboseLabel": "Asset impairment, restructuring, and other special charges" } } }, "localname": "RestructuringSettlementAndImpairmentProvisions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails", "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations", "http://www.elanco.com/role/SelectedQuarterlyDataunauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringSettlementAndImpairmentProvisionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring, Settlement and Impairment Provisions [Abstract]", "terseLabel": "Restructuring charges" } } }, "localname": "RestructuringSettlementAndImpairmentProvisionsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r28", "r247", "r536" ], "calculation": { "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanSponsorLocationAxis": { "auth_ref": [ "r301", "r305" ], "lang": { "en-US": { "role": { "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Axis]", "terseLabel": "Retirement Plan Sponsor Location [Axis]" } } }, "localname": "RetirementPlanSponsorLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanSponsorLocationDomain": { "auth_ref": [ "r301", "r305" ], "lang": { "en-US": { "role": { "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Domain]", "terseLabel": "Retirement Plan Sponsor Location [Domain]" } } }, "localname": "RetirementPlanSponsorLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r262", "r263", "r300", "r301", "r315" ], "lang": { "en-US": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsAccumulatedBenefitObligationsinExcessofPlanAssetsDetails", "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinCombinedBalanceSheetDetails", "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinOtherComprehensiveLossDetails", "http://www.elanco.com/role/RetirementBenefitsChangeinBenefitObligationChangeinPlanAssetsandFundedStatusDetails", "http://www.elanco.com/role/RetirementBenefitsFairValueofPensionPlanAssetsDetails", "http://www.elanco.com/role/RetirementBenefitsNarrativeDetails", "http://www.elanco.com/role/RetirementBenefitsNetPensionExpenseDetails", "http://www.elanco.com/role/RetirementBenefitsProjectedBenefitObligationsinExcessofPlanAssetsDetails", "http://www.elanco.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsDetails", "http://www.elanco.com/role/RetirementBenefitsWeightedAverageAssumptionsRelatedtoPensionPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r262", "r263", "r300", "r301", "r315" ], "lang": { "en-US": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsAccumulatedBenefitObligationsinExcessofPlanAssetsDetails", "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinCombinedBalanceSheetDetails", "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinOtherComprehensiveLossDetails", "http://www.elanco.com/role/RetirementBenefitsChangeinBenefitObligationChangeinPlanAssetsandFundedStatusDetails", "http://www.elanco.com/role/RetirementBenefitsFairValueofPensionPlanAssetsDetails", "http://www.elanco.com/role/RetirementBenefitsNarrativeDetails", "http://www.elanco.com/role/RetirementBenefitsNetPensionExpenseDetails", "http://www.elanco.com/role/RetirementBenefitsProjectedBenefitObligationsinExcessofPlanAssetsDetails", "http://www.elanco.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsDetails", "http://www.elanco.com/role/RetirementBenefitsWeightedAverageAssumptionsRelatedtoPensionPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r254", "r255" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r254", "r255" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Revenue", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations", "http://www.elanco.com/role/GeographicInformationRevenueandLonglivedAssetsbySelectedGeographicAreaInformationDetails", "http://www.elanco.com/role/SelectedQuarterlyDataunauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r162" ], "lang": { "en-US": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue from Contract with Customer Benchmark [Member]", "terseLabel": "Net Revenue" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r124", "r261" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r261" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r172" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "terseLabel": "Revenue by Selected Geographic Area Information" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r91", "r549" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue from Related Parties", "terseLabel": "Revenue from related parties" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuePerformanceObligationDescriptionOfTiming": { "auth_ref": [ "r253" ], "lang": { "en-US": { "role": { "documentation": "Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service.", "label": "Revenue, Performance Obligation, Description of Timing", "terseLabel": "Payment terms" } } }, "localname": "RevenuePerformanceObligationDescriptionOfTiming", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationRevenueandLonglivedAssetsbySelectedGeographicAreaInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving credit facility", "verboseLabel": "Revolving credit facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/ImpactofSeparationDetails", "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r483", "r488" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/LeasesImpactofOperatingLeasestoCondensedConsolidatedFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Total net proceeds, after underwriting discounts and commissions", "verboseLabel": "Total cash received upon sale closing" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/NatureofBusinessandOrganizationDetails", "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/EarningsPerShareDetails", "http://www.elanco.com/role/NatureofBusinessandOrganizationDetails", "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Number of shares issued (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/EarningsPerShareDetails", "http://www.elanco.com/role/NatureofBusinessandOrganizationDetails", "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction.", "label": "Sale of Stock, Percentage of Ownership before Transaction", "terseLabel": "Percentage of total outstanding shares" } } }, "localname": "SaleOfStockPercentageOfOwnershipBeforeTransaction", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/NatureofBusinessandOrganizationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Price per share (usd per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/NatureofBusinessandOrganizationDetails", "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r162" ], "lang": { "en-US": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": { "auth_ref": [ "r302", "r303", "r313" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of benefit obligation and plan assets of defined benefit plan with accumulated benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block]", "terseLabel": "Accumulated Benefit Obligations in Excess of Plan Assets" } } }, "localname": "ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": { "auth_ref": [ "r280" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.", "label": "Schedule of Allocation of Plan Assets [Table Text Block]", "terseLabel": "Fair Value of Pension Plan Assets" } } }, "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock": { "auth_ref": [ "r279" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amounts that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized.", "label": "Schedule of Amounts Recognized in Balance Sheet [Table Text Block]", "terseLabel": "Amounts Recognized in Combined Balance Sheet" } } }, "localname": "ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.", "label": "Defined Benefit Plan, Assumptions [Table Text Block]", "terseLabel": "Weighted-Average Assumptions Related to Pension Plans" } } }, "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": { "auth_ref": [ "r302", "r313" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]", "terseLabel": "Projected Benefit Obligations in Excess of Plan Assets" } } }, "localname": "ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": { "auth_ref": [ "r421" ], "lang": { "en-US": { "role": { "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]", "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r404", "r405" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsNarrativeDetails", "http://www.elanco.com/role/AcquisitionsSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Cash Payments of Income Taxes" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r393" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Composition of Income Tax Expense (Benefit)" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r52", "r129", "r243", "r244", "r245", "r246", "r469", "r470", "r472", "r529" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-term Debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r385" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Significant Components of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in plan assets and benefit obligations recognized in other comprehensive income (loss) during the period.", "label": "Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Amounts Recognized in Other Comprehensive Loss" } } }, "localname": "ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r300", "r301", "r304", "r305", "r313" ], "lang": { "en-US": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsAccumulatedBenefitObligationsinExcessofPlanAssetsDetails", "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinCombinedBalanceSheetDetails", "http://www.elanco.com/role/RetirementBenefitsAmountsRecognizedinOtherComprehensiveLossDetails", "http://www.elanco.com/role/RetirementBenefitsChangeinBenefitObligationChangeinPlanAssetsandFundedStatusDetails", "http://www.elanco.com/role/RetirementBenefitsFairValueofPensionPlanAssetsDetails", "http://www.elanco.com/role/RetirementBenefitsNarrativeDetails", "http://www.elanco.com/role/RetirementBenefitsNetPensionExpenseDetails", "http://www.elanco.com/role/RetirementBenefitsProjectedBenefitObligationsinExcessofPlanAssetsDetails", "http://www.elanco.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsDetails", "http://www.elanco.com/role/RetirementBenefitsWeightedAverageAssumptionsRelatedtoPensionPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r368" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Reconciliation of Income Tax Expense (Benefit)" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r319", "r346", "r352" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock-Based Compensation Expenses" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": { "auth_ref": [ "r285" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.", "label": "Schedule of Expected Benefit Payments [Table Text Block]", "terseLabel": "Schedule of Expected Benefit Payments" } } }, "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r195", "r200" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangiblesComponentsofIntangibleAssetsOtherThanGoodwillDetails", "http://www.elanco.com/role/GoodwillandIntangiblesNarrativeDetails", "http://www.elanco.com/role/GoodwillandIntangiblesRemainingWeightedAverageAmortizationPeriodsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r195", "r200" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Components of Finite-Lived Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangiblesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r130" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Composition of Income (Loss) Before Income Tax Expense (Benefit)" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r204", "r207" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangiblesComponentsofIntangibleAssetsOtherThanGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r204", "r207" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Components of Indefinite-Lived Intangible Assets" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangiblesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "auth_ref": [ "r191" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "terseLabel": "Schedule of Weighted-Average Amortization Periods For Finite-Lived Intangible Assets" } } }, "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangiblesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r12", "r33", "r34", "r35" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r287" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Net Pension Expense" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r137", "r139", "r154", "r155", "r157" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]", "terseLabel": "Description of Accounting Standards Adopted and Not Yet Adopted" } } }, "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r41", "r217" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/PropertyandEquipmentNarrativeDetails", "http://www.elanco.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.", "label": "Quarterly Financial Information [Table Text Block]", "terseLabel": "Schedule of Selected Quarterly Data" } } }, "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SelectedQuarterlyDataunauditedTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r408" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Summary of Amounts Recognized for Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r128", "r492", "r493", "r494", "r495", "r496" ], "lang": { "en-US": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAllocationofServicesDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAmountsDueFromDueToLillyDetails", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "Schedule of Related Party Transactions [Table Text Block]", "terseLabel": "Amounts Due From/(Due To) Lilly and Allocations of Services" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRentExpenseTableTextBlock": { "auth_ref": [ "r473" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of rental expense from operating leases for each period for which an income statement is presented with separate amounts for minimum rentals, contingent rentals, and sublease rentals. Rental payments under leases with terms of a month or less that were not renewed need not be included.", "label": "Schedule of Rent Expense [Table Text Block]", "terseLabel": "Rental Expense for All Leases" } } }, "localname": "ScheduleOfRentExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/PropertyandEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r225", "r226", "r230" ], "lang": { "en-US": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r225", "r226", "r230" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Total Charges Related to Asset Impairment, Restructuring and Other Special Charges" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r224", "r231" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Summary of Activity in Reserves" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r84", "r86", "r174" ], "lang": { "en-US": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationRevenueandLonglivedAssetsbySelectedGeographicAreaInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r320", "r349" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationNarrativeDetails", "http://www.elanco.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails", "http://www.elanco.com/role/StockBasedCompensationScheduleofRestrictedStockUnitandPerformanceAwardActivityDetails", "http://www.elanco.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r326" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of Restricted Stock Unit Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r326", "r337", "r339" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r378", "r394" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Reconciliation of Gross Unrecognized Tax Benefits" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r200" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Estimated Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GoodwillandIntangiblesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r176" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Geographic Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r94", "r183" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Marketing, selling and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [ "r96" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Marketing, selling and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsAllocationofServicesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "auth_ref": [ "r123", "r356" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.", "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]", "terseLabel": "Expenses Related to Certain Corporate Functions" } } }, "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/ImpactofSeparationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r114", "r223", "r227", "r232" ], "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "order": 2.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Severance and other costs" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r113" ], "calculation": { "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.", "label": "Share-based Payment Arrangement, Accelerated Cost", "terseLabel": "Accelerated stock based compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r321" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r331" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofRestrictedStockUnitandPerformanceAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r336" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofRestrictedStockUnitandPerformanceAwardActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r334" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofRestrictedStockUnitandPerformanceAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r334" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofRestrictedStockUnitandPerformanceAwardActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r333" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Ending nonvested balance (in shares)", "periodStartLabel": "Beginning nonvested balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofRestrictedStockUnitandPerformanceAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Outstanding Restricted Stock Units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofRestrictedStockUnitandPerformanceAwardActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r333" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending nonvested balance (in dollars per share)", "periodStartLabel": "Beginning nonvested balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofRestrictedStockUnitandPerformanceAwardActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted-Average Restricted Stock Unit Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofRestrictedStockUnitandPerformanceAwardActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r335" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofRestrictedStockUnitandPerformanceAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r335" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofRestrictedStockUnitandPerformanceAwardActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r343" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r342" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected stock price volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r344" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationNarrativeDetails", "http://www.elanco.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails", "http://www.elanco.com/role/StockBasedCompensationScheduleofRestrictedStockUnitandPerformanceAwardActivityDetails", "http://www.elanco.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Stock Option Activity, Additional Disclosures" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r329" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r329" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r332" ], "lang": { "en-US": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedTerseLabel": "Forfeited or expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r332" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited or expired (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)", "verboseLabel": "Stock options granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationNarrativeDetails", "http://www.elanco.com/role/StockBasedCompensationScheduleofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r338" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant date fair value per stock option (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r349" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of outstanding options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r328", "r349" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at end of period (in shares)", "periodStartLabel": "Outstanding at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Shares of Common Stock Attributable to Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r327" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at end of period (usd per share)", "periodStartLabel": "Outstanding at beginning of period (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted-Average Exercise Price of Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r318", "r323" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationNarrativeDetails", "http://www.elanco.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails", "http://www.elanco.com/role/StockBasedCompensationScheduleofRestrictedStockUnitandPerformanceAwardActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock": { "auth_ref": [ "r325" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.", "label": "Share-based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block]", "terseLabel": "Schedule of Performance Awards Activity" } } }, "localname": "ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r322" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r341", "r351" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r349" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of exercisable options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r349" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "verboseLabel": "Weighted-average remaining contractual term of the exercisable options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r340" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average remaining contractual term of the outstanding options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance at end of period (in shares)", "periodStartLabel": "Balance at beginning of period (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r480", "r488" ], "calculation": { "http://www.elanco.com/role/LeasesImpactofOperatingLeasestoCondensedConsolidatedFinancialStatementsDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/LeasesImpactofOperatingLeasestoCondensedConsolidatedFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r136" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r23", "r24", "r25", "r242" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r56", "r242" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity", "http://www.elanco.com/role/RelatedPartyAgreementsandTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r24", "r25", "r247" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Issuance to Aratana shareholders for acquisition (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r24", "r25", "r242", "r247" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r24", "r25", "r242", "r247" ], "lang": { "en-US": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of stock under employee stock plans, net (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r24", "r25", "r242", "r247", "r330" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/StockBasedCompensationScheduleofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r56", "r242", "r247" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Issuance to Aratana shareholders for acquisition" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r24", "r25", "r242", "r247" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock", "verboseLabel": "Issuance of stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity", "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r25", "r29", "r30", "r180" ], "calculation": { "http://www.elanco.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets", "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r249" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Impact of Separation" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ImpactofSeparation" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r248" ], "lang": { "en-US": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Stock split ratio" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/EarningsPerShareDetails" ], "xbrltype": "pureItemType" }, "us-gaap_StockholdersEquityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.", "label": "Stockholders' Equity, Other", "negatedLabel": "Other" } } }, "localname": "StockholdersEquityOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityPolicyTextBlock": { "auth_ref": [ "r122", "r123", "r241" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.", "label": "Stockholders' Equity, Policy [Policy Text Block]", "terseLabel": "Equity Balance" } } }, "localname": "StockholdersEquityPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r498" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r498" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r498" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r499" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/EarningsPerShareDetails", "http://www.elanco.com/role/NatureofBusinessandOrganizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/EarningsPerShareDetails", "http://www.elanco.com/role/NatureofBusinessandOrganizationDetails", "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/EarningsPerShareDetails", "http://www.elanco.com/role/NatureofBusinessandOrganizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SummaryOfIncomeTaxExaminationsTextBlock": { "auth_ref": [ "r372", "r394" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the increase or decrease in the liability from the prior period, and any penalties and interest that have been recorded.", "label": "Summary of Income Tax Examinations [Table Text Block]", "terseLabel": "Income Tax Expense (Benefit) Related to Interest and Penalties" } } }, "localname": "SummaryOfIncomeTaxExaminationsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SummaryOfValuationAllowanceTextBlock": { "auth_ref": [ "r384" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.", "label": "Summary of Valuation Allowance [Table Text Block]", "terseLabel": "Movements in the Valuation Allowance" } } }, "localname": "SummaryOfValuationAllowanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r387" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax credit carryovers" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit": { "auth_ref": [ "r396" ], "calculation": { "http://www.elanco.com/role/IncomeTaxesCompositionofIncomeTaxExpenseBenefitDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of reasonable estimate for income tax expense (benefit) for which accounting for tax effect is incomplete pursuant to Tax Cuts and Jobs Act.", "label": "Tax Cuts and Jobs Act, Incomplete Accounting, Provisional Income Tax Expense (Benefit)", "terseLabel": "2017 Tax Act" } } }, "localname": "TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesCompositionofIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxPeriodAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information about the period subject to enacted tax laws.", "label": "Tax Period [Axis]", "terseLabel": "Tax Period [Axis]" } } }, "localname": "TaxPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identified tax period.", "label": "Tax Period [Domain]", "terseLabel": "Tax Period [Domain]" } } }, "localname": "TaxPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UndistributedEarningsOfForeignSubsidiaries": { "auth_ref": [ "r361", "r399", "r530", "r547" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile.", "label": "Undistributed Earnings of Foreign Subsidiaries", "terseLabel": "Unremitted earnings of foreign subsidiaries" } } }, "localname": "UndistributedEarningsOfForeignSubsidiaries", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r362", "r373" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesReconciliationofGrossUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation": { "auth_ref": [ "r373" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from foreign currency translation.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation", "negatedTerseLabel": "Changes related to the impact of foreign currency translation" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesReconciliationofGrossUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r374" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedLabel": "Changes for tax positions of prior years" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesReconciliationofGrossUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "auth_ref": [ "r376" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "negatedTerseLabel": "Settlements" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesReconciliationofGrossUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r375" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Additions based on tax positions related to the current year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesReconciliationofGrossUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r374" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Changes for tax positions of prior years" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesReconciliationofGrossUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r377" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits that, if recognized, would affect effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": { "auth_ref": [ "r134" ], "lang": { "en-US": { "role": { "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward.", "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]", "terseLabel": "Valuation Allowance, Deferred Tax Asset" } } }, "localname": "ValuationAllowanceOfDeferredTaxAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesMovementsintheValuationAllowanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r135" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "negatedPeriodEndLabel": "Ending balance", "negatedPeriodStartLabel": "Beginning balance" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesMovementsintheValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "auth_ref": [ "r135" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "negatedTerseLabel": "Increase (1)" } } }, "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesMovementsintheValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r135" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "terseLabel": "Release" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesMovementsintheValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesMovementsintheValuationAllowanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r135" ], "lang": { "en-US": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesMovementsintheValuationAllowanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r481", "r488" ], "calculation": { "http://www.elanco.com/role/LeasesImpactofOperatingLeasestoCondensedConsolidatedFinancialStatementsDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/LeasesImpactofOperatingLeasestoCondensedConsolidatedFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r149" ], "lang": { "en-US": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Weighted average number diluted shares outstanding adjustment (in shares)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r145", "r149" ], "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": { "auth_ref": [ "r143", "r144", "r151" ], "lang": { "en-US": { "role": { "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).", "label": "Weighted Average Number of Shares Issued, Basic", "terseLabel": "Weighted average number of shares issued basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesIssuedBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r143", "r149" ], "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.elanco.com/role/ConsolidatedandCombinedStatementsofOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(ColumnA))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r136": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e2646-109256" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r153": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e725-108305" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e765-108305" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=118952077&loc=d3e1280-108306" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.10-01.(b)(6))", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699" }, "r158": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "270", "URI": "http://asc.fasb.org/topic&trid=2126967" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "b", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599" }, "r176": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314" }, "r186": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "40", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2599-110228" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r222": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r234": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21459-112644" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770" }, "r249": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130554-203045" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r261": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(b)(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r316": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r355": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28200-109314" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32059-109318" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32123-109318" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117331294&loc=d3e36027-109320" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.EE.Q2(b))", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=SL116722634-122817" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r4": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=SL65897772-128472" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5227-128473" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.15)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "c", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r423": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=117331979&loc=d3e41228-113958" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(iii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109974929&loc=SL110061172-113977" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "54B", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117332851&loc=SL7495116-110257" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13476-108611" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20,22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41499-112717" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r489": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r497": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r499": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6479915&loc=d3e66715-112838" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6487024&loc=d3e29054-158556" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=116637345&loc=SL114874292-224272" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r554": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4),(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e689-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724391-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-03(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868656-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" } }, "version": "2.1" } XML 133 R42.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2019
Income Tax Disclosure [Abstract]  
Composition of Income (Loss) Before Income Tax Expense (Benefit)
Following is the composition of income (loss) before income tax expense (benefit):
201920182017
Federal$55.5  $12.2  $(133.2) 
Foreign22.7  101.9  (99.4) 
Income (loss) before income taxes$78.2  $114.1  $(232.6) 
Composition of Income Tax Expense (Benefit)
Following is the composition of income tax expense (benefit):
201920182017
Current:
Federal$(5.5) $45.1  $—  
Foreign13.4  45.5  91.6  
State2.3  (2.3) (0.1) 
Total current tax expense10.2  88.3  91.5  
Deferred:
Federal14.5  (56.8) 42.6  
Foreign(7.5) (5.6) (16.6) 
State(6.9) 1.7  (6.3) 
2017 Tax Act—  —  (33.1) 
Total deferred tax expense (benefit)0.1  (60.7) (13.4) 
Income taxes$10.3  $27.6  $78.1  
Significant Components of Deferred Tax Assets and Liabilities
Significant components of our deferred tax assets and liabilities as of December 31 are as follows:
20192018
Deferred tax assets:
Compensation and benefits$25.3  $32.2  
Accruals and reserves13.7  26.9  
Tax credit carryovers12.8  6.2  
Tax loss carryovers69.5  17.4  
Inventories20.1  18.3  
Restructuring and other reserves24.6  6.0  
Operating lease liabilities20.5  —  
Other2.3  20.1  
Total gross deferred tax assets188.8  127.1  
Valuation allowances(32.7) (21.4) 
Total deferred tax assets156.1  105.7  
Deferred tax liabilities:
Right-of-use assets(20.5) —  
Intangibles(134.5) (130.8) 
Property and equipment(56.4) (50.8) 
Other(0.6) (2.7) 
Total deferred tax liabilities(212.0) (184.3) 
Deferred tax liabilities - net$(55.9) $(78.6) 
Movements in the Valuation Allowance
The movements in the valuation allowance are as follows:
20192018
January 1$(21.4) $(127.7) 
Adjustment related to Separation—  110.4  
January 1(21.4) (17.3) 
Increase (1)
(23.2) (5.8) 
Release11.9  1.7  
December 31$(32.7) $(21.4) 
(1) The increase in the valuation allowance during 2019 is primarily attributable to the acquisition of Aratana Therapeutics, Inc. and Prevtec Microbia Inc. (see Note 6: Acquisitions).
Cash Payments of Income Taxes
Cash payments of income taxes were as follows:
201920182017
Cash payments of income taxes$42.5  $26.9  $35.7  
Reconciliation of Income Tax Expense (Benefit)
The following is a reconciliation of the income tax expense (benefit) applying the U.S. federal statutory rate to income before income taxes to reported income tax expense:
201920182017
Income tax at the U.S. federal statutory tax rate$16.4  $24.0  $(81.4) 
Add (deduct):
Taxation of international operations20.7  20.5  59.8  
State taxes2.9  4.4  5.4  
Income tax credits(9.8) (17.3) (1.8) 
Non-deductible employee compensation4.2  (1.9) —  
IPO and separation costs—  2.3  —  
Other permanent adjustments(4.2) (1.0) 0.8  
Change in uncertain tax positions(14.7) (1.7) 6.2  
Change in valuation allowance(5.2) (1.7) 122.2  
2017 Tax Act—  —  (33.1) 
Income taxes$10.3  $27.6  $78.1  
Reconciliation of Gross Unrecognized Tax Benefits
A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:
201920182017
Beginning balance at January 1$14.7  $29.6  $25.7  
Adjustments related to Separation(2.2) (17.6) —  
Adjusted beginning balance at January 112.5  12.0  25.7  
Additions based on tax positions related to the current year1.3  2.2  7.9  
Changes for tax positions of prior years(1.2) 4.0  —  
Settlements(4.3) (3.0) (4.0) 
Changes related to the impact of foreign currency translation(0.1) (0.5) —  
Ending balance at December 31$8.2  $14.7  $29.6  
Income Tax Expense (Benefit) Related to Interest and Penalties We recognized income tax expense (benefit) related to interest and penalties as follows:
201920182017
Income tax expense (benefit)$(10.6) $(2.5) $2.5  
XML 134 R61.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Debt - Narrative (Details) - USD ($)
Sep. 05, 2018
Dec. 31, 2019
Dec. 31, 2018
Sep. 24, 2018
Aug. 28, 2018
Credit Facility | Revolving credit facility          
Debt Instrument [Line Items]          
Debt maturity term 5 years        
Credit facility, maximum borrowing capacity $ 750,000,000.0     $ 750,000,000.0  
Borrowings outstanding   $ 0 $ 0    
Credit Facility | Term credit facility          
Debt Instrument [Line Items]          
Debt maturity term 3 years        
Credit facility, maximum borrowing capacity $ 500,000,000.0     $ 500,000,000.0  
Borrowings outstanding   $ 371,400,000 $ 492,500,000    
Interest rate at period end   3.01% 3.77%    
Quarterly principal payments percentage 1.50%        
Senior Notes          
Debt Instrument [Line Items]          
Aggregate principal amount         $ 2,000,000,000.0
Senior Notes | 3.912% Senior Notes due 2021          
Debt Instrument [Line Items]          
Borrowings outstanding   $ 500,000,000.0 $ 500,000,000.0    
Aggregate principal amount         $ 500,000,000.0
Interest rate         3.912%
Senior Notes | 4.272% Senior Notes due 2023          
Debt Instrument [Line Items]          
Borrowings outstanding   750,000,000.0 750,000,000.0    
Aggregate principal amount         $ 750,000,000.0
Interest rate         4.272%
Senior Notes | 4.900% Senior Notes due 2028          
Debt Instrument [Line Items]          
Borrowings outstanding   $ 750,000,000.0 $ 750,000,000.0    
Aggregate principal amount         $ 750,000,000.0
Interest rate         4.90%
XML 135 R91.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Geographic Information - Revenue and Long-lived Assets by Selected Geographic Area Information (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]                      
Revenue $ 787.0 $ 771.3 $ 781.6 $ 731.1 $ 799.3 $ 761.1 $ 770.2 $ 736.2 $ 3,071.0 $ 3,066.8 $ 2,889.0
Long-lived assets 1,147.1       985.9       1,147.1 985.9 999.3
United States                      
Revenues from External Customers and Long-Lived Assets [Line Items]                      
Revenue                 1,524.7 1,483.2 1,373.0
Long-lived assets 709.8       602.6       709.8 602.6 604.7
International                      
Revenues from External Customers and Long-Lived Assets [Line Items]                      
Revenue                 1,546.3 1,583.6 1,516.0
United Kingdom                      
Revenues from External Customers and Long-Lived Assets [Line Items]                      
Long-lived assets 192.6       187.5       192.6 187.5 204.4
Other foreign countries                      
Revenues from External Customers and Long-Lived Assets [Line Items]                      
Long-lived assets $ 244.7       $ 195.8       $ 244.7 $ 195.8 $ 190.2
XML 136 R95.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Retirement Benefits - Weighted-Average Assumptions Related to Pension Plans (Details)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Defined Benefit Plan Disclosure [Line Items]      
Rate of compensation increase for benefit obligation 2.30% 2.20% 2.10%
Rate of compensation increase for net benefit costs 2.20% 2.10% 3.10%
Pension Plans      
Defined Benefit Plan Disclosure [Line Items]      
Discount rate for benefit obligation 0.60% 1.50% 1.10%
Discount rate for net benefit costs 1.40% 1.10% 1.00%
Expected return on plan assets for net benefit costs 4.00% 4.00% 4.40%
XML 137 R65.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Goodwill and Intangibles - Components of Intangible Assets Other Than Goodwill (Details) - USD ($)
$ in Millions
Dec. 31, 2019
Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]    
Carrying Amount, Gross $ 3,520.2 $ 3,347.9
Accumulated Amortization (1,086.8) (862.7)
Carrying Amount, Net 2,433.4 2,485.2
Other intangibles    
Carrying Amount, Gross 3,569.6 3,367.5
Accumulated Amortization (1,086.8) (862.7)
Carrying Amount, Net 2,482.8 2,504.8
Acquired in-process research and development    
Indefinite-lived Intangible Assets [Line Items]    
Indefinite-lived intangible assets 49.4 19.6
Marketed products    
Finite-Lived Intangible Assets [Line Items]    
Carrying Amount, Gross 3,302.7 3,193.5
Accumulated Amortization (980.6) (779.2)
Carrying Amount, Net 2,322.1 2,414.3
Other intangibles    
Accumulated Amortization (980.6) (779.2)
Software    
Finite-Lived Intangible Assets [Line Items]    
Carrying Amount, Gross 159.2 101.3
Accumulated Amortization (72.2) (49.5)
Carrying Amount, Net 87.0 51.8
Other intangibles    
Accumulated Amortization (72.2) (49.5)
Other    
Finite-Lived Intangible Assets [Line Items]    
Carrying Amount, Gross 58.3 53.1
Accumulated Amortization (34.0) (34.0)
Carrying Amount, Net 24.3 19.1
Other intangibles    
Accumulated Amortization $ (34.0) $ (34.0)
XML 138 R69.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)
$ in Millions
Dec. 31, 2019
Dec. 31, 2018
Property, Plant and Equipment [Line Items]    
Property and equipment, gross   $ 1,801.0
Finance lease asset $ 0.5  
Property and equipment gross 1,885.8  
Less accumulated depreciation (930.5)  
Less accumulated depreciation   (878.6)
Property and equipment, net 955.3  
Property and equipment, net 955.3 922.4
Land    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 28.3 27.6
Buildings    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 608.5 567.2
Equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 1,109.4 1,025.1
Construction in progress    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 139.1 $ 181.1
XML 139 R99.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Retirement Benefits - Net Pension Expense (Details) - Pension Plans - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Defined Benefit Plan Disclosure [Line Items]      
Service cost $ 9.3 $ 11.3 $ 10.5
Interest cost 2.2 2.5 1.8
Expected return on plan assets (4.2) (6.2) (2.4)
Amortization of prior service cost (1.7) 0.2 0.1
Amortization of net actuarial loss 1.1 1.9 1.4
Other 0.0 0.5 0.0
Net pension expense $ 6.7 $ 10.2 $ 11.4

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end XML 39 R4.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2019
Dec. 31, 2018
Current Assets    
Cash and cash equivalents $ 334.0 $ 474.8
Accounts receivable, net of allowances of $6.2 (2019) and $8.4 (2018) 816.9 651.8
Other receivables 73.0 57.6
Inventories (Note 8) 1,050.7 1,004.1
Prepaid expenses and other 87.4 113.9
Restricted cash (Note 20) 11.1 202.7
Total current assets 2,373.1 2,504.9
Noncurrent Assets    
Goodwill (Note 11) 2,989.6 2,958.0
Other intangibles, net (Note 11) 2,482.8 2,504.8
Other noncurrent assets 185.0 66.6
Property and equipment, net (Note 12) 955.3 922.4
Total assets 8,985.8 8,956.7
Current Liabilities    
Accounts payable 222.6 205.2
Employee compensation 99.6 98.9
Sales rebates and discounts 211.0 169.9
Current portion of long term debt (Note 9) 24.5 29.0
Other current liabilities 244.4 199.0
Payable to Lilly (Note 20) 16.4 268.7
Total current liabilities 818.5 970.7
Noncurrent Liabilities    
Long-term debt (Note 9) 2,330.5 2,443.3
Accrued retirement benefits (Note 18) 82.5 109.1
Deferred taxes (Note 15) 100.8 114.6
Other noncurrent liabilities 106.6 121.5
Total liabilities 3,438.9 3,759.2
Commitments and Contingencies (Note 16)
Equity    
Preferred stock, 1,000,000,000 shares authorized, no par value; none issued 0.0 0.0
Common stock, 5,000,000,000 shares authorized, no par value; 373,011,513 and 365,643,911 shares issued and outstanding as of December 31, 2019 and 2018, respectively 0.0 0.0
Additional paid-in capital 5,636.3 5,403.3
Retained earnings 84.3 16.4
Accumulated other comprehensive loss (173.7) (222.2)
Total equity 5,546.9 5,197.5
Total liabilities and equity $ 8,985.8 $ 8,956.7